Torsade O O
de O O
pointes O O
ventricular O O
tachycardia O O
during O O
low O O
dose O O
intermittent O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
a O O
patient O O
with O O
dilated O O
cardiomyopathy O O
and O O
congestive O O
heart O O
failure O O
. O O

The O O
authors O O
describe O O
the O O
case O O
of O O
a O O
56 O O
- O O
year O O
- O O
old O O
woman O O
with O O
chronic O O
, O O
severe O O
heart O O
failure O O
secondary O O
to O O
dilated O O
cardiomyopathy O O
and O O
absence O O
of O O
significant O O
ventricular O O
arrhythmias O O
who O O
developed O O
QT O O
prolongation O O
and O O
torsade O O
de O O
pointes O O
ventricular O O
tachycardia O O
during O O
one O O
cycle O O
of O O
intermittent O O
low O O
dose O O
( O O
2 O O
. O O
5 O O
mcg O O
/ O O
kg O O
per O O
min O O
) O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
report O O
of O O
torsade O O
de O O
pointes O O
ventricular O O
tachycardia O O
during O O
intermittent O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
supports O O
the O O
hypothesis O O
that O O
unpredictable O O
fatal O O
arrhythmias O O
may O O
occur O O
even O O
with O O
low O O
doses O O
and O O
in O O
patients O O
with O O
no O O
history O O
of O O
significant O O
rhythm O O
disturbances O O
. O O

The O O
mechanisms O O
of O O
proarrhythmic O O
effects O O
of O O
Dubutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

Positive O O
skin O O
tests O O
in O O
late O O
reactions O O
to O O
radiographic O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
last O O
few O O
years O O
delayed O O
reactions O O
several O O
hours O O
after O O
the O O
injection O O
of O O
radiographic O O
and O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
materials I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PRC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
have O O
been O O
described O O
with O O
increasing O O
frequency O O
. O O

The O O
authors O O
report O O
two O O
observations O O
on O O
patients O O
with O O
delayed O O
reactions O O
in O O
whom O O
intradermoreactions O O
( O O
IDR O O
) O O
and O O
patch O O
tests O O
to O O
a O O
series O O
of O O
ionic O O
and O O
non O O
ionic O O
PRC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
. O O

After O O
angiography O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
the O O
venous O B_PERSON/B_LOCATION
route O I_PERSON/I_LOCATION
in O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
n O O
degree O B_MEASURE
1 O I_MEASURE
a O O
biphasic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
( O O
dyspnea O B_DISEASE
, O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
consciousness O B_DISEASE/B_MEASURE
) O O
and O O
delayed O B_DISEASE_ADJECTIVE[DISEASE]
macro O I_DISEASE_ADJECTIVE[DISEASE]
- O O
papular O B_DISEASE
rash O I_DISEASE
appeared O O
, O O
whilst O O
patient O B_PERSON
n O O
degree O B_MEASURE
2 O I_MEASURE
developed O O
a O O
generalised O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
heat O B_DISEASE/B_BIO
, O O
persistent O B_DISEASE
pain O I_DISEASE
at O O
the O O
site O B_LOCATION
of O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immediately O O
and O O
a O O
generalised O B_DISEASE
macro O I_DISEASE
- O O
papular O B_DISEASE
reaction O I_DISEASE
after O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

The O O
skin O O
tests O O
revealed O O
positive O O
delayed O O
reactions O O
of O O
24 O O
hours O O
and O O
48 O O
hours O O
by O O
IDR O O
and O O
patch O O
tests O O
to O O
only O O
some O O
PRC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
common O O
chains O O
in O O
their O O
structures O O
. O O

The O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
skin O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
in O O
favour O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
immunological O B_DISEASE
reactions O I_DISEASE
and O O
may O O
help O O
in O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
allergy O B_DISEASE
in O O
the O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Risk O O
of O O
transient O O
hyperammonemic O O
encephalopathy O O
in O O
cancer O O
patients O O
who O O
received O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
the O O
complication O O
of O O
dehydration O O
and O O
infection O O
. O O

From O O
1986 O O
to O O
1998 O O
, O O
29 O O
cancer O O
patients O O
who O O
had O O
32 O O
episodes O O
of O O
transient O O
hyperammonemic O O
encephalopathy O O
related O O
to O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
were O O
identified O O
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON
had O O
decompensated O O
liver O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
. O O

Onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hyperammonemic O B_DISEASE
encephalopathy O I_DISEASE
varied O O
from O O
0 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
to O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
( O O
mean O B_MEASURE/B_LOCATION
: O O
2 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
3 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
) O O
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Plasma O O
ammonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
ranged O O
from O O
248 O O
to O O
2387 O O
microg O O
% O O
( O O
mean O O
: O O
626 O O
+ O O
/ O O
- O O
431 O O
microg O O
% O O
) O O
. O O

Among O O
the O O
32 O B_PERSON/B_TIME[MEASURE]
episodes O I_PERSON/I_TIME[MEASURE]
, O O
26 O B_MEASURE
( O O
81 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
various O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees O B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
azotemia O B_DISEASE
, O O
18 O B_MEASURE
( O O
56 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
occurred O O
during O O
bacterial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infections O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
14 O B_MEASURE
( O O
44 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
without O O
infection O B_DISEASE/B_PERSON
occurred O O
during O O
periods O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
dehydration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Higher O O
plasma O O
ammonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
and O O
more O O
rapid O O
onset O O
of O O
hyperammonemia O O
were O O
seen O O
in O O
18 O O
patients O O
with O O
bacterial O O
infections O O
( O O
p O O
= O O
0 O O
. O O
003 O O
and O O
0 O O
. O O
0006 O O
, O O
respectively O O
) O O
and O O
in O O
nine O O
patients O O
receiving O O
high O O
daily O O
doses O O
( O O
2600 O O
or O O
1800 O O
mg O O
/ O O
m2 O O
) O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O O
= O O
0 O O
. O O
0001 O O
and O O
< O O
0 O O
. O O
0001 O O
, O O
respectively O O
) O O
. O O

In O O
25 O O
out O O
of O O
32 O O
episodes O O
( O O
78 O O
% O O
) O O
, O O
plasma O O
ammonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
and O O
mental O O
status O O
returned O O
to O O
normal O O
within O O
2 O O
days O O
after O O
adequate O O
management O O
. O O

In O O
conclusion O O
, O O
hyperammonemic O O
encephalopathy O O
can O O
occur O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Azotemia O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O O
body O B_DISEASE/B_SPECIES[BIO]
fluid O B_DISEASE/I_SPECIES[BIO]
insufficiency O B_DISEASE/I_SPECIES[BIO]
and O O
bacterial O B_DISEASE
infections O I_DISEASE
were O O
frequently O O
found O O
in O O
these O O
patients O B_PERSON/B_BIO
. O O

It O O
is O O
therefore O O
important O O
to O O
recognize O O
this O O
condition O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effects O O
of O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
conditioned O O
place O O
preference O O
and O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
rats O O
. O O

1 O B_NUMBER[MEASURE]
. O O

The O O
effects O O
of O O
two O O
unselective O O
potassium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
K B B_PROTEIN[GENE]/B_LOCATION
( O O
+ O O
) O O
- O O
) O O
channel O O
blockers O O
, O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
12 O O
. O O
5 O O
, O O
25 O O
and O O
50 O O
mg O O
/ O O
kg O O
) O O
and O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
) O O
, O O
on O O
conditioned O O
place O O
preference O O
and O O
biphasic O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mg O O
/ O O
kg O O
) O O
were O O
tested O O
in O O
Wistar O O
rats O O
. O O

Quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
block O O
voltage O O
- O O
, O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
and O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
sensitive O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O O
) O O
- O O
channels O O
while O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
known O O
to O O
block O O
voltage O O
- O O
sensitive O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
. O O

2 O B_NUMBER[MEASURE]
. O O

In O O
the O O
counterbalanced O O
method O O
, O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuated O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
place O O
preference O O
, O O
whereas O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
ineffective O O
. O O

In O O
the O O
motor O O
activity O O
test O O
measured O O
with O O
an O O
Animex O O
- O O
activity O O
meter O O
neither O O
of O O
the O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
channel O O
blockers O O
affected O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypoactivity O O
, O O
but O O
both O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channel O O
blockers O O
prevented O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
secondary O O
hyperactivity O O
. O O

3 O B_NUMBER[MEASURE]
. O O

These O O
results O O
suggest O O
the O O
involvement O O
of O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sensitive O O
but O O
not O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
in O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reward O O
. O O

It O O
is O O
also O O
suggested O O
that O O
the O O
blockade O O
of O O
K B B_OTHER/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
sensitive O O
to O O
these O O
blockers O O
is O O
not O O
sufficient O O
to O O
prevent O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypoactivity O O
whereas O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
seems O O
to O O
be O O
connected O O
to O O
both O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
channels O O
. O O

Nociceptin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
orphanin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
nocistatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
learning O O
and O O
memory O O
impairment O O
induced O O
by O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
mice O O
. O O

1 O B_NUMBER[MEASURE]
. O O

Nociceptin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
also O O
known O O
as O O
orphanin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
is O O
an O O
endogenous O O
ligand O O
for O O
the O O
orphan O O
opioid O O
receptor O O
- O O
like O O
receptor O O
1 O O
( O O
ORL1 O O
) O O
and O O
involves O O
in O O
various O O
functions O O
in O O
the O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
. O O

On O O
the O O
other O O
hand O O
, O O
nocistatin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
recently O O
isolated O O
from O O
the O O
same O O
precursor O O
as O O
nociceptin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
blocks O O
nociceptin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
allodynia O O
and O O
hyperalgesia O O
. O O

2 O B_NUMBER[MEASURE]
. O O

Although O O
ORL1 O B_GENE
receptors O I_GENE
which O O
display O O
a O O
high O B_MEASURE/B_LOCATION
degree O I_MEASURE/I_LOCATION
of O O
sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homology O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
classical O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
opioid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
regarding O O
their O O
role O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
learning O B_DISEASE
and O O
memory O B_DISEASE
. O O

3 O B_NUMBER[MEASURE]
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
whether O O
nociceptin B B_GENE/B_PERSON
/ O O
orphanin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FQ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nocistatin B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
modulate O O
impairment O O
of O O
learning O O
and O O
memory O O
induced O O
by O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
muscarinic O O
cholinergic O O
receptor O O
antagonist O O
, O O
using O O
spontaneous O O
alternation O O
of O O
Y O O
- O O
maze O O
and O O
step O O
- O O
down O O
type O O
passive O O
avoidance O O
tasks O O
in O O
mice O O
. O O

4 O B_NUMBER[MEASURE]
. O O

While O O
nocistatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
0 O O
. O O
5 O O
- O O
5 O O
. O O
0 O O
nmol O O
mouse O O
- O O
1 O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
administered O O
30 O O
min O O
before O O
spontaneous O O
alternation O O
performance O O
or O O
the O O
training O O
session O O
of O O
the O O
passive O O
avoidance O O
task O O
, O O
had O O
no O O
effect O O
on O O
spontaneous O O
alternation O O
or O O
passive O O
avoidance O O
behaviours O O
, O O
a O O
lower O O
per O O
cent O O
alternation O O
and O O
shorter O O
median O O
step O O
- O O
down O O
latency O O
in O O
the O O
retention O O
test O O
were O O
obtained O O
in O O
nociceptin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
. O O
5 O O
and O O
/ O O
or O O
5 O O
. O O
0 O O
nmol O O
mouse O O
- O O
1 O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
- O O
treated O O
normal O O
mice O O
. O O

5 O B_NUMBER[MEASURE]
. O O

Administration O O
of O O
nocistatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
1 O O
. O O
5 O O
and O O
/ O O
or O O
5 O O
. O O
0 O O
nmol O O
mouse O O
- O O
1 O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
30 O O
min O O
before O O
spontaneous O O
alternation O O
performance O O
or O O
the O O
training O O
session O O
of O O
the O O
passive O O
avoidance O O
task O O
, O O
attenuated O O
the O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
impairment O O
of O O
spontaneous O O
alternation O O
and O O
passive O O
avoidance O O
behaviours O O
. O O

6 O B_NUMBER[MEASURE]
. O O

These O O
results O O
indicated O O
that O O
nocistatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
new O O
biologically O O
active O O
peptide O O
, O O
ameliorates O O
impairments O O
of O O
spontaneous O O
alternation O O
and O O
passive O O
avoidance O O
induced O O
by O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
suggested O O
that O O
these O O
peptides O O
play O O
opposite O O
roles O O
in O O
learning O O
and O O
memory O O
. O O

Meloxicam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
liver O O
toxicity O O
. O O

We O O
report O O
the O O
case O O
of O O
a O O
female O O
patient O O
with O O
rheumatoid O O
arthritis O O
who O O
developed O O
acute O O
cytolytic O O
hepatitis O O
due O O
to O O
meloxicam B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recently O O
introduced O O
in O O
Belgium O O
, O O
meloxicam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O O
nonsteroidal O O
antiinflammatory O O
drug O O
with O O
selective O O
action O O
on O O
the O O
inducible O O
form O O
of O O
cyclooxygenase O O
2 O O
. O O

The O O
acute O O
cytolytic O O
hepatitis O O
occurred O O
rapidly O O
after O O
meloxicam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
and O O
was O O
associated O O
with O O
the O O
development O O
of O O
antinuclear O O
antibodies O O
suggesting O O
a O O
hypersensitivity O O
mechanism O O
. O O

This O O
first O O
case O O
of O O
meloxicam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
liver O O
toxicity O O
demonstrates O O
the O O
potential O O
of O O
this O O
drug O O
to O O
induce O O
hepatic O O
damage O O
. O O

Induction O O
of O O
apoptosis O O
by O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
metabolites O O
in O O
HL60 O O
and O O
CD34 O O
+ O O
/ O O
CD19 O O
- O O
human O O
bone O O
marrow O O
progenitor O O
cells O O
: O O
potential O O
relevance O O
to O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
aplastic O O
anemia O O
. O O

The O O
antipsychotic O O
agent O O
, O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O O
( B B_TIME[MEASURE]/B_LOCATION
S I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
3 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
bromo I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
N I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
[ I I_TIME[MEASURE]/I_LOCATION
( I I_TIME[MEASURE]/I_LOCATION
1 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
ethyl I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
2 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
pyrrolidinyl I I_TIME[MEASURE]/I_LOCATION
) I I_TIME[MEASURE]/I_LOCATION
methyl I I_TIME[MEASURE]/I_LOCATION
] I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
2 I I_TIME[MEASURE]/I_LOCATION
, I I_TIME[MEASURE]/I_LOCATION
6 I I_TIME[MEASURE]/I_LOCATION
- I I_TIME[MEASURE]/I_LOCATION
dimethoxybenz I I_TIME[MEASURE]/I_LOCATION
amide I I_TIME[MEASURE]/I_LOCATION
] O O
has O O
been O O
associated O O
with O O
acquired O O
aplastic O O
anemia O O
. O O

We O O
have O O
examined O O
the O O
ability O O
of O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
three O O
pyrrolidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ring O O
metabolites O O
and O O
five O O
aromatic O O
ring O O
metabolites O O
of O O
the O O
parent O O
compound O O
to O O
induce O O
apoptosis O O
in O O
HL60 O O
cells O O
and O O
human O O
bone O O
marrow O O
progenitor O O
( O O
HBMP O O
) O O
cells O O
. O O

Cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
treated O O
for O O
0 O B_MEASURE
- O O
24 O B_MEASURE
h O I_MEASURE
with O O
each O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
- O O
200 O B_MEASURE
microM O I_MEASURE
) O O
. O O

Apoptosis O O
was O O
assessed O O
by O O
fluorescence O O
microscopy O O
in O O
Hoechst B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33342 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
propidium B B_TIME[MEASURE]/B_COLOR
iodide I I_TIME[MEASURE]/I_COLOR
stained O O
cell O O
samples O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
confirmed O O
by O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
internucleosomal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragmentation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
HL60 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
terminal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
deoxynucleotidyl O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
transferase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
HBMP O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
catechol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydroquinone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metabolites O O
, O O
NCQ436 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
NCQ344 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
induced O O
apoptosis O O
in O O
HL60 O O
and O O
HBMP O O
cells O O
in O O
a O O
time O O
- O O
and O O
concentration O O
dependent O O
manner O O
, O O
while O O
the O O
phenols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
NCR181 O O
, O O
FLA873 O O
, O O
and O O
FLA797 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
the O O
derivatives O O
formed O O
by O O
oxidation O O
of O O
the O O
pyrrolidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ring O O
, O O
FLA838 O O
, O O
NCM001 O O
, O O
and O O
NCL118 O O
, O O
had O O
no O O
effect O O
. O O

No O O
necrosis O O
was O O
observed O O
in O O
cells O O
treated O O
with O O
NCQ436 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O O
NCQ344 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
biphasic O O
effect O O
in O O
both O O
cell O O
types O O
, O O
inducing O O
apoptosis O O
at O O
lower O O
concentrations O O
and O O
necrosis O O
at O O
higher O O
concentrations O O
. O O

These O O
data O O
show O O
that O O
the O O
catechol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydroquinone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metabolites O O
of O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
direct O O
toxic O O
effects O O
in O O
HL60 O O
and O O
HBMP O O
cells O O
, O O
leading O O
to O O
apoptosis O O
, O O
while O O
the O O
phenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O O
were O O
inactive O O
. O O

Similarly O O
, O O
benzene B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
derived O O
catechol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydroquinone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
but O O
not O O
phenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
induce O O
apoptosis O O
in O O
HBMP O O
cells O O
[ O O
Moran O O
et O O
al O O
. O O
, O O
Mol O O
. O O
Pharmacol O O
. O O
, O O
50 O O
( O O
1996 O O
) O O
610 O O
- O O
615 O O
] O O
. O O

We O O
propose O O
that O O
remoxipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
benzene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
induce O O
aplastic O O
anemia O O
via O O
production O O
of O O
similar O O
reactive O O
metabolites O O
and O O
that O O
the O O
ability O O
of O O
NCQ436 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NCQ344 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
induce O O
apoptosis O O
in O O
HBMP O O
cells O O
may O O
contribute O O
to O O
the O O
mechanism O O
underlying O O
acquired O O
aplastic O O
anemia O O
that O O
has O O
been O O
associated O O
with O O
remoxipride B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Synthesis O O
and O O
preliminary O O
pharmacological O O
investigations O O
of O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dihydro I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acenaphthylenyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
piperazine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivatives O O
as O O
potential O O
atypical O O
antipsychotic O O
agents O O
in O O
mice O O
. O O

In O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
new O B_DISEASE
atypical O I_DISEASE
antipsychotic O I_DISEASE
agents O I_DISEASE
, O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
that O O
the O O
dopaminergic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
be O O
modulated O O
through O O
manipulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
synthesis O O
and O O
preliminary O O
pharmacological O O
evaluation O O
of O O
a O O
series O O
of O O
potential O O
atypical O O
antipsychotic O O
agents O O
based O O
on O O
the O O
structure O O
of O O
1 B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
( I I_LOCATION/I_ORGANIZATION
1 I I_LOCATION/I_ORGANIZATION
, I I_LOCATION/I_ORGANIZATION
2 I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
dihydro I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
2 I I_LOCATION/I_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
acenaphthylenyl I I_LOCATION/I_ORGANIZATION
) I I_LOCATION/I_ORGANIZATION
piperazine I I_LOCATION/I_ORGANIZATION
( O O
7 O O
) O O
is O O
described O O
. O O

Compound O O
7e O O
, O O
5 B B_MEASURE/B_LOCATION
- I I_MEASURE/I_LOCATION
{ I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
[ I I_MEASURE/I_LOCATION
4 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
1 I I_MEASURE/I_LOCATION
, I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
dihydro I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
acenaphthylenyl I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
piperazinyl I I_MEASURE/I_LOCATION
] I I_MEASURE/I_LOCATION
ethyl I I_MEASURE/I_LOCATION
} I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
, I I_MEASURE/I_LOCATION
3 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
dihy I I_MEASURE/I_LOCATION
dro I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
1H I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
indol I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
2 I I_MEASURE/I_LOCATION
- I I_MEASURE/I_LOCATION
one I I_MEASURE/I_LOCATION
, O O
from O O
this O O
series O O
showed O O
significant O O
affinities O O
at O O
the O O
5 O O
- O O
HT1A O O
and O O
5 O O
- O O
HT2A O O
receptors O O
and O O
moderate O O
affinity O O
at O O
the O O
D2 O O
receptor O O
. O O

7e O O
exhibits O O
a O O
high O O
reversal O O
of O O
catalepsy O O
induced O O
by O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicating O O
its O O
atypical O O
antipsychotic O O
nature O O
. O O

Sub O O
- O O
chronic O O
inhibition O O
of O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O O
modifies O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
catalepsy O O
and O O
the O O
number O O
of O O
NADPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
diaphorase O O
neurons O O
in O O
mice O O
. O O

RATIONALE O O
: O O
NG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nitro I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
arginine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O O
, O O
an O O
inhibitor O O
of O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O O
( O O
NOS O O
) O O
, O O
induces O O
catalepsy O O
in O O
mice O O
. O O

This O O
effect O O
undergoes O O
rapid O O
tolerance O O
, O O
showing O O
a O O
significant O O
decrease O O
after O O
2 O O
days O O
of O O
sub O O
- O O
chronic O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O O
. O O

Nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
has O O
been O O
shown O O
to O O
influence O O
dopaminergic O O
neurotransmission O O
in O O
the O O
striatum O O
. O O

Neuroleptic O O
drugs O O
such O O
as O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
block O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
, O O
also O O
cause O O
catalepsy O O
in O O
rodents O O
. O O

OBJECTIVES O O
: O O
To O O
investigate O O
the O O
effects O O
of O O
subchronic O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
catalepsy O O
and O O
the O O
number O O
of O O
NOS O O
neurons O O
in O O
areas O O
related O O
to O O
motor O O
control O O
. O O

METHODS O O
: O O
Male O O
albino O O
Swiss O O
mice O O
were O O
treated O O
sub O O
- O O
chronically O O
( O O
twice O O
a O O
day O O
for O O
4 O O
days O O
) O O
with O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
40 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
or O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
. O O

Catalepsy O B_DISEASE_ADJECTIVE[DISEASE]
was O O
evaluated O O
at O O
the O O
beginning O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SEQUENCE[MEASURE]
and O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
treatments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reduced O O
nicotinamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dinucleotide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
diaphorase O O
( O O
NADPH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d O O
) O O
histochemistry O O
was O O
also O O
employed O O
to O O
visualize O O
NOS O O
as O O
an O O
index O O
of O O
enzyme O O
expression O O
in O O
mice O O
brain O O
regions O O
related O O
to O O
motor O O
control O O
. O O

RESULTS O O
: O O
L B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sub O O
- O O
chronic O O
administration O O
produced O O
tolerance O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
of O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
catalepsy O O
. O O

It O O
also O O
induced O O
an O O
increase O O
in O O
the O O
number O O
of O O
NADPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
d O O
- O O
positive O O
cells O O
in O O
the O O
dorsal O O
part O O
of O O
the O O
caudate O O
and O O
accumbens O O
nuclei O O
compared O O
with O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
pedunculopontine O O
tegmental O O
nucleus O O
compared O O
with O O
saline O O
. O O

In O O
contrast O O
, O O
there O O
was O O
a O O
decrease O O
in O O
NADPH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d O O
neuron O O
number O O
in O O
the O O
substantia O O
nigra O O
, O O
pars O O
compacta O O
in O O
both O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
and O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
animals O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
give O O
further O O
support O O
to O O
the O O
hypothesis O O
that O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
a O O
role O O
in O O
motor O O
behavior O O
control O O
and O O
suggest O O
that O O
it O O
may O O
take O O
part O O
in O O
the O O
synaptic O O
changes O O
produced O O
by O O
antipsychotic O O
treatment O O
. O O

Prolonged O O
left O O
ventricular O O
dysfunction O O
occurs O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
after O O
both O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
exercise O O
induced O O
myocardial O O
ischaemia O O
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
determine O O
whether O O
pharmacological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
prolonged O O
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
left O O
ventricular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON
with O O
coronary O B_DISEASE
artery O I_DISEASE
disease O I_DISEASE
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
that O O
seen O O
after O O
exercise O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

DESIGN O O
: O O
A O O
randomised O O
crossover O O
study O O
of O O
recovery O O
time O O
of O O
systolic O O
and O O
diastolic O O
left O O
ventricular O O
function O O
after O O
exercise O O
and O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
ischaemia O O
. O O

SUBJECTS O B_PERSON/B_MEASURE
: O O
10 O B_PERSON
patients O I_PERSON
with O O
stable O B_DISEASE_ADJECTIVE[DISEASE]
angina O I_DISEASE_ADJECTIVE[DISEASE]
, O O
angiographically O O
proven O O
coronary O B_DISEASE/B_LOCATION
artery O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
, O O
and O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

INTERVENTIONS O O
: O O
Treadmill O O
exercise O O
and O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O O
were O O
performed O O
on O O
different O O
days O O
. O O

Quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
systolic O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
diastolic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
transthoracic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
echocardiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
at O O
regular O B_TIME[MEASURE]/B_LOCATION
intervals O I_TIME[MEASURE]/I_LOCATION
after O O
each O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Both O O
forms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
stress O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O O
to O O
prolonged O O
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
systolic O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
diastolic O B_DISEASE
dysfunction O I_DISEASE
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
the O O
maximum O B_MEASURE/B_DISEASE
double O B_MEASURE/I_DISEASE
product O B_MEASURE/I_DISEASE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
53 O B_MEASURE
) O O
or O O
ST O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
depression O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
63 O B_MEASURE
) O O
with O O
either O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
stress O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

After O O
exercise O O
, O O
ejection O O
fraction O O
was O O
reduced O O
at O O
15 O O
and O O
30 O O
minutes O O
compared O O
with O O
baseline O O
( O O
mean O O
( O O
SEM O O
) O O
, O O
- O O
5 O O
. O O
6 O O
( O O
1 O O
. O O
5 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
05 O O
; O O
and O O
- O O
6 O O
. O O
1 O O
( O O
2 O O
. O O
2 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
at O O
30 O O
and O O
45 O O
minutes O O
after O O
dobutamine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
- O O
10 O O
. O O
8 O O
( O O
1 O O
. O O
8 O O
) O O
% O O
and O O
- O O
5 O O
. O O
5 O O
( O O
1 O O
. O O
8 O O
) O O
% O O
, O O
both O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Regional O O
analysis O O
showed O O
a O O
reduction O O
in O O
the O O
worst O O
affected O O
segment O O
15 O O
and O O
30 O O
minutes O O
after O O
exercise O O
( O O
- O O
27 O O
. O O
9 O O
( O O
7 O O
. O O
2 O O
) O O
% O O
and O O
- O O
28 O O
. O O
6 O O
( O O
5 O O
. O O
7 O O
) O O
% O O
, O O
both O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
at O O
30 O O
minutes O O
after O O
dobutamine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
- O O
32 O O
( O O
5 O O
. O O
3 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

The O O
isovolumic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relaxation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
period O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
prolonged O O
45 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
each O O
form O B_TIME[MEASURE]/B_LOCATION
of O O
stress O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
In O O
patients O O
with O O
coronary O O
artery O O
disease O O
, O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
ischaemia O O
results O O
in O O
prolonged O O
reversible O O
left O O
ventricular O O
dysfunction O O
, O O
presumed O O
to O O
be O O
myocardial O O
stunning O O
, O O
similar O O
to O O
that O O
seen O O
after O O
exercise O O
. O O

Dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
ischaemia O O
could O O
therefore O O
be O O
used O O
to O O
study O O
the O O
pathophysiology O O
of O O
this O O
phenomenon O O
further O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

Anorexigens O B_DISEASE/B_BIO
and O O
pulmonary O B_DISEASE/B_PERSON
hypertension O I_DISEASE/I_PERSON
in O O
the O O
United O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
States O B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
surveillance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
North O B_DISEASE
American O I_DISEASE
pulmonary O I_DISEASE
hypertension O I_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
The O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
appetite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Europe O B_LOCATION/B_PERSON
has O O
been O O
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
primary O B_DISEASE
pulmonary O I_DISEASE
hypertension O I_DISEASE
( O O
PPH O B_DISEASE/B_GENE
) O O
. O O

Recently O O
, O O
fenfluramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
appetite O O
suppressants O O
became O O
widely O O
used O O
in O O
the O O
United O O
States O O
but O O
were O O
withdrawn O O
in O O
September O O
1997 O O
because O O
of O O
concerns O O
over O O
adverse O O
effects O O
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
We O O
conducted O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
patients O B_PERSON
diagnosed O O
with O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
at O O
12 O B_LOCATION
large O I_LOCATION
referral O I_LOCATION
centers O I_LOCATION
in O O
North O B_LOCATION
America O I_LOCATION
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
collected O O
on O O
patients O B_PERSON/B_ENT
seen O O
from O O
September O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
1996 O B_MEASURE
, O O
to O O
December O B_TIME[MEASURE]
31 O I_TIME[MEASURE]
, O O
1997 O B_MEASURE
, O O
included O O
the O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]
hypertension O I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O B_PERSON/B_BIO
with O O
no O O
identifiable O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pulmonary O B_DISEASE/B_GENE
hypertension O I_DISEASE/I_GENE
were O O
classed O O
as O O
PPH O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

A O O
history O O
of O O
drug O O
exposure O O
also O O
was O O
taken O O
with O O
special O O
attention O O
on O O
the O O
use O O
of O O
antidepressants O O
, O O
anorexigens O O
, O O
and O O
amphetamines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_MEASURE
: O O
Five O B_NUMBER[MEASURE]
hundred O I_NUMBER[MEASURE]
seventy O I_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
studied O O
, O O
205 O B_MEASURE
with O O
PPH O B_DISEASE/B_GENE
and O O
374 O B_NUMBER[MEASURE]
with O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
from O O
other O B_DISEASE/B_LOCATION
causes O I_DISEASE/I_LOCATION
( O O
secondary O B_DISEASE/B_LOCATION
pulmonary O I_DISEASE/I_LOCATION
hypertension O I_DISEASE/I_LOCATION
[ O O
SPH O B_MEASURE/B_DISEASE
] O I_MEASURE/I_DISEASE
) O O
. O O

The O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
both O O
groups O B_ORGANIZATION/B_LOCATION
. O O

However O O
, O O
of O O
the O O
medications O O
surveyed O O
, O O
only O O
the O O
fenfluramines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
had O O
a O O
significant O O
preferential O O
association O O
with O O
PPH O O
as O O
compared O O
with O O
SPH O O
( O O
adjusted O O
odds O O
ratio O O
for O O
use O O
> O O
6 O O
months O O
, O O
7 O O
. O O
5 O O
; O O
95 O O
% O O
confidence O O
interval O O
, O O
1 O O
. O O
7 O O
to O O
32 O O
. O O
4 O O
) O O
. O O

The O O
association O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
stronger O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
longer O B_TIME[MEASURE]
duration O I_TIME[MEASURE]
of O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
when O O
compared O O
to O O
shorter O B_TIME[MEASURE]
duration O I_TIME[MEASURE]
of O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
was O O
more O O
pronounced O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
recent O B_PERSON/B_LOCATION
users O I_PERSON/I_LOCATION
than O O
in O O
remote O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
. O O

An O O
unexpectedly O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
11 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
number O B_MEASURE/B_PERSON
of O O
patients O B_PERSON
with O O
SPH O B_DISEASE/B_GENE
had O O
used O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

CONCLUSION O O
: O O
The O O
magnitude O O
of O O
the O O
association O O
with O O
PPH O O
, O O
the O O
increase O O
of O O
association O O
with O O
increasing O O
duration O O
of O O
use O O
, O O
and O O
the O O
specificity O O
for O O
fenfluramines B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
consistent O O
with O O
previous O O
studies O O
indicating O O
that O O
fenfluramines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O O
causally O O
related O O
to O O
PPH O O
. O O

The O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
anorexigen O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_LOCATION
with O O
SPH O B_DISEASE/B_GENE
also O O
raises O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
these O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precipitate O O
pulmonary O B_DISEASE
hypertension O I_DISEASE
in O O
patients O B_PERSON/B_ORGANIZATION
with O O
underlying O B_DISEASE/B_GENE
conditions O I_DISEASE
associated O O
with O O
SPH O B_DISEASE/B_GENE
. O O

Clinical O O
aspects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
and O O
thrombosis O O
and O O
other O O
side O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

Heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
first O O
used O O
to O O
prevent O O
the O O
clotting O O
of O O
blood O O
in O O
vitro O O
, O O
has O O
been O O
clinically O O
used O O
to O O
treat O O
thrombosis O O
for O O
more O O
than O O
50 O O
years O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O O
the O O
anticoagulant O O
of O O
choice O O
to O O
treat O O
acute O O
thrombotic O O
episodes O O
. O O

The O O
clinical O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Bleeding O O
is O O
the O O
primary O O
untoward O O
effect O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Major O O
bleeding O O
is O O
of O O
primary O O
concern O O
in O O
patients O O
receiving O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

However O O
, O O
additional O O
important O O
untoward O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
include O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
, O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
osteoporosis O O
, O O
eosinophilia O O
, O O
skin O O
reactions O O
, O O
allergic O O
reactions O O
other O O
than O O
thrombocytopenia O O
, O O
alopecia O O
, O O
transaminasemia O O
, O O
hyperkalemia O O
, O O
hypoaldosteronism O O
, O O
and O O
priapism O O
. O O

These O O
side O O
effects O O
are O O
relatively O O
rare O O
in O O
a O O
given O O
individual O O
, O O
but O O
given O O
the O O
extremely O O
widespread O O
use O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
some O O
are O O
quite O O
common O O
, O O
particularly O O
HITT O O
and O O
osteoporosis O O
. O O

Although O O
reasonable O O
incidences O O
of O O
many O O
of O O
these O O
side O O
effects O O
can O O
be O O
" O O
softly O O
" O O
deduced O O
from O O
current O O
reports O O
dealing O O
with O O
unfractionated O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
at O O
present O O
the O O
incidences O O
of O O
these O O
side O O
effects O O
with O O
newer O O
low O O
molecular O O
weight O O
heparins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
appear O O
to O O
be O O
much O O
less O O
common O O
. O O

However O O
, O O
only O O
longer O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
more O O
clearly O O
define O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
each O O
side O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
low O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
case O O
of O O
bilateral O O
optic O O
neuropathy O O
in O O
a O O
patient O O
on O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FK506 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
therapy O O
after O O
liver O O
transplantation O O
. O O

PURPOSE O O
: O O
To O O
report O O
a O O
case O O
of O O
bilateral O O
optic O O
neuropathy O O
in O O
a O O
patient O O
receiving O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FK B B_PERSON/B_LOCATION
506 I B_PERSON/I_LOCATION
, O O
Prograf O O
; O O
Fujisawa O O
USA O O
, O O
Inc O O
, O O
Deerfield O O
, O O
Illinois O O
) O O
for O O
immunosuppression O O
after O O
orthotropic O O
liver O O
transplantation O O
. O O

METHOD O B_MEASURE/B_LOCATION
: O O
Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
a O O
58 O O
- O O
year O O
- O O
old O O
man O O
receiving O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
orthotropic O O
liver O O
transplantation O O
, O O
serial O O
neuro O O
- O O
ophthalmologic O O
examinations O O
and O O
laboratory O O
studies O O
were O O
performed O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
The O O
patient O B_PERSON
had O O
episodic O B_DISEASE_ADJECTIVE[DISEASE]
deterioration O I_DISEASE_ADJECTIVE[DISEASE]
of O O
vision O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
both O O
eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
with O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
resembling O O
ischemic O B_DISEASE
optic O I_DISEASE
neuropathies O I_DISEASE
. O O

Deterioration O O
of O O
vision O O
occurred O O
despite O O
discontinuation O O
of O O
the O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
Tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
other O O
immunosuppressive O O
agents O O
may O O
be O O
associated O O
with O O
optic O O
nerve O O
toxicity O O
. O O

Hypercalcemia O B_DISEASE
, O O
arrhythmia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
mood O B_DISEASE
stabilizers O I_DISEASE
. O O

Recent O O
findings O O
in O O
a O O
bipolar O O
patient O O
receiving O O
maintenance O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
who O O
developed O O
hypercalcemia O O
and O O
severe O O
bradyarrhythmia O O
prompted O O
the O O
authors O O
to O O
conduct O O
a O O
retrospective O O
study O O
of O O
bipolar O O
patients O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
hypercalcemia O O
. O O

A O O
printout O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
all O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypercalcemia O B_DISEASE
that O O
presented O O
during O O
a O O
1 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
period O I_TIME[MEASURE]
was O O
generated O O
. O O

After O O
eliminating O O
spurious O O
hypercalcemias O O
or O O
those O O
associated O O
with O O
intravenous O O
fluids O O
, O O
the O O
authors O O
identified O O
18 O O
non O O
- O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O O
with O O
hypercalcemias O O
related O O
to O O
malignancies O O
and O O
other O O
medical O O
conditions O O
( O O
group O O
A O O
) O O
and O O
12 O O
patients O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
hypercalcemia O O
( O O
group O O
B O O
) O O
. O O

Patients O B_PERSON
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
not O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
those O O
in O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
as O O
the O O
latter O B_NUMBER[MEASURE]/B_PERSON
were O O
medically O O
compromised O O
and O O
were O O
receiving O O
multiple O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
two O O
control O O
groups O O
were O O
generated O O
: O O
group O O
C1 O O
, O O
which O O
included O O
age O O
- O O
and O O
sex O O
- O O
comparable O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
bipolar O O
normocalcemic O O
patients O O
, O O
and O O
group O O
C2 O O
, O O
which O O
included O O
bipolar O O
normocalcemic O O
patients O O
treated O O
with O O
anticonvulsant O O
mood O O
stabilizers O O
. O O

The O O
electrocardiographic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
ECG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
patients O B_PERSON/B_DISEASE
in O O
group O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
with O O
those O O
of O O
patients O B_PERSON
in O O
groups O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
C2 O B_PROTEIN[GENE]
. O O

It O O
was O O
found O O
that O O
these O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
differ O O
in O O
their O O
overall O B_MEASURE
frequency O I_MEASURE
of O O
ECG O B_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
there O O
were O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
differences O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
frequency O B_MEASURE
of O O
conduction O B_DISEASE/B_LOCATION
defects O I_DISEASE/I_LOCATION
. O O

Patients O O
with O O
hypercalcemia O O
resulting O O
from O O
medical O O
diseases O O
and O O
bipolar O O
patients O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
hypercalcemia O O
had O O
significantly O O
higher O O
frequencies O O
of O O
conduction O O
defects O O
. O O

Patients O B_PERSON
in O O
group O B_NUMBER[MEASURE]/B_LOCATION
A O I_NUMBER[MEASURE]/I_LOCATION
had O O
significant O B_DISEASE/B_MEASURE
mortality O I_DISEASE/I_MEASURE
at O O
2 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
follow O I_TIME[MEASURE]/I_LOCATION
- O O
up O B_TIME[MEASURE]/B_LOCATION
( O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
in O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
zero O B_PERSON/B_DISEASE
mortality O I_PERSON/I_DISEASE
in O O
the O O
other O B_MEASURE/B_LOCATION
three O B_MEASURE/I_LOCATION
groups O B_MEASURE/I_LOCATION
. O O

The O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implications O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
. O O

Attenuation O O
of O O
nephrotoxicity O O
by O O
a O O
novel O O
lipid O O
nanosphere O O
( O O
NS O O
- O O
718 O O
) O O
incorporating O O
amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

NS O O
- O O
718 O O
, O O
a O O
lipid O O
nanosphere O O
incorporating O O
amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
effective O O
against O O
pathogenic O O
fungi O O
and O O
has O O
low O O
toxicity O O
. O O

We O O
compared O O
the O O
toxicity O O
of O O
NS O O
- O O
718 O O
with O O
that O O
of O O
Fungizone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
amphotericin B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deoxycholate I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
AmB I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
in O O
vitro O O
using O O
renal O O
cell O O
cultures O O
and O O
in O O
vivo O O
by O O
biochemical O O
analysis O O
, O O
histopathological O O
study O O
of O O
the O O
kidney O O
and O O
pharmacokinetic O O
study O O
of O O
amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
following O O
intravenous O O
infusion O O
of O O
the O O
formulation O O
in O O
rats O O
. O O

Incubation O O
with O O
NS O O
- O O
718 O O
resulted O O
in O O
significantly O O
less O O
damage O O
of O O
cultured O O
human O O
renal O O
proximal O O
tubular O O
epithelial O O
cells O O
compared O O
with O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Serum O O
blood O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O O
increased O O
significantly O O
in O O
rats O O
given O O
an O O
iv O O
infusion O O
of O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AmB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O O
mg O O
/ O O
kg O O
but O O
not O O
in O O
those O O
given O O
the O O
same O O
dose O O
of O O
NS O O
- O O
718 O O
. O O

Histopathological O O
examination O O
of O O
the O O
kidney O O
showed O O
tubular O O
necrosis O O
in O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
treated O O
rats O O
but O O
no O O
change O O
in O O
NS O O
- O O
718 O O
- O O
treated O O
rats O O
. O O

Amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
concentrations O O
in O O
the O O
kidney O O
in O O
NS O O
- O O
718 O O
- O O
treated O O
rats O O
were O O
higher O O
than O O
those O O
in O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
treated O O
rats O O
. O O

Our O O
in O O
vitro O O
and O O
in O O
vivo O O
results O O
suggest O O
that O O
incorporation O O
of O O
amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O O
lipid O O
nanospheres O O
of O O
NS O O
- O O
718 O O
attenuates O O
the O O
nephrotoxicity O O
of O O
amphotericin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patterns O O
of O O
sulfadiazine B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
acute O O
nephrotoxicity O O
. O O

Sulfadiazine B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acute O O
nephrotoxicity O O
is O O
reviving O O
specially O O
because O O
of O O
its O O
use O O
in O O
toxoplasmosis O O
in O O
HIV O O
- O O
positive O O
patients O O
. O O

We O O
report O O
4 O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
, O O
one O B_NUMBER[MEASURE]
of O O
them O O
in O O
a O O
previously O O
healthy O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
person O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Under O O
treatment O O
with O O
sulfadiazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
they O O
developed O O
oliguria O O
, O O
abdominal O O
pain O O
, O O
renal O O
failure O O
and O O
showed O O
multiple O O
radiolucent O O
renal O O
calculi O O
in O O
echography O O
. O O

All O O
patients O B_PERSON
recovered O O
their O O
previous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
renal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hydration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
alcalinization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
nephrostomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
tube O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
had O O
to O O
be O O
placed O O
in O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
patients O B_PERSON/B_LOCATION
for O O
ureteral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
lithiasis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
single O B_TIME[MEASURE]/B_LOCATION
functional O B_TIME[MEASURE]/I_LOCATION
kidney O B_TIME[MEASURE]/I_LOCATION
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
them O O
needed O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
a O O
renal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
a O O
typical O B_DISEASE
benign O I_DISEASE
course O I_DISEASE
. O O

Treatment O O
with O O
sulfadiazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
requires O O
exquisite O O
control O O
of O O
renal O O
function O O
, O O
an O O
increase O O
in O O
water O O
ingestion O O
and O O
possibly O O
the O O
alcalinization O O
of O O
the O O
urine O O
. O O

We O O
communicate O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
previously O O
healthy O B_PERSON/B_TIME[MEASURE]
person O B_PERSON/I_TIME[MEASURE]
, O O
a O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O O
found O O
in O O
the O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Probably O O
many O B_PERSON
more O I_PERSON
cases O I_PERSON
are O O
not O O
detected O O
. O O

We O O
think O O
that O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
would O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Downbeat O O
nystagmus O O
associated O O
with O O
intravenous O O
patient O O
- O O
controlled O O
administration O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IMPLICATIONS O O
: O O
This O O
case O O
documents O O
a O O
patient O O
who O O
developed O O
dizziness O O
with O O
downbeating O O
nystagmus O O
while O O
receiving O O
a O O
relatively O O
large O O
dose O O
of O O
IV O O
patient O O
- O O
controlled O O
analgesia O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
there O O
have O O
been O O
case O O
reports O O
of O O
epidural O O
morphine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
these O O
symptoms O O
and O O
signs O O
, O O
this O O
has O O
not O O
been O O
previously O O
documented O O
with O O
IV O O
or O O
patient O O
- O O
controlled O O
analgesia O O
morphine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O O

Hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
animals O O
with O O
a O O
healed O O
myocardial O O
infarction O O
. O O

The O O
hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
noniodinated O O
compound O O
structurally O O
related O O
to O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
were O O
compared O O
with O O
those O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
prolonged O O
oral O O
administration O O
, O O
both O O
at O O
rest O O
and O O
during O O
sympathetic O O
stimulation O O
in O O
conscious O O
dogs O O
with O O
a O O
healed O O
myocardial O O
infarction O O
. O O

All O O
dogs O O
( O O
n O O
= O O
6 O O
) O O
randomly O O
received O O
orally O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
and O O
placebo O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
with O O
a O O
3 O O
- O O
week O O
washout O O
between O O
consecutive O O
treatments O O
. O O

Heart O O
rate O O
( O O
HR O O
) O O
, O O
mean O O
arterial O O
pressure O O
( O O
MBP O O
) O O
, O O
positive O O
rate O O
of O O
increase O O
of O O
left O O
ventricular O O
pressure O O
( O O
+ O O
LVdP O O
/ O O
dt O O
) O O
, O O
echocardiographically O O
assessed O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
, O O
and O O
fractional O O
shortening O O
( O O
FS O O
) O O
, O O
as O O
well O O
as O O
chronotropic O O
response O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
exercise O O
- O O
induced O O
sympathetic O O
stimulation O O
were O O
evaluated O O
under O O
baseline O O
and O O
posttreatment O O
conditions O O
. O O

Resting O O
values O O
of O O
LVEF O O
, O O
FS O O
, O O
+ O O
LVdP O O
/ O O
dt O O
, O O
and O O
MBP O O
remained O O
unchanged O O
whatever O O
the O O
drug O O
and O O
the O O
dosing O O
regimen O O
, O O
whereas O O
resting O O
HR O O
was O O
significantly O O
and O O
dose O O
- O O
dependently O O
lowered O O
after O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
to O O
a O O
lesser O O
extent O O
after O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
reduced O O
the O O
exercise O O
- O O
induced O O
tachycardia O O
and O O
, O O
at O O
the O O
highest O O
dose O O
, O O
decreased O O
the O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
tachycardia O O
. O O

Thus O O
, O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O O
a O O
similar O O
level O O
of O O
antiadrenergic O O
effect O O
and O O
did O O
not O O
impair O O
the O O
resting O O
left O O
ventricular O O
function O O
. O O

Consequently O O
, O O
dronedarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
particularly O O
suitable O O
for O O
the O O
treatment O O
and O O
prevention O O
of O O
various O O
clinical O O
arrhythmias O O
, O O
without O O
compromising O O
the O O
left O O
ventricular O O
function O O
. O O

Phase O O
2 O O
trial O O
of O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
in O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
refractory O O
ovarian O O
and O O
fallopian O O
tube O O
cancers O O
and O O
primary O O
carcinoma O O
of O O
the O O
peritoneum O O
. O O

BACKGROUND O O
: O O
Several O O
studies O O
have O O
demonstrated O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Doxil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
to O O
be O O
an O O
active O O
antineoplastic O O
agent O O
in O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
resistant O O
ovarian O O
cancer O O
, O O
with O O
dose O O
limiting O O
toxicity O O
of O O
the O O
standard O O
dosing O O
regimen O O
( O O
50 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
) O O
being O O
severe O O
erythrodysesthesia O O
( O O
" O O
hand O O
- O O
foot O O
syndrome O O
" O O
) O O
and O O
stomatitis O O
. O O

We O O
wished O O
to O O
develop O O
a O O
more O O
tolerable O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
regimen O O
and O O
document O O
its O O
level O O
of O O
activity O O
in O O
a O O
well O O
- O O
defined O O
patient O O
population O O
with O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
refractory O O
disease O O
. O O

METHODS O O
AND O O
MATERIALS O O
: O O
Patients O O
with O O
ovarian O O
or O O
fallopian O O
tube O O
cancers O O
or O O
primary O O
peritoneal O O
carcinoma O O
with O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
refractory O O
disease O O
( O O
stable O O
or O O
progressive O O
disease O O
following O O
treatment O O
with O O
these O O
agents O O
or O O
previous O O
objective O O
response O O
< O O
3 O O
months O O
in O O
duration O O
) O O
were O O
treated O O
with O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
total O B_MEASURE
of O O
49 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
( O O
median O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
: O O
60 O B_MEASURE
; O O
range O B_MEASURE/B_LOCATION
41 O I_MEASURE/I_LOCATION
- O O
81 O B_MEASURE
) O O
entered O O
this O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
median O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
of O O
prior O B_PERSON/B_ORGANIZATION
regimens O I_PERSON/I_ORGANIZATION
was O O
2 O B_MEASURE
( O O
range O B_MEASURE/B_LOCATION
: O O
1 O B_NUMBER[MEASURE]
- O O
6 O B_MEASURE
) O O
. O O

Six O B_NUMBER[MEASURE]
( O O
12 O B_MEASURE
% O I_MEASURE
) O O
and O O
4 O B_NUMBER[MEASURE]
( O O
8 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
patients O B_PERSON/B_LOCATION
experienced O O
grade O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
2 O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
hand O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
foot O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
stomatitis O B_DISEASE
, O O
respectively O O
( O O
no O O
episodes O B_DISEASE/B_ENT
of O O
grade O B_DISEASE
3 O I_DISEASE
) O O
. O O

One O B_PERSON
patient O I_PERSON
developed O O
grade O B_DISEASE
3 O I_DISEASE
diarrhea O I_DISEASE
requiring O O
hospitalization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
hydration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Six O B_NUMBER[MEASURE]
( O O
12 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
) O O
individuals O B_PERSON/B_LOCATION
required O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
median O O
number O O
of O O
courses O O
of O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O O
on O O
this O O
protocol O O
was O O
2 O O
( O O
range O O
: O O
1 O O
- O O
12 O O
) O O
. O O

Four O B_NUMBER[MEASURE]
of O O
44 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
evaluable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exhibited O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
subjective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
antineoplastic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
This O O
modified O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O O
results O O
in O O
less O O
toxicity O O
( O O
stomatitis O O
, O O
hand O O
- O O
foot O O
syndrome O O
) O O
than O O
the O O
standard O O
FDA O O
- O O
approved O O
dose O O
schedule O O
. O O

Definite O O
, O O
although O O
limited O O
, O O
antineoplastic O O
activity O O
is O O
observed O O
in O O
patients O O
with O O
well O O
- O O
defined O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
refractory O O
ovarian O O
cancer O O
. O O

Efficacy O O
of O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
acute O O
bipolar O O
mania O O
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
. O O

The O O
Olanzipine B B_LOCATION
HGGW O O
Study O O
Group O O
. O O

BACKGROUND O O
: O O
We O O
compared O O
the O O
efficacy O O
and O O
safety O O
of O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
placebo O O
for O O
the O O
treatment O O
of O O
acute O O
bipolar O O
mania O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Four O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_PERSON
, O O
randomized O O
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
total O O
of O O
115 O O
patients O O
with O O
a O O
DSM O O
- O O
IV O O
diagnosis O O
of O O
bipolar O O
disorder O O
, O O
manic O O
or O O
mixed O O
, O O
were O O
randomized O O
to O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O O
to O O
20 O O
mg O O
/ O O
d O O
( O O
n O O
= O O
55 O O
) O O
, O O
or O O
placebo O O
( O O
n O O
= O O
60 O O
) O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
the O O
Young O B_PERSON/B_NUMBER[MEASURE]
- O O
Mania O B_MEASURE/B_PERSON
Rating O B_MEASURE/I_PERSON
Scale O B_MEASURE/I_PERSON
( O O
Y O B_OTHER/B_PERSON
- O O
MRS O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
total O B_MEASURE
score O I_MEASURE
. O O

Response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
euthymia O B_DISEASE_ADJECTIVE[DISEASE]
were O O
defined O O
, O O
a O O
priori O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
as O O
at O O
least O O
a O O
50 O B_MEASURE
% O I_MEASURE
improvement O I_MEASURE
from O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
as O O
a O O
score O B_MEASURE
of O O
no O O
less O B_MEASURE
than O O
12 O B_NUMBER[MEASURE]
at O O
end O B_LOCATION/B_MEASURE
point O I_LOCATION/I_MEASURE
in O O
the O O
Y O B_OTHER/B_LOCATION
- O O
MRS O B_MEASURE/B_LOCATION
total O I_MEASURE/I_LOCATION
score O I_MEASURE/I_LOCATION
, O O
respectively O O
. O O

Safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
assessed O O
using O O
adverse O B_DISEASE
events O I_DISEASE
, O O
Extrapyramidal O B_DISEASE
Symptom O I_DISEASE
( O O
EPS O B_LOCATION
) O O
rating O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scales O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
laboratory O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
values O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
electrocardiograms O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
vital O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
weight O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
change O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O O
: O O
Olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O O
demonstrated O O
a O O
statistically O O
significant O O
greater O O
mean O O
( O O
+ O O
/ O O
- O O
SD O O
) O O
improvement O O
in O O
Y O O
- O O
MRS O O
total O O
score O O
than O O
placebo O O
- O O
treated O O
patients O O
( O O
- O O
14 O O
. O O
8 O O
+ O O
/ O O
- O O
12 O O
. O O
5 O O
and O O
- O O
8 O O
. O O
1 O O
+ O O
/ O O
- O O
12 O O
. O O
7 O O
, O O
respectively O O
; O O
P O O
< O O
. O O
001 O O
) O O
, O O
which O O
was O O
evident O O
at O O
the O O
first O O
postbaseline O O
observation O O
1 O O
week O O
after O O
randomization O O
and O O
was O O
maintained O O
throughout O O
the O O
study O O
( O O
last O O
observation O O
carried O O
forward O O
) O O
. O O

Olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
patients O O
demonstrated O O
a O O
higher O O
rate O O
of O O
response O O
( O O
65 O O
% O O
vs O O
43 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
. O O
02 O O
) O O
and O O
euthymia O O
( O O
61 O O
% O O
vs O O
36 O O
% O O
, O O
respectively O O
; O O
P O O
= O O
. O O
01 O O
) O O
than O O
placebo O O
- O O
treated O O
patients O O
. O O

There O O
were O O
no O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
EPSs O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

However O O
, O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O O
had O O
a O O
statistically O O
significant O O
greater O O
mean O O
( O O
+ O O
/ O O
- O O
SD O O
) O O
weight O O
gain O O
than O O
placebo O O
- O O
treated O O
patients O O
( O O
2 O O
. O O
1 O O
+ O O
/ O O
- O O
2 O O
. O O
8 O O
vs O O
0 O O
. O O
45 O O
+ O O
/ O O
- O O
2 O O
. O O
3 O O
kg O O
, O O
respectively O O
) O O
and O O
also O O
experienced O O
more O O
treatment O O
- O O
emergent O O
somnolence O O
( O O
21 O O
patients O O
[ O O
38 O O
. O O
2 O O
% O O
] O O
vs O O
5 O O
[ O O
8 O O
. O O
3 O O
% O O
] O O
, O O
respectively O O
) O O
. O O

CONCLUSION O O
: O O
Olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
greater O O
efficacy O O
than O O
placebo O O
in O O
the O O
treatment O O
of O O
acute O O
bipolar O O
mania O O
and O O
was O O
generally O O
well O O
tolerated O O
. O O

The O O
effect O O
of O O
pupil O O
dilation O O
with O O
tropicamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
vision O O
and O O
driving O O
simulator O O
performance O O
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
assess O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pupil O B_DISEASE
dilation O I_DISEASE
on O O
vision O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
driving O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

METHODS O O
: O O
A O O
series O O
of O O
tests O O
on O O
various O O
parameters O O
of O O
visual O O
function O O
and O O
driving O O
simulator O O
performance O O
were O O
performed O O
on O O
12 O O
healthy O O
drivers O O
, O O
before O O
and O O
after O O
pupil O O
dilation O O
using O O
guttae O O
tropicamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
1 O O
% O O
. O O

A O O
driving O O
simulator O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Transport O B_LOCATION/B_ORGANIZATION
Research O I_LOCATION/I_ORGANIZATION
Laboratory O I_LOCATION/I_ORGANIZATION
) O O
was O O
used O O
to O O
measure O O
reaction O B_MEASURE
time O I_MEASURE
( O O
RT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O O
, O O
speed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maintenance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
steering O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accuracy O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
basic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
contrast O B_MEASURE
visual O I_MEASURE
acuity O I_MEASURE
( O O
HCVA O B_LOCATION/B_ORGANIZATION
and O O
LCVA O B_LOCATION/B_ORGANIZATION
) O O
, O O
Pelli O B_PERSON
- O O
Robson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
threshold O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
Goldmann O B_MEASURE
perimetry O I_MEASURE
( O O
FIELDS O B_LOCATION/B_ORGANIZATION
) O O
. O O

Useful O B_LOCATION/B_PERSON
Field O I_LOCATION/I_PERSON
of O O
View O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
UFOV O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
a O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
visual O B_DISEASE/B_ORGANISM_FUNCTION
attention O I_DISEASE/I_ORGANISM_FUNCTION
) O O
was O O
also O O
undertaken O O
. O O

The O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
post O B_LOCATION/B_DISEASE
- O O
dilatation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
for O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
the O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
level O I_MEASURE/I_LOCATION
using O O
one O B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
paired O O
t O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Pupillary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
deterioration O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
HCVA O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
only O O
. O O

Five O B_NUMBER[MEASURE]/B_LOCATION
of O O
12 O B_PERSON
drivers O I_PERSON
also O O
exhibited O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
LCVA O B_LOCATION/B_ORGANIZATION
, O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
RT O B_LOCATION
. O O

Little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
emerged O O
for O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
FIELDS O B_DISEASE/B_PROTEIN[GENE]
and O O
UFOV O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Also O O
, O O
7 O B_NUMBER[MEASURE]/B_ORGANIZATION
of O O
12 O B_MEASURE/B_PERSON
drivers O B_MEASURE/I_PERSON
appeared O O
to O O
adjust O O
their O O
driving O O
behaviour O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
reducing O O
their O O
speed O B_MEASURE/B_SPORT[ENT]
on O O
the O O
driving O O
simulator O B_LOCATION/B_PERSON
, O O
leading O O
to O O
improved O B_DISEASE/B_LOCATION
steering O I_DISEASE/I_LOCATION
accuracy O I_DISEASE/I_LOCATION
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Pupillary O B_DISEASE/B_PERSON
dilation O I_DISEASE/I_PERSON
may O O
lead O O
to O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
vision O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
daylight O B_DISEASE/B_MEASURE
driving O I_DISEASE/I_MEASURE
performance O I_DISEASE/I_MEASURE
in O O
young O B_PERSON/B_DISEASE
people O I_PERSON/I_DISEASE
. O O

A O O
larger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
a O O
broader O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectrum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
subjects O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
warranted O O
before O O
guidelines O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
can O O
be O O
recommended O O
. O O

A O O
case O B_PERSON/B_MEASURE
of O O
isotretinoin O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
embryopathy O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
bilateral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anotia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
Taussig O B_PERSON
- O O
Bing O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
malformation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
report O O
a O O
newborn O O
infant O O
with O O
multiple O O
congenital O O
anomalies O O
( O O
anotia O O
and O O
Taussig O O
- O O
Bing O O
malformation O O
) O O
due O O
to O O
exposure O O
to O O
isotretinoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
the O O
first O O
trimester O O
. O O

In O O
this O O
paper O O
we O O
aim O O
to O O
draw O O
to O O
the O O
fact O O
that O O
caution O O
is O O
needed O O
when O O
prescribing O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
drugs O O
to O O
women O O
of O O
childbearing O O
years O O
. O O

Effect O O
of O O
methoxamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
maximum O O
urethral O O
pressure O O
in O O
women O O
with O O
genuine O O
stress O O
incontinence O O
: O O
a O O
placebo O O
- O O
controlled O O
, O O
double O O
- O O
blind O O
crossover O O
study O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
to O O
evaluate O O
the O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
selective O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
urinary O B_DISEASE/B_LOCATION
stress O I_DISEASE/I_LOCATION
incontinence O I_DISEASE/I_LOCATION
. O O

A O O
randomised O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
, O O
crossover O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
employed O O
. O O

Half O O
log O O
incremental O O
doses O O
of O O
intravenous O O
methoxamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O O
( O O
saline O O
) O O
were O O
administered O O
to O O
a O O
group O O
of O O
women O O
with O O
genuine O O
stress O O
incontinence O O
while O O
measuring O O
maximum O O
urethral O O
pressure O O
( O O
MUP O O
) O O
, O O
blood O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
symptomatic O O
side O O
effects O O
. O O

Methoxamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
evoked O O
non O O
- O O
significant O O
increases O O
in O O
MUP O O
and O O
diastolic O O
blood O O
pressure O O
but O O
caused O O
a O O
significant O O
rise O O
in O O
systolic O O
blood O O
pressure O O
and O O
significant O O
fall O O
in O O
heart O O
rate O O
at O O
maximum O O
dosage O O
. O O

Systemic O B_DISEASE_ADJECTIVE[DISEASE]
side O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
including O O
piloerection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
headache O B_DISEASE
, O O
and O O
cold O B_DISEASE
extremities O I_DISEASE
were O O
experienced O O
in O O
all O O
subjects O B_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
peripherally O O
acting O O
sub O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
type O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
selective O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stress O B_DISEASE/B_LOCATION
incontinence O I_DISEASE/I_LOCATION
may O O
be O O
limited O O
by O O
associated O O
piloerection O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cardiovascular O B_DISEASE
side O I_DISEASE
effects O I_DISEASE
. O O

Hyperglycemic O O
effect O O
of O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
compounds O O
structurally O O
related O O
to O O
caproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O O
. O O

The O O
chronic O O
feeding O O
of O O
small O O
amounts O O
( O O
0 O O
. O O
3 O O
- O O
3 O O
% O O
of O O
diet O O
weight O O
) O O
of O O
certain O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O O
of O O
caproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
hyperglycemia O O
, O O
an O O
elevated O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
curve O O
and O O
, O O
occasionally O O
, O O
glucosuria O O
. O O

Effective O O
compounds O O
included O O
norleucine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
norvaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
epsilon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminocaproate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
methionine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
leucine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Toleration O O
of O O
high O O
doses O O
of O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O O
with O O
chronic O O
heart O O
failure O O
: O O
results O O
from O O
the O O
ATLAS O O
trial O O
. O O

The O O
Assessment O O
of O O
Treatment O O
with O O
Lisinopril B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Survival O O
. O O

BACKGROUND O O
: O O
Treatment O O
with O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ACE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O O
mortality O O
and O O
morbidity O O
in O O
patients O O
with O O
chronic O O
heart O O
failure O O
( O O
CHF O O
) O O
, O O
but O O
most O O
affected O O
patients O O
are O O
not O O
receiving O O
these O O
agents O O
or O O
are O O
being O O
treated O O
with O O
doses O O
lower O O
than O O
those O O
found O O
to O O
be O O
efficacious O O
in O O
trials O O
, O O
primarily O O
because O O
of O O
concerns O O
about O O
the O O
safety O O
and O O
tolerability O O
of O O
these O O
agents O O
, O O
especially O O
at O O
the O O
recommended O O
doses O O
. O O

The O O
present O O
study O O
examines O O
the O O
safety O O
and O O
tolerability O O
of O O
high O O
- O O
compared O O
with O O
low O O
- O O
dose O O
lisinopril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CHF O O
. O O

METHODS O O
: O O
The O O
Assessment O O
of O O
Lisinopril B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
Survival O O
study O O
was O O
a O O
multicenter O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
trial O O
in O O
which O O
patients O O
with O O
or O O
without O O
previous O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment O O
were O O
stabilized O O
receiving O O
medium O O
- O O
dose O O
lisinopril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
12 O O
. O O
5 O O
or O O
15 O O
. O O
0 O O
mg O O
once O O
daily O O
[ O O
OD O O
] O O
) O O
for O O
2 O O
to O O
4 O O
weeks O O
and O O
then O O
randomized O O
to O O
high O O
- O O
( O O
35 O O
. O O
0 O O
or O O
32 O O
. O O
5 O O
mg O O
OD O O
) O O
or O O
low O O
- O O
dose O O
( O O
5 O O
. O O
0 O O
or O O
2 O O
. O O
5 O O
mg O O
OD O O
) O O
groups O O
. O O

Patients O B_PERSON
with O O
New O B_DISEASE_ADJECTIVE[DISEASE]
York O I_DISEASE_ADJECTIVE[DISEASE]
Heart O I_DISEASE_ADJECTIVE[DISEASE]
Association O I_DISEASE_ADJECTIVE[DISEASE]
classes O I_DISEASE_ADJECTIVE[DISEASE]
II O I_DISEASE_ADJECTIVE[DISEASE]
to O O
IV O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
CHF O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
left O O
ventricular O B_MEASURE/B_DISEASE
ejection O I_MEASURE/I_DISEASE
fractions O I_MEASURE/I_DISEASE
of O O
no O O
greater O B_MEASURE
than O O
0 O B_MEASURE
. O O
30 O B_MEASURE
( O O
n O B_OTHER/B_LOCATION
= O O
3164 O B_MEASURE
) O O
were O O
randomized O O
and O O
followed O O
up O O
for O O
a O O
median O B_MEASURE
of O O
46 O B_NUMBER[MEASURE]
months O I_NUMBER[MEASURE]
. O O

We O O
examined O O
the O O
occurrence O B_DISEASE/B_MEASURE
of O O
adverse O B_DISEASE
events O I_DISEASE
and O O
the O O
need O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
a O O
focus O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
hypotension O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal O B_DISEASE
dysfunction O I_DISEASE
. O O

RESULTS O O
: O O
Of O O
405 O O
patients O O
not O O
previously O O
receiving O O
an O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
doses O O
in O O
only O O
4 O O
. O O
2 O O
% O O
could O O
not O O
be O O
titrated O O
to O O
the O O
medium O O
doses O O
required O O
for O O
randomization O O
because O O
of O O
symptoms O O
possibly O O
related O O
to O O
hypotension O O
( O O
2 O O
. O O
0 O O
% O O
) O O
or O O
because O O
of O O
renal O O
dysfunction O O
or O O
hyperkalemia O O
( O O
2 O O
. O O
3 O O
% O O
) O O
. O O

Doses O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
more O B_MEASURE
than O O
90 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
high O B_MEASURE/B_LOCATION
- O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
were O O
titrated O O
to O O
their O O
assigned O O
target O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
the O O
mean O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
blinded O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Withdrawals O B_DISEASE
occurred O O
in O O
27 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
of O O
the O O
high O B_MEASURE/B_LOCATION
- O O
and O O
30 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
. O O

Subgroups O O
presumed O O
to O O
be O O
at O O
higher O O
risk O O
for O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intolerance O O
( O O
blood O O
pressure O O
, O O
< O O
120 O O
mm O O
Hg O O
; O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
> O O
or O O
= O O
132 O O
. O O
6 O O
micromol O O
/ O O
L O O
[ O O
> O O
or O O
= O O
1 O O
. O O
5 O O
mg O O
/ O O
dL O O
] O O
; O O
age O O
, O O
> O O
or O O
= O O
70 O O
years O O
; O O
and O O
patients O O
with O O
diabetes O O
) O O
generally O O
tolerated O O
the O O
high O O
- O O
dose O O
strategy O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
demonstrate O O
that O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
most O O
patients O O
with O O
CHF O O
can O O
be O O
successfully O O
titrated O O
to O O
and O O
maintained O O
at O O
high O O
doses O O
, O O
and O O
that O O
more O O
aggressive O O
use O O
of O O
these O O
agents O O
is O O
warranted O O
. O O

Cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
cocaethylene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxity O O
in O O
an O O
animal O O
model O O
of O O
cocaine O O
and O O
ethanol O O
abuse O O
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Simultaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abuse O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethanol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affects O O
12 O B_PERSON/B_ENT
million O I_PERSON/I_ENT
Americans O I_PERSON/I_ENT
annually O O
. O O

In O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
substances O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
substantially O O
more O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
than O O
either O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alone O O
. O O

Their O O
combined O O
cardiac O O
toxicity O O
may O O
be O O
due O O
to O O
independent O O
effects O O
of O O
each O O
drug O O
; O O
however O O
, O O
they O O
may O O
also O O
be O O
due O O
to O O
cocaethylene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
, O O
a O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolite O O
formed O O
only O O
in O O
the O O
presence O O
of O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
delineate O O
the O O
role O O
of O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
combined O O
cardiotoxicity O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
model O O
simulating O O
their O O
abuse O O
. O O

METHODS O O
: O O
Twenty O O
- O O
three O O
dogs O O
were O O
randomized O O
to O O
receive O O
either O O
1 O O
) O O
three O O
intravenous O O
( O O
IV O O
) O O
boluses O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O O
. O O
5 O O
mg O O
/ O O
kg O O
with O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
g O O
/ O O
kg O O
) O O
as O O
an O O
IV O O
infusion O O
( O O
C O O
+ O O
E O O
, O O
n O O
= O O
8 O O
) O O
, O O
2 O O
) O O
three O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boluses O O
only O O
( O O
C O O
, O O
n O O
= O O
6 O O
) O O
, O O
3 O O
) O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
only O O
( O O
E O O
, O O
n O O
= O O
5 O O
) O O
, O O
or O O
4 O O
) O O
placebo O O
boluses O O
and O O
infusion O O
( O O
n O O
= O O
4 O O
) O O
. O O

Hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
electrocardiograms O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
serum O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
obtained O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
then O O
at O O
fixed O O
time O B_MEASURE/B_LOCATION
intervals O I_MEASURE/I_LOCATION
after O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Two O B_NUMBER[MEASURE]
of O O
eight O B_PERSON/B_ENT
dogs O I_PERSON/I_ENT
in O O
the O O
C O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
E O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
experienced O O
cardiovascular O B_DISEASE
collapse O I_DISEASE
. O O

The O O
most O O
dramatic O O
hemodynamic O O
changes O O
occurred O O
after O O
each O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bolus O O
in O O
the O O
C O O
+ O O
E O O
and O O
C O O
only O O
groups O O
; O O
however O O
, O O
persistent O O
hemodynamic O O
changes O O
occurred O O
in O O
the O O
C O O
+ O O
E O O
group O O
. O O

Peak O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
associated O O
with O O
a O O
45 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
22 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
22 O O
% O O
to O O
69 O O
% O O
) O O
decrease O O
in O O
cardiac O O
output O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
, O O
a O O
56 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
23 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
32 O O
% O O
to O O
80 O O
% O O
) O O
decrease O O
in O O
dP O O
/ O O
dt O O
( O O
max O O
) O O
( O O
p O O
< O O
. O O
006 O O
) O O
, O O
and O O
a O O
23 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
15 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
7 O O
% O O
to O O
49 O O
% O O
) O O
decrease O O
in O O
SVO O O
( O O
2 O O
) O O
( O O
p O O
< O O
0 O O
. O O
025 O O
) O O
. O O

Ventricular O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
arrhythmias O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
primarily O O
observed O O
in O O
the O O
C O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
+ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
E O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
in O O
which O O
four O B_NUMBER[MEASURE]/B_LOCATION
of O O
eight O B_PERSON/B_ENT
dogs O I_PERSON/I_ENT
experienced O O
ventricular O B_DISEASE
tachycardia O I_DISEASE
. O O

CONCLUSIONS O O
: O O
Cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
combination O O
were O O
more O O
toxic O O
than O O
either O O
substance O O
alone O O
. O O

Co O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
resulted O O
in O O
prolonged O B_DISEASE
cardiac O I_DISEASE
toxicity O I_DISEASE
and O O
was O O
dysrhythmogenic O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Peak O O
serum O O
cocaethylene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O O
were O O
associated O O
with O O
prolonged O O
myocardial O O
depression O O
. O O

Worsening O O
of O O
Parkinsonism O O
after O O
the O O
use O O
of O O
veralipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
treatment O O
of O O
menopause O O
: O O
case O O
report O O
. O O

We O O
describe O O
a O O
female O O
patient O O
with O O
stable O O
Parkinson O O
' O O
s O O
disease O O
who O O
has O O
shown O O
a O O
marked O O
worsening O O
of O O
her O O
motor O O
functions O O
following O O
therapy O O
of O O
menopause O O
related O O
symptoms O O
with O O
veralipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
the O O
improvement O O
of O O
her O O
symptoms O O
back O O
to O O
baseline O O
after O O
discontinuation O O
of O O
the O O
drug O O
. O O

We O O
emphasize O O
the O O
anti O O
- O O
dopaminergic O O
effect O O
of O O
veralipride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Viracept B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
and O O
irregular O O
heartbeat O O
warning O O
. O O

A O O
group O O
of O O
doctors O O
in O O
Boston O O
warn O O
that O O
the O O
protease O O
inhibitor O O
Viracept B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
may O O
cause O O
an O O
irregular O O
heart O O
beat O O
, O O
known O O
as O O
bradycardia O O
, O O
in O O
people O O
with O O
HIV O O
. O O

Bradycardia O O
occurred O O
in O O
a O O
45 O O
- O O
year O O
- O O
old O O
male O O
patient O O
who O O
was O O
Viracept B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
in O O
combination O O
with O O
other O O
anti O O
- O O
HIV O O
drugs O O
. O O

The O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ceased O O
after O O
switching O O
to O O
another O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Frequency O O
of O O
appearance O O
of O O
myeloperoxidase O O
- O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
in O O
Graves O O
' O O
disease O O
patients O O
treated O O
with O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
relationship O O
between O O
MPO O O
- O O
ANCA O O
and O O
clinical O O
manifestations O O
. O O

OBJECTIVE O O
: O O
Myeloperoxidase O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
- O O
positive O O
vasculitis O O
has O O
been O O
reported O O
in O O
patients O O
with O O
Graves O O
' O O
disease O O
who O O
were O O
treated O O
with O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

The O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
in O O
these O O
cases O O
was O O
suspected O O
of O O
being O O
related O O
to O O
PTU B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
the O O
titres O O
of O O
MPO O O
- O O
ANCA O O
decreased O O
when O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
stopped O O
. O O

Nevertheless O O
, O O
there O O
have O O
been O O
no O O
studies O O
on O O
the O O
temporal O O
relationship O O
between O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
and O O
vasculitis O O
during O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
or O O
on O O
the O O
incidence O O
of O O
MPO O O
- O O
ANCA O O
in O O
untreated O O
Graves O O
' O O
disease O O
patients O O
. O O

Therefore O O
, O O
we O O
sought O O
to O O
address O O
these O O
parameters O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON
with O O
Graves O B_DISEASE/B_LOCATION
' O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
. O O

PATIENTS O O
: O O
We O O
investigated O O
102 O O
untreated O O
patients O O
with O O
hyperthyroidism O O
due O O
to O O
Graves O O
' O O
disease O O
for O O
the O O
presence O O
of O O
MPO O O
- O O
ANCA O O
, O O
and O O
for O O
the O O
development O O
vasculitis O O
after O O
starting O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
therapy O O
. O O

Twenty O O
- O O
nine O O
of O O
them O O
were O O
later O O
excluded O O
because O O
of O O
adverse O O
effects O O
of O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
because O O
the O O
observation O O
period O O
was O O
less O O
than O O
3 O O
months O O
. O O

The O O
remaining O O
73 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
55 O B_MEASURE/B_SPORT[ENT]
women O I_MEASURE/I_SPORT[ENT]
and O O
18 O B_PERSON
men O I_PERSON
) O O
, O O
all O O
of O O
whom O O
were O O
examined O O
for O O
more O B_TIME[MEASURE]
than O O
3 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
were O O
adopted O O
as O O
the O O
subjects O B_PERSON
of O O
the O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
median O B_TIME[MEASURE]/B_LOCATION
observation O I_TIME[MEASURE]/I_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
was O O
23 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_LOCATION/B_MEASURE
: O O
3 O B_MEASURE
- O O
37 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
. O O

MEASUREMENTS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
MPO O B_MEASURE/B_PROTEIN[GENE]
- O O
ANCA O B_MEASURE/B_DISEASE
was O O
measured O O
at O O
intervals O B_MEASURE/B_LOCATION
of O O
2 O B_NUMBER[MEASURE]
- O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Before O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
MPO O B_PROTEIN[GENE]/B_MEASURE
- O O
ANCA O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
titres O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
102 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
untreated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Graves O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
within O O
the O O
reference O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
range O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
below O O
10 O B_MEASURE
U O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
) O O
. O O

Three O O
( O O
4 O O
. O O
1 O O
% O O
) O O
of O O
the O O
73 O O
patients O O
were O O
positive O O
for O O
MPO O O
- O O
ANCA O O
at O O
13 O O
, O O
16 O O
and O O
17 O O
months O O
, O O
respectively O O
, O O
after O O
the O O
start O O
of O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
. O O

In O O
two O O
of O O
them O O
, O O
the O O
MPO O O
- O O
ANCA O O
titres O O
transiently O O
increased O O
to O O
12 O O
. O O
8 O O
and O O
15 O O
. O O
0 O O
U O O
/ O O
ml O O
, O O
respectively O O
, O O
despite O O
continued O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
but O O
no O O
vasculitic O O
disorders O O
developed O O
. O O

In O O
the O O
third O O
patient O O
, O O
the O O
MPO O O
- O O
ANCA O O
titre O O
increased O O
to O O
204 O O
U O O
/ O O
ml O O
and O O
she O O
developed O O
a O O
higher O O
fever O O
, O O
oral O O
ulcers O O
and O O
polyarthralgia O O
, O O
but O O
the O O
symptoms O O
resolved O O
2 O O
weeks O O
after O O
stopping O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
, O O
and O O
the O O
MPO O O
- O O
ANCA O O
titre O O
decreased O O
to O O
20 O O
. O O
7 O O
U O O
/ O O
ml O O
by O O
4 O O
months O O
after O O
discontinuing O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
may O O
be O O
related O O
to O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
, O O
but O O
MPO O O
- O O
ANCA O O
does O O
not O O
appear O O
to O O
be O O
closely O O
related O O
to O O
vasculitis O O
. O O

Prevalence O O
of O O
heart O O
disease O O
in O O
asymptomatic O O
chronic O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

To O O
determine O O
the O O
prevalence O O
of O O
heart O O
disease O O
in O O
outpatient O O
young O O
asymptomatic O O
chronic O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O O
, O O
35 O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
and O O
32 O O
age O O
- O O
matched O O
controls O O
underwent O O
resting O O
and O O
exercise O O
electrocardiography O O
( O O
ECG O O
) O O
and O O
Doppler O O
echocardiography O O
. O O

Findings O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
coronary O B_DISEASE/B_LOCATION
artery O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
were O O
detected O O
in O O
12 O B_MEASURE
( O O
34 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
patients O B_PERSON
and O O
3 O B_MEASURE
( O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
controls O B_PERSON
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Decreased O O
left O O
ventricular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systolic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
demonstrated O O
in O O
5 O B_NUMBER[MEASURE]
( O O
14 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
patients O B_PERSON
, O O
but O O
in O O
none O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
controls O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
055 O B_MEASURE
) O O
. O O

Finally O O
, O O
resting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
peak O B_MEASURE
exercise O O
abnormal O B_DISEASE
left O I_DISEASE
ventricular O I_DISEASE
filling O I_DISEASE
was O O
detected O O
in O O
38 O B_MEASURE
and O O
35 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_BIO
as O O
compared O O
to O O
19 O B_MEASURE
and O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
controls O B_PERSON/B_BIO
, O O
respectively O O
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
11 O B_MEASURE
and O O
0 O B_MEASURE
. O O
02 O B_MEASURE
, O O
respectively O O
) O O
. O O

We O O
conclude O O
that O O
coronary O O
artery O O
or O O
myocardial O O
disease O O
is O O
common O O
( O O
38 O O
% O O
) O O
in O O
young O O
asymptomatic O O
chronic O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

Therefore O O
, O O
screening O O
ECG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
echocardiography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
be O O
warranted O O
in O O
these O O
patients O B_PERSON/B_LOCATION
. O O

Cardioprotective O O
effects O O
of O O
Picrorrhiza O O
kurroa O O
against O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
stress O O
in O O
rats O O
. O O

The O O
cardioprotective O O
effect O O
of O O
the O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extract O O
of O O
Picrorrhiza O O
kurroa O O
rhizomes O O
and O O
roots O O
( O O
PK O O
) O O
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
infarction O O
in O O
rats O O
with O O
respect O O
to O O
lipid O O
metabolism O O
in O O
serum O O
and O O
heart O O
tissue O O
has O O
been O O
investigated O O
. O O

Oral O O
pre O O
- O O
treatment O O
with O O
PK O O
( O O
80 O O
mg O O
kg O O
( O O
- O O
1 O O
) O O
day O O
( O O
- O O
1 O O
) O O
for O O
15 O O
days O O
) O O
significantly O O
prevented O O
the O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
infarction O O
and O O
maintained O O
the O O
rats O O
at O O
near O O
normal O O
status O O
. O O

Phase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
early O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
afterdepolarization O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O O
a O O
trigger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
polymorphic O B_DISEASE
ventricular O I_DISEASE
tachycardia O I_DISEASE
in O O
acquired O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
QT O B_DISEASE/B_LOCATION
syndrome O I_DISEASE/I_LOCATION
: O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recordings O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
intact O B_BODY_PART_OR_ORGAN_COMPONENT
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
wall O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

BACKGROUND O O
: O O
This O O
study O O
examined O O
the O O
role O O
of O O
phase O O
2 O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
in O O
producing O O
a O O
trigger O O
to O O
initiate O O
torsade O O
de O O
pointes O O
( O O
TdP O O
) O O
with O O
QT O O
prolongation O O
induced O O
by O O
dl O O
- O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
azimilide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
contribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
transmural O B_MEASURE
dispersion O I_MEASURE
of O O
repolarization O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
TDR O B_LOCATION/B_DISEASE
) O O
to O O
transmural O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propagation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
EAD O B_DISEASE
and O O
the O O
maintenance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
TdP O B_PROTEIN[GENE]/B_DISEASE
was O O
also O O
evaluated O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Transmembrane O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potentials O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
epicardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
midmyocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
endocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O O
recorded O O
simultaneously O O
, O O
together O O
with O O
a O O
transmural O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ECG O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
arterially O O
perfused O O
canine O B_SPECIES[BIO]
and O O
rabbit O B_SPECIES[BIO]
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
preparations O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

dl O O
- O O
Sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
prolonged O O
action O O
potential O O
duration O O
( O O
APD O O
) O O
in O O
M O O
cells O O
dose O O
- O O
dependently O O
( O O
1 O O
to O O
100 O O
micromol O O
/ O O
L O O
) O O
, O O
leading O O
to O O
QT O O
prolongation O O
and O O
an O O
increase O O
in O O
TDR O O
. O O

Azimilide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
however O O
, O O
significantly O O
prolonged O O
APD O O
and O O
QT O O
interval O O
at O O
concentrations O O
from O O
0 O O
. O O
1 O O
to O O
10 O O
micromol O O
/ O O
L O O
but O O
shortened O O
them O O
at O O
30 O O
micromol O O
/ O O
L O O
. O O

Unlike O O
dl O O
- O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
azimilide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
> O O
3 O O
micromol O O
/ O O
L O O
) O O
increased O O
epicardial O O
APD O O
markedly O O
, O O
causing O O
a O O
diminished O O
TDR O O
. O O

Although O O
both O O
dl O O
- O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
azimilide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rarely O O
induced O O
EADs O O
in O O
canine O O
left O O
ventricles O O
, O O
they O O
produced O O
frequent O O
EADs O O
in O O
rabbits O O
, O O
in O O
which O O
more O O
pronounced O O
QT O O
prolongation O O
was O O
seen O O
. O O

An O O
increase O O
in O O
TDR O O
by O O
dl O O
- O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facilitated O O
transmural O O
propagation O O
of O O
EADs O O
that O O
initiated O O
multiple O O
episodes O O
of O O
spontaneous O O
TdP O O
in O O
3 O O
of O O
6 O O
rabbit O O
left O O
ventricles O O
. O O

Of O O
note O O
, O O
although O O
azimilide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
to O O
10 O O
micromol O O
/ O O
L O O
) O O
increased O O
APD O O
more O O
than O O
dl O O
- O O
sotalol B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
its O O
EADs O O
often O O
failed O O
to O O
propagate O O
transmurally O O
, O O
probably O O
because O O
of O O
a O O
diminished O O
TDR O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
direct O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
intracellular O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
action O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
potential O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
recordings O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
EAD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
can O O
be O O
generated O O
from O O
intact O B_BODY_PART_OR_ORGAN_COMPONENT
ventricular O I_BODY_PART_OR_ORGAN_COMPONENT
wall O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
produce O O
a O O
trigger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
initiate O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TdP O B_PROTEIN[GENE]/B_DISEASE
under O O
QT O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O O
echocardiography O O
in O O
the O O
emergency O O
department O O
evaluation O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
. O O

STUDY O O
OBJECTIVE O O
: O O
Chest O O
pain O O
in O O
the O O
setting O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
poses O O
a O O
diagnostic O O
dilemma O O
. O O

Dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stress O O
echocardiography O O
( O O
DSE O O
) O O
is O O
a O O
widely O O
available O O
and O O
sensitive O O
test O O
for O O
evaluating O O
cardiac O O
ischemia O O
. O O

Because O O
of O O
the O O
theoretical O O
concern O O
regarding O O
administration O O
of O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
setting O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
, O O
we O O
conducted O O
a O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
DSE O O
in O O
emergency O O
department O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
. O O

METHODS O B_MEASURE
: O O
A O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
in O O
the O O
intensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
the O O
ED O B_PERSON/B_LOCATION
of O O
an O O
urban O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
tertiary O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
care O B_LOCATION/B_ORGANIZATION
teaching O I_LOCATION/I_ORGANIZATION
hospital O I_LOCATION/I_ORGANIZATION
. O O

Patients O O
were O O
eligible O O
for O O
DSE O O
if O O
they O O
had O O
used O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
24 O O
hours O O
preceding O O
the O O
onset O O
of O O
chest O O
pain O O
and O O
had O O
a O O
normal O O
ECG O O
and O O
tropinin O O
I O O
level O O
. O O

Patients O O
exhibiting O O
signs O O
of O O
continuing O O
cocaine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O O
were O O
excluded O O
from O O
the O O
study O O
. O O

All O O
patients O B_PERSON
were O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
for O O
serial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
the O O
DSE O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
testing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
the O O
intensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Twenty O B_NUMBER[MEASURE]
- O O
four O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
enrolled O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
had O O
inadequate O B_DISEASE/B_LOCATION
resting O I_DISEASE/I_LOCATION
images O I_DISEASE/I_LOCATION
, O O
one O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DSE O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
terminated O O
because O O
of O O
inferior O B_DISEASE
hypokinesis O I_DISEASE
, O O
another O O
DSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
terminated O O
because O O
of O O
a O O
rate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
atrial O B_DISEASE
conduction O I_DISEASE
deficit O I_DISEASE
, O O
and O O
1 O B_PERSON/B_NUMBER[MEASURE]
patient O B_PERSON/I_NUMBER[MEASURE]
did O O
not O O
reach O O
the O O
target O B_MEASURE/B_LOCATION
heart O B_MEASURE/I_LOCATION
rate O B_MEASURE/I_LOCATION
. O O

Thus O O
, O O
19 O B_PERSON
patients O I_PERSON
completed O O
a O O
DSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reached O O
their O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
heart O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON
experienced O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
exaggerated O B_DISEASE
adrenergic O I_DISEASE
response O I_DISEASE
, O O
which O O
was O O
defined O O
as O O
a O O
systolic O B_DISEASE/B_MEASURE
blood O B_DISEASE/I_MEASURE
pressure O B_DISEASE/I_MEASURE
of O O
greater O B_MEASURE
than O O
200 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
Hg O I_NUMBER[MEASURE]
or O O
the O O
occurrence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tachydysrhythmias O B_DISEASE
( O O
excluding O O
sinus O B_DISEASE
tachycardia O I_DISEASE
) O O
. O O

Further O O
suggesting O O
lack O O
of O O
exaggerated O O
adrenergic O O
response O O
, O O
13 O O
( O O
65 O O
% O O
) O O
of O O
20 O O
patients O O
required O O
supplemental O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
reach O O
their O O
target O O
heart O O
rates O O
. O O

CONCLUSION O O
: O O
No O O
exaggerated O O
adrenergic O O
response O O
was O O
detected O O
when O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
to O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
chest O O
pain O O
. O O

Prenatal O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
and O O
cranial O O
sonographic O O
findings O O
in O O
preterm O O
infants O O
. O O

PURPOSE O O
: O O
Prenatal O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
has O O
been O O
linked O O
with O O
subependymal O O
hemorrhage O O
and O O
the O O
formation O O
of O O
cysts O O
that O O
are O O
detectable O O
on O O
cranial O O
sonography O O
in O O
neonates O O
born O O
at O O
term O O
. O O

We O O
sought O O
to O O
determine O O
if O O
prenatal O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
increases O O
the O O
incidence O O
of O O
subependymal O O
cysts O O
in O O
preterm O O
infants O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
retrospectively O O
reviewed O O
the O O
medical O B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANIZATION
records O I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANIZATION
and O O
cranial O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sonograms O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
during O O
a O O
1 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
period O I_TIME[MEASURE]
on O O
122 O B_NUMBER[MEASURE]/B_PERSON
premature O I_NUMBER[MEASURE]/I_PERSON
( O O
< O B_TIME[MEASURE]/B_LOCATION
36 O I_TIME[MEASURE]/I_LOCATION
weeks O I_TIME[MEASURE]/I_LOCATION
of O O
gestation O B_ORGANISM_FUNCTION
) O O
infants O B_PERSON/B_BIO
. O O

Infants O O
were O O
categorized O O
into O O
1 O O
of O O
2 O O
groups O O
: O O
those O O
exposed O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
those O O
not O O
exposed O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Infants O O
were O O
assigned O O
to O O
the O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
group O O
if O O
there O O
was O O
a O O
maternal O O
history O O
of O O
cocaine O O
abuse O O
during O O
pregnancy O O
or O O
if O O
maternal O O
or O O
neonatal O O
urine O O
toxicology O O
results O O
were O O
positive O O
at O O
the O O
time O O
of O O
delivery O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Five O B_NUMBER[MEASURE]
of O O
the O O
122 O B_PERSON
infants O I_PERSON
were O O
excluded O O
from O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
of O O
insufficient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
histories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
incidence O B_MEASURE
of O O
subependymal O B_DISEASE
cysts O I_DISEASE
in O O
the O O
117 O B_NUMBER[MEASURE]
remaining O O
infants O B_PERSON/B_DISEASE
was O O
14 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
16 O B_MEASURE/B_LOCATION
of O O
117 O B_MEASURE/B_PERSON
) O O
. O O

The O O
incidence O O
of O O
subependymal O O
cysts O O
in O O
infants O O
exposed O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prenatally O O
was O O
44 O O
% O O
( O O
8 O O
of O O
18 O O
) O O
compared O O
with O O
8 O O
% O O
( O O
8 O O
of O O
99 O O
) O O
in O O
the O O
unexposed O O
group O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

CONCLUSIONS O O
: O O
We O O
found O O
an O O
increased O O
incidence O O
of O O
subependymal O O
cyst O O
formation O O
in O O
preterm O O
infants O O
who O O
were O O
exposed O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prenatally O O
. O O

This O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
term O B_LOCATION
infants O I_LOCATION
. O O

Thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy O O
in O O
patients O O
treated O O
for O O
metastatic O O
prostate O O
cancer O O
. O O

We O O
prospectively O O
evaluated O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neuropathy O O
using O O
electrodiagnostic O O
studies O O
. O O

Sixty O O
- O O
seven O O
men O O
with O O
metastatic O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
independent O O
prostate O O
cancer O O
in O O
an O O
open O O
- O O
label O O
trial O O
of O O
oral O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O O
neurologic O O
examinations O O
and O O
nerve O O
conduction O O
studies O O
( O O
NCS O O
) O O
prior O O
to O O
and O O
at O O
3 O O
- O O
month O O
intervals O O
during O O
treatment O O
. O O

NCS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O O
recording O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sensory O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNAPs O B_DISEASE
) O O
from O O
median O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O O
radial O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ulnar O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
sural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerves O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SNAP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplitudes O B_MEASURE/B_ENT
for O O
each O O
nerve O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
were O O
expressed O O
as O O
the O O
percentage O B_MEASURE
of O O
its O O
baseline O B_MEASURE/B_LOCATION
, O O
and O O
the O O
mean O B_MEASURE
of O O
the O O
four O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
termed O O
the O O
SNAP O B_MEASURE/B_LOCATION
index O I_MEASURE/I_LOCATION
. O O

A O O
40 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
decline O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
SNAP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
considered O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
in O O
55 O O
patients O O
for O O
lack O O
of O O
therapeutic O O
response O O
. O O

Of O O
67 O O
patients O O
initially O O
enrolled O O
, O O
24 O O
remained O O
on O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O O
months O O
, O O
8 O O
remained O O
at O O
6 O O
months O O
, O O
and O O
3 O O
remained O O
at O O
9 O O
months O O
. O O

Six O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
developed O O
neuropathy O B_DISEASE
. O O

Clinical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
a O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
SNAP O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
index O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
occurred O O
concurrently O O
. O O

Older O B_MEASURE
age O I_MEASURE
and O O
cumulative O B_MEASURE/B_PERSON
dose O B_MEASURE/I_PERSON
were O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributing O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Neuropathy O O
may O O
thus O O
be O O
a O O
common O O
complication O O
of O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
older O O
patients O O
. O O

The O O
SNAP O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O O
be O O
used O O
to O O
monitor O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
neuropathy O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
for O O
early O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Overexpression O O
of O O
copper B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
zinc B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dismutase O O
protects O O
from O O
kanamycin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hearing O O
loss O O
. O O

The O O
participation O O
of O O
reactive O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O O
in O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
ototoxicity O O
has O O
been O O
deduced O O
from O O
observations O O
that O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
iron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes O O
catalyze O O
the O O
formation O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radicals O O
in O O
vitro O O
and O O
that O O
antioxidants O O
attenuate O O
ototoxicity O O
in O O
vivo O O
. O O

We O O
therefore O O
hypothesized O O
that O O
overexpression O O
of O O
Cu B B_LOCATION
/ O O
Zn B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
( O O
h O O
- O O
SOD1 O O
) O O
should O O
protect O O
transgenic O O
mice O O
from O O
ototoxicity O O
. O O

Immunocytochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
confirmed O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
h O O
- O O
SOD1 O B_GENE
in O O
inner O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ear O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
transgenic O B_GENE/B_MEASURE
C57BL O I_GENE/I_MEASURE
/ O O
6 O B_MEASURE
- O O
TgN O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SOD1 O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
3Cje O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Transgenic O O
and O O
nontransgenic O O
littermates O O
received O O
kanamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
400 O O
mg O O
/ O O
kg O O
body O O
weight O O
/ O O
day O O
) O O
for O O
10 O O
days O O
beginning O O
on O O
day O O
10 O O
after O O
birth O O
. O O

Auditory O B_PERSON/B_ORGANIZATION
thresholds O I_PERSON/I_ORGANIZATION
were O O
tested O O
by O O
evoked O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
auditory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
brain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
stem O O
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
1 O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
after O O
birth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
nontransgenic O O
animals O O
, O O
the O O
threshold O O
in O O
the O O
kanamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
treated O O
group O O
was O O
45 O O
- O O
50 O O
dB O O
higher O O
than O O
in O O
saline O O
- O O
injected O O
controls O O
. O O

In O O
the O O
transgenic O O
group O O
, O O
kanamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
increased O O
the O O
threshold O O
by O O
only O O
15 O O
dB O O
over O O
the O O
respective O O
controls O O
. O O

The O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
12 O B_MEASURE
and O O
24 O B_MEASURE/B_LOCATION
kHz O I_MEASURE/I_LOCATION
. O O

The O O
protection O O
by O O
overexpression O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
supports O O
the O O
hypothesis O O
that O O
oxidant O O
stress O O
plays O O
a O O
significant O O
role O O
in O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
ototoxicity O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
suggest O O
transgenic O B_SPECIES[BIO]/B_PERSON
animals O I_SPECIES[BIO]/I_PERSON
as O O
suitable O B_PERSON/B_LOCATION
models O I_PERSON/I_LOCATION
to O O
investigate O O
the O O
underlying O O
mechanisms O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Fatty O O
liver O O
induced O O
by O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
rat O O
. O O

Dose O B_TIME[MEASURE]/B_PERSON
- O O
response O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sex O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Dose O O
- O O
response O O
relationships O O
, O O
biochemical O O
mechanisms O O
, O O
and O O
sex O O
differences O O
in O O
the O O
experimental O O
fatty O O
liver O O
induced O O
by O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
the O O
intact O O
rat O O
and O O
with O O
the O O
isolated O O
perfused O O
rat O O
liver O O
in O O
vitro O O
. O O

In O O
the O O
intact O O
male O O
and O O
female O O
rat O O
, O O
no O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
hepatic O O
accumulation O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

With O O
provision O O
of O O
adequate O O
oleic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
substrate O O
for O O
the O O
isolated O O
perfused O O
liver O O
, O O
a O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
both O O
accumulation O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
liver O O
and O O
depression O O
of O O
output O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
livers O O
from O O
male O O
and O O
female O O
rats O O
. O O

Marked O O
differences O O
were O O
observed O O
between O O
female O O
and O O
male O O
rats O O
with O O
regard O O
to O O
base O O
line O O
( O O
control O O
) O O
hepatic O O
concentration O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
output O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Accumulation O O
of O O
hepatic O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
as O O
a O O
per O O
cent O O
of O O
control O O
values O O
, O O
in O O
response O O
to O O
graded O O
doses O O
of O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
did O O
not O O
differ O O
significantly O O
between O O
male O O
, O O
female O O
and O O
pregnant O O
rat O O
livers O O
. O O

However O O
, O O
livers O O
from O O
female O O
, O O
and O O
especially O O
pregnant O O
female O O
rats O O
, O O
were O O
strikingly O O
resistant O O
to O O
the O O
effects O O
of O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
depression O O
of O O
output O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
under O O
these O O
experimental O O
conditions O O
. O O

These O O
differences O O
between O O
the O O
sexes O O
could O O
not O O
be O O
related O O
to O O
altered O O
disposition O O
of O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
altered O O
uptake O O
of O O
oleic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Depressed O O
hepatic O O
secretion O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
accounted O O
only O O
for O O
30 O O
to O O
50 O O
% O O
of O O
accumulated O O
hepatic O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
additional O O
mechanisms O O
must O O
be O O
involved O O
in O O
the O O
production O O
of O O
the O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
rich O O
fatty O O
liver O O
in O O
response O O
to O O
tetracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
anxiety O O
and O O
glial O O
cerebral O O
changes O O
in O O
rats O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
whether O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PDN B B_DISEASE/B_PROTEIN[GENE]
) O O
produces O O
anxiety O O
and O O
/ O O
or O O
cerebral O O
glial O O
changes O O
in O O
rats O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Male O B_BIO/B_GENE
Wistar O I_BIO/I_GENE
rats O I_BIO/I_GENE
were O O
studied O O
and O O
3 O B_ORGANIZATION/B_PERSON
groups O I_ORGANIZATION/I_PERSON
were O O
formed O O
( O O
8 O B_NUMBER[MEASURE]
rats O I_NUMBER[MEASURE]
per O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
moderate O O
- O O
dose O O
group O O
received O O
5 O O
mg O O
/ O O
kg O O
/ O O
day O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
released O O
from O O
a O O
subcutaneous O O
implant O O
. O O

In O O
the O O
high O O
- O O
dose O O
group O O
, O O
implants O O
containing O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
equivalent O O
to O O
60 O O
mg O O
/ O O
kg O O
/ O O
day O O
were O O
applied O O
. O O

In O O
the O O
control O O
group O O
implants O O
contained O O
no O O
PDN B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anxiety O B_DISEASE
was O O
assessed O O
using O O
an O O
open O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
field O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
elevated O O
plus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
maze O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devices O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
number O B_MEASURE/B_LOCATION
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
cytoplasmic O B_MEASURE/B_LOCATION
transformation O I_MEASURE/I_LOCATION
of O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
assessed O O
by O O
immunohistochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Anxiety O O
was O O
documented O O
in O O
both O O
groups O O
of O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treated O O
rats O O
compared O O
with O O
controls O O
. O O

The O O
magnitude O O
of O O
transformation O O
of O O
the O O
microglia O O
assessed O O
by O O
the O O
number O O
of O O
intersections O O
was O O
significantly O O
higher O O
in O O
the O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups O O
than O O
in O O
controls O O
in O O
the O O
prefrontal O O
cortex O O
( O O
moderate O O
- O O
dose O O
, O O
24 O O
. O O
1 O O
; O O
high O O
- O O
dose O O
, O O
23 O O
. O O
6 O O
; O O
controls O O
18 O O
. O O
7 O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
striatum O O
( O O
moderate O O
- O O
dose O O
25 O O
. O O
6 O O
; O O
high O O
- O O
dose O O
26 O O
. O O
3 O O
; O O
controls O O
18 O O
. O O
9 O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
but O O
not O O
in O O
hippocampus O O
. O O

The O O
number O O
of O O
stained O O
microglia O O
cells O O
was O O
significantly O O
higher O O
in O O
the O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treated O O
groups O O
in O O
the O O
prefrontal O O
cortex O O
than O O
in O O
controls O O
( O O
moderate O O
- O O
dose O O
, O O
29 O O
. O O
1 O O
; O O
high O O
- O O
dose O O
, O O
28 O O
. O O
4 O O
; O O
control O O
, O O
17 O O
. O O
7 O O
cells O O
per O O
field O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Stained O O
microglia O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O O
significantly O O
more O O
numerous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
striatum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
high O B_MEASURE/B_LOCATION
- O O
dose O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
controls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

CONCLUSION O O
: O O
Subacute O O
exposure O O
to O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induced O O
anxiety O O
and O O
reactivity O O
of O O
microglia O O
. O O

The O O
relevance O O
of O O
these O O
features O O
for O O
patients O O
using O O
PDN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
remains O O
to O O
be O O
elucidated O O
. O O

Phase O O
II O O
study O O
of O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
recurrent O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
cervix O O
. O O

BACKGROUND O O
: O O
The O O
activity O O
of O O
the O O
combination O O
of O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
tested O O
in O O
a O O
Phase O O
II O O
study O O
of O O
patients O O
with O O
recurrent O O
cervical O O
carcinoma O O
. O O

METHODS O O
: O O
The O O
combination O O
of O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
area O O
under O O
the O O
concentration O O
curve O O
[ O O
AUC O O
] O O
, O O
5 O O
) O O
and O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Doxil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
; O O
starting O O
dose O O
, O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
was O O
administered O O
intravenously O O
every O O
28 O O
days O O
to O O
37 O O
patients O O
with O O
recurrent O O
squamous O O
cell O O
cervical O O
carcinoma O O
to O O
determine O O
antitumor O O
activity O O
and O O
toxicity O O
profile O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Twenty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
assessable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
35 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
assessable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
toxicity O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
overall O B_MEASURE
response O I_MEASURE
rate O I_MEASURE
was O O
38 O B_MEASURE
% O I_MEASURE
, O O
the O O
median O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
to O O
response O O
was O O
10 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
, O O
the O O
median O B_MEASURE/B_LOCATION
duration O I_MEASURE/I_LOCATION
of O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
26 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
, O O
and O O
the O O
median O B_MEASURE
survival O I_MEASURE
was O O
37 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
. O O

The O O
main O B_DISEASE_ADJECTIVE[DISEASE]
toxic O I_DISEASE_ADJECTIVE[DISEASE]
effect O I_DISEASE_ADJECTIVE[DISEASE]
was O O
myelosuppression O B_DISEASE
, O O
with O O
Grade O B_MEASURE/B_DISEASE
3 O I_MEASURE/I_DISEASE
and O O
4 O B_DISEASE/B_MEASURE
neutropenia O I_DISEASE/I_MEASURE
in O O
16 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
anemia O B_DISEASE
in O O
12 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
, O O
thrombocytopenia O B_DISEASE
in O O
11 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
, O O
and O O
neutropenic O B_DISEASE
fever O I_DISEASE
in O O
3 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
. O O

Four O O
patients O O
had O O
five O O
infusion O O
- O O
related O O
reactions O O
during O O
the O O
infusion O O
of O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leading O O
to O O
treatment O O
discontinuation O O
in O O
three O O
patients O O
. O O

Grade O B_MEASURE/B_PERSON
> O I_MEASURE/I_PERSON
or O O
= O O
2 O B_MEASURE
nonhematologic O I_MEASURE
toxicity O I_MEASURE
included O O
nausea O B_DISEASE
in O O
17 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
emesis O B_DISEASE
in O O
14 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
, O O
fatigue O B_DISEASE
in O O
9 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
mucositis O B_DISEASE
and O O
/ O O
or O O
stomatitis O B_DISEASE
in O O
8 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
constipation O B_DISEASE
in O O
6 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
, O O
weight O B_DISEASE
loss O I_DISEASE
in O O
5 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
foot O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
2 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
and O O
skin O B_DISEASE
reactions O I_DISEASE
in O O
3 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
liposomal O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
modest O O
activity O O
in O O
patients O O
with O O
recurrent O O
cervical O O
carcinoma O O
. O O

Antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
( O O
antibiomania O B_DISEASE/B_MEASURE
) O O
: O O
a O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
spontaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviewed O O
reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episodes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
MEDLINE O B_ORGANIZATION
and O O
PsychLit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
search O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
. O O

Unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
requested O O
from O O
the O O
World O B_ORGANIZATION/B_PERSON
Health O I_ORGANIZATION/I_PERSON
Organization O I_ORGANIZATION/I_PERSON
( O O
WHO O B_ORGANIZATION/B_LOCATION
) O O
and O O
the O O
Food O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Drug O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Administration O I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FDA O B_ORGANIZATION/B_LOCATION
) O O
. O O

Twenty O B_NUMBER[MEASURE]/B_LOCATION
- O O
one O B_NUMBER[MEASURE]/B_ORGANIZATION
reports O I_NUMBER[MEASURE]/I_ORGANIZATION
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
were O O
found O O
in O O
the O O
literature O B_PERSON/B_LOCATION
. O O

There O O
were O O
6 O O
cases O O
implicating O O
clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
13 O O
implicating O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
1 O O
case O O
each O O
implicating O O
erythromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amoxicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
WHO O O
reported O O
82 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Of O O
these O O
, O O
clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
implicated O O
in O O
23 O O
( O O
27 O O
. O O
6 O O
% O O
) O O
cases O O
, O O
ciprofloxacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
12 O O
( O O
14 O O
. O O
4 O O
% O O
) O O
cases O O
, O O
and O O
ofloxacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
10 O O
( O O
12 O O
% O O
) O O
cases O O
. O O

Cotrimoxazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
metronidazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
erythromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
involved O O
in O O
15 O O
reported O O
manic O O
episodes O O
. O O

Cases O O
reported O O
by O O
the O O
FDA O O
showed O O
clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ciprofloxacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
the O O
most O O
frequently O O
associated O O
with O O
the O O
development O O
of O O
mania O O
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
would O O
not O O
have O O
demonstrated O O
a O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
statistical O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
correlative O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
risk O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
was O O
therefore O O
not O O
undertaken O O
. O O

Patients O B_PERSON/B_BIO
have O O
an O O
increased O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
developing O O
mania O B_DISEASE
while O O
being O O
treated O O
with O O
antimicrobials O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
this O O
is O O
not O O
a O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
physicians O B_PERSON
must O O
be O O
aware O B_PERSON
of O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
reversibility O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearly O O
is O O
required O O
to O O
determine O O
the O O
incidence O B_MEASURE
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE
, O O
the O O
relative O B_MEASURE
risk O I_MEASURE
factors O I_MEASURE
of O O
developing O O
an O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
manic O B_DISEASE
episode O I_DISEASE
among O O
various O B_PERSON
demographic O I_PERSON
populations O I_PERSON
, O O
and O O
the O O
incidence O B_MEASURE
of O O
patients O B_PERSON
who O O
continue O O
to O O
have O O
persistent O B_DISEASE
affective O I_DISEASE
disorders O I_DISEASE
once O O
the O O
initial O B_DISEASE
episode O I_DISEASE
, O O
which O O
occurs O O
while O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
taking O O
antibiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
subsides O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

The O O
authors O B_PERSON/B_ORGANIZATION
elected O O
to O O
name O O
this O O
syndrome O B_DISEASE/B_BIO
" O O
antibiomania O B_BACTERIUM[BIO]/B_GENE
. O O
" O O

Levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O O
dyskinesias O O
in O O
Parkinson O O
' O O
s O O
disease O O
. O O

Levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O O
dyskinesias O O
are O O
very O O
uncommon O O
. O O

Usually O O
they O O
occur O O
simultaneously O O
with O O
limb O B_MEASURE/B_LOCATION
peak O I_MEASURE/I_LOCATION
- O O
dose O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
choreatic O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dyskinesias O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

We O O
report O O
on O O
a O O
patient O O
with O O
leftward O O
and O O
upward O O
deviations O O
of O O
gaze O O
during O O
the O O
peak O O
effect O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
hypothesize O O
that O O
a O O
severe O O
dopaminergic O O
denervation O O
in O O
the O O
caudate O O
nucleus O O
is O O
needed O O
for O O
the O O
appearance O O
of O O
these O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induce O O
ocular O O
dyskinesias O O
. O O

A O O
comparison O O
of O O
glyceryl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trinitrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea O O
: O O
an O O
open O O
, O O
randomized O O
, O O
cross O O
- O O
over O O
trial O O
. O O

Primary O O
dysmenorrhea O O
is O O
a O O
syndrome O O
characterized O O
by O O
painful O O
uterine O O
contractility O O
caused O O
by O O
a O O
hypersecretion O O
of O O
endometrial O O
prostaglandins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
; O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
are O O
the O O
first O O
choice O O
for O O
its O O
treatment O O
. O O

However O O
, O O
in O O
vivo O O
and O O
in O O
vitro O O
studies O O
have O O
demonstrated O O
that O O
myometrial O O
cells O O
are O O
also O O
targets O O
of O O
the O O
relaxant O O
effects O O
of O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
the O O
efficacy O O
of O O
glyceryl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trinitrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GTN B B_ORGANIZATION/B_LOCATION
) O O
, O O
an O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
donor O O
, O O
in O O
the O O
resolution O O
of O O
primary O O
dysmenorrhea O O
in O O
comparison O O
with O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DCF B B_LOCATION/B_ORGANIZATION
) O O
. O O

A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
24 O B_PERSON
patients O I_PERSON
with O O
the O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
severe O B_DISEASE
primary O I_DISEASE
dysmenorrhea O I_DISEASE
were O O
studied O O
during O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
consecutive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
menstrual O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
cycles O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
an O O
open O O
, O O
cross O O
- O O
over O O
, O O
controlled O O
design O O
, O O
patients O O
were O O
randomized O O
to O O
receive O O
either O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
per O O
os O O
or O O
GTN B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches O O
the O O
first O O
days O O
of O O
menses O O
, O O
when O O
menstrual O O
cramps O O
became O O
unendurable O O
. O O

In O O
the O O
subsequent O B_TIME[MEASURE]/B_LOCATION
cycle O I_TIME[MEASURE]/I_LOCATION
the O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
. O O

Patients O O
received O O
up O O
to O O
3 O O
doses O O
/ O O
day O O
of O O
50 O O
mg O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
2 O O
. O O
5 O O
mg O O
/ O O
24 O O
h O O
transdermal O O
GTN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
first O O
3 O O
days O O
of O O
the O O
cycle O O
, O O
according O O
to O O
their O O
needs O O
. O O

The O O
participants O B_PERSON
recorded O O
menstrual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptoms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
possible O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
different O B_MEASURE/B_ENT
times O I_MEASURE/I_ENT
( O O
0 O B_MEASURE
, O O
30 O B_MEASURE
, O O
60 O B_MEASURE
, O O
120 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
) O O
after O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
day O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
the O O
cycle O B_TIME[MEASURE]
, O O
with O O
both O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
difference O B_MEASURE
in O O
pain O B_DISEASE
intensity O I_DISEASE
score O I_DISEASE
( O O
DPI O B_DISEASE/B_LOCATION
) O O
was O O
the O O
main O B_MEASURE
outcome O I_MEASURE
variable O I_MEASURE
. O O

Both O O
treatments O O
significantly O O
reduced O O
DPI O O
by O O
the O O
30th O O
minute O O
( O O
GTN B B_LOCATION
, O O
- O O
12 O O
. O O
8 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
; O O
DCF B B_LOCATION/B_ORGANIZATION
, O O
- O O
18 O O
. O O
9 O O
+ O O
/ O O
- O O
16 O O
. O O
6 O O
) O O
. O O

However O O
, O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
to O O
be O O
effective O O
in O O
reducing O O
pelvic O O
pain O O
for O O
two O O
hours O O
, O O
whereas O O
GTN B B_DISEASE/B_MEASURE
scores O O
remained O O
more O O
or O O
less O O
stable O O
after O O
30 O O
min O O
and O O
significantly O O
higher O O
than O O
those O O
for O O
DFC O O
( O O
after O O
one O O
hour O O
: O O
GTN B B_LOCATION/B_PROTEIN[GENE]
, O O
- O O
12 O O
. O O
8 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
; O O
DFC O O
, O O
- O O
18 O O
. O O
9 O O
+ O O
/ O O
- O O
16 O O
. O O
6 O O
and O O
after O O
two O O
hours O O
: O O
GTN B B_LOCATION/B_PROTEIN[GENE]
, O O
- O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
20 O O
. O O
5 O O
; O O
DFC O O
, O O
- O O
59 O O
. O O
7 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
, O O
p O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Low O B_DISEASE/B_PERSON
back O I_DISEASE/I_PERSON
pain O I_DISEASE/I_PERSON
was O O
also O O
relieved O O
by O O
both O O
drugs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Headache O O
was O O
significantly O O
increased O O
by O O
GTN B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
by O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Eight O O
patients O O
stopped O O
using O O
GTN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O O
headache O O
- O O
- O O
attributed O O
to O O
its O O
use O O
- O O
- O O
became O O
intolerable O O
. O O

These O O
findings O O
indicate O O
that O O
GTN B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
reduced O O
efficacy O O
and O O
tolerability O O
by O O
comparison O O
with O O
DCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea O O
. O O

Temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
converting O O
enzyme O O
inhibitor O O
, O O
modulates O O
glomerular O O
injury O O
in O O
chronic O O
puromycin B B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DISEASE_ADJECTIVE[DISEASE]
nephrosis O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
whether O O
chronic O O
administration O O
of O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin B B_GENE
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitor O O
, O O
reduced O O
proteinuria O O
, O O
inhibited O O
glomerular O O
hypertrophy O O
and O O
prevented O O
glomerulosclerosis O O
in O O
chronic O O
puromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PAN B B_DISEASE
) O O
- O O
induced O O
nephrotic O O
rats O O
. O O

Nephrosis O O
was O O
induced O O
by O O
injection O O
of O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
15mg O O
/ O O
100g O O
body O O
weight O O
) O O
in O O
male O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

Four O O
groups O O
were O O
used O O
, O O
i O O
) O O
the O O
PAN B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
( O O
14 O O
) O O
, O O
ii O O
) O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
13 O O
) O O
, O O
iii O O
) O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
14 O O
) O O
and O O
iv O O
) O O
untreated O O
controls O O
( O O
15 O O
) O O
. O O

Temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
8 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
was O O
administered O O
to O O
the O O
rats O O
which O O
were O O
killed O O
at O O
weeks O O
4 O O
, O O
14 O O
or O O
20 O O
. O O

At O O
each O O
time O B_MEASURE/B_LOCATION
point O B_MEASURE/I_LOCATION
, O O
systolic O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
( O O
BP O B_DISEASE/B_GENE
) O O
, O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT
protein O I_BODY_PART_OR_ORGAN_COMPONENT
excretion O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histopathological O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
evaluated O O
, O O
and O O
morphometric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
done O O
. O O

Systolic O O
BP O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
was O O
significantly O O
high O O
at O O
4 O O
, O O
14 O O
and O O
20 O O
weeks O O
, O O
but O O
was O O
normal O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
temocapril B B_LOCATION
group O O
. O O

Urinary O O
protein O O
excretion O O
in O O
the O O
PAN B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
increased O O
significantly O O
, O O
peaking O O
at O O
8 O O
days O O
, O O
then O O
decreased O O
at O O
4 O O
weeks O O
, O O
but O O
rose O O
again O O
significantly O O
at O O
14 O O
and O O
20 O O
weeks O O
. O O

Temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
did O O
not O O
attenuate O O
proteinuria O O
at O O
8 O O
days O O
, O O
but O O
it O O
did O O
markedly O O
lower O O
it O O
from O O
weeks O O
4 O O
to O O
20 O O
. O O

The O O
glomerulosclerosis O O
index O O
( O O
GSI O O
) O O
was O O
6 O O
. O O
21 O O
% O O
at O O
4 O O
weeks O O
and O O
respectively O O
25 O O
. O O
35 O O
% O O
and O O
30 O O
. O O
49 O O
% O O
at O O
14 O O
and O O
20 O O
weeks O O
in O O
the O O
PAN B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
. O O

There O O
was O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
urinary O B_LOCATION/B_ORGANIZATION
protein O I_LOCATION/I_ORGANIZATION
excretion O I_LOCATION/I_ORGANIZATION
and O O
GSI O B_DISEASE/B_GENE
( O O
r O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE/B_LOCATION
. O O
808 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

The O O
ratio O O
of O O
glomerular O O
tuft O O
area O O
to O O
the O O
area O O
of O O
Bowman O O
' O O
s O O
capsules O O
( O O
GT O O
/ O O
BC O O
) O O
in O O
the O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
was O O
significantly O O
increased O O
, O O
but O O
it O O
was O O
significantly O O
lower O O
in O O
the O O
PAN B B_LOCATION/B_ORGANIZATION
/ O O
temocapril B B_LOCATION/B_ORGANIZATION
group O O
. O O

It O O
appears O O
that O O
temocapril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
effective O O
in O O
retarding O O
renal O O
progression O O
and O O
protected O O
renal O O
function O O
in O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neprotic O O
rats O O
. O O

Pulmonary O O
hypertension O O
after O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prophylaxis O O
in O O
very O O
preterm O O
infants O O
. O O

We O O
report O O
three O O
cases O O
of O O
severe O O
hypoxaemia O O
after O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
during O O
a O O
randomised O O
controlled O O
trial O O
of O O
prophylactic O O
treatment O O
of O O
patent O O
ductus O O
arteriosus O O
with O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
premature O O
infants O O
born O O
at O O
less O O
than O O
28 O O
weeks O O
of O O
gestation O O
. O O

Echocardiography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
severely O O
decreased O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hypoxaemia O O
resolved O O
quickly O O
on O O
inhaled O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

We O O
suggest O O
that O O
investigators O O
involved O O
in O O
similar O O
trials O O
pay O O
close O O
attention O O
to O O
pulmonary O O
pressure O O
if O O
hypoxaemia O O
occurs O O
after O O
prophylactic O O
administration O O
of O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hyponatremia O O
and O O
syndrome O O
of O O
inappropriate O O
anti O O
- O O
diuretic O O
hormone O O
reported O O
with O O
the O O
use O O
of O O
Vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
an O O
over O O
- O O
representation O O
of O O
Asians O O
? O O

PURPOSE O O
: O O
This O O
retrospective O O
study O O
used O O
a O O
pharmaceutical O O
company O O
' O O
s O O
global O O
safety O O
database O O
to O O
determine O O
the O O
reporting O O
rate O O
of O O
hyponatremia O O
and O O
/ O O
or O O
syndrome O O
of O O
inappropriate O O
secretion O O
of O O
anti O O
- O O
diuretic O O
hormone O O
( O O
SIADH O O
) O O
among O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O O
and O O
to O O
explore O O
the O O
possibility O O
of O O
at O O
- O O
risk O O
population O O
subgroups O O
. O O

METHOD O O
: O O
We O O
searched O O
the O O
Eli O O
Lilly O O
and O O
Company O O
' O O
s O O
computerized O O
adverse O O
event O O
database O O
for O O
all O O
reported O O
cases O O
of O O
hyponatremia O O
and O O
/ O O
or O O
SIADH O O
as O O
of O O
1 O O
November O O
1999 O O
that O O
had O O
been O O
reported O O
during O O
the O O
use O O
of O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
A O O
total O O
of O O
76 O O
cases O O
of O O
hyponatremia O O
and O O
/ O O
or O O
SIADH O O
associated O O
with O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
were O O
identified O O
. O O

The O O
overall O B_MEASURE/B_PERSON
reporting O I_MEASURE/I_PERSON
rate O I_MEASURE/I_PERSON
was O O
estimated O O
to O O
be O O
1 O B_MEASURE
. O O
3 O B_MEASURE
/ O O
100 O B_MEASURE
, O O
000 O B_MEASURE
treated O O
patients O B_PERSON/B_LOCATION
. O O

The O O
average O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_LOCATION
was O O
35 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
28 O B_MEASURE
. O O
3 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
, O O
and O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
were O O
males O B_PERSON
. O O

Approximately O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
patients O B_PERSON
were O O
receiving O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
leukemia O B_DISEASE
or O O
lymphoma O B_DISEASE
. O O

Among O O
the O O
39 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
included O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
race O B_SPORT[ENT]/B_PERSON
, O O
the O O
racial O B_MEASURE/B_PERSON
distribution O I_MEASURE/I_PERSON
was O O
: O O
1 O B_PERSON/B_NUMBER[MEASURE]
Black O B_PERSON/I_NUMBER[MEASURE]
, O O
3 O B_PERSON/B_COLOR
Caucasian O I_PERSON/I_COLOR
, O O
and O O
35 O B_NUMBER[MEASURE]/B_PERSON
Asian O I_NUMBER[MEASURE]/I_PERSON
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
Asian O O
patients O O
may O O
be O O
at O O
increased O O
risk O O
of O O
hyponatremia O O
and O O
/ O O
or O O
SIADH O O
associated O O
with O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

Although O O
the O O
overall O O
reported O O
rate O O
of O O
SIADH O O
associated O O
with O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
very O O
low O O
, O O
physicians O O
caring O O
for O O
Asian O O
oncology O O
patients O O
should O O
be O O
aware O O
of O O
this O O
potential O O
serious O O
but O O
reversible O O
adverse O O
event O O
. O O

Delayed O O
toxicity O O
of O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
bladder O O
of O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mouse O O
. O O

The O O
present O O
study O O
describes O O
the O O
delayed O O
development O O
of O O
a O O
severe O O
bladder O O
pathology O O
in O O
a O O
susceptible O O
strain O O
of O O
mice O O
( O O
DBA O O
/ O O
2 O O
) O O
but O O
not O O
in O O
a O O
resistant O O
strain O O
( O O
C57BL O O
/ O O
6 O O
) O O
when O O
both O O
were O O
treated O O
with O O
a O O
single O O
300 O O
mg O O
/ O O
kg O O
dose O O
of O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

Inbred O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mice O O
were O O
injected O O
with O O
CY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
bladder O O
was O O
assessed O O
during O O
100 O O
days O O
by O O
light O O
microscopy O O
using O O
different O O
staining O O
procedures O O
, O O
and O O
after O O
30 O O
days O O
by O O
conventional O O
electron O O
microscopy O O
. O O

Early O O
CY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
toxicity O O
caused O O
a O O
typical O O
haemorrhagic O O
cystitis O O
in O O
both O O
strains O O
that O O
was O O
completely O O
repaired O O
in O O
about O O
7 O O
- O O
10 O O
days O O
. O O

After O O
30 O O
days O O
of O O
CY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O O
ulcerous O O
and O O
non O O
- O O
ulcerous O O
forms O O
of O O
chronic O O
cystitis O O
appeared O O
in O O
86 O O
% O O
of O O
DBA O O
/ O O
2 O O
mice O O
but O O
only O O
in O O
4 O O
% O O
of O O
C57BL O O
/ O O
6 O O
mice O O
. O O

Delayed O B_DISEASE
cystitis O I_DISEASE
was O O
characterized O O
by O O
infiltration O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
transepithelial O B_DISEASE_ADJECTIVE[DISEASE]
passage O I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
lumen O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O O
inflammatory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
frequent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exfoliation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
urothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Mast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
appeared O O
in O O
the O O
connective O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
muscular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
layers O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT
at O O
a O O
much O O
higher O B_MEASURE
number O I_MEASURE
in O O
DBA O B_PROTEIN[GENE]/B_DISEASE
/ O O
2 O B_MEASURE/B_PROTEIN[GENE]
mice O I_MEASURE/I_PROTEIN[GENE]
than O O
in O O
C57BL O B_PROTEIN[GENE]/B_BIO
/ O O
6 O B_MEASURE
mice O I_MEASURE
or O O
untreated O B_PERSON/B_MEASURE
controls O I_PERSON/I_MEASURE
. O O

Electron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disclosed O O
the O O
absence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
typical O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
discoidal O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vesicles O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
normally O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
of O O
surface O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Instead O O
, O O
numerous O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
vesicles O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
containing O O
one O B_NUMBER[MEASURE]
or O O
several O B_NUMBER[MEASURE]/B_PERSON
dark O I_NUMBER[MEASURE]/I_PERSON
granules O I_NUMBER[MEASURE]/I_PERSON
were O O
observed O O
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O O
all O O
the O O
epithelial O B_LOCATION/B_DISEASE
layers O I_LOCATION/I_DISEASE
. O O

Delayed O B_DISEASE_ADJECTIVE[DISEASE]
cystitis O I_DISEASE_ADJECTIVE[DISEASE]
still O O
persisted O O
in O O
DBA O B_MEASURE/B_PROTEIN[GENE]
/ O O
2 O B_PROTEIN[GENE]/B_DISEASE
mice O I_PROTEIN[GENE]/I_DISEASE
100 O I_PROTEIN[GENE]/I_DISEASE
days O I_PROTEIN[GENE]/I_DISEASE
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

These O O
results O O
indicate O O
that O O
delayed O O
toxicity O O
of O O
CY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
female O O
DBA O O
/ O O
2 O O
mice O O
causes O O
a O O
bladder O O
pathology O O
that O O
is O O
not O O
observed O O
in O O
C57BL O O
/ O O
6 O O
mice O O
. O O

This O O
pathology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resembles O O
interstitial O B_DISEASE/B_LOCATION
cystitis O I_DISEASE/I_LOCATION
in O O
humans O B_PERSON/B_SPECIES[BIO]
and O O
could O O
perhaps O O
be O O
used O O
as O O
an O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
the O O
disease O B_DISEASE
. O O

High O O
- O O
dose O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
combination O O
with O O
three O O
- O O
weekly O O
mitomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
advanced O O
gastric O O
cancer O O
. O O

A O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

BACKGROUND O O
: O O
The O O
24 O O
- O O
hour O O
continuous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
FU I I_LOCATION/I_PROTEIN[GENE]
) O O
and O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FA B B_LOCATION
) O O
as O O
part O O
of O O
several O O
new O O
multidrug O O
chemotherapy O O
regimens O O
in O O
advanced O O
gastric O O
cancer O O
( O O
AGC O O
) O O
has O O
shown O O
to O O
be O O
effective O O
, O O
with O O
low O O
toxicity O O
. O O

In O O
a O O
previous O O
phase O O
II O O
study O O
with O O
3 O O
- O O
weekly O O
bolus O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
FA B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mitomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
we O O
found O O
a O O
low O O
toxicity O O
rate O O
and O O
response O O
rates O O
comparable O O
to O O
those O O
of O O
regimens O O
such O O
as O O
ELF O O
, O O
FAM O O
or O O
FAMTX O O
, O O
and O O
a O O
promising O O
median O O
overall O O
survival O O
. O O

In O O
order O O
to O O
improve O O
this O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O O
schedule O O
we O O
initiated O O
a O O
phase O O
II O O
study O O
with O O
high O O
- O O
dose O O
5 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
FU I I_LOCATION/I_PERSON
/ O O
FA B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
3 O O
- O O
weekly O O
bolus O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
From O O
February O O
, O O
1998 O O
to O O
September O O
, O O
2000 O O
we O O
recruited O O
33 O O
patients O O
with O O
AGC O O
to O O
receive O O
weekly O O
24 O O
- O O
hour O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 O O
, O O
600 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
preceded O O
by O O
2 O O
- O O
hour O O
FA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
for O O
6 O O
weeks O O
, O O
followed O O
by O O
a O O
2 O O
- O O
week O O
rest O O
period O O
. O O

Bolus O O
MMC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
was O O
added O O
in O O
3 O O
- O O
weekly O O
intervals O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
given O O
on O O
an O O
outpatient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
basis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
using O O
portable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
repeated O O
on O O
day O B_TIME[MEASURE]/B_LOCATION
57 O I_TIME[MEASURE]/I_LOCATION
. O O

Patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
: O O
male O B_PERSON
/ O O
female O B_MEASURE/B_PERSON
ratio O I_MEASURE/I_PERSON
20 O I_MEASURE/I_PERSON
/ O O
13 O B_MEASURE
; O O
median O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
57 O I_MEASURE/I_PERSON
( O O
27 O B_MEASURE
- O O
75 O B_MEASURE
) O O
years O B_TIME[MEASURE]/B_ORGANIZATION
; O O
median O B_LOCATION/B_MEASURE
WHO O O
status O B_MEASURE
1 O I_MEASURE
( O O
0 O B_MEASURE
- O O
2 O B_MEASURE
) O O
. O O

18 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
had O O
a O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
AGC O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
and O O
15 O B_NUMBER[MEASURE]
showed O O
a O O
relapsed O B_DISEASE/B_LOCATION
AGC O I_DISEASE/I_LOCATION
. O O

Median O B_TIME[MEASURE]/B_PERSON
follow O I_TIME[MEASURE]/I_PERSON
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
11 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_MEASURE/B_LOCATION
of O O
those O O
surviving O O
: O O
2 O B_MEASURE
. O O
7 O B_MEASURE
- O O
11 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
32 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
were O O
evaluable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
complete O B_MEASURE
remission O I_MEASURE
9 O I_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
( O O
n O B_MEASURE/B_PROTEIN[GENE]
= O O
3 O B_MEASURE
) O O
, O O
partial O B_TIME[MEASURE]
remission O I_TIME[MEASURE]
45 O I_TIME[MEASURE]
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
15 O B_MEASURE
) O O
, O O
no O O
change O B_TIME[MEASURE]
27 O I_TIME[MEASURE]
. O O
3 O B_MEASURE
% O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
9 O B_MEASURE
) O O
, O O
progressive O B_MEASURE
disease O I_MEASURE
15 O I_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
5 O B_MEASURE
) O O
. O O

Median O B_TIME[MEASURE]/B_PERSON
overall O I_TIME[MEASURE]/I_PERSON
survival O I_TIME[MEASURE]/I_PERSON
time O I_TIME[MEASURE]/I_PERSON
was O O
10 O B_MEASURE
. O O
2 O B_MEASURE
months O I_MEASURE
[ O I_MEASURE
95 O I_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
( O O
CI O B_LOCATION
) O O
: O O
8 O B_MEASURE
. O O
7 O B_MEASURE
- O O
11 O B_MEASURE
. O O
6 O B_MEASURE
] O I_MEASURE
, O O
and O O
median O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_TIME[MEASURE]/B_LOCATION
survival O I_TIME[MEASURE]/I_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
was O O
7 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
95 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
CI O I_TIME[MEASURE]/I_LOCATION
: O O
4 O B_MEASURE
. O O
4 O B_MEASURE
- O O
10 O B_MEASURE
. O O
9 O B_MEASURE
) O O
. O O

The O O
worst O B_DISEASE/B_MEASURE
toxicities O I_DISEASE/I_MEASURE
( O O
% O B_PROTEIN[GENE]/B_DISEASE
) O O
observed O O
were O O
( O O
CTC O B_MEASURE/B_LOCATION
- O O
NCI O B_MEASURE
1 O I_MEASURE
/ O O
2 O B_MEASURE
/ O O
3 O B_MEASURE
) O O
: O O
leukopenia O B_MEASURE
45 O I_MEASURE
. O O
5 O B_MEASURE
/ O O
18 O B_MEASURE
. O O
2 O B_MEASURE
/ O O
6 O B_MEASURE
. O O
1 O B_MEASURE
, O O
thrombocytopenia O B_MEASURE
33 O I_MEASURE
. O O
3 O B_MEASURE
/ O O
9 O B_MEASURE
. O O
1 O B_MEASURE
/ O O
6 O B_MEASURE
. O O
1 O B_MEASURE
, O O
vomitus O B_TIME[MEASURE]
24 O I_TIME[MEASURE]
. O O
2 O B_MEASURE
/ O O
9 O B_MEASURE
. O O
1 O B_MEASURE
/ O O
0 O B_MEASURE
, O O
diarrhea O B_TIME[MEASURE]
36 O I_TIME[MEASURE]
. O O
4 O B_MEASURE
/ O O
6 O B_MEASURE
. O O
1 O B_MEASURE
/ O O
3 O B_MEASURE
. O O
0 O B_NUMBER[MEASURE]
, O O
stomatitis O B_MEASURE
18 O I_MEASURE
. O O
2 O B_MEASURE
/ O O
9 O B_MEASURE
. O O
1 O B_MEASURE
/ O O
0 O B_MEASURE
, O O
hand O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
foot O B_MEASURE
syndrome O I_MEASURE
12 O I_MEASURE
. O O
1 O B_MEASURE
/ O O
0 O B_MEASURE
/ O O
0 O B_MEASURE
. O O

Two O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
developed O O
hemolytic O B_DISEASE
- O O
uremic O B_DISEASE
syndrome O I_DISEASE
( O O
HUS O B_MEASURE/B_DISEASE
) O O
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
5 B B_LOCATION/B_PERSON
- I I_LOCATION/I_PERSON
FU I I_LOCATION/I_PERSON
/ O O
FA B B_LOCATION
/ O O
MMC B B_LOCATION/B_ORGANIZATION
is O O
an O O
effective O O
and O O
well O O
- O O
tolerated O O
outpatient O O
regimen O O
for O O
AGC O O
( O O
objective O O
response O O
rate O O
54 O O
. O O
6 O O
% O O
) O O
. O O

It O O
may O O
serve O O
as O O
an O O
alternative O O
to O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
containing O O
regimens O O
; O O
however O O
, O O
it O O
has O O
to O O
be O O
considered O O
that O O
possibly O O
HUS O O
may O O
occur O O
. O O

Persistent O O
sterile O O
leukocyturia O O
is O O
associated O O
with O O
impaired O O
renal O O
function O O
in O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
- O O
infected O O
children O O
treated O O
with O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O O
: O O
Prolonged O O
administration O O
of O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
associated O O
with O O
the O O
occurrence O O
of O O
a O O
variety O O
of O O
renal O O
complications O O
in O O
adults O O
. O O

These O O
well O O
- O O
documented O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O O
restricted O O
the O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
this O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_DISEASE
. O O

DESIGN O O
: O O
A O O
prospective O O
study O O
to O O
monitor O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
related O O
nephrotoxicity O O
in O O
a O O
cohort O O
of O O
30 O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
- O O
infected O O
children O O
treated O O
with O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O O
: O O
Urinary O O
pH O O
, O O
albumin O O
, O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
presence O O
of O O
erythrocytes O O
, O O
leukocytes O O
, O O
bacteria O O
and O O
crystals O O
, O O
and O O
culture O O
were O O
analyzed O O
every O O
3 O O
months O O
for O O
96 O O
weeks O O
. O O

Serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
routinely O O
determined O O
at O O
the O O
same O O
time O O
points O O
. O O

Steady O O
- O O
state O O
pharmacokinetics O O
of O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
done O O
at O O
week O O
4 O O
after O O
the O O
initiation O O
of O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
cumulative O B_MEASURE
incidence O I_MEASURE
of O O
persistent O B_DISEASE
sterile O I_DISEASE
leukocyturia O I_DISEASE
( O O
> O B_MEASURE/B_OTHER
or O O
= O O
75 O B_MEASURE
cells O I_MEASURE
/ O O
micro O B_TIME[MEASURE]/B_LOCATION
L O I_TIME[MEASURE]/I_LOCATION
in O O
at O O
least O O
2 O B_NUMBER[MEASURE]/B_PERSON
consecutive O I_NUMBER[MEASURE]/I_PERSON
visits O I_NUMBER[MEASURE]/I_PERSON
) O O
after O O
96 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
53 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Persistent O O
sterile O O
leukocyturia O O
was O O
frequently O O
associated O O
with O O
a O O
mild O O
increase O O
in O O
the O O
urine O O
albumin O O
/ O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ratio O O
and O O
by O O
microscopic O O
hematuria O O
. O O

The O O
cumulative O O
incidence O O
of O O
serum O O
creatinine B B_MEASURE/B_GENE
levels O O
> O O
50 O O
% O O
above O O
normal O O
was O O
33 O O
% O O
after O O
96 O O
weeks O O
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia O O
more O O
frequently O O
had O O
serum O O
creatinine B B_MEASURE/B_GENE
levels O O
of O O
50 O O
% O O
above O O
normal O O
than O O
those O O
children O O
without O O
persistent O O
sterile O O
leukocyturia O O
. O O

In O O
children O B_MEASURE/B_PERSON
younger O I_MEASURE/I_PERSON
than O O
5 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
persistent O B_DISEASE
sterile O I_DISEASE
leukocyturia O I_DISEASE
was O O
significantly O O
more O O
frequent O B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
older O B_PERSON/B_ORGANIZATION
children O I_PERSON/I_ORGANIZATION
. O O

A O O
higher O O
cumulative O O
incidence O O
of O O
persistent O O
leukocyturia O O
was O O
found O O
in O O
children O O
with O O
an O O
area O O
under O O
the O O
curve O O
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
or O O
a O O
peak O O
serum O O
level O O
of O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
> O O
12 O O
mg O O
/ O O
L O O
. O O

In O O
4 O O
children O O
, O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
discontinued O O
because O O
of O O
nephrotoxicity O O
. O O

Subsequently O O
, O O
the O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
decreased O O
, O O
the O O
urine O O
albumin O O
/ O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ratios O O
returned O O
to O O
zero O O
, O O
and O O
the O O
leukocyturia O O
disappeared O O
within O O
3 O O
months O O
. O O

CONCLUSIONS O O
: O O
Children O O
treated O O
with O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
a O O
high O O
cumulative O O
incidence O O
of O O
persistent O O
sterile O O
leukocyturia O O
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia O O
more O O
frequently O O
had O O
an O O
increase O O
in O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
of O O
> O O
50 O O
% O O
above O O
normal O O
. O O

Younger O B_PERSON/B_ENT
children O I_PERSON/I_ENT
have O O
an O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
renal O B_DISEASE
complications O I_DISEASE
. O O

The O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
renal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
these O O
children O B_PERSON/B_BIO
occurred O O
in O O
the O O
absence O B_DISEASE/B_MEASURE
of O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
of O O
nephrolithiasis O B_DISEASE/B_GENE
. O O

Indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
associated O O
nephrotoxicity O O
must O O
be O O
monitored O O
closely O O
, O O
especially O O
in O O
children O O
with O O
risk O O
factors O O
such O O
as O O
persistent O O
sterile O O
leukocyturia O O
, O O
age O O
< O O
5 O O
. O O
6 O O
years O O
, O O
an O O
area O O
under O O
the O O
curve O O
of O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
, O O
and O O
a O O
C O O
( O O
max O O
) O O
> O O
12 O O
mg O O
/ O O
L O O
. O O

Utility O O
of O O
troponin O O
I O O
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
. O O

Baseline O O
electrocardiogram O O
abnormalities O O
and O O
market O O
elevations O O
not O O
associated O O
with O O
myocardial O O
necrosis O O
make O O
accurate O O
diagnosis O O
of O O
myocardial O O
infarction O O
( O O
MI O O
) O O
difficult O O
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
. O O

Troponin O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sampling O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O O
offer O O
greater O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
patients O B_PERSON/B_LOCATION
. O O

OBJECTIVE O O
: O O
To O O
assess O O
outcomes O O
based O O
on O O
troponin O O
positivity O O
in O O
patients O O
with O O
cocaine B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chest O O
pain O O
admitted O O
for O O
exclusion O O
of O O
MI O O
. O O

METHODS O O
: O O
Outcomes O O
were O O
examined O O
in O O
patients O O
admitted O O
for O O
possible O O
MI O O
after O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
. O O

All O O
patients O O
underwent O O
a O O
rapid O O
rule O O
- O O
in O O
protocol O O
that O O
included O O
serial O O
sampling O O
of O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O O
( O O
CK O O
) O O
, O O
CK O O
- O O
MB O O
, O O
and O O
cardiac O O
troponin O O
I O O
( O O
cTnI O O
) O O
over O O
eight O O
hours O O
. O O

Outcomes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
CK O B_MEASURE/B_GENE
- O O
MB O B_DISEASE/B_PROTEIN[GENE]
MI O B_DISEASE/I_PROTEIN[GENE]
( O O
CK O B_GENE/B_LOCATION
- O O
MB O B_LOCATION/B_MEASURE
> O I_LOCATION/I_MEASURE
or O O
= O O
8 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
mL O B_MEASURE/B_LOCATION
with O O
a O O
relative O B_MEASURE/B_LOCATION
index O I_MEASURE/I_LOCATION
[ O I_MEASURE/I_LOCATION
( O O
CK O B_GENE/B_LOCATION
- O O
MB O B_LOCATION/B_PROTEIN[GENE]
x O O
100 O B_MEASURE
) O O
/ O O
total O B_MEASURE
CK O I_MEASURE
] O O
> O B_MEASURE/B_OTHER
or O O
= O O
4 O B_MEASURE
, O O
cardiac O B_DISEASE
death O I_DISEASE
, O O
and O O
significant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coronary O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
> O B_MEASURE
or O O
= O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Of O O
the O O
246 O B_MEASURE
admitted O O
patients O B_PERSON
, O O
34 O B_MEASURE
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
met O O
CK O B_PROTEIN[GENE]/B_DISEASE
- O O
MB O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
MI O B_DISEASE/B_LOCATION
and O O
38 O B_MEASURE
( O O
16 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
cTnI O B_DISEASE/B_LOCATION
elevations O I_DISEASE/I_LOCATION
. O O

Angiography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
performed O O
in O O
29 O B_NUMBER[MEASURE]
of O O
38 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
who O O
were O O
cTnI O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
significant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
25 O B_NUMBER[MEASURE]/B_PERSON
( O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
four O B_PERSON
patients O I_PERSON
without O O
significant O B_DISEASE/B_LOCATION
disease O I_DISEASE/I_LOCATION
who O O
had O O
cTnI O B_DISEASE/B_LOCATION
elevations O I_DISEASE/I_LOCATION
met O O
CK O B_PROTEIN[GENE]/B_LOCATION
- O O
MB O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
MI O B_DISEASE/B_LOCATION
, O O
and O O
the O O
other O B_SEQUENCE[MEASURE]/B_LOCATION
had O O
a O O
peak O B_LOCATION
CK O I_LOCATION
- O O
MB O B_MEASURE/B_LOCATION
level O B_MEASURE/I_LOCATION
of O O
13 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
mL O B_MEASURE/B_LOCATION
. O O

Sensitivities O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
specificities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
negative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
likelihood O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
ratios O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
predicting O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]
death O I_DISEASE_ADJECTIVE[DISEASE]
or O O
significant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
both O O
CK O B_PROTEIN[GENE]/B_MEASURE
- O O
MB O B_MEASURE/B_DISEASE
MI O I_MEASURE/I_DISEASE
and O O
cTnI O B_LOCATION
and O O
were O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Most O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
cTnI O B_DISEASE/B_LOCATION
elevations O I_DISEASE/I_LOCATION
meet O O
CK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
MB O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
criteria O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O O
MI O B_DISEASE/B_LOCATION
, O O
as O O
well O O
as O O
have O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
underlying O B_DISEASE/B_GENE
significant O I_DISEASE/I_GENE
disease O I_DISEASE/I_GENE
. O O

Troponin O O
appears O O
to O O
have O O
an O O
equivalent O O
diagnostic O O
accuracy O O
compared O O
with O O
CK O O
- O O
MB O O
for O O
diagnosing O O
necrosis O O
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
and O O
suspected O O
MI O O
. O O

Acute O O
interstitial O O
nephritis O O
due O O
to O O
nicergoline B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Sermion B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
interstitial O O
nephritis O O
( O O
AIN O O
) O O
due O O
to O O
nicergoline B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Sermion B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
. O O

A O O
50 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
patient O I_PERSON
admitted O O
to O O
our O O
hospital O B_LOCATION
for O O
fever O B_DISEASE
and O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
. O O

Before O O
admission O O
, O O
he O O
had O O
been O O
taking O O
nicergoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
bendazac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
retinal O O
vein O O
occlusion O O
at O O
ophthalmologic O O
department O O
. O O

Thereafter O O
, O O
he O O
experienced O O
intermittent O B_DISEASE
fever O I_DISEASE
and O O
skin O B_DISEASE
rash O I_DISEASE
. O O

On O O
admission O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
( O O
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
arthralgia O B_DISEASE
and O O
fever O B_DISEASE
) O O
and O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
i O O
. O O
e O O
. O O
eosinophilia O B_DISEASE
and O O
renal O B_DISEASE/B_GENE
failure O I_DISEASE/I_GENE
) O O
suggested O O
AIN O B_DISEASE
, O O
and O O
which O O
was O O
confirmed O O
by O O
pathologic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
renal O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
lymphocyte O O
transformation O O
test O O
demonstrated O O
a O O
positive O O
result O O
against O O
nicergoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Treatment O O
was O O
consisted O O
of O O
withdrawal O O
of O O
nicergoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intravenous O O
methylprednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
his O O
renal O O
function O O
was O O
completely O O
recovered O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
of O O
nicergoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
AIN O O
. O O

Neuroleptic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complicated O O
by O O
massive O B_DISEASE
intestinal O I_DISEASE
bleeding O I_DISEASE
in O O
a O O
patient O B_PERSON/B_BIO
with O O
chronic O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
. O O

A O O
patient O O
with O O
chronic O O
renal O O
failure O O
( O O
CRF O O
) O O
developed O O
neuroleptic O O
malignant O O
syndrome O O
( O O
NMS O O
) O O
after O O
administration O O
of O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
levomepromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
typical O B_DISEASE
symptoms O I_DISEASE
of O O
NMS O B_DISEASE/B_GENE
, O O
massive O B_DISEASE
intestinal O I_DISEASE
bleeding O I_DISEASE
was O O
observed O O
during O O
the O O
episode O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggests O O
that O O
NMS O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
patient O B_PERSON/B_BIO
with O O
CRF O B_DISEASE
may O O
be O O
complicated O O
by O O
intestinal O B_DISEASE
bleeding O I_DISEASE
and O O
needs O O
special O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
complication O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Blood O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
brain O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
right O B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
and O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_SEQUENCE[MEASURE]
- O O
pawed O O
female O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
rats O B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
assessed O O
by O O
a O O
new O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
asymmetrical O B_DISEASE_ADJECTIVE[DISEASE]
breakdown O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
BBB O B_LOCATION/B_ORGANIZATION
) O O
was O O
studied O O
in O O
female O B_SPECIES[BIO]/B_DISEASE
rats O I_SPECIES[BIO]/I_DISEASE
. O O

Paw O B_PERSON/B_DISEASE
preference O I_PERSON/I_DISEASE
was O O
assessed O O
by O O
a O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaching O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
was O O
used O O
to O O
destroy O O
the O O
BBB O O
, O O
which O O
was O O
evaluated O O
using O O
triphenyltetrazolium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
TTC B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
staining O O
of O O
the O O
brain O O
slices O O
just O O
after O O
giving O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
30 O O
s O O
. O O

In O O
normal O O
rats O O
, O O
the O O
whole O O
brain O O
sections O O
exhibited O O
complete O O
staining O O
with O O
TTC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
for O O
30 O O
s O O
, O O
there O O
were O O
large O O
unstained O O
areas O O
in O O
the O O
left O O
brain O O
in O O
right O O
- O O
pawed O O
animals O O
, O O
and O O
vice O O
versa O O
in O O
left O O
- O O
pawed O O
animals O O
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
obtained O O
in O O
seizure O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
breakdown O B_DISEASE
of O O
BBB O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
explained O O
by O O
an O O
asymmetric O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cerebral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O O
upon O O
the O O
paw O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
preference O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
was O O
suggested O O
that O O
this O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
contralateral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
motor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O O
may O O
be O O
important O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
determining O O
the O O
dominant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cerebral O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
hemisphere O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
animals O B_BIO/B_DISEASE
. O O

Carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protects O O
against O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
mitochondrial O O
cardiomyopathy O O
. O O

Several O O
cytopathic O O
mechanisms O O
have O O
been O O
suggested O O
to O O
mediate O O
the O O
dose O O
- O O
limiting O O
cumulative O O
and O O
irreversible O O
cardiomyopathy O O
caused O O
by O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicates O O
that O O
oxidative O B_DISEASE/B_GENE
stress O I_DISEASE/I_GENE
and O O
mitochondrial O B_DISEASE/B_GENE
dysfunction O I_DISEASE/I_GENE
are O O
key O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
pathogenic O B_DISEASE_ADJECTIVE[DISEASE]
process O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
objective O O
of O O
this O O
investigation O O
was O O
to O O
test O O
the O O
hypothesis O O
that O O
carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
nonselective O O
beta O O
- O O
adrenergic O O
receptor O O
antagonist O O
with O O
potent O O
antioxidant O O
properties O O
, O O
protects O O
against O O
the O O
cardiac O O
and O O
hepatic O O
mitochondrial O O
bioenergetic O O
dysfunction O O
associated O O
with O O
subchronic O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
toxicity O O
. O O

Heart O O
and O O
liver O O
mitochondria O O
were O O
isolated O O
from O O
rats O O
treated O O
for O O
7 O O
weeks O O
with O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
mg O O
/ O O
kg O O
sc O O
/ O O
week O O
) O O
, O O
carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mg O O
/ O O
kg O O
ip O O
/ O O
week O O
) O O
, O O
or O O
the O O
combination O O
of O O
the O O
two O O
drugs O O
. O O

Heart O O
mitochondria O O
isolated O O
from O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
rats O O
exhibited O O
depressed O O
rates O O
for O O
state O O
3 O O
respiration O O
( O O
336 O O
+ O O
/ O O
- O O
26 O O
versus O O
425 O O
+ O O
/ O O
- O O
53 O O
natom O O
O O O
/ O O
min O O
/ O O
mg O O
protein O O
) O O
and O O
a O O
lower O O
respiratory O O
control O O
ratio O O
( O O
RCR O O
) O O
( O O
4 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
versus O O
5 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
) O O
compared O O
with O O
cardiac O O
mitochondria O O
isolated O O
from O O
saline O O
- O O
treated O O
rats O O
. O O

Mitochondrial O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
loading O O
capacity O O
and O O
the O O
activity O O
of O O
NADH O O
- O O
dehydrogenase O O
were O O
also O O
suppressed O O
in O O
cardiac O O
mitochondria O O
from O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
rats O O
. O O

Doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O O
also O O
caused O O
a O O
decrease O O
in O O
RCR O O
for O O
liver O O
mitochondria O O
( O O
3 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
versus O O
5 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
for O O
control O O
rats O O
) O O
and O O
inhibition O O
of O O
hepatic O O
cytochrome O O
oxidase O O
activity O O
. O O

Coadministration O O
of O O
carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
the O O
extent O O
of O O
cellular O O
vacuolization O O
in O O
cardiac O O
myocytes O O
and O O
prevented O O
the O O
inhibitory O O
effect O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mitochondrial O O
respiration O O
in O O
both O O
heart O O
and O O
liver O O
. O O

Carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
prevented O O
the O O
decrease O O
in O O
mitochondrial O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
loading O O
capacity O O
and O O
the O O
inhibition O O
of O O
the O O
respiratory O O
complexes O O
of O O
heart O O
mitochondria O O
caused O O
by O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
itself O O
did O O
not O O
affect O O
any O O
of O O
the O O
parameters O O
measured O O
for O O
heart O O
or O O
liver O O
mitochondria O O
. O O

It O O
is O O
concluded O O
that O O
this O O
protection O O
by O O
carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
both O O
the O O
structural O O
and O O
functional O O
cardiac O O
tissue O O
damage O O
may O O
afford O O
significant O O
clinical O O
advantage O O
in O O
minimizing O O
the O O
dose O O
- O O
limiting O O
mitochondrial O O
dysfunction O O
and O O
cardiomyopathy O O
that O O
accompanies O O
long O O
- O O
term O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
cancer O O
patients O O
. O O

Cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hyperactivity O O
is O O
more O O
influenced O O
by O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
than O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
. O O

The O O
influence O O
of O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
and O O
antagonists O O
on O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
was O O
examined O O
in O O
mice O O
. O O

All O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
significantly O O
decreased O O
the O O
locomotor O O
activity O O
in O O
mice O O
, O O
and O O
the O O
effects O O
were O O
dose O O
- O O
dependent O O
. O O

It O O
seems O O
that O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 O O
and O O
A2 O O
receptors O O
might O O
be O O
involved O O
in O O
this O O
reaction O O
. O O

Moreover O O
, O O
all O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
: O O
2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxyethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenethylamino I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylcarboxamidoadenosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CGS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
21680 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
, O O
A2A O O
receptor O O
agonist O O
, O O
N6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclopentyladenosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
, O O
A1 O O
receptor O O
agonist O O
, O O
and O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylcarboxamidoadenosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NECA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
A2 O O
/ O O
A1 O O
receptor O O
agonist O O
significantly O O
and O O
dose O O
- O O
dependently O O
decreased O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O O
activity O O
. O O

CPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduced O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O O
at O O
the O O
doses O O
which O O
, O O
given O O
alone O O
, O O
did O O
not O O
influence O O
motility O O
, O O
while O O
CGS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21680 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NECA B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
the O O
action O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
the O O
doses O O
which O O
, O O
given O O
alone O O
, O O
decreased O O
locomotor O O
activity O O
in O O
animals O O
. O O

These O O
results O O
suggest O O
the O O
involvement O O
of O O
both O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
in O O
the O O
action O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
although O O
agonists O O
of O O
A1 O O
receptors O O
seem O O
to O O
have O O
stronger O O
influence O O
on O O
it O O
. O O

The O O
selective O O
blockade O O
of O O
A2 O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptor O O
by O O
DMPX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
3 B B_TIME[MEASURE]/B_LOCATION
, I B_TIME[MEASURE]/I_LOCATION
7 I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
dimethyl I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
1 I B_TIME[MEASURE]/I_LOCATION
- I B_TIME[MEASURE]/I_LOCATION
propargylxanthine I B_TIME[MEASURE]/I_LOCATION
) O O
significantly O O
enhanced O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O O
activity O O
of O O
animals O O
. O O

Caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
similar O O
action O O
but O O
the O O
effect O O
was O O
not O O
significant O O
. O O

CPT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
8 B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclopentyltheophylline I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
- O O
A1 O O
receptor O O
antagonist O O
, O O
did O O
not O O
show O O
any O O
influence O O
in O O
this O O
test O O
. O O

Similarly O O
, O O
all O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
decreased O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
, O O
but O O
at O O
the O O
higher O O
doses O O
than O O
those O O
which O O
were O O
active O O
in O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
. O O

The O O
selective O O
blockade O O
of O O
A2 O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
( O O
DMPX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
non O O
- O O
selective O O
blockade O O
of O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors O O
( O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
significantly O O
increased O O
the O O
action O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
locomotor O O
activity O O
test O O
. O O

Our O O
results O O
have O O
shown O O
that O O
all O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
( O O
A1 O O
and O O
A2 O O
) O O
reduce O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O O
activity O O
and O O
indicate O O
that O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
hyperactivity O O
is O O
more O O
influenced O O
by O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
agonists O O
( O O
particularly O O
A1 O O
receptors O O
) O O
than O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperactivity O O
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
the O O
risk O O
of O O
bradyarrhythmia O O
requiring O O
permanent O O
pacemaker O O
in O O
elderly O O
patients O O
with O O
atrial O O
fibrillation O O
and O O
prior O O
myocardial O O
infarction O O
. O O

OBJECTIVES O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
the O O
use O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
atrial O O
fibrillation O O
( O O
AF O O
) O O
increases O O
the O O
risk O O
of O O
bradyarrhythmia O O
requiring O O
a O O
permanent O O
pacemaker O O
. O O

BACKGROUND O O
: O O
Reports O O
of O O
severe O O
bradyarrhythmia O O
during O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
are O O
infrequent O O
and O O
limited O O
to O O
studies O O
assessing O O
the O O
therapy O O
' O O
s O O
use O O
in O O
the O O
management O O
of O O
patients O O
with O O
ventricular O O
arrhythmias O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
8 O B_MEASURE
, O O
770 O B_MEASURE
patients O I_MEASURE
age O I_MEASURE
> O I_MEASURE
or O O
= O O
65 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
with O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AF O B_DISEASE
was O O
identified O O
from O O
a O O
provincewide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
Quebec O B_PERSON/B_ORGANIZATION
residents O I_PERSON/I_ORGANIZATION
with O O
a O O
myocardial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
MI O B_LOCATION
) O O
between O O
1991 O B_MEASURE
and O O
1999 O B_MEASURE
. O O

Using O O
a O O
nested O B_PERSON/B_MEASURE
case O I_PERSON/I_MEASURE
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
477 O B_PERSON/B_MEASURE
cases O I_PERSON/I_MEASURE
of O O
bradyarrhythmia O B_DISEASE
requiring O O
a O O
permanent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pacemaker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
matched O O
( O O
1 O B_MEASURE
: O O
4 O B_MEASURE
) O O
to O O
1 O B_MEASURE
, O O
908 O B_MEASURE/B_PERSON
controls O I_MEASURE/I_PERSON
. O O

Multivariable O O
logistic O O
regression O O
was O O
used O O
to O O
estimate O O
the O O
odds O O
ratio O O
( O O
OR O O
) O O
of O O
pacemaker O O
insertion O O
associated O O
with O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
, O O
controlling O O
for O O
baseline O O
risk O O
factors O O
and O O
exposure O O
to O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
Class O O
I O O
antiarrhythmic O O
agents O O
, O O
beta O O
- O O
blockers O O
, O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blockers O O
, O O
and O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

RESULTS O O
: O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
was O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
pacemaker O O
insertion O O
( O O
OR O O
: O O
2 O O
. O O
14 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
: O O
1 O O
. O O
30 O O
to O O
3 O O
. O O
54 O O
) O O
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
modified O O
by O O
gender O B_PERSON/B_DISEASE
, O O
with O O
a O O
greater O B_MEASURE
risk O I_MEASURE
in O O
women O B_PERSON/B_BIO
versus O O
men O B_PERSON
( O O
OR O O
: O O
3 O B_MEASURE
. O O
86 O B_MEASURE
, O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
: O O
1 O B_MEASURE
. O O
70 O B_MEASURE
to O O
8 O B_NUMBER[MEASURE]
. O O
75 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O
OR O O
: O O
1 O B_MEASURE
. O O
52 O B_MEASURE
, O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
: O O
0 O B_MEASURE
. O O
80 O B_MEASURE
to O O
2 O B_MEASURE
. O O
89 O B_MEASURE
) O O
. O O

Digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
the O O
only O O
other O O
medication O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
pacemaker O O
insertion O O
( O O
OR O O
: O O
1 O O
. O O
78 O O
, O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
37 O O
to O O
2 O O
. O O
31 O O
) O O
. O O

CONCLUSIONS O O
: O O
This O O
study O O
suggests O O
that O O
the O O
use O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
elderly O O
patients O O
with O O
AF O O
and O O
a O O
previous O O
MI O O
increases O O
the O O
risk O O
of O O
bradyarrhythmia O O
requiring O O
a O O
permanent O O
pacemaker O O
. O O

The O O
finding O O
of O O
an O O
augmented O O
risk O O
of O O
pacemaker O O
insertion O O
in O O
elderly O O
women O O
receiving O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requires O O
further O O
investigation O O
. O O

Indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
morphologic O O
changes O O
in O O
the O O
rat O O
urinary O O
bladder O O
epithelium O O
. O O

OBJECTIVES O O
: O O
To O O
evaluate O O
the O O
morphologic O O
changes O O
in O O
rat O O
urothelium O O
induced O O
by O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
induced O O
cystitis O B_DISEASE
is O O
a O O
poorly O O
recognized O O
and O O
under O O
- O O
reported O O
condition O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
to O O
tiaprofenic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
reported O O
to O O
be O O
associated O O
with O O
this O O
condition O O
. O O

METHODS O O
: O O
Three O O
groups O O
were O O
established O O
: O O
a O O
control O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
a O O
high O O
- O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
treated O O
with O O
one O O
intraperitoneal O O
injection O O
of O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 O O
mg O O
/ O O
kg O O
, O O
and O O
a O O
therapeutic O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
in O O
which O O
oral O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
3 O O
. O O
25 O O
mg O O
/ O O
kg O O
body O O
weight O O
daily O O
for O O
3 O O
weeks O O
. O O

The O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
then O O
killed O O
and O O
the O O
bladders O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
removed O O
for O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electron O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
some O O
focal O B_DISEASE
epithelial O I_DISEASE
degeneration O I_DISEASE
that O O
was O O
more O O
prominent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
high O B_MEASURE/B_PERSON
- O O
dose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

When O O
compared O O
with O O
the O O
control O O
group O O
, O O
both O O
indomethacin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
groups O O
revealed O O
statistically O O
increased O O
numbers O O
of O O
mast O O
cells O O
in O O
the O O
mucosa O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
penetration O O
of O O
lanthanum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
intercellular O O
areas O O
of O O
the O O
epithelium O O
. O O

Furthermore O O
, O O
the O O
difference O B_MEASURE
in O O
mast O B_MEASURE/B_DISEASE
cell O B_MEASURE/I_DISEASE
counts O B_MEASURE/I_DISEASE
between O O
the O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
therapeutic O B_MEASURE
dose O I_MEASURE
groups O I_MEASURE
was O O
also O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
Indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O O
in O O
histopathologic O O
findings O O
typical O O
of O O
interstitial O O
cystitis O O
, O O
such O O
as O O
leaky O O
bladder O O
epithelium O O
and O O
mucosal O O
mastocytosis O O
. O O

The O O
true O B_MEASURE/B_LOCATION
incidence O B_MEASURE/I_LOCATION
of O O
nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
induced O O
cystitis O B_DISEASE
in O O
humans O B_PERSON/B_BIO
must O O
be O O
clarified O O
by O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

An O O
open O O
- O O
label O O
phase O O
II O O
study O O
of O O
low O O
- O O
dose O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
independent O O
prostate O O
cancer O O
. O O

The O O
antiangiogenic O O
effects O O
of O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
assessed O O
in O O
clinical O O
trials O O
in O O
patients O O
with O O
various O O
solid O O
and O O
haematological O O
malignancies O O
. O O

Thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blocks O O
the O O
activity O O
of O O
angiogenic O O
agents O O
including O O
bFGF O O
, O O
VEGF O O
and O O
IL O O
- O O
6 O O
. O O

We O O
undertook O O
an O O
open O O
- O O
label O O
study O O
using O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
mg O O
once O O
daily O O
for O O
up O O
to O O
6 O O
months O O
in O O
20 O O
men O O
with O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
independent O O
prostate O O
cancer O O
. O O

The O O
mean O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
of O O
study O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
109 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
( O O
median O B_TIME[MEASURE]/B_LOCATION
107 O I_TIME[MEASURE]/I_LOCATION
, O O
range O B_MEASURE/B_LOCATION
4 O I_MEASURE/I_LOCATION
- O O
184 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
) O O
. O O

Patients O O
underwent O O
regular O O
measurement O O
of O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
, O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electrolytes O O
, O O
serum O O
bFGF O O
and O O
VEGF O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
men O I_NUMBER[MEASURE]/I_PERSON
( O O
15 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
showed O O
a O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
serum O B_DISEASE
PSA O I_DISEASE
of O O
at O O
least O O
50 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
, O O
sustained O O
throughout O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Of O O
16 O B_PERSON/B_BIO
men O I_PERSON/I_BIO
treated O O
for O O
at O O
least O O
2 O B_TIME[MEASURE]/B_DISEASE
months O I_TIME[MEASURE]/I_DISEASE
, O O
six O B_NUMBER[MEASURE]
( O O
37 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
showed O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
absolute O B_MEASURE/B_DISEASE
PSA O I_MEASURE/I_DISEASE
by O O
a O O
median O B_MEASURE/B_LOCATION
of O O
48 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
. O O

Increasing O O
levels O B_MEASURE/B_GENE
of O O
serum O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bFGF O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
VEGF O B_GENE/B_DISEASE
were O O
associated O O
with O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
; O O
five O B_NUMBER[MEASURE]/B_PERSON
of O O
six O B_NUMBER[MEASURE]/B_PERSON
men O I_NUMBER[MEASURE]/I_PERSON
who O O
demonstrated O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
PSA O B_GENE
also O O
showed O O
a O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
bFGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
VEGF O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
four O B_NUMBER[MEASURE]/B_ENT
men O I_NUMBER[MEASURE]/I_ENT
with O O
a O O
rising O O
PSA O B_MEASURE/B_DISEASE
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
both O O
growth O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Adverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O O
constipation O B_DISEASE
, O O
morning O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drowsiness O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dizziness O B_DISEASE
and O O
rash O B_DISEASE
, O O
and O O
resulted O O
in O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
three O B_PERSON/B_ENT
men O I_PERSON/I_ENT
. O O

Evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
peripheral O B_DISEASE
sensory O I_DISEASE
neuropathy O I_DISEASE
was O O
found O O
in O O
nine O B_NUMBER[MEASURE]
of O O
13 O B_PERSON
men O I_PERSON
before O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
the O O
seven O O
men O O
who O O
completed O O
six O O
months O O
on O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
subclinical O O
evidence O O
of O O
peripheral O O
neuropathy O O
was O O
found O O
in O O
four O O
before O O
treatment O O
, O O
but O O
in O O
all O O
seven O O
at O O
repeat O O
testing O O
. O O

The O O
findings O O
indicate O O
that O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
be O O
an O O
option O O
for O O
patients O O
who O O
have O O
failed O O
other O O
forms O O
of O O
therapy O O
, O O
provided O O
close O O
follow O O
- O O
up O O
is O O
maintained O O
for O O
development O O
of O O
peripheral O O
neuropathy O O
. O O

Central O O
nervous O O
system O O
toxicity O O
following O O
the O O
administration O O
of O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
lumbar O O
plexus O O
block O O
: O O
A O O
report O O
of O O
two O O
cases O O
. O O

BACKGROUND O B_TIME[MEASURE]/B_LOCATION
AND O O
OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cardiac O B_DISEASE
toxicity O I_DISEASE
following O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
recognized O O
complication O B_DISEASE
of O O
regional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O O
the O O
pure O O
S O O
( O O
- O O
) O O
enantiomer O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
developed O O
to O O
improve O O
the O O
cardiac O O
safety O O
profile O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
describe O O
2 O O
cases O O
of O O
grand O O
mal O O
seizures O O
following O O
accidental O O
intravascular O O
injection O O
of O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CASE O B_MEASURE
REPORT O I_MEASURE
: O O
Two O B_PERSON
patients O I_PERSON
presenting O O
for O O
elective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
orthopedic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
underwent O O
blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
lumbar O B_BODY_PART_OR_ORGAN_COMPONENT
plexus O I_BODY_PART_OR_ORGAN_COMPONENT
via O O
the O O
posterior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
approach O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Immediately O O
after O O
the O O
administration O O
of O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
5 O O
% O O
with O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O O
. O O
5 O O
microgram O O
/ O O
mL O O
, O O
the O O
patients O O
developed O O
grand O O
mal O O
seizures O O
, O O
despite O O
negative O O
aspiration O O
for O O
blood O O
and O O
no O O
clinical O O
signs O O
of O O
intravenous O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

The O O
seizures O O
were O O
successfully O O
treated O O
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiopental I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
addition O O
to O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
1 O O
patient O O
. O O

Neither O O
patient O B_PERSON/B_BIO
developed O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
cardiovascular O B_DISEASE
toxicity O I_DISEASE
. O O

Both O O
patients O O
were O O
treated O O
preoperatively O O
with O O
beta O O
- O O
adrenergic O O
antagonist O O
medications O O
, O O
which O O
may O O
have O O
masked O O
the O O
cardiovascular O O
signs O O
of O O
the O O
unintentional O O
intravascular O O
administration O O
of O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Although O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
have O O
a O O
safer O O
cardiac O O
toxicity O O
profile O O
than O O
racemic O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
if O O
adequate O O
amounts O O
of O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reach O O
the O O
circulation O O
, O O
it O O
will O O
result O O
in O O
convulsions O O
. O O

Plasma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
sufficient O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O O
result O O
in O O
central O B_DISEASE
nervous O I_DISEASE
system O I_DISEASE
toxicity O I_DISEASE
did O O
not O O
produce O O
manifestations O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
toxicity O I_DISEASE
in O O
these O O
2 O B_PERSON/B_BIO
patients O B_PERSON/I_BIO
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
torsade O O
de O O
pointes O O
during O O
bladder O O
irrigation O O
: O O
an O O
unusual O O
presentation O O
- O O
- O O
a O O
case O O
report O O
. O O

The O O
authors O O
present O O
a O O
case O O
of O O
early O O
( O O
within O O
4 O O
days O O
) O O
development O O
of O O
torsade O O
de O O
pointes O O
( O O
TdP O O
) O O
associated O O
with O O
oral O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Consistent O O
with O O
other O O
reports O O
this O O
case O O
of O O
TdP O O
occurred O O
in O O
the O O
context O O
of O O
multiple O O
exacerbating O O
factors O O
including O O
hypokalemia O O
and O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O O
. O O

Transient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
QT O B_DISEASE/B_PROTEIN[GENE]
during O O
bladder O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
irrigation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
prompted O O
the O O
episode O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
TdP O B_DISEASE/B_GENE
. O O

It O O
is O O
well O O
known O O
that O O
bradycardia O B_DISEASE
exacerbates O O
acquired O O
TdP O B_DISEASE/B_GENE
. O O

The O O
authors O O
speculate O O
that O O
the O O
increased O O
vagal O O
tone O O
during O O
bladder O O
irrigation O O
, O O
a O O
vagal O O
maneuver O O
, O O
in O O
the O O
context O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
resulted O O
in O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
proarrhythmia O O
. O O

In O O
the O O
absence O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
a O O
second O O
bladder O O
irrigation O O
did O O
not O O
induce O O
TdP O O
despite O O
hypokalemia O O
and O O
hypomagnesemia O O
. O O

Anaesthetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
myotonia O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congenita O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
myotonic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disorders O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Myotonia O O
congenita O O
( O O
MC O O
) O O
is O O
caused O O
by O O
a O O
defect O O
in O O
the O O
skeletal O O
muscle O O
chloride B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
function O O
, O O
which O O
may O O
cause O O
sustained O O
membrane O O
depolarisation O O
. O O

We O O
describe O O
a O O
previously O O
healthy O O
32 O O
- O O
year O O
- O O
old O O
woman O O
who O O
developed O O
a O O
life O O
- O O
threatening O O
muscle O O
spasm O O
and O O
secondary O O
ventilation O O
difficulties O O
following O O
a O O
preoperative O O
injection O O
of O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
muscle O B_DISEASE
spasms O I_DISEASE
disappeared O O
spontaneously O O
and O O
the O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
proceeded O O
without O O
further O B_DISEASE_ADJECTIVE[DISEASE]
problems O I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
subsequently O O
questioned O O
, O O
she O O
reported O O
minor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
a O O
myotonic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Myotonia O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O O
found O O
on O O
clinical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
EMG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
diagnosis O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MC O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
genetically O O
. O O

Neither O O
the O O
patient O B_PERSON
nor O O
the O O
anaesthetist O B_PERSON/B_LOCATION
were O O
aware O B_PERSON
of O O
the O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
this O O
potentially O O
lethal O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complication O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
. O O

We O O
give O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
ion O B_DISEASE_ADJECTIVE[DISEASE]
channel O I_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
including O O
malignant O B_DISEASE/B_PERSON
hyperthermia O I_DISEASE/I_PERSON
and O O
their O O
anaesthetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
considerations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Respiratory O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
epilepsy O B_DISEASE/B_LOCATION
. O O

PURPOSE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Apnea O B_DISEASE
is O O
known O O
to O O
occur O O
during O O
seizures O B_DISEASE/B_LOCATION
, O O
but O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
ictal O B_DISEASE
respiratory O I_DISEASE
changes O I_DISEASE
in O O
adults O B_PERSON/B_BIO
are O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
during O O
interictal O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
periods O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
also O O
are O O
scarce O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
we O O
sought O O
to O O
generate O O
information O O
with O O
regard O O
to O O
the O O
interictal O O
period O O
in O O
animals O O
with O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
epilepsy O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Twelve O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
( O O
six O B_NUMBER[MEASURE]
chronically O O
epileptic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
animals O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
six O B_NUMBER[MEASURE]/B_PERSON
controls O I_NUMBER[MEASURE]/I_PERSON
) O O
were O O
anesthetized O O
, O O
given O O
tracheotomies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
subjected O O
to O O
hyperventilation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
hypoventilation O B_DISEASE
conditions O I_DISEASE
. O O

Breathing O B_PERSON/B_LOCATION
movements O I_PERSON/I_LOCATION
caused O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
thoracic O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
and O O
forced O O
air O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
flow O O
tidally O O
through O O
a O O
pneumotachograph O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
flow O B_MEASURE/B_SPORT[ENT]
was O O
measured O O
by O O
using O O
a O O
differential O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transducer O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
passed O O
through O O
a O O
polygraph O B_MEDICAL_DEVICE[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
from O O
this O O
to O O
a O O
computer O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
with O O
custom O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
derived O O
ventilation O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
VE O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
tidal O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
( O O
VT O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
inspiratory O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
( O O
TI O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
expiratory O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
( O O
TE O B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
breathing O B_MEASURE/B_LOCATION
frequency O I_MEASURE/I_LOCATION
( O O
f O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
and O O
mean O B_MEASURE/B_LOCATION
inspiratory O I_MEASURE/I_LOCATION
flow O I_MEASURE/I_LOCATION
( O O
VT O B_PROTEIN[GENE]/B_DISEASE
/ O O
TI O B_PROTEIN[GENE]/B_DISEASE
) O O
on O O
a O O
breath O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
by O O
- O O
breath O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

RESULTS O O
: O O
The O O
hyperventilation O O
maneuver O O
caused O O
a O O
decrease O O
in O O
spontaneous O O
ventilation O O
in O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
and O O
control O O
rats O O
. O O

Although O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
both O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
epileptic O B_TIME[MEASURE]/B_ORGANIZATION
group O I_TIME[MEASURE]/I_ORGANIZATION
, O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
due O O
to O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O O
< O B_MEASURE
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
TE O B_MEASURE/B_LOCATION
peak O I_MEASURE/I_LOCATION
in O O
relation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
that O O
of O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

The O O
hypoventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
maneuver O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
arterial O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
Paco2 O I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
followed O O
by O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

In O O
the O O
epileptic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O O
mediated O O
by O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_OTHER/B_MEASURE
< O B_MEASURE
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
TE O B_MEASURE/B_LOCATION
peak O I_MEASURE/I_LOCATION
compared O O
with O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

Systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
KCN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
to O O
evaluate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreception O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O O
led O O
to O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

CONCLUSIONS O O
: O O
The O O
data O O
indicate O O
that O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
animals O O
have O O
an O O
altered O O
ability O O
to O O
react O O
to O O
( O O
or O O
compensate O O
for O O
) O O
blood O O
gas O O
changes O O
with O O
changes O O
in O O
ventilation O O
and O O
suggest O O
that O O
it O O
is O O
centrally O O
determined O O
. O O

We O O
speculate O O
on O O
the O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
treating O O
different O B_DISEASE
epilepsy O I_DISEASE
- O O
associated O O
conditions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Fatal O O
myeloencephalopathy O O
due O O
to O O
intrathecal O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

Vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
accidentally O O
given O O
intrathecally O O
to O O
a O O
child O O
with O O
leukaemia O O
, O O
producing O O
sensory O O
and O O
motor O O
dysfunction O O
followed O O
by O O
encephalopathy O O
and O O
death O O
. O O

Separate O O
times O O
for O O
administering O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
intrathecal O O
therapy O O
is O O
recommended O O
. O O

Progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentiation O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmogenicity O O
in O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
anesthetized O O
rats O O
and O O
beating O O
rat O O
heart O O
cell O O
cultures O O
. O O

The O O
effects O O
of O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
on O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmogenicity O O
in O O
beating O O
rat O O
heart O O
myocyte O O
cultures O O
and O O
on O O
anesthetized O O
rats O O
were O O
determined O O
. O O

After O O
determining O O
the O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
AD50 O O
( O O
the O O
concentration O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
caused O O
50 O O
% O O
of O O
all O O
beating O O
rat O O
heart O O
myocyte O O
cultures O O
to O O
become O O
arrhythmic O O
) O O
, O O
we O O
determined O O
the O O
effect O O
of O O
1 O O
- O O
hour O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
HCl B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exposure O O
on O O
myocyte O O
contractile O O
rhythm O O
. O O

Each O O
concentration O O
of O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O O
. O O
25 O O
, O O
12 O O
. O O
5 O O
, O O
25 O O
, O O
and O O
50 O O
micrograms O O
/ O O
ml O O
) O O
caused O O
a O O
significant O O
and O O
concentration O O
- O O
dependent O O
reduction O O
in O O
the O O
AD50 O O
for O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O O
also O O
increased O O
the O O
arrhythmogenicity O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
myocyte O O
cultures O O
, O O
but O O
was O O
only O O
one O O
fourth O O
as O O
potent O O
as O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neither O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
on O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
arrhythmogenicity O O
were O O
potentiated O O
by O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chronic O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O O
( O O
5 O O
mg O O
/ O O
kg O O
/ O O
day O O
for O O
21 O O
days O O
) O O
caused O O
a O O
significant O O
increase O O
in O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrhythmogenicity O O
in O O
intact O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
anesthetized O O
rats O O
. O O

There O O
was O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
arrhythmia O B_DISEASE
as O O
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonprogesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_MEASURE
. O O
2 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_MEASURE
. O O
3 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O
30 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
, O O
mean O O
+ O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
- O O
SE O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

The O O
results O O
of O O
this O O
study O O
indicate O O
that O O
progesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
potentiate O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrhythmogenicity O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

Potentiation O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmia O O
in O O
myocyte O O
cultures O O
suggests O O
that O O
this O O
effect O O
is O O
at O O
least O O
partly O O
mediated O O
at O O
the O O
myocyte O O
level O O
. O O

Increased O O
serum O O
soluble O O
Fas O O
in O O
patients O O
with O O
acute O O
liver O O
failure O O
due O O
to O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
overdose O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O O
AIMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
suggested O O
that O O
apoptosis O B_DISEASE/B_GENE
via O O
the O O
Fas O B_GENE/B_DISEASE
/ O O
Fas O B_GENE/B_PERSON
Ligand O I_GENE/I_PERSON
signaling O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
acute O B_DISEASE
liver O I_DISEASE
failure O I_DISEASE
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
to O O
investigate O O
the O O
soluble O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
form O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
Fas O B_GENE
in O O
patients O B_PERSON/B_BIO
with O O
acute O B_DISEASE/B_LOCATION
liver O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
. O O

METHODOLOGY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
: O O
Serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
sFas O B_GENE/B_DISEASE
( O O
soluble O B_PROTEIN[GENE]/B_LOCATION
Fas O I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
measured O O
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
24 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
acute O B_DISEASE/B_LOCATION
liver O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
and O O
10 O B_DISEASE
normal O I_DISEASE
control O I_DISEASE
subjects O I_DISEASE
. O O

Serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alpha O B_PROTEIN[GENE]
and O O
interferon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
gamma O B_PROTEIN[GENE]/B_MEASURE
were O O
also O O
determined O O
by O O
ELISA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Serum O B_GENE
sFas O I_GENE
was O O
significantly O O
increased O O
in O O
patients O B_PERSON/B_BIO
with O O
acute O B_DISEASE/B_LOCATION
liver O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
( O O
median O B_MEASURE
, O O
26 O B_MEASURE
. O O
8 O B_MEASURE/B_LOCATION
U O I_MEASURE/I_LOCATION
/ O O
mL O B_MEASURE/B_LOCATION
; O O
range O B_LOCATION/B_MEASURE
, O O
6 O B_MEASURE
. O O
9 O B_MEASURE
- O O
52 O B_MEASURE
. O O
7 O B_MEASURE/B_LOCATION
U O I_MEASURE/I_LOCATION
/ O O
mL O B_MEASURE/B_LOCATION
) O O
compared O O
to O O
the O O
normal O B_PERSON/B_MEASURE
controls O I_PERSON/I_MEASURE
( O O
median O B_MEASURE/B_GENE
, O O
8 O B_MEASURE
. O O
6 O B_MEASURE
U O I_MEASURE
/ O O
mL O B_MEASURE/B_LOCATION
; O O
range O B_LOCATION/B_MEASURE
, O O
6 O B_MEASURE
. O O
5 O B_MEASURE
- O O
12 O B_MEASURE
. O O
0 O B_MEASURE/B_LOCATION
U O I_MEASURE/I_LOCATION
/ O O
mL O B_MEASURE/B_LOCATION
, O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

Levels O O
were O O
significantly O O
greater O O
in O O
patients O O
with O O
acute O O
liver O O
failure O O
due O O
to O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
overdose O O
( O O
median O O
, O O
28 O O
. O O
7 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
12 O O
. O O
8 O O
- O O
52 O O
. O O
7 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
17 O O
) O O
than O O
those O O
due O O
to O O
non O O
- O O
A O O
to O O
E O O
hepatitis O O
( O O
median O O
, O O
12 O O
. O O
5 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6 O O
. O O
9 O O
- O O
46 O O
. O O
0 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
7 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

There O O
was O O
no O O
relationship O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sFas O B_GENE/B_DISEASE
to O O
eventual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
patients O B_PERSON/B_LOCATION
. O O

A O O
significant O O
correlation O O
was O O
observed O O
between O O
serum O O
sFas O O
levels O O
and O O
aspartate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O O
( O O
r O O
= O O
0 O O
. O O
613 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
increased O O
concentration O B_MEASURE/B_LOCATION
of O O
sFas O B_GENE
in O O
serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
acute O B_DISEASE/B_LOCATION
liver O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
may O O
reflect O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
Fas O B_GENE
- O O
mediated O O
apoptosis O B_DISEASE/B_GENE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
this O O
together O O
with O O
increased O O
tumor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
alpha O B_PROTEIN[GENE]
may O O
be O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
liver O B_DISEASE
cell O I_DISEASE
loss O I_DISEASE
. O O

Bilateral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
subthalamic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nucleus O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
Parkinson O B_DISEASE/B_PERSON
' O I_DISEASE
s O B_DISEASE
disease O I_DISEASE
. O O

High O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
frequency O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
subthalamic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
nucleus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O O
STN O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
known O O
to O O
ameliorate O O
the O O
signs O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
symptoms O B_DISEASE
of O O
advanced O B_DISEASE
Parkinson O I_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
. O O

AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
studied O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
frequency O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
STN O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
23 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

METHOD O O
: O O
Twenty O O
- O O
three O O
patients O O
suffering O O
from O O
severe O O
Parkinson O O
' O O
s O O
disease O O
( O O
Stages O O
III O O
- O O
V O O
on O O
Hoehn O O
and O O
Yahr O O
scale O O
) O O
and O O
, O O
particularly O O
bradykinesia O O
, O O
rigidity O O
, O O
and O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesias O O
underwent O O
bilateral O O
implantation O O
of O O
electrodes O O
in O O
the O O
STN O O
. O O

Preoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
postoperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assessments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
patients O B_PERSON
at O O
1 O B_SEQUENCE[MEASURE]
, O O
3 O B_SEQUENCE[MEASURE]
, O O
6 O B_NUMBER[MEASURE]
and O O
12 O B_NUMBER[MEASURE]/B_PERSON
months O I_NUMBER[MEASURE]/I_PERSON
follow O O
- O O
up O O
, O O
in O O
" O O
on O O
" O O
and O O
" O O
off O O
" O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
was O O
carried O O
out O O
using O O
Unified O B_PERSON
Parkinson O I_PERSON
' O I_PERSON
s O I_PERSON
Disease O I_PERSON
Rating O I_PERSON
Scale O I_PERSON
, O O
Hoehn O B_DISEASE/B_LOCATION
and O O
Yahr O B_LOCATION/B_ENT
staging O I_LOCATION/I_ENT
, O O
England O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
daily O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
living O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
score O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
video O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recordings O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
After O O
one O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
year O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
electrical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
STN O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
the O O
patients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
daily O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
living O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O O
motor O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Unified O B_MEASURE/B_LOCATION
Parkinson O B_MEASURE/I_LOCATION
' O B_MEASURE/I_LOCATION
s O B_MEASURE/I_LOCATION
Disease O B_MEASURE/I_LOCATION
Rating O B_MEASURE/I_LOCATION
Scale O B_MEASURE/I_LOCATION
parts O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
and O O
III O B_TIME[MEASURE]
) O O
off O O
medication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
improved O O
by O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
61 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
respectively O O
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
0005 O B_MEASURE
) O O
. O O

The O O
subscores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
akinesia O B_DISEASE/B_MEASURE
, O O
rigidity O B_DISEASE
, O O
tremor O B_DISEASE
and O O
gait O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
also O O
improved O O
. O O

( O O
p O O
< O O
0 O B_MEASURE
. O O
0005 O B_MEASURE
) O O
. O O

The O O
average O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
decreased O O
from O O
813 O O
mg O O
to O O
359 O O
mg O O
. O O

The O O
cognitive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O B_PERSON
patients O I_PERSON
developed O O
device O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
related O O
complications O B_DISEASE
and O O
two O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
experienced O O
abnormal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weight O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Bilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subthalamic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
nucleus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
an O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
advanced O B_DISEASE/B_LOCATION
Parkinson O I_DISEASE/I_LOCATION
' O I_DISEASE/I_LOCATION
s O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
. O O

It O O
reduces O O
the O O
severity O O
of O O
" O O
off O O
" O O
phase O O
symptoms O O
, O O
improves O O
the O O
axial O O
symptoms O O
and O O
reduces O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O O
. O O

The O O
reduction O O
in O O
the O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
is O O
useful O O
in O O
controlling O O
drug O O
- O O
induced O O
dyskinesias O O
. O O

Acute O O
renal O O
failure O O
occurring O O
during O O
intravenous O O
desferrioxamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
: O O
recovery O O
after O O
haemodialysis O O
. O O

A O O
patient O O
with O O
transfusion O O
- O O
dependent O O
thalassemia O O
was O O
undergoing O O
home O O
intravenous O O
desferrioxamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
DFX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
treatment O O
by O O
means O O
of O O
a O O
totally O O
implanted O O
system O O
because O O
of O O
his O O
poor O O
compliance O O
with O O
the O O
nightly O O
subcutaneous O O
therapy O O
. O O

Due O O
to O O
an O O
accidental O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malfunctioning O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
infusion O B_PRODUCT[OBJECT]/B_LOCATION
pump O I_PRODUCT[OBJECT]/I_LOCATION
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
inadvertently O O
administered O O
a O O
toxic O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosage O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
caused O O
renal O B_DISEASE
insufficiency O I_DISEASE
. O O

Given O O
the O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deterioration O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
the O O
laboratory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
despite O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
a O O
decision O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
made O O
to O O
introduce O O
haemodialytical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
order O B_MEASURE/B_PERSON
to O O
remove O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduce O O
the O O
nephrotoxicity O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
results O O
obtained O O
, O O
haemodialysis O O
can O O
therefore O O
be O O
suggested O O
as O O
a O O
useful O O
therapy O O
in O O
rare O O
cases O O
of O O
progressive O O
acute O O
renal O O
failure O O
caused O O
by O O
desferrioxamine B B_DISEASE
. O O

Ocular O O
motility O O
changes O O
after O O
subtenon O O
carboplatin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
chemotherapy O O
for O O
retinoblastoma O O
. O O

BACKGROUND O O
: O O
Focal O O
subtenon O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O O
have O O
recently O O
been O O
used O O
as O O
a O O
presumably O O
toxicity O O
- O O
free O O
adjunct O O
to O O
systemic O O
chemotherapy O O
for O O
intraocular O O
retinoblastoma O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
our O O
clinical O O
experience O O
with O O
abnormal O O
ocular O O
motility O O
in O O
patients O O
treated O O
with O O
subtenon O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chemotherapy O O
. O O

METHODS O O
: O O
We O O
noted O O
abnormal O O
ocular O O
motility O O
in O O
10 O O
consecutive O O
patients O O
with O O
retinoblastoma O O
who O O
had O O
received O O
subtenon O O
carboplatin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

During O O
ocular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
under O O
general O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
assessed O O
their O O
eyes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
forced O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
duction O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
testing O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
comparing O O
ocular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motility O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
tumor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
ocular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motility O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subsequently O O
enucleated O O
because O O
of O O
treatment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
n O B_PROTEIN[GENE]/B_LOCATION
= O I_PROTEIN[GENE]/I_LOCATION
4 O I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
examined O O
histologically O O
. O O

RESULTS O O
: O O
Limitation O O
of O O
ocular O O
motility O O
was O O
detected O O
in O O
all O O
12 O O
eyes O O
of O O
10 O O
patients O O
treated O O
for O O
intraocular O O
retinoblastoma O O
with O O
1 O O
to O O
6 O O
injections O O
of O O
subtenon O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
part O O
of O O
multimodality O O
therapy O O
. O O

Histopathological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O O
many O B_DISEASE
lipophages O I_DISEASE
in O O
the O O
periorbital O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fat O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
surrounding O O
the O O
optic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nerve O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
1 O B_PERSON/B_BIO
eye O I_PERSON/I_BIO
, O O
indicative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phagocytosis O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
previously O O
existing O O
fat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggesting O O
prior O B_DISEASE
fat O I_DISEASE
necrosis O I_DISEASE
. O O

The O O
enucleations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O O
technically O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hazardous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
globe O B_DISEASE/B_PERSON
rupture O I_DISEASE/I_PERSON
because O O
of O O
extensive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
orbital O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
soft O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSIONS O O
: O O
Subtenon O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy O O
is O O
associated O O
with O O
significant O O
fibrosis O O
of O O
orbital O O
soft O O
tissues O O
, O O
leading O O
to O O
mechanical O O
restriction O O
of O O
eye O O
movements O O
and O O
making O O
subsequent O O
enucleation O O
difficult O O
. O O

Subtenon O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
free O O
of O O
toxicity O O
, O O
and O O
its O O
use O O
is O O
best O O
restricted O O
to O O
specific O O
indications O O
. O O

Ethambutol B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
optic O O
neuropathy O O
. O O

PURPOSE O O
: O O
To O O
demonstrate O O
the O O
association O O
between O O
ethambutol B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
optic O O
neuropathy O O
. O O

METHOD O O
: O O
Thirteen O O
patients O O
who O O
developed O O
optic O O
neuropathy O O
after O O
being O O
treated O O
with O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
tuberculosis O O
of O O
the O O
lung O O
or O O
lymph O O
node O O
at O O
Siriraj O O
Hospital O O
between O O
1997 O O
and O O
2001 O O
were O O
retrospectively O O
reviewed O O
. O O

The O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
final O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
analyzed O O
to O O
determine O O
visual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
All O O
patients O O
had O O
optic O O
neuropathy O O
between O O
1 O O
to O O
6 O O
months O O
( O O
mean O O
= O O
2 O O
. O O
9 O O
months O O
) O O
after O O
starting O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
at O O
a O O
dosage O O
ranging O O
from O O
13 O O
to O O
20 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
mean O O
= O O
17 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
. O O

Seven O B_NUMBER[MEASURE]
( O O
54 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
13 O B_PERSON
patients O I_PERSON
experienced O O
visual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
stopping O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
6 O B_PERSON
patients O I_PERSON
with O O
irreversible O B_DISEASE
visual O I_DISEASE
impairment O I_DISEASE
, O O
4 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
had O O
diabetes O B_DISEASE
mellitus O I_DISEASE
, O O
glaucoma O B_DISEASE
and O O
a O O
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
heavy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
smoking O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSION O O
: O O
Early O O
recognition O O
of O O
optic O O
neuropathy O O
should O O
be O O
considered O O
in O O
patients O O
with O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

A O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dose O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
prompt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
discontinuation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
recommended O O
particularly O O
in O O
individuals O B_PERSON/B_LOCATION
with O O
diabetes O B_DISEASE
mellitus O I_DISEASE
, O O
glaucoma O B_DISEASE
or O O
who O O
are O O
heavy O B_DISEASE/B_PERSON
smokers O I_DISEASE/I_PERSON
. O O

Treatment O O
of O O
compensatory O O
gustatory O O
hyperhidrosis O O
with O O
topical O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Gustatory O B_DISEASE
hyperhidrosis O I_DISEASE
is O O
facial O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
sweating O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
usually O O
associated O O
with O O
the O O
eating O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
hot O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
spicy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
food O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
or O O
even O O
smelling O O
this O O
food O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Current O O
options O O
of O O
treatment O O
include O O
oral O O
anticholinergic O O
drugs O O
, O O
the O O
topical O O
application O O
of O O
anticholinergics O O
or O O
aluminum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
injection O O
of O O
botulinum O O
toxin O O
. O O

Thirteen O O
patients O O
have O O
been O O
treated O O
to O O
date O O
with O O
1 O O
. O O
5 O O
% O O
or O O
2 O O
% O O
topical O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
patients O B_PERSON
had O O
gustatory O B_DISEASE
hyperhidrosis O I_DISEASE
, O O
which O O
interfered O O
with O O
their O O
social O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
after O O
transthroacic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
endoscopic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
sympathectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O O
and O O
which O O
was O O
associated O O
with O O
compensatory O B_DISEASE
focal O I_DISEASE
hyperhidrosis O I_DISEASE
. O O

After O O
applying O O
topical O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
subjective O O
effect O O
was O O
excellent O O
( O O
no O O
sweating O O
after O O
eating O O
hot O O
spicy O O
food O O
) O O
in O O
10 O O
patients O O
( O O
77 O O
% O O
) O O
, O O
and O O
fair O O
( O O
clearly O O
reduced O O
sweating O O
) O O
in O O
3 O O
patients O O
( O O
23 O O
% O O
) O O
. O O

All O O
had O O
reported O O
incidents O B_PERSON/B_DISEASE
of O O
being O O
very O O
embarrassed O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
whilst O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
eating O O
hot O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spicy O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
foods O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Adverse O O
effects O O
included O O
a O O
mildly O O
dry O O
mouth O O
and O O
a O O
sore O O
throat O O
in O O
2 O O
patients O O
( O O
2 O O
% O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
light O O
headache O O
in O O
1 O O
patient O O
( O O
1 O O
. O O
5 O O
% O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
topical O O
application O O
of O O
a O O
glycopyrrolate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pad O O
appeared O O
to O O
be O O
safe O O
, O O
efficacious O O
, O O
well O O
tolerated O O
, O O
and O O
a O O
convenient O O
method O O
of O O
treatment O O
for O O
moderate O O
to O O
severe O O
symptoms O O
of O O
gustatory O O
hyperhidrosis O O
in O O
post O O
transthoracic O O
endoscopic O O
sympathectomy O O
or O O
sympathicotomy O O
patients O O
, O O
with O O
few O O
side O O
effects O O
. O O

Neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
hyperprolactinemia O O
. O O

Can O O
it O O
be O O
treated O O
with O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Six O O
stable O O
psychiatric O O
outpatients O O
with O O
hyperprolactinemia O O
and O O
amenorrhea O O
/ O O
oligomenorrhea O O
associated O O
with O O
their O O
neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
medications I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
treated O O
with O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Daily O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dosages O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
5 O B_NUMBER[MEASURE]
- O O
10 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corrected O O
the O O
hyperprolactinemia O B_DISEASE_ADJECTIVE[DISEASE]
and O O
restored O O
menstruation O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O O
four O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
six O B_PERSON
patients O I_PERSON
. O O

One O O
woman O O
, O O
however O O
, O O
developed O O
worsened O O
psychiatric O O
symptoms O O
while O O
taking O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
it O O
was O O
discontinued O O
. O O

Thus O O
, O O
three O O
of O O
six O O
patients O O
had O O
their O O
menstrual O O
irregularity O O
successfully O O
corrected O O
with O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

This O O
suggests O O
that O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
further O O
evaluated O O
as O O
potential O O
therapy O O
for O O
neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
hyperprolactinemia O O
and O O
amenorrhea O O
/ O O
galactorrhea O O
. O O

Ethacrynic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
convulsions O O
and O O
brain O O
neurotransmitters O O
in O O
mice O O
. O O

Intracerebroventricular O O
injection O O
of O O
ethacrynic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O O
% O O
convulsive O O
dose O O
; O O
50 O O
micrograms O O
/ O O
mouse O O
) O O
accelerated O O
the O O
synthesis O O
/ O O
turnover O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hydroxytryptamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
5 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
but O O
suppressed O O
the O O
synthesis O O
of O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
acetylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mouse O O
brain O O
. O O

These O O
effects O O
were O O
completely O O
antagonized O O
by O O
pretreatment O O
with O O
a O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
, O O
aminophosphonovaleric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
ethacrynic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
convulsions O O
, O O
these O O
neurotransmitter O O
systems O O
may O O
be O O
differentially O O
modulated O O
, O O
probably O O
through O O
activation O O
of O O
glutaminergic O O
neurons O O
in O O
the O O
brain O O
. O O

Pharmacology O O
of O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acidA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor O O
complex O O
after O O
the O O
in O O
vivo O O
administration O O
of O O
the O O
anxioselective O O
and O O
anticonvulsant O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O O
abecarnil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
rodents O O
, O O
the O O
effect O O
of O O
the O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O O
isopropyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benzyloxy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methoxymethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
abecarrnil B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
a O O
new O O
ligand O O
for O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O O
possessing O O
anxiolytic O O
and O O
anticonvulsant O O
properties O O
, O O
was O O
evaluated O O
on O O
the O O
function O O
of O O
central O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GABA B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
A O O
receptor O O
complex O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Added O O
in O O
vitro O O
to O O
rat O O
cortical O O
membrane O O
preparation O O
, O O
abecarnil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
increased O O
[ O O
3H O O
] O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
, O O
enhanced O O
muscimol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
36Cl O O
- O O
uptake O O
and O O
reduced O O
the O O
binding O O
of O O
t B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
butylbicyclophosphorothionate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
. O O

These O O
effects O O
were O O
similar O O
to O O
those O O
induced O O
by O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
the O O
partial O O
agonist O O
Ro B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6028 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
tert B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyl I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromo I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13a I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydro I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxo I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9H I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imidazo I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrrolo I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benzodiazepine I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylate I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
showed O O
very O O
weak O O
efficacy O O
in O O
these O O
biochemical O O
tests O O
. O O

After O O
i O O
. O O
p O O
. O O
injection O O
to O O
rats O O
, O O
abecarnil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
in O O
a O O
time O O
- O O
dependent O O
and O O
dose O O
- O O
related O O
( O O
0 O O
. O O
25 O O
- O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
manner O O
[ B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
35S I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TBPS I I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
measured O O
ex O O
vivo O O
in O O
the O O
cerebral O O
cortex O O
. O O

Moreover O O
, O O
both O O
drugs O O
at O O
the O O
dose O O
of O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
antagonized O O
completely O O
the O O
convulsant O O
activity O O
and O O
the O O
increase O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
induced O O
by O O
isoniazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
350 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
as O O
well O O
as O O
the O O
increase O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
induced O O
by O O
foot O O
- O O
shock O O
stress O O
. O O

To O O
better O O
correlate O O
the O O
biochemical O O
and O O
the O O
pharmacological O O
effects O O
, O O
we O O
studied O O
the O O
action O O
of O O
abecarnil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
, O O
exploratory O O
motility O O
and O O
on O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
biochemical O O
and O O
pharmacological O O
effects O O
in O O
mice O O
. O O

In O O
these O O
animals O O
, O O
abecarnil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
a O O
paralleled O O
dose O O
- O O
dependent O O
( O O
0 O O
. O O
05 O O
- O O
1 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
reduction O O
of O O
both O O
motor O O
behavior O O
and O O
cortical O O
[ O O
35S O O
] O O
TBPS O O
binding O O
. O O

Moreover O O
, O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
of O O
this O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduced O O
markedly O O
the O O
increase O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
and O O
the O O
convulsions O O
induced O O
by O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
200 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Recurrent O O
myocardial O O
infarction O O
in O O
a O O
postpartum O O
patient O O
receiving O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Myocardial O B_DISEASE
infarction O I_DISEASE
in O O
puerperium O B_BIO/B_DISEASE
is O O
infrequently O O
reported O O
. O O

Spasm O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dissection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
or O O
atheromatous O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
etiology O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
described O O
. O O

Bromocriptine B B_PERSON
has O O
been O O
implicated O O
in O O
several O O
previous O O
case O O
reports O O
of O O
myocardial O O
infarction O O
in O O
the O O
puerperium O O
. O O

Our O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
including O O
an O O
inadvertent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rechallenge O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
suggests O O
such O O
a O O
relationship O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
generally O O
regarded O O
as O O
" O O
safe O O
, O O
" O O
possible O O
serious O O
cardiac O O
effects O O
of O O
bromocriptine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
acknowledged O O
. O O

Asterixis O O
induced O O
by O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

There O O
are O O
very O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O O
asterixis O B_DISEASE/B_BIO
as O O
a O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
psychopharmacologic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
we O O
present O O
four O O
patients O O
treated O O
with O O
a O O
combination O O
of O O
different O O
psychotropic O O
drugs O O
, O O
in O O
whom O O
asterixis O O
was O O
triggered O O
either O O
by O O
adding O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
to O O
a O O
treatment O O
regimen O O
, O O
or O O
by O O
increasing O O
its O O
dosage O O
. O O

Neither O O
dosage O O
nor O O
serum O O
levels O O
of O O
CBZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
in O O
a O O
higher O O
range O O
. O O

We O O
consider O O
asterixis O O
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity O O
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
used O O
in O O
combination O O
with O O
CBZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pharmacodynamics O O
of O O
the O O
hypotensive O O
effect O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
parkinsonian O O
patients O O
. O O

Blood O O
pressure O O
effects O O
of O O
i O O
. O O
v O O
. O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
examined O O
in O O
parkinsonian O O
patients O O
with O O
stable O O
and O O
fluctuating O O
responses O O
to O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
magnitude O O
of O O
the O O
hypotensive O O
effect O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
concentration O O
dependent O O
and O O
was O O
fit O O
to O O
an O O
Emax O O
model O O
in O O
fluctuating O O
responders O O
. O O

Stable O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responders O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
a O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hypotensive O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Baseline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
fluctuating O O
patients O B_PERSON/B_LOCATION
; O O
a O O
higher O B_MEASURE
baseline O I_MEASURE
blood O I_MEASURE
pressure O I_MEASURE
correlated O O
with O O
greater O B_DISEASE
hypotensive O I_DISEASE
effects O I_DISEASE
. O O

Antiparkinsonian O O
effects O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temporally O O
correlated O O
with O O
blood O O
pressure O O
changes O O
. O O

Phenylalanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
a O O
large O O
neutral O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LNAA O O
) O O
competing O O
with O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
transport O O
across O O
the O O
blood O O
- O O
brain O O
barrier O O
, O O
reduced O O
the O O
hypotensive O O
and O O
antiparkinsonian O O
effects O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
conclude O O
that O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
central O O
hypotensive O O
action O O
that O O
parallels O O
the O O
motor O O
effects O O
in O O
fluctuating O O
patients O O
. O O

The O O
hypotensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
appears O O
to O O
be O O
related O O
to O O
the O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
baseline O I_DISEASE_ADJECTIVE[DISEASE]
blood O I_DISEASE_ADJECTIVE[DISEASE]
pressure O I_DISEASE_ADJECTIVE[DISEASE]
we O O
observed O O
in O O
fluctuating O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relative O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
stable O B_PERSON
patients O I_PERSON
. O O

Syndrome O O
of O O
inappropriate O O
secretion O O
of O O
antidiuretic O O
hormone O O
after O O
infusional O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
77 O O
- O O
year O O
- O O
old O O
woman O O
with O O
refractory O O
multiple O O
myeloma O O
was O O
treated O O
with O O
a O O
4 O O
- O O
day O O
continuous O O
intravenous O O
infusion O O
of O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
4 O O
days O O
of O O
oral O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nine O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
her O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
she O O
presented O O
with O O
lethargy O B_DISEASE
and O O
weakness O B_DISEASE
associated O O
with O O
hyponatremia O B_DISEASE
. O O

Evaluation O O
revealed O O
the O O
syndrome O O
of O O
inappropriate O O
secretion O O
of O O
antidiuretic O O
hormone O O
, O O
which O O
was O O
attributed O O
to O O
the O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O O
. O O

After O O
normal O O
serum O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
returned O O
, O O
further O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O O
without O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
produce O O
this O O
complication O O
. O O

Heart O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
to O O
digitalise O O
or O O
not O O
? O O

The O O
view O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O O
. O O

Despite O O
extensive O O
clinical O O
experience O O
the O O
role O O
of O O
digoxin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
still O O
not O O
well O O
defined O O
. O O

In O O
patients O O
with O O
atrial O O
fibrillation O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
beneficial O O
for O O
ventricular O O
rate O O
control O O
. O O

For O O
patients O B_PERSON
in O O
sinus O B_DISEASE
rhythm O I_DISEASE
and O O
heart O B_DISEASE
failure O I_DISEASE
the O O
situation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
less O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
narrow O O
therapeutic O O
: O O
toxic O O
ratio O O
and O O
concentrations O O
are O O
affected O O
by O O
a O O
number O O
of O O
drugs O O
. O O

Also O O
, O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
undesirable O O
effects O O
such O O
as O O
increasing O O
peripheral O O
resistance O O
and O O
myocardial O O
demands O O
, O O
and O O
causing O O
arrhythmias O O
. O O

There O O
is O O
a O O
paucity O B_DISEASE/B_MEASURE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O O
well O O
- O O
designed O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
are O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
generally O O
small O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
with O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
these O O
show O B_MEASURE
variation O I_MEASURE
in O O
patient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

More O O
convincing O O
evidence O O
is O O
required O O
showing O O
that O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O O
symptoms O O
or O O
exercise O O
capacity O O
. O O

Furthermore O O
, O O
no O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O O
had O O
sufficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
power O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
evaluate O O
mortality O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pooled O O
analysis O O
of O O
the O O
effects O O
of O O
other O O
inotropic O O
drugs O O
shows O O
an O O
excess O O
mortality O O
and O O
there O O
is O O
a O O
possibility O O
that O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O O
increase O O
mortality O O
after O O
myocardial O O
infarction O O
( O O
MI O O
) O O
. O O

Angiotensin B B_GENE
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
should O O
be O O
used O O
first O O
as O O
they O O
are O O
safer O O
, O O
do O O
not O O
require O O
blood O O
level O O
monitoring O O
, O O
modify O O
progression O O
of O O
disease O O
, O O
relieve O O
symptoms O O
, O O
improve O O
exercise O O
tolerance O O
and O O
reduce O O
mortality O O
. O O

Caution O O
should O O
be O O
exercised O O
in O O
using O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O O
large O O
mortality O O
trials O O
are O O
completed O O
showing O O
either O O
benefit O O
or O O
harm O O
. O O

Until O O
then O O
digoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
considered O O
a O O
third O O
- O O
line O O
therapy O O
. O O

Isradipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O O
for O O
hypertension O O
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

A O O
6 O O
- O O
week O O
open O O
study O O
of O O
the O O
introduction O O
of O O
isradipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
was O O
conducted O O
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

303 O B_PERSON/B_BIO
Chinese O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
with O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
moderate O B_DISEASE
hypertension O I_DISEASE
entered O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
reported O O
in O O
21 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
and O O
caused O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
3 O B_TIME[MEASURE]/B_PERSON
patients O I_TIME[MEASURE]/I_PERSON
. O O

The O O
main O O
side O O
- O O
effects O O
were O O
headache O O
, O O
dizziness O O
, O O
palpitation O O
and O O
flushing O O
and O O
these O O
were O O
not O O
more O O
frequent O O
than O O
reported O O
in O O
other O O
studies O O
with O O
isradipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
with O O
placebo O O
. O O

Supine O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
was O O
reduced O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
from O O
170 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
20 O B_MEASURE
/ O O
102 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
to O O
153 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
19 O B_MEASURE
/ O O
92 O B_MEASURE
+ O O
/ O O
- O O
8 O B_MEASURE
, O O
147 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
/ O O
88 O B_MEASURE
+ O O
/ O O
- O O
7 O B_MEASURE
and O O
144 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
14 O B_MEASURE
/ O O
87 O B_MEASURE
+ O O
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
at O O
2 O B_NUMBER[MEASURE]
, O O
4 O B_MEASURE
and O O
6 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
respectively O O
in O O
evaluable O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

Similar O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
in O O
standing O O
blood O B_MEASURE/B_DISEASE
pressure O I_MEASURE/I_DISEASE
and O O
there O O
was O O
no O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
postural O B_DISEASE
hypotension O I_DISEASE
. O O

Normalization O B_DISEASE/B_PERSON
and O O
responder O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
6 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
were O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
69 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
respectively O O
. O O

Dosage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
increased O O
from O O
2 O B_MEASURE
. O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O
to O O
5 O B_MEASURE
mg O I_MEASURE
b O O
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O
at O O
4 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O B_PERSON/B_BIO
with O O
diastolic O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
blood O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
90 O B_MEASURE/B_LOCATION
mmHg O I_MEASURE/I_LOCATION
and O O
their O O
further O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
greater O B_MEASURE
than O O
those O O
remaining O O
on O O
2 O B_NUMBER[MEASURE]
. O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O

Pharmacological O O
characteristics O O
and O O
side O O
effects O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
without O O
soyabean O O
oil O O
. O O

We O O
compared O O
the O O
pharmacokinetics O O
, O O
pharmacodynamics O O
and O O
safety O O
profile O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AM149 O O
1 O O
% O O
) O O
, O O
which O O
does O O
not O O
contain O O
soyabean O O
oil O O
, O O
with O O
a O O
standard O O
formulation O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Disoprivan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O O
% O O
) O O
. O O

In O O
a O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
cross O O
- O O
over O O
study O O
, O O
30 O O
healthy O O
volunteers O O
received O O
a O O
single O O
intravenous O O
bolus O O
injection O O
of O O
2 O O
. O O
5 O O
mg O O
. O O
kg O O
- O O
1 O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Plasma O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
measured O O
for O O
48 O O
h O O
following O O
drug O O
administration O O
and O O
evaluated O O
according O O
to O O
a O O
three O O
- O O
compartment O O
model O O
. O O

The O O
pharmacodynamic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessed O O
included O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
emergence O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
pain O B_DISEASE/B_MEASURE
on O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Patients O B_PERSON/B_BIO
were O O
monitored O O
for O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O O
48 O B_MEASURE
h O O
. O O

Owing O O
to O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]
incidence O I_DISEASE_ADJECTIVE[DISEASE]
of O O
thrombophlebitis O B_DISEASE
, O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
terminated O O
prematurely O O
and O O
only O O
the O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
parallel O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
15 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
in O O
each O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
analysed O O
. O O

Plasma O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O O
not O O
differ O O
significantly O O
between O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formulations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anaesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O O
emergence O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
respiratory O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cardiovascular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
variables O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
showed O O
no O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pain O O
on O O
injection O O
( O O
80 O O
vs O O
. O O
20 O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
thrombophlebitis O O
( O O
93 O O
. O O
3 O O
vs O O
. O O
6 O O
. O O
6 O O
% O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
occurred O O
more O O
frequently O O
with O O
AM149 O O
than O O
with O O
Disoprivan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
both O O
formulations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
similar O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacokinetic O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
pharmacodynamic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
the O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
not O O
suitable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
due O O
to O O
the O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
thrombophlebitis O B_DISEASE
produced O O
. O O

Pure O O
red O O
cell O O
aplasia O O
, O O
toxic O O
dermatitis O O
and O O
lymphadenopathy O O
in O O
a O O
patient O O
taking O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
patient O O
taking O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O O
weeks O O
developed O O
a O O
generalized O O
skin O O
rash O O
, O O
lymphadenopathy O O
and O O
pure O O
red O O
cell O O
aplasia O O
. O O

After O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pharmacon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O O
symptoms O B_DISEASE
disappeared O O
spontaneously O O
. O O

Skin O O
rash O O
is O O
a O O
well O O
- O O
known O O
complication O O
of O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
as O O
is O O
benign O O
and O O
malignant O O
lymphadenopathy O O
. O O

Pure O O
red O O
cell O O
aplasia O O
associated O O
with O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O O
has O O
been O O
reported O O
in O O
3 O O
patients O O
. O O

The O O
exact O O
mechanism O O
by O O
which O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O O
its O O
toxic O O
effects O O
is O O
not O O
known O O
. O O

In O O
this O O
patient O O
the O O
time O O
relation O O
between O O
the O O
ingestion O O
of O O
diphenylhydantoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
the O O
occurrence O O
of O O
the O O
skin O O
rash O O
, O O
lymphadenopathy O O
and O O
pure O O
red O O
cell O O
aplasia O O
is O O
very O O
suggestive O O
of O O
a O O
direct O O
connection O O
. O O

Vinorelbine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
cardiac O O
events O O
: O O
a O O
meta O O
- O O
analysis O O
of O O
randomized O O
clinical O O
trials O O
. O O

Several O O
cases O O
of O O
cardiac O O
adverse O O
reactions O O
related O O
to O O
vinorelbine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VNR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
been O O
reported O O
in O O
the O O
literature O O
. O O

In O O
order O O
to O O
quantify O O
the O O
incidence O O
of O O
these O O
cardiac O O
events O O
, O O
we O O
performed O O
a O O
meta O O
- O O
analysis O O
of O O
clinical O O
trials O O
comparing O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
other O O
chemotherapeutic O O
agents O O
in O O
the O O
treatment O O
of O O
various O O
malignancies O O
. O O

Randomized O O
clinical O O
trials O O
comparing O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
other O O
drugs O O
in O O
the O O
treatment O O
of O O
cancer O O
were O O
searched O O
in O O
Medline O O
, O O
Embase O O
, O O
Evidence O O
- O O
based O O
Medicine O O
Reviews O O
databases O O
and O O
the O O
Cochrane O O
library O O
from O O
1987 O O
to O O
2002 O O
. O O

Outcomes O B_PERSON/B_LOCATION
of O O
interest O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
severe O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
events O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
toxic O B_DISEASE
deaths O I_DISEASE
and O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
deaths O B_DISEASE
reported O O
in O O
each O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

We O O
found O O
19 O O
trials O O
, O O
involving O O
2441 O O
patients O O
treated O O
by O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
2050 O O
control O O
patients O O
. O O

The O O
incidence O O
of O O
cardiac O O
events O O
with O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
1 O O
. O O
19 O O
% O O
[ O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
( O O
0 O O
. O O
75 O O
; O O
1 O O
. O O
67 O O
) O O
] O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
risk O O
of O O
cardiac O O
events O O
between O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O O
drugs O O
[ O O
odds O O
ratio O O
: O O
0 O O
. O O
92 O O
, O O
95 O O
% O O
CI O O
( O O
0 O O
. O O
54 O O
; O O
1 O O
. O O
55 O O
) O O
] O O
. O O

The O O
risk O O
of O O
VNR B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cardiac O O
events O O
was O O
similar O O
to O O
vindesine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VDS B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
other O O
cardiotoxic O O
drugs O O
[ O O
fluorouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
anthracyclines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
gemcitabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
em O O
leader O O
] O O
. O O

Even O O
if O O
it O O
did O O
not O O
reach O O
statistical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
because O O
of O O
a O O
few O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
risk O B_DISEASE/B_MEASURE
was O O
lower O B_MEASURE
in O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
excluding O O
patients O B_PERSON
with O O
cardiac O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
seemed O O
to O O
be O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
including O O
patients O B_PERSON
with O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
existing O O
cardiac O B_DISEASE
diseases O I_DISEASE
. O O

Vinorelbine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
cardiac O O
events O O
concern O O
about O O
1 O O
% O O
of O O
treated O O
patients O O
in O O
clinical O O
trials O O
. O O

However O O
, O O
the O O
risk O O
associated O O
with O O
VNR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seems O O
to O O
be O O
similar O O
to O O
that O O
of O O
other O O
chemotherapeutic O O
agents O O
in O O
the O O
same O O
indications O O
. O O

MRI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
hypoxic O B_DISEASE/B_LOCATION
cortical O I_DISEASE/I_LOCATION
laminar O I_DISEASE/I_LOCATION
necrosis O I_DISEASE/I_LOCATION
in O O
a O O
child O B_PERSON/B_LOCATION
with O O
hemolytic O B_DISEASE/B_GENE
anemia O I_DISEASE/I_GENE
crisis O I_DISEASE/I_GENE
. O O

We O O
present O O
magnetic O O
resonance O O
imaging O O
findings O O
of O O
a O O
5 O O
- O O
year O O
- O O
old O O
girl O O
who O O
had O O
a O O
rapidly O O
installing O O
hemolytic O O
anemia O O
crisis O O
induced O O
by O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sulfomethoxazole I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
resulting O O
in O O
cerebral O O
anoxia O O
leading O O
to O O
permanent O O
damage O O
. O O

Magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
cortical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
laminar O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
necrosis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
arterial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
border O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
zones O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
both O O
cerebral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hemispheres O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
subcortical O B_LOCATION/B_BIO
white O I_LOCATION/I_BIO
matter O I_LOCATION/I_BIO
of O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cerebral O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hemisphere O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
in O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
putamen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
cortical O B_DISEASE
laminar O I_DISEASE
necrosis O I_DISEASE
is O O
a O O
classic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
entity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
adulthood O B_PERSON/B_DISEASE
related O O
to O O
conditions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
energy O B_DISEASE
depletions O I_DISEASE
, O O
there O O
are O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
wide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
presented O O
. O O

The O O
natural O O
history O O
of O O
Vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O O
visual O O
field O O
defects O O
in O O
patients O O
electing O O
to O O
continue O O
their O O
medication O O
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
natural O O
history O O
of O O
visual O O
field O O
defects O O
in O O
a O O
group O O
of O O
patients O O
known O O
to O O
have O O
Vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
changes O O
who O O
elected O O
to O O
continue O O
the O O
medication O O
because O O
of O O
good O O
seizure O O
control O O
. O O

METHODS O O
: O O
All O O
patients O O
taking O O
Vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
in O O
combination O O
with O O
other O O
antiepileptic O O
drugs O O
for O O
at O O
least O O
5 O O
years O O
( O O
range O O
5 O O
- O O
12 O O
years O O
) O O
were O O
entered O O
into O O
a O O
visual O O
surveillance O O
programme O O
. O O

Patients O B_PERSON
were O O
followed O O
up O O
at O O
6 O B_NUMBER[MEASURE]/B_LOCATION
- O O
monthly O B_TIME[MEASURE]
intervals O I_TIME[MEASURE]
for O O
not O O
less O B_TIME[MEASURE]
than O O
18 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_MEASURE/B_LOCATION
18 O I_MEASURE/I_LOCATION
- O O
43 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
. O O

In O O
all O O
, O O
16 O B_PERSON
patients O I_PERSON
with O O
unequivocal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
the O O
medication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Following O O
already O O
published O O
methodology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
Eye O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2002 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
16 O B_MEASURE
; O O
567 O B_MEASURE
- O O
571 O B_MEASURE
) O O
monocular O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radial O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MRDs O B_MEASURE/B_PROTEIN[GENE]
) O O
to O O
the O O
I O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
4e O B_MEASURE/B_PROTEIN[GENE]
isopter O I_MEASURE/I_PROTEIN[GENE]
on O O
Goldmann O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perimetry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
calculated O O
for O O
the O O
right O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
at O O
the O O
time O B_MEASURE/B_LOCATION
of O O
discovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
visual O B_DISEASE
field O I_DISEASE
defect O I_DISEASE
and O O
again O O
after O O
not O O
less O B_TIME[MEASURE]
than O O
18 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
follow O I_TIME[MEASURE]
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Mean O O
right O B_DISEASE/B_MEASURE
eye O I_DISEASE/I_MEASURE
MRD O I_DISEASE/I_MEASURE
at O O
presentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
36 O B_MEASURE
. O O
98 O B_MEASURE
degrees O I_MEASURE
( O O
range O B_MEASURE/B_LOCATION
22 O I_MEASURE/I_LOCATION
. O O
25 O B_MEASURE
- O O
51 O B_MEASURE
. O O
0 O B_MEASURE
) O O
, O O
compared O O
to O O
38 O B_MEASURE
. O O
40 O B_MEASURE
degrees O I_MEASURE
( O O
range O B_MEASURE/B_LOCATION
22 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
- O O
49 O B_MEASURE
. O O
75 O B_MEASURE
) O O
after O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
; O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
338 O B_MEASURE
unpaired O I_MEASURE
t O I_MEASURE
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Only O O
one O B_PERSON
patient O I_PERSON
demonstrated O O
a O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
visual O B_DISEASE
field O I_DISEASE
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
discontinued O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSION O O
: O O
Established O O
visual O O
field O O
defects O O
presumed O O
to O O
be O O
due O O
to O O
Vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
did O O
not O O
usually O O
progress O O
in O O
spite O O
of O O
continuing O O
use O O
of O O
the O O
medication O O
. O O

These O O
data O O
give O O
support O O
to O O
the O O
hypothesis O O
that O O
the O O
pathogenesis O O
of O O
Vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
visual O O
field O O
defects O O
may O O
be O O
an O O
idiosyncratic O O
adverse O O
drug O O
reaction O O
rather O O
than O O
dose O O
- O O
dependent O O
toxicity O O
. O O

Induction O O
of O O
rosaceiform O O
dermatitis O O
during O O
treatment O O
of O O
facial O O
inflammatory O O
dermatoses O O
with O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O O
. O O

BACKGROUND O O
: O O
Tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ointment O O
is O O
increasingly O O
used O O
for O O
anti O O
- O O
inflammatory O O
treatment O O
of O O
sensitive O O
areas O O
such O O
as O O
the O O
face O O
, O O
and O O
recent O O
observations O O
indicate O O
that O O
the O O
treatment O O
is O O
effective O O
in O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
aggravated O O
rosacea O O
and O O
perioral O O
dermatitis O O
. O O

We O O
report O O
on O O
rosaceiform O O
dermatitis O O
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O O
. O O

OBSERVATIONS O O
: O O
Six O O
adult O O
patients O O
with O O
inflammatory O O
facial O O
dermatoses O O
were O O
treated O O
with O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O O
because O O
of O O
the O O
ineffectiveness O O
of O O
standard O O
treatments O O
. O O

Within O O
2 O B_NUMBER[MEASURE]/B_LOCATION
to O O
3 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
initially O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
well O O
- O O
tolerated O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
with O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
of O O
rosacea O B_DISEASE
and O O
1 O B_NUMBER[MEASURE]/B_PERSON
with O O
a O O
history O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acne O B_DISEASE
experienced O O
sudden O B_DISEASE_ADJECTIVE[DISEASE]
worsening O O
with O O
pustular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rosaceiform O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Biopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
an O O
abundance O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Demodex O B_DISEASE
mites O I_DISEASE
in O O
2 O B_NUMBER[MEASURE]
of O O
these O O
patients O B_PERSON/B_LOCATION
. O O

In O O
1 O B_PERSON/B_BIO
patient O I_PERSON/I_BIO
with O O
eyelid O B_DISEASE
eczema O I_DISEASE
, O O
rosaceiform O B_DISEASE
periocular O I_DISEASE
dermatitis O I_DISEASE
gradually O O
appeared O O
after O O
3 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
1 O B_PERSON/B_BIO
patient O I_PERSON/I_BIO
with O O
atopic O B_DISEASE/B_LOCATION
dermatitis O I_DISEASE/I_LOCATION
, O O
telangiectatic O B_DISEASE
and O O
papular O B_DISEASE
rosacea O I_DISEASE
insidiously O O
appeared O O
after O O
5 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

CONCLUSIONS O O
: O O
Our O O
observations O O
suggest O O
that O O
the O O
spectrum O O
of O O
rosaceiform O O
dermatitis O O
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O O
is O O
heterogeneous O O
. O O

A O O
variety O O
of O O
factors O O
, O O
such O O
as O O
vasoactive O O
properties O O
of O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
proliferation O O
of O O
Demodex O O
due O O
to O O
local O O
immunosuppression O O
, O O
and O O
the O O
occlusive O O
properties O O
of O O
the O O
ointment O O
, O O
may O O
be O O
involved O O
in O O
the O O
observed O O
phenomena O O
. O O

Future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
to O O
identify O O
individual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
factors O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Intravascular O O
hemolysis O O
and O O
acute O O
renal O O
failure O O
following O O
intermittent O O
rifampin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Renal O O
failure O O
is O O
a O O
rare O O
complication O O
associated O O
with O O
the O O
use O O
of O O
rifampin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Intravascular O O
hemolysis O O
leading O O
to O O
acute O O
renal O O
failure O O
following O O
rifampin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
is O O
extremely O O
rare O O
. O O

Two O O
patients O O
with O O
leprosy O O
who O O
developed O O
hemolysis O O
and O O
acute O O
renal O O
failure O O
following O O
rifampin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O O
reported O O
. O O

Structural O O
abnormalities O O
in O O
the O O
brains O O
of O O
human O O
subjects O O
who O O
use O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
visualize O O
, O O
for O O
the O O
first O O
time O O
, O O
the O O
profile O O
of O O
structural O O
deficits O O
in O O
the O O
human O O
brain O O
associated O O
with O O
chronic O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
abuse O O
. O O

Studies O O
of O O
human O O
subjects O O
who O O
have O O
used O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chronically O O
have O O
revealed O O
deficits O O
in O O
dopaminergic O O
and O O
serotonergic O O
systems O O
and O O
cerebral O O
metabolic O O
abnormalities O O
. O O

Using O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
and O O
new O O
computational O O
brain O O
- O O
mapping O O
techniques O O
, O O
we O O
determined O O
the O O
pattern O O
of O O
structural O O
brain O O
alterations O O
associated O O
with O O
chronic O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O O
in O O
human O O
subjects O O
and O O
related O O
these O O
deficits O O
to O O
cognitive O O
impairment O O
. O O

We O O
used O O
high O O
- O O
resolution O O
MRI O O
and O O
surface O O
- O O
based O O
computational O O
image O O
analyses O O
to O O
map O O
regional O O
abnormalities O O
in O O
the O O
cortex O O
, O O
hippocampus O O
, O O
white O O
matter O O
, O O
and O O
ventricles O O
in O O
22 O O
human O O
subjects O O
who O O
used O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
21 O O
age O O
- O O
matched O O
, O O
healthy O O
controls O O
. O O

Cortical O O
maps O O
revealed O O
severe O O
gray O O
- O O
matter O O
deficits O O
in O O
the O O
cingulate O O
, O O
limbic O O
, O O
and O O
paralimbic O O
cortices O O
of O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O O
( O O
averaging O O
11 O O
. O O
3 O O
% O O
below O O
control O O
; O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

On O O
average O O
, O O
MA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O O
had O O
7 O O
. O O
8 O O
% O O
smaller O O
hippocampal O O
volumes O O
than O O
control O O
subjects O O
( O O
p O O
< O O
0 O O
. O O
01 O O
; O O
left O O
, O O
p O O
= O O
0 O O
. O O
01 O O
; O O
right O O
, O O
p O O
< O O
0 O O
. O O
05 O O
) O O
and O O
significant O O
white O O
- O O
matter O O
hypertrophy O O
( O O
7 O O
. O O
0 O O
% O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Hippocampal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficits O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
mapped O O
and O O
correlated O O
with O O
memory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
word O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
recall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_DISEASE
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

MRI O O
- O O
based O O
maps O O
suggest O O
that O O
chronic O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O O
causes O O
a O O
selective O O
pattern O O
of O O
cerebral O O
deterioration O O
that O O
contributes O O
to O O
impaired O O
memory O O
performance O O
. O O

MA B B_LOCATION/B_DISEASE
may O O
selectively O O
damage O O
the O O
medial O O
temporal O O
lobe O O
and O O
, O O
consistent O O
with O O
metabolic O O
studies O O
, O O
the O O
cingulate O O
- O O
limbic O O
cortex O O
, O O
inducing O O
neuroadaptation O O
, O O
neuropil O O
reduction O O
, O O
or O O
cell O O
death O O
. O O

Prominent O B_PERSON/B_COLOR
white O B_PERSON/I_COLOR
- O O
matter O B_DISEASE
hypertrophy O I_DISEASE
may O O
result O O
from O O
altered O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myelination O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
adaptive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glial O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
gliosis O B_DISEASE_ADJECTIVE[DISEASE]
secondary O I_DISEASE_ADJECTIVE[DISEASE]
to O O
neuronal O B_DISEASE
damage O I_DISEASE
. O O

These O O
brain O O
substrates O O
may O O
help O O
account O O
for O O
the O O
symptoms O O
of O O
MA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O O
, O O
providing O O
therapeutic O O
targets O O
for O O
drug O O
- O O
induced O O
brain O O
injury O O
. O O

Disruption O O
of O O
hepatic O O
lipid O O
homeostasis O O
in O O
mice O O
after O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
is O O
associated O O
with O O
peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
- O O
alpha O O
target O O
gene O O
activation O O
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
an O O
efficacious O O
and O O
widely O O
used O O
antiarrhythmic O O
agent O O
, O O
has O O
been O O
reported O O
to O O
cause O O
hepatotoxicity O O
in O O
some O O
patients O O
. O O

To O O
gain O O
insight O O
into O O
the O O
mechanism O O
of O O
this O O
unwanted O O
effect O O
, O O
mice O O
were O O
administered O O
various O O
doses O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
examined O O
for O O
changes O O
in O O
hepatic O O
histology O O
and O O
gene O O
regulation O O
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
hepatomegaly O O
, O O
hepatocyte O O
microvesicular O O
lipid O O
accumulation O O
, O O
and O O
a O O
significant O O
decrease O O
in O O
serum O O
triglycerides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glucose B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Northern O O
blot O O
analysis O O
of O O
hepatic O O
RNA O O
revealed O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
expression O O
of O O
a O O
number O O
of O O
genes O O
critical O O
for O O
fatty B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxidation O O
, O O
lipoprotein O O
assembly O O
, O O
and O O
lipid O O
transport O O
. O O

Many O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
genes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O O
regulated O O
by O O
the O O
peroxisome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
activated O O
receptor O B_GENE
- O O
alpha O B_PROTEIN[GENE]
( O O
PPARalpha O B_GENE
) O O
, O O
a O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
activated O O
nuclear O B_GENE
hormone O I_GENE
receptor O I_GENE
transcription O I_GENE
factor O I_GENE
. O O

The O O
absence O O
of O O
induction O O
of O O
these O O
genes O O
as O O
well O O
as O O
hepatomegaly O O
in O O
PPARalpha O O
knockout O O
[ O O
PPARalpha O O
- O O
/ O O
- O O
] O O
mice O O
indicated O O
that O O
the O O
effects O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
dependent O O
upon O O
the O O
presence O O
of O O
a O O
functional O O
PPARalpha O O
gene O O
. O O

Compared O O
to O O
wild O O
- O O
type O O
mice O O
, O O
treatment O O
of O O
PPARalpha O O
- O O
/ O O
- O O
mice O O
with O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
resulted O O
in O O
an O O
increased O O
rate O O
and O O
extent O O
of O O
total O O
body O O
weight O O
loss O O
. O O

The O O
inability O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
directly O O
activate O O
either O O
human O O
or O O
mouse O O
PPARalpha O O
transiently O O
expressed O O
in O O
human O O
HepG2 O O
hepatoma O O
cells O O
indicates O O
that O O
the O O
effects O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
function O O
of O O
this O O
receptor O O
were O O
indirect O O
. O O

Based O O
upon O O
these O O
results O O
, O O
we O O
conclude O O
that O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disrupts O O
hepatic O O
lipid O O
homeostasis O O
and O O
that O O
the O O
increased O O
expression O O
of O O
PPARalpha O O
target O O
genes O O
is O O
secondary O O
to O O
this O O
toxic O O
effect O O
. O O

These O O
results O O
provide O O
important O O
new O O
mechanistic O O
information O O
regarding O O
the O O
hepatotoxic O O
effects O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
indicate O O
that O O
PPARalpha O O
protects O O
against O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hepatotoxicity O O
. O O

Safety O O
and O O
compliance O O
with O O
once O O
- O O
daily O O
niacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
initial O O
therapy O O
in O O
the O O
Impact O O
of O O
Medical O O
Subspecialty O O
on O O
Patient O O
Compliance O O
to O O
Treatment O O
( O O
IMPACT O O
) O O
study O O
. O O

Niacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
new O O
combination O O
product O O
approved O O
for O O
treatment O O
of O O
primary O O
hypercholesterolemia O O
and O O
mixed O O
dyslipidemia O O
. O O

This O O
open O O
- O O
labeled O O
, O O
multicenter O O
study O O
evaluated O O
the O O
safety O O
of O O
bedtime O O
niacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
dosed O O
as O O
initial O O
therapy O O
and O O
patient O O
compliance O O
to O O
treatment O O
in O O
various O O
clinical O O
practice O O
settings O O
. O O

A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4 O B_MEASURE
, O O
499 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
with O O
dyslipidemia O B_DISEASE
requiring O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intervention O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
enrolled O O
at O O
1 O B_MEASURE
, O O
081 O B_MEASURE/B_ORGANIZATION
sites O I_MEASURE/I_ORGANIZATION
. O O

Patients O O
were O O
treated O O
with O O
1 O O
tablet O O
( O O
500 O O
mg O O
of O O
niacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended O O
- O O
release O O
/ O O
20 O O
mg O O
of O O
lovastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
once O O
nightly O O
for O O
4 O O
weeks O O
and O O
then O O
2 O O
tablets O O
for O O
8 O O
weeks O O
. O O

Patients O O
also O O
received O O
dietary O O
counseling O O
, O O
educational O O
materials O O
, O O
and O O
reminders O O
to O O
call O O
a O O
toll O O
- O O
free O O
number O O
that O O
provided O O
further O O
education O O
about O O
dyslipidemia O O
and O O
niacin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
study O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
liver O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminases O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
> O O
3 O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
the O O
upper O B_MEASURE/B_LOCATION
limit O I_MEASURE/I_LOCATION
of O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
and O O
clinical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myopathy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Final O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
4 O B_MEASURE
, O O
217 O B_MEASURE
patients O I_MEASURE
( O O
94 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Compliance O O
to O O
niacin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
extended I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
release I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
/ I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
lovastatin I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
77 O O
% O O
, O O
with O O
3 O O
, O O
245 O O
patients O O
completing O O
the O O
study O O
. O O

Patients O B_PERSON/B_LOCATION
in O O
the O O
southeast O B_LOCATION/B_ORGANIZATION
and O O
those O O
enrolled O O
by O O
endocrinologists O B_LOCATION/B_ORGANIZATION
had O O
the O O
lowest O B_MEASURE
compliance O I_MEASURE
and O O
highest O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Flushing O B_DISEASE
was O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
event O I_DISEASE_ADJECTIVE[DISEASE]
, O O
reported O O
by O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_LOCATION
and O O
leading O O
to O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O O
6 O B_PERSON
% O I_PERSON
. O O

Incidence O O
of O O
increased O O
aspartate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O O
and O O
/ O O
or O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O O
> O O
3 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
was O O
< O O
0 O O
. O O
3 O O
% O O
. O O

An O O
increase O O
of O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
phosphokinase O O
to O O
> O O
5 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
occurred O O
in O O
0 O O
. O O
24 O O
% O O
of O O
patients O O
, O O
and O O
no O O
cases O O
of O O
drug O O
- O O
induced O O
myopathy O O
were O O
observed O O
. O O

Niacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extended I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
release I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
lovastatin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 O O
, O O
000 O O
/ O O
40 O O
mg O O
, O O
dosed O O
as O O
initial O O
therapy O O
, O O
was O O
associated O O
with O O
good O O
compliance O O
and O O
safety O O
and O O
had O O
very O O
low O O
incidences O O
of O O
increased O O
liver O O
and O O
muscle O O
enzymes O O
. O O

Protective O O
effect O O
of O O
Terminalia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
chebula I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
against O O
experimental O O
myocardial O O
injury O O
induced O O
by O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cardioprotective O O
effect O O
of O O
ethanolic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extract I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Terminalia I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chebula I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fruits I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
500 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
was O O
examined O O
in O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
200 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
induced O O
myocardial O O
damage O O
in O O
rats O O
. O O

In O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administered O O
rats O O
, O O
the O O
level O O
of O O
lipid O O
peroxides B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
increased O O
significantly O O
in O O
the O O
serum O O
and O O
heart O O
. O O

A O O
significant O B_MEASURE
decrease O I_MEASURE
was O O
observed O O
in O O
the O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
myocardial O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
marker O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
concomitant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
their O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Histopathological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
to O O
confirm O O
the O O
myocardial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chebula I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extract I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pretreatment O O
was O O
found O O
to O O
ameliorate O O
the O O
effect O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
lipid O O
peroxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
formation O O
and O O
retained O O
the O O
activities O O
of O O
the O O
diagnostic O O
marker O O
enzymes O O
. O O

A O O
case O O
of O O
postoperative O O
anxiety O O
due O O
to O O
low O O
dose O O
droperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
with O O
patient O O
- O O
controlled O O
analgesia O O
. O O

A O O
multiparous O B_PERSON
woman O I_PERSON
in O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
psychological O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
health O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
underwent O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
urgent O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
caesarean O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
section O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
in O O
labour O B_PERSON/B_LOCATION
. O O

Postoperatively O O
, O O
she O O
was O O
given O O
a O O
patient O O
- O O
controlled O O
analgesia O O
device O O
delivering O O
boluses O O
of O O
diamorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
0 O O
. O O
5 O O
mg O O
and O O
droperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
025 O O
mg O O
. O O

Whilst O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
the O O
device O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O O
gradually O O
became O O
anxious O B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
feeling O B_PERSON/B_DISEASE
worsening O O
after O O
each O O
bolus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
diagnosis O O
of O O
droperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
psychological O O
disturbance O O
was O O
not O O
made O O
straight O O
away O O
although O O
on O O
subsequent O O
close O O
questioning O O
the O O
patient O O
gave O O
a O O
very O O
clear O O
history O O
. O O

After O O
she O O
had O O
received O O
a O O
total O O
of O O
only O O
0 O O
. O O
9 O O
mg O O
droperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
syringe O O
containing O O
diamorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O O
was O O
substituted O O
and O O
her O O
unease O O
resolved O O
completely O O
. O O

We O O
feel O O
that O O
, O O
although O O
the O O
dramatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extrapyramidal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
well O O
known O O
, O O
more O O
subtle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
easily O O
be O O
overlooked O O
. O O

Accurate O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patient O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
history O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
contributes O O
to O O
differentiating O O
diabetes O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insipidus O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

This O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
highlights O O
the O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contribution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
nursing O B_PERSON
in O O
obtaining O O
an O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
case O B_PERSON/B_DISEASE
discussed O O
herein O B_LOCATION/B_TIME[MEASURE]
initially O O
appeared O O
to O O
be O O
neurogenic O B_DISEASE
diabetes O I_DISEASE
insipidus O O
( O O
DI O B_DISEASE/B_PROTEIN[GENE]
) O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
traumatic O B_DISEASE
brain O I_DISEASE
injury O I_DISEASE
. O O

The O O
nursing O O
staff O O
, O O
by O O
reviewing O O
the O O
patient O O
' O O
s O O
health O O
history O O
with O O
his O O
family O O
, O O
discovered O O
a O O
history O O
of O O
polydipsia O O
and O O
long O O
- O O
standing O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

Lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
implicated O O
in O O
drug O O
- O O
induced O O
nephrogenic O O
DI O O
, O O
and O O
because O O
the O O
patient O O
had O O
not O O
received O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
being O O
admitted O O
to O O
the O O
hospital O O
, O O
his O O
treatment O O
changed O O
to O O
focus O O
on O O
nephrogenic O O
DI O O
. O O

By O O
combining O O
information O O
from O O
the O O
patient O O
history O O
, O O
the O O
physical O O
examination O O
, O O
and O O
radiologic O O
and O O
laboratory O O
studies O O
, O O
the O O
critical O O
care O O
team O O
demonstrated O O
that O O
the O O
patient O O
had O O
been O O
self O O
- O O
treating O O
his O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephrogenic O O
DI O O
and O O
developed O O
neurogenic O O
DI O O
secondary O O
to O O
brain O O
trauma O O
. O O

Thus O O
successful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
required O O
that O O
nephrogenic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
neurogenic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
DI O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
be O O
treated O O
concomitantly O O
. O O

Factors O O
contributing O O
to O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anemia O O
. O O

BACKGROUND O O
AND O O
AIM O O
: O O
Interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
combination O O
therapy O O
for O O
chronic O O
hepatitis O O
C O O
produces O O
hemolytic O O
anemia O O
. O O

This O O
study O O
was O O
conducted O O
to O O
identify O O
the O O
factors O O
contributing O O
to O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anemia O O
. O O

METHODS O O
: O O
Eighty O O
- O O
eight O O
patients O O
with O O
chronic O O
hepatitis O O
C O O
who O O
received O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2b I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
a O O
dose O O
of O O
6 O O
MU O O
administered O O
intramuscularly O O
for O O
24 O O
weeks O O
in O O
combination O O
with O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O O
orally O O
at O O
a O O
dose O O
of O O
600 O O
mg O O
or O O
800 O O
mg O O
participated O O
in O O
the O O
study O O
. O O

A O O
hemoglobin O O
concentration O O
of O O
< O O
10 O O
g O O
/ O O
dL O O
was O O
defined O O
as O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
anemia O O
. O O

RESULTS O O
: O O
Ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
anemia O O
occurred O O
in O O
18 O O
( O O
20 O O
. O O
5 O O
% O O
) O O
patients O O
during O O
treatment O O
. O O

A O O
2 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_MEASURE
decrease O I_MEASURE
in O O
hemoglobin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
patients O B_PERSON/B_BIO
with O O
anemia O B_DISEASE
was O O
observed O O
at O O
week O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
hemoglobin O B_MEASURE
concentration O I_MEASURE
in O O
patients O B_PERSON/B_BIO
with O O
> O B_MEASURE
or O O
= O O
2 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_MEASURE
decrease O I_MEASURE
at O O
week O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O O
observed O O
to O O
be O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
even O O
after O O
week O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O O
in O O
patients O B_PERSON
with O O
< O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
g O I_MEASURE/I_LOCATION
/ O O
dL O B_MEASURE/B_LOCATION
decrease O B_MEASURE/I_LOCATION
( O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

A O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
between O O
the O O
rate O B_MEASURE
of O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hemoglobin O B_DISEASE/B_GENE
concentrations O B_DISEASE/I_GENE
at O O
week O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
anemia O B_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Such O O
factors O O
as O O
sex O O
( O O
female O O
) O O
, O O
age O O
( O O
> O O
or O O
= O O
60 O O
years O O
old O O
) O O
, O O
and O O
the O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
by O O
body O O
weight O O
( O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
) O O
were O O
significant O O
by O O
univariate O O
analysis O O
. O O

CONCLUSIONS O O
: O O
Careful O O
administration O O
is O O
necessary O O
in O O
patients O O
> O O
or O O
= O O
60 O O
years O O
old O O
, O O
in O O
female O O
patients O O
, O O
and O O
in O O
patients O O
receiving O O
a O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
of O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
. O O

Patients O B_PERSON
who O O
experience O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
hemoglobin O B_MEASURE/B_DISEASE
concentrations O I_MEASURE/I_DISEASE
of O O
2 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_TIME[MEASURE]/B_PROTEIN[GENE]
or O O
more O B_MEASURE
at O O
week O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
start O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O O
be O O
monitored O O
with O O
particular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O O

Zidovudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
hepatitis O O
. O O

A O O
case O O
of O O
acute O O
hepatitis O O
induced O O
by O O
zidovudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
38 O O
- O O
year O O
- O O
old O O
patient O O
with O O
AIDS O O
is O O
presented O O
. O O

The O O
mechanism O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
whereby O O
the O O
hepatitis O B_DISEASE
was O O
induced O O
is O O
not O O
known O O
. O O

However O O
, O O
the O O
patient O O
tolerated O O
well O O
an O O
alternative O O
reverse O O
transcriptase O O
inhibitor O O
, O O
2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dideoxyinosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Physicians O B_PERSON/B_ORGANIZATION
caring O O
for O O
patients O B_PERSON
with O O
AIDS O B_DISEASE
should O O
be O O
aware O B_PERSON/B_TIME[MEASURE]
of O O
this O O
hitherto O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rarely O O
reported O O
complication O B_DISEASE
. O O

Oxidative O O
damage O O
precedes O O
nitrative O O
damage O O
in O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
mitochondrial O O
injury O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
if O O
elevated O O
reactive O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
ROS O O
) O O
/ O O
nitrogen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O O
( O O
RNS O O
) O O
reported O O
to O O
be O O
present O O
in O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ADR B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
induced O O
cardiotoxicity O O
actually O O
resulted O O
in O O
cardiomyocyte O O
oxidative O O
/ O O
nitrative O O
damage O O
, O O
and O O
to O O
quantitatively O O
determine O O
the O O
time O O
course O O
and O O
subcellular O O
localization O O
of O O
these O O
postulated O O
damage O O
products O O
using O O
an O O
in O O
vivo O O
approach O O
. O O

B6C3 O O
mice O O
were O O
treated O O
with O O
a O O
single O O
dose O O
of O O
20 O O
mg O O
/ O O
kg O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ultrastructural O O
damage O O
and O O
levels O O
of O O
4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nonenal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
4HNE B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
protein O O
adducts O O
and O O
3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrotyrosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3NT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
were O O
analyzed O O
. O O

Quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ultrastructural O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
damage O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
computerized O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
cardiomyocyte O B_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
as O O
early O O
as O O
3 O B_MEASURE/B_ENT
hours O I_MEASURE/I_ENT
, O O
with O O
mitochondria O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
being O O
the O O
most O O
extensively O O
and O O
progressively O O
injured O B_DISEASE_ADJECTIVE[DISEASE]
subcellular O I_DISEASE_ADJECTIVE[DISEASE]
organelle O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Analysis O O
of O O
4HNE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
adducts O O
by O O
immunogold O O
electron O O
microscopy O O
showed O O
appearance O O
of O O
4HNE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O O
adducts O O
in O O
mitochondria O O
as O O
early O O
as O O
3 O O
hours O O
, O O
with O O
a O O
peak O O
at O O
6 O O
hours O O
and O O
subsequent O O
decline O O
at O O
24 O O
hours O O
. O O

3NT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
significantly O O
increased O O
in O O
all O O
subcellular O O
compartments O O
at O O
6 O O
hours O O
and O O
subsequently O O
declined O O
at O O
24 O O
hours O O
. O O

Our O O
data O O
showed O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
4HNE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
protein O O
adducts O O
in O O
mitochondria O O
at O O
the O O
same O O
time O O
point O O
as O O
when O O
mitochondrial O O
injury O O
initially O O
appeared O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
document O O
for O O
the O O
first O B_TIME[MEASURE]/B_PERSON
time O I_TIME[MEASURE]/I_PERSON
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
that O O
mitochondrial O B_DISEASE/B_GENE
oxidative O I_DISEASE/I_GENE
damage O I_DISEASE/I_GENE
precedes O O
nitrative O B_DISEASE
damage O I_DISEASE
. O O

The O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mitochondrial O B_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
mitochondria O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O O
not O O
other O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subcellular O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
organelles O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
are O O
the O O
major O B_LOCATION
site O I_LOCATION
of O O
intracellular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
coronary O O
spasm O O
in O O
a O O
patient O O
with O O
dilated O O
cardiomyopathy O O
associated O O
with O O
sustained O O
ventricular O O
tachycardia O O
. O O

A O O
54 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
man O I_PERSON
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
left O O
ventricular O B_DISEASE/B_LOCATION
dysfunction O I_DISEASE/I_LOCATION
due O O
to O O
dilated O O
cardiomyopathy O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
referred O O
to O O
our O O
hospital O B_LOCATION/B_PERSON
for O O
symptomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incessant O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sustained O O
ventricular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
VT O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

After O O
the O O
administration O O
of O O
nifekalant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sustained O O
VT O O
was O O
terminated O O
. O O

An O O
alternate O O
class O O
III O O
agent O O
, O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
also O O
effective O O
for O O
the O O
prevention O O
of O O
VT O O
. O O

However O O
, O O
one O O
month O O
after O O
switching O O
over O O
nifekalant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
short O O
duration O O
of O O
ST O O
elevation O O
was O O
documented O O
in O O
ECG O O
monitoring O O
at O O
almost O O
the O O
same O O
time O O
for O O
three O O
consecutive O O
days O O
. O O

ST O O
elevation O O
with O O
chest O O
discomfort O O
disappeared O O
since O O
he O O
began O O
taking O O
long O O
- O O
acting O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Coronary O O
vasospasm O O
may O O
be O O
induced O O
by O O
the O O
non O O
- O O
selective O O
beta O O
- O O
blocking O O
properties O O
of O O
sotalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Effects O O
of O O
the O O
antidepressant O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O O
/ O O
2C O O
receptor O O
antagonist O O
, O O
on O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O O
behaviors O O
in O O
rats O O
. O O

RATIONALE O O
: O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Hydroxytryptamine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
via O O
stimulation O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O O
receptors O O
, O O
exerts O O
a O O
tonic O O
inhibitory O O
influence O O
on O O
dopaminergic O O
neurotransmission O O
, O O
whereas O O
activation O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2A O O
receptors O O
enhances O O
stimulated O O
DAergic O O
neurotransmission O O
. O O

The O O
antidepressant O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
a O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O O
/ O O
2C O O
receptor O O
antagonist O O
. O O

OBJECTIVES O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
on O O
behaviors O O
dependent O O
on O O
the O O
functional O O
status O O
of O O
the O O
nigrostriatal O O
DAergic O O
system O O
. O O

METHODS O O
: O O
The O O
effect O O
of O O
pretreatment O O
with O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dexamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
oral O O
stereotypies O O
, O O
on O O
catalepsy O O
induced O O
by O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
, O O
on O O
ergometrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
wet O O
dog O O
shake O O
( O O
WDS O O
) O O
behavior O O
and O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
penile O O
erections O O
was O O
studied O O
in O O
rats O O
. O O

We O O
also O O
investigated O O
whether O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
catalepsy O O
in O O
rats O O
. O O

RESULTS O O
: O O
Trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
2 O O
. O O
5 O O
- O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
did O O
not O O
induce O O
catalepsy O O
, O O
and O O
did O O
not O O
antagonize O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
. O O
5 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
stereotypy O O
and O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
) O O
- O O
induced O O
catalepsy O O
. O O

However O O
, O O
pretreatment O O
with O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhanced O O
dexamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypy O O
, O O
and O O
antagonized O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
catalepsy O O
, O O
ergometrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
WDS O O
behavior O O
and O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
penile O O
erections O O
. O O

Trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
30 O O
, O O
40 O O
and O O
50 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
induced O O
catalepsy O O
and O O
antagonized O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypies O O
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
indicate O O
that O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
2 O O
. O O
5 O O
- O O
20 O O
mg O O
/ O O
kg O O
does O O
not O O
block O O
pre O O
- O O
and O O
postsynaptic O O
striatal O O
D2 O O
DA O O
receptors O O
, O O
while O O
at O O
30 O O
, O O
40 O O
and O O
50 O O
mg O O
/ O O
kg O O
it O O
blocks O O
postsynaptic O O
striatal O O
D2 O O
DA O O
receptors O O
. O O

Furthermore O O
, O O
at O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
, O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2A O O
and O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O O
receptors O O
. O O

We O O
suggest O O
that O O
trazodone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
) O O
, O O
by O O
blocking O O
the O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O O
receptors O O
, O O
releases O O
the O O
nigrostriatal O O
DAergic O O
neurons O O
from O O
tonic O O
inhibition O O
caused O O
by O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HT I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
thereby O O
potentiates O O
dexamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypy O O
and O O
antagonizes O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalepsy O O
. O O

Swallowing O O
abnormalities O B_DISEASE_ADJECTIVE[DISEASE]
and O O
dyskinesia O B_DISEASE
in O O
Parkinson O B_PERSON/B_DISEASE
' O O
s O B_DISEASE
disease O I_DISEASE
. O O

Gastrointestinal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
Parkinson O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
PD O B_DISEASE/B_PROTEIN[GENE]
) O O
have O O
been O O
known O O
for O O
almost O O
two O B_TIME[MEASURE]/B_PERSON
centuries O I_TIME[MEASURE]/I_PERSON
, O O
but O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concerning O O
their O O
pathophysiology O B_DISEASE
have O O
not O O
been O O
completely O O
clarified O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
characterize O O
the O O
oropharyngeal O O
dynamics O O
in O O
PD O O
patients O O
with O O
and O O
without O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesia O O
. O O

Fifteen O B_TIME[MEASURE]/B_ORGANIZATION
dyskinetic O I_TIME[MEASURE]/I_ORGANIZATION
, O O
12 O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nondyskinetic O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
and O O
a O O
control O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
were O O
included O O
. O O

Patients O B_PERSON
were O O
asked O O
about O O
dysphagia O B_DISEASE
and O O
evaluated O O
with O O
the O O
Unified O B_NUMBER[MEASURE]/B_DISEASE
Parkinson O I_NUMBER[MEASURE]/I_DISEASE
' O I_NUMBER[MEASURE]/I_DISEASE
s O I_NUMBER[MEASURE]/I_DISEASE
Disease O I_NUMBER[MEASURE]/I_DISEASE
Rating O I_NUMBER[MEASURE]/I_DISEASE
Scale O I_NUMBER[MEASURE]/I_DISEASE
Parts O I_NUMBER[MEASURE]/I_DISEASE
II O I_NUMBER[MEASURE]/I_DISEASE
and O O
III O B_SEQUENCE[MEASURE]
and O O
the O O
Hoehn O B_PERSON
and O O
Yahr O B_PERSON/B_LOCATION
scale O I_PERSON/I_LOCATION
. O O

Deglutition O O
was O O
assessed O O
using O O
modified O O
barium B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
swallow O O
with O O
videofluoroscopy O O
. O O

Nondyskinetic O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
but O O
not O O
the O O
dyskinetic O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
ones O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
showed O O
less O O
oropharyngeal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
swallowing O O
efficiency O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
OPSE O B_LOCATION/B_ORGANIZATION
) O O
for O O
liquid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
food O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
than O O
controls O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Dunnett O B_PERSON/B_DISEASE
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
02 O B_MEASURE
) O O
. O O

Dyskinetic O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
tended O O
to O O
have O O
a O O
greater O B_DISEASE/B_MEASURE
OPSE O I_DISEASE/I_MEASURE
than O O
nondyskinetic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
( O O
Dunnett O B_PERSON/B_PROTEIN[GENE]
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
06 O B_MEASURE
) O O
. O O

Patients O O
who O O
were O O
using O O
a O O
higher O O
dose O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
greater O O
OPSE O O
and O O
a O O
trend O O
toward O O
a O O
smaller O O
oral O O
transit O O
time O O
( O O
Pearson O O
' O O
s O O
correlation O O
, O O
P O O
= O O
0 O O
. O O
01 O O
and O O
0 O O
. O O
08 O O
, O O
respectively O O
) O O
. O O

Neither O O
the O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
dysphagia O B_DISEASE
nor O O
any O O
of O O
the O O
PD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
severity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlated O O
to O O
the O O
videofluoroscopic O B_DISEASE_ADJECTIVE[DISEASE]
variables O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
the O O
current O O
study O O
, O O
dyskinetic O O
patients O O
performed O O
better O O
in O O
swallowing O O
function O O
, O O
which O O
could O O
be O O
explained O O
on O O
the O O
basis O O
of O O
a O O
greater O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dose O O
. O O

Our O O
results O O
suggest O O
a O O
role O O
for O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
oral O O
phase O O
of O O
deglutition O O
and O O
confirm O O
that O O
dysphagia O O
is O O
not O O
a O O
good O O
predictor O O
of O O
deglutition O O
alterations O O
in O O
PD O O
. O O

Inhibition O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial O O
nephritis O O
induced O O
by O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

BACKGROUND O O
: O O
Animals O O
treated O O
with O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
show O O
residual O O
areas O O
of O O
interstitial O O
fibrosis O O
in O O
the O O
renal O O
cortex O O
. O O

This O O
study O O
investigated O O
the O O
expression O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
, O O
mitogen O O
- O O
activated O O
protein O O
( O O
MAP O O
) O O
kinases O O
and O O
macrophages O O
in O O
the O O
renal O O
cortex O O
and O O
structural O O
and O O
functional O O
renal O O
changes O O
of O O
rats O O
treated O O
with O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
pyrrolidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dithiocarbamate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PDTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
an O O
NF O O
- O O
kappaB O O
inhibitor O O
. O O

METHODS O O
: O O
38 O O
female O O
Wistar O O
rats O O
were O O
injected O O
with O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
40 O O
mg O O
/ O O
kg O O
, O O
twice O O
a O O
day O O
for O O
9 O O
days O O
, O O
38 O O
with O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
PDTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
28 O O
with O O
0 O O
. O O
15 O O
M O O
NaCl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O O
. O O

The O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
killed O O
5 O B_MEASURE
and O O
30 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
after O O
these O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
the O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O O
removed O O
for O O
histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
scored O O
according O O
to O O
the O O
extent O B_MEASURE
of O O
staining O O
. O O

The O O
fractional O B_MEASURE/B_LOCATION
interstitial O B_MEASURE/I_LOCATION
area O B_MEASURE/I_LOCATION
was O O
determined O O
by O O
morphometry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O O
presented O O
a O O
transitory O O
increase O O
in O O
plasma O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Increased O O
ED O O
- O O
1 O O
, O O
MAP O O
kinases O O
and O O
NF O O
- O O
kappaB O O
staining O O
were O O
also O O
observed O O
in O O
the O O
renal O O
cortex O O
from O O
all O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
rats O O
compared O O
to O O
control O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

The O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killed O O
on O O
day O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
presented O O
fibrosis O B_DISEASE
in O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
despite O O
the O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
renal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Treatment O O
with O O
PDTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O O
the O O
functional O O
and O O
structural O O
changes O O
induced O O
by O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

CONCLUSIONS O O
: O O
These O O
data O O
show O O
that O O
inhibition O O
of O O
NF O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial O O
nephritis O O
induced O O
by O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Glucose B B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O O
in O O
patients O O
with O O
schizophrenia O O
treated O O
with O O
atypical O O
antipsychotic O O
agents O O
: O O
a O O
frequently O O
sampled O O
intravenous O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
test O O
and O O
minimal O O
model O O
analysis O O
. O O

BACKGROUND O O
: O O
While O O
the O O
incidence O O
of O O
new O O
- O O
onset O O
diabetes O O
mellitus O O
may O O
be O O
increasing O O
in O O
patients O O
with O O
schizophrenia O O
treated O O
with O O
certain O O
atypical O O
antipsychotic O O
agents O O
, O O
it O O
remains O O
unclear O O
whether O O
atypical O O
agents O O
are O O
directly O O
affecting O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O O
or O O
simply O O
increasing O O
known O O
risk O O
factors O O
for O O
diabetes O O
. O O

OBJECTIVE O O
: O O
To O O
study O O
the O O
2 O O
drugs O O
most O O
clearly O O
implicated O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
test O O
. O O

DESIGN O O
: O O
A O O
cross O O
- O O
sectional O O
design O O
in O O
stable O O
, O O
treated O O
patients O O
with O O
schizophrenia O O
evaluated O O
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
test O O
and O O
the O O
Bergman O O
minimal O O
model O O
analysis O O
. O O

SETTING O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Subjects O B_PERSON
were O O
recruited O O
from O O
an O O
urban O B_LOCATION/B_ORGANIZATION
community O B_LOCATION/I_ORGANIZATION
mental O B_LOCATION/I_ORGANIZATION
health O B_LOCATION/I_ORGANIZATION
clinic O B_LOCATION/I_ORGANIZATION
and O O
were O O
studied O O
at O O
a O O
general O B_LOCATION/B_MEASURE
clinical O I_LOCATION/I_MEASURE
research O I_LOCATION/I_MEASURE
center O I_LOCATION/I_MEASURE
. O O

Patients O O
Fifty O O
subjects O O
signed O O
informed O O
consent O O
and O O
41 O O
underwent O O
the O O
frequently O O
sampled O O
intravenous O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O O
test O O
. O O

Thirty O O
- O O
six O O
nonobese O O
subjects O O
with O O
schizophrenia O O
or O O
schizoaffective O O
disorder O O
, O O
matched O O
by O O
body O O
mass O O
index O O
and O O
treated O O
with O O
either O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
included O O
in O O
the O O
analysis O O
. O O

MAIN O O
OUTCOME O O
MEASURES O O
: O O
Fasting O O
plasma O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
fasting O O
serum O O
insulin O O
levels O O
, O O
insulin O O
sensitivity O O
index O O
, O O
homeostasis O O
model O O
assessment O O
of O O
insulin O O
resistance O O
, O O
and O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O O
. O O

RESULTS O O
: O O
The O O
mean O O
+ O O
/ O O
- O O
SD O O
duration O O
of O O
treatment O O
with O O
the O O
identified O O
atypical O O
antipsychotic O O
agent O O
was O O
68 O O
. O O
3 O O
+ O O
/ O O
- O O
28 O O
. O O
9 O O
months O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
29 O O
. O O
5 O O
+ O O
/ O O
- O O
17 O O
. O O
5 O O
months O O
( O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
40 O O
. O O
9 O O
+ O O
/ O O
- O O
33 O O
. O O
7 O O
( O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Fasting O O
serum O O
insulin O O
concentrations O O
differed O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
3 O O
. O O
35 O O
; O O
P O O
= O O
. O O
047 O O
) O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
with O O
significant O O
differences O O
between O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
32 O O
; O O
P O O
= O O
. O O
03 O O
) O O
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
15 O O
; O O
P O O
= O O
. O O
04 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
in O O
insulin O O
sensitivity O O
index O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
10 O O
. O O
66 O O
; O O
P O O
< O O
. O O
001 O O
) O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
< O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
, O O
with O O
subjects O O
who O O
received O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibiting O O
significant O O
insulin O O
resistance O O
compared O O
with O O
subjects O O
who O O
were O O
treated O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vs O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
t O O
( O O
33 O O
) O O
= O O
- O O
4 O O
. O O
29 O O
; O O
P O O
< O O
. O O
001 O O
; O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
t O O
( O O
33 O O
) O O
= O O
- O O
3 O O
. O O
62 O O
; O O
P O O
= O O
. O O
001 O O
[ O O
P O O
< O O
. O O
001 O O
] O O
) O O
. O O

The O O
homeostasis O O
model O O
assessment O O
of O O
insulin O O
resistance O O
also O O
differed O O
significantly O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
4 O O
. O O
92 O O
; O O
P O O
= O O
. O O
01 O O
) O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
94 O O
; O O
P O O
= O O
. O O
006 O O
; O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
42 O O
; O O
P O O
= O O
. O O
02 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
among O O
groups O O
in O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O O
( O O
F O O
( O O
30 O O
) O O
= O O
4 O O
. O O
18 O O
; O O
P O O
= O O
. O O
02 O O
) O O
( O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
< O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
with O O
significant O O
differences O O
between O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
t O O
( O O
30 O O
) O O
= O O
- O O
2 O O
. O O
59 O O
; O O
P O O
= O O
. O O
02 O O
) O O
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
t O O
( O O
30 O O
) O O
= O O
- O O
2 O O
. O O
34 O O
, O O
P O O
= O O
. O O
03 O O
) O O
. O O

CONCLUSIONS O O
: O O
Both O O
nonobese O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
groups O O
displayed O O
significant O O
insulin O O
resistance O O
and O O
impairment O O
of O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O O
compared O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
subjects O O
. O O

Patients O O
taking O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
be O O
examined O O
for O O
insulin O O
resistance O O
and O O
its O O
consequences O O
. O O

Thoracic O O
hematomyelia O O
secondary O O
to O O
coumadin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant O O
therapy O O
: O O
a O O
case O O
report O O
. O O

A O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
thoracic O B_DISEASE_ADJECTIVE[DISEASE]
hematomyelia O I_DISEASE_ADJECTIVE[DISEASE]
secondary O I_DISEASE_ADJECTIVE[DISEASE]
to O O
anticoagulant O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
presented O O
. O O

Clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
features O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
similar O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
2 O B_NUMBER[MEASURE]/B_PERSON
other O I_NUMBER[MEASURE]/I_PERSON
previously O O
reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
discussed O O
. O O

A O O
high O B_MEASURE/B_DISEASE
index O I_MEASURE/I_DISEASE
of O O
suspicion O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
lead O O
to O O
a O O
quick O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decompressive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Mania O O
associated O O
with O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
adolescents O O
. O O

Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
a O O
selective O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O O
inhibitor O O
, O O
is O O
gaining O O
increased O O
acceptance O O
in O O
the O O
treatment O O
of O O
adolescent O O
depression O O
. O O

Generally O O
safe O O
and O O
well O O
tolerated O O
by O O
adults O O
, O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
reported O O
to O O
induce O O
mania O O
. O O

The O O
cases O O
of O O
five O O
depressed O O
adolescents O O
, O O
14 O O
- O O
16 O O
years O O
of O O
age O O
, O O
who O O
developed O O
mania O O
during O O
pharmacotherapy O O
with O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
reported O O
here O O
. O O

Apparent O O
risk O O
factors O O
for O O
the O O
development O O
of O O
mania O O
or O O
hypomania O O
during O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapy O O
in O O
this O O
population O O
were O O
the O O
combination O O
of O O
attention O O
- O O
deficit O O
hyperactivity O O
disorder O O
and O O
affective O O
instability O O
; O O
major O O
depression O O
with O O
psychotic O O
features O O
; O O
a O O
family O O
history O O
of O O
affective O O
disorder O O
, O O
especially O O
bipolar O O
disorder O O
; O O
and O O
a O O
diagnosis O O
of O O
bipolar O O
disorder O O
. O O

Further O O
study O O
is O O
needed O O
to O O
determine O O
the O O
optimal O O
dosage O O
and O O
to O O
identify O O
risk O O
factors O O
that O O
increase O O
individual O O
vulnerability O O
to O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
mania O O
in O O
adolescents O O
. O O

Acute O O
renal O O
insufficiency O O
after O O
high O O
- O O
dose O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
primary O O
systemic O O
amyloidosis O O
during O O
stem O O
cell O O
transplantation O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Patients O B_PERSON/B_BIO
with O O
primary O B_DISEASE
systemic O I_DISEASE
amyloidosis O I_DISEASE
( O O
AL O B_LOCATION/B_PERSON
) O O
have O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]
prognosis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Median O B_TIME[MEASURE]/B_PERSON
survival O I_TIME[MEASURE]/I_PERSON
time O I_TIME[MEASURE]/I_PERSON
from O O
standard O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
only O O
17 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

High O O
- O O
dose O O
intravenous O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
peripheral O O
blood O O
stem O O
cell O O
transplant O O
( O O
PBSCT O O
) O O
appears O O
to O O
be O O
the O O
most O O
promising O O
therapy O O
, O O
but O O
treatment O O
mortality O O
can O O
be O O
high O O
. O O

The O O
authors O O
have O O
noted O O
the O O
development O O
of O O
acute O O
renal O O
insufficiency O O
immediately O O
after O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
conditioning O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
undertaken O O
to O O
further O O
examine O O
its O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
posttransplant O B_DISEASE
mortality O I_DISEASE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Consecutive O B_PERSON
AL O I_PERSON
patients O I_PERSON
who O O
underwent O O
PBSCT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
studied O O
retrospectively O O
. O O

Acute O O
renal O O
insufficiency O O
( O O
ARI O O
) O O
after O O
high O O
- O O
dose O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
defined O O
by O O
a O O
minimum O O
increase O O
of O O
0 O O
. O O
5 O O
mg O O
/ O O
dL O O
( O O
44 O O
micromol O O
/ O O
L O O
) O O
in O O
the O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
that O O
is O O
greater O O
than O O
50 O O
% O O
of O O
baseline O O
immediately O O
after O O
conditioning O O
. O O

Urine O B_MEASURE/B_PERSON
sediment O B_MEASURE/I_PERSON
score O B_MEASURE/I_PERSON
was O O
the O O
sum O B_MEASURE/B_PERSON
of O O
the O O
individual O B_MEASURE
types O I_MEASURE
of O O
sediment O B_BIO/B_DISEASE
identified O O
on O O
urine O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
Of O O
the O O
80 O O
patients O O
studied O O
, O O
ARI O O
developed O O
in O O
18 O O
. O O
8 O O
% O O
of O O
the O O
patients O O
after O O
high O O
- O O
dose O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Univariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
identified O O
age O B_DISEASE/B_TIME[MEASURE]
, O O
hypoalbuminemia O B_DISEASE/B_PERSON
, O O
heavy O B_DISEASE
proteinuria O I_DISEASE
, O O
diuretic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
urine O B_DISEASE/B_GENE
sediment O I_DISEASE/I_GENE
score O I_DISEASE/I_GENE
( O O
> O B_LOCATION/B_DISEASE
3 O I_LOCATION/I_DISEASE
) O O
as O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Age O B_DISEASE/B_GENE
and O O
urine O B_DISEASE/B_MEASURE
sediment O I_DISEASE/I_MEASURE
score O I_DISEASE/I_MEASURE
remained O O
independently O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Patients O O
who O O
had O O
ARI O O
after O O
high O O
- O O
dose O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O O
dialysis O O
more O O
often O O
( O O
P O O
= O O
0 O O
. O O
007 O O
) O O
, O O
and O O
had O O
a O O
worse O O
1 O O
- O O
year O O
survival O O
( O O
P O O
= O O
0 O O
. O O
03 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
timing O O
of O O
renal O O
injury O O
strongly O O
suggests O O
melphalan B B_DISEASE/B_VIRUS[BIO]
as O O
the O O
causative O O
agent O O
. O O

Ongoing O O
tubular O O
injury O O
may O O
be O O
a O O
prerequisite O O
for O O
renal O O
injury O O
by O O
melphalan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O O
evidenced O O
by O O
the O O
active O O
urinary O O
sediment O O
. O O

Development O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
ARI O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adversely O O
affected O O
the O O
outcome O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
PBSCT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
preventive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
measures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
may O O
help O O
decrease O O
the O O
treatment O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mortality O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
PBSCT O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AL O B_LOCATION/B_PERSON
patients O I_LOCATION/I_PERSON
. O O

Focal O O
cerebral O O
ischemia O O
in O O
rats O O
: O O
effect O O
of O O
phenylephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
during O O
reperfusion O O
. O O

After O O
180 O O
min O O
of O O
temporary O O
middle O O
cerebral O O
artery O O
occlusion O O
in O O
spontaneously O O
hypertensive O O
rats O O
, O O
the O O
effect O O
of O O
phenylephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
on O O
ischemic O O
brain O O
injury O O
and O O
blood O O
- O O
brain O O
barrier O O
permeability O O
was O O
determined O O
. O O

Blood O B_DISEASE
pressure O I_DISEASE
was O O
manipulated O O
by O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
following O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
schedules O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
during O O
120 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
of O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O O
Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
normotensive O B_DISEASE_ADJECTIVE[DISEASE]
reperfusion O I_DISEASE_ADJECTIVE[DISEASE]
; O O
90 O B_MEASURE
/ O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
90 O B_MEASURE
/ O O
HTN O B_LOCATION
) O O
, O O
blood O B_DISEASE/B_MEASURE
pressure O I_DISEASE/I_MEASURE
was O O
increased O O
by O O
35 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
initial O B_TIME[MEASURE]/B_LOCATION
90 O I_TIME[MEASURE]/I_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
of O O
reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
only O O
; O O
15 O B_MEASURE
/ O O
hypertension O B_DISEASE/B_MEASURE
( O O
15 O B_MEASURE
/ O O
HTN O B_DISEASE/B_LOCATION
) O O
, O O
normotensive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reperfusion O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
30 O B_TIME[MEASURE]/B_PERSON
min O B_TIME[MEASURE]/I_PERSON
followed O O
by O O
15 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
75 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
normotension O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Part O O
A O O
, O O
for O O
eight O O
rats O O
in O O
each O O
group O O
brain O O
injury O O
was O O
evaluated O O
by O O
staining O O
tissue O O
using O O
2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
triphenyltetrazolium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
edema O O
was O O
evaluated O O
by O O
microgravimetry O O
. O O

Part O B_MEASURE/B_LOCATION
B O I_MEASURE/I_LOCATION
, O O
for O O
eight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
each O O
group O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
brain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
barrier O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
permeability O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
evaluated O O
by O O
measuring O O
the O O
amount O B_MEASURE/B_LOCATION
and O O
extent O B_MEASURE/B_LOCATION
of O O
extravasation O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
Evans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Brain O B_DISEASE/B_PERSON
injury O I_DISEASE/I_PERSON
( O O
percentage O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
ischemic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
was O O
less O B_MEASURE
in O O
the O O
15 O B_MEASURE
/ O O
HTN O B_MEASURE/B_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
( O O
16 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
, O O
mean O O
+ O B_OTHER/B_DISEASE
/ O O
- O O
SD O B_MEASURE/B_DISEASE
) O O
versus O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
90 O B_MEASURE
/ O O
HTN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
30 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
) O O
, O O
which O O
was O O
in O O
turn O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
control O B_MEASURE/B_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
( O O
42 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
) O O
. O O

Specific O B_MEASURE/B_PERSON
gravity O B_MEASURE/I_PERSON
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
15 O B_MEASURE
/ O O
HTN O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE
. O O
043 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
versus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O O
90 O B_MEASURE
/ O O
HTN O B_MEASURE
( O O
1 O B_NUMBER[MEASURE]
. O O
036 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
003 O B_MEASURE
) O O
and O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
1 O B_NUMBER[MEASURE]
. O O
037 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
003 O B_MEASURE
) O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Evans B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mug O O
g O O
- O O
1 O O
of O O
brain O O
tissue O O
) O O
was O O
greater O O
in O O
the O O
90 O O
/ O O
HTN O O
group O O
( O O
24 O O
. O O
4 O O
+ O O
/ O O
- O O
6 O O
. O O
0 O O
) O O
versus O O
the O O
control O O
group O O
( O O
12 O O
. O O
3 O O
+ O O
/ O O
- O O
4 O O
. O O
1 O O
) O O
, O O
which O O
was O O
in O O
turn O O
greater O O
than O O
the O O
15 O O
/ O O
HTN O O
group O O
( O O
7 O O
. O O
3 O O
+ O O
/ O O
- O O
3 O O
. O O
2 O O
) O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supports O O
a O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
during O O
reperfusion O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
a O O
short O B_MEASURE
interval O I_MEASURE
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases O O
brain O B_DISEASE/B_GENE
injury O I_DISEASE/I_GENE
and O O
edema O B_DISEASE
; O O
and O O
that O O
sustained O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O O
the O O
risk O B_MEASURE
of O O
vasogenic O B_DISEASE
edema O I_DISEASE
. O O

People O O
aged O O
over O O
75 O O
in O O
atrial O O
fibrillation O O
on O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
the O O
rate O O
of O O
major O O
hemorrhage O O
and O O
stroke O O
in O O
more O O
than O O
500 O O
patient O O
- O O
years O O
of O O
follow O O
- O O
up O O
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
incidence O O
of O O
major O O
hemorrhage O O
and O O
stroke O O
in O O
people O O
aged O O
76 O O
and O O
older O O
with O O
atrial O O
fibrillation O O
on O O
adjusted O O
- O O
dose O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O O
had O O
been O O
recently O O
been O O
admitted O O
to O O
hospital O O
. O O

DESIGN O B_PERSON/B_MEASURE
: O O
A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observational O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SETTING O B_LOCATION
: O O
A O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
healthcare O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involving O O
four O B_PERSON/B_LOCATION
tertiary O I_PERSON/I_LOCATION
hospitals O I_PERSON/I_LOCATION
. O O

PARTICIPANTS O O
: O O
Two O O
hundred O O
thirty O O
- O O
five O O
patients O O
aged O O
76 O O
and O O
older O O
admitted O O
to O O
a O O
major O O
healthcare O O
network O O
between O O
July O O
1 O O
, O O
2001 O O
, O O
and O O
June O O
30 O O
, O O
2002 O O
, O O
with O O
atrial O O
fibrillation O O
on O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
enrolled O O
. O O

MEASUREMENTS O O
: O O
Information O O
regarding O O
major O O
bleeding O O
episodes O O
, O O
strokes O O
, O O
and O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
was O O
obtained O O
from O O
patients O O
, O O
relatives O O
, O O
primary O O
physicians O O
, O O
and O O
medical O O
records O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Two O B_NUMBER[MEASURE]
hundred O I_NUMBER[MEASURE]
twenty O I_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
42 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
men O I_PERSON/I_MEASURE
) O O
with O O
a O O
mean O B_MEASURE/B_DISEASE
age O I_MEASURE/I_DISEASE
of O O
81 O B_MEASURE
. O O
1 O B_MEASURE
( O O
range O B_MEASURE/B_LOCATION
76 O I_MEASURE/I_LOCATION
- O O
94 O B_MEASURE
) O O
were O O
included O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Total O O
follow O O
- O O
up O O
on O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
530 O O
years O O
( O O
mean O O
28 O O
months O O
) O O
. O O

There O O
were O O
53 O B_MEASURE/B_PERSON
major O I_MEASURE/I_PERSON
hemorrhages O I_MEASURE/I_PERSON
, O O
for O O
an O O
annual O B_MEASURE
rate O I_MEASURE
of O O
10 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
, O O
including O O
24 O B_NUMBER[MEASURE]
( O O
45 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
) O O
life O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
threatening O O
and O O
five O B_NUMBER[MEASURE]
( O O
9 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
fatal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeds O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
annual O O
stroke O O
rate O O
after O O
initiation O O
of O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
2 O O
. O O
6 O O
% O O
. O O

CONCLUSION O O
: O O
The O O
rate O O
of O O
major O O
hemorrhage O O
was O O
high O O
in O O
this O O
old O O
, O O
frail O O
group O O
, O O
but O O
excluding O O
fatalities O O
, O O
resulted O O
in O O
no O O
long O O
- O O
term O O
sequelae O O
, O O
and O O
the O O
stroke O O
rate O O
on O O
warfarin B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
low O O
, O O
demonstrating O O
how O O
effective O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
is O O
. O O

Safety O O
of O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
patients O O
with O O
adverse O O
skin O O
reactions O O
to O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
nimesulide B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
or O O
not O O
with O O
common O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

BACKGROUND O O
: O O
Acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
- O O
P B B_OTHER/B_LOCATION
) O O
and O O
Nimesulide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N B B_OTHER/B_LOCATION
) O O
are O O
widely O O
used O O
analgesic O O
- O O
antipyretic O O
/ O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

The O O
rate O B_MEASURE
of O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
hypersensitivity O I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
to O O
these O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
generally O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

On O O
the O O
contrary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
non O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
are O O
commonly O O
involved O O
in O O
such O B_DISEASE/B_LOCATION
reactions O I_DISEASE/I_LOCATION
. O O

Celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
CE B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
novel O O
drug O O
, O O
with O O
high O O
selectivity O O
and O O
affinity O O
for O O
COX O O
- O O
2 O O
enzyme O O
. O O

OBJECTIVE O O
: O O
We O O
evaluated O O
the O O
tolerability O O
of O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
a O O
group O O
of O O
patients O O
with O O
documented O O
history O O
of O O
adverse O O
cutaneous O O
reactions O O
to O O
P B B_OTHER/B_LOCATION
and O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
associated O O
or O O
not O O
to O O
classic O O
NSAIDs O O
. O O

METHODS O O
: O O
We O O
studied O O
9 O O
patients O O
with O O
hypersensitivity O O
to O O
P B B_OTHER/B_LOCATION
and O O
N B B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
or O O
without O O
associated O O
reactions O O
to O O
classic O O
NSAIDs O O
. O O

The O O
diagnosis O O
of O O
P B B_LOCATION
and O O
N B B_OTHER/B_LOCATION
- O O
induced O O
skin O O
reactions O O
was O O
based O O
in O O
vivo O O
challenge O O
. O O

The O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O O
blindly O O
administered O O
at O O
the O O
beginning O B_TIME[MEASURE]/B_LOCATION
of O O
each O O
challenge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

After O O
three O O
days O O
, O O
a O O
cumulative O O
dosage O O
of O O
200 O O
mg O O
of O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
refracted O O
doses O O
were O O
given O O
. O O

After O O
2 O B_NUMBER[MEASURE]/B_LOCATION
- O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
, O O
a O O
single O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
. O O

All O O
patients O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
for O O
6 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
after O O
each O O
challenge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
controlled O O
again O O
after O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O O
exclude O O
delayed O O
reactions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
challenge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
considered O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
one O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
following O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appeared O O
: O O
erythema O B_DISEASE
, O O
rush O B_DISEASE
or O O
urticaria O B_DISEASE
- O O
angioedema O B_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
No O O
reaction O O
was O O
observed O O
with O O
placebo O O
and O O
eight O O
patients O O
( O O
88 O O
. O O
8 O O
% O O
) O O
tolerated O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Only O O
one O B_PERSON
patient O I_PERSON
developed O O
a O O
moderate O B_DISEASE
angioedema O I_DISEASE
of O O
the O O
lips O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

CONCLUSION O O
: O O
Only O O
one O O
hypersensitivity O O
reaction O O
to O O
CE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
documented O O
among O O
9 O O
P B B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
highly O O
NSAIDs O O
intolerant O O
patients O O
. O O

Thus O O
, O O
we O O
conclude O O
that O O
CE B B_LOCATION/B_PERSON
is O O
a O O
reasonably O O
safe O O
alternative O O
to O O
be O O
used O O
in O O
subjects O O
who O O
do O O
not O O
tolerate O O
P B B_OTHER/B_LOCATION
and O O
N B B_OTHER/B_LOCATION
. O O

Case O B_PERSON/B_TIME[MEASURE]
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
regular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
nonsteroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renal O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

BACKGROUND O O
: O O
Studies O O
on O O
the O O
association O O
between O O
the O O
long O O
- O O
term O O
use O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
other O O
analgesic O O
and O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
and O O
end O O
- O O
stage O O
renal O O
disease O O
( O O
ESRD O O
) O O
have O O
given O O
conflicting O O
results O O
. O O

In O O
order O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
examine O O
this O O
association O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
a O O
case O B_PERSON/B_DISEASE
- O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
incident O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ESRD O B_DISEASE/B_LOCATION
was O O
carried O O
out O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
cases O B_PERSON/B_MEASURE
were O O
all O O
patients O B_PERSON/B_LOCATION
entering O O
the O O
local O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dialysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
because O O
of O O
ESRD O B_DISEASE
in O O
the O O
study O B_LOCATION
area O I_LOCATION
between O O
June O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
1995 O B_MEASURE
and O O
November O B_TIME[MEASURE]
30 O I_TIME[MEASURE]
, O O
1997 O B_MEASURE
. O O

They O O
were O O
classified O O
according O O
to O O
the O O
underlying O B_DISEASE
disease O I_DISEASE
, O O
which O O
had O O
presumably O O
led O O
them O O
to O O
ESRD O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Controls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
were O O
patients O B_PERSON/B_TIME[MEASURE]
admitted O O
to O O
the O O
same O B_LOCATION/B_ORGANIZATION
hospitals O I_LOCATION/I_ORGANIZATION
from O O
where O O
the O O
cases O B_PERSON/B_DISEASE
arose O O
, O O
also O O
matched O O
by O O
age O B_TIME[MEASURE]/B_DISEASE
and O O
sex O B_PERSON/B_LOCATION
. O O

Odds O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
calculated O O
using O O
a O O
conditional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
including O O
potential O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
for O O
the O O
whole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
for O O
the O O
various O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
underlying O O
diseases O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Five O B_NUMBER[MEASURE]/B_LOCATION
hundred O I_NUMBER[MEASURE]/I_LOCATION
and O O
eighty O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
cases O I_NUMBER[MEASURE]
and O O
1190 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
included O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
an O O
overall O B_MEASURE
odds O I_MEASURE
ratio O I_MEASURE
of O O
1 O B_MEASURE
. O O
22 O B_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
, O O
0 O B_MEASURE
. O O
89 O B_MEASURE
- O O
1 O B_MEASURE
. O O
66 O B_MEASURE
) O O
. O O

For O O
specific O O
groups O O
of O O
drugs O O
, O O
the O O
risks O O
were O O
1 O O
. O O
56 O O
( O O
1 O O
. O O
05 O O
- O O
2 O O
. O O
30 O O
) O O
for O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O O
. O O
03 O O
( O O
0 O O
. O O
60 O O
- O O
1 O O
. O O
76 O O
) O O
for O O
pyrazolones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
0 O O
. O O
80 O O
( O O
0 O O
. O O
39 O O
- O O
1 O O
. O O
63 O O
) O O
for O O
paracetamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
0 O O
. O O
94 O O
( O O
0 O O
. O O
57 O O
- O O
1 O O
. O O
56 O O
) O O
for O O
nonaspirin O O
NSAIDs O O
. O O

The O O
risk O O
of O O
ESRD O O
associated O O
with O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
related O O
to O O
the O O
cumulated O O
dose O O
and O O
duration O O
of O O
use O O
, O O
and O O
it O O
was O O
particularly O O
high O O
among O O
the O O
subset O O
of O O
patients O O
with O O
vascular O O
nephropathy O O
as O O
underlying O O
disease O O
[ O O
2 O O
. O O
35 O O
( O O
1 O O
. O O
17 O O
- O O
4 O O
. O O
72 O O
) O O
] O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
that O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nonaspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analgesic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
associated O O
with O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ESRD O B_DISEASE
. O O

However O O
, O O
the O O
chronic O O
use O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
increase O O
the O O
risk O O
of O O
ESRD O O
. O O

Two O O
cases O O
of O O
amisulpride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdose O O
: O O
a O O
cause O O
for O O
prolonged O O
QT O O
syndrome O O
. O O

Two O O
cases O O
of O O
deliberate O O
self O O
- O O
poisoning O O
with O O
5 O O
g O O
and O O
3 O O
. O O
6 O O
g O O
of O O
amisulpride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
, O O
are O O
reported O O
. O O

In O O
both O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
QT O B_DISEASE
prolongation O I_DISEASE
and O O
hypocalcaemia O B_DISEASE
were O O
noted O O
. O O

The O O
QT O O
prolongation O O
appeared O O
to O O
respond O O
to O O
administration O O
of O O
i O O
. O O
v O O
. O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gluconate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Growth O O
- O O
associated O O
protein O O
43 O O
expression O O
in O O
hippocampal O O
molecular O O
layer O O
of O O
chronic O O
epileptic O O
rats O O
treated O O
with O O
cycloheximide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
: O O
GAP43 O B_GENE/B_DISEASE
has O O
been O O
thought O O
to O O
be O O
linked O O
with O O
mossy O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fiber O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sprouting O O
( O O
MFS O B_LOCATION/B_ORGANIZATION
) O O
in O O
various O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
experimental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
epilepsy O B_DISEASE
. O O

To O O
investigate O O
how O O
GAP43 O O
expression O O
( O O
GAP43 O O
- O O
ir O O
) O O
correlates O O
with O O
MFS O O
, O O
we O O
assessed O O
the O O
intensity O O
( O O
densitometry O O
) O O
and O O
extension O O
( O O
width O O
) O O
of O O
GAP43 O O
- O O
ir O O
in O O
the O O
inner O O
molecular O O
layer O O
of O O
the O O
dentate O O
gyrus O O
( O O
IML O O
) O O
of O O
rats O O
subject O O
to O O
status O O
epilepticus O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Pilo B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
previously O O
injected O O
or O O
not O O
with O O
cycloheximide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CHX B B_LOCATION/B_ORGANIZATION
) O O
, O O
which O O
has O O
been O O
shown O O
to O O
inhibit O O
MFS O O
. O O

METHODS O O
: O O
CHX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
injected O O
before O O
the O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
injection O O
in O O
adult O O
Wistar O O
rats O O
. O O

The O O
Pilo B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
was O O
injected O O
with O O
the O O
same O O
drugs O O
, O O
except O O
for O O
CHX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Animals O B_BIO/B_PERSON
were O O
killed O O
between O O
30 O B_MEASURE
and O O
60 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
, O O
and O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sections O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
processed O O
for O O
GAP43 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunohistochemistry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Densitometry O O
showed O O
no O O
significant O O
difference O O
regarding O O
GAP43 O O
- O O
ir O O
in O O
the O O
IML O O
between O O
Pilo B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CHX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
and O O
control O O
groups O O
. O O

However O O
, O O
the O O
results O O
of O O
the O O
width O O
of O O
the O O
GAP43 O O
- O O
ir O O
band O O
in O O
the O O
IML O O
showed O O
that O O
CHX B B_DISEASE
+ O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
control O O
animals O O
had O O
a O O
significantly O O
larger O O
band O O
( O O
p O O
= O O
0 O O
. O O
03 O O
) O O
as O O
compared O O
with O O
that O O
in O O
the O O
Pilo B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
. O O

CONCLUSIONS O O
: O O
Our O O
current O O
finding O O
that O O
animals O O
in O O
the O O
CHX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
have O O
a O O
GAP43 O O
- O O
ir O O
band O O
in O O
the O O
IML O O
, O O
similar O O
to O O
that O O
of O O
controls O O
, O O
reinforces O O
prior O O
data O O
on O O
the O O
blockade O O
of O O
MFS O O
in O O
these O O
animals O O
. O O

The O O
change O O
in O O
GAP43 O O
- O O
ir O O
present O O
in O O
Pilo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
animals O O
was O O
a O O
thinning O O
of O O
the O O
band O O
to O O
a O O
very O O
narrow O O
layer O O
just O O
above O O
the O O
granule O O
cell O O
layer O O
that O O
is O O
likely O O
to O O
be O O
associated O O
with O O
the O O
loss O O
of O O
hilar O O
cell O O
projections O O
that O O
express O O
GAP O O
- O O
43 O O
. O O

Nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
but O O
not O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anxiogenic O O
effect O O
in O O
mice O O
. O O

RATIONALE O O
: O O
Nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
widely O O
consumed O O
licit O O
psychoactive O O
drugs O O
worldwide O O
. O O

Epidemiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
they O O
were O O
generally O O
used O O
concurrently O O
. O O

Although O O
some O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experimental O B_LOCATION/B_ORGANIZATION
animals O I_LOCATION/I_ORGANIZATION
indicate O O
clear O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacological O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
them O O
, O O
no O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
shown O O
a O O
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
anxiety O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
responses O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
investigates O O
the O O
effects O O
of O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
anxiety O O
induced O O
by O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
another O O
anxiogenic O O
drug O O
, O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
mice O O
. O O

The O O
elevated O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
plus O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
maze O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
EPM O B_LOCATION/B_DISEASE
) O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
used O O
to O O
evaluate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
anxiety O B_DISEASE
. O O

METHODS O O
: O O
Adult O O
male O O
Swiss O O
Webster O O
mice O O
( O O
25 O O
- O O
32 O O
g O O
) O O
were O O
given O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
or O O
saline O O
10 O O
min O O
before O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
70 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
or O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
15 O O
and O O
30 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
injections O O
. O O

After O O
15 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
min O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
mice O B_BIO/B_PERSON
were O O
evaluated O O
for O O
their O O
open O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
and O O
closed O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
arm O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
time O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
entries O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
EPM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
a O O
10 O B_MEASURE
- O O
min O B_TIME[MEASURE]/B_LOCATION
session O I_TIME[MEASURE]/I_LOCATION
. O O

Locomotor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
recorded O O
for O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
using O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
EPM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
test O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

RESULTS O O
: O O
Nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
itself O O
did O O
not O O
produce O O
any O O
significant O O
effect O O
in O O
the O O
EPM O O
test O O
, O O
whereas O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
70 O O
mg O O
/ O O
kg O O
) O O
and O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O O
mg O O
/ O O
kg O O
) O O
produced O O
an O O
anxiogenic O O
effect O O
, O O
apparent O O
with O O
decreases O O
in O O
open O O
- O O
arm O O
time O O
and O O
entry O O
. O O

Nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
pretreatment O O
blocked O O
the O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
but O O
not O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anxiety O O
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
their O O
combinations O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
produce O O
any O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
locomotor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
suggest O O
that O O
the O O
antagonistic O O
effect O O
of O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
anxiety O O
is O O
specific O O
to O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
instead O O
of O O
a O O
non O O
- O O
specific O O
anxiolytic O O
effect O O
. O O

Thus O O
, O O
it O O
may O O
extend O O
the O O
current O O
findings O O
on O O
the O O
interaction O O
between O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Long O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
perimenopausal O B_PERSON
and O O
postmenopausal O B_PERSON/B_DISEASE
women O I_PERSON/I_DISEASE
. O O

BACKGROUND O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
HT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
) O O
is O O
widely O O
used O O
for O O
controlling O O
menopausal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
also O O
been O O
used O O
for O O
the O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiovascular O B_DISEASE
disease O I_DISEASE
, O O
osteoporosis O B_DISEASE
and O O
dementia O B_DISEASE
in O O
older O B_PERSON/B_BIO
women O I_PERSON/I_BIO
but O O
the O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supporting O O
its O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
indications O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
largely O O
observational O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
assess O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
HT O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
mortality O B_DISEASE
, O O
heart O B_DISEASE
disease O I_DISEASE
, O O
venous O B_DISEASE
thromboembolism O I_DISEASE
, O O
stroke O B_DISEASE
, O O
transient O B_DISEASE
ischaemic O I_DISEASE
attacks O I_DISEASE
, O O
breast O B_DISEASE
cancer O I_DISEASE
, O O
colorectal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ovarian O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
endometrial O B_DISEASE
cancer O I_DISEASE
, O O
gallbladder O B_DISEASE
disease O I_DISEASE
, O O
cognitive O B_DISEASE
function O I_DISEASE
, O O
dementia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
fractures O B_DISEASE
and O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SEARCH O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
STRATEGY O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
We O O
searched O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
databases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
up O O
to O O
November O B_TIME[MEASURE]
2004 O I_TIME[MEASURE]
: O O
the O O
Cochrane O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Menstrual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Disorders O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
Subfertility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Register O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
Cochrane O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Central O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Register O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
Controlled O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CENTRAL O B_LOCATION/B_TIME[MEASURE]
) O O
, O O
MEDLINE O B_ORGANIZATION/B_PERSON
, O O
EMBASE O B_ORGANIZATION/B_LOCATION
, O O
Biological O B_ORGANIZATION/B_LOCATION
Abstracts O I_ORGANIZATION/I_LOCATION
. O O

Relevant O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
non O O
- O O
indexed O O
journals O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
abstracts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O O
also O O
searched O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
double O O
- O O
blind O O
trials O O
of O O
HT O O
( O O
oestrogens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
or O O
without O O
progestogens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
versus O O
placebo O O
, O O
taken O O
for O O
at O O
least O O
one O O
year O O
by O O
perimenopausal O O
or O O
postmenopausal O O
women O O
. O O

DATA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
COLLECTION O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
ANALYSIS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Fifteen O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCTs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
included O O
. O O

Trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
assessed O O
for O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
two O B_PERSON/B_LOCATION
review O I_PERSON/I_LOCATION
authors O I_PERSON/I_LOCATION
extracted O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independently O O
. O O

They O O
calculated O O
risk O B_MEASURE
ratios O I_MEASURE
for O O
dichotomous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
weighted O B_MEASURE
mean O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
continuous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterogeneity O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
precluded O O
meta O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
most O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

MAIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RESULTS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
All O O
the O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
derived O O
from O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
biggest O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O O

In O O
relatively O O
healthy O B_PERSON/B_TIME[MEASURE]
women O I_PERSON/I_TIME[MEASURE]
, O O
combined O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
increased O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
venous O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
coronary O B_DISEASE/B_LOCATION
event O I_DISEASE/I_LOCATION
( O O
after O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
stroke O B_DISEASE
( O O
after O O
3 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
) O O
, O O
breast O B_DISEASE
cancer O I_DISEASE
( O O
after O O
5 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
years O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
gallbladder O B_DISEASE
disease O I_DISEASE
. O O

Long O O
- O O
term O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
only O O
HT O O
also O O
significantly O O
increased O O
the O O
risk O O
of O O
stroke O O
and O O
gallbladder O O
disease O O
. O O

Overall O O
, O O
the O O
only O B_NUMBER[MEASURE]/B_ORGANIZATION
statistically O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
a O O
decreased O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incidence O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fractures O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
colon O B_DISEASE
cancer O I_DISEASE
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Among O O
relatively O O
healthy O B_PERSON
women O I_PERSON
over O O
65 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
taking O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combined O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
was O O
a O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
dementia O B_DISEASE
. O O

Among O O
women O B_PERSON
with O O
cardiovascular O B_DISEASE
disease O I_DISEASE
, O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
combined O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
continuous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O O
increased O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
venous O B_DISEASE/B_LOCATION
thromboembolism O I_DISEASE/I_LOCATION
. O O

No O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
focussed O O
specifically O O
on O O
younger O B_PERSON/B_ENT
women O I_PERSON/I_ENT
. O O

However O O
, O O
one O O
trial O O
analysed O O
subgroups O O
of O O
2839 O O
relatively O O
healthy O O
50 O O
to O O
59 O O
year O O
- O O
old O O
women O O
taking O O
combined O O
continuous O O
HT O O
and O O
1637 O O
taking O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
only O O
HT O O
, O O
versus O O
similar O O
- O O
sized O O
placebo O O
groups O O
. O O

The O O
only O B_SEQUENCE[MEASURE]/B_ORGANIZATION
significantly O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
reported O O
was O O
for O O
venous O B_DISEASE
thromboembolism O I_DISEASE
in O O
women O B_PERSON/B_BIO
taking O O
combined O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
their O O
absolute O B_MEASURE/B_DISEASE
risk O I_MEASURE/I_DISEASE
remained O O
very O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

AUTHORS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONCLUSIONS O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
indicated O O
for O O
the O O
routine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chronic O B_DISEASE/B_PROTEIN[GENE]
disease O B_DISEASE/I_PROTEIN[GENE]
. O O

We O O
need O O
more O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
menopausal O B_PERSON/B_DISEASE
symptom O I_PERSON/I_DISEASE
control O I_PERSON/I_DISEASE
, O O
though O O
short O B_MEASURE
- O O
term O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
relatively O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O O
healthy O B_PERSON
younger O I_PERSON
women O I_PERSON
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
liver O B_DISEASE
injury O I_DISEASE
: O O
an O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
461 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
incidences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
submitted O O
to O O
the O O
Spanish O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
registry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
over O O
a O O
10 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O O
AIMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Progress O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
understanding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]
factors O I_DISEASE_ADJECTIVE[DISEASE]
to O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
liver O B_DISEASE
injury O I_DISEASE
( O O
DILI O B_DISEASE
) O O
and O O
outcome O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictability O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
hampered O O
by O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]
of O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
detect O O
bona O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fide O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
cooperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
network O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
created O O
in O O
1994 O B_MEASURE
in O O
Spain O B_LOCATION
to O O
identify O O
all O O
suspicions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
DILI O B_DISEASE
following O O
a O O
prospective O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structured O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
liver O B_DISEASE
damage O I_DISEASE
was O O
characterized O O
according O O
to O O
hepatocellular O B_DISEASE
, O O
cholestatic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
mixed O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
laboratory O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
criteria O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
to O O
histologic O O
criteria O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
causality O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
centrally O O
performed O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Since O O
April O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1994 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
August O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
461 O B_MEASURE
out O O
of O O
570 O B_MEASURE
submitted O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
involving O O
505 O B_PERSON/B_ORGANIZATION
drugs O I_PERSON/I_ORGANIZATION
, O O
were O O
deemed O O
to O O
be O O
related O O
to O O
DILI O B_DISEASE
. O O

The O O
antiinfective O O
group O O
of O O
drugs O O
was O O
the O O
more O O
frequently O O
incriminated O O
, O O
amoxicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
clavulanate I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
accounting O O
for O O
the O O
12 O O
. O O
8 O O
% O O
of O O
the O O
whole O O
series O O
. O O

The O O
hepatocellular O B_DISEASE/B_MEASURE
pattern O B_DISEASE/I_MEASURE
of O O
damage O B_DISEASE
was O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
( O O
58 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
, O O
was O O
inversely O O
correlated O O
with O O
age O B_DISEASE/B_MEASURE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
0001 O B_MEASURE
) O O
, O O
and O O
had O O
the O O
worst O B_MEASURE/B_LOCATION
outcome O I_MEASURE/I_LOCATION
( O O
Cox O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
034 O B_MEASURE
) O O
. O O

Indeed O O
, O O
the O O
incidence O B_MEASURE/B_PERSON
of O O
liver O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
this O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
11 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
if O O
patients O B_PERSON
had O O
jaundice O O
at O O
presentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
whereas O O
the O O
corresponding O B_MEASURE/B_LOCATION
figure O I_MEASURE/I_LOCATION
was O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
in O O
nonjaundiced O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
( O O
P O B_MEASURE
< O I_MEASURE
. O O
04 O B_MEASURE
) O O
. O O

Factors O O
associated O O
with O O
the O O
development O O
of O O
fulminant O O
hepatic O O
failure O O
were O O
female O O
sex O O
( O O
OR O O
= O O
25 O O
; O O
95 O O
% O O
CI O O
: O O
4 O O
. O O
1 O O
- O O
151 O O
; O O
P O O
< O O
. O O
0001 O O
) O O
, O O
hepatocellular O O
damage O O
( O O
OR O O
= O O
7 O O
. O O
9 O O
; O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
6 O O
- O O
37 O O
; O O
P O O
< O O
. O O
009 O O
) O O
, O O
and O O
higher O O
baseline O O
plasma O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
value O O
( O O
OR O O
= O O
1 O O
. O O
15 O O
; O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
09 O O
- O O
1 O O
. O O
22 O O
; O O
P O O
< O O
. O O
0001 O O
) O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Patients O B_PERSON/B_BIO
with O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hepatocellular O B_DISEASE
jaundice O I_DISEASE
have O O
11 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
chance O I_MEASURE/I_PERSON
of O O
progressing O O
to O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
transplantation O B_DISEASE/B_SURGICAL_AND_MEDICAL_PROCEDURES[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Amoxicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clavulanate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stands O O
out O O
as O O
the O O
most O O
common O O
drug O O
related O O
to O O
DILI O O
. O O

Morphological O O
evaluation O O
of O O
the O O
effect O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
evoked O O
cardiotoxicity O O
in O O
rats O O
. O O

The O O
influence O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myocardiopathy O O
in O O
rats O O
was O O
studied O O
. O O

Adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cumulative O O
dose O O
of O O
25 O O
mg O O
/ O O
kg O O
evoked O O
fully O O
developed O O
cardiac O O
toxicity O O
. O O

D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ribose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
multiple O O
doses O O
of O O
200 O O
mg O O
/ O O
kg O O
did O O
not O O
influence O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cardiotoxicity O O
. O O

In O O
vivo O O
evidences O O
suggesting O O
the O O
role O O
of O O
oxidative O O
stress O O
in O O
pathogenesis O O
of O O
vancomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephrotoxicity O O
: O O
protection O O
by O O
erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
vancomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VCM B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
oxidative O O
stress O O
that O O
promotes O O
production O O
of O O
reactive O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
species O O
( O O
ROS O O
) O O
and O O
to O O
investigate O O
the O O
role O O
of O O
erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
expectorant O O
agent O O
, O O
which O O
has O O
also O O
antioxidant O O
properties O O
, O O
on O O
kidney O O
tissue O O
against O O
the O O
possible O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
renal O O
impairment O O
in O O
rats O O
. O O

Rats O O
were O O
divided O O
into O O
three O O
groups O O
: O O
sham O O
, O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plus O O
erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
administrated O O
intraperitoneally O O
( O O
i O O
. O O
p O O
. O O
) O O
with O O
200mgkg O O
( O O
- O O
1 O O
) O O
twice O O
daily O O
for O O
7 O O
days O O
. O O

Erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
orally O O
. O O

VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
to O O
control O O
rats O O
significantly O O
increased O O
renal O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MDA B B_LOCATION
) O O
and O O
urinary O O
N O O
- O O
acetyl O O
- O O
beta O O
- O O
d O O
- O O
glucosaminidase O O
( O O
NAG O O
, O O
a O O
marker O O
of O O
renal O O
tubular O O
injury O O
) O O
excretion O O
but O O
decreased O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
( O O
SOD O O
) O O
and O O
catalase O O
( O O
CAT O O
) O O
activities O O
. O O

Erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O O
with O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
injections O O
caused O O
significantly O O
decreased O O
renal O O
MDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
urinary O O
NAG O O
excretion O O
, O O
and O O
increased O O
SOD O O
activity O O
, O O
but O O
not O O
CAT O O
activity O O
in O O
renal O O
tissue O O
when O O
compared O O
with O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O O
. O O

Erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O O
histopathological O O
protection O O
against O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephrotoxicity O O
. O O

There O O
were O O
a O O
significant O O
dilatation O O
of O O
tubular O O
lumens O O
, O O
extensive O O
epithelial O O
cell O O
vacuolization O O
, O O
atrophy O O
, O O
desquamation O O
, O O
and O O
necrosis O O
in O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
more O O
than O O
those O O
of O O
the O O
control O O
and O O
the O O
erdosteine B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O O
. O O

Erdosteine B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
a O O
marked O O
reduction O O
in O O
the O O
extent O O
of O O
tubular O O
damage O O
. O O

It O O
is O O
concluded O O
that O O
oxidative O O
tubular O O
damage O O
plays O O
an O O
important O O
role O O
in O O
the O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
nephrotoxicity O O
and O O
the O O
modulation O O
of O O
oxidative O O
stress O O
with O O
erdosteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
the O O
VCM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
kidney O O
damage O O
both O O
at O O
the O O
biochemical O O
and O O
histological O O
levels O O
. O O

Gemfibrozil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
lovastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
primary O O
hyperlipoproteinemias O O
. O O

The O O
specific O O
aim O O
of O O
this O O
retrospective O O
, O O
observational O O
study O O
was O O
to O O
assess O O
safety O O
and O O
efficacy O O
of O O
long O O
- O O
term O O
( O O
21 O O
months O O
/ O O
patient O O
) O O
, O O
open O O
- O O
label O O
, O O
gemfibrozil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
lovastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
80 O O
patients O O
with O O
primary O O
mixed O O
hyperlipidemia O O
( O O
68 O O
% O O
of O O
whom O O
had O O
atherosclerotic O O
vascular O O
disease O O
) O O
. O O

Because O O
ideal O O
lipid O O
targets O O
were O O
not O O
reached O O
( O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
less O O
than O O
130 O O
mg O O
/ O O
dl O O
, O O
high O O
- O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
greater O O
than O O
35 O O
mg O O
/ O O
dl O O
, O O
or O O
total O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
HDL O O
cholesterol B B_MEASURE/B_LOCATION
less O O
than O O
4 O O
. O O
5 O O
mg O O
/ O O
dl O O
) O O
with O O
diet O O
plus O O
a O O
single O O
drug O O
, O O
gemfibrozil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
1 O O
. O O
2 O O
g O O
/ O O
day O O
) O O
- O O
lovastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
primarily O O
20 O O
or O O
40 O O
mg O O
) O O
treatment O O
was O O
given O O
. O O

Follow O O
- O O
up O O
visits O O
were O O
scheduled O O
with O O
2 O O
- O O
drug O O
therapy O O
every O O
6 O O
to O O
8 O O
weeks O O
, O O
an O O
average O O
of O O
10 O O
. O O
3 O O
visits O O
per O O
patient O O
, O O
with O O
741 O O
batteries O O
of O O
6 O O
liver O O
function O O
tests O O
and O O
714 O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase O O
levels O O
measured O O
. O O

Only O O
1 O B_NUMBER[MEASURE]
of O O
the O O
4 O B_MEASURE
, O O
446 O B_MEASURE
liver O I_MEASURE
function O I_MEASURE
tests O I_MEASURE
( O O
0 O B_MEASURE
. O O
02 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
, O O
a O O
gamma O B_MEASURE/B_PERSON
glutamyl O I_MEASURE/I_PERSON
transferase O I_MEASURE/I_PERSON
, O O
was O O
greater O B_MEASURE
than O O
or O O
equal O B_MEASURE
to O O
3 O B_TIME[MEASURE]/B_LOCATION
times O B_TIME[MEASURE]/I_LOCATION
the O O
upper O B_MEASURE
normal O I_MEASURE
limit O I_MEASURE
. O O

Of O O
the O O
714 O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphokinase O O
levels O O
, O O
9 O O
% O O
were O O
high O O
; O O
only O O
1 O O
( O O
0 O O
. O O
1 O O
% O O
) O O
was O O
greater O O
than O O
or O O
equal O O
to O O
3 O O
times O O
the O O
upper O O
normal O O
limit O O
. O O

With O O
2 O O
- O O
drug O O
therapy O O
, O O
mean O O
total O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
22 O O
% O O
from O O
255 O O
to O O
200 O O
mg O O
/ O O
dl O O
, O O
triglyceride B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
decreased O O
35 O O
% O O
from O O
236 O O
to O O
154 O O
mg O O
/ O O
dl O O
, O O
LDL O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
decreased O O
26 O O
% O O
from O O
176 O O
to O O
131 O O
mg O O
/ O O
dl O O
, O O
and O O
the O O
total O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HDL O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio O O
decreased O O
24 O O
% O O
from O O
7 O O
. O O
1 O O
to O O
5 O O
. O O
4 O O
, O O
all O O
p O O
less O O
than O O
or O O
equal O O
to O O
0 O O
. O O
0001 O O
. O O

Myositis O O
, O O
attributable O O
to O O
the O O
drug O O
combination O O
and O O
symptomatic O O
enough O O
to O O
discontinue O O
it O O
, O O
occurred O O
in O O
3 O O
% O O
of O O
patients O O
, O O
and O O
in O O
1 O O
% O O
with O O
concurrent O O
high O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphokinase O O
( O O
769 O O
U O O
/ O O
liter O O
) O O
; O O
no O O
patients O O
had O O
rhabdomyolysis O O
or O O
myoglobinuria O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Does O O
domperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentiate O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
restless O O
legs O O
syndrome O O
? O O

There O O
is O O
now O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
suggest O O
a O O
central O B_DISEASE_ADJECTIVE[DISEASE]
role O I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
dopaminergic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
restless O B_DISEASE
legs O I_DISEASE
syndrome O I_DISEASE
( O O
RLS O B_DISEASE
) O O
. O O

For O O
example O O
, O O
the O O
symptoms O O
of O O
RLS O O
can O O
be O O
dramatically O O
improved O O
by O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonists O O
, O O
whereas O O
central O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O O
receptor O O
antagonists O O
can O O
induce O O
or O O
aggravate O O
RLS O O
symptoms O O
. O O

To O O
our O O
knowledge O O
, O O
there O O
is O O
no O O
previous O O
report O O
regarding O O
whether O O
domperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
peripheral O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O O
receptor O O
antagonist O O
, O O
can O O
also O O
induce O O
or O O
aggravate O O
symptoms O O
of O O
RLS O O
. O O

Mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
first O O
noradrenergic O O
and O O
specific O O
serotonergic O O
antidepressant O O
( O O
NaSSA O O
) O O
, O O
has O O
been O O
associated O O
with O O
RLS O O
in O O
several O O
recent O O
publications O O
. O O

The O O
authors O O
report O O
here O O
a O O
depressed O O
patient O O
comorbid O O
with O O
postprandial O O
dyspepsia O O
who O O
developed O O
RLS O O
after O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
been O O
added O O
to O O
his O O
domperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
therapy O O
. O O

Our O O
patient O O
started O O
to O O
have O O
symptoms O O
of O O
RLS O O
only O O
after O O
he O O
had O O
been O O
treated O O
with O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
his O O
RLS O O
symptoms O O
resolved O O
completely O O
upon O O
discontinuation O O
of O O
his O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Such O O
a O O
temporal O O
relationship O O
between O O
the O O
use O O
of O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
symptoms O O
of O O
RLS O O
in O O
our O O
patient O O
did O O
not O O
support O O
a O O
potentiating O O
effect O O
of O O
domperione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
RLS O O
. O O

However O O
, O O
physicians O O
should O O
be O O
aware O O
of O O
the O O
possibility O O
that O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
associated O O
with O O
RLS O O
in O O
some O O
individuals O O
, O O
especially O O
those O O
receiving O O
concomitant O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O O
receptor O O
antagonists O O
. O O

Antiandrogenic O B_DISEASE/B_PERSON
therapy O I_DISEASE/I_PERSON
can O O
cause O O
coronary O B_DISEASE
arterial O I_DISEASE
disease O I_DISEASE
. O O

AIM O B_MEASURE
: O O
To O O
study O O
the O O
change O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lipid O B_DISEASE/B_GENE
metabolism O B_DISEASE/I_GENE
by O O
antiandrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
prostate O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
studied O O
with O O
a O O
2 O O
. O O
5 O O
years O O
follow O O
- O O
up O O
the O O
changes O O
in O O
plasma O O
cholesterols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
C B B_OTHER/B_LOCATION
) O O
, O O
triglycerides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TG B B_LOCATION
) O O
, O O
lipoproteins O O
( O O
LP O O
) O O
, O O
and O O
apolipoproteins O O
( O O
Apo O O
) O O
B O O
- O O
100 O O
, O O
A O O
- O O
I O O
, O O
and O O
A O O
- O O
II O O
pro O O
fi O O
les O O
in O O
24 O O
patients O O
of O O
mean O O
age O O
60 O O
years O O
with O O
low O O
risk O O
prostate O O
cancer O O
( O O
stage O O
: O O
T1cN0M0 O O
, O O
Gleason O O
score O O
: O O
2 O O
- O O
5 O O
) O O
during O O
treatment O O
with O O
cyproterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA B B_LOCATION/B_ORGANIZATION
) O O
without O O
surgical O O
management O O
or O O
radiation O O
therapy O O
. O O

RESULTS O O
: O O
Significant O O
decreases O O
of O O
HDL O O
- O O
C O O
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
and O O
an O O
increase O O
of O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
levels O O
in O O
VLDL O O
were O O
induced O O
by O O
CPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

After O O
a O O
period O O
of O O
2 O O
. O O
5 O O
years O O
on O O
CPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
four O O
patients O O
out O O
of O O
twenty O O
- O O
four O O
were O O
found O O
to O O
be O O
affected O O
by O O
coronary O O
heart O O
disease O O
. O O

CONCLUSIONS O O
: O O
Ischaemic O O
coronary O O
arteriosclerosis O O
with O O
an O O
incidence O O
rate O O
of O O
16 O O
. O O
6 O O
% O O
as O O
caused O O
by O O
prolonged O O
CPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
is O O
mediated O O
through O O
changes O O
in O O
HDL O O
cholesterol B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
pro O O
fi O O
les O O
, O O
other O O
than O O
the O O
well O O
- O O
known O O
hyperglyceridemic O O
effect O O
caused O O
by O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

5 B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fluorouracil I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
induced O O
by O O
alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoro I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alanine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cardiotoxicity O O
is O O
a O O
rare O O
complication O O
occurring O O
during O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
treatment O O
for O O
malignancies O O
. O O

We O O
herein O O
report O O
the O O
case O O
of O O
a O O
70 O O
- O O
year O O
- O O
old O O
man O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
, O O
in O O
whom O O
a O O
high O O
serum O O
level O O
of O O
alpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoro I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alanine I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FBAL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
observed O O
. O O

The O O
patient O B_PERSON
, O O
who O O
had O O
unresectable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
colon O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cancer O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
was O O
referred O O
to O O
us O O
for O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
from O O
an O O
affiliated O B_LOCATION/B_PERSON
hospital O B_LOCATION/I_PERSON
; O O
he O O
had O O
no O O
cardiac O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

After O O
admission O O
, O O
the O O
patient O O
received O O
a O O
continuous O O
intravenous O O
infusion O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1000 O O
mg O O
/ O O
day O O
) O O
, O O
during O O
which O O
precordial O O
pain O O
with O O
right O O
bundle O O
branch O O
block O O
occurred O O
concomitantly O O
with O O
a O O
high O O
serum O O
FBAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
of O O
1955 O O
ng O O
/ O O
ml O O
. O O

Both O O
the O O
precordial O O
pain O O
and O O
the O O
electrocardiographic O O
changes O O
disappeared O O
spontaneously O O
after O O
the O O
discontinuation O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
the O O
precordial O O
pain O O
in O O
this O O
patient O O
was O O
considered O O
to O O
have O O
been O O
due O O
to O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
, O O
the O O
administration O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
abandoned O O
. O O

Instead O O
, O O
oral O O
administration O O
of O O
S O O
- O O
1 O O
( O O
a O O
derivative O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
at O O
200 O O
mg O O
/ O O
day O O
twice O O
a O O
week O O
, O O
was O O
instituted O O
, O O
because O O
S O O
- O O
1 O O
has O O
a O O
strong O O
inhibitory O O
effect O O
on O O
dihydropyrimidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dehydrogenase O O
, O O
which O O
catalyzes O O
the O O
degradative O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O O
FBAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
serum O O
FBAL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
subsequently O O
decreased O O
to O O
352 O O
ng O O
/ O O
ml O O
, O O
the O O
same O O
as O O
the O O
value O O
measured O O
on O O
the O O
first O O
day O O
of O O
S O O
- O O
1 O O
administration O O
. O O

Thereafter O O
, O O
no O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
. O O

The O O
patient O B_PERSON/B_BIO
achieved O O
a O O
partial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
6 O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
S O B_DISEASE/B_GENE
- O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
experience O O
of O O
this O O
case O O
, O O
together O O
with O O
a O O
review O O
of O O
the O O
literature O O
, O O
suggests O O
that O O
FBAL B B_DISEASE/B_GENE
is O O
related O O
to O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

S O O
- O O
1 O O
may O O
be O O
administered O O
safely O O
to O O
patients O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

Hepatocellular O O
carcinoma O O
in O O
Fanconi O O
' O O
s O O
anemia O O
treated O O
with O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
case O O
of O O
an O O
11 O O
- O O
year O O
- O O
old O O
boy O O
is O O
reported O O
who O O
was O O
known O O
to O O
have O O
Fanconi O O
' O O
s O O
anemia O O
for O O
3 O O
years O O
and O O
was O O
treated O O
with O O
androgens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
corticosteroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
transfusions O O
. O O

Two O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
before O O
his O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
he O O
was O O
readmitted O O
because O O
of O O
aplastic O B_DISEASE
crisis O I_DISEASE
with O O
septicemia O B_DISEASE
and O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
liver O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
died O O
of O O
hemorrhagic O B_DISEASE
bronchopneumonia O I_DISEASE
. O O

At O O
autopsy O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peliosis O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
multiple O B_DISEASE
hepatic O I_DISEASE
tumors O I_DISEASE
were O O
found O O
which O O
histologically O O
proved O O
to O O
be O O
well O O
- O O
differentiated O O
hepatocellular O B_DISEASE
carcinoma O I_DISEASE
. O O

This O O
case O O
contributes O O
to O O
the O O
previous O O
observations O O
that O O
non O O
- O O
metastasizing O O
hepatic O O
neoplasms O O
and O O
peliosis O O
can O O
develop O O
in O O
patients O O
with O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
Fanconi O O
' O O
s O O
anemia O O
. O O

The O O
influence O O
of O O
the O O
time O O
interval O O
between O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
on O O
the O O
protection O O
against O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
in O O
mice O O
. O O

PURPOSE O O
: O O
Despite O O
its O O
well O O
- O O
known O O
cardiotoxicity O O
, O O
the O O
anthracyclin O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
continues O O
to O O
be O O
an O O
effective O O
and O O
widely O O
used O O
chemotherapeutic O O
agent O O
. O O

DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
damage O O
presumably O O
results O O
from O O
the O O
formation O O
of O O
free O O
radicals O O
by O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Reactive O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O O
particularly O O
affect O O
the O O
cardiac O O
myocytes O O
because O O
these O O
cells O O
seem O O
to O O
have O O
a O O
relatively O O
poor O O
antioxidant O O
defense O O
system O O
. O O

The O O
semisynthetic O O
flavonoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monohydroxyethylrutoside B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
showed O O
cardioprotection O O
against O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiotoxicity O O
through O O
its O O
radical O O
scavenging O O
and O O
iron B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chelating O O
properties O O
. O O

Because O O
of O O
the O O
relatively O O
short O O
final O O
half O O
- O O
life O O
of O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
about O O
30 O O
min O O
) O O
, O O
it O O
is O O
expected O O
that O O
the O O
time O O
interval O O
between O O
monoHER B B_LOCATION/B_ORGANIZATION
and O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
be O O
of O O
influence O O
on O O
the O O
cardioprotective O O
effect O O
of O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
the O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
to O O
investigate O O
this O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

METHODS O O
: O O
Six O O
groups O O
of O O
6 O O
BALB O O
/ O O
c O O
mice O O
were O O
treated O O
with O O
saline O O
, O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
/ O O
kg O O
i O O
. O O
v O O
. O O
) O O
preceded O O
by O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
500 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
with O O
an O O
interval O O
of O O
10 O O
, O O
30 O O
, O O
60 O O
or O O
120 O O
min O O
. O O

After O O
a O O
6 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]
treatment O I_TIME[MEASURE]
period O I_TIME[MEASURE]
and O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
the O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sacrificed O O
. O O

Their O O
cardiac O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
processed O O
for O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
after O O
which O O
cardiomyocyte O B_DISEASE
damage O I_DISEASE
was O O
evaluated O O
according O O
to O O
Billingham O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
in O O
Cancer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Treat O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rep O B_MEASURE
62 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
6 O B_NUMBER[MEASURE]
) O O
: O O
865 O B_MEASURE
- O O
872 O B_MEASURE
, O O
1978 O B_MEASURE
) O O
. O O

Microscopic O O
evaluation O O
revealed O O
that O O
treatment O O
with O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
induced O O
significant O O
cardiac O O
damage O O
in O O
comparison O O
to O O
the O O
saline O O
control O O
group O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

RESULTS O O
: O O
The O O
number O O
of O O
damaged O O
cardiomyocytes O O
was O O
9 O O
. O O
6 O O
- O O
fold O O
( O O
95 O O
% O O
CI O O
4 O O
. O O
4 O O
- O O
21 O O
. O O
0 O O
) O O
higher O O
in O O
mice O O
treated O O
with O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O O
than O O
that O O
in O O
animals O O
of O O
the O O
control O O
group O O
. O O

The O O
ratio O O
of O O
aberrant O O
cardiomyocytes O O
in O O
mice O O
treated O O
with O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preceded O O
by O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
those O O
in O O
mice O O
treated O O
with O O
saline O O
ranged O O
from O O
1 O O
. O O
6 O O
to O O
2 O O
. O O
8 O O
( O O
mean O O
2 O O
. O O
2 O O
, O O
95 O O
% O O
CI O O
1 O O
. O O
2 O O
- O O
4 O O
. O O
1 O O
, O O
P O O
= O O
0 O O
. O O
019 O O
) O O
. O O

The O O
mean O O
protective O O
effect O O
by O O
adding O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O O
DOX B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
led O O
to O O
a O O
significant O O
4 O O
. O O
4 O O
- O O
fold O O
reduction O O
( O O
P O O
< O O
0 O O
. O O
001 O O
, O O
95 O O
% O O
CI O O
2 O O
. O O
3 O O
- O O
8 O O
. O O
2 O O
) O O
of O O
abnormal O O
cardiomyocytes O O
. O O

This O O
protective O O
effect O O
did O O
not O O
depend O O
on O O
the O O
time O O
interval O O
between O O
monoHER B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administration O O
( O O
P O O
= O O
0 O O
. O O
345 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
in O O
an O O
outpatient O O
clinical O O
setting O O
monoHER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
administered O O
shortly O O
before O O
DOX B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Clinical O O
evaluation O O
of O O
adverse O O
effects O O
during O O
bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
for O O
atrial O O
fibrillation O O
and O O
flutter O O
. O O

BACKGROUND O O
: O O
Bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Bpd B B_ORGANIZATION/B_LOCATION
) O O
has O O
attracted O O
attention O O
as O O
an O O
effective O O
drug O O
for O O
atrial O O
fibrillation O O
( O O
AF O O
) O O
and O O
atrial O O
flutter O O
( O O
AFL O O
) O O
. O O

However O O
, O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
torsade O B_DISEASE
de O I_DISEASE
pointes O I_DISEASE
( O O
Tdp O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
have O O
been O O
reported O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Adverse O O
effects O O
of O O
Bpd B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
requiring O O
discontinuation O O
of O O
treatment O O
were O O
evaluated O O
. O O

Bpd B B_DISEASE/B_PROTEIN[GENE]
was O O
administered O O
to O O
459 O O
patients O O
( O O
361 O O
males O O
, O O
63 O O
+ O O
/ O O
- O O
12 O O
years O O
old O O
) O O
comprising O O
378 O O
AF O O
and O O
81 O O
AFL O O
cases O O
. O O

Mean O O
left O O
ventricular O B_MEASURE/B_LOCATION
ejection O B_MEASURE/I_LOCATION
fraction O B_MEASURE/I_LOCATION
and O O
atrial O B_MEASURE
dimension O I_MEASURE
( O O
LAD O B_PERSON/B_DISEASE
) O O
were O O
66 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
11 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
40 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mm O I_MEASURE
, O O
respectively O O
. O O

Adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
in O O
19 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
during O O
an O O
average O B_MEASURE/B_LOCATION
follow O B_MEASURE/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
of O O
20 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
months O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
was O O
marked O O
QT O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
prolongation O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
55 O B_MEASURE
s O I_MEASURE
in O O
13 O B_MEASURE/B_PERSON
patients O B_MEASURE/I_PERSON
, O O
bradycardia O B_MEASURE
less O I_MEASURE
than O O
40 O B_MEASURE
beats O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
in O O
6 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
, O O
dizziness O B_DISEASE
and O O
general O B_DISEASE
fatigue O I_DISEASE
in O O
1 O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
each O O
. O O

In O O
4 O B_NUMBER[MEASURE]
of O O
13 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
with O O
QT O B_DISEASE
prolongation O I_DISEASE
, O O
Tdp O B_DISEASE/B_GENE
occurred O O
. O O

The O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triggering O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Tdp O B_DISEASE/B_GENE
were O O
hypokalemia O B_DISEASE
and O O
sudden O B_DISEASE_ADJECTIVE[DISEASE]
decrease O I_DISEASE_ADJECTIVE[DISEASE]
in O O
heart O B_MEASURE/B_DISEASE
rate O B_MEASURE/I_DISEASE
. O O

There O O
were O O
no O O
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
clinical O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
backgrounds O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
patients O B_PERSON
with O O
and O O
without O O
Tdp O B_DISEASE/B_GENE
other O I_DISEASE/I_GENE
than O O
LAD O B_PERSON/B_DISEASE
and O O
age O B_DISEASE/B_LOCATION
, O O
which O O
were O O
larger O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
older O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
patients O B_PERSON
with O O
Tdp O B_DISEASE/B_GENE
. O O

CONCLUSION O O
: O O
Careful O O
observation O O
of O O
serum O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
and O O
the O O
ECG O O
should O O
always O O
be O O
done O O
during O O
Bpd B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O O
, O O
particularly O O
in O O
elderly O O
patients O O
. O O

Enhanced O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
hypertrophy O O
in O O
transgenic O O
rats O O
with O O
low O O
brain O O
angiotensinogen O O
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
permanent O O
deficiency O O
in O O
the O O
brain O O
renin O O
- O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system O O
( O O
RAS O O
) O O
may O O
increase O O
the O O
sensitivity O O
of O O
the O O
baroreflex O O
control O O
of O O
heart O O
rate O O
. O O

In O O
this O O
study O O
we O O
aimed O O
at O O
studying O O
the O O
involvement O O
of O O
the O O
brain O O
RAS O O
in O O
the O O
cardiac O O
reactivity O O
to O O
the O O
beta O O
- O O
adrenoceptor O O
( O O
beta O O
- O O
AR O O
) O O
agonist O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Iso B B_ORGANIZATION/B_LOCATION
) O O
. O O

Transgenic O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
with O O
low O B_DISEASE
brain O I_DISEASE
angiotensinogen O I_DISEASE
( O O
TGR O B_LOCATION/B_ORGANIZATION
) O O
were O O
used O O
. O O

In O O
isolated O O
hearts O O
, O O
Iso B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O O
a O O
significantly O O
greater O O
increase O O
in O O
left O O
ventricular O O
( O O
LV O O
) O O
pressure O O
and O O
maximal O O
contraction O O
( O O
+ O O
dP O O
/ O O
dt O O
( O O
max O O
) O O
) O O
in O O
the O O
TGR O O
than O O
in O O
the O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

LV O O
hypertrophy O O
induced O O
by O O
Iso B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O O
was O O
significantly O O
higher O O
in O O
TGR O O
than O O
in O O
SD O O
rats O O
( O O
in O O
g O O
LV O O
wt O O
/ O O
100 O O
g O O
body O O
wt O O
, O O
0 O O
. O O
28 O O
+ O O
/ O O
- O O
0 O O
. O O
004 O O
vs O O
. O O
0 O O
. O O
24 O O
+ O O
/ O O
- O O
0 O O
. O O
004 O O
, O O
respectively O O
) O O
. O O

The O O
greater O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LV O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertrophy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
TGR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
associated O O
with O O
more O O
pronounced O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
downregulation O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
AR O B_GENE/B_DISEASE
and O O
upregulation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
LV O B_PROTEIN[GENE]
beta O I_PROTEIN[GENE]
- O O
AR O B_GENE/B_LOCATION
kinase O I_GENE/I_LOCATION
- O O
1 O B_GENE
mRNA O I_GENE
levels O I_GENE
compared O O
with O O
those O O
in O O
SD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

The O O
decrease O O
in O O
the O O
heart O O
rate O O
( O O
HR O O
) O O
induced O O
by O O
the O O
beta O O
- O O
AR O O
antagonist O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
conscious O O
rats O O
was O O
significantly O O
attenuated O O
in O O
TGR O O
compared O O
with O O
SD O O
rats O O
( O O
- O O
9 O O
. O O
9 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
% O O
vs O O
. O O
- O O
18 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
% O O
) O O
, O O
whereas O O
the O O
effect O O
of O O
parasympathetic O O
blockade O O
by O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
HR O O
was O O
similar O O
in O O
both O O
strains O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
TGR O B_PERSON/B_BIO
are O O
more O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
beta O O
- O O
AR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiac O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inotropic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
hypertrophy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
possibly O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O O
chronically O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sympathetic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
outflow O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
directed O O
to O O
the O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Drug O O
- O O
induced O O
long O O
QT O O
syndrome O O
in O O
injection O O
drug O O
users O O
receiving O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
high O O
frequency O O
in O O
hospitalized O O
patients O O
and O O
risk O O
factors O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
long O B_DISEASE
QT O I_DISEASE
syndrome O I_DISEASE
is O O
a O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
drug O I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolongs O O
the O O
QT O O
interval O O
in O O
vitro O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

In O O
the O O
inpatient O O
setting O O
, O O
the O O
frequency O O
of O O
QT O O
interval O O
prolongation O O
with O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
its O O
dose O O
dependence O O
, O O
and O O
the O O
importance O O
of O O
cofactors O O
such O O
as O O
drug O O
- O O
drug O O
interactions O O
remain O O
unknown O O
. O O

METHODS O O
: O O
We O O
performed O O
a O O
systematic O O
, O O
retrospective O O
study O O
comparing O O
active O O
or O O
former O O
intravenous O O
drug O O
users O O
receiving O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
those O O
not O O
receiving O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O O
all O O
patients O O
hospitalized O O
over O O
a O O
5 O O
- O O
year O O
period O O
in O O
a O O
tertiary O O
care O O
hospital O O
. O O

A O O
total O O
of O O
167 O O
patients O O
receiving O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fulfilled O O
the O O
inclusion O O
criteria O O
and O O
were O O
compared O O
with O O
a O O
control O O
group O O
of O O
80 O O
injection O O
drug O O
users O O
not O O
receiving O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
to O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
, O O
15 O O
demographic O O
, O O
biological O O
, O O
and O O
pharmacological O O
variables O O
were O O
considered O O
as O O
potential O O
risk O O
factors O O
for O O
QT O O
prolongation O O
. O O

RESULTS O O
: O O
Among O O
167 O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintenance O O
patients O O
, O O
the O O
prevalence O O
of O O
QTc O O
prolongation O O
to O O
0 O O
. O O
50 O O
second O O
( O O
( O O
1 O O
/ O O
2 O O
) O O
) O O
or O O
longer O O
was O O
16 O O
. O O
2 O O
% O O
compared O O
with O O
0 O O
% O O
in O O
80 O O
control O O
subjects O O
. O O

Six O O
patients O O
( O O
3 O O
. O O
6 O O
% O O
) O O
in O O
the O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O O
presented O O
torsades O O
de O O
pointes O O
. O O

QTc O O
length O O
was O O
weakly O O
but O O
significantly O O
associated O O
with O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
dose O O
( O O
Spearman O O
rank O O
correlation O O
coefficient O O
, O O
0 O O
. O O
20 O O
; O O
P O O
< O O
. O O
01 O O
) O O
. O O

Multivariate O O
regression O O
analysis O O
allowed O O
attribution O O
of O O
31 O O
. O O
8 O O
% O O
of O O
QTc O O
variability O O
to O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
, O O
cytochrome O O
P O O
- O O
450 O O
3A4 O O
drug O O
- O O
drug O O
interactions O O
, O O
hypokalemia O O
, O O
and O O
altered O O
liver O O
function O O
. O O

CONCLUSIONS O O
: O O
QT O O
interval O O
prolongation O O
in O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
maintenance O O
patients O O
hospitalized O O
in O O
a O O
tertiary O O
care O O
center O O
is O O
a O O
frequent O O
finding O O
. O O

Methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
, O O
presence O O
of O O
cytochrome O O
P O O
- O O
450 O O
3A4 O O
inhibitors O O
, O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
, O O
and O O
liver O O
function O O
contribute O O
to O O
QT O O
prolongation O O
. O O

Long O O
QT O O
syndrome O O
can O O
occur O O
with O O
low O O
doses O O
of O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mechanisms O O
of O O
hypertension O O
induced O O
by O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
deficiency O O
: O O
focus O O
on O O
venous O O
function O O
. O O

Loss O O
of O O
endothelial O O
cell O O
- O O
derived O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
in O O
hypertension O O
is O O
a O O
hallmark O O
of O O
arterial O O
dysfunction O O
. O O

Experimental O O
hypertension O O
created O O
by O O
the O O
removal O O
of O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
involves O O
mechanisms O O
in O O
addition O O
to O O
decreased O O
arterial O O
vasodilator O O
activity O O
. O O

These O O
include O O
augmented O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_TIME[MEASURE]
( O O
ET O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
1 O B_NUMBER[MEASURE]
) O O
release O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increased O O
sympathetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
elevated O O
tissue O B_DISEASE
oxidative O I_DISEASE
stress O I_DISEASE
. O O

We O O
hypothesized O O
that O O
increased O O
venous O O
smooth O O
muscle O O
( O O
venomotor O O
) O O
tone O O
plays O O
a O O
role O O
in O O
Nomega B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitro I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arginine I I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LNNA B B_LOCATION/B_DISEASE
) O O
hypertension O O
through O O
these O O
mechanisms O O
. O O

Rats O O
were O O
treated O O
with O O
the O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthase O O
inhibitor O O
LNNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O O
. O O
5 O O
g O O
/ O O
L O O
in O O
drinking O O
water O O
) O O
for O O
2 O O
weeks O O
. O O

Mean O O
arterial O O
pressure O O
of O O
conscious O O
rats O O
was O O
119 O O
+ O O
/ O O
- O O
2 O O
mm O O
Hg O O
in O O
control O O
and O O
194 O O
+ O O
/ O O
- O O
5 O O
mm O O
Hg O O
in O O
LNNA B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Carotid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
vena O B_BODY_PART_OR_ORGAN_COMPONENT
cava O I_BODY_PART_OR_ORGAN_COMPONENT
were O O
removed O O
for O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
isometric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contraction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Maximal O O
contraction O O
to O O
norepinephrine B B_LOCATION
was O O
modestly O O
reduced O O
in O O
arteries O O
from O O
LNNA B B_DISEASE/B_GENE
compared O O
with O O
control O O
rats O O
whereas O O
the O O
maximum O O
contraction O O
to O O
ET O O
- O O
1 O O
was O O
significantly O O
reduced O O
( O O
54 O O
% O O
control O O
) O O
. O O

Maximum O O
contraction O O
of O O
vena O O
cava O O
to O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
37 O O
% O O
control O O
) O O
also O O
was O O
reduced O O
but O O
no O O
change O O
in O O
response O O
to O O
ET O O
- O O
1 O O
was O O
observed O O
. O O

Mean O O
circulatory O O
filling O O
pressure O O
, O O
an O O
in O O
vivo O O
measure O O
of O O
venomotor O O
tone O O
, O O
was O O
not O O
elevated O O
in O O
LNNA B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertension O O
at O O
1 O O
or O O
2 O O
weeks O O
after O O
LNNA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scavenger O O
tempol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
micromol O O
kg O O
( O O
- O O
1 O O
) O O
, O O
IV O O
) O O
did O O
not O O
change O O
arterial O O
pressure O O
in O O
control O O
rats O O
but O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
LNNA B B_DISEASE
rats O O
( O O
- O O
18 O O
+ O O
/ O O
- O O
8 O O
, O O
- O O
26 O O
+ O O
/ O O
- O O
15 O O
, O O
and O O
- O O
54 O O
+ O O
/ O O
- O O
11 O O
mm O O
Hg O O
) O O
. O O

Similarly O O
, O O
ganglionic O O
blockade O O
with O O
hexamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
caused O O
a O O
significantly O O
greater O O
fall O O
in O O
LNNA B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertensive O O
rats O O
( O O
76 O O
+ O O
/ O O
- O O
9 O O
mm O O
Hg O O
) O O
compared O O
with O O
control O O
rats O O
( O O
35 O O
+ O O
/ O O
- O O
10 O O
mm O O
Hg O O
) O O
. O O

Carotid O O
arteries O O
, O O
vena O O
cava O O
, O O
and O O
sympathetic O O
ganglia O O
from O O
LNNA B B_DISEASE
rats O O
had O O
higher O O
basal O O
levels O O
of O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
with O O
those O O
from O O
control O O
rats O O
. O O

These O O
data O O
suggest O O
that O O
while O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O O
increases O O
oxidative O O
stress O O
and O O
sympathetic O O
activity O O
in O O
both O O
arterial O O
and O O
venous O O
vessels O O
, O O
the O O
impact O O
on O O
veins O O
does O O
not O O
make O O
a O O
major O O
contribution O O
to O O
this O O
form O O
of O O
hypertension O O
. O O

Association O O
of O O
DRD2 O O
polymorphisms O O
and O O
chlorpromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
extrapyramidal O O
syndrome O O
in O O
Chinese O O
schizophrenic O O
patients O O
. O O

AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Extrapyramidal O B_DISEASE
syndrome O I_DISEASE
( O O
EPS O B_DISEASE
) O O
is O O
most O O
commonly O O
affected O O
by O O
typical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antipsychotic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
have O O
a O O
high O B_LOCATION/B_MEASURE
affinity O I_LOCATION/I_MEASURE
with O O
the O O
D2 O B_GENE
receptor O I_GENE
. O O

Recently O O
, O O
many O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
reported O O
on O O
the O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
genetic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
DRD2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
therapeutic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
schizophrenia O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
variations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
receptor O B_GENE/B_LOCATION
in O O
modulating O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
this O O
study O O
, O O
we O O
evaluate O O
the O O
role O O
DRD2 O O
plays O O
in O O
chlorpromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
EPS O O
in O O
schizophrenic O O
patients O O
. O O

METHODS O O
: O O
We O O
identified O O
seven O O
SNP O O
( O O
single O O
nucleotide O O
polymorphism O O
) O O
( O O
- O O
141Cins O O
> O O
del O O
, O O
TaqIB O O
, O O
TaqID O O
, O O
Ser311Cys O O
, O O
rs6275 O O
, O O
rs6277 O O
and O O
TaqIA O O
) O O
in O O
the O O
DRD2 O O
gene O O
in O O
146 O O
schizophrenic O O
inpatients O O
( O O
59 O O
with O O
EPS O O
and O O
87 O O
without O O
EPS O O
according O O
to O O
the O O
Simpson O O
- O O
Angus O O
Scale O O
) O O
treated O O
with O O
chlorpromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
8 O O
weeks O O
. O O

The O O
alleles O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
all O O
loci O B_BIO/B_PERSON
were O O
determined O O
by O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
polymerase O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
Polymorphisms O B_MEASURE/B_GENE
TaqID O I_MEASURE/I_GENE
, O O
Ser311Cys O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
rs6277 O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
population O B_PERSON/B_LOCATION
recruited O O
in O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

No O O
statistical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
allele O B_MEASURE
distribution O I_MEASURE
of O O
- O O
141Cins O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
> O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
del O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TaqIB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
rs6275 O B_GENE/B_DISEASE
and O O
TaqIA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
in O O
the O O
estimated O O
haplotypes O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
constituted O O
by O O
TaqIB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
rs6275 O B_GENE/B_LOCATION
and O O
TaqIA O B_GENE/B_LOCATION
) O O
in O O
linkage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
disequilibrium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

CONCLUSION O O
: O O
Our O O
results O O
did O O
not O O
lend O O
strong O O
support O O
to O O
the O O
view O O
that O O
the O O
genetic O O
variation O O
of O O
the O O
DRD2 O O
gene O O
plays O O
a O O
major O O
role O O
in O O
the O O
individually O O
variable O O
adverse O O
effect O O
induced O O
by O O
chlorpromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
at O O
least O O
in O O
Chinese O O
patients O O
with O O
schizophrenia O O
. O O

Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirmed O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
the O O
relationship O B_PERSON/B_MEASURE
between O O
DRD2 O B_DISEASE/B_GENE
and O O
EPS O B_DISEASE/B_LOCATION
in O O
Caucasians O B_DISEASE/B_PERSON
. O O

Physical O O
training O O
decreases O O
susceptibility O O
to O O
subsequent O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
seizures O O
in O O
the O O
rat O O
. O O

Regular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
motor O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
many O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
mental O B_DISEASE/B_PERSON
and O O
physical O B_DISEASE_ADJECTIVE[DISEASE]
condition O I_DISEASE_ADJECTIVE[DISEASE]
but O O
its O O
implications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
epilepsy O B_DISEASE
are O O
still O O
controversial O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
order O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
elucidate O O
this O O
problem O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
have O O
studied O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_TIME[MEASURE]/B_LOCATION
physical O I_TIME[MEASURE]/I_LOCATION
activity O I_TIME[MEASURE]/I_LOCATION
on O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
subsequent O B_DISEASE
seizures O I_DISEASE
. O O

Male O B_PERSON
Wistar O I_PERSON
rats O I_PERSON
were O O
subjected O O
to O O
repeated O O
training O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sessions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
treadmill O B_LOCATION/B_ORGANIZATION
and O O
swimming O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pool O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thereafter O O
, O O
seizures O O
were O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections O O
in O O
trained O O
and O O
non O O
- O O
trained O O
control O O
groups O O
. O O

During O O
the O O
acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
status O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
measured O O
: O O
( O O
1 O O
) O O
the O O
latency O B_MEASURE
of O O
the O O
first O B_DISEASE
motor O I_DISEASE
sign O I_DISEASE
, O O
( O O
2 O B_NUMBER[MEASURE]/B_PERSON
) O O
the O O
intensity O B_MEASURE
of O O
seizures O B_DISEASE
, O O
( O O
3 O B_SEQUENCE[MEASURE]/B_LOCATION
) O O
the O O
time O B_TIME[MEASURE]
when O O
it O O
occurred O O
within O O
the O O
6 O B_MEASURE
- O O
h O B_TIME[MEASURE]/B_LOCATION
observation O I_TIME[MEASURE]/I_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
, O O
and O O
( O O
4 O O
) O O
the O O
time O B_TIME[MEASURE]
when O O
the O O
acute O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
period O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
ended O O
. O O

All O O
these O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
regular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
physical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exercises O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decrease O O
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
subsequently O O
induced O O
seizures O B_DISEASE
and O O
ameliorate O O
the O O
course O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
experimentally O O
induced O O
status O B_DISEASE
epilepticus O I_DISEASE
. O O

Tonic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dopaminergic O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
stimulation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
impairs O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
associative O I_DISEASE_ADJECTIVE[DISEASE]
learning O O
in O O
healthy O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
. O O

Endogenous O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
plays O O
a O O
central O O
role O O
in O O
salience O O
coding O O
during O O
associative O O
learning O O
. O O

Administration O O
of O O
the O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
precursor O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke O O
patients O O
. O O

Because O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O O
both O O
phasic O O
and O O
tonic O O
dopaminergic O O
neurotransmission O O
, O O
the O O
critical O O
mechanism O O
mediating O O
the O O
enhancement O O
of O O
learning O O
is O O
unresolved O O
. O O

We O O
here O O
probed O O
how O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tonic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
affects O O
associative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
learning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Forty O B_PERSON
healthy O I_PERSON
subjects O I_PERSON
were O O
trained O O
in O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vocabulary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
45 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concrete O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nouns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O O
the O O
course O B_LOCATION/B_TIME[MEASURE]
of O O
5 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
randomized O O
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
controlled O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Subjects O O
received O O
the O O
tonically O O
stimulating O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
receptor O O
agonist O O
pergolide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
0 O O
. O O
1 O O
mg O O
) O O
vs O O
placebo O O
120 O O
min O O
before O O
training O O
on O O
each O O
training O O
day O O
. O O

The O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist O O
significantly O O
impaired O O
novel O O
word O O
learning O O
compared O O
to O O
placebo O O
. O O

This O O
learning O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decrement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O O
up O O
to O O
the O O
last O B_MEASURE/B_PERSON
follow O O
- O O
up O O
4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
training O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Subjects O O
treated O O
with O O
pergolide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
showed O O
restricted O O
emotional O O
responses O O
compared O O
to O O
the O O
PLACEBO O O
group O O
. O O

The O O
extent O O
of O O
' O O
flattened O O
' O O
affect O O
with O O
pergolide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
related O O
to O O
the O O
degree O O
of O O
learning O O
inhibition O O
. O O

These O O
findings O O
suggest O O
that O O
tonic O O
occupation O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
impairs O O
learning O O
by O O
competition O O
with O O
phasic O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
signals O O
. O O

Thus O O
, O O
phasic O O
signaling O O
seems O O
to O O
be O O
the O O
critical O O
mechanism O O
by O O
which O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enhances O O
associative O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke O O
patients O O
. O O

Minocycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
vasculitis O O
fulfilling O O
the O O
criteria O O
of O O
polyarteritis O O
nodosa O O
. O O

A O O
47 O O
- O O
year O O
- O O
old O O
man O O
who O O
had O O
been O O
taking O O
minocycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
palmoplantar O O
pustulosis O O
developed O O
fever O O
, O O
myalgias O O
, O O
polyneuropathy O O
, O O
and O O
testicular O O
pain O O
, O O
with O O
elevated O O
C O O
- O O
reactive O O
protein O O
( O O
CRP O O
) O O
. O O

Neither O O
myeloperoxidase O B_GENE
- O O
nor O O
proteinase O B_GENE
- O O
3 O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
antineutrophil O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
manifestations O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
met O O
the O O
American O B_LOCATION/B_ORGANIZATION
College O B_LOCATION/I_ORGANIZATION
of O O
Rheumatology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1990 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criteria O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
classification O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
polyarteritis O B_DISEASE/B_LOCATION
nodosa O I_DISEASE/I_LOCATION
. O O

Stopping O O
minocycline B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O O
to O O
amelioration O O
of O O
symptoms O O
and O O
normalization O O
of O O
CRP O O
level O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
second O O
case O O
of O O
minocycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
vasculitis O O
satisfying O O
the O O
criteria O O
. O O

Differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
disease O B_DISEASE
is O O
invaluable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
for O O
patients O B_PERSON/B_BIO
with O O
classical O B_DISEASE
polyarteritis O I_DISEASE
nodosa O I_DISEASE
. O O

Intramuscular O O
hepatitis O O
B O O
immune O O
globulin O O
combined O O
with O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
prevention O O
of O O
hepatitis O O
B O O
recurrence O O
after O O
liver O O
transplantation O O
. O O

BACKGROUND O O
: O O
Combined O O
hepatitis O O
B O O
immune O O
globulin O O
( O O
HBIg O O
) O O
and O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
prophylaxis O O
of O O
the O O
recurrence O O
of O O
hepatitis O O
B O O
after O O
liver O O
transplantation O O
has O O
significantly O O
improved O O
the O O
survival O O
of O O
HBsAg B B_DISEASE/B_GENE
positive O O
patients O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
undertaken O O
to O O
evaluate O O
the O O
outcomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
patients O B_PERSON/B_DISEASE
with O O
hepatitis O B_DISEASE
B O I_DISEASE
virus O I_DISEASE
( O O
HBV O B_DISEASE
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chart O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
a O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
organ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
transplant O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
identified O O
51 O B_MEASURE
patients O I_MEASURE
( O O
43 O B_MEASURE/B_PERSON
men O I_MEASURE/I_PERSON
and O O
8 O B_PERSON/B_SPORT[ENT]
women O I_PERSON/I_SPORT[ENT]
) O O
transplanted O O
for O O
benign O B_DISEASE
HBV O I_DISEASE
- O O
related O O
cirrhotic O B_DISEASE
diseases O I_DISEASE
between O O
June O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2002 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O O
had O O
survived O O
more O B_MEASURE
than O O
3 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

HBIg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
administered O O
intravenously O O
during O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
intramuscularly O O
thereafter O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
At O O
a O O
median O B_MEASURE/B_LOCATION
follow O B_MEASURE/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
of O O
14 O B_MEASURE
. O O
1 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
the O O
overall O B_DISEASE
recurrence O I_DISEASE
rate O I_DISEASE
in O O
the O O
51 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
was O O
3 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
2 O B_MEASURE
/ O O
51 O B_MEASURE
) O O
. O O

The O O
overall O B_DISEASE
patient O I_DISEASE
survival O I_DISEASE
was O O
88 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
and O O
82 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
after O O
1 O B_SEQUENCE[MEASURE]
and O O
2 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
, O O
respectively O O
. O O

A O O
daily O O
oral O O
dose O O
of O O
100 O O
mg O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O O
weeks O O
before O O
transplantation O O
for O O
10 O O
patients O O
enabled O O
57 O O
. O O
1 O O
% O O
( O O
4 O O
/ O O
7 O O
) O O
and O O
62 O O
. O O
5 O O
% O O
( O O
5 O O
/ O O
8 O O
) O O
of O O
HBV O O
- O O
DNA O O
and O O
HBeAg B B_GENE/B_DISEASE
positive O O
patients O O
respectively O O
to O O
convert O O
to O O
be O O
negative O O
. O O

Intramuscular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
HBIg O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
was O O
well O O
tolerated O O
in O O
all O O
patients O B_PERSON/B_LOCATION
. O O

CONCLUSION O O
: O O
Lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
combined O O
with O O
intramuscular O O
HBIg O O
can O O
effectively O O
prevent O O
allograft O O
from O O
the O O
recurrence O O
of O O
HBV O O
after O O
liver O O
transplantation O O
. O O

Anticonvulsant O O
effect O O
of O O
eslicarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BIA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
093 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
on O O
seizures O O
induced O O
by O O
microperfusion O O
of O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
the O O
hippocampus O O
of O O
freely O O
moving O O
rats O O
. O O

Eslicarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BIA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
093 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
S B B_MEASURE/B_PERSON
- I I_MEASURE/I_PERSON
( I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
) I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
10 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
acetoxy I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
10 I I_MEASURE/I_PERSON
, I I_MEASURE/I_PERSON
11 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
dihydro I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
5H I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
dibenzo I I_MEASURE/I_PERSON
/ I I_MEASURE/I_PERSON
b I I_MEASURE/I_PERSON
, I I_MEASURE/I_PERSON
f I I_MEASURE/I_PERSON
/ I I_MEASURE/I_PERSON
azepine I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
5 I I_MEASURE/I_PERSON
- I I_MEASURE/I_PERSON
carboxamide I I_MEASURE/I_PERSON
) O O
is O O
a O O
novel O O
antiepileptic O O
drug O O
, O O
now O O
in O O
Phase O O
III O O
clinical O O
trials O O
, O O
designed O O
with O O
the O O
aim O O
of O O
improving O O
efficacy O O
and O O
safety O O
in O O
comparison O O
with O O
the O O
structurally O O
related O O
drugs O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBZ B B_LOCATION/B_ORGANIZATION
) O O
and O O
oxcarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OXC B B_LOCATION/B_ORGANIZATION
) O O
. O O

We O O
have O O
studied O O
the O O
effects O O
of O O
oral O O
treatment O O
with O O
eslicarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
a O O
whole O O
- O O
animal O O
model O O
in O O
which O O
partial O O
seizures O O
can O O
be O O
elicited O O
repeatedly O O
on O O
different O O
days O O
without O O
changes O O
in O O
threshold O O
or O O
seizure O O
patterns O O
. O O

In O O
the O O
animals O O
treated O O
with O O
threshold O O
doses O O
of O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
the O O
average O O
number O O
of O O
seizures O O
was O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
, O O
and O O
average O O
seizure O O
duration O O
was O O
39 O O
. O O
5 O O
+ O O
/ O O
- O O
8 O O
. O O
4s O O
. O O

Pre O O
- O O
treatment O O
with O O
a O O
dose O O
of O O
30 O O
mg O O
/ O O
kg O O
2h O O
before O O
picrotoxin B B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
microperfusion O O
prevented O O
seizures O O
in O O
the O O
75 O O
% O O
of O O
the O O
rats O O
. O O

Lower O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
3 O B_NUMBER[MEASURE]
and O O
10mg O B_MEASURE
/ O O
kg O B_MEASURE
) O O
did O O
not O O
suppress O O
seizures O B_DISEASE
, O O
however O O
, O O
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
10mg O B_MEASURE
/ O O
kg O B_MEASURE
, O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
seizures O B_MEASURE/B_DISEASE
duration O I_MEASURE/I_DISEASE
( O O
24 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
. O O
8s O B_MEASURE
) O O
and O O
seizure O B_MEASURE/B_DISEASE
number O I_MEASURE/I_DISEASE
( O O
1 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
34 O B_MEASURE
) O O
were O O
found O O
. O O

No O O
adverse O O
effects O O
of O O
eslicarbazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
in O O
the O O
behavioral O O
/ O O
EEG O O
patterns O O
studied O O
, O O
including O O
sleep O O
/ O O
wakefulness O O
cycle O O
, O O
at O O
the O O
doses O O
studied O O
. O O

Acute O O
renal O O
failure O O
associated O O
with O O
prolonged O O
intake O O
of O O
slimming O O
pills O O
containing O O
anthraquinones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Chinese B B_PERSON/B_ORGANIZATION
herbal I I_PERSON/I_ORGANIZATION
medicine O O
preparations O O
are O O
widely O O
available O O
and O O
often O O
regarded O O
by O O
the O O
public O O
as O O
natural O O
and O O
safe O O
remedies O O
for O O
a O O
variety O O
of O O
medical O O
conditions O O
. O O

Nephropathy O O
caused O O
by O O
Chinese B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
previously O O
been O O
reported O O
, O O
usually O O
involving O O
the O O
use O O
of O O
aristolochic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
report O O
a O O
23 O O
- O O
year O O
- O O
old O O
woman O O
who O O
developed O O
acute O O
renal O O
failure O O
following O O
prolonged O O
use O O
of O O
a O O
proprietary O O
Chinese B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
slimming O O
pill O O
that O O
contained O O
anthraquinone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derivatives O O
, O O
extracted O O
from O O
Rhizoma O O
Rhei O O
( O O
rhubarb O O
) O O
. O O

The O O
renal O O
injury O O
was O O
probably O O
aggravated O O
by O O
the O O
concomitant O O
intake O O
of O O
a O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drug O O
, O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Renal O B_PERSON/B_ORGANIZATION
pathology O I_PERSON/I_ORGANIZATION
was O O
that O O
of O O
hypocellular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
interstitial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fibrosis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Spontaneous O B_DISEASE_ADJECTIVE[DISEASE]
renal O I_DISEASE_ADJECTIVE[DISEASE]
recovery O I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
upon O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
slimming O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pills O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
interstitial O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fibrosis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
tubular O B_DISEASE
atrophy O I_DISEASE
was O O
still O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histologically O O
4 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
later O O
. O O

Although O O
a O O
causal O O
relationship O O
between O O
the O O
use O O
of O O
an O O
anthraquinone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
containing O O
herbal O O
agent O O
and O O
renal O O
injury O O
remains O O
to O O
be O O
proven O O
, O O
phytotherapy O O
- O O
associated O O
interstitial O O
nephropathy O O
should O O
be O O
considered O O
in O O
patients O O
who O O
present O O
with O O
unexplained O O
renal O O
failure O O
. O O

Chloroacetaldehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O O
a O O
sulfhydryl B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reagent O O
: O O
the O O
role O O
of O O
critical O O
thiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O O
in O O
ifosfamide B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O O
. O O

Chloroacetaldehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
CAA B B_LOCATION
) O O
is O O
a O O
metabolite O O
of O O
the O O
alkylating O O
agent O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IFO B B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
putatively O O
responsible O O
for O O
renal O O
damage O O
following O O
anti O O
- O O
tumor O O
therapy O O
with O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Depletion O O
of O O
sulfhydryl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
groups O O
has O O
been O O
reported O O
from O O
cell O O
culture O O
, O O
animal O O
and O O
clinical O O
studies O O
. O O

In O O
this O O
work O O
the O O
effect O O
of O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
human O O
proximal O O
tubule O O
cells O O
in O O
primary O O
culture O O
( O O
hRPTEC O O
) O O
was O O
investigated O O
. O O

Toxicity O O
of O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
determined O O
by O O
protein O O
content O O
, O O
cell O O
number O O
, O O
LDH O O
release O O
, O O
trypan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blue I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exclusion O O
assay O O
and O O
caspase O O
- O O
3 O O
activity O O
. O O

Free O O
thiols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
measured O O
by O O
the O O
method O O
of O O
Ellman O O
. O O

CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduced O O
hRPTEC O O
cell O O
number O O
and O O
protein O O
, O O
induced O O
a O O
loss O O
in O O
free O O
intracellular O O
thiols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
an O O
increase O O
in O O
necrosis O O
markers O O
. O O

CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
acrolein B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O O
the O O
cysteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proteases O O
caspase O O
- O O
3 O O
, O O
caspase O O
- O O
8 O O
and O O
cathepsin O O
B O O
. O O

Caspase O O
activation O O
by O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
inhibited O O
by O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
cells O O
stained O O
with O O
fluorescent O O
dyes O O
targeting O O
lysosomes O O
, O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induced O O
an O O
increase O O
in O O
lysosomal O O
size O O
and O O
lysosomal O O
leakage O O
. O O

The O O
effects O O
of O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
cysteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
protease O O
activities O O
and O O
thiols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O O
be O O
reproduced O O
in O O
cell O O
lysate O O
. O O

Acidification O O
, O O
which O O
slowed O O
the O O
reaction O O
of O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
thiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
donors O O
, O O
could O O
also O O
attenuate O O
effects O O
of O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
necrosis O O
markers O O
, O O
thiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
depletion O O
and O O
cysteine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protease O O
inhibition O O
in O O
living O O
cells O O
. O O

Thus O O
, O O
CAA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
directly O O
reacts O O
with O O
cellular O O
protein O O
and O O
non O O
- O O
protein O O
thiols B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mediating O O
its O O
toxicity O O
on O O
hRPTEC O O
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
reduced O O
by O O
acidification O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Therefore O O
, O O
urinary O O
acidification O O
could O O
be O O
an O O
option O O
to O O
prevent O O
IFO B B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
in O O
patients O O
. O O

Stereological O O
methods O O
reveal O O
the O O
robust O O
size O O
and O O
stability O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
after O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
status O O
epilepticus O O
in O O
the O O
adult O O
rat O O
. O O

Following O O
status O B_DISEASE
epilepticus O I_DISEASE
in O O
the O O
rat O B_SPECIES[BIO]/B_GENE
, O O
dentate O O
granule O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurogenesis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
increases O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
greatly O O
, O O
and O O
many O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
of O O
the O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appear O O
to O O
develop O O
ectopically O O
, O O
in O O
the O O
hilar O B_LOCATION/B_MEASURE
region O I_LOCATION/I_MEASURE
of O O
the O O
hippocampal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
formation O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
has O O
been O O
suggested O O
that O O
the O O
ectopic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hilar O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
granule O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
could O O
contribute O O
to O O
the O O
spontaneous O B_DISEASE_ADJECTIVE[DISEASE]
seizures O I_DISEASE_ADJECTIVE[DISEASE]
that O O
ultimately O O
develop O O
after O O
status O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
the O O
population O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
never O O
been O O
quantified O O
, O O
so O O
it O O
is O O
unclear O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
whether O O
it O O
is O O
substantial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enough O O
to O O
have O O
a O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
epileptogenesis O B_PERSON/B_ORGANIZATION
. O O

To O O
quantify O O
this O O
population O O
, O O
the O O
total O O
number O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
was O O
estimated O O
using O O
unbiased O O
stereology O O
at O O
different O O
times O O
after O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
status O O
epilepticus O O
. O O

The O O
number O B_MEASURE
of O O
hilar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Prox O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_NUMBER[MEASURE]
, O O
a O O
granule O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O O
specific O B_PROTEIN[GENE]/B_MEASURE
marker O I_PROTEIN[GENE]/I_MEASURE
, O O
was O O
estimated O O
using O O
the O O
optical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fractionator O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
size O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
the O O
hilar O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ectopic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
granule O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
population O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
status O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
substantial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
and O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
over O O
time O B_TIME[MEASURE]
. O O

Interestingly O O
, O O
the O O
size O B_MEASURE/B_PERSON
of O O
the O O
population O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
appears O O
to O O
be O O
correlated O O
with O O
the O O
frequency O B_MEASURE/B_LOCATION
of O O
behavioral O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
because O O
animals O B_BIO/B_PERSON
with O O
more O O
ectopic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granule O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
hilus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
have O O
more O O
frequent O B_DISEASE
behavioral O I_DISEASE
seizures O I_DISEASE
. O O

The O O
hilar O B_MEASURE
ectopic O I_MEASURE
granule O I_MEASURE
cell O I_MEASURE
population O I_MEASURE
does O O
not O O
appear O O
to O O
vary O O
systematically O O
across O O
the O O
septotemporal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
it O O
is O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
volume O B_MEASURE
of O O
the O O
hilus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
. O O

The O O
results O O
provide O O
new O O
insight O O
into O O
the O O
potential O O
role O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
in O O
the O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
model O O
of O O
temporal O O
lobe O O
epilepsy O O
. O O

A O O
prospective O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
autistic O O
disorder O O
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Post O B_LOCATION/B_DISEASE
- O O
mortem O B_PERSON
studies O I_PERSON
have O O
reported O O
abnormalities O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
cholinergic O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
autism O B_DISEASE/B_SPECIES[BIO]
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
assess O O
the O O
use O O
of O O
galantamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
acetylcholinesterase O O
inhibitor O O
and O O
nicotinic O O
receptor O O
modulator O O
, O O
in O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism O O
. O O

METHODS O O
: O O
Thirteen O O
medication O O
- O O
free O O
children O O
with O O
autism O O
( O O
mean O O
age O O
, O O
8 O O
. O O
8 O O
+ O O
/ O O
- O O
3 O O
. O O
5 O O
years O O
) O O
participated O O
in O O
a O O
12 O O
- O O
week O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O B_PERSON/B_BIO
were O O
rated O O
monthly O O
by O O
parents O B_PERSON
on O O
the O O
Aberrant O B_LOCATION/B_PERSON
Behavior O B_LOCATION/I_PERSON
Checklist O B_LOCATION/I_PERSON
( O O
ABC O B_ORGANIZATION/B_DISEASE
) O O
and O O
the O O
Conners O B_TIME[MEASURE]/B_ORGANIZATION
' O I_TIME[MEASURE]/I_ORGANIZATION
Parent O I_TIME[MEASURE]/I_ORGANIZATION
Rating O I_TIME[MEASURE]/I_ORGANIZATION
Scale O I_TIME[MEASURE]/I_ORGANIZATION
- O O
Revised O O
, O O
and O O
by O O
a O O
physician O B_PERSON/B_ORGANIZATION
using O O
the O O
Children O B_ORGANIZATION/B_LOCATION
' O I_ORGANIZATION/I_LOCATION
s O I_ORGANIZATION/I_LOCATION
Psychiatric O I_ORGANIZATION/I_LOCATION
Rating O I_ORGANIZATION/I_LOCATION
Scale O I_ORGANIZATION/I_LOCATION
and O O
the O O
Clinical O B_ORGANIZATION/B_MEASURE
Global O I_ORGANIZATION/I_MEASURE
Impressions O I_ORGANIZATION/I_MEASURE
scale O I_ORGANIZATION/I_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
parent O B_PERSON/B_LOCATION
- O O
rated O O
irritability O B_DISEASE_ADJECTIVE[DISEASE]
and O O
social O B_DISEASE_ADJECTIVE[DISEASE]
withdrawal O I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
ABC O B_DISEASE
as O O
well O O
as O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
improvements O I_DISEASE_ADJECTIVE[DISEASE]
in O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]
lability O I_DISEASE_ADJECTIVE[DISEASE]
and O O
inattention O B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
Conners O B_MEASURE/B_DISEASE
' O I_MEASURE/I_DISEASE
Parent O I_MEASURE/I_DISEASE
Rating O I_MEASURE/I_DISEASE
Scale O I_MEASURE/I_DISEASE
- O O
- O O
Revised O O
. O O

Similarly O O
, O O
clinician O B_PERSON
ratings O I_PERSON
showed O O
reductions O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
anger O B_MEASURE/B_ENT
subscale O I_MEASURE/I_ENT
of O O
the O O
Children O B_DISEASE
' O I_DISEASE
s O I_DISEASE
Psychiatric O I_DISEASE
Rating O I_DISEASE
Scale O I_DISEASE
. O O

Eight O B_NUMBER[MEASURE]
of O O
13 O B_NUMBER[MEASURE]/B_PERSON
participants O B_NUMBER[MEASURE]/I_PERSON
were O O
rated O O
as O O
responders O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
their O O
improvement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scores O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
the O O
Clinical O B_MEASURE/B_DISEASE
Global O B_MEASURE/I_DISEASE
Impressions O B_MEASURE/I_DISEASE
scale O B_MEASURE/I_DISEASE
. O O

Overall O O
, O O
galantamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
well O O
- O O
tolerated O O
, O O
with O O
no O O
significant O O
adverse O O
effects O O
apart O O
from O O
headaches O O
in O O
one O O
patient O O
. O O

CONCLUSION O O
: O O
In O O
this O O
open O O
trial O O
, O O
galantamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
well O O
- O O
tolerated O O
and O O
appeared O O
to O O
be O O
beneficial O O
for O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism O O
, O O
particularly O O
aggression O O
, O O
behavioral O O
dyscontrol O O
, O O
and O O
inattention O O
. O O

Further O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controlled O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
warranted O O
. O O

Randomized O O
comparison O O
of O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
treatment O O
of O O
first O O
- O O
episode O O
schizophrenia O O
: O O
4 O O
- O O
month O O
outcomes O O
. O O

OBJECTIVE O O
: O O
The O O
authors O O
compared O O
4 O O
- O O
month O O
treatment O O
outcomes O O
for O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
first O O
- O O
episode O O
schizophrenia O O
spectrum O O
disorders O O
. O O

METHOD O O
: O O
One O O
hundred O O
twelve O O
subjects O O
( O O
70 O O
% O O
male O O
; O O
mean O O
age O O
= O O
23 O O
. O O
3 O O
years O O
[ O O
SD O O
= O O
5 O O
. O O
1 O O
] O O
) O O
with O O
first O O
- O O
episode O O
schizophrenia O O
( O O
75 O O
% O O
) O O
, O O
schizophreniform O O
disorder O O
( O O
17 O O
% O O
) O O
, O O
or O O
schizoaffective O O
disorder O O
( O O
8 O O
% O O
) O O
were O O
randomly O O
assigned O O
to O O
treatment O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
. O O
5 O O
- O O
20 O O
mg O O
/ O O
day O O
) O O
or O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
- O O
6 O O
mg O O
/ O O
day O O
) O O
. O O

RESULTS O O
: O O
Response O O
rates O O
did O O
not O O
significantly O O
differ O O
between O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
43 O O
. O O
7 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
28 O O
. O O
8 O O
% O O
- O O
58 O O
. O O
6 O O
% O O
) O O
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
54 O O
. O O
3 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
39 O O
. O O
9 O O
% O O
- O O
68 O O
. O O
7 O O
% O O
) O O
. O O

Among O O
those O O
responding O O
to O O
treatment O O
, O O
more O O
subjects O O
in O O
the O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
( O O
40 O O
. O O
9 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
16 O O
. O O
8 O O
% O O
- O O
65 O O
. O O
0 O O
% O O
) O O
than O O
in O O
the O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
( O O
18 O O
. O O
9 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
0 O O
% O O
- O O
39 O O
. O O
2 O O
% O O
) O O
had O O
subsequent O O
ratings O O
not O O
meeting O O
response O O
criteria O O
. O O

Negative O B_DISEASE_ADJECTIVE[DISEASE]
symptom O I_DISEASE_ADJECTIVE[DISEASE]
outcomes O I_DISEASE_ADJECTIVE[DISEASE]
and O O
measures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
parkinsonism O B_DISEASE
and O O
akathisia O B_DISEASE
did O O
not O O
differ O O
between O O
medications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Extrapyramidal O O
symptom O O
severity O O
scores O O
were O O
1 O O
. O O
4 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
2 O O
- O O
1 O O
. O O
6 O O
) O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O O
. O O
2 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
0 O O
- O O
1 O O
. O O
4 O O
) O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Significantly O O
more O O
weight O O
gain O O
occurred O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
the O O
increase O O
in O O
weight O O
at O O
4 O O
months O O
relative O O
to O O
baseline O O
weight O O
was O O
17 O O
. O O
3 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
14 O O
. O O
2 O O
% O O
- O O
20 O O
. O O
5 O O
% O O
) O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
11 O O
. O O
3 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
8 O O
. O O
4 O O
% O O
- O O
14 O O
. O O
3 O O
% O O
) O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Body O O
mass O O
index O O
at O O
baseline O O
and O O
at O O
4 O O
months O O
was O O
24 O O
. O O
3 O O
( O O
95 O O
% O O
CI O O
= O O
22 O O
. O O
8 O O
- O O
25 O O
. O O
7 O O
) O O
versus O O
28 O O
. O O
2 O O
( O O
95 O O
% O O
CI O O
= O O
26 O O
. O O
7 O O
- O O
29 O O
. O O
7 O O
) O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
23 O O
. O O
9 O O
( O O
95 O O
% O O
CI O O
= O O
22 O O
. O O
5 O O
- O O
25 O O
. O O
3 O O
) O O
versus O O
26 O O
. O O
7 O O
( O O
95 O O
% O O
CI O O
= O O
25 O O
. O O
2 O O
- O O
28 O O
. O O
2 O O
) O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Clinical O O
outcomes O O
with O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
equal O O
to O O
those O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
response O O
may O O
be O O
more O O
stable O O
. O O

Olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
have O O
an O O
advantage O O
for O O
motor O O
side O O
effects O O
. O O

Both O O
medications O O
caused O O
substantial O O
rapid O O
weight O O
gain O O
, O O
but O O
weight O O
gain O O
was O O
greater O O
with O O
olanzapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Early O O
paracentral O O
visual O O
field O O
loss O O
in O O
patients O O
taking O O
hydroxychloroquine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

OBJECTIVE O O
: O O
To O O
review O O
the O O
natural O O
history O O
and O O
ocular O O
and O O
systemic O O
adverse O O
effects O O
of O O
patients O O
taking O O
hydroxychloroquine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
who O O
attended O O
an O O
ophthalmic O O
screening O O
program O O
. O O

DESIGN O B_PERSON/B_NUMBER[MEASURE]
: O O
Retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

RESULTS O O
: O O
Records O O
of O O
262 O O
patients O O
who O O
were O O
taking O O
hydroxychloroquine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
screened O O
in O O
the O O
Department O O
of O O
Ophthalmology O O
were O O
reviewed O O
. O O

Of O O
the O O
262 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
14 O B_MEASURE
( O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
76 O B_NUMBER[MEASURE]/B_PERSON
who O O
had O O
stopped O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experienced O O
documented O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Systemic O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
occurred O O
in O O
8 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
10 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
and O O
ocular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adverse O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
effects O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
in O O
5 O B_NUMBER[MEASURE]
( O O
6 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
. O O

Thirty O O
- O O
five O O
patients O O
( O O
13 O O
. O O
4 O O
% O O
) O O
had O O
visual O O
field O O
abnormalities O O
, O O
which O O
were O O
attributed O O
to O O
hydroxychloroquine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O O
in O O
4 O O
patients O O
( O O
1 O O
. O O
5 O O
% O O
) O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
4 O B_PERSON
patients O I_PERSON
were O O
taking O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
6 O B_MEASURE
. O O
5 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_MEASURE
per O O
day O B_TIME[MEASURE]/B_PERSON
and O O
all O O
patients O B_PERSON/B_NUMBER[MEASURE]
had O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
renal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
liver O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
test O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
results O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
used O O
a O O
protocol O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
visual O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
color O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vision O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
funduscopy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
Humphrey O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
2 O B_MEASURE
visual O I_MEASURE
field O I_MEASURE
testing O I_MEASURE
and O O
shows O O
that O O
visual O B_DISEASE_ADJECTIVE[DISEASE]
field O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
appeared O O
before O O
any O O
corresponding O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
any O O
other O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
tested O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O O
the O O
defects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O O
taking O O
hydroxychloroquine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
demonstrate O O
a O O
toxic O O
reaction O O
in O O
the O O
retina O O
despite O O
the O O
absence O O
of O O
known O O
risk O O
factors O O
. O O

Screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
Humphrey O B_MEASURE/B_LOCATION
10 O B_MEASURE/I_LOCATION
- O O
2 O B_MEASURE
visual O I_MEASURE
field O I_MEASURE
assessment O I_MEASURE
, O O
is O O
recommended O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
after O O
the O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
baseline O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
yearly O O
thereafter O O
. O O

Peri O O
- O O
operative O O
atrioventricular O O
block O O
as O O
a O O
result O O
of O O
chemotherapy O O
with O O
epirubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
47 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
woman O I_PERSON
presented O O
for O O
mastectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
latissimus O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dorsi O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flap O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reconstruction O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
having O O
been O O
diagnosed O O
with O O
carcinoma O B_DISEASE/B_GENE
of O O
the O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
6 O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
months O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
previously O O
. O O

In O O
the O O
preceding O O
months O O
she O O
had O O
received O O
neo O O
- O O
adjuvant O O
chemotherapy O O
with O O
epirubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Taxol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
had O O
been O O
apparently O O
uncomplicated O B_DISEASE_ADJECTIVE[DISEASE]
and O O
she O O
had O O
maintained O O
a O O
remarkably O O
high O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
of O O
physical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

She O O
was O O
found O O
to O O
be O O
bradycardic O B_DISEASE_ADJECTIVE[DISEASE]
at O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
but O O
had O O
no O O
cardiac O B_DISEASE
symptoms O I_DISEASE
. O O

Second O B_PERSON
degree O I_PERSON
Mobitz O I_PERSON
type O I_PERSON
II O I_PERSON
atrioventricular O I_PERSON
block O I_PERSON
was O O
diagnosed O O
on O O
electrocardiogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
temporary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transvenous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instituted O O
in O O
the O O
peri O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

We O O
discuss O O
how O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
guidelines O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
would O O
not O O
have O O
been O O
helpful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
how O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
can O O
exhibit O O
substantial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O O
may O O
develop O O
over O O
many O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

We O O
suggest O O
that O O
patients O B_PERSON
who O O
have O O
received O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
any O O
time O B_MEASURE/B_LOCATION
should O O
have O O
a O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
operative O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrocardiogram O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O O
if O O
they O O
are O O
asymptomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

Risks O O
and O O
benefits O O
of O O
COX B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DISEASE_ADJECTIVE[DISEASE]
vs O O
non O O
- O O
selective O O
NSAIDs O O
: O O
does O O
their O O
cardiovascular O O
risk O O
exceed O O
their O O
gastrointestinal O O
benefit O O
? O O

A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

OBJECTIVES O O
: O O
The O O
risk O O
of O O
acute O O
myocardial O O
infarction O O
( O O
AMI O O
) O O
with O O
COX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
offset O O
their O O
gastrointestinal O O
( O O
GI O O
) O O
benefit O O
compared O O
with O O
non O O
- O O
selective O O
( O O
NS O O
) O O
non B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroidal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NSAIDs O O
) O O
. O O

We O O
aimed O O
to O O
compare O O
the O O
risks O O
of O O
hospitalization O O
for O O
AMI O O
and O O
GI O O
bleeding O O
among O O
elderly O O
patients O O
using O O
COX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
NS O O
- O O
NSAIDs O O
and O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O O
: O O
We O O
conducted O O
a O O
retrospective O O
cohort O O
study O O
using O O
administrative O O
data O O
of O O
patients O O
> O O
or O O
= O O
65 O O
years O O
of O O
age O O
who O O
filled O O
a O O
prescription O O
for O O
NSAID O O
or O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
1999 O O
- O O
2002 O O
. O O

Outcomes O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
using O O
Cox O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
time O B_MEASURE/B_LOCATION
- O O
dependent O B_MEASURE
exposures O I_MEASURE
. O O

RESULTS O O
: O O
Person O O
- O O
years O O
of O O
exposure O O
among O O
non O O
- O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
: O O
75 O O
, O O
761 O O
to O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
42 O O
, O O
671 O O
to O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
65 O O
, O O
860 O O
to O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
37 O O
, O O
495 O O
to O O
NS O O
- O O
NSAIDs O O
. O O

Among O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
they O O
were O O
: O O
14 O O
, O O
671 O O
to O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
22 O O
, O O
875 O O
to O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
9 O O
, O O
832 O O
to O O
NS O O
- O O
NSAIDs O O
and O O
38 O O
, O O
048 O O
to O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Among O O
non O O
- O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
adjusted O O
hazard O O
ratios O O
( O O
95 O O
% O O
confidence O O
interval O O
) O O
of O O
hospitalization O O
for O O
AMI O O
/ O O
GI O O
vs O O
the O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
with O O
no O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
group O O
were O O
: O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
27 O O
( O O
1 O O
. O O
13 O O
, O O
1 O O
. O O
42 O O
) O O
, O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
93 O O
( O O
0 O O
. O O
83 O O
, O O
1 O O
. O O
03 O O
) O O
, O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
59 O O
( O O
1 O O
. O O
31 O O
, O O
1 O O
. O O
93 O O
) O O
, O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
17 O O
( O O
0 O O
. O O
99 O O
, O O
1 O O
. O O
38 O O
) O O
and O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
05 O O
( O O
0 O O
. O O
74 O O
, O O
1 O O
. O O
51 O O
) O O
. O O

Among O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
they O O
were O O
: O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
73 O O
( O O
1 O O
. O O
52 O O
, O O
1 O O
. O O
98 O O
) O O
, O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
34 O O
( O O
1 O O
. O O
19 O O
, O O
1 O O
. O O
52 O O
) O O
, O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
51 O O
( O O
0 O O
. O O
95 O O
, O O
2 O O
. O O
41 O O
) O O
, O O
diclofenac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
69 O O
( O O
1 O O
. O O
35 O O
, O O
2 O O
. O O
10 O O
) O O
, O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
35 O O
( O O
0 O O
. O O
97 O O
, O O
1 O O
. O O
88 O O
) O O
and O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
. O O
29 O O
( O O
1 O O
. O O
17 O O
, O O
1 O O
. O O
42 O O
) O O
. O O

CONCLUSION O O
: O O
Among O O
non O O
- O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
seemed O O
to O O
carry O O
the O O
highest O O
risk O O
for O O
AMI O O
/ O O
GI O O
bleeding O O
. O O

The O O
AMI O O
/ O O
GI O O
toxicity O O
of O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
similar O O
to O O
that O O
of O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
seemed O O
to O O
be O O
better O O
than O O
those O O
of O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
NS O O
- O O
NSAIDs O O
. O O

Among O O
users O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
celecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seemed O O
to O O
be O O
the O O
least O O
toxic O O
. O O

Quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
arrhythmia O O
in O O
a O O
patient O O
with O O
severe O O
malaria O O
. O O

It O O
was O O
reported O O
that O O
there O O
was O O
a O O
case O O
of O O
severe O O
malaria O O
patient O O
with O O
jaundice O O
who O O
presented O O
with O O
arrhythmia O O
( O O
premature O O
ventricular O O
contraction O O
) O O
while O O
getting O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O O
was O O
reported O O
. O O

A O O
man O B_PERSON
, O O
25 O B_ENT/B_PERSON
years O B_ENT/I_PERSON
old O B_ENT/I_PERSON
, O O
was O O
admitted O O
to O O
hospital O B_LOCATION
with O O
high O B_DISEASE
fever O I_DISEASE
, O O
chill O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
vomiting O B_DISEASE
, O O
jaundice O B_DISEASE
. O O

The O O
patient O B_PERSON
was O O
fully O O
conscious O B_PERSON
, O O
blood O B_MEASURE
pressure O I_MEASURE
120 O I_MEASURE
/ O O
80 O B_MEASURE
mmHg O I_MEASURE
, O O
pulse O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
100 O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
x O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
/ O O
minute O B_MEASURE
, O O
regular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

On O O
admission O O
, O O
laboratory O O
examination O O
showed O O
Plasmodium O O
falciparum O O
( O O
+ O O
+ O O
+ O O
+ O O
) O O
, O O
total O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
8 O O
. O O
25 O O
mg O O
/ O O
dL O O
, O O
conjugated O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 O O
. O O
36 O O
mg O O
/ O O
dL O O
, O O
unconjugated O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O O
. O O
89 O O
mg O O
/ O O
dL O O
, O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O O
. O O
52 O O
meq O O
/ O O
L O O
Patient O O
was O O
diagnosed O O
as O O
severe O O
malaria O O
with O O
jaundice O O
and O O
got O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O O
in O O
dextrose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O O
% O O
500 O O
mg O O
/ O O
8 O O
hour O O
. O O

On O O
the O O
second O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
the O O
patient O B_PERSON
had O O
vomitus O O
, O O
diarrhea O B_DISEASE
, O O
tinnitus O B_DISEASE
, O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
hearing O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

After O O
30 O O
hours O O
of O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O O
the O O
patient O O
felt O O
palpitation O O
and O O
electrocardiography O O
( O O
ECG O O
) O O
recording O O
showed O O
premature O O
ventricular O O
contraction O O
( O O
PVC O O
) O O
> O O
5 O O
x O O
/ O O
minute O O
, O O
trigemini O O
, O O
constant O O
type O O
- O O
- O O
sinoatrial O O
block O O
, O O
positive O O
U O O
wave O O
. O O

He O O
was O O
treated O O
with O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
mg O O
intravenously O O
followed O O
by O O
infusion O O
1500 O O
mg O O
in O O
dextrose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O O
% O O
/ O O
24 O O
hour O O
and O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tablet O O
. O O

Quinine B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
was O O
discontinued O O
and O O
changed O O
with O O
sulfate O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tablets O O
. O O

Three O O
hours O O
later O O
the O O
patient O O
felt O O
better O O
, O O
the O O
frequency O O
of O O
PVC O O
reduced O O
to O O
4 O O
- O O
5 O O
x O O
/ O O
minute O O
and O O
on O O
the O O
third O O
day O O
ECG O O
was O O
normal O O
, O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
was O O
3 O O
. O O
34 O O
meq O O
/ O O
L O O
. O O

He O O
was O O
discharged O O
on O O
7th O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
day O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
good O B_TIME[MEASURE]/B_PERSON
condition O I_TIME[MEASURE]/I_PERSON
. O O

Quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
like O O
quinidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
a O O
chincona O O
alkaloid O O
that O O
has O O
anti O O
- O O
arrhythmic O O
property O O
, O O
although O O
it O O
also O O
pro O O
- O O
arrhythmic O O
that O O
can O O
cause O O
various O O
arrhythmias O O
, O O
including O O
severe O O
arrhythmia O O
such O O
as O O
multiple O O
PVC O O
. O O

Administration O O
of O O
parenteral O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
must O O
be O O
done O O
carefully O O
and O O
with O O
good O O
observation O O
because O O
of O O
its O O
pro O O
- O O
arrhythmic O O
effect O O
, O O
especially O O
in O O
older O O
patients O O
who O O
have O O
heart O O
diseases O O
or O O
patients O O
with O O
electrolyte O O
disorder O O
( O O
hypokalemia O O
) O O
which O O
frequently O O
occurs O O
due O O
to O O
vomiting O O
and O O
or O O
diarrhea O O
in O O
malaria O O
cases O O
. O O

Penicillamine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
lichenoid O O
dermatitis O O
and O O
utility O O
of O O
zinc B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
Wilson O O
disease O O
patient O O
with O O
hepatic O O
presentation O O
, O O
anxiety O O
and O O
SPECT O O
abnormalities O O
. O O

Wilson O O
' O O
s O O
disease O O
is O O
an O O
autosomal O O
recessive O O
disorder O O
of O O
hepatic O O
copper B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O O
with O O
consequent O O
copper B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
accumulation O O
and O O
toxicity O O
in O O
many O O
tissues O O
and O O
consequent O O
hepatic O O
, O O
neurologic O O
and O O
psychiatric O O
disorders O O
. O O

We O O
report O O
a O O
case O B_PERSON/B_MEASURE
of O O
Wilson O B_PERSON
' O I_PERSON
s O I_PERSON
disease O I_PERSON
with O O
chronic O B_DISEASE
liver O I_DISEASE
disease O I_DISEASE
; O O
moreover O O
, O O
in O O
our O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
presenting O O
also O O
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
of O O
state O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anxiety O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
depression O B_DISEASE
, O O
99mTc O B_LOCATION
- O O
ECD O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
SPECT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
showed O O
cortical O B_DISEASE_ADJECTIVE[DISEASE]
hypoperfusion O I_DISEASE_ADJECTIVE[DISEASE]
in O O
frontal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lobes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
more O O
marked O O
on O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
frontal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lobe O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

During O O
the O O
follow O O
- O O
up O O
of O O
our O O
patient O O
, O O
penicillamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
interrupted O O
after O O
the O O
appearance O O
of O O
a O O
lichenoid O O
dermatitis O O
, O O
and O O
zinc B B_LOCATION
acetate I I_LOCATION
permitted O O
to O O
continue O O
the O O
successful O O
treatment O O
of O O
the O O
patient O O
without O O
side O O
- O O
effects O O
. O O

In O O
our O O
case O O
the O O
therapy O O
with O O
zinc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
represented O O
an O O
effective O O
treatment O O
for O O
a O O
Wilson O O
' O O
s O O
disease O O
patient O O
in O O
which O O
penicillamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
related O O
side O O
effects O O
appeared O O
. O O

The O O
safety O O
of O O
the O O
zinc B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
allowed O O
us O O
to O O
avoid O O
other O O
potentially O O
toxic O O
chelating O O
drugs O O
; O O
this O O
observation O O
is O O
in O O
line O O
with O O
the O O
growing O O
evidence O O
on O O
the O O
efficacy O O
of O O
the O O
drug O O
in O O
the O O
treatment O O
of O O
Wilson O O
' O O
s O O
disease O O
. O O

Since O O
most O O
of O O
Wilson O O
' O O
s O O
disease O O
penicillamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
patients O O
do O O
not O O
seem O O
to O O
develop O O
this O O
skin O O
lesion O O
, O O
it O O
could O O
be O O
conceivable O O
that O O
a O O
specific O O
genetic O O
factor O O
is O O
involved O O
in O O
drug O O
response O O
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
for O O
a O O
better O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clarification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Wilson O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
in O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
differentiate O O
specific O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O O
different O B_DISEASE/B_PERSON
Wilson O I_DISEASE/I_PERSON
' O I_DISEASE/I_PERSON
s O I_DISEASE/I_PERSON
disease O I_DISEASE/I_PERSON
phenotypes O I_DISEASE/I_PERSON
. O O

A O O
dramatic O O
drop O O
in O O
blood O O
pressure O O
following O O
prehospital O O
GTN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
. O O

A O O
male O B_PERSON
in O O
his O O
sixties O B_TIME[MEASURE]/B_LOCATION
with O O
no O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chest O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
awoke O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
chest O B_DISEASE
pain O I_DISEASE
following O O
an O O
afternoon O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sleep O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
did O O
not O O
self O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medicate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
patient O O
' O O
s O O
observations O O
were O O
within O O
normal O O
limits O O
, O O
he O O
was O O
administered O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
a O O
face O O
mask O O
and O O
glyceryl B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
trinitrate I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
GTN B B_DISEASE/B_LOCATION
) O O
. O O

Several O O
minutes O O
after O O
the O O
GTN B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
the O O
patient O O
experienced O O
a O O
sudden O O
drop O O
in O O
blood O O
pressure O O
and O O
heart O O
rate O O
, O O
this O O
was O O
rectified O O
by O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
fluid O O
challenge O O
. O O

There O O
was O O
no O O
further O B_DISEASE_ADJECTIVE[DISEASE]
deterioration O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
patient O B_PERSON
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
condition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O O
transport O B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
hospital O B_LOCATION
. O O

There O O
are O O
very O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
documented O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
like O O
this O O
in O O
the O O
prehospital O B_LOCATION
scientific O I_LOCATION
literature O I_LOCATION
. O O

The O O
cause O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
the O O
Bezold O B_PERSON/B_LOCATION
- O O
Jarish O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflex O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
stimulation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
walls O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outflow O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
vasomotor O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centre O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Prehospital O B_PERSON
care O I_PERSON
providers O I_PERSON
who O O
are O O
managing O O
any O O
patient O B_PERSON/B_DISEASE
with O O
a O O
syncopal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episode O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O O
fails O O
to O O
recover O O
within O O
a O O
reasonable O B_TIME[MEASURE]
time O I_TIME[MEASURE]
frame O I_TIME[MEASURE]
should O O
consider O O
the O O
Bezold O B_PERSON
- O O
Jarisch O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
reflex O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O O
the O O
cause O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
manage O O
the O O
patient O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accordingly O O
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
rostral O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
ventrolateral O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
medulla O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
in O O
spontaneously O O
hypertensive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
studied O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selective O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuronal O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
rostral O B_LOCATION/B_DISEASE
ventrolateral O B_LOCATION/I_DISEASE
medulla O B_LOCATION/I_DISEASE
on O O
mean O B_DISEASE/B_GENE
arterial O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
, O O
heart O B_DISEASE
rate O I_DISEASE
, O O
and O O
neurogenic O B_DISEASE
tone O I_DISEASE
in O O
conscious O B_PERSON
, O O
unrestrained O O
spontaneously O O
hypertensive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
lesions O O
were O O
placed O O
via O O
bilateral O O
microinjections O O
of O O
30 O O
nmol O O
/ O O
200 O O
nl O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
restimulation O O
of O O
this O O
area O O
with O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
15 O O
days O O
postlesion O O
failed O O
to O O
produce O O
a O O
pressor O O
response O O
. O O

One O B_MEASURE/B_ENT
day O I_MEASURE/I_ENT
postlesion O I_MEASURE/I_ENT
, O O
the O O
resting O B_DISEASE/B_GENE
mean O B_DISEASE/I_GENE
arterial O B_DISEASE/I_GENE
pressure O B_DISEASE/I_GENE
was O O
significantly O O
decreased O O
in O O
lesioned O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O O
compared O O
with O O
sham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
100 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
versus O I_MEASURE
173 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
, O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Fifteen O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
, O O
the O O
lesioned O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O O
showed O O
values O B_MEASURE/B_DISEASE
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
sham O B_PERSON/B_MEASURE
group O B_PERSON/I_MEASURE
( O O
150 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
versus O I_MEASURE
167 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
, O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

No O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
between O O
the O O
sham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
lesioned O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
ganglionic O O
blocker O O
trimethaphan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
/ O O
kg O O
i O O
. O O
v O O
. O O
) O O
caused O O
similar O O
reductions O O
in O O
mean O O
arterial O O
pressure O O
in O O
both O O
lesioned O O
and O O
sham O O
groups O O
. O O

The O O
trimethaphan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypotension O O
was O O
accompanied O O
by O O
a O O
significant O O
bradycardia O O
in O O
lesioned O O
rats O O
( O O
- O O
32 O O
+ O O
/ O O
- O O
13 O O
beats O O
per O O
minute O O
) O O
but O O
a O O
tachycardia O O
in O O
sham O O
rats O O
( O O
+ O O
33 O O
+ O O
/ O O
- O O
12 O O
beats O O
per O O
minute O O
) O O
1 O O
day O O
postlesion O O
. O O

Therefore O O
, O O
rostral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventrolateral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medulla O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
to O O
play O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
role O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
maintaining O O
hypertension O B_DISEASE/B_GENE
in O O
conscious O B_PERSON/B_NUMBER[MEASURE]
spontaneously O O
hypertensive O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
suprabulbar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
gradual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
hypertension O B_DISEASE
in O O
the O O
lesioned O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acute O O
encephalopathy O O
and O O
cerebral O O
vasospasm O O
after O O
multiagent O O
chemotherapy O O
including O O
PEG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asparaginase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intrathecal O O
cytarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
treatment O O
of O O
acute O O
lymphoblastic O O
leukemia O O
. O O

A O O
7 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
girl O I_PERSON
with O O
an O O
unusual O B_DISEASE
reaction O I_DISEASE
to O O
induction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
precursor O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
B O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- O O
cell O B_DISEASE
acute O I_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
( O O
ALL O B_DISEASE
) O O
is O O
described O O
. O O

The O O
patient O O
developed O O
acute O O
encephalopathy O O
evidenced O O
by O O
behavioral O O
changes O O
, O O
aphasia O O
, O O
incontinence O O
, O O
visual O O
hallucinations O O
, O O
and O O
right O O
- O O
sided O O
weakness O O
with O O
diffuse O O
cerebral O O
vasospasm O O
on O O
magnetic O O
resonance O O
angiography O O
after O O
the O O
administration O O
of O O
intrathecal O O
cytarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
polyethylene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asparaginase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
administered O O
before O O
the O O
episode O O
as O O
part O O
of O O
induction O O
therapy O O
. O O

Neurologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
status O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O O
to O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
the O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
event O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
magnetic O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
angiography O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O O
to O O
normal O B_TIME[MEASURE]
4 O I_TIME[MEASURE]
months O I_TIME[MEASURE]
later O O
. O O

Comparison O O
of O O
valsartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
hydrochlorothiazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O O
therapy O O
at O O
doses O O
up O O
to O O
320 O O
/ O O
25 O O
mg O O
versus O O
monotherapy O O
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
followed O O
by O O
long O O
- O O
term O O
combination O O
therapy O O
in O O
hypertensive O O
adults O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
One O B_MEASURE/B_PERSON
third O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_BIO
treated O O
for O O
hypertension O B_DISEASE
attain O O
adequate O B_DISEASE
blood O I_DISEASE
pressure O I_DISEASE
( O O
BP O B_PROTEIN[GENE]/B_DISEASE
) O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
multidrug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimens O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
often O O
required O O
. O O

Given O O
the O O
lifelong O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
there O O
is O O
a O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
to O O
evaluate O O
the O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
tolerability O B_DISEASE_ADJECTIVE[DISEASE]
of O O
higher O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
hypertensive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapies O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
This O O
study O O
investigated O O
the O O
efficacy O O
and O O
tolerability O O
of O O
valsartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VAL B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
hydrochlorothiazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HCTZ B B_LOCATION/B_ORGANIZATION
) O O
- O O
monotherapy O O
and O O
higher O O
- O O
dose O O
combinations O O
in O O
patients O O
with O O
essential O O
hypertension O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
part O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
an O O
8 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_PERSON
, O O
multicenter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlled O O
, O O
parallel O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Patients O O
with O O
essential O O
hypertension O O
( O O
mean O O
sitting O O
diastolic O O
BP O O
[ O O
MSDBP O O
] O O
, O O
> O O
or O O
= O O
95 O O
mm O O
Hg O O
and O O
< O O
110 O O
mm O O
Hg O O
) O O
were O O
randomized O O
to O O
1 O O
of O O
8 O O
treatment O O
groups O O
: O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
160 O O
or O O
320 O O
mg O O
; O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 O O
. O O
5 O O
or O O
25 O O
mg O O
; O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
160 O O
/ O O
12 O O
. O O
5 O O
, O O
320 O O
/ O O
12 O O
. O O
5 O O
, O O
or O O
320 O O
/ O O
25 O O
mg O O
; O O
or O O
placebo O O
. O O

Mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MSDBP O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
mean O O
sitting O O
systolic O B_MEASURE/B_LOCATION
BP O I_MEASURE/I_LOCATION
( O O
MSSBP O B_DISEASE/B_LOCATION
) O O
were O O
analyzed O O
at O O
the O O
8 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_LOCATION
core O I_TIME[MEASURE]/I_LOCATION
study O I_TIME[MEASURE]/I_LOCATION
end O I_TIME[MEASURE]/I_LOCATION
point O I_TIME[MEASURE]/I_LOCATION
. O O

VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HCTZ B B_MEASURE/B_PROTEIN[GENE]
320 O O
/ O O
12 O O
. O O
5 O O
and O O
320 O O
/ O O
25 O O
mg O O
were O O
further O O
investigated O O
in O O
a O O
54 O O
- O O
week O O
, O O
open O O
- O O
label O O
extension O O
. O O

Response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
defined O O
as O O
MSDBP O B_DISEASE/B_LOCATION
< O O
90 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
Hg O I_MEASURE/I_LOCATION
or O O
a O O
> O B_MEASURE
or O O
= O O
10 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
decrease O I_MEASURE
compared O O
to O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
defined O O
as O O
MSDBP O B_DISEASE/B_MEASURE
< O O
90 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
compared O O
with O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Tolerability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
assessed O O
by O O
monitoring O O
adverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
events O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
randomization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
all O O
subsequent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visits O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
regular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hematology O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
blood O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemistry O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
1346 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
were O O
randomized O O
into O O
the O O
8 O B_NUMBER[MEASURE]
- O O
week O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
core O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
734 O B_MEASURE/B_PERSON
men O I_MEASURE/I_PERSON
, O O
612 O B_MEASURE/B_PERSON
women O I_MEASURE/I_PERSON
; O O
924 O B_MEASURE/B_PERSON
white O I_MEASURE/I_PERSON
, O O
291 O B_PERSON/B_COLOR
black O I_PERSON/I_COLOR
, O O
23 O B_MEASURE/B_PERSON
Asian O I_MEASURE/I_PERSON
, O O
108 O B_MEASURE/B_PERSON
other O I_MEASURE/I_PERSON
; O O
mean O O
age O B_TIME[MEASURE]/B_PERSON
, O O
52 O B_MEASURE
. O O
7 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
; O O
mean O B_MEASURE/B_PERSON
weight O I_MEASURE/I_PERSON
, O O
92 O B_MEASURE
. O O
6 O B_MEASURE
kg O I_MEASURE
) O O
. O O

All O O
active O O
treatments O O
were O O
associated O O
with O O
significantly O O
reduced O O
MSSBP O O
and O O
MSDBP O O
during O O
the O O
core O O
8 O O
- O O
week O O
study O O
, O O
with O O
each O O
monotherapy O O
significantly O O
contributing O O
to O O
the O O
overall O O
effect O O
of O O
combination O O
therapy O O
( O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
HCTZ B B_LOCATION
, O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Each O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
associated O O
with O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
MSSBP O B_DISEASE/B_GENE
and O O
MSDBP O B_DISEASE/B_GENE
compared O O
with O O
the O O
monotherapies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
all O O
, O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
mean O O
reduction O O
in O O
MSSBP O O
/ O O
MSDBP O O
with O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
HCTZ B B_MEASURE/B_PROTEIN[GENE]
320 O O
/ O O
25 O O
mg O O
was O O
24 O O
. O O
7 O O
/ O O
16 O O
. O O
6 O O
mm O O
Hg O O
, O O
compared O O
with O O
5 O O
. O O
9 O O
/ O O
7 O O
. O O
0 O O
mm O O
Hg O O
with O O
placebo O O
. O O

The O O
reduction O O
in O O
MSSBP O O
was O O
significantly O O
greater O O
with O O
VAL B B_LOCATION/B_ORGANIZATION
/ O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 O O
/ O O
25 O O
mg O O
compared O O
with O O
VAL B B_LOCATION/B_ORGANIZATION
/ O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
160 O O
/ O O
12 O O
. O O
5 O O
mg O O
( O O
P O O
< O O
0 O O
. O O
002 O O
) O O
. O O

Rates O B_MEASURE
of O O
response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
groups O B_ORGANIZATION/B_PERSON
that O O
received O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compared O O
with O O
those O O
that O O
received O O
monotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
incidence O O
of O O
hypokalemia O O
was O O
lower O O
with O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
HCTZ B B_LOCATION
combinations O O
( O O
1 O O
. O O
8 O O
% O O
- O O
6 O O
. O O
1 O O
% O O
) O O
than O O
with O O
HCTZ B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monotherapies O O
( O O
7 O O
. O O
1 O O
% O O
- O O
13 O O
. O O
3 O O
% O O
) O O
. O O

The O O
majority O B_MEASURE
of O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
core O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
of O O
mild O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
severity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
efficacy O O
and O O
tolerability O O
of O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
HCTZ B B_LOCATION
combinations O O
were O O
maintained O O
during O O
the O O
extension O O
( O O
797 O O
patients O O
) O O
. O O

CONCLUSIONS O O
: O O
In O O
this O O
study O O
population O O
, O O
combination O O
therapies O O
with O O
VAL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
HCTZ B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
associated O O
with O O
significantly O O
greater O O
BP O O
reductions O O
compared O O
with O O
either O O
monotherapy O O
, O O
were O O
well O O
tolerated O O
, O O
and O O
were O O
associated O O
with O O
less O O
hypokalemia O O
than O O
HCTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alone O O
. O O

Succimer B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
chelation O O
improves O O
learning O O
, O O
attention O O
, O O
and O O
arousal O O
regulation O O
in O O
lead B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
exposed O O
rats O O
but O O
produces O O
lasting O O
cognitive O O
impairment O O
in O O
the O O
absence O O
of O O
lead B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
. O O

BACKGROUND O O
: O O
There O O
is O O
growing O O
pressure O O
for O O
clinicians O O
to O O
prescribe O O
chelation O O
therapy O O
at O O
only O O
slightly O O
elevated O O
blood O O
lead B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
. O O

However O O
, O O
very O O
few O O
studies O O
have O O
evaluated O O
whether O O
chelation O O
improves O O
cognitive O O
outcomes O O
in O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
children O O
, O O
or O O
whether O O
these O O
agents O O
have O O
adverse O O
effects O O
that O O
may O O
affect O O
brain O O
development O O
in O O
the O O
absence O O
of O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
was O O
designed O O
to O O
answer O O
these O O
questions O O
, O O
using O O
a O O
rodent O O
model O O
of O O
early O O
childhood O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O O
and O O
treatment O O
with O O
succimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
a O O
widely O O
used O O
chelating O O
agent O O
for O O
the O O
treatment O O
of O O
Pb O O
poisoning O O
. O O

RESULTS O O
: O O
Pb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O O
produced O O
lasting O O
impairments O O
in O O
learning O O
, O O
attention O O
, O O
inhibitory O O
control O O
, O O
and O O
arousal O O
regulation O O
, O O
paralleling O O
the O O
areas O O
of O O
dysfunction O O
seen O O
in O O
Pb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
children O O
. O O

Succimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O O
of O O
the O O
Pb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
rats O O
significantly O O
improved O O
learning O O
, O O
attention O O
, O O
and O O
arousal O O
regulation O O
, O O
although O O
the O O
efficacy O O
of O O
the O O
treatment O O
varied O O
as O O
a O O
function O O
of O O
the O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exposure O O
level O O
and O O
the O O
specific O O
functional O O
deficit O O
. O O

In O O
contrast O O
, O O
succimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O O
of O O
rats O O
not O O
previously O O
exposed O O
to O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
produced O O
lasting O O
and O O
pervasive O O
cognitive O O
and O O
affective O O
dysfunction O O
comparable O O
in O O
magnitude O O
to O O
that O O
produced O O
by O O
the O O
higher O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exposure O O
regimen O O
. O O

CONCLUSIONS O O
: O O
These O O
are O O
the O O
first O O
data O O
, O O
to O O
our O O
knowledge O O
, O O
to O O
show O O
that O O
treatment O O
with O O
any O O
chelating O O
agent O O
can O O
alleviate O O
cognitive O O
deficits O O
due O O
to O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
. O O

These O O
findings O O
suggest O O
that O O
it O O
may O O
be O O
possible O O
to O O
identify O O
a O O
succimer B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
treatment O O
protocol O O
that O O
improves O O
cognitive O O
outcomes O O
in O O
Pb B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
children O O
. O O

However O O
, O O
they O O
also O O
suggest O O
that O O
succimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O O
should O O
be O O
strongly O O
discouraged O O
for O O
children O O
who O O
do O O
not O O
have O O
elevated O O
tissue O O
levels O O
of O O
Pb B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
other O O
heavy O O
metals O O
. O O

Caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O O
test O O
in O O
panic O O
disorder O O
and O O
depression O O
with O O
panic O O
attacks O O
. O O

Our O O
aim O O
was O O
to O O
observe O O
if O O
patients O O
with O O
panic O O
disorder O O
( O O
PD O O
) O O
and O O
patients O O
with O O
major O O
depression O O
with O O
panic O O
attacks O O
( O O
MDP O O
) O O
( O O
Diagnostic O O
and O O
Statistical O O
Manual O O
of O O
Mental O O
Disorders O O
, O O
Fourth O O
Edition O O
criteria O O
) O O
respond O O
in O O
a O O
similar O O
way O O
to O O
the O O
induction O O
of O O
panic O O
attacks O O
by O O
an O O
oral O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O O
test O O
. O O

We O O
randomly O O
selected O O
29 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
with O O
PD O B_DISEASE
, O O
27 O B_MEASURE
with O O
MDP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
25 O B_MEASURE
with O O
major O B_DISEASE
depression O I_DISEASE
without O O
panic O B_DISEASE
attacks O I_DISEASE
( O O
MD O B_DISEASE
) O O
, O O
and O O
28 O B_NUMBER[MEASURE]/B_PERSON
healthy O I_NUMBER[MEASURE]/I_PERSON
volunteers O I_NUMBER[MEASURE]/I_PERSON
. O O

The O O
patients O B_PERSON/B_LOCATION
had O O
no O O
psychotropic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O O
at O O
least O O
a O O
4 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

In O O
a O O
randomized O O
double O O
- O O
blind O O
experiment O O
performed O O
in O O
2 O O
occasions O O
7 O O
days O O
apart O O
, O O
480 O O
mg O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
free O O
( O O
placebo O O
) O O
solution O O
were O O
administered O O
in O O
a O O
coffee O O
form O O
and O O
anxiety O O
scales O O
were O O
applied O O
before O O
and O O
after O O
each O O
test O O
. O O

A O O
total O O
of O O
58 O O
. O O
6 O O
% O O
( O O
n O O
= O O
17 O O
) O O
of O O
patients O O
with O O
PD O O
, O O
44 O O
. O O
4 O O
% O O
( O O
n O O
= O O
12 O O
) O O
of O O
patients O O
with O O
MDP O O
, O O
12 O O
. O O
0 O O
% O O
( O O
n O O
= O O
3 O O
) O O
of O O
patients O O
with O O
MD O O
, O O
and O O
7 O O
. O O
1 O O
% O O
( O O
n O O
= O O
2 O O
) O O
of O O
control O O
subjects O O
had O O
a O O
panic O O
attack O O
after O O
the O O
480 O O
- O O
mg O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O O
test O O
( O O
chi O O
( O O
2 O O
) O O
( O O
3 O O
) O O
= O O
16 O O
. O O
22 O O
, O O
P O O
= O O
. O O
001 O O
) O O
. O O

The O O
patients O O
with O O
PD O O
and O O
MDP O O
were O O
more O O
sensitive O O
to O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
were O O
patients O O
with O O
MD O O
and O O
healthy O O
volunteers O O
. O O

No O O
panic O O
attack O O
was O O
observed O O
after O O
the O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
free O O
solution O O
intake O O
. O O

The O O
patients O B_PERSON/B_ORGANIZATION
with O O
MD O B_DISEASE/B_LOCATION
had O O
a O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
test O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O O
all O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
2 O B_NUMBER[MEASURE]
- O O
way O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
variance O B_TIME[MEASURE]/B_PERSON
, O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
time O B_MEASURE/B_ORGANIZATION
interaction O I_MEASURE/I_ORGANIZATION
with O O
Greenhouse O B_LOCATION/B_PERSON
- O O
Geisser O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
F O B_OTHER/B_LOCATION
( O O
3 O B_MEASURE
, O O
762 O B_MEASURE
) O O
= O O
2 O B_MEASURE
. O O
85 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
. O O
026 O B_MEASURE
) O O
. O O

Our O O
data O O
suggest O O
that O O
there O O
is O O
an O O
association O O
between O O
panic O O
attacks O O
, O O
no O O
matter O O
if O O
associated O O
with O O
PD O O
or O O
MDP O O
, O O
and O O
hyperreactivity O O
to O O
an O O
oral O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O O
test O O
. O O

Mitral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
annuloplasty O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
a O O
ventricular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
method O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
the O O
failing O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
pilot O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
AND O O
AIM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O O
THE O O
STUDY O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Undersized O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mitral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
annuloplasty O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MAP O B_LOCATION/B_ORGANIZATION
) O O
is O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON
with O O
dilated O B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy O I_DISEASE_ADJECTIVE[DISEASE]
and O O
functional O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regurgitation O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
MR O B_LOCATION
) O O
since O O
, O O
as O O
well O O
as O O
addressing O O
the O O
MR O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
the O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O O
also O O
reshape O O
the O O
dilated O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
LV O B_LOCATION
) O O
base O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

However O O
, O O
the O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefits O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reshaping O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
LV O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
absence O B_DISEASE/B_LOCATION
of O O
underlying O O
MR O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O O
incompletely O O
understood O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aim O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
identify O O
these O O
benefits O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
a O O
canine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
acute O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
. O O

METHODS O B_MEASURE
: O O
Six O B_ENT/B_PERSON
dogs O B_ENT/I_PERSON
underwent O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
a O O
prosthetic O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
band O I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
the O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitral O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
annulus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
using O O
four O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mattress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sutures O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
sutures O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
were O O
passed O O
individually O O
through O O
four O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPORT[ENT]
tourniquets O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_SPORT[ENT]
and O O
exteriorized O O
untied O O
via O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_PRODUCT[OBJECT]
atriotomy O I_BODY_PART_OR_ORGAN_COMPONENT/I_PRODUCT[OBJECT]
. O O

Sonomicrometry O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
crystals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
implanted O O
around O O
the O O
mitral O B_BODY_PART_OR_ORGAN_COMPONENT
annulus O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
left O O
ventricle O B_BODY_PART_OR_ORGAN_COMPONENT
to O O
measure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
geometry O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
regional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Acute O O
heart O O
failure O O
was O O
induced O O
by O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
volume O O
loading O O
after O O
weaning O O
from O O
cardiopulmonary O O
bypass O O
; O O
an O O
absence O O
of O O
MR O O
was O O
confirmed O O
by O O
echocardiography O O
. O O

MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
accomplished O O
by O O
cinching O O
the O O
tourniquets O B_LOCATION
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
acquired O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
after O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
acute O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
, O O
and O O
after O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O O
mitral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
annular O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dimensions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
both O O
commissure O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
commissure O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
septal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
lateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
directions O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Concomitantly O O
, O O
the O O
diastolic O B_MEASURE/B_LOCATION
diameter O I_MEASURE/I_LOCATION
of O O
the O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
base O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sphericity O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
( O O
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
, O O
improved O O
) O O
from O O
37 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
9 O B_MEASURE
. O O
3 O B_MEASURE
to O O
35 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_MEASURE
mm O I_MEASURE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
063 O B_MEASURE
) O O
, O O
and O O
from O O
67 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
to O O
65 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
016 O B_MEASURE
) O O
, O O
respectively O O
. O O

Decreases O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diastolic O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
( O O
from O O
17 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
to O O
15 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
0480 O B_MEASURE
and O O
Tau O B_PROTEIN[GENE]/B_DISEASE
( O O
from O O
48 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
to O O
45 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
ms O I_MEASURE
, O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
while O O
fractional O B_MEASURE/B_GENE
shortening O B_MEASURE/I_GENE
at O O
the O O
LV O B_MEASURE/B_PROTEIN[GENE]
base O B_MEASURE/I_PROTEIN[GENE]
increased O O
from O O
7 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
to O O
9 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_NUMBER[MEASURE]
. O O
045 O B_MEASURE
) O O
. O O

After O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
were O O
identified O O
in O O
both O O
cardiac O B_MEASURE/B_ORGANIZATION
output O B_MEASURE/I_ORGANIZATION
( O O
from O O
1 O B_MEASURE
. O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
57 O B_MEASURE
to O O
1 O B_MEASURE
. O O
65 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
57 O B_MEASURE/B_PERSON
1 O I_MEASURE/I_PERSON
/ O O
min O B_MEASURE/B_PERSON
) O O
and O O
Emax O B_DISEASE/B_GENE
( O O
from O O
1 O B_MEASURE
. O O
86 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
9 O B_MEASURE
to O O
2 O B_MEASURE
. O O
41 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
31 O B_MEASURE
mmHg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquired O O
suggest O O
that O O
isolated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MAP O B_LOCATION/B_BIO
may O O
have O O
certain O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
LV O B_MEASURE
dimension O I_MEASURE
/ O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
acute O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
, O O
even O O
in O O
the O O
absence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MR O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
warranted O O
in O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
chronic O B_DISEASE
heart O I_DISEASE
failure O I_DISEASE
. O O

Piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tazobactam I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
seizure O O
rapidly O O
reversed O O
by O O
high O O
flux O O
hemodialysis O O
in O O
a O O
patient O O
on O O
peritoneal O O
dialysis O O
. O O

Despite O O
popular O O
use O O
of O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
dire O O
neurotoxicity O O
associated O O
with O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
still O O
goes O O
unrecognized O O
, O O
leading O O
to O O
a O O
delay O O
in O O
appropriate O O
management O O
. O O

We O O
report O O
a O O
57 O O
- O O
year O O
- O O
old O O
woman O O
with O O
end O O
- O O
stage O O
renal O O
disease O O
receiving O O
continuous O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
CAPD O O
) O O
, O O
who O O
developed O O
slurred O O
speech O O
, O O
tremor O O
, O O
bizarre O O
behavior O O
, O O
progressive O O
mental O O
confusion O O
, O O
and O O
2 O O
episodes O O
of O O
generalized O O
tonic O O
- O O
clonic O O
seizure O O
( O O
GTCS O O
) O O
after O O
5 O O
doses O O
of O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tazobactam I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
g O O
/ O O
250 O O
mg O O
) O O
were O O
given O O
for O O
bronchiectasis O O
with O O
secondary O O
infection O O
. O O

The O O
laboratory O O
data O O
revealed O O
normal O O
plasma O O
electrolyte O O
and O O
ammonia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
but O O
leukocytosis O O
. O O

Neurologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examinations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
dysarthria O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
bilateral O B_DISEASE
Babinski O I_DISEASE
sign O I_DISEASE
. O O

Computed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
electroencephalogram O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O O
unremarkable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Despite O O
the O O
use O O
of O O
antiepileptic O O
agents O O
, O O
another O O
GTCS O O
episode O O
recurred O O
after O O
the O O
sixth O O
dose O O
of O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tazobactam I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Brain O B_PERSON
magnetic O I_PERSON
resonance O I_PERSON
imaging O I_PERSON
did O O
not O O
demonstrate O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
infarction O I_DISEASE_ADJECTIVE[DISEASE]
and O O
organic O B_DISEASE
brain O I_DISEASE
lesions O I_DISEASE
. O O

Initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
flux O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hemodialysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rapidly O O
reversed O O
the O O
neurologic O B_DISEASE
symptoms O I_DISEASE
within O O
4 O B_TIME[MEASURE]
hours O I_TIME[MEASURE]
. O O

Piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
encephalopathy O O
should O O
be O O
considered O O
in O O
any O O
uremic O O
patients O O
with O O
unexplained O O
neurological O O
manifestations O O
. O O

CAPD O O
is O O
inefficient O O
in O O
removing O O
piperacillin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
hemodialysis O O
can O O
rapidly O O
terminate O O
the O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
encephalopathy O O
. O O

Frequency O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
transient O B_DISEASE
ipsilateral O I_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
paralysis O I_DISEASE
in O O
patients O B_PERSON/B_BIO
undergoing O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Especially O O
because O O
of O O
improvements O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
neurologic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
, O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
done O O
under O O
local O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
become O O
the O O
technique O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
choice O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O O
several O B_LOCATION/B_NUMBER[MEASURE]
centers O I_LOCATION/I_NUMBER[MEASURE]
. O O

Temporary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ipsilateral O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vocal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
palsies O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
local O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anesthetics O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O O
been O O
described O O
, O O
however O O
. O O

Such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
complications O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
situations O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
where O O
there O O
is O O
a O O
pre O B_LOCATION/B_DISEASE
- O O
existing O O
contralateral O B_DISEASE
paralysis O I_DISEASE
. O O

We O O
therefore O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
local O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
vocal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
better O O
understand O O
its O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
28 O B_PERSON
patients O I_PERSON
undergoing O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Vocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cord O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
evaluated O O
before O O
, O O
during O O
, O O
and O O
after O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
postoperative O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
using O O
flexible O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
laryngoscopy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Anesthesia O O
was O O
performed O O
by O O
injecting O O
20 O O
to O O
40 O O
mL O O
of O O
a O O
mixture O O
of O O
long O O
- O O
acting O O
( O O
ropivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
short O O
- O O
acting O O
( O O
prilocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
anesthetic O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
All O O
patients O B_PERSON/B_BIO
had O O
normal O B_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
function O I_DISEASE
preoperatively O O
. O O

Twelve O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
43 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
found O O
to O O
have O O
intraoperative O B_DISEASE
ipsilateral O I_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
paralysis O I_DISEASE
. O O

It O O
resolved O O
in O O
all O O
cases O B_TIME[MEASURE]/B_LOCATION
< O I_TIME[MEASURE]/I_LOCATION
or O O
= O O
24 O B_MEASURE/B_SPORT[ENT]
hours O I_MEASURE/I_SPORT[ENT]
. O O

There O O
were O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
differences O I_DISEASE_ADJECTIVE[DISEASE]
in O O
operating O B_MEASURE
time O I_MEASURE
or O O
volume O B_MEASURE
or O O
frequency O B_MEASURE
of O O
anesthetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
temporary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vocal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
with O O
those O O
without O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Local O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
temporary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ipsilateral O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vocal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
almost O O
half O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
patients O B_PERSON/B_ENT
. O O

Because O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
existing O O
paralysis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
a O O
relevant O B_MEASURE
frequency O I_MEASURE
( O O
up O O
to O O
3 O B_MEASURE
% O I_MEASURE
) O O
, O O
a O O
preoperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vocal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
carotid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
recommended O O
to O O
avoid O O
intraoperative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bilateral O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
patients O B_PERSON
with O O
preoperative O B_DISEASE
contralateral O I_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
paralysis O I_DISEASE
, O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
under O O
general O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
considered O O
. O O

Impaired O O
fear O O
recognition O O
in O O
regular O O
recreational O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

INTRODUCTION O B_TIME[MEASURE]/B_PERSON
: O O
The O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
read O O
facial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expressions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
essential O B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
human O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
social O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
interaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
conduct O O
the O O
first O O
investigation O O
of O O
facial O O
expression O O
recognition O O
performance O O
in O O
recreational O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Three O O
groups O O
, O O
comprised O O
of O O
21 O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
naive O O
participants O O
( O O
CN O O
) O O
, O O
30 O O
occasional O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
OC O O
) O O
, O O
and O O
48 O O
regular O O
recreational O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RC O O
) O O
users O O
, O O
were O O
compared O O
. O O

An O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facial O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
EFE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consisting O O
of O O
a O O
male O B_PERSON/B_COLOR
and O O
female O B_PERSON
face O I_PERSON
expressing O O
six O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
emotions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
happiness O B_DISEASE/B_PERSON
, O O
surprise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sadness O B_DISEASE/B_PERSON
, O O
anger O B_DISEASE/B_PERSON
, O O
fear O B_DISEASE/B_PERSON
, O O
and O O
disgust O B_DISEASE/B_PERSON
) O O
was O O
administered O O
. O O

Mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percent O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
latencies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
correct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O O
eight O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
presentations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
each O O
basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emotion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
derived O O
. O O

Participants O B_PERSON/B_BIO
were O O
also O O
assessed O O
with O O
the O O
" O O
Eyes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
" O O
to O O
investigate O O
their O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
recognize O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emotional O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
Symptom O B_MEASURE/B_PROTEIN[GENE]
CheckList O B_MEASURE/I_PROTEIN[GENE]
- O O
90 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Revised O O
to O O
measure O O
psychopathology O B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
There O O
were O O
no O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
psychopathology O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
" O O
eyes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
" O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
performance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
the O O
RC O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
, O O
who O O
otherwise O O
had O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
illicit O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
substance O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
use O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
histories O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
the O O
OC O B_LOCATION/B_ORGANIZATION
group O I_LOCATION/I_ORGANIZATION
, O O
exhibited O O
impaired O B_DISEASE_ADJECTIVE[DISEASE]
fear O I_DISEASE_ADJECTIVE[DISEASE]
recognition O I_DISEASE_ADJECTIVE[DISEASE]
accuracy O I_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
the O O
OC O B_LOCATION/B_PERSON
and O O
CN O B_LOCATION
groups O I_LOCATION
. O O

The O O
RC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
correctly O O
identified O O
anger O B_DISEASE/B_PERSON
, O O
fear O B_DISEASE/B_PERSON
, O O
happiness O B_DISEASE/B_PERSON
, O O
and O O
surprise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
more O O
slowly O O
than O O
CN O B_DISEASE/B_LOCATION
, O O
but O O
not O O
OC O B_PERSON/B_LOCATION
participants O B_PERSON/I_LOCATION
. O O

The O O
OC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
slower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
CN O B_DISEASE/B_MEASURE
when O O
correctly O O
identifying O O
disgust O B_DISEASE/B_PERSON
. O O

The O O
selective O O
deficit O O
in O O
fear O O
recognition O O
accuracy O O
manifested O O
by O O
the O O
RC O O
group O O
cannot O O
be O O
explained O O
by O O
the O O
subacute O O
effects O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
because O O
recent O O
and O O
less O O
recent O O
users O O
of O O
these O O
drugs O O
within O O
this O O
group O O
were O O
similarly O O
impaired O O
. O O

Possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parallels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
RC O B_DISEASE/B_LOCATION
users O I_DISEASE/I_LOCATION
and O O
psychopaths O B_PERSON/B_DISEASE
with O O
respect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
impaired O B_DISEASE
fear O I_DISEASE
recognition O I_DISEASE
, O O
amygdala O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
etiology O B_DISEASE
are O O
discussed O O
. O O

Damage O O
of O O
substantia O O
nigra O O
pars O O
reticulata O O
during O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
status O O
epilepticus O O
in O O
the O O
rat O O
: O O
immunohistochemical O O
study O O
of O O
neurons O O
, O O
astrocytes O O
and O O
serum O O
- O O
protein O O
extravasation O O
. O O

The O O
substantia O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
gating O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlling O O
the O O
spread O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
epileptic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
seizure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Additionally O O
, O O
in O O
models O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]
status O I_DISEASE_ADJECTIVE[DISEASE]
epilepticus O O
the O O
pars O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
reticulata O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
substantia O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SNR O B_PROTEIN[GENE]/B_DISEASE
) O O
suffers O O
from O O
a O O
massive O B_DISEASE
lesion O I_DISEASE
which O O
may O O
arise O O
from O O
a O O
massive O B_DISEASE
metabolic O I_DISEASE
derangement O I_DISEASE
and O O
hyperexcitation O B_DISEASE_ADJECTIVE[DISEASE]
developing O O
in O O
the O O
activated O O
SNR O B_LOCATION/B_BIO
. O O

In O O
this O O
study O O
, O O
status O O
epilepticus O O
was O O
induced O O
by O O
systemic O O
injection O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O O
. O O

The O O
neuropathology O B_DISEASE_ADJECTIVE[DISEASE]
of O O
SNR O B_DISEASE
was O O
investigated O O
using O O
immunohistochemical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emphasis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
- O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surviving O O
20 O B_MEASURE
, O O
30 O B_MEASURE
, O O
40 O B_MEASURE
, O O
60 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
, O O
2 O B_MEASURE
, O O
3 O B_NUMBER[MEASURE]
, O O
6 O B_NUMBER[MEASURE]/B_SPORT[ENT]
hours O I_NUMBER[MEASURE]/I_SPORT[ENT]
, O O
1 O B_SEQUENCE[MEASURE]
, O O
2 O B_NUMBER[MEASURE]
, O O
and O O
3 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
after O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
status O B_DISEASE
epilepticus O I_DISEASE
were O O
perfusion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
fixed O O
, O O
and O O
brains O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
processed O O
for O O
immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
SNR O B_GENE/B_DISEASE
. O O

Nissl O O
- O O
staining O O
and O O
antibodies O O
against O O
the O O
neuron O O
- O O
specific O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
binding O O
protein O O
, O O
parvalbumin O O
, O O
served O O
to O O
detect O O
neuronal O O
damage O O
in O O
SNR O O
. O O

Antibodies O O
against O O
the O O
astroglia O O
- O O
specific O O
cytoskeletal O O
protein O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
( O O
GFAP O O
) O O
, O O
and O O
against O O
the O O
glial O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
binding O O
protein O O
, O O
S O O
- O O
100 O O
protein O O
, O O
were O O
used O O
to O O
assess O O
the O O
status O O
of O O
astrocytes O O
. O O

Immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
serum O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
albumin O B_GENE
and O O
immunoglobulins O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
taken O O
as O O
indicator O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disturbances O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
vasogenic O B_DISEASE_ADJECTIVE[DISEASE]
edema O I_DISEASE_ADJECTIVE[DISEASE]
formation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Immunohistochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
GFAP O B_GENE
- O O
staining O O
already O O
at O O
30 O B_MEASURE/B_LOCATION
min O I_MEASURE/I_LOCATION
after O O
induction O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
seizures O B_DISEASE/B_GENE
in O O
an O O
oval O B_LOCATION/B_DISEASE
focus O I_LOCATION/I_DISEASE
situated O O
in O O
the O O
center O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
SNR O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
while O O
sparing O O
medial O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspects O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

At O O
1 O B_MEASURE
h O O
there O O
was O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vacuolation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
S O B_PROTEIN[GENE]/B_DISEASE
- O O
100 O B_MEASURE/B_LOCATION
protein O I_MEASURE/I_LOCATION
staining O I_MEASURE/I_LOCATION
. O O

By O O
2 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hours O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
parvalbumin O B_GENE
- O O
staining O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
changed O O
in O O
the O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
SNR O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
indicating O O
neuronal O B_DISEASE
damage O I_DISEASE
, O O
and O O
Nissl O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
staining O B_PERSON
visualized O O
some O O
neuronal O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
distortion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Staining O O
for O O
serum O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
proteins O B_GENE/B_DISEASE
occurred O O
in O O
a O O
patchy O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
manner O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
throughout O O
the O O
forebrain O B_BODY_PART_OR_ORGAN_COMPONENT
during O O
the O O
first O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
. O O

By O O
6 O B_TIME[MEASURE]/B_LOCATION
h O O
, O O
vasogenic O B_PERSON
edema O I_PERSON
covered O O
the O O
lesioned O O
SNR O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

By O O
24 O B_TIME[MEASURE]/B_LOCATION
h O O
, O O
glial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
neuronal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
a O O
massive O B_DISEASE/B_MEASURE
lesion O I_DISEASE/I_MEASURE
in O O
the O O
center O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
SNR O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

By O O
48 O B_MEASURE
- O O
72 O B_TIME[MEASURE]
h O I_TIME[MEASURE]
, O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
surrounding O O
the O O
lesion O B_DISEASE
increased O O
in O O
size O B_MEASURE
, O O
and O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phagocytotic O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
invaded O O
the O O
damaged O O
area O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

In O O
a O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surviving O O
1 O B_NUMBER[MEASURE]/B_LOCATION
to O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
, O O
conventional O B_DISEASE_ADJECTIVE[DISEASE]
paraffin O I_DISEASE_ADJECTIVE[DISEASE]
- O O
sections O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
confirmed O O
the O O
neuronal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
glial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
SNR O B_DISEASE
. O O

Additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
similar O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
globus O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
pallidus O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Since O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
always O O
damaged O O
in O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
SNR O B_DISEASE/B_PROTEIN[GENE]
it O O
is O O
proposed O O
that O O
the O O
anatomical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interrelationship O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
particularly O O
tight O B_DISEASE_ADJECTIVE[DISEASE]
in O O
SNR O B_DISEASE/B_PROTEIN[GENE]
. O O

Both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
elements O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
may O O
suffer O O
in O O
common O B_DISEASE/B_LOCATION
from O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
disturbance O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
neurotransmitter O B_DISEASE
dysfunction O I_DISEASE
as O O
occur O O
during O O
massive O B_DISEASE/B_ORGANISM_FUNCTION
status O I_DISEASE/I_ORGANISM_FUNCTION
epilepticus O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Neuroprotective O O
effects O O
of O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O O
the O O
offspring O O
cerebellar O O
cortex O O
in O O
the O O
rat O O
model O O
of O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
cortical O O
dysplasia O O
. O O

Cortical O B_DISEASE/B_GENE
dysplasia O I_DISEASE/I_GENE
is O O
a O O
malformation O B_DISEASE
characterized O O
by O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
proliferation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
migration O B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
maturation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
alterations O O
in O O
offspring O O
rat O O
cerebellum O O
induced O O
by O O
maternal O O
exposure O O
to O O
carmustine B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- O O
[ O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloroethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrosoure I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
( O O
BCNU B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
to O O
investigate O O
the O O
effects O O
of O O
exogenous O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O O
cerebellar O O
BCNU B B_DISEASE
- O O
induced O O
cortical O O
dysplasia O O
, O O
using O O
histological O O
and O O
biochemical O O
analyses O O
. O O

Pregnant O O
Wistar O O
rats O O
were O O
assigned O O
to O O
five O O
groups O O
: O O
intact O O
- O O
control O O
, O O
saline O O
- O O
control O O
, O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
, O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
exposed O O
and O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
exposed O O
plus O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Rats O O
were O O
exposed O O
to O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
embryonic O O
day O O
15 O O
and O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
given O O
until O O
delivery O O
. O O

Immuno O O
/ O O
histochemistry O O
and O O
electron O O
microscopy O O
were O O
carried O O
out O O
on O O
the O O
offspring O O
cerebellum O O
, O O
and O O
levels O O
of O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
were O O
determined O O
. O O

Histopathologically O O
, O O
typical O O
findings O O
were O O
observed O O
in O O
the O O
cerebella O O
from O O
the O O
control O O
groups O O
, O O
but O O
the O O
findings O O
consistent O O
with O O
early O O
embryonic O O
development O O
were O O
noted O O
in O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
exposed O O
cortical O O
dysplasia O O
group O O
. O O

There O O
was O O
a O O
marked O O
increase O O
in O O
the O O
number O O
of O O
TUNEL O O
positive O O
cells O O
and O O
nestin O O
positive O O
cells O O
in O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
group O O
, O O
but O O
a O O
decreased O O
immunoreactivity O O
to O O
glial O O
fibrillary O O
acidic O O
protein O O
, O O
synaptophysin O O
and O O
transforming O O
growth O O
factor O O
beta1 O O
was O O
observed O O
, O O
indicating O O
a O O
delayed O O
maturation O O
, O O
and O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
reversed O O
these O O
changes O O
. O O

Malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
in O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
exposed O O
group O O
was O O
higher O O
than O O
those O O
in O O
control O O
groups O O
and O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decreased O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
in O O
BCNU B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
, O O
while O O
there O O
were O O
no O O
significant O O
differences O O
in O O
the O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dismutase O O
levels O O
between O O
these O O
groups O O
. O O

These O O
data O O
suggest O O
that O O
exposure O O
of O O
animals O O
to O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O O
pregnancy O O
leads O O
to O O
delayed O O
maturation O O
of O O
offspring O O
cerebellum O O
and O O
melatonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protects O O
the O O
cerebellum O O
against O O
the O O
effects O O
of O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Reduced O O
cardiotoxicity O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
in O O
the O O
form O O
of O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
hydroxypropyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
methacrylamide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
conjugates O O
: O O
and O O
experimental O O
study O O
in O O
the O O
rat O O
. O O

A O O
rat O O
model O O
was O O
used O O
to O O
evaluate O O
the O O
general O O
acute O O
toxicity O O
and O O
the O O
late O O
cardiotoxicity O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
given O O
either O O
as O O
free O O
drug O O
or O O
in O O
the O O
form O O
of O O
three O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxypropyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methacrylamide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
copolymer O O
conjugates O O
. O O

In O O
these O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymers O O
, O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
covalently O O
bound O O
via O O
peptide O O
linkages O O
that O O
were O O
either O O
non O O
- O O
biodegradable O O
( O O
Gly O O
- O O
Gly O O
) O O
or O O
degradable O O
by O O
lysosomal O O
proteinases O O
( O O
Gly B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Phe I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Leu I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gly I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
addition O O
, O O
one O O
biodegradable O O
conjugate O O
containing O O
galactosamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
was O O
used O O
; O O
this O O
residue O O
was O O
targeted O O
to O O
the O O
liver O O
. O O

Over O O
the O O
first O O
3 O O
weeks O O
after O O
the O O
i O O
. O O
v O O
. O O
administration O O
of O O
free O O
and O O
polymer O O
- O O
bound O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
all O O
animals O O
showed O O
a O O
transient O O
reduction O O
in O O
body O O
weight O O
. O O

However O O
, O O
the O O
maximal O O
reduction O O
in O O
body O O
weight O O
seen O O
in O O
animals O O
that O O
received O O
polymer O O
- O O
bound O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
/ O O
kg O O
) O O
was O O
significantly O O
lower O O
than O O
that O O
observed O O
in O O
those O O
that O O
received O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
/ O O
kg O O
) O O
or O O
a O O
mixture O O
of O O
the O O
unmodified O O
parent O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O O
and O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
/ O O
kg O O
; O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

Throughout O O
the O O
study O O
( O O
20 O O
weeks O O
) O O
, O O
deaths O O
related O O
to O O
cardiotoxicity O O
were O O
observed O O
only O O
in O O
animals O O
that O O
received O O
either O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
mixture O O
of O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O O
and O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O O
in O O
these O O
cases O O
, O O
histological O O
investigations O O
revealed O O
marked O O
changes O O
in O O
the O O
heart O O
that O O
were O O
consistent O O
with O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

Sequential O O
measurements O O
of O O
cardiac O O
output O O
in O O
surviving O O
animals O O
that O O
received O O
either O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
mixture O O
of O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O O
and O O
free O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
showed O O
a O O
reduction O O
of O O
approximately O O
30 O O
% O O
in O O
function O O
beginning O O
at O O
the O O
4th O O
week O O
after O O
drug O O
administration O O
. O O

The O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
in O O
these O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
approximately O O
12 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
lower O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
measured O O
in O O
age O B_MEASURE/B_LOCATION
- O O
matched O O
control O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Animals O O
that O O
were O O
given O O
the O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O O
conjugates O O
containing O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exhibited O O
no O O
significant O O
change O O
in O O
cardiac O O
output O O
throughout O O
the O O
study O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
addition O O
, O O
no O O
significant O O
histological O O
change O O
was O O
observed O O
in O O
the O O
heart O O
of O O
animals O O
that O O
received O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
form O O
of O O
HPMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
copolymer O O
conjugates O O
and O O
were O O
killed O O
at O O
the O O
end O O
of O O
the O O
study O O
. O O

However O O
, O O
these O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
shown O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
heart O B_DISEASE
rate O I_DISEASE
beginning O O
at O O
8 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_LOCATION
TRUNCATED O I_TIME[MEASURE]/I_LOCATION
AT O O
400 O B_LOCATION/B_PERSON
WORDS O I_LOCATION/I_PERSON
) O O

Corneal O O
ulcers O O
associated O O
with O O
aerosolized O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
report O O
4 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
corneal O B_DISEASE
ulcers O I_DISEASE
associated O O
with O O
drug O B_DISEASE
abuse O I_DISEASE
. O O

The O O
pathogenesis O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
ulcers O B_DISEASE/B_BIO
and O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
these O O
patients O B_PERSON/B_DISEASE
are O O
also O O
reviewed O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
all O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
corneal O B_DISEASE/B_LOCATION
ulcers O I_DISEASE/I_LOCATION
associated O O
with O O
drug O B_DISEASE
abuse O I_DISEASE
seen O O
at O O
our O O
institution O B_LOCATION/B_ORGANIZATION
from O O
July O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Four O O
patients O O
with O O
corneal O O
ulcers O O
associated O O
with O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
were O O
reviewed O O
. O O

All O O
corneal O B_DISEASE/B_BIO
ulcers O I_DISEASE/I_BIO
were O O
cultured O O
, O O
and O O
the O O
patients O B_PERSON/B_BIO
were O O
admitted O O
to O O
the O O
hospital O B_LOCATION
for O O
intensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
topical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibiotic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Each O O
patient O B_PERSON/B_LOCATION
received O O
comprehensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
substance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
abuse O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
consultations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O O

Streptococcal O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organisms O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
in O O
3 O B_MEASURE
cases O I_MEASURE
and O O
Capnocytophaga O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Brevibacterium O B_BACTERIUM[BIO]
casei O I_BACTERIUM[BIO]
in O O
1 O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
. O O

The O O
infections O B_DISEASE/B_PERSON
responded O O
to O O
antibiotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_PERSON
patients O I_PERSON
needed O O
a O O
lateral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
tarsorrhaphy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epithelial O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
defects O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSIONS O O
: O O
Aerosolized O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
can O O
be O O
associated O O
with O O
the O O
development O O
of O O
corneal O O
ulcers O O
. O O

Drug O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
challenges O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
management O B_PERSON
. O O

Not O O
only O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
infections O B_DISEASE
but O O
also O O
the O O
overall O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poor O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
patients O B_PERSON/B_LOCATION
and O O
increased O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
noncompliance O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
need O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
addressed O O
. O O

Comprehensive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O O
provide O O
the O O
patient O B_PERSON
the O O
opportunity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
discontinue O O
their O O
substance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
improve O O
their O O
overall O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
prevent O O
future O B_DISEASE_ADJECTIVE[DISEASE]
corneal O I_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Topical O O
0 O O
. O O
025 O O
% O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
chronic O O
post O O
- O O
herpetic O O
neuralgia O O
: O O
efficacy O O
, O O
predictors O O
of O O
response O O
and O O
long O O
- O O
term O O
course O O
. O O

In O O
order O O
to O O
evaluate O O
the O O
efficacy O O
, O O
time O O
- O O
course O O
of O O
action O O
and O O
predictors O O
of O O
response O O
to O O
topical O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
39 O O
patients O O
with O O
chronic O O
post O O
- O O
herpetic O O
neuralgia O O
( O O
PHN O O
) O O
, O O
median O O
duration O O
24 O O
months O O
, O O
were O O
treated O O
with O O
0 O O
. O O
025 O O
% O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cream O O
for O O
8 O O
weeks O O
. O O

During O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
patients O B_PERSON/B_ORGANIZATION
rated O O
their O O
pain O B_DISEASE
on O O
a O O
visual O B_MEASURE
analogue O I_MEASURE
scale O I_MEASURE
( O O
VAS O B_DISEASE/B_LOCATION
) O O
and O O
a O O
verbal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
follow O O
- O O
up O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
10 O B_NUMBER[MEASURE]
- O O
12 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
after O O
study O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
onset O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O O
the O O
patients O B_PERSON
who O O
had O O
improved O O
. O O

Nineteen O O
patients O O
( O O
48 O O
. O O
7 O O
% O O
) O O
substantially O O
improved O O
after O O
the O O
8 O O
- O O
week O O
trial O O
; O O
5 O O
( O O
12 O O
. O O
8 O O
% O O
) O O
discontinued O O
therapy O O
due O O
to O O
side O O
- O O
effects O O
such O O
as O O
intolerable O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
burning O O
sensations O O
( O O
4 O O
) O O
or O O
mastitis O O
( O O
1 O O
) O O
; O O
15 O O
( O O
38 O O
. O O
5 O O
% O O
) O O
reported O O
no O O
benefit O O
. O O

The O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
VAS O B_MEASURE
ratings O I_MEASURE
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O O
2 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
continuous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Of O O
the O O
responders O B_MEASURE
72 O I_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
were O O
still O O
improved O O
at O O
the O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O O
up O B_LOCATION/B_TIME[MEASURE]
; O O
only O O
one O B_NUMBER[MEASURE]
- O O
third O B_SEQUENCE[MEASURE]
of O O
them O O
had O O
continued O O
application O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irregularly O O
. O O

Treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O O
patient O B_PERSON
' O O
s O B_MEASURE/B_DISEASE
age O I_MEASURE/I_DISEASE
, O O
duration O B_MEASURE/B_LOCATION
or O O
localization O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
PHN O B_DISEASE
( O O
trigeminal O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
excluded O O
) O O
, O O
sensory O B_DISEASE
disturbance O I_DISEASE
or O O
pain O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
character O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O O
response O O
was O O
not O O
correlated O O
with O O
the O O
incidence O O
, O O
time O O
- O O
course O O
or O O
severity O O
of O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
burning O O
. O O

If O O
confirmed O O
in O O
controlled O O
trials O O
, O O
the O O
long O O
- O O
term O O
results O O
of O O
this O O
open O O
, O O
non O O
- O O
randomized O O
study O O
might O O
indicate O O
that O O
the O O
analgesic O O
effect O O
of O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
PHN O O
is O O
mediated O O
by O O
both O O
interference O O
with O O
neuropeptide O O
metabolism O O
and O O
morphological O O
changes O O
( O O
perhaps O O
degeneration O O
) O O
of O O
nociceptive O O
afferents O O
. O O

Myo B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inositol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MIP B B_GENE
) O O
synthase O O
inhibition O O
: O O
in O O
- O O
vivo O O
study O O
in O O
rats O O
. O O

Lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
the O O
prototypic O O
mood O O
stabilizers O O
and O O
have O O
diverse O O
structures O O
and O O
targets O O
. O O

Both O O
drugs O O
influence O O
inositol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O O
. O O

Lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibits O O
IMPase O O
and O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O O
MIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthase O O
. O O

This O O
study O O
shows O O
that O O
MIP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthase O O
inhibition O O
does O O
not O O
replicate O O
or O O
augment O O
the O O
effects O O
of O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
inositol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitive O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizures O O
model O O
. O O

This O O
lack O O
of O O
effects O O
may O O
stem O O
from O O
the O O
low O O
contribution O O
of O O
de O O
- O O
novo O O
synthesis O O
to O O
cellular O O
inositol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supply O O
or O O
to O O
the O O
inhibition O O
of O O
the O O
de O O
- O O
novo O O
synthesis O O
by O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
itself O O
. O O

Non O B_DISEASE/B_MEASURE
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
associated O O
acute O B_DISEASE
interstitial O I_DISEASE
nephritis O I_DISEASE
with O O
granular O B_DISEASE
tubular O I_DISEASE
basement O I_DISEASE
membrane O I_DISEASE
deposits O I_DISEASE
. O O

Acute O B_DISEASE_ADJECTIVE[DISEASE]
tubulo O I_DISEASE_ADJECTIVE[DISEASE]
- O O
interstitial O B_DISEASE
nephritis O I_DISEASE
( O O
ATIN O B_LOCATION/B_ORGANIZATION
) O O
is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
resulting O O
from O O
a O O
variety O B_ENT/B_MEASURE
of O O
insults O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
including O O
immune O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
tubulo O B_DISEASE
- O O
interstitial O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
injury O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
but O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
non O B_DISEASE/B_PROTEIN[GENE]
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
are O O
a O O
far O O
more O O
frequent O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cause O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Overall O O
, O O
as O O
an O O
entity O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ATIN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
remains O O
under O O
- O O
diagnosed O O
, O O
as O O
symptoms O B_DISEASE
resolve O O
spontaneously O O
if O O
the O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
stopped O O
. O O

We O O
report O O
on O O
a O O
14 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
boy O I_PERSON
who O O
developed O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
2 O I_DISEASE
weeks O I_DISEASE
after O O
aortic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

He O O
was O O
put O O
on O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
surgery O O
and O O
took O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
fever O O
for O O
nearly O O
a O O
week O O
prior O O
to O O
presentation O O
. O O

He O O
then O O
presented O O
to O O
the O O
emergency O O
department O O
feeling O O
quite O O
ill O O
and O O
was O O
found O O
to O O
have O O
a O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BUN B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
concentration O O
of O O
of O O
147 O O
mg O O
/ O O
dl O O
, O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
15 O O
. O O
3 O O
mg O O
/ O O
dl O O
and O O
serum O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
8 O O
. O O
7 O O
mEq O O
/ O O
l O O
. O O

Dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O O
immediately O O
initiated O O
. O O

A O O
kidney O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
biopsy O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
inflammatory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infiltrate O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
consistent O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
ATIN O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
in O O
the O O
tubular O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
basement O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
membrane O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TBM O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
very O O
intense O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
granular O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deposits O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
polyclonal O B_PROTEIN[GENE]
IgG O I_PROTEIN[GENE]
and O O
C3 O B_GENE
were O O
noted O O
. O O

He O O
needed O O
dialysis O O
for O O
2 O O
weeks O O
and O O
was O O
treated O O
successfully O O
with O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
6 O O
months O O
. O O

His O O
renal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
disappearance O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
proteinuria O B_DISEASE
took O O
a O O
year O B_TIME[MEASURE]/B_LOCATION
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
this O O
is O O
a O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
ATIN O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
showing O O
deposits O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
granular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immune O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
present O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O O
in O O
the O O
TBM O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
not O O
in O O
the O O
glomeruli O B_DISEASE/B_LOCATION
. O O

Rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
segmental O O
necrotizing O O
glomerulonephritis O O
in O O
staphylococcal O O
endocarditis O O
. O O

Segmental O O
necrotising O O
glomerulonephritis O O
has O O
been O O
reported O O
as O O
complication O O
of O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
in O O
patients O O
receiving O O
treatment O O
for O O
tuberculosis O O
. O O

Changing O O
epidemiology O O
of O O
infections O O
such O O
as O O
infective O O
endocarditis O O
( O O
IE O O
) O O
has O O
led O O
to O O
an O O
increase O O
in O O
the O O
use O O
of O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Staphylococcal O O
infections O O
. O O

We O O
describe O O
a O O
case O O
of O O
a O O
patient O O
with O O
Staphylococcal O O
IE O O
who O O
developed O O
acute O O
renal O O
failure O O
secondary O O
to O O
a O O
segmental O O
necrotising O O
glomerulonephritis O O
while O O
being O O
treated O O
with O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
review O O
the O O
literature O O
regarding O O
this O O
complication O O
of O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
untreated O O
Iranian O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
virus O O
infection O O
. O O

BACKGROUND O O
: O O
Lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
used O O
for O O
the O O
treatment O O
of O O
chronic O O
hepatitis O O
B O O
patients O O
. O O

Recent O O
studies O O
show O O
that O O
the O O
YMDD O O
motif O O
mutants O O
( O O
resistant O O
hepatitis O O
B O O
virus O O
) O O
occur O O
as O O
natural O O
genome O O
variability O O
in O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
untreated O O
chronic O O
hepatitis O O
B O O
patients O O
. O O

In O O
this O O
study O O
we O O
aimed O O
to O O
determine O O
the O O
rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
untreated O O
chronic O O
hepatitis O O
B O O
patients O O
in O O
Iran O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
77 O O
chronic O O
hepatitis O O
B O O
patients O O
who O O
had O O
not O O
been O O
treated O O
with O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
included O O
in O O
the O O
study O O
. O O

Serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
patients O B_PERSON/B_LOCATION
were O O
tested O O
by O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
restriction O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PCR O B_LOCATION
- O O
RFLP O B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
YMDD O B_DISEASE/B_GENE
motif O B_DISEASE/I_GENE
mutants O B_DISEASE/I_GENE
. O O

All O O
patients O O
were O O
also O O
tested O O
for O O
liver O O
enzymes O O
, O O
anti O O
- O O
HCV O O
, O O
HBeAg B B_DISEASE/B_GENE
, O O
and O O
anti O O
- O O
HBe O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Of O O
the O O
77 O B_PERSON
patients O I_PERSON
enrolled O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
73 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
were O O
male O B_PERSON/B_COLOR
and O O
27 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
were O O
female O B_PERSON/B_LOCATION
. O O

Mean O B_MEASURE/B_LOCATION
ALT O I_MEASURE/I_LOCATION
and O O
AST O B_GENE
levels O I_GENE
were O O
124 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
73 O B_MEASURE
. O O
4 O B_MEASURE
and O O
103 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
81 O B_MEASURE/B_LOCATION
IU O I_MEASURE/I_LOCATION
/ O O
l O B_OTHER/B_MEASURE
, O O
respectively O O
. O O

HBeAg B B_DISEASE/B_GENE
was O O
positive O O
in O O
40 O O
% O O
and O O
anti O O
- O O
HBe O O
in O O
60 O O
% O O
of O O
the O O
patients O O
. O O

Anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HCV O B_DISEASE
was O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
of O O
them O O
. O O

YMDD O O
motif O O
mutants O O
were O O
not O O
detected O O
in O O
any O O
of O O
the O O
patients O O
despite O O
the O O
liver O O
enzyme O O
levels O O
and O O
the O O
presence O O
of O O
HBeAg B B_DISEASE/B_GENE
or O O
anti O O
- O O
HBe O O
. O O

CONCLUSION O O
: O O
Although O O
the O O
natural O O
occurrence O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
untreated O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
has O O
been O O
reported O O
, O O
these O O
mutants O O
were O O
not O O
detected O O
in O O
Iranian O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
untreated O O
chronic O O
hepatitis O O
B O O
patients O O
. O O

Branch O O
retinal O O
vein O O
occlusion O O
and O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

A O O
case O O
of O O
branch O O
retinal O O
vein O O
occlusion O O
associated O O
with O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
secondary O O
hypertension O O
is O O
described O O
. O O

Although O O
an O O
infrequent O O
complication O O
of O O
selective O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O O
inhibitor O O
therapy O O
, O O
it O O
is O O
important O O
that O O
ophthalmologists O O
are O O
aware O O
that O O
these O O
agents O O
can O O
cause O O
hypertension O O
because O O
this O O
class O O
of O O
drugs O O
is O O
widely O O
prescribed O O
. O O

The O O
differential O O
effects O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
release O O
, O O
cyclooxygenase O O
gene O O
expression O O
and O O
pain O O
in O O
a O O
clinical O O
pain O O
model O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
blocking O O
nociceptive O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
input O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
surgical O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sites O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
long O O
- O O
acting O O
local O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
might O O
directly O O
modulate O O
inflammation O B_DISEASE/B_BACTERIUM[BIO]
. O O

In O O
the O O
present O O
study O O
, O O
we O O
describe O O
the O O
proinflammatory O O
effects O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
local O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PGE2 B B_GENE
) O O
production O O
and O O
cyclooxygenase O O
( O O
COX O O
) O O
gene O O
expression O O
that O O
increases O O
postoperative O O
pain O O
in O O
human O O
subjects O O
. O O

METHODS O O
: O O
Subjects O O
( O O
n O O
= O O
114 O O
) O O
undergoing O O
extraction O O
of O O
impacted O O
third O O
molars O O
received O O
either O O
2 O O
% O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
0 O O
. O O
5 O O
% O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
surgery O O
and O O
either O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
mg O O
or O O
placebo O O
orally O O
90 O O
min O O
before O O
surgery O O
and O O
for O O
the O O
following O O
48 O O
h O O
. O O

Oral O B_NUMBER[MEASURE]/B_PERSON
mucosal O I_NUMBER[MEASURE]/I_PERSON
biopsies O I_NUMBER[MEASURE]/I_PERSON
were O O
taken O O
before O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
48 O B_TIME[MEASURE]/B_LOCATION
h O B_TIME[MEASURE]/I_LOCATION
after O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

After O O
extraction O O
, O O
a O O
microdialysis O O
probe O O
was O O
placed O O
at O O
the O O
surgical O O
site O O
for O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
thromboxane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TXB2 B B_GENE
) O O
measurements O O
. O O

RESULTS O O
: O O
The O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
rofecoxib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
reported O O
significantly O O
less O O
pain O O
, O O
as O O
assessed O O
by O O
a O O
visual O O
analog O O
scale O O
, O O
compared O O
with O O
the O O
other O O
three O O
treatment O O
groups O O
over O O
the O O
first O O
4 O O
h O O
. O O

However O O
, O O
the O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
placebo O O
group O O
reported O O
significantly O O
more O O
pain O O
at O O
24 O O
h O O
and O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
during O O
the O O
first O O
4 O O
h O O
were O O
significantly O O
higher O O
than O O
the O O
other O O
three O O
treatment O O
groups O O
. O O

Moreover O O
, O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
increased O O
COX O O
- O O
2 O O
gene O O
expression O O
at O O
48 O O
h O O
as O O
compared O O
with O O
the O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
placebo O O
group O O
. O O

Thromboxane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
not O O
significantly O O
affected O O
by O O
any O O
of O O
the O O
treatments O O
, O O
indicating O O
that O O
the O O
effects O O
seen O O
were O O
attributable O O
to O O
inhibition O O
of O O
COX O O
- O O
2 O O
, O O
but O O
not O O
COX O O
- O O
1 O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulates O O
COX O O
- O O
2 O O
gene O O
expression O O
after O O
tissue O O
injury O O
, O O
which O O
is O O
associated O O
with O O
higher O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
and O O
pain O O
after O O
the O O
local O O
anesthetic O O
effect O O
dissipates O O
. O O

p75NTR O O
expression O O
in O O
rat O O
urinary O O
bladder O O
sensory O O
neurons O O
and O O
spinal O O
cord O O
with O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cystitis O O
. O O

A O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
nerve O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
contributing O O
to O O
increased O O
voiding O B_MEASURE/B_DISEASE
frequency O B_MEASURE/I_DISEASE
and O O
altered O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
suggested O O
. O O

Previous O O
studies O O
have O O
examined O O
the O O
expression O O
and O O
regulation O O
of O O
tyrosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O O
receptors O O
( O O
Trks O O
) O O
in O O
micturition O O
reflexes O O
with O O
urinary O O
bladder O O
inflammation O O
. O O

The O O
present O O
studies O O
examine O O
the O O
expression O O
and O O
regulation O O
of O O
another O O
receptor O O
known O O
to O O
bind O O
NGF O O
, O O
p75 O O
( O O
NTR O O
) O O
, O O
after O O
various O O
durations O O
of O O
bladder O O
inflammation O O
induced O O
by O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYP B B_LOCATION/B_ORGANIZATION
) O O
. O O

CYP B B_DISEASE/B_BIO
- O O
induced O O
cystitis O O
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
001 O O
) O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
the O O
superficial O O
lateral O O
and O O
medial O O
dorsal O O
horn O O
in O O
L1 O O
- O O
L2 O O
and O O
L6 O O
- O O
S1 O O
spinal O O
segments O O
. O O

The O O
number O O
of O O
p75 O O
( O O
NTR O O
) O O
- O O
immunoreactive O O
( O O
- O O
IR O O
) O O
cells O O
in O O
the O O
lumbosacral O O
dorsal O O
root O O
ganglia O O
( O O
DRG O O
) O O
also O O
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
05 O O
) O O
with O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
cystitis O O
( O O
acute O O
, O O
intermediate O O
, O O
and O O
chronic O O
) O O
. O O

Quantitative O O
, O O
real O O
- O O
time O O
polymerase O O
chain O O
reaction O O
also O O
demonstrated O O
significant O O
increases O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
01 O O
) O O
in O O
p75 O O
( O O
NTR O O
) O O
mRNA O O
in O O
DRG O O
with O O
intermediate O O
and O O
chronic O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
cystitis O O
. O O

Retrograde O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
tracing O O
techniques O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
Fastblue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
used O O
to O O
identify O O
presumptive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
afferent O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
lumbosacral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
DRG O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
bladder O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
afferent O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
DRG O B_DISEASE/B_MEASURE
, O O
p75 O B_GENE
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
IR O B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
increased O O
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
or O O
= O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
with O O
cystitis O B_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
p75 O B_GENE
( O O
NTR O B_LOCATION
) O O
- O O
IR O B_LOCATION/B_PROTEIN[GENE]
in O O
DRG O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
bodies O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
increases O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
or O O
= O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
in O O
pericellular O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
encircling O O
DRG O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cells O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
) O O
p75 O B_GENE
( O O
NTR O B_LOCATION/B_ORGANIZATION
) O O
- O O
IR O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
DRG O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
also O O
increased O O
. O O

Confocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O O
that O O
pericellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p75 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
IR O B_MEASURE/B_PROTEIN[GENE]
was O O
not O O
colocalized O O
with O O
the O O
glial O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marker O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
glial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GFAP O B_GENE
) O O
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O O
that O O
p75 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expression O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
micturition O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflexes O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constitutively O O
and O O
modified O O
by O O
bladder O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
p75 O B_GENE
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expression O B_GENE
in O O
micturition O B_DISEASE
reflexes O I_DISEASE
remains O O
to O O
be O O
determined O O
. O O

Azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
suicidal O O
erythrocyte O O
death O O
. O O

BACKGROUND O O
: O O
Azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
widely O O
used O O
as O O
an O O
immunosuppressive O O
drug O O
. O O

The O O
side O O
effects O O
of O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O O
anemia O O
, O O
which O O
has O O
been O O
attributed O O
to O O
bone O O
marrow O O
suppression O O
. O O

Alternatively O O
, O O
anemia O O
could O O
result O O
from O O
accelerated O O
suicidal O O
erythrocyte O O
death O O
or O O
eryptosis O O
, O O
which O O
is O O
characterized O O
by O O
exposure O O
of O O
phosphatidylserine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PS B B_PROTEIN[GENE]/B_LOCATION
) O O
at O O
the O O
erythrocyte O O
surface O O
and O O
by O O
cell O O
shrinkage O O
. O O

METHODS O O
: O O
The O O
present O O
experiments O O
explored O O
whether O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
influences O O
eryptosis O O
. O O

According O O
to O O
annexin O O
V O O
binding O O
, O O
erythrocytes O O
from O O
patients O O
indeed O O
showed O O
a O O
significant O O
increase O O
of O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
within O O
1 O O
week O O
of O O
treatment O O
with O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
a O O
second O O
series O O
, O O
cytosolic O O
Ca2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
activity O O
( O O
Fluo3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluorescence O O
) O O
, O O
cell O O
volume O O
( O O
forward O O
scatter O O
) O O
, O O
and O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
exposure O O
( O O
annexin O O
V O O
binding O O
) O O
were O O
determined O O
by O O
FACS O O
analysis O O
in O O
erythrocytes O O
from O O
healthy O O
volunteers O O
. O O

RESULTS O O
: O O
Exposure O O
to O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
> O O
or O O
= O O
2 O O
microg O O
/ O O
mL O O
) O O
for O O
48 O O
hours O O
increased O O
cytosolic O O
Ca2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O O
activity O O
and O O
annexin O O
V O O
binding O O
and O O
decreased O O
forward O O
scatter O O
. O O

The O O
effect O O
of O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
both O O
annexin O O
V O O
binding O O
and O O
forward O O
scatter O O
was O O
significantly O O
blunted O O
in O O
the O O
nominal O O
absence O O
of O O
extracellular O O
Ca2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
. O O

CONCLUSIONS O O
: O O
Azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
triggers O O
suicidal O O
erythrocyte O O
death O O
, O O
an O O
effect O O
presumably O O
contributing O O
to O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anemia O O
. O O

Levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
an O O
adjunct O O
to O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
in O O
cats O O
with O O
suspected O O
idiopathic O O
epilepsy O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
pharmacokinetics O O
, O O
efficacy O O
, O O
and O O
tolerability O O
of O O
oral O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O O
as O O
an O O
adjunct O O
to O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
in O O
cats O O
with O O
poorly O O
controlled O O
suspected O O
idiopathic O O
epilepsy O O
. O O

DESIGN O B_PERSON/B_MEASURE
- O O
Open O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
label O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
noncomparative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

ANIMALS O O
: O O
12 O O
cats O O
suspected O O
to O O
have O O
idiopathic O O
epilepsy O O
that O O
was O O
poorly O O
controlled O O
with O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
that O O
had O O
unacceptable O O
adverse O O
effects O O
when O O
treated O O
with O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PROCEDURES O O
: O O
Cats O O
were O O
treated O O
with O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O O
mg O O
/ O O
kg O O
[ O O
9 O O
. O O
1 O O
mg O O
/ O O
lb O O
] O O
, O O
PO O O
, O O
q O O
8 O O
h O O
) O O
. O O

After O O
a O O
minimum O O
of O O
1 O O
week O O
of O O
treatment O O
, O O
serum O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O O
were O O
measured O O
before O O
and O O
2 O O
, O O
4 O O
, O O
and O O
6 O O
hours O O
after O O
drug O O
administration O O
, O O
and O O
maximum O O
and O O
minimum O O
serum O O
concentrations O O
and O O
elimination O O
half O O
- O O
life O O
were O O
calculated O O
. O O

Seizure O O
frequencies O O
before O O
and O O
after O O
initiation O O
of O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
were O O
compared O O
, O O
and O O
adverse O O
effects O O
were O O
recorded O O
. O O

RESULTS O O
: O O
Median O O
maximum O O
serum O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O O
was O O
25 O O
. O O
5 O O
microg O O
/ O O
mL O O
, O O
median O O
minimum O O
serum O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O O
was O O
8 O O
. O O
3 O O
microg O O
/ O O
mL O O
, O O
and O O
median O O
elimination O O
half O O
- O O
life O O
was O O
2 O O
. O O
9 O O
hours O O
. O O

Median O O
seizure O O
frequency O O
prior O O
to O O
treatment O O
with O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
. O O
1 O O
seizures O O
/ O O
mo O O
) O O
was O O
significantly O O
higher O O
than O O
median O O
seizure O O
frequency O O
after O O
initiation O O
of O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
( O O
0 O O
. O O
42 O O
seizures O O
/ O O
mo O O
) O O
, O O
and O O
7 O O
of O O
10 O O
cats O O
were O O
classified O O
as O O
having O O
responded O O
to O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
( O O
ie O O
, O O
reduction O O
in O O
seizure O O
frequency O O
of O O
> O O
or O O
= O O
50 O O
% O O
) O O
. O O

Two O B_PERSON/B_ENT
cats O I_PERSON/I_ENT
had O O
transient O B_DISEASE
lethargy O I_DISEASE
and O O
inappetence O B_DISEASE
. O O

CONCLUSIONS O O
AND O O
CLINICAL O O
RELEVANCE O O
: O O
Results O O
suggested O O
that O O
levetiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
well O O
tolerated O O
in O O
cats O O
and O O
may O O
be O O
useful O O
as O O
an O O
adjunct O O
to O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
in O O
cats O O
with O O
idiopathic O O
epilepsy O O
. O O

Serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O O
inhibitors O O
, O O
paranoia O O
, O O
and O O
the O O
ventral O O
basal O O
ganglia O O
. O O

Antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
previously O O
been O O
associated O O
with O O
paranoid O B_DISEASE
reactions O I_DISEASE
in O O
psychiatric O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Five O O
cases O O
of O O
paranoid O O
exacerbation O O
with O O
the O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O O
inhibitors O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amitriptyline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
reported O O
here O O
. O O

Elements O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
common O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
these O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
paranoid O B_DISEASE
symptomatology O I_DISEASE
and O O
the O O
concomitant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
occurrence O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
depressive O B_DISEASE
and O O
psychotic O B_DISEASE
symptoms O I_DISEASE
. O O

Complicated O O
depressive O O
disorders O O
( O O
including O O
atypicality O O
of O O
course O O
and O O
symptomatology O O
, O O
chronicity O O
, O O
psychosis O O
, O O
bipolarity O O
, O O
and O O
secondary O O
onset O O
in O O
the O O
course O O
of O O
a O O
primary O O
psychosis O O
) O O
may O O
present O O
particular O O
vulnerability O O
to O O
paranoid O O
exacerbations O O
associated O O
with O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O O
inhibitors O O
. O O

Although O O
the O O
pharmacology O O
and O O
neurobiology O O
of O O
paranoia O O
remain O O
cryptic O O
, O O
several O O
mechanisms O O
, O O
including O O
5HT3 O O
receptor O O
- O O
mediated O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O O
, O O
beta O O
- O O
noradrenergic O O
receptor O O
downregulation O O
, O O
or O O
GABAB O O
receptor O O
upregulation O O
acting O O
in O O
the O O
vicinity O O
of O O
the O O
ventral O O
basal O O
ganglia O O
( O O
possibly O O
in O O
lateral O O
orbitofrontal O O
or O O
anterior O O
cingulate O O
circuits O O
) O O
, O O
might O O
apply O O
to O O
this O O
phenomenon O O
. O O

These O O
cases O O
call O O
attention O O
to O O
possible O O
paranoid O O
exacerbations O O
with O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O O
blockers O O
in O O
select O O
patients O O
and O O
raise O O
neurobiological O O
considerations O O
regarding O O
paranoia O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
cardiorespiratory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O O
unilateral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conventional O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Spinal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
widely O O
employed O O
in O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
practice O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
but O O
has O O
the O O
main O B_DISEASE_ADJECTIVE[DISEASE]
drawback O I_DISEASE_ADJECTIVE[DISEASE]
of O O
post O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
spinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
block O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
hypotension O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Efforts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
must O O
therefore O O
continue O O
to O O
be O O
made O O
to O O
obviate O O
this O O
setback O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OBJECTIVE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
evaluate O O
the O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
unilateral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conventional O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
With O O
ethical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approval O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
we O O
studied O O
74 O B_ORGANIZATION/B_PERSON
American O I_ORGANIZATION/I_PERSON
Society O I_ORGANIZATION/I_PERSON
of O O
Anesthesiologists O B_PERSON/B_DISEASE
( O O
ASA O B_ORGANIZATION/B_LOCATION
) O O
, O O
physical O B_MEASURE/B_PERSON
status O I_MEASURE/I_PERSON
class O I_MEASURE/I_PERSON
1 O I_MEASURE/I_PERSON
and O O
2 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
scheduled O O
for O O
elective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
unilateral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lower O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O B_PERSON
were O O
randomly O O
allocated O O
into O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
two O B_NUMBER[MEASURE]/B_PERSON
groups O I_NUMBER[MEASURE]/I_PERSON
: O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conventional O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
spinal O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
anaesthesia O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
groups O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

In O O
the O O
lateral O O
position O O
with O O
operative O O
side O O
down O O
, O O
patients O O
recived O O
10 O O
mg O O
( O O
2mls O O
) O O
of O O
0 O O
. O O
5 O O
% O O
hyperbaric O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
a O O
25 O O
- O O
gauge O O
spinal O O
needle O O
. O O

Patients O B_PERSON
in O O
the O O
unilateral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O O
maintained O O
in O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
position O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
for O O
15 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
following O O
spinal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
while O O
those O O
in O O
the O O
conventional O B_LOCATION/B_ORGANIZATION
group O I_LOCATION/I_ORGANIZATION
were O O
turned O O
supine O B_LOCATION/B_PERSON
immediately O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Blood O O
pressure O O
, O O
heart O O
rate O O
, O O
respiratory O O
rate O O
and O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
saturation O O
were O O
monitored O O
over O O
1 O O
hour O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Three O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
( O O
8 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
in O O
the O O
unilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
5 O B_NUMBER[MEASURE]/B_PERSON
( O O
13 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
in O O
the O O
conventional O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
developed O O
hypotension O B_DISEASE
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
71 O B_MEASURE
. O O

Four O O
( O O
10 O O
. O O
8 O O
% O O
) O O
patients O O
in O O
the O O
conventional O O
group O O
and O O
1 O O
( O O
2 O O
. O O
7 O O
% O O
) O O
in O O
the O O
unilateral O O
group O O
, O O
P O O
= O O
0 O O
. O O
17 O O
required O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
to O O
treat O O
hypotension O O
. O O

Patients O B_PERSON
in O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
systolic O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressures O I_DISEASE/I_GENE
at O O
15 O B_MEASURE
, O O
30 O B_MEASURE
and O O
45 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
when O O
compared O O
to O O
the O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
003 O B_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
and O O
0 O B_MEASURE
. O O
004 O B_MEASURE
) O O
. O O

The O O
mean O O
respiratory O O
rate O O
and O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
saturations O O
in O O
the O O
two O O
groups O O
were O O
similar O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Compared O O
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
unilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
associated O O
with O O
fewer O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perturbations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Also O O
, O O
the O O
type O O
of O O
spinal O O
block O O
instituted O O
affected O O
neither O O
the O O
respiratory O O
rate O O
nor O O
the O O
arterial O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation O O
. O O

Spectrum O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
after O O
generic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
HAART O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
southern O B_DISEASE
Indian O I_DISEASE
HIV O I_DISEASE
- O O
infected O O
patients O B_PERSON/B_LOCATION
. O O

To O O
determine O O
the O O
incidence O B_MEASURE
of O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
after O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
fixed O O
- O O
dose O B_MEASURE/B_LOCATION
, O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
highly O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiretroviral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HAART O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
among O O
HIV O B_DISEASE
- O O
infected O O
individuals O B_PERSON/B_LOCATION
in O O
South O B_LOCATION/B_MEASURE
India O I_LOCATION/I_MEASURE
, O O
we O O
examined O O
the O O
experiences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
3154 O B_DISEASE
HIV O I_DISEASE
- O O
infected O O
individuals O B_PERSON
who O O
received O O
a O O
minimum O B_MEASURE
of O O
3 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
of O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
February O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1996 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
tertiary O B_LOCATION
HIV O I_LOCATION
care O I_LOCATION
referral O I_LOCATION
center O I_LOCATION
in O O
South O B_LOCATION
India O I_LOCATION
. O O

The O O
most O O
common O O
regimens O O
were O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
d4T B B_PROTEIN[GENE]
+ O O
nevirapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NVP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
54 O O
. O O
8 O O
% O O
) O O
, O O
zidovudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
AZT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
+ O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
NVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
14 O O
. O O
5 O O
% O O
) O O
, O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
d4T B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
efavirenz B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
EFV B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
20 O O
. O O
1 O O
% O O
) O O
, O O
and O O
AZT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
3TC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O O
EFV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
. O O
4 O O
% O O
) O O
. O O

The O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adverse O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
events O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
median O B_DISEASE
CD4 O I_DISEASE
at O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
event O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
rash O B_DISEASE
( O O
15 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
; O O
CD4 O B_MEASURE
, O O
285 O B_MEASURE/B_BIO
cells O I_MEASURE/I_BIO
/ O O
microL O B_MEASURE/B_LOCATION
) O O
and O O
peripheral O B_DISEASE
neuropathy O I_DISEASE
( O O
9 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
and O O
348 O B_MEASURE
cells O I_MEASURE
/ O O
microL O B_MEASURE/B_PERSON
) O O
. O O

Clinically O O
significant O O
anemia O O
( O O
hemoglobin O O
< O O
7 O O
g O O
/ O O
dL O O
) O O
was O O
observed O O
in O O
5 O O
. O O
4 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
165 O O
cells O O
/ O O
microL O O
) O O
and O O
hepatitis O O
( O O
clinical O O
jaundice O O
with O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O O
> O O
5 O O
times O O
upper O O
limits O O
of O O
normal O O
) O O
in O O
3 O O
. O O
5 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
260 O O
cells O O
/ O O
microL O O
) O O
. O O

Women O B_PERSON/B_BIO
were O O
significantly O O
more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
experience O O
lactic O B_DISEASE
acidosis O I_DISEASE
, O O
while O O
men O B_PERSON
were O O
significantly O O
more O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
experience O O
immune O B_DISEASE
reconstitution O I_DISEASE
syndrome O I_DISEASE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Among O O
the O O
patients O O
with O O
1 O O
year O O
of O O
follow O O
- O O
up O O
, O O
NVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O O
was O O
significantly O O
associated O O
with O O
developing O O
rash O O
and O O
d4T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
with O O
developing O O
peripheral O O
neuropathy O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Anemia O B_DISEASE
and O O
hepatitis O B_DISEASE
often O O
occur O O
within O O
12 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
initiating O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Frequent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
toxicities O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
in O O
developing O O
countries O B_LOCATION/B_ORGANIZATION
where O O
generic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HAART O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
increasingly O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
sensory O O
neurotoxicity O O
: O O
a O O
neurophysiological O O
study O O
. O O

BACKGROUND O O
: O O
Recent O O
studies O O
confirmed O O
a O O
high O O
incidence O O
of O O
sensory O O
axonal O O
neuropathy O O
in O O
patients O O
treated O O
with O O
different O O
doses O O
of O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
study O O
' O O
s O O
aims O O
were O O
to O O
measure O O
variations O O
in O O
sural O O
nerve O O
sensory O O
action O O
potential O O
( O O
SAP O O
) O O
amplitude O O
in O O
patients O O
with O O
refractory O O
cutaneous O O
lupus O O
erythematosus O O
( O O
CLE O O
) O O
treated O O
with O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
use O O
these O O
findings O O
to O O
identify O O
the O O
neurotoxic O O
potential O O
of O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
recovery O O
capacity O O
of O O
sensory O O
fibres O O
after O O
discontinuation O O
of O O
treatment O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Clinical O O
and O O
electrophysiological O O
data O O
in O O
12 O O
female O O
patients O O
with O O
CLE O O
during O O
treatment O O
with O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
up O O
to O O
47 O O
months O O
after O O
discontinuation O O
of O O
treatment O O
were O O
analysed O O
. O O

Sural O B_MEASURE/B_PERSON
nerve O I_MEASURE/I_PERSON
SAP O I_MEASURE/I_PERSON
amplitude O I_MEASURE/I_PERSON
reduction O I_MEASURE/I_PERSON
> O I_MEASURE/I_PERSON
or O O
= O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
was O O
the O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
discontinuing O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
During O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
11 O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
showed O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
sural O B_DISEASE/B_GENE
nerve O I_DISEASE/I_GENE
SAP O I_DISEASE/I_GENE
amplitude O I_DISEASE/I_GENE
compared O O
to O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
9 O B_NUMBER[MEASURE]/B_PERSON
with O O
a O O
reduction O B_MEASURE
> O I_MEASURE
or O O
= O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
2 O B_MEASURE
< O I_MEASURE
50 O I_MEASURE
% O I_MEASURE
) O O
. O O

One O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patient O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
no O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
SAP O B_MEASURE/B_DISEASE
amplitude O B_MEASURE/I_DISEASE
. O O

Five O B_PERSON
patients O I_PERSON
complained O O
of O O
paresthesias O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
leg O B_DISEASE
cramps O I_DISEASE
. O O

After O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
sural O O
SAP O O
amplitude O O
recovered O O
in O O
3 O O
patients O O
. O O

At O O
detection O O
of O O
reduction O O
in O O
sural O O
nerve O O
SAP O O
amplitude O O
, O O
the O O
median O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cumulative O O
dose O O
was O O
21 O O
. O O
4 O O
g O O
. O O

The O O
threshold O B_MEASURE/B_LOCATION
neurotoxic O I_MEASURE/I_LOCATION
dosage O I_MEASURE/I_LOCATION
is O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
previously O O
reported O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Sural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nerve O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
amplitude O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
a O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marker O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
degeneration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
recovery O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fibres O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

This O O
electrophysiological O O
parameter O O
provides O O
information O O
about O O
subclinical O O
neurotoxic O O
potential O O
of O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O O
is O O
not O O
helpful O O
in O O
predicting O O
the O O
appearance O O
of O O
sensory O O
symptoms O O
. O O

Five O O
cases O O
of O O
encephalitis O O
during O O
treatment O O
of O O
loiasis O O
with O O
diethylcarbamazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Five O O
cases O O
of O O
encephalitis O O
following O O
treatment O O
with O O
diethylcarbamazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DEC B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
observed O O
in O O
Congolese O O
patients O O
with O O
Loa O O
loa O O
filariasis O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
had O O
a O O
fatal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
outcome O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
one O B_NUMBER[MEASURE]/B_PERSON
resulted O O
in O O
severe O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequelae O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
notable O O
fact O O
was O O
that O O
this O O
complication O O
occurred O O
in O O
three O O
patients O O
hospitalized O O
before O O
treatment O O
began O O
, O O
with O O
whom O O
particularly O O
strict O O
therapeutic O O
precautions O O
were O O
taken O O
, O O
i O O
. O O
e O O
. O O
, O O
initial O O
dose O O
less O O
than O O
10 O O
mg O O
of O O
DEC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
very O O
gradual O O
dose O O
increases O O
, O O
and O O
associated O O
anti O O
- O O
allergic O O
treatment O O
. O O

This O O
type O B_MEASURE/B_DISEASE
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
complication O B_DISEASE
may O O
not O O
be O O
that O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
in O O
highly O O
endemic O B_PERSON/B_NUMBER[MEASURE]
regions O I_PERSON/I_NUMBER[MEASURE]
. O O

It O O
occurs O O
primarily O O
, O O
but O O
not O O
exclusively O O
, O O
in O O
subjects O B_PERSON/B_BIO
presenting O O
with O O
a O O
high O B_DISEASE/B_PERSON
microfilarial O I_DISEASE/I_PERSON
load O I_DISEASE/I_PERSON
. O O

The O O
relationship O B_PERSON/B_MEASURE
between O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
encephalitis O B_DISEASE
and O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
microfilaremia O B_DISEASE/B_GENE
is O O
evident O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pathophysiological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
in O O
the O O
light O B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
the O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
other O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
comments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
this O O
subject O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
published O O
in O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
pulmonary O O
mass O O
and O O
unique O O
membranous O O
glomerulonephritis O O
in O O
a O O
patient O O
with O O
valvular O O
heart O O
disease O O
: O O
Diagnostic O O
pitfall O O
and O O
new O O
findings O O
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
an O O
anti O O
- O O
arrhythmic O O
drug O O
for O O
life O O
- O O
threatening O O
tachycardia O O
, O O
but O O
various O O
adverse O O
effects O O
have O O
been O O
reported O O
. O O

Reported O O
herein O O
is O O
an O O
autopsy O O
case O O
of O O
valvular O O
heart O O
disease O O
, O O
in O O
a O O
patient O O
who O O
developed O O
a O O
lung O O
mass O O
( O O
1 O O
. O O
5 O O
cm O O
in O O
diameter O O
) O O
and O O
proteinuria O O
( O O
2 O O
. O O
76 O O
g O O
/ O O
day O O
) O O
after O O
treatment O O
with O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
long O O
time O O
. O O

The O O
lung O O
mass O O
was O O
highly O O
suspected O O
to O O
be O O
lung O O
cancer O O
on O O
CT O O
and O O
positron O O
emission O O
tomography O O
, O O
but O O
histologically O O
the O O
lesion O O
was O O
composed O O
of O O
lymphoplasmacytic O O
infiltrates O O
in O O
alveolar O O
walls O O
and O O
intra O O
- O O
alveolar O O
accumulation O O
of O O
foamy O O
macrophages O O
containing O O
characteristic O O
myelinoid O O
bodies O O
, O O
indicating O O
that O O
it O O
was O O
an O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
lesion O O
. O O

In O O
addition O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
the O O
lung O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
had O O
unevenly O O
distributed O O
hemosiderin O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
and O O
abnormally O O
tortuous O B_DISEASE_ADJECTIVE[DISEASE]
capillaries O I_DISEASE_ADJECTIVE[DISEASE]
were O O
seen O O
in O O
the O O
mass O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
heavily O O
hemosiderotic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
portions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
outside O O
the O O
mass O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

In O O
the O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
glomeruli O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
had O O
membrane O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
prominent O B_DISEASE/B_LOCATION
swelling O B_DISEASE/I_LOCATION
of O O
podocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
subepithelial O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposits O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
were O O
sometimes O O
large O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O O
hump O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
like O B_LOCATION/B_BIO
. O O

Autoimmune O B_DISEASE/B_MEASURE
diseases O I_DISEASE/I_MEASURE
, O O
viral O B_DISEASE/B_BIO
hepatitis O I_DISEASE/I_BIO
, O O
malignant O B_DISEASE
neoplasms O I_DISEASE
or O O
other O B_DISEASE
diseases O I_DISEASE
with O O
a O O
known O O
relationship O B_PERSON/B_MEASURE
to O O
membranous O B_DISEASE
glomerulonephritis O I_DISEASE
were O O
not O O
found O O
. O O

The O O
present O O
case O O
highlights O O
the O O
possibility O O
that O O
differential O O
diagnosis O O
between O O
an O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
pulmonary O O
lesion O O
and O O
a O O
neoplasm O O
can O O
be O O
very O O
difficult O O
radiologically O O
, O O
and O O
suggests O O
that O O
membranous O O
glomerulonephritis O O
might O O
be O O
another O O
possible O O
complication O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
. O O

Risk O O
of O O
coronary O O
artery O O
disease O O
associated O O
with O O
initial O O
sulphonylurea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
of O O
patients O O
with O O
type O O
2 O O
diabetes O O
: O O
a O O
matched O O
case O O
- O O
control O O
study O O
. O O

AIMS O O
: O O
This O O
study O O
sought O O
to O O
assess O O
the O O
risk O O
of O O
developing O O
coronary O O
artery O O
disease O O
( O O
CAD O O
) O O
associated O O
with O O
initial O O
treatment O O
of O O
type O O
2 O O
diabetes O O
with O O
different O O
sulphonylureas B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
In O O
type O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diabetic O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cases O B_PERSON
who O O
developed O O
CAD O B_DISEASE
were O O
compared O O
retrospectively O O
with O O
controls O B_PERSON/B_LOCATION
that O O
did O O
not O O
. O O

The O O
20 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
risk O I_TIME[MEASURE]/I_LOCATION
of O O
CAD O B_DISEASE
at O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
diabetes O B_DISEASE/B_LOCATION
, O O
using O O
the O O
UKPDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
risk O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
engine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
was O O
used O O
to O O
match O O
cases O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
controls O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
76 O B_PERSON/B_MEASURE
cases O I_PERSON/I_MEASURE
of O O
CAD O B_DISEASE/B_LOCATION
were O O
compared O O
with O O
152 O B_MEASURE/B_PERSON
controls O I_MEASURE/I_PERSON
. O O

The O O
hazard O O
of O O
developing O O
CAD O O
( O O
95 O O
% O O
CI O O
) O O
associated O O
with O O
initial O O
treatment O O
increased O O
by O O
2 O O
. O O
4 O O
- O O
fold O O
( O O
1 O O
. O O
3 O O
- O O
4 O O
. O O
3 O O
, O O
P O O
= O O
0 O O
. O O
004 O O
) O O
with O O
glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
2 O O
- O O
fold O O
( O O
0 O O
. O O
9 O O
- O O
4 O O
. O O
6 O O
, O O
P O O
= O O
0 O O
. O O
099 O O
) O O
with O O
glipizide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
2 O O
. O O
9 O O
- O O
fold O O
( O O
1 O O
. O O
6 O O
- O O
5 O O
. O O
1 O O
, O O
P O O
= O O
0 O O
. O O
000 O O
) O O
with O O
either O O
, O O
and O O
was O O
unchanged O O
with O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
hazard O O
decreased O O
0 O O
. O O
3 O O
- O O
fold O O
( O O
0 O O
. O O
7 O O
- O O
1 O O
. O O
7 O O
, O O
P O O
= O O
0 O O
. O O
385 O O
) O O
with O O
glimepiride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O O
. O O
4 O O
- O O
fold O O
( O O
0 O O
. O O
7 O O
- O O
1 O O
. O O
3 O O
, O O
P O O
= O O
0 O O
. O O
192 O O
) O O
with O O
gliclazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
0 O O
. O O
4 O O
- O O
fold O O
( O O
0 O O
. O O
7 O O
- O O
1 O O
. O O
1 O O
, O O
P O O
= O O
0 O O
. O O
09 O O
) O O
with O O
either O O
. O O

CONCLUSIONS O O
: O O
Initiating O O
treatment O O
of O O
type O O
2 O O
diabetes O O
with O O
glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
glipizide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
associated O O
with O O
increased O O
risk O O
of O O
CAD O O
in O O
comparison O O
to O O
gliclazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
glimepiride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

If O O
confirmed O O
, O O
this O O
may O O
be O O
important O O
because O O
most O O
Indian O O
patients O O
receive O O
the O O
cheaper O O
older O O
sulphonylureas B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
present O O
guidelines O O
do O O
not O O
distinguish O O
between O O
individual O O
agents O O
. O O

Reduced O O
progression O O
of O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
in O O
spontaneously O O
hypertensive O O
rats O O
treated O O
by O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
The O O
aim O O
of O O
the O O
study O O
was O O
to O O
investigate O O
the O O
antihypertensive O O
effects O O
of O O
angiotensin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O O
- O O
1 O O
receptor O O
blocker O O
, O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
its O O
potential O O
in O O
slowing O O
down O O
renal O O
disease O O
progression O O
in O O
spontaneously O O
hypertensive O O
rats O O
( O O
SHR O O
) O O
with O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
nephropathy O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Six O B_NUMBER[MEASURE]
- O O
month O B_TIME[MEASURE]
- O O
old O B_PERSON
female O I_PERSON
SHR O I_PERSON
were O O
randomly O O
selected O O
in O O
six O B_TIME[MEASURE]/B_ENT
groups O I_TIME[MEASURE]/I_ENT
. O O

Two O B_LOCATION/B_PERSON
control O I_LOCATION/I_PERSON
groups O I_LOCATION/I_PERSON
( O O
SH O B_LOCATION
( O O
6 O B_MEASURE
) O O
, O O
SH O B_LOCATION
( O O
12 O B_MEASURE
) O O
) O O
received O O
vehicle O B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Groups O O
ADR B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O O
) O O
, O O
ADR B B_LOCATION
+ O O
LOS B B_DISEASE/B_PERSON
( O O
6 O O
) O O
and O O
ADR B B_LOCATION
( O O
12 O O
) O O
, O O
and O O
ADR B B_LOCATION
+ O O
LOS B B_PERSON/B_LOCATION
( O O
12 O O
) O O
received O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
mg O O
/ O O
kg O O
/ O O
b O O
. O O
w O O
. O O
i O O
. O O
v O O
. O O
) O O
twice O O
in O O
a O O
3 O O
- O O
week O O
interval O O
. O O

Group O O
ADR B B_LOCATION
+ O O
LOS B B_PERSON/B_LOCATION
( O O
6 O O
) O O
received O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
10 O O
mg O O
/ O O
kg O O
/ O O
b O O
. O O
w O O
. O O
/ O O
day O O
by O O
gavages O O
) O O
for O O
6 O O
weeks O O
and O O
group O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O O
LOS B B_PERSON/B_DISEASE
( O O
12 O O
) O O
for O O
12 O O
weeks O O
after O O
second O O
injection O O
of O O
ADR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Animals O B_BIO/B_NUMBER[MEASURE]
were O O
killed O O
after O O
6 O B_NUMBER[MEASURE]
or O O
12 O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
, O O
respectively O O
. O O

Haemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
performed O O
on O O
anaesthetized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
urine O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
taken O O
for O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kidney O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
processed O O
for O O
morphological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Short O O
- O O
term O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
, O O
besides O O
antihypertensive O O
effect O O
, O O
improved O O
glomerular O O
filtration O O
rate O O
and O O
ameliorated O O
glomerulosclerosis O O
resulting O O
in O O
decreased O O
proteinuria O O
. O O

Prolonged O O
treatment O O
with O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
further O O
reduction O O
of O O
glomerulosclerosis O O
associated O O
with O O
reduced O O
progression O O
of O O
tubular O O
atrophy O O
and O O
interstitial O O
fibrosis O O
, O O
thus O O
preventing O O
heavy O O
proteinuria O O
and O O
chronic O O
renal O O
failure O O
. O O

Losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
reduced O O
uraemia O O
and O O
increased O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
clearance O O
in O O
advanced O O
ADR B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy O O
in O O
SHR O O
. O O

Histological O O
examination O O
showed O O
that O O
losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
prevent O O
tubular O O
atrophy O O
, O O
interstitial O O
infiltration O O
and O O
fibrosis O O
in O O
ADR B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy O O
. O O

CONCLUSION O O
: O O
Losartan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
the O O
rate O O
of O O
progression O O
of O O
ADR B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
induced O O
focal O O
segmental O O
glomerulosclerosis O O
to O O
end O O
- O O
stage O O
renal O O
disease O O
in O O
SHR O O
. O O

The O O
risks O O
of O O
aprotinin O O
and O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
cardiac O O
surgery O O
: O O
a O O
one O O
- O O
year O O
follow O O
- O O
up O O
of O O
1188 O O
consecutive O O
patients O O
. O O

BACKGROUND O O
: O O
Our O O
aim O O
was O O
to O O
investigate O O
postoperative O O
complications O O
and O O
mortality O O
after O O
administration O O
of O O
aprotinin O O
compared O O
to O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
an O O
unselected O O
, O O
consecutive O O
cohort O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Perioperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
consecutive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
cardiac O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
patients O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
were O O
prospectively O O
collected O O
between O O
September O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2005 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
June O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
university O B_LOCATION/B_ORGANIZATION
- O O
affiliated O O
clinic O B_LOCATION/B_ORGANIZATION
( O O
n O B_MEASURE/B_LOCATION
= O O
1188 O B_MEASURE
) O O
. O O

During O O
the O O
first O O
5 O O
mo O O
, O O
596 O O
patients O O
received O O
aprotinin O O
( O O
Group O O
A O O
) O O
; O O
in O O
the O O
next O O
5 O O
mo O O
, O O
592 O O
patients O O
were O O
treated O O
with O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Group O O
T O O
) O O
. O O

Except O O
for O O
antifibrinolytic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
the O O
anesthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protocols O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
intraoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
comparable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Postoperatively O O
, O O
a O O
significantly O O
higher O B_MEASURE
incidence O I_MEASURE
of O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
in O O
Group O B_PERSON/B_BIO
T O I_PERSON/I_BIO
( O O
4 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
, O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

This O O
difference O B_MEASURE
was O O
also O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
primary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
risk O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
subgroups O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
7 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
1 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
003 O B_MEASURE
; O O
7 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
vs O O
2 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
035 O B_MEASURE
, O O
respectively O O
) O O
. O O

Persistent O B_DISEASE
atrial O I_DISEASE
fibrillation O I_DISEASE
( O O
7 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
2 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
020 O B_MEASURE
) O O
and O O
renal O B_DISEASE
failure O I_DISEASE
( O O
9 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
1 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
were O O
also O O
more O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
Group O B_MEASURE/B_PERSON
T O I_MEASURE/I_PERSON
, O O
in O O
the O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
valve O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
surgery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
subgroup O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

On O O
the O O
contrary O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
among O O
primary O B_PERSON
coronary O I_PERSON
artery O I_PERSON
bypass O I_PERSON
surgery O I_PERSON
patients O I_PERSON
, O O
there O O
were O O
more O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
myocardial O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
infarctions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal O B_DISEASE
dysfunction O I_DISEASE
in O O
Group O B_PERSON/B_LOCATION
A O I_PERSON/I_LOCATION
( O O
5 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
2 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
027 O B_MEASURE
; O O
22 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
vs O O
15 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
036 O B_MEASURE
, O O
respectively O O
) O O
. O O

The O O
1 O B_MEASURE
- O O
yr O B_MEASURE/B_LOCATION
mortality O I_MEASURE/I_LOCATION
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
after O O
aprotinin O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
in O O
the O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
surgery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
17 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
9 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
034 O B_MEASURE
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Both O O
antifibrinolytic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
bear O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O O
on O O
the O O
type O B_DISEASE/B_MEASURE
of O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Administration O O
of O O
aprotinin O O
should O O
be O O
avoided O O
in O O
coronary O O
artery O O
bypass O O
graft O O
and O O
high O O
risk O O
patients O O
, O O
whereas O O
administration O O
of O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
recommended O O
in O O
valve O O
surgery O O
. O O

Delirium O O
in O O
an O O
elderly O O
woman O O
possibly O O
associated O O
with O O
administration O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
associated O O
with O O
adverse O O
reactions O O
, O O
including O O
gastrointestinal O O
symptoms O O
, O O
gynecologic O O
problems O O
, O O
and O O
headache O O
. O O

Changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
mental O B_DISEASE_ADJECTIVE[DISEASE]
status O I_DISEASE_ADJECTIVE[DISEASE]
, O O
however O O
, O O
have O O
not O O
been O O
reported O O
. O O

We O O
present O O
a O O
case O O
in O O
which O O
an O O
89 O O
- O O
year O O
- O O
old O O
woman O O
in O O
a O O
long O O
- O O
term O O
care O O
facility O O
became O O
confused O O
after O O
the O O
initiation O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

The O O
patient O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mental O B_DISEASE
status O I_DISEASE
was O O
first O O
reported O O
nine O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Her O O
delirium O O
significantly O O
improved O O
after O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
and O O
her O O
mental O O
status O O
returned O O
to O O
normal O O
within O O
a O O
week O O
. O O

Because O O
no O O
other O O
factors O O
related O O
to O O
this O O
patient O O
changed O O
significantly O O
, O O
the O O
delirium O O
experienced O O
by O O
this O O
patient O O
possibly O O
resulted O O
from O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

The O O
biological O O
properties O O
of O O
the O O
optical O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
effects O O
on O O
cardiac O O
arrhythmias O O
. O O

1 O B_NUMBER[MEASURE]
. O O

The O O
optical O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
compared O O
for O O
their O O
beta O O
- O O
blocking O O
and O O
antiarrhythmic O O
activities O O
. O O
2 O O
. O O

In O O
blocking O O
the O O
positive O O
inotropic O O
and O O
chronotropic O O
responses O O
to O O
isoprenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
( O O
+ O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
less O O
than O O
one O O
hundredth O O
the O O
potency O O
of O O
( O O
- O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

At O O
dose O O
levels O O
of O O
( O O
+ O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
attenuated O O
the O O
responses O O
to O O
isoprenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram O O
. O O
3 O O
. O O

The O O
metabolic O O
responses O O
to O O
isoprenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
dogs O O
( O O
an O O
increase O O
in O O
circulating O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
free O O
fatty B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
all O O
blocked O O
by O O
( O O
- O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

( O O
+ O O
) O O
- O O
Propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
no O O
effect O O
on O O
fatty B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O O
but O O
significantly O O
reduced O O
the O O
increments O O
in O O
both O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O
4 O O
. O O

Both O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possessed O O
similar O O
depressant O O
potency O O
on O O
isolated O O
atrial O O
muscle O O
taken O O
from O O
guinea O O
- O O
pigs O O
. O O
5 O O
. O O

The O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O O
similar O O
local O O
anaesthetic O O
potencies O O
on O O
an O O
isolated O O
frog O O
nerve O O
preparation O O
at O O
a O O
level O O
approximately O O
three O O
times O O
that O O
of O O
procaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
racemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
less O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
either O O
isomer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O O
6 O B_MEASURE/B_LOCATION
. O O

Both O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
capable O O
of O O
preventing O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiac O O
arrhythmias O O
in O O
cats O O
anaesthetized O O
with O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
the O O
mean O O
dose O O
of O O
( O O
- O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
0 O O
. O O
09 O O
+ O O
/ O O
- O O
0 O O
. O O
02 O O
mg O O
/ O O
kg O O
whereas O O
that O O
of O O
( O O
+ O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
4 O O
. O O
2 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
mg O O
/ O O
kg O O
. O O

At O O
the O O
effective O O
dose O O
level O O
of O O
( O O
+ O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram O O
. O O

Blockade O O
of O O
arrhythmias O O
with O O
both O O
isomers O O
was O O
surmountable O O
by O O
increasing O O
the O O
dose O O
of O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
7 O O
. O O

Both O O
isomers O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
capable O O
of O O
reversing O O
ventricular O O
tachycardia O O
caused O O
by O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
anaesthetized O O
cats O O
and O O
dogs O O
. O O

The O O
dose O O
of O O
( O O
- O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
smaller O O
than O O
that O O
of O O
( O O
+ O O
) O O
- O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
species O O
but O O
much O O
higher O O
than O O
that O O
required O O
to O O
produce O O
evidence O O
of O O
beta O O
- O O
blockade O O
. O O
8 O O
. O O

The O O
implications O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
. O O

Topotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
combination O O
with O O
radiotherapy O O
in O O
unresectable O O
glioblastoma O O
: O O
a O O
phase O O
2 O O
study O O
. O O

Improving O O
glioblastoma O B_DISEASE
multiforme O I_DISEASE
( O O
GBM O B_LOCATION/B_ORGANIZATION
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
radio O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O O
a O O
challenge O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Topotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
attractive O O
option O O
as O O
it O O
exhibits O O
growth O O
inhibition O O
of O O
human O O
glioma O O
as O O
well O O
as O O
brain O O
penetration O O
. O O

The O O
present O O
study O O
assessed O O
the O O
combination O O
of O O
radiotherapy O O
( O O
60 O O
Gy O O
/ O O
30 O O
fractions O O
/ O O
40 O O
days O O
) O O
and O O
topotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O O
. O O
9 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
on O O
days O O
1 O O
- O O
5 O O
on O O
weeks O O
1 O O
, O O
3 O O
and O O
5 O O
) O O
in O O
50 O O
adults O O
with O O
histologically O O
proven O O
and O O
untreated O O
GBM O O
. O O

The O O
incidence O B_MEASURE
of O O
non O B_DISEASE
- O O
hematological O B_DISEASE
toxicities O I_DISEASE
was O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
grade O B_MEASURE/B_DISEASE
3 O I_MEASURE/I_DISEASE
- O O
4 O B_MEASURE/B_DISEASE
hematological O I_MEASURE/I_DISEASE
toxicities O I_MEASURE/I_DISEASE
were O O
reported O O
in O O
20 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
mainly O O
lymphopenia O B_DISEASE
and O O
neutropenia O B_DISEASE
) O O
. O O

Partial O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
and O O
stabilization O B_DISEASE
rates O I_DISEASE
were O O
2 O B_MEASURE
% O I_MEASURE
and O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
, O O
with O O
an O O
overall O B_TIME[MEASURE]
time O I_TIME[MEASURE]
to O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
12 O B_TIME[MEASURE]
weeks O I_TIME[MEASURE]
. O O

One O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_PERSON
overall O I_TIME[MEASURE]/I_PERSON
survival O I_TIME[MEASURE]/I_PERSON
( O O
OS O B_DISEASE
) O O
rate O B_MEASURE
was O O
42 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
a O O
median O B_MEASURE/B_LOCATION
OS O I_MEASURE/I_LOCATION
of O O
40 O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
. O O

Topotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
combination O O
with O O
radiotherapy O O
was O O
well O O
tolerated O O
. O O

However O O
, O O
while O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
stabilization O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concerned O O
one O B_NUMBER[MEASURE]
- O O
third O B_SEQUENCE[MEASURE]
of O O
the O O
patients O B_PERSON
, O O
the O O
study O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
show O O
increased O O
benefits O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
survival O B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
unresectable O B_DISEASE/B_LOCATION
GBM O I_DISEASE/I_LOCATION
. O O

Long O O
- O O
term O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
leading O O
to O O
hyperparathyroidism O O
: O O
a O O
case O O
report O O
. O O

PURPOSE O O
: O O
This O O
paper O O
reviews O O
the O O
effect O O
of O O
chronic O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
on O O
serum O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
and O O
parathyroid O O
glands O O
, O O
its O O
pathogenesis O O
, O O
and O O
treatment O O
options O O
. O O

We O O
examined O O
the O O
case O O
of O O
a O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
patient O O
who O O
had O O
recurrent O O
hypercalcemia O O
to O O
better O O
understand O O
the O O
disease O O
process O O
. O O

CONCLUSION O O
: O O
Primary O O
hyperparathyroidism O O
is O O
a O O
rare O O
but O O
potentially O O
life O O
- O O
threatening O O
side O O
effect O O
of O O
long O O
- O O
term O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
. O O

Careful O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patient O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_TIME[MEASURE]
follow O I_TIME[MEASURE]
- O O
up O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O O
reduce O O
morbidity O B_DISEASE/B_MEASURE
. O O

PRACTICAL O O
IMPLICATIONS O O
: O O
As O O
much O O
as O O
15 O O
% O O
of O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
patients O O
become O O
hypercalcemic O O
. O O

By O O
routinely O O
monitoring O O
serum O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
, O O
healthcare O O
providers O O
can O O
improve O O
the O O
quality O O
of O O
life O O
of O O
this O O
patient O O
group O O
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
laryngeal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mask O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
endotracheal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tube O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
anesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O O
endoscopic O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

BACKGROUND O O
: O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
compare O O
surgical O O
conditions O O
, O O
including O O
the O O
amount O O
of O O
intraoperative O O
bleeding O O
as O O
well O O
as O O
intraoperative O O
blood O O
pressure O O
, O O
during O O
functional O O
endoscopic O O
sinus O O
surgery O O
( O O
FESS O O
) O O
using O O
flexible O O
reinforced O O
laryngeal O O
mask O O
airway O O
( O O
FRLMA O O
) O O
versus O O
endotracheal O O
tube O O
( O O
ETT O O
) O O
in O O
maintaining O O
controlled O O
hypotension O O
anesthesia O O
induced O O
by O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
remifentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total O O
i O O
. O O
v O O
. O O
anesthesia O O
( O O
TIVA O O
) O O
. O O

METHODS O O
: O O
Sixty O O
normotensive O O
American O O
Society O O
of O O
Anesthesiologists O O
I O O
- O O
II O O
adult O O
patients O O
undergoing O O
FESS O O
under O O
controlled O O
hypotension O O
anesthesia O O
caused O O
by O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
remifentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
TIVA O O
were O O
randomly O O
assigned O O
into O O
two O O
groups O O
: O O
group O O
I O O
, O O
FRLMA O O
; O O
group O O
II O O
, O O
ETT O O
. O O

Hemorrhage O B_DISEASE
was O O
measured O O
and O O
the O O
visibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
operative O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
evaluated O O
according O O
to O O
a O O
six O B_NUMBER[MEASURE]
- O O
point O B_MEASURE/B_LOCATION
scale O I_MEASURE/I_LOCATION
. O O

RESULTS O O
: O O
Controlled O O
hypotension O O
was O O
achieved O O
within O O
a O O
shorter O O
period O O
using O O
laryngeal O O
mask O O
using O O
lower O O
rates O O
of O O
remifentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
and O O
lower O O
total O O
dose O O
of O O
remifentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
In O O
summary O O
, O O
our O O
results O O
indicate O O
that O O
airway O O
management O O
using O O
FRLMA O O
during O O
controlled O O
hypotension O O
anesthesia O O
provided O O
better O O
surgical O O
conditions O O
in O O
terms O O
of O O
quality O O
of O O
operative O O
field O O
and O O
blood O O
loss O O
and O O
allowed O O
for O O
convenient O O
induced O O
hypotension O O
with O O
low O O
doses O O
of O O
remifentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
TIVA O O
in O O
patients O O
undergoing O O
FESS O O
. O O

Nonalcoholic O O
fatty O O
liver O O
disease O O
during O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
. O O

Valproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
is O O
effective O O
for O O
the O O
treatment O O
of O O
many O O
types O O
of O O
epilepsy O O
, O O
but O O
its O O
use O O
can O O
be O O
associated O O
with O O
an O O
increase O O
in O O
body O O
weight O O
. O O

We O O
report O O
a O O
case O O
of O O
nonalcoholic O O
fatty O O
liver O O
disease O O
( O O
NAFLD O O
) O O
arising O O
in O O
a O O
child O O
who O O
developed O O
obesity O O
during O O
VPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
. O O

Laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O O
hyperinsulinemia O B_DISEASE/B_PERSON
with O O
insulin O B_DISEASE
resistance O I_DISEASE
. O O

After O O
the O O
withdrawal O O
of O O
VPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
our O O
patient O O
showed O O
a O O
significant O O
weight O O
loss O O
, O O
a O O
decrease O O
of O O
body O O
mass O O
index O O
, O O
and O O
normalization O O
of O O
metabolic O O
and O O
endocrine O O
parameters O O
; O O
moreover O O
, O O
ultrasound O O
measurements O O
showed O O
a O O
complete O O
normalization O O
. O O

The O O
present O O
case O O
suggests O O
that O O
obesity O O
, O O
hyperinsulinemia O O
, O O
insulin O O
resistance O O
, O O
and O O
long O O
- O O
term O O
treatment O O
with O O
VPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
all O O
associated O O
with O O
the O O
development O O
of O O
NAFLD O O
; O O
this O O
side O O
effect O O
is O O
reversible O O
after O O
VPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
withdrawal O O
. O O

Carbimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
ANCA O O
positive O O
vasculitis O O
. O O

Anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thyroid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
like O O
carbimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
are O O
commonly O O
prescribed O O
for O O
the O O
treatment O O
of O O
hyperthyroidism O O
. O O

One O O
should O O
be O O
aware O O
of O O
the O O
side O O
effects O O
of O O
antithyroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Antineutrophil O O
cytoplasmic O O
antibody O O
( O O
ANCA O O
) O O
- O O
- O O
associated O O
vasculitis O O
is O O
a O O
potentially O O
life O O
- O O
threatening O O
adverse O O
effect O O
of O O
antithyroidmedications B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
report O O
a O O
patient O O
with O O
Graves O O
' O O
disease O O
who O O
developed O O
ANCA O O
positive O O
carbimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
vasculitis O O
. O O

The O O
episode O B_DISEASE/B_ENT
was O O
characterized O O
by O O
a O O
vasculitic O B_DISEASE
skin O I_DISEASE
rash O I_DISEASE
associated O O
with O O
large O B_DISEASE
joint O I_DISEASE
arthritis O I_DISEASE
, O O
pyrexia O B_DISEASE
and O O
parotiditis O B_DISEASE
but O O
no O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
involvement O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

He O O
was O O
referred O O
to O O
us O O
for O O
neurological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
he O O
had O O
difficulty O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
getting O O
up O O
from O O
squatting O O
position O B_LOCATION/B_MEASURE
and O O
was O O
suspected O O
to O O
have O O
myositis O B_DISEASE
. O O

Carbimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
a O O
lower O O
incidence O O
of O O
reported O O
ANCA O O
positive O O
side O O
effects O O
than O O
PUT O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
ANCA O O
positive O O
carbimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
vasculitis O O
case O O
reported O O
from O O
India O O
. O O

Aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
primary O O
prevention O O
of O O
cardiovascular O O
events O O
: O O
an O O
update O O
of O O
the O O
evidence O O
for O O
the O O
U O O
. O O
S O O
. O O

Preventive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Services O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Force O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

BACKGROUND O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Coronary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
cerebrovascular O B_DISEASE
disease O I_DISEASE
are O O
leading O O
causes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
death O B_DISEASE
in O O
the O O
United O B_LOCATION/B_PERSON
States O I_LOCATION/I_PERSON
. O O

In O O
2002 O B_MEASURE
, O O
the O O
U O B_OTHER/B_LOCATION
. O O
S O B_OTHER/B_LOCATION
. O O

Preventive O O
Services O O
Task O O
Force O O
( O O
USPSTF O O
) O O
strongly O O
recommended O O
that O O
clinicians O O
discuss O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
adults O O
who O O
are O O
at O O
increased O O
risk O O
for O O
coronary O O
heart O O
disease O O
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
benefits O O
and O O
harms O O
of O O
taking O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
primary O O
prevention O O
of O O
myocardial O O
infarctions O O
, O O
strokes O O
, O O
and O O
death O O
. O O

DATA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
SOURCES O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O O
MEDLINE O B_ORGANIZATION/B_PERSON
and O O
Cochrane O B_ORGANIZATION/B_LOCATION
Library O I_ORGANIZATION/I_LOCATION
( O O
search O B_MEASURE/B_LOCATION
dates O B_MEASURE/I_LOCATION
, O O
1 O B_TIME[MEASURE]/B_PERSON
January O I_TIME[MEASURE]/I_PERSON
2001 O I_TIME[MEASURE]/I_PERSON
to O O
28 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
August O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2008 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
recent O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systematic O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews O I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
lists O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
retrieved O O
articles O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
suggestions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
experts O B_PERSON/B_ORGANIZATION
. O O

STUDY O O
SELECTION O O
: O O
English O O
- O O
language O O
randomized O O
, O O
controlled O O
trials O O
( O O
RCTs O O
) O O
; O O
case O O
- O O
control O O
studies O O
; O O
meta O O
- O O
analyses O O
; O O
and O O
systematic O O
reviews O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O O
control O O
for O O
the O O
primary O O
prevention O O
of O O
cardiovascular O O
disease O O
( O O
CVD O O
) O O
were O O
selected O O
to O O
answer O O
the O O
following O O
questions O O
: O O
Does O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decrease O O
coronary O O
heart O O
events O O
, O O
strokes O O
, O O
death O O
from O O
coronary O O
heart O O
events O O
or O O
stroke O O
, O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
adults O O
without O O
known O O
CVD O O
? O O

Does O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increase O O
gastrointestinal O O
bleeding O O
or O O
hemorrhagic O O
strokes O O
? O O

DATA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EXTRACTION O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
All O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O O
reviewed O O
, O O
abstracted O O
, O O
and O O
rated O O
for O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O O
using O O
predefined O O
USPSTF O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

DATA O O
SYNTHESIS O O
: O O
New O O
evidence O O
from O O
1 O O
good O O
- O O
quality O O
RCT O O
, O O
1 O O
good O O
- O O
quality O O
meta O O
- O O
analysis O O
, O O
and O O
2 O O
fair O O
- O O
quality O O
subanalyses O O
of O O
RCTs O O
demonstrates O O
that O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
use O O
reduces O O
the O O
number O O
of O O
CVD O O
events O O
in O O
patients O O
without O O
known O O
CVD O O
. O O

Men O B_PERSON
in O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experienced O O
fewer O B_DISEASE/B_MEASURE
myocardial O I_DISEASE/I_MEASURE
infarctions O I_DISEASE/I_MEASURE
and O O
women O B_PERSON
experienced O O
fewer O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strokes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
does O O
not O O
seem O O
to O O
affect O O
CVD O O
mortality O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
either O O
men O O
or O O
women O O
. O O

The O O
use O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
primary O O
prevention O O
increases O O
the O O
risk O O
for O O
major O O
bleeding O O
events O O
, O O
primarily O O
gastrointestinal O O
bleeding O O
events O O
, O O
in O O
both O O
men O O
and O O
women O O
. O O

Men O O
have O O
an O O
increased O O
risk O O
for O O
hemorrhagic O O
strokes O O
with O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
use O O
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCT O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
meta O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
risk O B_DISEASE
for O O
hemorrhagic O B_DISEASE
strokes O I_DISEASE
in O O
women O B_PERSON/B_BIO
is O O
not O O
statistically O O
significantly O O
increased O O
. O O

LIMITATIONS O O
: O O
New O O
evidence O O
on O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
the O O
primary O O
prevention O O
of O O
CVD O O
is O O
limited O O
. O O

The O O
dose O O
of O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
in O O
the O O
RCTs O O
varied O O
, O O
which O O
prevented O O
the O O
estimation O O
of O O
the O O
most O O
appropriate O O
dose O O
for O O
primary O O
prevention O O
. O O

Several O B_NUMBER[MEASURE]
of O O
the O O
RCTs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
conducted O O
within O O
populations O B_LOCATION/B_ORGANIZATION
of O O
health O B_PERSON/B_LOCATION
professionals O I_PERSON/I_LOCATION
, O O
which O O
potentially O O
limits O O
generalizability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

CONCLUSION O O
: O O
Aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduces O O
the O O
risk O O
for O O
myocardial O O
infarction O O
in O O
men O O
and O O
strokes O O
in O O
women O O
. O O

Aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
use O O
increases O O
the O O
risk O O
for O O
serious O O
bleeding O O
events O O
. O O

Reducing O O
harm O O
associated O O
with O O
anticoagulation O O
: O O
practical O O
considerations O O
of O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
. O O

Argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
hepatically O O
metabolized O O
, O O
direct O O
thrombin O O
inhibitor O O
used O O
for O O
prophylaxis O O
or O O
treatment O O
of O O
thrombosis O O
in O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
( O O
HIT O O
) O O
and O O
for O O
patients O O
with O O
or O O
at O O
risk O O
of O O
HIT O O
undergoing O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

The O O
objective O O
of O O
this O O
review O O
is O O
to O O
summarize O O
practical O O
considerations O O
of O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
in O O
HIT O O
. O O

The O O
US O O
FDA O O
- O O
recommended O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose O O
in O O
HIT O O
is O O
2 O O
microg O O
/ O O
kg O O
/ O O
min O O
( O O
reduced O O
in O O
patients O O
with O O
hepatic O O
impairment O O
and O O
in O O
paediatric O O
patients O O
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
partial O O
thromboplastin O O
times O O
( O O
aPTTs O O
) O O
1 O O
. O O
5 O O
- O O
3 O O
times O O
baseline O O
( O O
not O O
> O O
100 O O
seconds O O
) O O
. O O

Contemporary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O O
that O O
reduced O O
doses O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
also O O
needed O O
in O O
patients O B_PERSON/B_ORGANIZATION
with O O
conditions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O O
with O O
hepatic O B_DISEASE
hypoperfusion O I_DISEASE
, O O
e O B_GENE/B_DISEASE
. O O
g O B_GENE/B_MEASURE
. O O
heart O B_DISEASE
failure O I_DISEASE
, O O
yet O O
are O O
unnecessary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
renal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dysfunction O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
adult O B_DISEASE
age O I_DISEASE
, O O
sex O B_PERSON/B_DISEASE
, O O
race O B_SPORT[ENT]/B_PERSON
/ O O
ethnicity O B_PERSON/B_LOCATION
or O O
obesity O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 O O
. O O
5 O O
- O O
1 O O
. O O
2 O O
microg O O
/ O O
kg O O
/ O O
min O O
typically O O
supports O O
therapeutic O O
aPTTs O O
. O O

The O O
FDA O B_ORGANIZATION/B_TIME[MEASURE]
- O O
recommended O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
during O O
PCI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
25 O B_MEASURE
microg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
min O B_PERSON/B_TIME[MEASURE]
( O O
350 O B_MEASURE
microg O I_MEASURE
/ O O
kg O B_MEASURE
initial O I_MEASURE
bolus O I_MEASURE
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
clotting O B_TIME[MEASURE]/B_LOCATION
times O B_TIME[MEASURE]/I_LOCATION
( O O
ACTs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
of O O
300 O B_MEASURE
- O O
450 O B_MEASURE
sec O I_MEASURE
. O O

For O O
PCI O O
, O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
not O O
been O O
investigated O O
in O O
hepatically O O
impaired O O
patients O O
; O O
dose O O
adjustment O O
is O O
unnecessary O O
for O O
adult O O
age O O
, O O
sex O O
, O O
race O O
/ O O
ethnicity O O
or O O
obesity O O
, O O
and O O
lesser O O
doses O O
may O O
be O O
adequate O O
with O O
concurrent O O
glycoprotein O O
IIb O O
/ O O
IIIa O O
inhibition O O
. O O

Argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prolongs O O
the O O
International O O
Normalized O O
Ratio O O
, O O
and O O
published O O
approaches O O
for O O
monitoring O O
the O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O O
to O O
- O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition O O
should O O
be O O
followed O O
. O O

Major O O
bleeding O O
with O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
0 O O
- O O
10 O O
% O O
in O O
the O O
non O O
- O O
interventional O O
setting O O
and O O
0 O O
- O O
5 O O
. O O
8 O O
% O O
periprocedurally O O
. O O

Argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
no O O
specific O O
antidote O O
, O O
and O O
if O O
excessive O O
anticoagulation O O
occurs O O
, O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
infusion O O
should O O
be O O
stopped O O
or O O
reduced O O
. O O

Improved O O
familiarity O O
of O O
healthcare O O
professionals O O
with O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
HIT O O
, O O
including O O
in O O
special O O
populations O O
and O O
during O O
PCI O O
, O O
may O O
facilitate O O
reduction O O
of O O
harm O O
associated O O
with O O
HIT O O
( O O
e O O
. O O
g O O
. O O
fewer O O
thromboses O O
) O O
or O O
its O O
treatment O O
( O O
e O O
. O O
g O O
. O O
fewer O O
argatroban B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
medication O O
errors O O
) O O
. O O

Rhabdomyolysis O O
and O O
brain O O
ischemic O O
stroke O O
in O O
a O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O O
male O O
under O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintenance O O
therapy O O
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
There O O
are O O
several O B_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
heroin O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
some O O
of O O
which O O
are O O
life O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
threatening O O
. O O

Methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
aggravate O O
this O O
problem O O
. O O

METHOD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
A O O
33 O O
- O O
year O O
- O O
old O O
man O O
presented O O
with O O
rhabdomyolysis O O
and O O
cerebral O O
ischemic O O
stroke O O
after O O
intravenous O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

He O O
had O O
used O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
age O O
20 O O
, O O
and O O
had O O
used O O
150 O O
mg O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
for O O
6 O O
months O O
. O O

He O O
was O O
found O O
unconsciousness O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O O
home O B_LOCATION/B_TIME[MEASURE]
and O O
was O O
sent O O
to O O
our O O
hospital O B_LOCATION
. O O

In O O
the O O
ER O B_LOCATION
, O O
his O O
opiate O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
was O O
4497 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
. O O

In O O
the O O
ICU O B_PERSON/B_LOCATION
, O O
we O O
found O O
rhabdomyolysis O B_DISEASE
, O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
and O O
acute O B_DISEASE
respiratory O I_DISEASE
failure O I_DISEASE
. O O

After O O
transfer O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
an O O
internal O B_LOCATION
ward O I_LOCATION
, O O
we O O
noted O O
aphasia O B_DISEASE
and O O
weakness O B_DISEASE
of O O
his O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

After O O
MRI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
found O O
cerebral O B_DISEASE_ADJECTIVE[DISEASE]
ischemic O I_DISEASE_ADJECTIVE[DISEASE]
infarction O I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O O
: O O
Those O O
using O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simultaneously O O
may O O
increase O O
risk O O
of O O
rhabdomyolysis O O
and O O
ischemic O O
stroke O O
. O O

Patients O O
under O O
methadone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
maintenance O O
therapy O O
should O O
be O O
warned O O
regarding O O
these O O
serious O O
adverse O O
events O O
. O O

Hypotheses O O
of O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
rhabdomyolysis O O
and O O
stroke O O
in O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O O
are O O
discussed O O
. O O

Increased O O
vulnerability O O
to O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
hydroxydopamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
lesion O O
and O O
reduced O O
development O O
of O O
dyskinesias O O
in O O
mice O O
lacking O O
CB1 O O
cannabinoid O O
receptors O O
. O O

Motor O O
impairment O O
, O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
neuronal O O
activity O O
and O O
proenkephalin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
PENK B B_LOCATION/B_PERSON
) O O
gene O O
expression O O
in O O
the O O
caudate O O
- O O
putamen O O
( O O
CPu O O
) O O
were O O
measured O O
in O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
lesioned O O
and O O
treated O O
( O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
DOPA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
+ I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
benserazide I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
CB1 O O
KO O O
and O O
WT O O
mice O O
. O O

A O O
lesion O O
induced O O
by O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
produced O O
more O O
severe O O
motor O O
deterioration O O
in O O
CB1 O O
KO O O
mice O O
accompanied O O
by O O
more O O
loss O O
of O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurons O O
and O O
increased O O
PENK B B_GENE
gene O O
expression O O
in O O
the O O
CPu O O
. O O

Oxidative O B_DISEASE_ADJECTIVE[DISEASE]
/ O O
nitrosative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
neuroinflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
estimated O O
in O O
the O O
CPu O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cingulate O B_PERSON/B_LOCATION
cortex O I_PERSON/I_LOCATION
( O O
Cg O B_DISEASE/B_LOCATION
) O O
. O O

CB1 O O
KO O O
mice O O
exhibited O O
higher O O
MDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
levels O O
and O O
iNOS O O
protein O O
expression O O
in O O
the O O
CPu O O
and O O
Cg O O
compared O O
to O O
WT O O
mice O O
. O O

Treatment O O
with O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DOPA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
benserazide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
12 O O
weeks O O
) O O
resulted O O
in O O
less O O
severe O O
dyskinesias O O
in O O
CB1 O O
KO O O
than O O
in O O
WT O O
mice O O
. O O

The O O
results O O
revealed O O
that O O
the O O
lack O O
of O O
cannabinoid O O
CB1 O O
receptors O O
increased O O
the O O
severity O O
of O O
motor O O
impairment O O
and O O
DA B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesion O O
, O O
and O O
reduced O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOPA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
dyskinesias O O
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
CB1 O O
receptors O O
offers O O
neuroprotection O O
against O O
dopaminergic O O
lesion O O
and O O
the O O
development O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOPA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
dyskinesias O O
. O O

Hepatocellular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
oxidant O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
stress O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
following O O
intestinal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
reperfusion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Reperfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intestine O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
acute O B_DISEASE
liver O I_DISEASE
dysfunction O I_DISEASE
characterized O O
by O O
hepatocellular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enzyme O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
release O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O O
plasma O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
, O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
bile O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
neutrophil O B_DISEASE
sequestration O I_DISEASE
within O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

The O O
pathophysiology O B_DISEASE
underlying O O
this O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injury O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
undertaken O O
to O O
determine O O
whether O O
oxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
associated O O
with O O
the O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]
injury O I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
determine O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indirect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
assessing O O
oxidant O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Rats O B_BIO/B_PERSON
were O O
subjected O O
to O O
a O O
standardized O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
intestinal O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ischemia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
reperfusion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Hepatic O O
tissue O O
was O O
assayed O O
for O O
lipid O O
peroxidation O O
products O O
and O O
oxidized B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduced I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glutathione I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

There O O
was O O
no O O
change O O
in O O
hepatic O O
tissue O O
total O O
glutathione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
following O O
intestinal O O
ischemia O O
- O O
reperfusion O O
injury O O
. O O

Oxidized B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutathione I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GSSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
increased O O
significantly O O
following O O
30 O O
and O O
60 O O
min O O
of O O
reperfusion O O
. O O

There O O
was O O
no O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
any O O
of O O
the O O
products O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
this O O
injury O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

An O O
increase O O
in O O
GSSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within O O
hepatic O O
tissue O O
during O O
intestinal O O
reperfusion O O
suggests O O
exposure O O
of O O
hepatocytes O O
to O O
an O O
oxidant O O
stress O O
. O O

The O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
products O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
the O O
oxidant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
insufficient O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
result O O
in O O
irreversible O B_DISEASE
injury O I_DISEASE
to O O
hepatocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
also O O
suggest O O
that O O
the O O
measurement O O
of O O
tissue O O
GSSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
a O O
more O O
sensitive O O
indicator O O
of O O
oxidant O O
stress O O
than O O
measurement O O
of O O
products O O
of O O
lipid O O
peroxidation O O
. O O

Animal O O
model O O
of O O
mania O O
induced O O
by O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Evidence O O
of O O
oxidative O O
stress O O
in O O
submitochondrial O O
particles O O
of O O
the O O
rat O O
brain O O
. O O

The O O
intracerebroventricular O O
( O O
ICV O O
) O O
administration O O
of O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
a O O
Na B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
/ O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
ATPase O O
inhibitor O O
) O O
in O O
rats O O
has O O
been O O
suggested O O
to O O
mimic O O
some O O
symptoms O O
of O O
human O O
bipolar O O
mania O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
shown O O
that O O
bipolar O B_DISEASE/B_GENE
disorder O I_DISEASE/I_GENE
may O O
be O O
related O O
to O O
mitochondrial O B_DISEASE
dysfunction O I_DISEASE
. O O

Herein O O
, O O
we O O
investigated O O
the O O
behavioral O O
and O O
biochemical O O
effects O O
induced O O
by O O
the O O
ICV O O
administration O O
of O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O O
. O O

To O O
achieve O O
this O O
aim O O
, O O
the O O
effects O O
of O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
immediately O O
after O O
and O O
7 O O
days O O
following O O
a O O
single O O
ICV O O
administration O O
( O O
at O O
concentrations O O
of O O
10 O O
( O O
- O O
2 O O
) O O
and O O
10 O O
( O O
- O O
3 O O
) O O
M O O
) O O
on O O
locomotion O O
was O O
measured O O
using O O
the O O
open O O
- O O
field O O
test O O
. O O

Additionally O O
, O O
thiobarbituric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reactive O O
substances O O
( O O
TBARSs O O
) O O
and O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
were O O
measured O O
in O O
submitochondrial O O
particles O O
of O O
the O O
prefrontal O O
cortex O O
, O O
hippocampus O O
, O O
striatum O O
and O O
amygdala O O
. O O

Our O O
findings O O
demonstrated O O
that O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
10 O O
( O O
- O O
2 O O
) O O
and O O
10 O O
( O O
- O O
3 O O
) O O
M O O
induced O O
hyperlocomotion O O
in O O
rats O O
, O O
and O O
this O O
response O O
remained O O
up O O
to O O
7 O O
days O O
following O O
a O O
single O O
ICV O O
injection O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
the O O
persistent O O
increase O O
in O O
the O O
rat O O
spontaneous O O
locomotion O O
is O O
associated O O
with O O
increased O O
TBARS O O
levels O O
and O O
superoxide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
generation O O
in O O
submitochondrial O O
particles O O
in O O
the O O
prefrontal O O
cortex O O
, O O
striatum O O
and O O
amygdala O O
. O O

In O O
conclusion O O
, O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
mania O O
- O O
like O O
behavior O O
may O O
provide O O
a O O
useful O O
animal O O
model O O
to O O
test O O
the O O
hypothesis O O
of O O
the O O
involvement O O
of O O
oxidative O O
stress O O
in O O
bipolar O O
disorder O O
. O O

Intraoperative O O
dialysis O O
during O O
liver O O
transplantation O O
with O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dialysate O O
. O O

Liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
acutely O O
ill O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
with O O
fulminant O B_DISEASE
liver O I_DISEASE
failure O I_DISEASE
carries O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intraoperative O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
immediate O B_DISEASE_ADJECTIVE[DISEASE]
postoperative O I_DISEASE_ADJECTIVE[DISEASE]
risks O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
are O O
increased O O
with O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
concomitant O B_DISEASE
acute O I_DISEASE
kidney O I_DISEASE
injury O I_DISEASE
( O O
AKI O B_DISEASE
) O O
and O O
intraoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialysis O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
sometimes O O
required O O
to O O
allow O O
the O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
proceed O O
. O O

The O O
derangements O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
procoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
anticoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathways O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
fulminant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
lead O O
to O O
difficulties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
anticoagulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
especially O O
when O O
continued O O
in O O
the O O
operating O B_PERSON/B_TIME[MEASURE]
room O B_PERSON/I_TIME[MEASURE]
. O O

Systemic O O
anticoagulation O O
is O O
unsafe O O
and O O
regional O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anticoagulation O O
in O O
the O O
absence O O
of O O
a O O
functional O O
liver O O
carries O O
the O O
risk O O
of O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O O
. O O

Citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dialysate O O
, O O
a O O
new O O
dialysate O O
with O O
citric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O O
be O O
used O O
for O O
anticoagulation O O
in O O
patients O O
who O O
cannot O O
tolerate O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O O
regional O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
report O O
a O O
case O O
of O O
a O O
40 O O
- O O
year O O
- O O
old O O
female O O
with O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
fulminant O O
liver O O
failure O O
with O O
associated O O
AKI O O
who O O
underwent O O
intraoperative O O
dialytic O O
support O O
during O O
liver O O
transplantation O O
anticoagulated O O
with O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dialysate O O
during O O
the O O
entire O O
procedure O O
. O O

The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
without O O
any O O
signs O O
of O O
citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O O
and O O
maintained O O
adequate O O
anticoagulation O O
for O O
patency O O
of O O
the O O
dialysis O O
circuit O O
. O O

Citrate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dialysate O O
is O O
a O O
safe O O
alternative O O
for O O
intradialytic O O
support O O
of O O
liver O O
transplantation O O
in O O
fulminant O O
liver O O
failure O O
. O O

Delirium O O
in O O
a O O
patient O O
with O O
toxic O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O O
concentrations O O
: O O
the O O
role O O
of O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
To O O
describe O O
a O O
case O O
of O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
delirium O O
associated O O
with O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CASE O B_TIME[MEASURE]/B_PERSON
SUMMARY O I_TIME[MEASURE]/I_PERSON
: O O
A O O
69 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
white O I_PERSON
female O I_PERSON
presented O O
to O O
the O O
emergency O B_PERSON/B_LOCATION
department O I_PERSON/I_LOCATION
with O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
confusion O B_DISEASE
and O O
paranoia O B_DISEASE
over O O
the O O
past O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
several O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
days O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

On O O
admission O O
the O O
patient O O
was O O
taking O O
carvedilol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 O O
mg O O
twice O O
daily O O
, O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O O
mg O O
/ O O
day O O
, O O
folic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
mg O O
/ O O
day O O
, O O
levothyroxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
microg O O
/ O O
day O O
, O O
pantoprazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O O
mg O O
/ O O
day O O
, O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O O
mg O O
/ O O
day O O
, O O
and O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
mg O O
twice O O
daily O O
. O O

Flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
had O O
been O O
started O O
2 O O
weeks O O
prior O O
for O O
atrial O O
fibrillation O O
. O O

Laboratory O O
test O O
findings O O
on O O
admission O O
were O O
notable O O
only O O
for O O
a O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O O
concentration O O
of O O
1360 O O
microg O O
/ O O
L O O
( O O
reference O O
range O O
200 O O
- O O
1000 O O
) O O
. O O

A O O
metabolic O O
drug O O
interaction O O
between O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
the O O
patient O O
had O O
been O O
taking O O
for O O
more O O
than O O
5 O O
years O O
, O O
was O O
considered O O
. O O

Paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
and O O
the O O
dose O O
of O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
to O O
50 O O
mg O O
twice O O
daily O O
. O O

Her O O
delirium O B_DISEASE
resolved O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
. O O

DISCUSSION O O
: O O
Flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pharmacologically O O
similar O O
agents O O
that O O
interact O O
with O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
channels O O
may O O
cause O O
delirium O O
in O O
susceptible O O
patients O O
. O O

A O O
MEDLINE O O
search O O
( O O
1966 O O
- O O
January O O
2009 O O
) O O
revealed O O
one O O
in O O
vivo O O
pharmacokinetic O O
study O O
on O O
the O O
interaction O O
between O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
CYP2D6 O O
substrate O O
, O O
and O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
CYP2D6 O O
inhibitor O O
, O O
as O O
well O O
as O O
3 O O
case O O
reports O O
of O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
delirium O O
. O O

According O O
to O O
the O O
Naranjo O O
probability O O
scale O O
, O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
the O O
probable O O
cause O O
of O O
the O O
patient O O
' O O
s O O
delirium O O
; O O
the O O
Horn O O
Drug O O
Interaction O O
Probability O O
Scale O O
indicates O O
a O O
possible O O
pharmacokinetic O O
drug O O
interaction O O
between O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Supratherapeutic O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O O
concentrations O O
may O O
cause O O
delirium O O
. O O

Because O O
toxicity O O
may O O
occur O O
when O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
prescribed O O
with O O
paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
other O O
potent O O
CYP2D6 O O
inhibitors O O
, O O
flecainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O O
concentrations O O
should O O
be O O
monitored O O
closely O O
with O O
commencement O O
of O O
CYP2D6 O O
inhibitors O O
. O O

Efficacy O O
of O O
everolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RAD001 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
patients O O
with O O
advanced O O
NSCLC O O
previously O O
treated O O
with O O
chemotherapy O O
alone O O
or O O
with O O
chemotherapy O O
and O O
EGFR O O
inhibitors O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
options O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
scarce O B_DISEASE_ADJECTIVE[DISEASE]
in O O
pretreated O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
advanced O O
non O B_DISEASE/B_GENE
- O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
cell O B_DISEASE
lung O I_DISEASE
cancer O I_DISEASE
( O O
NSCLC O B_DISEASE
) O O
patients O B_PERSON
. O O

RAD001 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
an O O
oral O O
inhibitor O O
of O O
the O O
mammalian O O
target O O
of O O
rapamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
mTOR O O
) O O
, O O
has O O
shown O O
phase O O
I O O
efficacy O O
in O O
NSCLC O O
. O O

METHODS O O
: O O
Stage O O
IIIb O O
or O O
IV O O
NSCLC O O
patients O O
, O O
with O O
two O O
or O O
fewer O O
prior O O
chemotherapy O O
regimens O O
, O O
one O O
platinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
( O O
stratum O O
1 O O
) O O
or O O
both O O
chemotherapy O O
and O O
epidermal O O
growth O O
factor O O
receptor O O
tyrosine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O O
inhibitors O O
( O O
stratum O O
2 O O
) O O
, O O
received O O
RAD001 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O O
mg O O
/ O O
day O O
until O O
progression O O
or O O
unacceptable O O
toxicity O O
. O O

Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
objective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
overall O B_DISEASE
response O I_DISEASE
rate O I_DISEASE
( O O
ORR O B_DISEASE/B_LOCATION
) O O
. O O

Analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
markers O B_GENE/B_DISEASE
associated O O
with O O
the O O
mTOR O B_DISEASE/B_GENE
pathway O I_DISEASE/I_GENE
were O O
carried O O
out O O
on O O
archival O B_DISEASE/B_PERSON
tumor O I_DISEASE/I_PERSON
from O O
a O O
subgroup O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
immunohistochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IHC O B_LOCATION/B_ORGANIZATION
) O O
and O O
direct O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequencing O O
. O O

RESULTS O B_MEASURE
: O O
Eighty O B_NUMBER[MEASURE]
- O O
five O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
enrolled O O
, O O
42 O B_MEASURE
in O O
stratum O B_PERSON/B_LOCATION
1 O B_PERSON/I_LOCATION
and O O
43 O B_MEASURE
in O O
stratum O B_LOCATION/B_PERSON
. O O

ORR O B_DISEASE/B_PERSON
was O O
4 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
7 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
stratum O I_MEASURE
1 O I_MEASURE
; O O
2 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
stratum O I_MEASURE
2 O I_MEASURE
) O O
. O O

Overall O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
control O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rate O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O O
47 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
. O O

Median O B_TIME[MEASURE]/B_PERSON
progression O I_TIME[MEASURE]/I_PERSON
- O O
free O B_TIME[MEASURE]/B_ORGANIZATION
survivals O I_TIME[MEASURE]/I_ORGANIZATION
( O O
PFSs O B_DISEASE
) O O
were O O
2 O B_MEASURE
. O O
6 O B_MEASURE
( O O
stratum O B_TIME[MEASURE]/B_PERSON
1 O I_TIME[MEASURE]/I_PERSON
) O O
and O O
2 O B_MEASURE
. O O
7 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
stratum O B_PERSON
2 O I_PERSON
) O O
. O O

Common O B_MEASURE/B_PERSON
> O B_MEASURE/I_PERSON
or O O
= O O
grade O B_MEASURE/B_DISEASE
3 O B_MEASURE/I_DISEASE
events O B_MEASURE/I_DISEASE
were O O
fatigue O B_DISEASE
, O O
dyspnea O B_DISEASE
, O O
stomatitis O B_DISEASE
, O O
anemia O B_DISEASE
, O O
and O O
thrombocytopenia O B_DISEASE
. O O

Pneumonitis O B_DISEASE
, O O
probably O O
or O O
possibly O O
related O B_DISEASE_ADJECTIVE[DISEASE]
, O O
mainly O O
grade O B_PROTEIN[GENE]/B_DISEASE
1 O I_PROTEIN[GENE]/I_DISEASE
/ O O
2 O B_NUMBER[MEASURE]
, O O
occurred O O
in O O
25 O B_LOCATION
% O I_LOCATION
. O O

Cox O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IHC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scores O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
found O O
that O O
only O O
phospho O B_GENE
AKT O I_GENE
( O O
pAKT O B_PROTEIN[GENE]/B_LOCATION
) O O
was O O
a O O
significant O B_MEASURE
independent O I_MEASURE
predictor O I_MEASURE
of O O
worse O B_DISEASE
PFS O I_DISEASE
. O O

CONCLUSIONS O O
: O O
RAD001 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O O
mg O O
/ O O
day O O
was O O
well O O
tolerated O O
, O O
showing O O
modest O O
clinical O O
activity O O
in O O
pretreated O O
NSCLC O O
. O O

Evaluation O O
of O O
RAD001 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
standard O O
therapy O O
for O O
metastatic O O
NSCLC O O
continues O O
. O O

Posttransplant O O
anemia O O
: O O
the O O
role O O
of O O
sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Posttransplant O B_DISEASE
anemia O I_DISEASE
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
may O O
hinder O O
patients O B_TIME[MEASURE]/B_LOCATION
' O I_TIME[MEASURE]/I_LOCATION
quality O I_TIME[MEASURE]/I_LOCATION
of O O
life O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
occurs O O
in O O
12 O B_MEASURE
to O O
76 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
patients O B_PERSON/B_DISEASE
, O O
and O O
is O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
immediate O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
posttransplant O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
period O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
variety O B_ENT/B_MEASURE
of O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
identified O O
that O O
increase O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
posttransplant O B_DISEASE
anemia O I_DISEASE
, O O
of O O
which O O
the O O
level O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
renal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
most O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
mammalian O O
target O O
of O O
rapamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor O O
, O O
has O O
been O O
implicated O O
as O O
playing O O
a O O
special O O
role O O
in O O
posttransplant O O
anemia O O
. O O

This O O
review O O
considers O O
anemia O O
associated O O
with O O
sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
including O O
its O O
presentation O O
, O O
mechanisms O O
, O O
and O O
management O O
. O O

Coronary O O
computerized O O
tomography O O
angiography O O
for O O
rapid O O
discharge O O
of O O
low O O
- O O
risk O O
patients O O
with O O
cocaine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
chest O O
pain O O
. O O

BACKGROUND O O
: O O
Most O O
patients O O
presenting O O
to O O
emergency O O
departments O O
( O O
EDs O O
) O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
are O O
admitted O O
for O O
at O O
least O O
12 O O
hours O O
and O O
receive O O
a O O
" O O
rule O O
out O O
acute O O
coronary O O
syndrome O O
" O O
protocol O O
, O O
often O O
with O O
noninvasive O O
testing O O
prior O O
to O O
discharge O O
. O O

In O O
patients O O
without O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
, O O
coronary O O
computerized O O
tomography O O
angiography O O
( O O
CTA O O
) O O
has O O
been O O
shown O O
to O O
be O O
useful O O
for O O
identifying O O
a O O
group O O
of O O
patients O O
at O O
low O O
risk O O
for O O
cardiac O O
events O O
who O O
can O O
be O O
safely O O
discharged O O
. O O

It O O
is O O
unclear O O
whether O O
a O O
coronary O O
CTA O O
strategy O O
would O O
be O O
efficacious O O
in O O
cocaine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
chest O O
pain O O
, O O
as O O
coronary O O
vasospasm O O
may O O
account O O
for O O
some O O
of O O
the O O
ischemia O O
. O O

We O O
studied O O
whether O O
a O O
negative O O
coronary O O
CTA O O
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
could O O
identify O O
a O O
subset O O
safe O O
for O O
discharge O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
prospectively O O
evaluated O O
the O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
risk O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
who O O
presented O O
to O O
the O O
ED O B_PERSON/B_LOCATION
with O O
cocaineassociated O B_DISEASE
chest O I_DISEASE
pain O I_DISEASE
( O O
self O B_PERSON/B_LOCATION
- O O
reported O O
or O O
positive O B_DISEASE_ADJECTIVE[DISEASE]
urine O I_DISEASE_ADJECTIVE[DISEASE]
test O I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Consecutive O B_PERSON
patients O I_PERSON
received O O
either O O
immediate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
ED O B_DISEASE/B_TIME[MEASURE]
( O O
without O O
serial O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
underwent O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
serial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiac O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
marker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Patients O B_PERSON/B_BIO
with O O
negative O B_DISEASE
coronary O I_DISEASE
CTA O I_DISEASE
( O O
maximal O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stenosis O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
less O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
50 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
were O O
discharged O O
. O O

The O O
main O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
30 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]/B_LOCATION
cardiovascular O I_TIME[MEASURE]/I_LOCATION
death O I_TIME[MEASURE]/I_LOCATION
or O O
myocardial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O O
: O O
A O O
total O O
of O O
59 O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chest O O
pain O O
were O O
evaluated O O
. O O

Patients O B_PERSON
had O O
a O O
mean O B_MEASURE/B_DISEASE
age O I_MEASURE/I_DISEASE
of O O
45 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
yrs O I_TIME[MEASURE]
and O O
were O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
black O I_MEASURE/I_PERSON
, O O
66 O B_PERSON/B_LOCATION
% O B_PERSON/I_LOCATION
male O B_PERSON/I_LOCATION
. O O

Seventy O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
had O O
a O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
nonspecific O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ECG O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
85 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
had O O
a O O
TIMI O B_MEASURE/B_LOCATION
score O I_MEASURE/I_LOCATION
< O O
2 O B_MEASURE
. O O

Twenty O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
received O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immediately O O
in O O
the O O
ED O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
18 O B_NUMBER[MEASURE]
of O O
whom O O
were O O
discharged O O
following O O
CTA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
( O O
90 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
received O O
coronary O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
with O O
37 O B_NUMBER[MEASURE]
discharged O O
home O B_LOCATION/B_PERSON
following O O
CTA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Six O B_PERSON
patients O I_PERSON
had O O
coronary O B_MEASURE/B_DISEASE
stenosis O I_MEASURE/I_DISEASE
> O I_MEASURE/I_DISEASE
or O O
= O B_MEASURE
50 O I_MEASURE
% O I_MEASURE
. O O

During O O
the O O
30 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
follow O O
- O O
up O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
no O O
patients O B_PERSON
died O O
of O O
a O O
cardiovascular O B_DISEASE
event O I_DISEASE
( O O
0 O B_MEASURE
% O I_MEASURE
; O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
, O O
0 O B_NUMBER[MEASURE]
- O O
6 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
and O O
no O O
patient O B_PERSON
sustained O O
a O O
nonfatal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
0 O B_MEASURE
% O I_MEASURE
; O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
, O O
0 O B_NUMBER[MEASURE]
- O O
6 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
Although O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
myocardial O O
ischemia O O
can O O
result O O
from O O
coronary O O
vasoconstriction O O
, O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O O
chest O O
pain O O
, O O
a O O
non O O
- O O
ischemic O O
ECG O O
, O O
and O O
a O O
TIMI O O
risk O O
score O O
< O O
2 O O
may O O
be O O
safely O O
discharged O O
from O O
the O O
ED O O
after O O
a O O
negative O O
coronary O O
CTA O O
with O O
a O O
low O O
risk O O
of O O
30 O O
- O O
day O O
adverse O O
events O O
. O O

Bilateral O O
haemorrhagic O O
infarction O O
of O O
the O O
globus O O
pallidus O O
after O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
intoxication O O
. O O

Cocaine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
risk O O
factor O O
for O O
both O O
ischemic O O
and O O
haemorrhagic O O
stroke O O
. O O

We O O
present O O
the O O
case O O
of O O
a O O
31 O O
- O O
year O O
- O O
old O O
man O O
with O O
bilateral O O
ischemia O O
of O O
the O O
globus O O
pallidus O O
after O O
excessive O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
intranasal O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

Drug O O
- O O
related O O
globus O O
pallidus O O
infarctions O O
are O O
most O O
often O O
associated O O
with O O
heroin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bilateral O O
basal O O
ganglia O O
infarcts O O
after O O
the O O
use O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
without O O
concurrent O O
heroin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
, O O
have O O
never O O
been O O
reported O O
. O O

In O O
our O O
patient O O
, O O
transient O O
cardiac O O
arrhythmia O O
or O O
respiratory O O
dysfunction O O
related O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
/ O O
or O O
ethanol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
were O O
the O O
most O O
likely O O
causes O O
of O O
cerebral O O
hypoperfusion O O
. O O

Late O B_DISEASE_ADJECTIVE[DISEASE]
fulminant O I_DISEASE_ADJECTIVE[DISEASE]
posterior O I_DISEASE_ADJECTIVE[DISEASE]
reversible O I_DISEASE_ADJECTIVE[DISEASE]
encephalopathy O I_DISEASE_ADJECTIVE[DISEASE]
syndrome O I_DISEASE_ADJECTIVE[DISEASE]
after O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Posterior O B_DISEASE
leukoencephalopathy O I_DISEASE
due O O
to O O
calcineurin O B_GENE
- O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
neurotoxicity O B_DISEASE
is O O
a O O
rare O B_DISEASE_ADJECTIVE[DISEASE]
but O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
complication O I_DISEASE_ADJECTIVE[DISEASE]
that O O
results O O
from O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
immunosuppressive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
primarily O O
those O O
administered O O
after O O
a O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
kidney O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

The O O
pathophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
that O O
disorder O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

CASE O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
We O O
report O O
the O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
46 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
woman O I_PERSON
who O O
received O O
a O O
liver O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
our O O
center O B_LOCATION
as O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
alcoholic O B_DISEASE/B_GENE
cirrhosis O I_DISEASE/I_GENE
and O O
in O O
whom O O
either O O
a O O
fulminant O B_DISEASE
course O I_DISEASE
of O O
posterior O B_DISEASE
leukoencephalopathy O I_DISEASE
or O O
posterior O B_DISEASE
reversible O I_DISEASE
encephalopathy O I_DISEASE
syndrome O I_DISEASE
developed O O
110 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

After O O
an O O
initially O O
uneventful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
course O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
after O O
the O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rapidly O O
fell O O
into O O
deep O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coma O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Cerebral O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
typical O B_DISEASE/B_LOCATION
signs O B_DISEASE/I_LOCATION
of O O
enhancement O B_DISEASE
in O O
the O O
pontine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Switching O O
the O O
immunosuppressive O O
regimen O O
from O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
improve O O
the O O
clinical O O
situation O O
. O O

The O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
any O O
calcineurin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resolution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
that O O
complication O B_DISEASE
. O O

CONCLUSIONS O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Posterior O B_DISEASE
reversible O I_DISEASE
encephalopathy O I_DISEASE
syndrome O I_DISEASE
after O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
rare O B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
recommend O O
a O O
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cessation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
calcineurin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rather O O
than O O
a O O
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypothermia O I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
bridge O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
cerebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
intracranial O B_DISEASE
hypertension O I_DISEASE
associated O O
with O O
fulminant O B_DISEASE
hepatic O I_DISEASE
failure O I_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
To O O
review O O
evidence O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
based O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
options O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O O
patients O B_PERSON/B_LOCATION
with O O
cerebral O B_DISEASE/B_GENE
edema O I_DISEASE/I_GENE
complicating O O
fulminant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
FHF O B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
discuss O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypothermia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

METHOD O O
: O O
Case O O
- O O
based O O
observations O O
from O O
a O O
medical O O
intensive O O
care O O
unit O O
( O O
MICU O O
) O O
in O O
a O O
tertiary O O
care O O
facility O O
in O O
a O O
27 O O
- O O
year O O
- O O
old O O
female O O
with O O
FHF O O
from O O
acetaminophen B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resultant O O
cerebral O O
edema O O
. O O

RESULTS O O
: O O
Our O O
patient O O
was O O
admitted O O
to O O
the O O
MICU O O
after O O
being O O
found O O
unresponsive O O
with O O
presumed O O
toxicity O O
from O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
was O O
ingested O O
over O O
a O O
2 O O
- O O
day O O
period O O
. O O

The O O
patient O B_PERSON
had O O
depressed O O
of O O
mental O B_DISEASE
status O I_DISEASE
lasting O O
at O O
least O O
24 O B_TIME[MEASURE]/B_PERSON
h O I_TIME[MEASURE]/I_PERSON
prior O I_TIME[MEASURE]/I_PERSON
to O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Initial O O
evaluation O O
confirmed O O
FHF O O
from O O
acetaminophen B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cerebral O O
edema O O
. O O

The O O
patient O B_PERSON/B_DISEASE
was O O
treated O O
with O O
hyperosmolar O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
hyperventilation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sedation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
chemical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
paralysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Her O O
intracranial O B_GENE
pressure O I_GENE
remained O O
elevated O O
despite O O
maximal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
then O O
initiated O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypothermia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O O
was O O
continued O O
for O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

At O O
re O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
warming O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
patient O B_PERSON
had O O
resolution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
her O O
cerebral O B_DISEASE
edema O I_DISEASE
and O O
intracranial O B_DISEASE
hypertension O I_DISEASE
. O O

At O O
discharge O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
she O O
had O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
neurological O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
In O O
patients O O
with O O
FHF O O
and O O
cerebral O O
edema O O
from O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdose O O
, O O
prolonged O O
therapeutic O O
hypothermia O O
could O O
potentially O O
be O O
used O O
as O O
a O O
life O O
saving O O
therapy O O
and O O
a O O
bridge O O
to O O
hepatic O O
and O O
neurological O O
recovery O O
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypothermia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
with O O
this O O
condition O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
. O O

Binasal O O
visual O O
field O O
defects O O
are O O
not O O
specific O O
to O O
vigabatrin B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
investigated O O
the O O
visual O O
defects O O
associated O O
with O O
the O O
antiepileptic O O
drug O O
vigabatrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

Two O O
hundred O O
four O O
people O O
with O O
epilepsy O O
were O O
grouped O O
on O O
the O O
basis O O
of O O
antiepileptic O O
drug O O
therapy O O
( O O
current O O
, O O
previous O O
, O O
or O O
no O O
exposure O O
to O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

Groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
matched O O
with O O
respect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
age O B_MEASURE/B_PERSON
, O O
gender O B_PERSON/B_MEASURE
, O O
and O O
seizure O B_MEASURE/B_PERSON
frequency O B_MEASURE/I_PERSON
. O O

All O O
patients O B_PERSON
underwent O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electrophysiological O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
wide O B_NUMBER[MEASURE]/B_LOCATION
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
multifocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
electroretinography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
and O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
static O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
perimetry O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
. O O

Bilateral O O
visual O O
field O O
constriction O O
was O O
observed O O
in O O
59 O O
% O O
of O O
patients O O
currently O O
taking O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
43 O O
% O O
of O O
patients O O
who O O
previously O O
took O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
24 O O
% O O
of O O
patients O O
with O O
no O O
exposure O O
to O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Assessment O O
of O O
retinal O O
function O O
revealed O O
abnormal O O
responses O O
in O O
48 O O
% O O
of O O
current O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
and O O
22 O O
% O O
of O O
prior O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O O
, O O
but O O
in O O
none O O
of O O
the O O
patients O O
without O O
previous O O
exposure O O
to O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Bilateral O B_DISEASE_ADJECTIVE[DISEASE]
visual O I_DISEASE_ADJECTIVE[DISEASE]
field O I_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]
are O O
common O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
treated O O
epilepsy O B_PERSON
population O I_PERSON
, O O
irrespective O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Assessment O O
by O O
conventional O O
static O O
perimetry O O
may O O
neither O O
be O O
sufficiently O O
sensitive O O
nor O O
specific O O
to O O
reliably O O
identify O O
retinal O O
toxicity O O
associated O O
with O O
VGB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Smoking O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O O
a O O
risk O O
factor O O
for O O
HIV O O
infection O O
among O O
people O O
who O O
use O O
injection O O
drugs O O
. O O

BACKGROUND O O
: O O
Little O O
is O O
known O O
about O O
the O O
possible O O
role O O
that O O
smoking O O
crack B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cocaine I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O O
on O O
the O O
incidence O O
of O O
HIV O O
infection O O
. O O

Given O O
the O O
increasing O O
use O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
sought O O
to O O
examine O O
whether O O
use O O
of O O
this O O
illicit O O
drug O O
has O O
become O O
a O O
risk O O
factor O O
for O O
HIV O O
infection O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
included O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
people O B_PERSON
participating O O
in O O
the O O
Vancouver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Injection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Users O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
who O O
reported O O
injecting O O
illicit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
least O O
once O O
in O O
the O O
month O B_TIME[MEASURE]/B_LOCATION
before O O
enrolment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
lived O O
in O O
the O O
greater O B_LOCATION
Vancouver O I_LOCATION
area O I_LOCATION
, O O
were O O
HIV O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
enrolment O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
completed O O
at O O
least O O
1 O B_NUMBER[MEASURE]/B_PERSON
follow O O
- O O
up O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
determine O O
whether O O
the O O
risk O O
of O O
HIV O O
seroconversion O O
among O O
daily O O
smokers O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
changed O O
over O O
time O O
, O O
we O O
used O O
Cox O O
proportional O O
hazards O O
regression O O
and O O
divided O O
the O O
study O O
into O O
3 O O
periods O O
: O O
May O O
1 O O
, O O
1996 O O
- O O
Nov O O
. O O

30 O B_MEASURE
, O O
1999 O B_MEASURE
( O O
period O B_TIME[MEASURE]/B_LOCATION
1 O I_TIME[MEASURE]/I_LOCATION
) O O
, O O
Dec O B_LOCATION/B_GENE
. O O

1 O B_TIME[MEASURE]
, O O
1999 O B_TIME[MEASURE]
- O O
Nov O B_LOCATION/B_TIME[MEASURE]
. O O

30 O B_MEASURE
, O O
2002 O B_TIME[MEASURE]
( O O
period O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
) O O
, O O
and O O
Dec O B_TIME[MEASURE]/B_LOCATION
. O O

1 O B_TIME[MEASURE]
, O O
2002 O B_TIME[MEASURE]
- O O
Dec O B_TIME[MEASURE]
. O O

30 O B_TIME[MEASURE]/B_LOCATION
, O O
2005 O B_MEASURE
( O O
period O B_TIME[MEASURE]
3 O I_TIME[MEASURE]
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Overall O O
, O O
1048 O B_NUMBER[MEASURE]/B_PERSON
eligible O I_NUMBER[MEASURE]/I_PERSON
injection O I_NUMBER[MEASURE]/I_PERSON
drug O I_NUMBER[MEASURE]/I_PERSON
users O I_NUMBER[MEASURE]/I_PERSON
were O O
included O O
in O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
these O O
, O O
137 O B_NUMBER[MEASURE]
acquired O O
HIV O B_DISEASE/B_GENE
infection O I_DISEASE/I_GENE
during O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mean O O
proportion O O
of O O
participants O O
who O O
reported O O
daily O O
smoking O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
increased O O
from O O
11 O O
. O O
6 O O
% O O
in O O
period O O
1 O O
to O O
39 O O
. O O
7 O O
% O O
in O O
period O O
3 O O
. O O

After O O
adjusting O O
for O O
potential O O
confounders O O
, O O
we O O
found O O
that O O
the O O
risk O O
of O O
HIV O O
seroconversion O O
among O O
participants O O
who O O
were O O
daily O O
smokers O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
increased O O
over O O
time O O
( O O
period O O
1 O O
: O O
hazard O O
ratio O O
[ O O
HR O O
] O O
1 O O
. O O
03 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
0 O O
. O O
57 O O
- O O
1 O O
. O O
85 O O
; O O
period O O
2 O O
: O O
HR O O
1 O O
. O O
68 O O
, O O
95 O O
% O O
CI O O
1 O O
. O O
01 O O
- O O
2 O O
. O O
80 O O
; O O
and O O
period O O
3 O O
: O O
HR O O
2 O O
. O O
74 O O
, O O
95 O O
% O O
CI O O
1 O O
. O O
06 O O
- O O
7 O O
. O O
11 O O
) O O
. O O

INTERPRETATION O O
: O O
Smoking O O
of O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
found O O
to O O
be O O
an O O
independent O O
risk O O
factor O O
for O O
HIV O O
seroconversion O O
among O O
people O O
who O O
were O O
injection O O
drug O O
users O O
. O O

This O O
finding O O
points O O
to O O
the O O
urgent O O
need O O
for O O
evidence O O
- O O
based O O
public O O
health O O
initiatives O O
targeted O O
at O O
people O O
who O O
smoke O O
crack B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improves O O
the O O
memory O O
deficits O O
caused O O
by O O
the O O
chemotherapy O O
agent O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cancer O B_PERSON
patients O I_PERSON
who O O
have O O
been O O
treated O O
with O O
systemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjuvant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
described O O
experiencing O O
deteriorations O B_DISEASE_ADJECTIVE[DISEASE]
in O O
cognition O B_DISEASE
. O O

A O O
widely O O
used O O
chemotherapeutic O O
agent O O
, O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
readily O O
crosses O O
the O O
blood O O
- O O
brain O O
barrier O O
and O O
so O O
could O O
have O O
a O O
direct O O
effect O O
on O O
brain O O
function O O
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
anti O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mitotic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
reduce O O
cell O B_DISEASE
proliferation O I_DISEASE
in O O
the O O
neurogenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
adult O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
reports O O
indicate O O
that O O
hippocampal O O
dependent O O
neurogenesis O O
and O O
cognition O O
are O O
enhanced O O
by O O
the O O
SSRI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antidepressant O O
Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
investigation O O
the O O
behavioural O O
effects O O
of O O
chronic O O
( O O
two O O
week O O
) O O
treatment O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
( O O
three O O
weeks O O
) O O
with O O
Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
separately O O
or O O
in O O
combination O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
tested O O
on O O
adult O O
Lister O O
hooded O O
rats O O
. O O

Behavioural O O
effects O O
were O O
tested O O
using O O
a O O
context O O
dependent O O
conditioned O O
emotional O O
response O O
test O O
( O O
CER O O
) O O
which O O
showed O O
that O O
animals O O
treated O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
significant O O
reduction O O
in O O
freezing O O
time O O
compared O O
to O O
controls O O
. O O

A O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
animals O B_BIO/B_PERSON
was O O
tested O O
using O O
a O O
hippocampal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
spatial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
working O O
memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
object O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
location O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
OLR O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Animals O O
treated O O
only O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
significant O O
deficits O O
in O O
their O O
ability O O
to O O
carry O O
out O O
the O O
OLR O O
task O O
but O O
co O O
administration O O
of O O
Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
improved O O
their O O
performance O O
. O O

5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O O
caused O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
proliferating O O
cells O O
in O O
the O O
sub O O
granular O O
zone O O
of O O
the O O
dentate O O
gyrus O O
compared O O
to O O
controls O O
. O O

This O O
reduction O O
was O O
eliminated O O
when O O
Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
co O O
administered O O
with O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
its O O
own O O
had O O
no O O
effect O O
on O O
proliferating O O
cell O O
number O O
or O O
behaviour O O
. O O

These O O
findings O O
suggest O O
that O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
negatively O O
affect O O
both O O
cell O O
proliferation O O
and O O
hippocampal O O
dependent O O
working O O
memory O O
and O O
that O O
these O O
deficits O O
can O O
be O O
reversed O O
by O O
the O O
simultaneous O O
administration O O
of O O
the O O
antidepressant O O
Fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Liver O O
- O O
specific O O
ablation O O
of O O
integrin O O
- O O
linked O O
kinase O O
in O O
mice O O
results O O
in O O
enhanced O O
and O O
prolonged O O
cell O O
proliferation O O
and O O
hepatomegaly O O
after O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

We O O
have O O
recently O O
demonstrated O O
that O O
disruption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
extracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
ECM O B_PROTEIN[GENE]/B_LOCATION
) O O
/ O O
integrin O B_GENE
signaling O O
via O O
elimination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integrin O B_GENE
- O O
linked O O
kinase O B_ENZYME[GENE]/B_LOCATION
( O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
hepatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
interferes O O
with O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
leading O O
to O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
liver O B_DISEASE/B_ORGANISM_FUNCTION
regeneration O B_DISEASE/I_ORGANISM_FUNCTION
. O O

This O O
study O O
investigates O O
the O O
role O O
of O O
ILK O O
in O O
liver O O
enlargement O O
induced O O
by O O
phenobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
PB B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
. O O

Wild O O
- O O
type O O
( O O
WT O O
) O O
and O O
ILK O O
: O O
liver O O
- O O
/ O O
- O O
mice O O
were O O
given O O
PB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
0 O O
. O O
1 O O
% O O
in O O
drinking O O
water O O
) O O
for O O
10 O O
days O O
. O O

Livers O O
were O O
harvested O O
on O O
2 O O
, O O
5 O O
, O O
and O O
10 O O
days O O
during O O
PB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O O
. O O

In O O
the O O
hepatocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]
ILK O I_DISEASE_ADJECTIVE[DISEASE]
/ O O
liver O B_GENE/B_DISEASE
- O O
/ O B_GENE
- O O
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
: O O
body O B_MEASURE
weight O I_MEASURE
ratio O I_MEASURE
was O O
more O B_MEASURE
than O O
double O O
as O O
compared O O
to O O
0 O B_MEASURE
h O O
at O O
day O B_TIME[MEASURE]/B_PERSON
2 O I_TIME[MEASURE]/I_PERSON
( O O
2 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
) O O
, O O
while O O
at O O
days O B_TIME[MEASURE]
5 O I_TIME[MEASURE]
and O O
10 O B_NUMBER[MEASURE]
, O O
it O O
was O O
enlarged O O
three O B_TIME[MEASURE]
times O I_TIME[MEASURE]
. O O

In O O
the O O
WT O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
mice O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
the O O
increase O B_DISEASE/B_MEASURE
was O O
as O O
expected O O
from O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
1 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
) O O
and O O
seems O O
to O O
have O O
leveled O O
off O O
after O O
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

There O O
were O O
slightly O O
increased O O
proliferating O O
cell O O
nuclear O O
antigen O O
- O O
positive O O
cells O O
in O O
the O O
ILK O O
/ O O
liver O O
- O O
/ O O
- O O
animals O O
at O O
day O O
2 O O
as O O
compared O O
to O O
WT O O
after O O
PB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
. O O

In O O
the O O
WT O B_LOCATION/B_ORGANIZATION
animals O I_LOCATION/I_ORGANIZATION
, O O
the O O
proliferative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
had O O
come O O
back O O
to O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
days O B_TIME[MEASURE]
5 O I_TIME[MEASURE]
and O O
10 O B_NUMBER[MEASURE]
. O O

Hepatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O O
the O O
ILK O B_DISEASE/B_PROTEIN[GENE]
/ O O
liver O B_GENE/B_DISEASE
- O O
/ O B_PERSON/B_PROTEIN[GENE]
- O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
to O O
proliferate O O
up O O
until O O
day O B_DISEASE/B_ORGANISM_FUNCTION
10 O I_DISEASE/I_ORGANISM_FUNCTION
. O O

ILK O O
/ O O
liver O O
- O O
/ O O
- O O
mice O O
also O O
showed O O
increased O O
expression O O
of O O
key O O
genes O O
involved O O
in O O
hepatocyte O O
proliferation O O
at O O
different O O
time O O
points O O
during O O
PB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

In O O
summary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ECM O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
communicate O O
with O O
the O O
signaling O O
machinery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
dividing O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
via O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
regulate O O
hepatocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
proliferative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Lack O O
of O O
ILK O O
in O O
the O O
hepatocytes O O
imparts O O
prolonged O O
proliferative O O
response O O
not O O
only O O
to O O
stimuli O O
related O O
to O O
liver O O
regeneration O O
but O O
also O O
to O O
xenobiotic O O
chemical O O
mitogens O O
, O O
such O O
as O O
PB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Decreased O O
Expression O O
of O O
Na B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
in O O
Gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
Nephropathy O O
. O O

The O O
present O O
study O O
was O O
aimed O O
to O O
determine O O
whether O O
there O O
is O O
an O O
altered O O
regulation O O
of O O
tubular O O
transporters O O
in O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
. O O

Sprague O O
- O O
Dawley O O
male O O
rats O O
( O O
200 O O
~ O O
250 O O
g O O
) O O
were O O
subcutaneously O O
injected O O
with O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
100 O O
mg O O
/ O O
kg O O
per O O
day O O
) O O
for O O
7 O O
days O O
, O O
and O O
the O O
expression O O
of O O
tubular O O
transporters O O
was O O
determined O O
by O O
immunoblotting O O
and O O
immunohistochemistry O O
. O O

The O O
mRNA O B_GENE
and O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
OAT O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
determined O O
. O O

Gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O O
exhibited O O
significantly O O
decreased O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
clearance O O
along O O
with O O
increased O O
plasma O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Accordingly O O
, O O
the O O
fractional O O
excretion O O
of O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O O
. O O

Urine O B_MEASURE/B_PERSON
volume O I_MEASURE/I_PERSON
was O O
increased O O
, O O
while O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
decreased O O
. O O

Immunoblotting O O
and O O
immunohistochemistry O O
revealed O O
decreased O O
expression O O
of O O
Na B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
/ O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
and O O
AQP1 O O
in O O
the O O
kidney O O
of O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O O
. O O

The O O
expression O B_GENE/B_MEASURE
of O O
OAT1 O B_GENE
and O O
OAT3 O B_GENE
was O O
also O O
decreased O O
. O O

Gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
may O O
at O O
least O O
in O O
part O O
be O O
causally O O
related O O
with O O
a O O
decreased O O
expression O O
of O O
Na B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
/ O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
. O O

Acute O O
renal O O
failure O O
after O O
high O O
- O O
dose O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
. O O

High O O
- O O
dose O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HD O O
- O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
is O O
an O O
important O O
treatment O O
for O O
Burkitt O O
lymphoma O O
, O O
but O O
can O O
cause O O
hepatic O O
and O O
renal O O
toxicity O O
when O O
its O O
clearance O O
is O O
delayed O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
renal O O
failure O O
after O O
HD O O
- O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
, O O
The O O
patient O O
was O O
a O O
3 O O
- O O
year O O
- O O
old O O
boy O O
who O O
had O O
received O O
a O O
living O O
- O O
related O O
liver O O
transplantation O O
for O O
congenital O O
biliary O O
atresia O O
. O O

At O O
day O B_TIME[MEASURE]/B_LOCATION
833 O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
he O O
was O O
diagnosed O O
with O O
PTLD O B_DISEASE
( O O
post O B_DISEASE/B_MEASURE
- O O
transplantation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lymphoproliferative O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disorder O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
Burkitt O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE/B_PERSON
malignant O I_DISEASE/I_PERSON
lymphoma O I_DISEASE/I_PERSON
) O O
. O O

During O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
he O O
suffered O O
ileal O B_DISEASE
perforation O I_DISEASE
and O O
ileostomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
performed O O
. O O

Subsequent O O
HD O O
- O O
MTX B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
caused O O
acute O O
renal O O
failure O O
that O O
required O O
continuous O O
hemodialysis O O
. O O

We O O
supposed O O
that O O
intravascular O B_DISEASE
hypovolemia O I_DISEASE
due O O
to O O
substantial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drainage O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
ileostoma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
caused O O
acute O B_DISEASE
prerenal O I_DISEASE
failure O I_DISEASE
. O O

After O O
recovery O O
of O O
his O O
renal O O
function O O
, O O
we O O
could O O
safely O O
treat O O
the O O
patient O O
with O O
HD O O
- O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
by O O
controlling O O
drainage O O
from O O
ileostoma O O
with O O
total O O
parenteral O O
nutrition O O
. O O

Longitudinal O O
association O O
of O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
with O O
HIV O O
disease O O
progression O O
and O O
psychological O O
health O O
of O O
women O O
with O O
HIV O O
. O O

We O O
evaluated O O
the O O
association O O
of O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
consumption O O
and O O
depression O O
, O O
and O O
their O O
effects O O
on O O
HIV O O
disease O O
progression O O
among O O
women O O
with O O
HIV O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O O
871 O B_PERSON
women O I_PERSON
with O O
HIV O B_DISEASE/B_LOCATION
who O O
were O O
recruited O O
from O O
1993 O B_MEASURE
- O O
1995 O B_MEASURE
in O O
four O B_LOCATION
US O I_LOCATION
cities O I_LOCATION
. O O

The O O
participants O O
had O O
physical O O
examination O O
, O O
medical O O
record O O
extraction O O
, O O
and O O
venipuncture O O
, O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
determination O O
, O O
measurement O O
of O O
depression O O
symptoms O O
( O O
using O O
the O O
self O O
- O O
report O O
Center O O
for O O
Epidemiological O O
Studies O O
- O O
Depression O O
Scale O O
) O O
, O O
and O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
assessment O O
at O O
enrollment O O
, O O
and O O
semiannually O O
until O O
March O O
2000 O O
. O O

Multilevel O B_TIME[MEASURE]/B_ORGANIZATION
random O I_TIME[MEASURE]/I_ORGANIZATION
coefficient O I_TIME[MEASURE]/I_ORGANIZATION
ordinal O I_TIME[MEASURE]/I_ORGANIZATION
models O I_TIME[MEASURE]/I_ORGANIZATION
as O O
well O O
as O O
multilevel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
joint O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
used O O
in O O
the O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
was O O
no O O
significant O O
association O O
between O O
level O O
of O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
. O O

When O O
participants O O
were O O
stratified O O
by O O
antiretroviral O O
therapy O O
( O O
ART O O
) O O
use O O
, O O
the O O
association O O
between O O
alcohol B B_DISEASE
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
did O O
not O O
reach O O
statistical O O
significance O O
. O O

The O O
association O O
between O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
consumption O O
and O O
depression O O
was O O
significant O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Depression O B_TIME[MEASURE]/B_DISEASE
had O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
CD4 O B_GENE/B_MEASURE
+ O I_GENE/I_MEASURE
T O I_GENE/I_MEASURE
- O O
cell O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counts O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O O
time O B_TIME[MEASURE]/B_PERSON
regardless O O
of O O
ART O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
findings O O
suggest O O
that O O
alcohol B B_BIO/B_DISEASE
consumption O O
has O O
a O O
direct O O
association O O
with O O
depression O O
. O O

Moreover O O
, O O
depression O B_DISEASE/B_GENE
is O O
associated O O
with O O
HIV O B_DISEASE
disease O I_DISEASE
progression O I_DISEASE
. O O

Our O O
findings O O
have O O
implications O O
for O O
the O O
provision O O
of O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
interventions O O
and O O
psychological O O
resources O O
to O O
improve O O
the O O
health O O
of O O
women O O
with O O
HIV O O
. O O

Chemokine O O
CCL2 O O
and O O
its O O
receptor O O
CCR2 O O
are O O
increased O O
in O O
the O O
hippocampus O O
following O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
status O O
epilepticus O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
: O O
Neuroinflammation O B_DISEASE/B_GENE
occurs O O
after O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
is O O
implicated O O
in O O
epileptogenesis O B_DISEASE_ADJECTIVE[DISEASE]
. O O

CCR2 O B_GENE
is O O
a O O
chemokine O B_GENE/B_PERSON
receptor O I_GENE/I_PERSON
for O O
CCL2 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
their O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mediates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
monocyte O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infiltration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
neuroinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cascade O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
triggered O O
in O O
different O B_DISEASE/B_LOCATION
brain O I_DISEASE/I_LOCATION
pathologies O I_DISEASE/I_LOCATION
. O O

In O O
this O O
work O O
CCR2 O O
and O O
CCL2 O O
expression O O
were O O
examined O O
following O O
status O O
epilepticus O O
( O O
SE O O
) O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

METHODS O O
: O O
SE O O
was O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

Control O O
rats O O
were O O
injected O O
with O O
saline O O
instead O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Five O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
SE O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
CCR2 O B_GENE
staining O O
in O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
glial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
examined O O
using O O
imunohistochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
number O B_MEASURE/B_LOCATION
of O O
CCR2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O O
determined O O
using O O
stereology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

CCL2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
was O O
examined O O
by O O
molecular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Increased O O
CCR2 O B_GENE/B_DISEASE
was O O
observed O O
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
after O O
SE O B_DISEASE
. O O

Seizures O B_DISEASE/B_LOCATION
also O O
resulted O O
in O O
alterations O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O O
CCR2 O B_GENE
. O O

Increased O O
numbers O B_MEASURE
of O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
expressed O O
CCR2 O B_GENE
was O O
observed O O
following O O
SE O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Microglial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
more O O
closely O O
apposed O O
to O O
the O O
CCR2 O B_GENE
- O O
labeled O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O O
SE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
experienced O O
SE O B_DISEASE
exhibited O O
CCR2 O B_GENE
- O O
labeling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
in O O
populations O B_LOCATION
of O O
hypertrophied O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
astrocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
especially O O
in O O
CA1 O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O O
dentate O B_BODY_PART_OR_ORGAN_COMPONENT
gyrus O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
CCR2 O B_GENE
+ O O
astroctytes O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
observed O O
in O O
control O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CCL2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
it O O
was O O
elevated O O
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
following O O
SE O B_DISEASE
. O O

CONCLUSION O O
: O O
The O O
data O O
show O O
that O O
CCR2 O O
and O O
CCL2 O O
are O O
up O O
- O O
regulated O O
in O O
the O O
hippocampus O O
after O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
SE O O
. O O

Seizures O B_DISEASE/B_LOCATION
also O O
result O O
in O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
CCR2 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
might O O
be O O
involved O O
in O O
detrimental O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroplasticity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
neuroinflammatory O B_DISEASE/B_ORGANISM_FUNCTION
changes O I_DISEASE/I_ORGANISM_FUNCTION
that O O
occur O O
following O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Metallothionein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction O O
reduces O O
caspase O O
- O O
3 O O
activity O O
and O O
TNFalpha O O
levels O O
with O O
preservation O O
of O O
cognitive O O
function O O
and O O
intact O O
hippocampal O O
neurons O O
in O O
carmustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
rats O O
. O O

Hippocampal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integrity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
cognitive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

On O O
the O O
other O O
hand O O
, O O
induction O O
of O O
metallothionein B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
MT B B_LOCATION/B_PROTEIN[GENE]
) O O
by O O
ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
its O O
role O O
in O O
neuroprotection O O
has O O
been O O
documented O O
. O O

The O O
present O O
study O O
aimed O O
to O O
explore O O
the O O
effect O O
of O O
MT B B_GENE/B_DISEASE
induction O O
on O O
carmustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
BCNU B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
hippocampal O O
cognitive O O
dysfunction O O
in O O
rats O O
. O O

A O O
total O O
of O O
60 O O
male O O
Wistar O O
albino O O
rats O O
were O O
randomly O O
divided O O
into O O
four O O
groups O O
( O O
15 O O
/ O O
group O O
) O O
: O O
The O O
control O O
group O O
injected O O
with O O
single O O
doses O O
of O O
normal O O
saline O O
( O O
i O O
. O O
c O O
. O O
v O O
) O O
followed O O
24 O O
h O O
later O O
by O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent O O
( O O
i O O
. O O
v O O
) O O
. O O

The O O
second O O
group O O
administered O O
ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i O O
. O O
c O O
. O O
v O O
, O O
once O O
) O O
then O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent O O
( O O
i O O
. O O
v O O
) O O
after O O
24 O O
h O O
. O O

Third O O
group O O
received O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
20 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
v O O
, O O
once O O
) O O
24 O O
h O O
after O O
injection O O
with O O
normal O O
saline O O
( O O
i O O
. O O
c O O
. O O
v O O
) O O
. O O

Fourth O O
group O O
received O O
a O O
single O O
dose O O
of O O
ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
0 O O
. O O
1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
then O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
20 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
v O O
, O O
once O O
) O O
after O O
24 O O
h O O
. O O

The O O
obtained O O
data O O
revealed O O
that O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
resulted O O
in O O
deterioration O O
of O O
learning O O
and O O
short O O
- O O
term O O
memory O O
( O O
STM O O
) O O
, O O
as O O
measured O O
by O O
using O O
radial O O
arm O O
water O O
maze O O
, O O
accompanied O O
with O O
decreased O O
hippocampal O O
glutathione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reductase O O
( O O
GR O O
) O O
activity O O
and O O
reduced O O
glutathione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
GSH B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
content O O
. O O

Also O O
, O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
increased O O
serum O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
hippocampal O O
MT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
MDA B B_LOCATION
) O O
contents O O
as O O
well O O
as O O
caspase O O
- O O
3 O O
activity O O
in O O
addition O O
to O O
histological O O
alterations O O
. O O

ZnSO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
pretreatment O O
counteracted O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
inhibition O O
of O O
GR O O
and O O
depletion O O
of O O
GSH B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resulted O O
in O O
significant O O
reduction O O
in O O
the O O
levels O O
of O O
MDA B B_GENE/B_BIO
and O O
TNFalpha O O
as O O
well O O
as O O
the O O
activity O O
of O O
caspase O O
- O O
3 O O
. O O

The O O
histological O O
features O O
were O O
improved O O
in O O
hippocampus O O
of O O
rats O O
treated O O
with O O
ZnSO B B_LOCATION
( I I_LOCATION
4 I I_LOCATION
) I I_LOCATION
+ O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
only O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
MT B B_GENE/B_DISEASE
induction O O
halts O O
BCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
hippocampal O O
toxicity O O
as O O
it O O
prevented O O
GR O O
inhibition O O
and O O
GSH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
depletion O O
and O O
counteracted O O
the O O
increased O O
levels O O
of O O
TNFalpha O O
, O O
MDA B B_GENE/B_BIO
and O O
caspase O O
- O O
3 O O
activity O O
with O O
subsequent O O
preservation O O
of O O
cognition O O
. O O

Fatal O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
fulminant O O
eosinophilic O O
( O O
hypersensitivity O O
) O O
myocarditis O O
: O O
emphasis O O
on O O
anatomical O O
and O O
histological O O
characteristics O O
, O O
mechanisms O O
and O O
genetics O O
of O O
drug O O
hypersensitivity O O
and O O
differential O O
diagnosis O O
. O O

The O O
most O O
severe O O
adverse O O
reactions O O
to O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
observed O O
in O O
the O O
haemopoietic O O
system O O
, O O
the O O
liver O O
and O O
the O O
cardiovascular O O
system O O
. O O

A O O
frequently O O
fatal O O
, O O
although O O
exceptionally O O
rare O O
side O O
effect O O
of O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
necrotizing O O
eosinophilic O O
( O O
hypersensitivity O O
) O O
myocarditis O O
. O O

We O O
report O O
a O O
case O O
of O O
hypersensitivity O O
myocarditis O O
secondary O O
to O O
administration O O
of O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Acute O B_DISEASE/B_PERSON
hypersensitivity O I_DISEASE/I_PERSON
myocarditis O I_DISEASE/I_PERSON
was O O
not O O
suspected O O
clinically O O
, O O
and O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
made O O
post O B_DISEASE/B_MEASURE
- O O
mortem O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Histology O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
diffuse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infiltration O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O O
myocyte O B_DISEASE
damage O I_DISEASE
. O O

Clinically O O
, O O
death O B_PERSON/B_DISEASE
was O O
due O O
to O O
cardiogenic O B_DISEASE
shock O I_DISEASE
. O O

To O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
second O O
case O O
of O O
fatal O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
myocarditis O O
reported O O
in O O
English O O
literature O O
. O O

Neuropsychiatric O O
behaviors O O
in O O
the O O
MPTP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marmoset O O
model O O
of O O
Parkinson O O
' O O
s O O
disease O O
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Neuropsychiatric O B_DISEASE
symptoms O I_DISEASE
are O O
increasingly O O
recognised O O
as O O
a O O
significant O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON
with O O
Parkinson O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
( O O
PD O B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

These O O
symptoms O O
may O O
be O O
due O O
to O O
' O O
sensitisation O O
' O O
following O O
repeated O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
or O O
a O O
direct O O
effect O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
disease O O
state O O
. O O

The O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
MPTP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
lesioned O O
marmoset O O
was O O
used O O
as O O
a O O
model O O
of O O
neuropsychiatric O O
symptoms O O
in O O
PD O O
patients O O
. O O

Here O O
we O O
compare O O
the O O
time O O
course O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
motor O O
fluctuations O O
and O O
neuropsychiatric O O
- O O
like O O
behaviors O O
to O O
determine O O
the O O
relationship O O
between O O
duration O O
of O O
treatment O O
and O O
onset O O
of O O
symptoms O O
. O O

METHODS O O
: O O
Marmosets O O
were O O
administered O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydropyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
. O O
0 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
for O O
five O O
days O O
, O O
resulting O O
in O O
stable O O
parkinsonism O O
. O O

Levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
15 O O
mg O O
/ O O
kg O O
and O O
benserazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O O
. O O
75 O O
mg O O
/ O O
kg O O
) O O
p O O
. O O
o O O
. O O

b O O
. O O
i O O
. O O
d O O
, O O
was O O
administered O O
for O O
30 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Animals O O
were O O
evaluated O O
for O O
parkinsonian O O
disability O O
, O O
dyskinesia O O
and O O
on O O
- O O
time O O
( O O
motor O O
fluctuations O O
) O O
and O O
neuropsychiatric O O
- O O
like O O
behaviors O O
on O O
Day O O
0 O O
( O O
prior O O
to O O
levodopa B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
on O O
Days O O
1 O O
, O O
7 O O
, O O
13 O O
, O O
27 O O
and O O
30 O O
of O O
treatment O O
using O O
post O O
hoc O O
DVD O O
analysis O O
by O O
a O O
trained O O
rater O O
, O O
blind O O
to O O
the O O
treatment O O
day O O
. O O

RESULTS O B_MEASURE
: O O
The O O
neuropsychiatric O B_DISEASE
- O O
like O B_DISEASE/B_PROTEIN[GENE]
behavior O B_DISEASE/I_PROTEIN[GENE]
rating O B_DISEASE/I_PROTEIN[GENE]
scale O B_DISEASE/I_PROTEIN[GENE]
demonstrated O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interrater O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reliability O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
three O B_NUMBER[MEASURE]/B_LOCATION
trained O O
raters O B_PERSON/B_ORGANIZATION
of O O
differing O O
professional O B_MEASURE/B_PERSON
backgrounds O I_MEASURE/I_PERSON
. O O

As O O
anticipated O O
, O O
animals O O
exhibited O O
a O O
progressive O O
increase O O
in O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
motor O O
fluctuations O O
, O O
dyskinesia O O
and O O
wearing O O
- O O
off O O
, O O
that O O
correlated O O
with O O
the O O
duration O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
. O O

In O O
contrast O O
, O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
neuropsychiatric O O
- O O
like O O
behaviors O O
were O O
present O O
on O O
Day O O
1 O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
and O O
their O O
severity O O
did O O
not O O
correlate O O
with O O
duration O O
of O O
treatment O O
. O O

CONCLUSIONS O O
: O O
The O O
data O O
suggest O O
that O O
neuropsychiatric O O
disorders O O
in O O
PD O O
are O O
more O O
likely O O
an O O
interaction O O
between O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
the O O
disease O O
state O O
than O O
a O O
consequence O O
of O O
sensitisation O O
to O O
repeated O O
dopaminergic O O
therapy O O
. O O

Contrast B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrotoxicity O O
after O O
renal O O
artery O O
and O O
coronary O O
angioplasty O O
. O O

BACKGROUND O O
: O O
Renal O O
dysfunction O O
induced O O
by O O
iodinated O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CM B B_TIME[MEASURE]/B_DISEASE
) O O
administration O O
can O O
minimize O O
the O O
benefit O O
of O O
the O O
interventional O O
procedure O O
in O O
patients O O
undergoing O O
renal O O
angioplasty O O
( O O
PTRA O O
) O O
. O O

PURPOSE O O
: O O
To O O
compare O O
the O O
susceptibility O O
to O O
nephrotoxic O O
effect O O
of O O
CM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
patients O O
undergoing O O
PTRA O O
with O O
that O O
of O O
patients O O
submitted O O
to O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
33 O O
patients O O
successfully O O
treated O O
with O O
PTRA O O
( O O
PTRA O O
group O O
, O O
mean O O
age O O
70 O O
+ O O
/ O O
- O O
12 O O
years O O
, O O
23 O O
female O O
, O O
basal O O
creatinine B B_MEASURE/B_LOCATION
1 O O
. O O
46 O O
+ O O
/ O O
- O O
0 O O
. O O
79 O O
, O O
range O O
0 O O
. O O
7 O O
- O O
4 O O
. O O
9 O O
mg O O
/ O O
dl O O
) O O
were O O
compared O O
with O O
33 O O
patients O O
undergoing O O
successful O O
PCI O O
( O O
PCI O O
group O O
) O O
, O O
matched O O
for O O
basal O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O O
. O O
44 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
, O O
range O O
0 O O
. O O
7 O O
- O O
3 O O
. O O
4 O O
mg O O
/ O O
dl O O
) O O
, O O
gender O O
, O O
and O O
age O O
. O O

In O O
both O O
groups O O
postprocedural O O
( O O
48 O O
h O O
) O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
measured O O
. O O

RESULTS O O
: O O
Postprocedural O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O O
decreased O O
nonsignificantly O O
in O O
the O O
PTRA O O
group O O
( O O
1 O O
. O O
46 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
vs O O
. O O
1 O O
. O O
34 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
mg O O
/ O O
dl O O
, O O
P O O
= O O
NS O O
) O O
and O O
increased O O
significantly O O
in O O
the O O
PCI O O
group O O
( O O
1 O O
. O O
44 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
vs O O
. O O
1 O O
. O O
57 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mg O O
/ O O
dl O O
, O O
P O O
< O O
0 O O
. O O
02 O O
) O O
. O O

Changes O O
in O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
intervention O O
( O O
after O O
- O O
before O O
) O O
were O O
significantly O O
different O O
between O O
the O O
PTRA O O
and O O
PCI O O
groups O O
( O O
- O O
0 O O
. O O
12 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
vs O O
. O O
0 O O
. O O
13 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
, O O
P O O
= O O
0 O O
. O O
014 O O
) O O
. O O

This O O
difference O O
was O O
not O O
related O O
to O O
either O O
a O O
different O O
clinical O O
risk O O
profile O O
or O O
to O O
the O O
volume O O
of O O
CM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administered O O
. O O

CONCLUSION O O
: O O
In O O
this O O
preliminary O O
study O O
patients O O
submitted O O
to O O
PTRA O O
showed O O
a O O
lower O O
susceptibility O O
to O O
renal O O
damage O O
induced O O
by O O
CM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O O
than O O
PCI O O
patients O O
. O O

The O O
effectiveness O O
of O O
PTRA O O
on O O
renal O O
function O O
seems O O
to O O
be O O
barely O O
influenced O O
by O O
CM B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O O
. O O

Diphenhydramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prevents O O
the O O
haemodynamic O O
changes O O
of O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
ICU O O
patients O O
. O O

Cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 O O
( O O
H2 O O
) O O
antagonist O O
, O O
produces O O
a O O
decrease O O
in O O
arterial O O
pressure O O
due O O
to O O
vasodilatation O O
, O O
especially O O
in O O
critically O O
ill O O
patients O O
. O O

This O O
may O O
be O O
because O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts O O
as O O
a O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
agonist O O
. O O

We O O
, O O
therefore O O
, O O
investigated O O
the O O
effects O O
of O O
the O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
( O O
H1 O O
) O O
receptor O O
antagonist O O
, O O
diphenhydramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
the O O
haemodynamic O O
changes O O
observed O O
after O O
cimetidine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
ICU O O
patients O O
. O O

Each O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
studied O O
on O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
separate O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
days O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

In O O
a O O
random O O
fashion O O
, O O
they O O
received O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O O
mg O O
iv O O
on O O
one O O
day O O
, O O
and O O
on O O
the O O
other O O
, O O
a O O
pretreatment O O
of O O
diphenhydramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O O
mg O O
iv O O
with O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O O
mg O O
iv O O
. O O

In O O
the O O
non O O
- O O
pretreatment O O
group O O
, O O
mean O O
arterial O O
pressure O O
( O O
MAP O O
) O O
decreased O O
from O O
107 O O
. O O
4 O O
+ O O
/ O O
- O O
8 O O
. O O
4 O O
mmHg O O
to O O
86 O O
. O O
7 O O
+ O O
/ O O
- O O
11 O O
. O O
4 O O
mmHg O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
two O O
minutes O O
after O O
cimetidine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Also O O
, O O
systemic O B_DISEASE
vascular O I_DISEASE
resistance O I_DISEASE
( O O
SVR O B_DISEASE/B_PROTEIN[GENE]
) O O
decreased O O
during O O
the O O
eight O B_NUMBER[MEASURE]
- O O
minute O B_TIME[MEASURE]/B_LOCATION
observation O I_TIME[MEASURE]/I_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
pretreatment O B_TIME[MEASURE]/B_LOCATION
group O B_TIME[MEASURE]/I_LOCATION
, O O
little O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haemodynamic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
seen O O
. O O

We O O
conclude O O
that O O
an O O
H1 O O
antagonist O O
may O O
be O O
useful O O
in O O
preventing O O
hypotension O O
caused O O
by O O
iv O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
since O O
the O O
vasodilating O O
activity O O
of O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
mediated O O
, O O
in O O
part O O
, O O
through O O
the O O
H1 O O
receptor O O
. O O

Medical O O
and O O
psychiatric O O
outcomes O O
for O O
patients O O
transplanted O O
for O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
liver O O
failure O O
: O O
a O O
case O O
- O O
control O O
study O O
. O O

BACKGROUND O O
: O O
Acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hepatotoxicity O O
is O O
the O O
most O O
common O O
cause O O
of O O
acute O O
liver O O
failure O O
( O O
ALF O O
) O O
in O O
the O O
UK O O
. O O

Patients O B_PERSON
often O O
consume O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
suicidal O B_DISEASE
intent O I_DISEASE
or O O
with O O
a O O
background O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
substance O B_DISEASE
dependence O I_DISEASE
. O O

AIMS O O
AND O O
METHODS O O
: O O
We O O
compared O O
the O O
severity O O
of O O
pretransplant O O
illness O O
, O O
psychiatric O O
co O O
- O O
morbidity O O
, O O
medical O O
and O O
psychosocial O O
outcomes O O
of O O
all O O
patients O O
who O O
had O O
undergone O O
liver O O
transplantation O O
( O O
LT O O
) O O
emergently O O
between O O
1999 O O
- O O
2004 O O
for O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
( O O
n O O
= O O
36 O O
) O O
with O O
age O O
- O O
and O O
sex O O
- O O
matched O O
patients O O
undergoing O O
emergent O O
LT O O
for O O
non O O
- O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
( O O
n O O
= O O
35 O O
) O O
and O O
elective O O
LT O O
for O O
chronic O O
liver O O
disease O O
( O O
CLD O O
, O O
n O O
= O O
34 O O
) O O
. O O

RESULTS O O
: O O
Acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
patients O O
undergoing O O
LT O O
had O O
a O O
greater O O
severity O O
of O O
pre O O
- O O
LT O O
illness O O
reflected O O
by O O
higher O O
Acute O O
Physiology O O
and O O
Chronic O O
Health O O
Evaluation O O
II O O
scores O O
and O O
requirement O O
for O O
organ O O
support O O
compared O O
with O O
the O O
other O O
two O O
groups O O
. O O

Twenty O O
( O O
56 O O
% O O
) O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ALF O O
patients O O
had O O
a O O
formal O O
psychiatric O O
diagnosis O O
before O O
LT O O
( O O
non O O
- O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
= O O
0 O O
/ O O
35 O O
, O O
CLD O O
= O O
2 O O
/ O O
34 O O
; O O
P O O
< O O
0 O O
. O O
01 O O
for O O
all O O
) O O
and O O
nine O O
( O O
25 O O
% O O
) O O
had O O
a O O
previous O O
suicide O O
attempt O O
. O O

During O O
follow O O
- O O
up O O
( O O
median O O
5 O O
years O O
) O O
, O O
there O O
were O O
no O O
significant O O
differences O O
in O O
rejection O O
( O O
acute O O
and O O
chronic O O
) O O
, O O
graft O O
failure O O
or O O
survival O O
between O O
the O O
groups O O
( O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ALF O O
1 O O
year O O
87 O O
% O O
, O O
5 O O
years O O
75 O O
% O O
; O O
non O O
- O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
88 O O
% O O
, O O
78 O O
% O O
; O O
CLD O O
93 O O
% O O
, O O
82 O O
% O O
: O O
P O O
> O O
0 O O
. O O
6 O O
log O O
rank O O
) O O
. O O

Two O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
patients O O
reattempted O O
suicide O O
post O O
- O O
LT O O
( O O
one O O
died O O
8 O O
years O O
post O O
- O O
LT O O
) O O
. O O

CONCLUSIONS O O
: O O
Despite O O
a O O
high O O
prevalence O O
of O O
psychiatric O O
disturbance O O
, O O
outcomes O O
for O O
patients O O
transplanted O O
emergently O O
for O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ALF O O
were O O
comparable O O
to O O
those O O
transplanted O O
for O O
non O O
- O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ALF O O
and O O
electively O O
for O O
CLD O O
. O O

Multidisciplinary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
approaches O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatric O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
contribute O O
to O O
low O B_DISEASE/B_MEASURE
post O I_DISEASE/I_MEASURE
- O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suicide O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
rates O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
seen O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
graft O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
non O B_DISEASE
- O O
compliance O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Antithrombotic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cerebral O B_DISEASE
microbleeds O I_DISEASE
, O O
and O O
intracerebral O B_DISEASE
hemorrhage O I_DISEASE
: O O
a O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
published O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O B_TIME[MEASURE]/B_LOCATION
AND O O
PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Cerebral O B_DISEASE
microbleeds O I_DISEASE
( O O
MB O B_LOCATION/B_PERSON
) O O
are O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
intracerebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ICH O B_DISEASE/B_LOCATION
) O O
, O O
but O O
it O O
is O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O O
they O O
are O O
a O O
contraindication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
using O O
antithrombotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Insights O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
gained O O
by O O
pooling O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
MB O B_MEASURE/B_DISEASE
frequency O B_MEASURE/I_DISEASE
stratified O O
by O O
antithrombotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
cohorts O B_PERSON
with O O
ICH O B_DISEASE/B_LOCATION
and O O
ischemic O B_DISEASE_ADJECTIVE[DISEASE]
stroke O I_DISEASE_ADJECTIVE[DISEASE]
( O O
IS O B_LOCATION
) O O
/ O O
transient O B_DISEASE_ADJECTIVE[DISEASE]
ischemic O I_DISEASE_ADJECTIVE[DISEASE]
attack O I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIA O B_LOCATION/B_ORGANIZATION
) O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
performed O O
a O O
systematic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
published O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
cohorts O B_PERSON/B_LOCATION
with O O
stroke O B_DISEASE/B_LOCATION
or O O
TIA O B_DISEASE/B_LOCATION
to O O
compare O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
MB O B_DISEASE/B_GENE
in O O
: O O
( O O
1 O O
) O O
antithrombotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
nonantithrombotic O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
with O O
ICH O B_DISEASE/B_LOCATION
; O O
( O O
2 O O
) O O
antithrombotic O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
nonusers O B_PERSON/B_DISEASE
with O O
IS O B_DISEASE/B_LOCATION
/ O O
TIA O B_LOCATION/B_ORGANIZATION
; O O
and O O
( O O
3 O B_NUMBER[MEASURE]
) O O
ICH O B_PERSON/B_LOCATION
vs O I_PERSON/I_LOCATION
ischemic O I_PERSON/I_LOCATION
events O I_PERSON/I_LOCATION
stratified O O
by O O
antithrombotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
also O O
analyzed O O
published O O
and O O
unpublished O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O O
- O O
up O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
determine O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ICH O B_DISEASE
in O O
antithrombotic O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
with O O
MB O B_DISEASE/B_GENE
. O O

RESULTS O O
: O O
In O O
a O O
pooled O O
analysis O O
of O O
1460 O O
ICH O O
and O O
3817 O O
IS O O
/ O O
TIA O O
, O O
MB O O
were O O
more O O
frequent O O
in O O
ICH O O
vs O O
IS O O
/ O O
TIA O O
in O O
all O O
treatment O O
groups O O
, O O
but O O
the O O
excess O O
increased O O
from O O
2 O O
. O O
8 O O
( O O
odds O O
ratio O O
; O O
range O O
, O O
2 O O
. O O
3 O O
- O O
3 O O
. O O
5 O O
) O O
in O O
nonantithrombotic O O
users O O
to O O
5 O O
. O O
7 O O
( O O
range O O
, O O
3 O O
. O O
4 O O
- O O
9 O O
. O O
7 O O
) O O
in O O
antiplatelet O O
users O O
and O O
8 O O
. O O
0 O O
( O O
range O O
, O O
3 O O
. O O
5 O O
- O O
17 O O
. O O
8 O O
) O O
in O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O O
( O O
P O O
difference O O
= O O
0 O O
. O O
01 O O
) O O
. O O

There O O
was O O
also O O
an O O
excess O O
of O O
MB O O
in O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
vs O O
nonusers O O
with O O
ICH O O
( O O
OR O O
, O O
2 O O
. O O
7 O O
; O O
95 O O
% O O
CI O O
, O O
1 O O
. O O
6 O O
- O O
4 O O
. O O
4 O O
; O O
P O O
< O O
0 O O
. O O
001 O O
) O O
but O O
none O O
in O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
users O O
with O O
IS O O
/ O O
TIA O O
( O O
OR O O
, O O
1 O O
. O O
3 O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
. O O
9 O O
- O O
1 O O
. O O
7 O O
; O O
P O O
= O O
0 O O
. O O
33 O O
; O O
P O O
difference O O
= O O
0 O O
. O O
01 O O
) O O
. O O

There O O
was O O
a O O
smaller O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
excess O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
MB O B_DISEASE/B_GENE
in O O
antiplatelet O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
vs O I_PERSON/I_ORGANIZATION
nonusers O I_PERSON/I_ORGANIZATION
with O O
ICH O B_LOCATION/B_PERSON
( O O
OR O O
, O O
1 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
; O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
, O O
1 O B_NUMBER[MEASURE]/B_LOCATION
. O O
3 O B_MEASURE
- O O
2 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
, O O
but O O
findings O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
antiplatelet O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
with O O
IS O B_LOCATION
/ O O
TIA O B_LOCATION/B_ORGANIZATION
( O O
OR O O
, O O
1 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
; O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
, O O
1 O B_NUMBER[MEASURE]
. O O
2 O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
; O O
P O B_MEASURE
< O I_MEASURE
0 O I_MEASURE
. O O
001 O B_MEASURE
; O O
P O B_LOCATION
difference O I_LOCATION
= O O
0 O B_MEASURE
. O O
25 O B_MEASURE
) O O
. O O

In O O
pooled O O
follow O O
- O O
up O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
768 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antithrombotic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
users O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MB O B_DISEASE/B_GENE
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
associated O O
with O O
a O O
substantially O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
subsequent O B_DISEASE
ICH O I_DISEASE
( O O
OR O O
, O O
12 O B_MEASURE
. O O
1 O B_MEASURE
; O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
, O O
3 O B_MEASURE
. O O
4 O B_MEASURE
- O O
42 O B_MEASURE
. O O
5 O B_MEASURE
; O O
P O B_MEASURE
< O I_MEASURE
0 O I_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
The O O
excess O O
of O O
MB O O
in O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
with O O
ICH O O
compared O O
to O O
other O O
groups O O
suggests O O
that O O
MB O O
increase O O
the O O
risk O O
of O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
ICH O O
. O O

Limited O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
prospective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
corroborate O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O O
but O O
larger O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prospective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
urgently O O
required O O
. O O

Studies O O
of O O
synergy O O
between O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
a O O
novel O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blocker O O
, O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic O O
pain O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
determined O O
the O O
antihyperalgesic O O
effect O O
of O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blocker O O
with O O
antioxidant O O
properties O O
given O O
alone O O
and O O
in O O
combinations O O
with O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic O O
pain O O
. O O

DESIGN O O
: O O
Dose O O
response O O
curves O O
for O O
nonsedating O O
doses O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
intraperitoneally O O
alone O O
and O O
together O O
in O O
combinations O O
were O O
constructed O O
for O O
antihyperalgesic O O
effect O O
using O O
paw O O
withdrawal O O
from O O
noxious O O
heat O O
in O O
two O O
rat O O
pain O O
models O O
: O O
carrageenan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
paw O O
inflammation O O
and O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
induced O O
diabetic O O
neuropathy O O
. O O

RESULTS O O
: O O
The O O
maximum O O
nonsedating O O
doses O O
were O O
: O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
; O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O O
. O O
0 O O
mg O O
/ O O
kg O O
; O O
5 O O
. O O
0 O O
mg O O
/ O O
kg O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
in O O
combination O O
. O O

The O O
doses O O
calculated O O
to O O
cause O O
50 O O
% O O
reversal O O
of O O
hyperalgesia O O
( O O
ED50 O O
) O O
were O O
7 O O
. O O
54 O O
( O O
1 O O
. O O
81 O O
) O O
and O O
4 O O
. O O
83 O O
( O O
1 O O
. O O
54 O O
) O O
in O O
the O O
carrageenan B B_DISEASE
model O O
and O O
44 O O
. O O
18 O O
( O O
1 O O
. O O
37 O O
) O O
and O O
9 O O
. O O
14 O O
( O O
1 O O
. O O
24 O O
) O O
in O O
the O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neuropathy O O
model O O
for O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

These O O
values O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
greater O B_MEASURE
than O O
the O O
maximum O B_MEASURE/B_PERSON
nonsedating O I_MEASURE/I_PERSON
doses O I_MEASURE/I_PERSON
. O O

The O O
ED50 O O
values O O
for O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
given O O
in O O
combination O O
with O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
less O O
than O O
the O O
maximum O O
nonsedating O O
dose O O
: O O
0 O O
. O O
56 O O
( O O
1 O O
. O O
55 O O
) O O
in O O
the O O
carrageenan B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
model O O
and O O
1 O O
. O O
37 O O
( O O
1 O O
. O O
23 O O
) O O
in O O
the O O
neuropathy O O
model O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

The O O
antinociception O O
after O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
) O O
was O O
increased O O
by O O
co O O
- O O
administration O O
with O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
28 O O
. O O
0 O O
and O O
31 O O
. O O
7 O O
% O O
to O O
114 O O
. O O
6 O O
and O O
56 O O
. O O
9 O O
% O O
reversal O O
of O O
hyperalgesia O O
in O O
the O O
inflammatory O O
and O O
neuropathic O O
models O O
, O O
respectively O O
( O O
P O O
< O O
0 O O
. O O
01 O O
; O O
one O O
- O O
way O O
analysis O O
of O O
variance O O
- O O
significantly O O
greater O O
than O O
either O O
drug O O
given O O
alone O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
maximum O O
antihyperalgesic O O
effect O O
achievable O O
with O O
nonsedating O O
doses O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
increased O O
significantly O O
when O O
the O O
drug O O
is O O
used O O
in O O
combination O O
with O O
CNSB002 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
thrombocytopenia O O
: O O
a O O
practical O O
review O O
. O O

Heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
( O O
HIT O O
) O O
remains O O
under O O
- O O
recognized O O
despite O O
its O O
potentially O O
devastating O O
outcomes O O
. O O

It O O
begins O O
when O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
stimulates O O
the O O
formation O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
platelet O O
factor O O
4 O O
antibodies O O
, O O
which O O
in O O
turn O O
triggers O O
the O O
release O O
of O O
procoagulant O O
platelet O O
particles O O
. O O

Thrombosis O B_DISEASE
and O O
thrombocytopenia O B_DISEASE
that O O
follow O O
comprise O O
the O O
2 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hallmark O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
traits O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
HIT O B_DISEASE/B_LOCATION
, O O
with O O
the O O
former O B_PERSON/B_DISEASE
largely O O
responsible O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
vascular O I_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
prevalence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
HIT O B_DISEASE
varies O O
among O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subgroups O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
with O O
greater O B_MEASURE
incidence O I_MEASURE
in O O
surgical O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
compared O O
with O O
medical O B_PERSON
populations O I_PERSON
. O O

HIT O O
must O O
be O O
acknowledged O O
for O O
its O O
intense O O
predilection O O
for O O
thrombosis O O
and O O
suspected O O
whenever O O
thrombosis O O
occurs O O
after O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
incorporates O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clues O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
paramount O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
timely O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
institution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
its O O
delay O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
result O O
in O O
catastrophic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
treatment O O
of O O
HIT O O
mandates O O
an O O
immediate O O
cessation O O
of O O
all O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exposure O O
and O O
the O O
institution O O
of O O
an O O
antithrombotic O O
therapy O O
, O O
most O O
commonly O O
using O O
a O O
direct B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thrombin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
diagnostic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
" O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
which O O
primarily O O
include O O
functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
antigenic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
have O O
more O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
confirmatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
than O O
diagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
management O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HIT O B_DISEASE/B_LOCATION
. O O

Special O O
attention O O
must O O
be O O
paid O O
to O O
cardiac O O
patients O O
who O O
are O O
often O O
exposed O O
to O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
multiple O O
times O O
during O O
their O O
course O O
of O O
treatment O O
. O O

Direct B B_NUMBER[MEASURE]/B_PERSON
thrombin I B_NUMBER[MEASURE]/I_PERSON
inhibitors I B_NUMBER[MEASURE]/I_PERSON
are O O
appropriate O O
, O O
evidence O O
- O O
based O O
alternatives O O
to O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
patients O O
with O O
a O O
history O O
of O O
HIT O O
, O O
who O O
need O O
to O O
undergo O O
percutaneous O O
coronary O O
intervention O O
. O O

As O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remains O O
one O O
of O O
the O O
most O O
frequently O O
used O O
medications O O
today O O
with O O
potential O O
for O O
HIT O O
with O O
every O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
, O O
a O O
close O O
vigilance O O
of O O
platelet O O
counts O O
must O O
be O O
practiced O O
whenever O O
heparin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
initiated O O
. O O

Abductor O O
paralysis O O
after O O
botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
for O O
adductor O O
spasmodic O O
dysphonia O O
. O O

OBJECTIVES O O
/ O O
HYPOTHESIS O O
: O O
Botulinum O O
toxin O O
( O O
Botox B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
injections O O
into O O
the O O
thyroarytenoid O O
muscles O O
are O O
the O O
current O O
standard O O
of O O
care O O
for O O
adductor O O
spasmodic O O
dysphonia O O
( O O
ADSD O O
) O O
. O O

Reported O O
adverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
include O O
a O O
period O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
breathiness O B_DISEASE
, O O
throat O B_DISEASE
pain O I_DISEASE
, O O
and O O
difficulty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
swallowing O O
liquids O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Here O O
we O O
report O O
multiple O O
cases O O
of O O
bilateral O O
abductor O O
paralysis O O
following O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O O
for O O
ADSD O O
, O O
a O O
complication O O
previously O O
unreported O O
. O O

STUDY O B_LOCATION/B_MEASURE
DESIGN O I_LOCATION/I_MEASURE
: O O
Retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

METHODS O O
: O O
Patients O O
that O O
received O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O O
for O O
spasmodic O O
dysphonia O O
between O O
January O O
2000 O O
and O O
October O O
2009 O O
were O O
evaluated O O
. O O

Patients O B_PERSON
with O O
ADSD O B_DISEASE/B_LOCATION
were O O
identified O O
. O O

The O O
number O B_MEASURE
of O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
received O O
and O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
noted O O
. O O

For O O
patients O O
with O O
bilateral O O
abductor O O
paralysis O O
, O O
age O O
, O O
sex O O
, O O
paralytic O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dose O O
, O O
prior O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
, O O
and O O
course O O
following O O
paralysis O O
were O O
noted O O
. O O

RESULTS O O
: O O
From O O
a O O
database O O
of O O
452 O O
patients O O
receiving O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
352 O O
patients O O
had O O
been O O
diagnosed O O
with O O
ADSD O O
. O O

Of O O
these O O
352 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
eight O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
suffered O O
bilateral O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abductor O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
two O B_NUMBER[MEASURE]/B_PERSON
suffered O O
this O O
complication O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
twice O O
. O O

All O O
affected O O
patients O B_PERSON
were O O
females O B_PERSON/B_LOCATION
over O O
the O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
50 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
. O O

Most O B_PERSON
patients O I_PERSON
had O O
received O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
abductor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
continued O O
receiving O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
after O O
paralysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Seven O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
recovered O O
after O O
a O O
brief O B_TIME[MEASURE]
period O I_TIME[MEASURE]
of O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
restrictions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
underwent O O
a O O
tracheotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
incidence O O
of O O
abductor O O
paralysis O O
after O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection O O
for O O
ADSD O O
was O O
0 O O
. O O
34 O O
% O O
. O O

CONCLUSIONS O O
: O O
Bilateral O O
abductor O O
paralysis O O
is O O
a O O
rare O O
complication O O
of O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O O
for O O
ADSD O O
, O O
causing O O
difficulty O O
with O O
breathing O O
upon O O
exertion O O
. O O

The O O
likely O O
mechanism O O
of O O
paralysis O O
is O O
diffusion O O
of O O
Botox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
around O O
the O O
muscular O O
process O O
of O O
the O O
arytenoid O O
to O O
the O O
posterior O O
cricoarytenoid O O
muscles O O
. O O

The O O
paralysis O B_DISEASE
is O O
temporary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
watchful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
waiting O O
with O O
restriction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O O
the O O
recommended O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

Mitochondrial O O
impairment O O
contributes O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
dysfunction O O
: O O
Prevention O O
by O O
the O O
targeted O O
antioxidant O O
MitoQ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
goal O O
of O O
this O O
study O O
was O O
to O O
assess O O
mitochondrial O O
function O O
and O O
ROS O O
production O O
in O O
an O O
experimental O O
model O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
dysfunction O O
. O O

We O O
hypothesized O O
that O O
cocaine O B_DISEASE
abuse O I_DISEASE
may O O
lead O O
to O O
altered O B_DISEASE
mitochondrial O I_DISEASE
function O I_DISEASE
that O O
in O O
turn O B_GENE/B_PERSON
may O O
cause O O
left O O
ventricular O B_DISEASE
dysfunction O I_DISEASE
. O O

Seven O O
days O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administration O O
to O O
rats O O
led O O
to O O
an O O
increased O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
detected O O
in O O
cardiac O O
fibers O O
, O O
specifically O O
through O O
complex O O
I O O
and O O
complex O O
III O O
. O O

ROS O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
increased O O
, O O
specifically O O
in O O
interfibrillar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
parallel O O
there O O
was O O
a O O
decrease O O
in O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
, O O
whereas O O
no O O
difference O O
was O O
observed O O
in O O
subsarcolemmal O O
mitochondria O O
. O O

This O O
uncoupling O O
effect O O
on O O
oxidative O O
phosphorylation O O
was O O
not O O
detectable O O
after O O
short O O
- O O
term O O
exposure O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
suggesting O O
that O O
these O O
mitochondrial O O
abnormalities O O
were O O
a O O
late O O
rather O O
than O O
a O O
primary O O
event O O
in O O
the O O
pathological O O
response O O
to O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

MitoQ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
mitochondrial O O
- O O
targeted O O
antioxidant O O
, O O
was O O
shown O O
to O O
completely O O
prevent O O
these O O
mitochondrial O O
abnormalities O O
as O O
well O O
as O O
cardiac O O
dysfunction O O
characterized O O
here O O
by O O
a O O
diastolic O O
dysfunction O O
studied O O
with O O
a O O
conductance O O
catheter O O
to O O
obtain O O
pressure O O
- O O
volume O O
data O O
. O O

Taken O O
together O O
, O O
these O O
results O O
extend O O
previous O O
studies O O
and O O
demonstrate O O
that O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
dysfunction O O
may O O
be O O
due O O
to O O
a O O
mitochondrial O O
defect O O
. O O

Trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
immune O O
hemolytic O O
anemia O O
in O O
a O O
pediatric O O
oncology O O
patient O O
presenting O O
as O O
an O O
acute O O
hemolytic O O
transfusion O O
reaction O O
. O O

A O O
10 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
male O I_PERSON
with O O
acute O B_DISEASE
leukemia O I_DISEASE
presented O O
with O O
post O B_DISEASE/B_MEASURE
- O O
chemotherapy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

During O O
red O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
transfusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
he O O
developed O O
hemoglobinuria O B_DISEASE
. O O

Transfusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workup O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
immune O B_DISEASE
hemolytic O I_DISEASE
anemia O I_DISEASE
was O O
suspected O O
because O O
of O O
positive O B_DISEASE
direct O I_DISEASE
antiglobulin O I_DISEASE
test O I_DISEASE
, O O
negative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
eluate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
microspherocytes O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
smear O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
post O B_DISEASE/B_MEASURE
- O O
transfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Drug O O
studies O O
using O O
the O O
indirect O O
antiglobulin O O
test O O
were O O
strongly O O
positive O O
with O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
negative O O
with O O
sulfamethoxazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

The O O
patient O B_PERSON/B_DISEASE
recovered O O
after O O
discontinuing O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
no O O
recurrence O B_DISEASE
in O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

Other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
anemia O B_DISEASE
should O O
be O O
considered O O
in O O
patients O B_PERSON/B_BIO
with O O
worse O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
than O O
- O O
expected O O
anemia O B_DISEASE
after O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Furthermore O O
, O O
hemolysis O B_DISEASE
during O O
transfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
not O O
always O O
a O O
transfusion O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
test O O
in O O
hyperprolactinemia O O
: O O
loss O O
of O O
prolactin O O
response O O
in O O
anatomic O O
or O O
functional O O
stalk O O
effect O O
. O O

AIM O O
: O O
Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
test O O
was O O
previously O O
investigated O O
as O O
a O O
tool O O
for O O
differential O O
diagnosis O O
of O O
hyperprolactinemia O O
, O O
but O O
with O O
conflicting O O
results O O
. O O

Macroprolactinemia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
never O O
considered O O
in O O
those O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Here O O
, O O
we O O
aimed O O
to O O
re O O
- O O
investigate O O
the O O
diagnostic O O
value O O
of O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
a O O
population O O
who O O
were O O
all O O
screened O O
for O O
macroprolactinemia O O
. O O

Prolactin O O
responses O O
to O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
65 O O
female O O
patients O O
( O O
age O O
: O O
29 O O
. O O
9 O O
+ O O
/ O O
- O O
8 O O
. O O
1 O O
years O O
) O O
with O O
hyperprolactinemia O O
were O O
tested O O
in O O
a O O
descriptive O O
, O O
matched O O
case O O
- O O
control O O
study O O
. O O

METHODS O O
: O O
Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
80 O O
mg O O
, O O
p O O
. O O
o O O
. O O
was O O
administered O O
, O O
and O O
then O O
PRL O O
levels O O
were O O
measured O O
at O O
8th O O
and O O
16th O O
hours O O
, O O
by O O
immunometric O O
chemiluminescence O O
. O O

Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O O
was O O
determined O O
by O O
peak O O
percent O O
change O O
in O O
basal O O
prolactin O O
levels O O
( O O
PRL O O
) O O
. O O

RESULTS O O
: O O
Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
increased O O
PRL O O
levels O O
in O O
healthy O O
controls O O
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
183 O O
% O O
) O O
, O O
macroprolactinoma O O
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
7 O O
% O O
) O O
, O O
microprolactinoma O O
( O O
N O O
. O O
19 O O
, O O
PRL O O
: O O
21 O O
% O O
) O O
, O O
macroprolactinemia O O
( O O
N O O
. O O
23 O O
, O O
PRL O O
: O O
126 O O
% O O
) O O
, O O
but O O
not O O
in O O
pseudoprolactinoma O O
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
0 O O
. O O
8 O O
% O O
) O O
, O O
and O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hyperprolactinemia O O
( O O
N O O
. O O
7 O O
, O O
PRL O O
: O O
3 O O
% O O
) O O
. O O

ROC O O
curve O O
analysis O O
revealed O O
that O O
unresponsiveness O O
to O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
defined O O
as O O
PRL O O
< O O
7 O O
% O O
, O O
discriminated O O
anatomical O O
or O O
functional O O
stalk O O
effect O O
( O O
sensitivity O O
: O O
74 O O
% O O
, O O
specificity O O
: O O
73 O O
% O O
, O O
AUC O O
: O O
0 O O
. O O
855 O O
+ O O
/ O O
- O O
0 O O
. O O
04 O O
, O O
P O O
< O O
0 O O
. O O
001 O O
, O O
CI O O
: O O
0 O O
. O O
768 O O
- O O
0 O O
. O O
942 O O
) O O
associated O O
with O O
pseudoprolactinoma O O
or O O
risperidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hyperprolactinemia O O
, O O
respectively O O
. O O

CONCLUSION O O
: O O
Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O O
is O O
not O O
a O O
reliable O O
finding O O
for O O
the O O
differential O O
diagnosis O O
of O O
hyperprolactinemia O O
. O O

However O O
, O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
unresponsiveness O O
discriminates O O
stalk O O
effect O O
( O O
i O O
. O O
e O O
. O O
, O O
anatomically O O
or O O
functionally O O
inhibited O O
dopaminergic O O
tonus O O
) O O
from O O
other O O
causes O O
of O O
hyperprolactinemia O O
with O O
varying O O
degrees O O
of O O
responsiveness O O
. O O

Blockade O O
of O O
endothelial O O
- O O
mesenchymal O O
transition O O
by O O
a O O
Smad3 O O
inhibitor O O
delays O O
the O O
early O O
development O O
of O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
diabetic O O
nephropathy O O
. O O

OBJECTIVE O O
: O O
A O O
multicenter O O
, O O
controlled O O
trial O O
showed O O
that O O
early O O
blockade O O
of O O
the O O
renin O O
- O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O O
in O O
patients O O
with O O
type O O
1 O O
diabetes O O
and O O
normoalbuminuria O O
did O O
not O O
retard O O
the O O
progression O O
of O O
nephropathy O O
, O O
suggesting O O
that O O
other O O
mechanism O O
( O O
s O O
) O O
are O O
involved O O
in O O
the O O
pathogenesis O O
of O O
early O O
diabetic O O
nephropathy O O
( O O
diabetic O O
nephropathy O O
) O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
endothelial O O
- O O
mesenchymal O O
- O O
transition O O
( O O
EndoMT O O
) O O
contributes O O
to O O
the O O
early O O
development O O
of O O
renal O O
interstitial O O
fibrosis O O
independently O O
of O O
microalbuminuria O O
in O O
mice O O
with O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
induced O O
diabetes O O
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
hypothesized O O
that O O
blocking O O
EndoMT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
the O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
development O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
diabetic O B_DISEASE/B_GENE
nephropathy O I_DISEASE/I_GENE
. O O

RESEARCH O B_NUMBER[MEASURE]/B_ORGANIZATION
DESIGN O I_NUMBER[MEASURE]/I_ORGANIZATION
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
EndoMT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
induced O O
in O O
a O O
mouse O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
microvascular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
line O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMEC O B_DISEASE/B_TIME[MEASURE]
) O O
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
advanced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
end O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AGEs O B_DISEASE/B_BACTERIUM[BIO]
) O O
and O O
in O O
the O O
endothelial O B_DISEASE/B_GENE
lineage O I_DISEASE/I_GENE
- O O
traceble O B_GENE/B_DISEASE
mouse O I_GENE/I_DISEASE
line O I_GENE/I_DISEASE
Tie2 O I_GENE/I_DISEASE
- O O
Cre O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Loxp O B_GENE/B_MEASURE
- O O
EGFP O B_GENE/B_MEASURE
by O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AGEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
with O O
nonglycated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serving O O
as O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Phosphorylated O B_PERSON/B_DISEASE
Smad3 O I_PERSON/I_DISEASE
was O O
detected O O
by O O
immunoprecipitation O B_LOCATION/B_PERSON
/ O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blocking O O
studies O O
using O O
receptor O O
for O O
AGE O O
siRNA O O
and O O
a O O
specific O O
inhibitor O O
of O O
Smad3 O O
( O O
SIS3 O O
) O O
were O O
performed O O
in O O
MMECs O O
and O O
in O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
diabetic O O
nephropathy O O
in O O
Tie2 O O
- O O
Cre O O
; O O
Loxp O O
- O O
EGFP O O
mice O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
real O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
that O O
AGEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O O
EndoMT O O
in O O
MMECs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
Tie2 O B_GENE
- O O
Cre O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Loxp O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
EGFP O B_GENE
mice O I_GENE
. O O

Immunoprecipitation O O
/ O O
Western O O
blotting O O
showed O O
that O O
Smad3 O O
was O O
activated O O
by O O
AGEs O O
but O O
was O O
inhibited O O
by O O
SIS3 O O
in O O
MMECs O O
and O O
in O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
diabetic O O
nephropathy O O
. O O

Confocal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
real O B_PERSON/B_MEASURE
- O O
time O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O O
demonstrated O O
that O O
SIS3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
abrogated O O
EndoMT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
renal O B_DISEASE/B_GENE
fibrosis O I_DISEASE/I_GENE
, O O
and O O
retarded O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nephropathy O B_DISEASE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
EndoMT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
novel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathway O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
leading O O
to O O
early O B_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
of O O
diabetic O B_DISEASE
nephropathy O I_DISEASE
. O O

Blockade O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
EndoMT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
SIS3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
provide O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strategy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
retard O O
the O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
diabetic O B_DISEASE
nephropathy O I_DISEASE
and O O
other O B_DISEASE/B_GENE
diabetes O I_DISEASE/I_GENE
complications O I_DISEASE/I_GENE
. O O

Cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
of O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
refractory O O
mantle O O
cell O O
lymphoma O O
. O O

Mantle O B_DISEASE
cell O I_DISEASE
lymphoma O I_DISEASE
( O O
MCL O B_DISEASE
) O O
is O O
a O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
aggressive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
type O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
B O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
cell O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
non O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
Hodgkin O B_DISEASE/B_GENE
' O O
s O B_DISEASE
lymphoma O I_DISEASE
. O O

Patients O B_PERSON/B_DISEASE
become O O
progressively O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
their O O
prognosis O B_DISEASE
is O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
a O O
38 O O
% O O
remission O O
rate O O
has O O
been O O
recently O O
reported O O
in O O
refractory O O
MCL O O
treated O O
with O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
mTOR O O
inhibitor O O
. O O
Here O O
we O O
had O O
the O O
opportunity O O
to O O
study O O
a O O
case O O
of O O
refractory O O
MCL O O
who O O
had O O
tumor O O
regression O O
two O O
months O O
after O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
and O O
a O O
progression O O
- O O
free O O
survival O O
of O O
10 O O
months O O
. O O

In O O
this O O
case O O
, O O
lymph O O
node O O
biopsies O O
were O O
performed O O
before O O
and O O
six O O
months O O
after O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Comparison O O
of O O
the O O
two O O
biopsies O O
showed O O
that O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibited O O
tumor O O
cell O O
proliferation O O
through O O
cell O O
cycle O O
arrest O O
, O O
but O O
did O O
not O O
induce O O
any O O
change O O
in O O
the O O
number O O
of O O
apoptotic O O
tumor O O
cells O O
. O O

Apart O O
from O O
this O O
cytostatic O O
effect O O
, O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
had O O
an O O
antiangiogenic O O
effect O O
with O O
decrease O O
of O O
tumor O O
microvessel O O
density O O
and O O
of O O
VEGF O O
expression O O
. O O

Moreover O O
, O O
numerous O O
patchy O O
, O O
well O O
- O O
limited O O
fibrotic O O
areas O O
, O O
compatible O O
with O O
post O O
- O O
necrotic O O
tissue O O
repair O O
, O O
were O O
found O O
after O O
6 O O
- O O
month O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

Thus O O
, O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reduced O O
tumor O O
burden O O
through O O
associated O O
cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
. O O
This O O
dual O O
effect O O
of O O
temsirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
tumor O O
tissue O O
could O O
contribute O O
to O O
its O O
recently O O
reported O O
efficiency O O
in O O
refractory O O
MCL O O
resistant O O
to O O
conventional O O
chemotherapy O O
. O O

Acute O O
renal O O
failure O O
due O O
to O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

A O O
23 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
male O I_PERSON
patient O I_PERSON
with O O
bacteriologically O O
proven O O
pulmonary O B_DISEASE
tuberculosis O I_DISEASE
was O O
treated O O
with O O
the O O
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
regimens O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
antituberculosis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
nearly O O
15 O B_TIME[MEASURE]/B_PERSON
months O I_TIME[MEASURE]/I_PERSON
. O O

Rifampicin B B_PERSON
was O O
administered O O
thrice O O
as O O
one O O
of O O
the O O
3 O O
- O O
4 O O
drug O O
regimen O O
and O O
each O O
time O O
he O O
developed O O
untoward O O
side O O
effects O O
like O O
nausea O O
, O O
vomiting O O
and O O
fever O O
with O O
chills O O
and O O
rigors O O
. O O

The O O
last O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
of O O
acute O B_DISEASE/B_LOCATION
renal O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
at O O
which O O
stage O B_TIME[MEASURE]/B_ENT
the O O
patient O B_PERSON/B_DISEASE
was O O
seen O O
by O O
the O O
authors O B_PERSON
of O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
patient O B_PERSON/B_ORGANIZATION
, O O
however O O
, O O
made O O
a O O
full O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Syncope O O
caused O O
by O O
hyperkalemia O O
during O O
use O O
of O O
a O O
combined O O
therapy O O
with O O
the O O
angiotensin B B_GENE
- O O
converting O O
enzyme O O
inhibitor O O
and O O
spironolactone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
76 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
- O O
old O B_PERSON
woman O I_PERSON
with O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bypass O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafting O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
prior O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
transferred O O
to O O
the O O
emergency O B_LOCATION
room O I_LOCATION
with O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
consciousness O B_DISEASE
due O O
to O O
marked O O
bradycardia O B_DISEASE
caused O O
by O O
hyperkalemia O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
concentration O O
of O O
serum O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
high O O
, O O
and O O
normal O O
sinus O O
rhythm O O
was O O
restored O O
after O O
correction O O
of O O
the O O
serum O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level O O
. O O

The O O
cause O O
of O O
hyperkalemia O O
was O O
considered O O
to O O
be O O
several O O
doses O O
of O O
spiranolactone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
aldosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antagonist O O
, O O
in O O
addition O O
to O O
the O O
long O O
- O O
term O O
intake O O
of O O
ramipril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
ACE O O
inhibitor O O
. O O

This O O
case O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
example O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
electrolyte O B_DISEASE
imbalance O I_DISEASE
causing O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
life O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
threatening O O
cardiac O B_DISEASE
events O I_DISEASE
. O O

Clinicians O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
of O O
hyperkalemia O O
, O O
especially O O
in O O
elderly O O
patients O O
using O O
ACE O O
/ O O
ARB O O
in O O
combination O O
with O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sparing O O
agents O O
and O O
who O O
have O O
mild O O
renal O O
disturbance O O
. O O

Diffuse O O
skeletal O O
pain O O
after O O
administration O O
of O O
alendronate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Osteoporosis O O
is O O
caused O O
by O O
bone O O
resorption O O
in O O
excess O O
of O O
bone O O
formation O O
, O O
and O O
bisphosphonates B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
are O O
used O O
to O O
inhibit O O
bone O O
resorption O O
. O O

Alendronate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
biphosphonate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
effective O O
for O O
both O O
the O O
treatment O O
and O O
prevention O O
of O O
osteoporosis O O
in O O
postmenopausal O O
women O O
. O O

Side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
relatively O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prominently O O
gastrointestinal O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Musculoskeletal O B_DISEASE
pain O I_DISEASE
may O O
be O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
patients O B_PERSON/B_DISEASE
. O O

We O O
presented O O
a O O
patient O O
admitted O O
to O O
our O O
out O O
- O O
patient O O
clinic O O
with O O
diffuse O O
skeletal O O
pain O O
after O O
three O O
consecutive O O
administration O O
of O O
alendronate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
: O O
We O O
conclude O O
that O O
patients O O
with O O
osteoporosis O O
can O O
report O O
pain O O
, O O
and O O
bisphosphonate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
pain O O
should O O
also O O
be O O
considered O O
before O O
ascribing O O
this O O
complaint O O
to O O
osteoporosis O O
. O O

Cerebrospinal O O
fluid O O
penetration O O
of O O
high O O
- O O
dose O O
daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
suspected O O
Staphylococcus O O
aureus O O
meningitis O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
methicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
sensitive O O
Staphylococcus O O
aureus O O
( O O
MSSA O O
) O O
bacteremia O O
with O O
suspected O O
MSSA O O
meningitis O O
treated O O
with O O
high O O
- O O
dose O O
daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
assessed O O
with O O
concurrent O O
serum O O
and O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
concentrations O O
. O O

CASE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
SUMMARY O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O O
A O O
54 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
male O I_PERSON
presented O O
to O O
the O O
emergency O B_LOCATION/B_PERSON
department O I_LOCATION/I_PERSON
with O O
generalized O B_DISEASE
weakness O I_DISEASE
and O O
presumed O O
health O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O O
care O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
associated O O
pneumonia O B_DISEASE
shown O O
on O O
chest O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiograph O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O O
was O O
empirically O O
initiated O O
with O O
vancomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
levofloxacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
piperacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
tazobactam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Blood O O
cultures O O
revealed O O
S O O
. O O
aureus O O
susceptible O O
to O O
oxacillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Empiric O O
antibiotic O O
treatment O O
was O O
narrowed O O
to O O
nafcillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O O
day O O
4 O O
. O O

On O O
day O O
8 O O
, O O
the O O
patient O O
developed O O
acute O O
renal O O
failure O O
( O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O O
. O O
9 O O
mg O O
/ O O
dL O O
, O O
increased O O
from O O
1 O O
. O O
2 O O
mg O O
/ O O
dL O O
the O O
previous O O
day O O
and O O
0 O O
. O O
8 O O
mg O O
/ O O
dL O O
on O O
admission O O
) O O
. O O

The O O
patient O B_PERSON/B_ORGANIZATION
' O O
s O B_MEASURE/B_DISEASE
Glasgow O I_MEASURE/I_DISEASE
Coma O I_MEASURE/I_DISEASE
Score O I_MEASURE/I_DISEASE
was O O
3 O B_MEASURE
, O O
with O O
normal O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O O
on O O
computed O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
head O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
72 O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hours O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
following O O
an O O
episode O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
arrest O I_DISEASE
on O O
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
10 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

The O O
patient O B_PERSON/B_ORGANIZATION
experienced O O
relapsing O O
MSSA O B_DISEASE
bacteremia O I_DISEASE
on O O
day O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
9 O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
increasing O O
the O O
suspicion O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nervous O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CNS O B_LOCATION/B_ORGANIZATION
) O O
infection O B_DISEASE/B_LOCATION
. O O

Nafcillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O O
discontinued O O
and O O
daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
9 O O
mg O O
/ O O
kg O O
daily O O
was O O
initiated O O
for O O
suspected O O
meningitis O O
and O O
was O O
continued O O
until O O
the O O
patient O O
' O O
s O O
death O O
on O O
day O O
16 O O
. O O

Daptomycin B B_MEASURE/B_BACTERIUM[BIO]
serum O O
and O O
CSF O O
trough O O
concentrations O O
were O O
11 O O
. O O
21 O O
ug O O
/ O O
mL O O
and O O
0 O O
. O O
52 O O
ug O O
/ O O
mL O O
, O O
respectively O O
, O O
prior O O
to O O
the O O
third O O
dose O O
. O O

Lumbar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
puncture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
inconclusive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
no O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cultures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
MSSA O B_DISEASE/B_BACTERIUM[BIO]
. O O

Creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O O
levels O O
were O O
normal O O
prior O O
to O O
daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
therapy O O
and O O
were O O
not O O
reassessed O O
. O O

DISCUSSION O O
: O O
Daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O O
initiated O O
in O O
our O O
patient O O
secondary O O
to O O
possible O O
nafcillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
induced O O
acute O O
interstitial O O
nephritis O O
and O O
relapsing O O
bacteremia O O
. O O

At O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
9 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
resultant O B_DISEASE_ADJECTIVE[DISEASE]
penetration O I_DISEASE_ADJECTIVE[DISEASE]
of O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
more O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
inflamed O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meninges O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
daptomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
may O O
be O O
an O O
alternative O O
option O O
for O O
MSSA O O
bacteremia O O
with O O
or O O
without O O
a O O
CNS O O
source O O
in O O
patients O O
who O O
have O O
failed O O
or O O
cannot O O
tolerate O O
standard O O
therapy O O
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
with O O
confirmed O B_DISEASE
meningitis O I_DISEASE
is O O
warranted O O
. O O

The O O
role O O
of O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
convulsions O O
induced O O
by O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
rats O O
. O O

Lindane B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
organochloride O O
pesticide O O
and O O
scabicide O O
. O O

It O O
evokes O O
convulsions O O
mainly O O
trough O O
the O O
blockage O O
of O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
A O O
) O O
receptors O O
. O O

Nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NO B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
gaseous O O
neurotransmitter O O
, O O
has O O
contradictor O O
role O O
in O O
epileptogenesis O O
due O O
to O O
opposite O O
effects O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
arginine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
precursor O O
of O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
syntheses O O
( O O
NOS O O
) O O
, O O
and O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NAME I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
NOS O O
inhibitor O O
) O O
observed O O
in O O
different O O
epilepsy O O
models O O
. O O

The O O
aim O O
of O O
the O O
current O O
study O O
was O O
to O O
determine O O
the O O
effects O O
of O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
behavioral O O
and O O
EEG O O
characteristics O O
of O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
epilepsy O O
in O O
male O O
Wistar O O
albino O O
rats O O
. O O

The O O
administration O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
arginine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
600 O O
, O O
800 O O
and O O
1000 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
in O O
dose O O
- O O
dependent O O
manner O O
significantly O O
increased O O
convulsion O O
incidence O O
and O O
severity O O
and O O
shortened O O
latency O O
time O O
to O O
first O O
convulsion O O
elicited O O
by O O
lower O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dose O O
( O O
4 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

On O O
the O O
contrary O O
, O O
pretreatment O O
with O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
NAME I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
500 O O
, O O
700 O O
and O O
900 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
decreased O O
convulsion O O
incidence O O
and O O
severity O O
and O O
prolonged O O
latency O O
time O O
to O O
convulsion O O
following O O
injection O O
with O O
a O O
convulsive O O
dose O O
of O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
8 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

EEG O O
analyses O O
showed O O
increase O O
of O O
number O O
and O O
duration O O
of O O
ictal O O
periods O O
in O O
EEG O O
of O O
rats O O
receiving O O
l B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
arginine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
prior O O
to O O
lindane B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
decrease O O
of O O
this O O
number O O
in O O
rats O O
pretreated O O
with O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NAME I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
support O O
the O O
conclusion O O
that O O
NO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
a O O
role O O
of O O
endogenous O O
convulsant O O
in O O
rat O O
model O O
of O O
lindane B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
seizures O O
. O O

Severe O O
polyneuropathy O O
and O O
motor O O
loss O O
after O O
intrathecal O O
thiotepa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
combination O O
chemotherapy O O
: O O
description O O
of O O
two O O
cases O O
. O O

Two O O
cases O O
of O O
severe O O
delayed O O
neurologic O O
toxicity O O
related O O
to O O
the O O
administration O O
of O O
intrathecal O O
( O O
IT O O
) O O
combination O O
chemotherapy O O
including O O
thiotepa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
TSPA B B_LOCATION/B_ORGANIZATION
) O O
are O O
presented O O
. O O

Both O O
cases O B_PERSON/B_LOCATION
developed O O
axonal O B_DISEASE/B_LOCATION
neuropathy O I_DISEASE/I_LOCATION
with O O
motor O B_DISEASE
predominance O I_DISEASE
in O O
the O O
lower O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
extremities O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
1 O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
after O O
IT O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
administered O O
. O O

Neurologic O O
toxicities O O
have O O
been O O
described O O
with O O
IT O O
- O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
IT O O
- O O
cytosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arabinoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
IT O O
- O O
TSPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
our O O
knowledge O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
axonal O B_DISEASE
neuropathy O I_DISEASE
following O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
these O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
previously O O
described O O
. O O

In O O
spite O O
of O O
the O O
fact O O
that O O
TSPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
useful O O
IT O O
agent O O
, O O
its O O
combination O O
with O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ara B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
radiotherapy O O
could O O
cause O O
severe O O
neurotoxicity O O
. O O

This O O
unexpected O O
complication O O
indicates O O
the O O
need O O
for O O
further O O
toxicology O O
research O O
on O O
IT O O
- O O
TSPA B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Effects O O
of O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
large O O
epicardial O O
and O O
small O O
coronary O O
arteries O O
in O O
conscious O O
dogs O O
. O O

The O O
effects O O
of O O
i O O
. O O
v O O
. O O
bolus O O
administration O O
of O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
- O O
10 O O
micrograms O O
/ O O
kg O O
) O O
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
- O O
100 O O
micrograms O O
/ O O
kg O O
) O O
on O O
large O O
( O O
circumflex O O
artery O O
) O O
and O O
small O O
coronary O O
arteries O O
and O O
on O O
systemic O O
hemodynamics O O
were O O
investigated O O
in O O
chronically O O
instrumented O O
conscious O O
dogs O O
and O O
compared O O
to O O
those O O
of O O
nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
03 O O
- O O
10 O O
micrograms O O
/ O O
kg O O
) O O
. O O

Nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
up O O
to O O
0 O O
. O O
3 O O
micrograms O O
/ O O
kg O O
, O O
selectively O O
increased O O
circumflex O O
artery O O
diameter O O
( O O
CxAD O O
) O O
without O O
simultaneously O O
affecting O O
any O O
other O O
cardiac O O
or O O
systemic O O
hemodynamic O O
parameter O O
. O O

In O O
contrast O O
, O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
all O O
doses O O
and O O
nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
doses O O
higher O O
than O O
0 O O
. O O
3 O O
micrograms O O
/ O O
kg O O
simultaneously O O
and O O
dose O O
- O O
dependently O O
increased O O
CxAD O O
, O O
coronary O O
blood O O
flow O O
and O O
heart O O
rate O O
and O O
decreased O O
coronary O O
vascular O O
resistance O O
and O O
aortic O O
pressure O O
. O O

Cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
approximately O O
8 O O
- O O
to O O
9 O O
. O O
5 O O
- O O
fold O O
more O O
potent O O
than O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
increasing O O
CxAD O O
. O O

Vasodilation O O
of O O
large O O
and O O
small O O
coronary O O
vessels O O
and O O
hypotension O O
induced O O
by O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
not O O
affected O O
by O O
prior O O
combined O O
beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenergic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscarinic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockade I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
drug O O
- O O
induced O O
tachycardia O O
was O O
abolished O O
. O O

When O O
circumflex O O
artery O O
blood O O
flow O O
was O O
maintained O O
constant O O
, O O
the O O
increases O O
in O O
CxAD O O
induced O O
by O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
, O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O O
micrograms O O
/ O O
kg O O
) O O
and O O
nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
micrograms O O
/ O O
kg O O
) O O
were O O
reduced O O
by O O
68 O O
+ O O
/ O O
- O O
7 O O
, O O
54 O O
+ O O
/ O O
- O O
9 O O
and O O
1 O O
+ O O
/ O O
- O O
1 O O
% O O
, O O
respectively O O
. O O

Thus O O
, O O
whereas O O
nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
and O O
flow O O
- O O
independently O O
dilates O O
large O O
coronary O O
arteries O O
, O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dilate O O
both O O
large O O
and O O
small O O
coronary O O
arteries O O
and O O
this O O
effect O O
is O O
not O O
dependent O O
upon O O
the O O
simultaneous O O
beta O O
adrenoceptors O O
- O O
mediated O O
rise O O
in O O
myocardial O O
metabolic O O
demand O O
. O O

Finally O O
, O O
two O O
mechanisms O O
at O O
least O O
, O O
direct O O
vasodilation O O
and O O
flow O O
dependency O O
, O O
are O O
involved O O
in O O
the O O
cromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
pinacidil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
increase O O
in O O
CxAD O O
. O O

Mefenamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neutropenia O O
and O O
renal O O
failure O O
in O O
elderly O O
females O O
with O O
hypothyroidism O O
. O O

We O O
report O O
mefenamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
non O O
- O O
oliguric O O
renal O O
failure O O
and O O
severe O O
neutropenia O O
occurring O O
simultaneously O O
in O O
two O O
elderly O O
females O O
. O O

The O O
neutropenia O B_DISEASE
was O O
due O O
to O O
maturation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrest O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
myeloid O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
series O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
one O B_PERSON/B_BIO
patient O B_PERSON/I_BIO
. O O

Both O O
patients O B_PERSON/B_BIO
were O O
also O O
hypothyroid O B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
it O O
is O O
not O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
whether O O
this O O
was O O
a O O
predisposing O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
adverse O B_DISEASE
reactions O I_DISEASE
. O O

However O O
, O O
it O O
would O O
seem O O
prudent O O
not O O
to O O
use O O
mefenamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
hypothyroid O O
patients O O
until O O
the O O
hypothyroidism O O
has O O
been O O
corrected O O
. O O

Etiology O O
of O O
hypercalcemia O O
in O O
hemodialysis O O
patients O O
on O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
carbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy O O
. O O

Fourteen O O
of O O
39 O O
dialysis O O
patients O O
( O O
36 O O
% O O
) O O
became O O
hypercalcemic O O
after O O
switching O O
to O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O O
their O O
principal O O
phosphate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
binder O O
. O O

In O O
order O O
to O O
identify O O
risk O O
factors O O
associated O O
with O O
the O O
development O O
of O O
hypercalcemia O O
, O O
indirect O O
parameters O O
of O O
intestinal O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reabsorption O O
and O O
bone O O
turnover O O
rate O O
in O O
these O O
14 O O
patients O O
were O O
compared O O
with O O
results O O
in O O
14 O O
eucalcemic O O
patients O O
matched O O
for O O
age O O
, O O
sex O O
, O O
length O O
of O O
time O O
on O O
dialysis O O
, O O
and O O
etiology O O
of O O
renal O O
disease O O
. O O

In O O
addition O O
to O O
experiencing O O
hypercalcemic O O
episodes O O
with O O
peak O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O O
of O O
2 O O
. O O
7 O O
to O O
3 O O
. O O
8 O O
mmol O O
/ O O
L O O
( O O
10 O O
. O O
7 O O
to O O
15 O O
. O O
0 O O
mg O O
/ O O
dL O O
) O O
, O O
patients O O
in O O
the O O
hypercalcemic O O
group O O
exhibited O O
a O O
significant O O
increase O O
in O O
the O O
mean O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
obtained O O
during O O
6 O O
months O O
before O O
the O O
switch O O
, O O
compared O O
with O O
the O O
mean O O
value O O
obtained O O
during O O
the O O
7 O O
months O O
of O O
observation O O
after O O
the O O
switch O O
( O O
2 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
03 O O
to O O
2 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
03 O O
mmol O O
/ O O
L O O
[ O O
9 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
to O O
10 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
mg O O
/ O O
dL O O
] O O
, O O
P O O
= O O
0 O O
. O O
006 O O
) O O
. O O

In O O
contrast O O
, O O
eucalcemic O O
patients O O
exhibited O O
no O O
change O O
in O O
mean O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O O
over O O
the O O
same O O
time O O
period O O
( O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
05 O O
to O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
05 O O
mmol O O
/ O O
L O O
[ O O
9 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
to O O
9 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
mg O O
/ O O
dL O O
] O O
) O O
. O O

CaCO3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O O
, O O
calculated O O
dietary O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O O
, O O
and O O
circulating O O
levels O O
of O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O O
were O O
similar O O
in O O
both O O
groups O O
. O O

Physical O O
activity O O
index O O
and O O
predialysis O O
serum O O
bicarbonate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
also O O
were O O
similar O O
in O O
both O O
groups O O
. O O

However O O
, O O
there O O
was O O
a O O
significant O B_MEASURE
difference O I_MEASURE
in O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reflecting O O
bone O B_DISEASE/B_GENE
turnover O I_DISEASE/I_GENE
rates O I_DISEASE/I_GENE
between O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED O I_TIME[MEASURE]/I_ORGANIZATION
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

Late O O
- O O
onset O O
scleroderma O O
renal O O
crisis O O
induced O O
by O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
case O O
report O O
. O O

Scleroderma O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SRC O B_LOCATION
) O O
is O O
a O O
rare O B_DISEASE
complication O I_DISEASE
of O O
systemic O B_DISEASE
sclerosis O I_DISEASE
( O O
SSc O B_LOCATION/B_ORGANIZATION
) O O
but O O
can O O
be O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
enough O O
to O O
require O O
temporary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
permanent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Moderate O O
to O O
high O O
dose O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
is O O
recognized O O
as O O
a O O
major O O
risk O O
factor O O
for O O
SRC O O
. O O

Furthermore O O
, O O
there O O
have O O
been O O
reports O O
of O O
thrombotic O O
microangiopathy O O
precipitated O O
by O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
patients O O
with O O
SSc O O
. O O

In O O
this O O
article O O
, O O
we O O
report O O
a O O
patient O O
with O O
SRC O O
induced O O
by O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
corticosteroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
aim O O
of O O
this O O
work O O
is O O
to O O
call O O
attention O O
to O O
the O O
risk O O
of O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O O
in O O
patients O O
with O O
SSc O O
. O O

Methyldopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hemolytic O O
anemia O O
in O O
a O O
15 O O
year O O
old O O
presenting O O
as O O
near O O
- O O
syncope O O
. O O

Methyldopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
an O O
antihypertensive O O
medication O O
which O O
is O O
available O O
generically O O
and O O
under O O
the O O
trade O O
name O O
Aldomet B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
is O O
widely O O
prescribed O O
in O O
the O O
adult O O
population O O
and O O
infrequently O O
used O O
in O O
children O O
. O O

Methyldopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
causes O O
an O O
autoimmune O O
hemolytic O O
anemia O O
in O O
a O O
small O O
percentage O O
of O O
patients O O
who O O
take O O
the O O
drug O O
. O O

We O O
report O O
a O O
case O O
of O O
methyldopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hemolytic O O
anemia O O
in O O
a O O
15 O O
- O O
year O O
- O O
old O O
boy O O
who O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
near O O
- O O
syncope O O
. O O

The O O
boy O O
had O O
been O O
treated O O
with O O
intravenous O O
methyldopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
a O O
trauma O O
admission O O
seven O O
weeks O O
prior O O
to O O
presentation O O
. O O

Evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O O
a O O
hemoglobin O B_MEASURE
of O O
three O B_MEASURE
grams O I_MEASURE
, O O
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coombs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
polyspecific O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
human O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
monospecific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgG O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reagents O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
warm O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reacting O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Transfusion O O
and O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy O O
resulted O O
in O O
a O O
complete O O
recovery O O
of O O
the O O
patient O O
. O O

Emergency O B_PERSON
physicians O I_PERSON
treating O O
children O B_PERSON/B_DISEASE
must O O
be O O
aware O B_PERSON
of O O
this O O
syndrome O B_DISEASE
in O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
diagnose O O
and O O
treat O O
it O O
correctly O O
. O O

A O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
autoimmune O B_DISEASE_ADJECTIVE[DISEASE]
and O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hemolytic O B_DISEASE
anemias O I_DISEASE
is O O
provided O O
. O O

The O O
risk O O
and O O
associated O O
factors O O
of O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
psychosis O O
in O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
dependent O O
patients O O
in O O
Malaysia O O
. O O

OBJECTIVE O O
: O O
The O O
objective O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
risk O O
of O O
lifetime O O
and O O
current O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
psychosis O O
in O O
patients O O
with O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dependence O O
. O O

The O O
association O O
between O O
psychiatric O O
co O O
- O O
morbidity O O
and O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
psychosis O O
was O O
also O O
studied O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
was O O
a O O
cross O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
sectional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducted O O
concurrently O O
at O O
a O O
teaching O O
hospital O B_LOCATION/B_ORGANIZATION
and O O
a O O
drug O B_LOCATION
rehabilitation O I_LOCATION
center O I_LOCATION
in O O
Malaysia O B_LOCATION
. O O

Patients O O
with O O
the O O
diagnosis O O
of O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
based O O
on O O
DSM O O
- O O
IV O O
were O O
interviewed O O
using O O
the O O
Mini O O
International O O
Neuropsychiatric O O
Interview O O
( O O
M O O
. O O
I O O
. O O
N O O
. O O
I O O
. O O
) O O
for O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
psychosis O O
and O O
other O O
Axis O O
I O O
psychiatric O O
disorders O O
. O O

The O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
sociodemographic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
drug O B_DISEASE_ADJECTIVE[DISEASE]
use O I_DISEASE_ADJECTIVE[DISEASE]
history O I_DISEASE_ADJECTIVE[DISEASE]
was O O
obtained O O
from O O
interview O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Of O O
292 O B_PERSON
subjects O I_PERSON
, O O
47 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
subjects O B_PERSON
had O O
a O O
past O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
psychotic O B_DISEASE
symptoms O I_DISEASE
and O O
13 O B_MEASURE
. O O
0 O B_MEASURE
% O I_MEASURE
of O O
the O O
patients O B_PERSON
were O O
having O O
current O B_DISEASE/B_LOCATION
psychotic O I_DISEASE/I_LOCATION
symptoms O I_DISEASE/I_LOCATION
. O O

Co O O
- O O
morbid O O
major O O
depressive O O
disorder O O
( O O
OR O O
= O O
7 O O
. O O
18 O O
, O O
95 O O
CI O O
= O O
2 O O
. O O
612 O O
- O O
19 O O
. O O
708 O O
) O O
, O O
bipolar O O
disorder O O
( O O
OR O O
= O O
13 O O
. O O
807 O O
, O O
95 O O
CI O O
= O O
5 O O
. O O
194 O O
- O O
36 O O
. O O
706 O O
) O O
, O O
antisocial O O
personality O O
disorder O O
( O O
OR O O
= O O
12 O O
. O O
619 O O
, O O
95 O O
CI O O
= O O
6 O O
. O O
702 O O
- O O
23 O O
. O O
759 O O
) O O
and O O
heavy O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uses O O
were O O
significantly O O
associated O O
with O O
lifetime O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
psychosis O O
after O O
adjusted O O
for O O
other O O
factors O O
. O O

Major O B_DISEASE/B_PERSON
depressive O I_DISEASE/I_PERSON
disorder O I_DISEASE/I_PERSON
( O O
OR O O
= O O
2 O B_MEASURE
. O O
870 O B_MEASURE
, O O
CI O B_LOCATION
= O O
1 O B_MEASURE
. O O
154 O B_MEASURE
- O O
7 O B_MEASURE
. O O
142 O B_MEASURE
) O O
and O O
antisocial O B_DISEASE/B_PERSON
personality O I_DISEASE/I_PERSON
disorder O I_DISEASE/I_PERSON
( O O
OR O O
= O O
3 O B_MEASURE
. O O
299 O B_MEASURE
, O O
95 O B_LOCATION
CI O I_LOCATION
= O O
1 O B_MEASURE
. O O
375 O B_MEASURE
- O O
7 O B_MEASURE
. O O
914 O B_MEASURE
) O O
were O O
the O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
current O B_DISEASE
psychosis O I_DISEASE
. O O

CONCLUSION O O
: O O
There O O
was O O
a O O
high O O
risk O O
of O O
psychosis O O
in O O
patients O O
with O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependence O O
. O O

It O O
was O O
associated O O
with O O
co O O
- O O
morbid O O
affective O O
disorder O O
, O O
antisocial O O
personality O O
, O O
and O O
heavy O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

It O O
is O O
recommended O O
that O O
all O O
cases O O
of O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependence O O
should O O
be O O
screened O O
for O O
psychotic O O
symptoms O O
. O O

Cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sensory O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
processing O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alterations O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
impact O O
motor O B_DISEASE_ADJECTIVE[DISEASE]
cortical O I_DISEASE_ADJECTIVE[DISEASE]
plasticity O I_DISEASE_ADJECTIVE[DISEASE]
in O O
Parkinson O B_PERSON/B_DISEASE
' O O
s O B_DISEASE
disease O I_DISEASE
: O O
clues O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O O
dyskinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
plasticity O O
of O O
primary O O
motor O O
cortex O O
( O O
M1 O O
) O O
in O O
patients O O
with O O
Parkinson O O
' O O
s O O
disease O O
( O O
PD O O
) O O
and O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesias O O
( O O
LIDs O O
) O O
is O O
severely O O
impaired O O
. O O

We O O
recently O O
reported O O
in O O
young O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healthy O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
inhibitory O O
cerebellar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
enhanced O O
the O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
M1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
was O O
induced O O
by O O
paired O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PAS O B_DISEASE/B_LOCATION
) O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O O
that O O
the O O
deficient O B_DISEASE/B_LOCATION
sensorimotor O I_DISEASE/I_LOCATION
M1 O I_DISEASE/I_LOCATION
plasticity O I_DISEASE/I_LOCATION
in O O
16 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
LIDs O B_DISEASE
could O O
be O O
reinstated O O
by O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
session O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
real O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibitory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
cerebellar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
but O O
not O O
sham O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

This O O
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
when O O
a O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
involved O O
in O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
plasticity O B_DISEASE
, O O
indicating O O
that O O
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensory O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
involved O O
in O O
the O O
resurgence O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
M1 O B_DISEASE/B_ORGANISM_FUNCTION
plasticity O I_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
inhibitory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cerebellar O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O O
LIDs O B_DISEASE
is O O
known O O
. O O

To O O
explore O O
whether O O
this O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
linked O O
to O O
the O O
restoration O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
M1 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
conducted O O
an O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
looking O O
at O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
LIDs O B_DISEASE_ADJECTIVE[DISEASE]
and O O
PAS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
plasticity O B_DISEASE
after O O
10 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
sessions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
either O O
bilateral O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
real O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitory O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cerebellar O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
sham O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Only O O
real O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
not O O
sham O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O O
an O O
antidyskinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
was O O
paralleled O O
by O O
a O O
resurgence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
M1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
alterations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]
sensory O I_DISEASE_ADJECTIVE[DISEASE]
processing O I_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
, O O
occurring O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
basal O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
ganglia O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
signals O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
reaching O O
it O O
, O O
may O O
be O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
element O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
contributing O O
to O O
the O O
maladaptive O B_DISEASE_ADJECTIVE[DISEASE]
sensorimotor O I_DISEASE_ADJECTIVE[DISEASE]
plasticity O I_DISEASE_ADJECTIVE[DISEASE]
of O O
M1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
emergence O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
abnormal O B_DISEASE
involuntary O I_DISEASE
movements O I_DISEASE
. O O

The O O
long O O
- O O
term O O
safety O O
of O O
danazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
women O O
with O O
hereditary O O
angioedema O O
. O O

Although O O
the O O
short O O
- O O
term O O
safety O O
( O O
less O O
than O O
or O O
equal O O
to O O
6 O O
months O O
) O O
of O O
danazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
been O O
established O O
in O O
a O O
variety O O
of O O
settings O O
, O O
no O O
information O O
exists O O
as O O
to O O
its O O
long O O
- O O
term O O
safety O O
. O O

We O O
therefore O O
investigated O O
the O O
long O O
- O O
term O O
safety O O
of O O
danazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
performing O O
a O O
retrospective O O
chart O O
review O O
of O O
60 O O
female O O
patients O O
with O O
hereditary O O
angioedema O O
treated O O
with O O
danazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
continuous O O
period O O
of O O
6 O O
months O O
or O O
longer O O
. O O

The O O
mean O B_TIME[MEASURE]/B_LOCATION
age O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON
was O O
35 O B_MEASURE
. O O
2 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
and O O
the O O
mean O B_TIME[MEASURE]/B_LOCATION
duration O I_TIME[MEASURE]/I_LOCATION
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
59 O B_MEASURE
. O O
7 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

Virtually O O
all O O
patients O B_PERSON
experienced O O
one O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_PERSON
adverse O I_NUMBER[MEASURE]/I_PERSON
reactions O I_NUMBER[MEASURE]/I_PERSON
. O O

Menstrual O B_DISEASE
abnormalities O I_DISEASE
( O O
79 O B_MEASURE
% O I_MEASURE
) O O
, O O
weight O B_DISEASE
gain O I_DISEASE
( O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
, O O
muscle O B_DISEASE
cramps O I_DISEASE
/ O O
myalgias O B_DISEASE
( O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
transaminase O B_DISEASE
elevations O I_DISEASE
( O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
discontinued O O
due O O
to O O
adverse O B_DISEASE
reactions O I_DISEASE
in O O
8 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

No O O
patient O B_PERSON
has O O
died O O
or O O
suffered O O
any O O
apparent O B_TIME[MEASURE]/B_PERSON
long O I_TIME[MEASURE]/I_PERSON
- O O
term O B_DISEASE_ADJECTIVE[DISEASE]
sequelae O I_DISEASE_ADJECTIVE[DISEASE]
that O O
were O O
directly O O
attributable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
the O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

We O O
conclude O O
that O O
, O O
despite O O
a O O
relatively O O
high O O
incidence O O
of O O
adverse O O
reactions O O
, O O
danazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
proven O O
to O O
be O O
remarkably O O
safe O O
over O O
the O O
long O O
- O O
term O O
in O O
this O O
group O O
of O O
patients O O
. O O

The O O
function O O
of O O
P2X3 O O
receptor O O
and O O
NK1 O O
receptor O O
antagonists O O
on O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cystitis O O
in O O
rats O O
. O O

PURPOSE O O
: O O
The O O
purpose O O
of O O
the O O
study O O
is O O
to O O
explore O O
the O O
function O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
antagonists O O
on O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYP B B_LOCATION/B_PROTEIN[GENE]
) O O
- O O
induced O O
cystitis O O
in O O
rats O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Sixty O B_PERSON
female O I_PERSON
Sprague O I_PERSON
- O O
Dawley O B_PERSON/B_MEASURE
( O O
SD O B_MEASURE/B_DISEASE
) O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
randomly O O
divided O O
into O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O O

The O O
rats O O
in O O
the O O
control O O
group O O
were O O
intraperitoneally O O
( O O
i O O
. O O
p O O
. O O
) O O
injected O O
with O O
0 O O
. O O
9 O O
% O O
saline O O
( O O
4 O O
ml O O
/ O O
kg O O
) O O
; O O
the O O
rats O O
in O O
the O O
model O O
group O O
were O O
i O O
. O O
p O O
. O O
injected O O
with O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
150 O O
mg O O
/ O O
kg O O
) O O
; O O
and O O
the O O
rats O O
in O O
the O O
intervention O O
group O O
were O O
i O O
. O O
p O O
. O O
injected O O
with O O
CYP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
subsequently O O
perfusion O O
of O O
bladder O O
with O O
P2X3 O O
and O O
NK1 O O
receptors O O
' O O
antagonists O O
, O O
Suramin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
82334 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Spontaneous O O
pain O O
behaviors O O
following O O
the O O
administration O O
of O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
observed O O
. O O

Urodynamic O B_TIME[MEASURE]/B_LOCATION
parameters O I_TIME[MEASURE]/I_LOCATION
, O O
bladder O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
- O O
volume O B_MEASURE/B_LOCATION
curve O I_MEASURE/I_LOCATION
, O O
maximum O B_MEASURE/B_LOCATION
voiding O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
( O O
MVP O B_PERSON/B_DISEASE
) O O
, O O
and O O
maximum O B_MEASURE/B_LOCATION
cystometric O I_MEASURE/I_LOCATION
capacity O I_MEASURE/I_LOCATION
( O O
MCC O B_DISEASE/B_GENE
) O O
, O O
were O O
recorded O O
. O O

Pathological O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O O
observed O O
. O O

Immunofluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
used O O
to O O
detect O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
P2X3 O B_GENE
and O O
NK1 O B_GENE
receptors O I_GENE
in O O
bladder O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

RESULTS O O
: O O
Cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
increased O O
the O O
spontaneous O O
pain O O
behaviors O O
scores O O
. O O

The O O
incidence O B_MEASURE
of O O
bladder O B_DISEASE
instability O I_DISEASE
during O O
urine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
storage O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
X O B_OTHER/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
= O O
7 O B_MEASURE
. O O
619 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
007 O B_MEASURE
) O O
and O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
X O B_OTHER/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
= O O
13 O B_MEASURE
. O O
755 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
000 O B_MEASURE
) O O
. O O

MCC O B_DISEASE/B_MEASURE
in O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Histological O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evident O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intervention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
groups O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
rats O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
' O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
bladder O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
included O O
edema O B_DISEASE
, O O
vasodilation O B_DISEASE
, O O
and O O
infiltration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inflammatory O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
the O O
expression O B_GENE/B_MEASURE
of O O
P2X3 O B_GENE
receptor O I_GENE
increased O O
in O O
urothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
suburothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
NK1 O B_GENE
receptor O I_GENE
increased O O
in O O
suburothelium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
the O O
expression O B_GENE/B_MEASURE
of O O
them O O
in O O
intervention O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
lower O B_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSIONS O O
: O O
In O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
cystitis O O
, O O
the O O
expression O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
increased O O
in O O
urothelium O O
and O O
/ O O
or O O
suburothelium O O
. O O

Perfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O O
P2X3 O B_GENE
and O O
NK1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ameliorated O O
the O O
bladder O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patient O O
tolerance O O
study O O
of O O
topical O O
chlorhexidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diphosphanilate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
new O O
topical O O
agent O O
for O O
burns O O
. O O

Effective O B_PERSON/B_LOCATION
topical O I_PERSON/I_LOCATION
antimicrobial O I_PERSON/I_LOCATION
agents O I_PERSON/I_LOCATION
decrease O O
infection O B_DISEASE
and O O
mortality O B_DISEASE/B_MEASURE
in O O
burn O B_BIO/B_DISEASE
patients O I_BIO/I_DISEASE
. O O

Chlorhexidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phosphanilate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
CHP B B_DISEASE/B_MEASURE
) O O
, O O
a O O
new O O
broad O O
- O O
spectrum O O
antimicrobial O O
agent O O
, O O
has O O
been O O
evaluated O O
as O O
a O O
topical O O
burn O O
wound O O
dressing O O
in O O
cream O O
form O O
, O O
but O O
preliminary O O
clinical O O
trials O O
reported O O
that O O
it O O
was O O
painful O O
upon O O
application O O
. O O

This O O
study O O
compared O O
various O O
concentrations O O
of O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
determine O O
if O O
a O O
tolerable O O
concentration O O
could O O
be O O
identified O O
with O O
retention O O
of O O
antimicrobial O O
efficacy O O
. O O

Twenty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]/B_PERSON
burn O I_NUMBER[MEASURE]/I_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
each O O
with O O
two O B_NUMBER[MEASURE]/B_DISEASE
similar O I_NUMBER[MEASURE]/I_DISEASE
burns O I_NUMBER[MEASURE]/I_DISEASE
which O O
could O O
be O O
separately O O
treated O O
, O O
were O O
given O O
pairs O B_PERSON/B_MEASURE
of O O
treatments O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
successive O B_MEASURE
12 O I_MEASURE
- O O
h O O
intervals O B_TIME[MEASURE]/B_LOCATION
over O O
a O O
3 O B_NUMBER[MEASURE]
- O O
day O B_TIME[MEASURE]
period O I_TIME[MEASURE]
. O O

One O O
burn O O
site O O
was O O
treated O O
with O O
each O O
of O O
four O O
different O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
, O O
from O O
0 O O
. O O
25 O O
per O O
cent O O
to O O
2 O O
per O O
cent O O
, O O
their O O
vehicle O O
, O O
and O O
1 O O
per O O
cent O O
silver B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphadiazine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AgSD B B_LOCATION/B_DISEASE
) O O
cream O O
, O O
an O O
antimicrobial O O
agent O O
frequently O O
used O O
for O O
topical O O
treatment O O
of O O
burn O O
wounds O O
. O O

The O O
other O O
site O O
was O O
always O O
treated O O
with O O
AgSD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cream O O
. O O

There O O
was O O
a O O
direct O O
relationship O O
between O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
and O O
patients O O
' O O
ratings O O
of O O
pain O O
on O O
an O O
analogue O O
scale O O
. O O

The O O
0 O O
. O O
25 O O
per O O
cent O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cream O O
was O O
closest O O
to O O
AgSD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
pain O O
tolerance O O
; O O
however O O
, O O
none O O
of O O
the O O
treatments O O
differed O O
statistically O O
from O O
AgSD B B_DISEASE/B_MEASURE
or O O
from O O
each O O
other O O
. O O

In O O
addition O O
, O O
ease O O
of O O
application O O
of O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creams O O
was O O
less O O
satisfactory O O
than O O
that O O
of O O
AgSD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
was O O
concluded O O
that O O
formulations O O
at O O
or O O
below O O
0 O O
. O O
5 O O
per O O
cent O O
CHP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
prove O O
acceptable O O
for O O
wound O O
care O O
, O O
but O O
the O O
vehicle O O
system O O
needs O O
pharmaceutical O O
improvement O O
to O O
render O O
it O O
more O O
tolerable O O
and O O
easier O O
to O O
use O O
. O O

Acute O O
hepatitis O O
associated O O
with O O
clopidogrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O
. O O

Drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hepatotoxicity O B_DISEASE
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]
cause O I_DISEASE_ADJECTIVE[DISEASE]
of O O
acute O B_DISEASE
hepatitis O I_DISEASE
, O O
and O O
the O O
recognition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
responsible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O O
be O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
describe O O
a O O
case O O
of O O
clopidogrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
acute O O
hepatitis O O
. O O

The O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
strongly O O
suggested O O
by O O
an O O
accurate O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
medical O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
history O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
liver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reports O O
about O O
cases O O
of O O
hepatotoxicity O O
due O O
to O O
clopidogrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
increasing O O
in O O
the O O
last O O
few O O
years O O
, O O
after O O
the O O
increased O O
use O O
of O O
this O O
drug O O
. O O

In O O
conclusion O O
, O O
we O O
believe O O
that O O
physicians O O
should O O
carefully O O
consider O O
the O O
risk O O
of O O
drug O O
- O O
induced O O
hepatic O O
injury O O
when O O
clopidogrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
prescribed O O
. O O

Bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
salvage O O
therapy O O
in O O
patients O O
with O O
relapsed O O
/ O O
refractory O O
multiple O O
myeloma O O
: O O
analysis O O
of O O
long O O
- O O
term O O
clinical O O
outcomes O O
. O O

Bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
bort B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
- O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
is O O
an O O
effective O O
therapy O O
for O O
relapsed O O
/ O O
refractory O O
( O O
R O O
/ O O
R O O
) O O
multiple O O
myeloma O O
( O O
MM O O
) O O
. O O

This O O
retrospective O O
study O O
investigated O O
the O O
combination O O
of O O
bort B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O O
. O O
3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
on O O
days O O
1 O O
, O O
4 O O
, O O
8 O O
, O O
and O O
11 O O
every O O
3 O O
weeks O O
) O O
and O O
dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O O
mg O O
on O O
the O O
day O O
of O O
and O O
the O O
day O O
after O O
bort B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
as O O
salvage O O
treatment O O
in O O
85 O O
patients O O
with O O
R O O
/ O O
R O O
MM O O
after O O
prior O O
autologous O O
stem O O
cell O O
transplantation O O
or O O
conventional O O
chemotherapy O O
. O O

The O O
median O B_MEASURE
number O I_MEASURE
of O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
lines O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
2 O B_NUMBER[MEASURE]
. O O

Eighty O O
- O O
seven O O
percent O O
of O O
the O O
patients O O
had O O
received O O
immunomodulatory O O
drugs O O
included O O
in O O
some O O
line O O
of O O
therapy O O
before O O
bort B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dex B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
median O O
number O O
of O O
bort B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cycles O O
was O O
6 O O
, O O
up O O
to O O
a O O
maximum O O
of O O
12 O O
cycles O O
. O O

On O O
an O O
intention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
treat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
55 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
patients O B_PERSON
achieved O O
at O O
least O O
partial O B_DISEASE/B_LOCATION
response O I_DISEASE/I_LOCATION
, O O
including O O
19 O B_DISEASE/B_LOCATION
% O I_DISEASE/I_LOCATION
CR O I_DISEASE/I_LOCATION
and O O
35 O B_PERSON
% O I_PERSON
achieved O O
at O O
least O O
very O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
partial O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
response O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Median O B_TIME[MEASURE]/B_PERSON
durations O I_TIME[MEASURE]/I_PERSON
of O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
time O B_TIME[MEASURE]/B_PERSON
to O O
next O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
free O B_TIME[MEASURE]/B_LOCATION
interval O I_TIME[MEASURE]/I_LOCATION
were O O
8 O B_MEASURE
, O O
11 O B_MEASURE
. O O
2 O B_MEASURE
, O O
and O O
5 O B_MEASURE
. O O
1 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
respectively O O
. O O

The O O
most O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
event O I_DISEASE_ADJECTIVE[DISEASE]
was O O
peripheral O B_DISEASE
neuropathy O I_DISEASE
, O O
which O O
occurred O O
in O O
78 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON
( O O
grade O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
38 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
; O O
grade O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
III O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
21 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
led O O
to O O
treatment O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
6 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
. O O

With O O
a O O
median O B_MEASURE
follow O O
up O O
of O O
22 O B_TIME[MEASURE]/B_DISEASE
months O B_TIME[MEASURE]/I_DISEASE
, O O
median O B_MEASURE/B_PERSON
time O I_MEASURE/I_PERSON
to O O
progression O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
progression O B_DISEASE_ADJECTIVE[DISEASE]
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
PFS O B_LOCATION
) O O
and O O
overall O B_DISEASE_ADJECTIVE[DISEASE]
survival O I_DISEASE_ADJECTIVE[DISEASE]
( O O
OS O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
8 O B_MEASURE
. O O
9 O B_MEASURE
, O O
8 O B_MEASURE
. O O
7 O B_MEASURE
, O O
and O O
22 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
respectively O O
. O O

Prolonged O O
PFS O O
and O O
OS O O
were O O
observed O O
in O O
patients O O
achieving O O
CR O O
and O O
receiving O O
bort B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
dex B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
single O O
line O O
of O O
prior O O
therapy O O
. O O

Bort B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
an O O
effective O O
salvage O O
treatment O O
for O O
MM O O
patients O O
, O O
particularly O O
for O O
those O O
in O O
first O O
relapse O O
. O O

Pubertal O O
exposure O O
to O O
Bisphenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increases O O
anxiety O O
- O O
like O O
behavior O O
and O O
decreases O O
acetylcholinesterase O O
activity O O
of O O
hippocampus O O
in O O
adult O O
male O O
mice O O
. O O

The O O
negative O O
effects O O
of O O
Bisphenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
on O O
neurodevelopment O O
and O O
behaviors O O
have O O
been O O
well O O
established O O
. O O

Acetylcholinesterase O B_ENZYME[GENE]
( O O
AChE O B_DISEASE/B_LOCATION
) O O
is O O
a O O
regulatory O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme O B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
is O O
involved O O
in O O
anxiety O B_DISEASE
- O O
like O B_DISEASE/B_LOCATION
behavior O I_DISEASE/I_LOCATION
. O O

This O O
study O O
investigated O O
behavioral O O
phenotypes O O
and O O
AChE O O
activity O O
in O O
male O O
mice O O
following O O
BPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
during O O
puberty O O
. O O

On O O
postnatal O O
day O O
( O O
PND O O
) O O
35 O O
, O O
male O O
mice O O
were O O
exposed O O
to O O
50mg O O
BPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
kg O O
diet O O
per O O
day O O
for O O
a O O
period O O
of O O
35 O O
days O O
. O O

On O O
PND71 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O O
a O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
the O O
elevated O O
plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maze O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
EPM O B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
the O O
light O B_COLOR
/ O O
dark O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

In O O
addition O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
AChE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
measured O O
in O O
the O O
prefrontal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
hypothalamus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Results O O
from O O
our O O
behavioral O O
phenotyping O O
indicated O O
that O O
anxiety O O
- O O
like O O
behavior O O
was O O
increased O O
in O O
mice O O
exposed O O
to O O
BPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

AChE O O
activity O O
was O O
significantly O O
decreased O O
in O O
the O O
hippocampus O O
of O O
mice O O
with O O
BPA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
control O O
mice O O
, O O
whereas O O
no O O
difference O O
was O O
found O O
in O O
the O O
prefrontal O O
cortex O O
, O O
hypothalamus O O
and O O
cerebellum O O
. O O

Our O O
findings O O
showed O O
that O O
pubertal O O
BPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
increased O O
anxiety O O
- O O
like O O
behavior O O
, O O
which O O
may O O
be O O
associated O O
with O O
decreased O O
AChE O O
activity O O
of O O
the O O
hippocampus O O
in O O
adult O O
male O O
mice O O
. O O

Further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
investigate O O
the O O
cholinergic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
signaling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O O
PBE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
anxiety O B_DISEASE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]
behaviors O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Solidago O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
virgaurea O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
extract O O
on O O
experimental O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cardiotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Cardiovascular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diseases O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CVDs O B_DISEASE/B_LOCATION
) O O
are O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
advanced O O
as O O
well O O
as O O
developing O O
countries O B_LOCATION/B_ORGANIZATION
of O O
the O O
world O B_LOCATION
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
protective O O
effect O O
of O O
the O O
Solidago O O
virgaurea O O
extract O O
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiotoxicity O O
in O O
rats O O
. O O

The O O
subcutaneous O O
injection O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
30 O O
mg O O
/ O O
kg O O
) O O
into O O
rats O O
twice O O
at O O
an O O
interval O O
of O O
24 O O
h O O
, O O
for O O
two O O
consecutive O O
days O O
, O O
led O O
to O O
a O O
significant O O
increase O O
in O O
serum O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O O
, O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase O O
, O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O O
, O O
aspartate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O O
, O O
and O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
converting O O
enzyme O O
activities O O
, O O
total O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
triglycerides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
free O O
serum O O
fatty B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
cardiac O O
tissue O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O O
, O O
and O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
and O O
a O O
significant O O
decrease O O
in O O
levels O O
of O O
glutathione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
superoxide B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O O
in O O
cardiac O O
tissue O O
as O O
compared O O
to O O
the O O
normal O O
control O O
group O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Pretreatment O O
with O O
S O O
. O O
virgaurea O O
extract O O
for O O
5 O O
weeks O O
at O O
a O O
dose O O
of O O
250 O O
mg O O
/ O O
kg O O
followed O O
by O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
significantly O O
prevented O O
the O O
observed O O
alterations O O
. O O

Captopril B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
given O O
orally O O
) O O
, O O
an O O
inhibitor O O
of O O
angiotensin B B_GENE
- O O
converting O O
enzyme O O
used O O
as O O
a O O
standard O O
cardioprotective O O
drug O O
, O O
was O O
used O O
as O O
a O O
positive O O
control O O
in O O
this O O
study O O
. O O

The O O
data O O
of O O
the O O
present O O
study O O
suggest O O
that O O
S O O
. O O
virgaurea O O
extract O O
exerts O O
its O O
protective O O
effect O O
by O O
decreasing O O
MDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
level O O
and O O
increasing O O
the O O
antioxidant O O
status O O
in O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O O
the O O
beneficial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
S O B_OTHER/B_LOCATION
. O O
virgaurea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
extract O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O O
a O O
cardioprotective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

" O O
Real O O
- O O
world O O
" O O
data O O
on O O
the O O
efficacy O O
and O O
safety O O
of O O
lenalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
relapsed O O
/ O O
refractory O O
multiple O O
myeloma O O
who O O
were O O
treated O O
according O O
to O O
the O O
standard O O
clinical O O
practice O O
: O O
a O O
study O O
of O O
the O O
Greek O O
Myeloma O O
Study O O
Group O O
. O O

Lenalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
RD B B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
a O O
standard O O
of O O
care O O
for O O
relapsed O O
/ O O
refractory O O
multiple O O
myeloma O O
( O O
RRMM O O
) O O
, O O
but O O
there O O
is O O
limited O O
published O O
data O O
on O O
its O O
efficacy O O
and O O
safety O O
in O O
the O O
" O O
real O O
world O O
" O O
( O O
RW O O
) O O
, O O
according O O
to O O
the O O
International O O
Society O O
of O O
Pharmacoeconomics O O
and O O
Outcomes O O
Research O O
definition O O
. O O

We O O
studied O O
212 O O
RRMM O O
patients O O
who O O
received O O
RD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
RW O O
. O O

Objective O B_LOCATION/B_PERSON
response O I_LOCATION/I_PERSON
( O O
> O B_LOCATION
PR O I_LOCATION
( O O
partial O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
response O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
) O O
rate O B_MEASURE/B_LOCATION
was O O
77 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
complete O B_LOCATION
response O I_LOCATION
( O O
CR O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
20 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
. O O

Median O B_TIME[MEASURE]/B_PERSON
time O I_TIME[MEASURE]/I_PERSON
to O O
first O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
best O B_SEQUENCE[MEASURE]/B_DISEASE
response O I_SEQUENCE[MEASURE]/I_DISEASE
was O O
2 O B_MEASURE
and O O
5 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
respectively O O
. O O

Median O O
time O O
to O O
CR O O
when O O
RD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
given O O
as O O
2nd O O
or O O
> O O
2 O O
( O O
nd O O
) O O
- O O
line O O
treatment O O
at O O
4 O O
and O O
11 O O
months O O
, O O
respectively O O
. O O

Quality O O
of O O
response O O
was O O
independent O O
of O O
previous O O
lines O O
of O O
therapies O O
or O O
previous O O
exposure O O
to O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Median O O
duration O O
of O O
response O O
was O O
34 O O
. O O
4 O O
months O O
, O O
and O O
it O O
was O O
higher O O
in O O
patients O O
who O O
received O O
RD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
until O O
progression O O
( O O
not O O
reached O O
versus O O
19 O O
months O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Improvement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
humoral O B_DISEASE
immunity O I_DISEASE
occurred O O
in O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
responders O B_PERSON/B_BIO
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
and O O
in O O
the O O
majority O B_PERSON/B_MEASURE
of O O
patients O B_PERSON/B_BIO
who O O
achieved O O
stable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Adverse O B_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
were O O
reported O O
in O O
68 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
( O O
myelosuppression O B_DISEASE_ADJECTIVE[DISEASE]
in O O
49 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
12 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
needed O O
hospitalization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Peripheral O B_DISEASE
neuropathy O I_DISEASE
was O O
observed O O
only O O
in O O
2 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
of O O
patients O B_PERSON/B_BIO
and O O
deep O B_DISEASE
vein O I_DISEASE
thrombosis O I_DISEASE
in O O
5 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Dose O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reductions O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
needed O O
in O O
31 O B_MEASURE
% O I_MEASURE
of O O
patients O B_PERSON/B_LOCATION
and O O
permanent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
38 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Median O B_TIME[MEASURE]/B_PERSON
time O I_TIME[MEASURE]/I_PERSON
to O O
treatment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
16 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

Performance O O
status O O
( O O
PS O O
) O O
and O O
initial O O
lenalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
predicted O O
for O O
treatment O O
discontinuation O O
. O O

Extra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
medullary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relapses O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
in O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_LOCATION
. O O

Our O O
study O O
confirms O O
that O O
RD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
effective O O
and O O
safe O O
in O O
RRMM O O
in O O
the O O
RW O O
; O O
it O O
produces O O
durable O O
responses O O
especially O O
in O O
patients O O
who O O
continue O O
on O O
treatment O O
till O O
progression O O
and O O
improves O O
humoral O O
immunity O O
even O O
in O O
patients O O
with O O
stable O O
disease O O
. O O

The O O
cytogenetic O O
action O O
of O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mesna B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
their O O
combination O O
on O O
peripheral O O
rabbit O O
lymphocytes O O
: O O
an O O
in O O
vivo O O
/ O O
in O O
vitro O O
cytogenetic O O
study O O
. O O

Ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IFO B B_LOCATION/B_DISEASE
) O O
is O O
an O O
alkylating O O
nitrogen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mustard O O
, O O
administrated O O
as O O
an O O
antineoplasmic O O
agent O O
. O O

It O O
is O O
characterized O O
by O O
its O O
intense O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urotoxic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leading O O
to O O
hemorrhagic O B_DISEASE
cystitis O I_DISEASE
. O O

This O O
side O O
effect O O
of O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
raises O O
the O O
requirement O O
for O O
the O O
co O O
- O O
administration O O
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sulfanylethanesulfonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Mesna B B_DISEASE
) O O
aiming O O
to O O
avoid O O
or O O
minimize O O
this O O
effect O O
. O O

IFO B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Mesna B B_LOCATION/B_PERSON
were O O
administrated O O
separately O O
on O O
rabbit O O
' O O
s O O
lymphocytes O O
in O O
vivo O O
, O O
which O O
were O O
later O O
developed O O
in O O
vitro O O
. O O

Cytogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
sister O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
chromatid O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exchanges O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
SCEs O B_LOCATION/B_ORGANIZATION
) O O
, O O
proliferation O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
index O B_MEASURE/I_LOCATION
( O O
PRI O B_LOCATION/B_ORGANIZATION
) O O
and O O
Mitotic O B_MEASURE/B_DISEASE
Index O B_MEASURE/I_DISEASE
were O O
recorded O O
. O O

Mesna B B_PERSON/B_COLOR
' O O
s O O
action O O
, O O
in O O
conjunction O O
with O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduces O O
the O O
frequency O O
of O O
SCEs O O
, O O
in O O
comparison O O
with O O
the O O
SCEs O O
recordings O O
obtained O O
when O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
administered O O
alone O O
. O O

In O O
addition O O
to O O
this O O
, O O
when O O
high O O
concentrations O O
of O O
Mesna B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
administered O O
alone O O
significant O O
reductions O O
of O O
the O O
PRI O O
were O O
noted O O
, O O
than O O
with O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acting O O
at O O
the O O
same O O
concentration O O
on O O
the O O
lymphocytes O O
. O O

Mesna B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
significantly O O
reduces O O
IFO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O O
s O O
genotoxicity O O
, O O
while O O
when O O
administered O O
in O O
high O O
concentrations O O
it O O
acts O O
in O O
an O O
inhibitory O O
fashion O O
on O O
the O O
cytostatic O O
action O O
of O O
the O O
drug O O
. O O

Risk O O
factors O O
and O O
predictors O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesia O O
among O O
multiethnic O O
Malaysians O O
with O O
Parkinson O O
' O O
s O O
disease O O
. O O

Chronic O O
pulsatile O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
Parkinson O O
' O O
s O O
disease O O
( O O
PD O O
) O O
leads O O
to O O
the O O
development O O
of O O
motor O O
fluctuations O O
and O O
dyskinesia O O
. O O

We O O
studied O O
the O O
prevalence O O
and O O
predictors O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesia O O
among O O
multiethnic O O
Malaysian O O
patients O O
with O O
PD O O
. O O

METHODS O O
: O O
This O O
is O O
a O O
cross O O
- O O
sectional O O
study O O
involving O O
95 O O
patients O O
with O O
PD O O
on O O
uninterrupted O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
at O O
least O O
6 O O
months O O
. O O

The O O
instrument O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
was O O
the O O
UPDRS O B_ENT/B_ORGANIZATION
questionnaires O I_ENT/I_ORGANIZATION
. O O

The O O
predictors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
dyskinesia O B_DISEASE
were O O
determined O O
using O O
multivariate O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
mean O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
was O O
65 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
8 O I_MEASURE
. O O
5 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
. O O

The O O
mean O B_MEASURE/B_PERSON
onset O I_MEASURE/I_PERSON
age O I_MEASURE/I_PERSON
was O O
58 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
9 O I_MEASURE
. O O
8 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
. O O

The O O
median O B_TIME[MEASURE]/B_PERSON
disease O I_TIME[MEASURE]/I_PERSON
duration O I_TIME[MEASURE]/I_PERSON
was O O
6 O B_NUMBER[MEASURE]
( O O
7 O B_MEASURE
) O O
years O B_TIME[MEASURE]/B_ORGANIZATION
. O O

Dyskinesia O O
was O O
present O O
in O O
44 O O
% O O
( O O
n O O
= O O
42 O O
) O O
with O O
median O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
of O O
3 O O
years O O
. O O

There O O
were O O
64 O B_MEASURE
. O O
3 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
Chinese O I_MEASURE/I_PERSON
, O O
31 O B_PERSON/B_LOCATION
% O I_PERSON/I_LOCATION
Malays O I_PERSON/I_LOCATION
, O O
and O O
3 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
Indians O I_MEASURE/I_PERSON
and O O
other O B_PERSON/B_LOCATION
ethnic O I_PERSON/I_LOCATION
groups O I_PERSON/I_LOCATION
. O O

Eighty O B_NUMBER[MEASURE]/B_LOCATION
- O O
one O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
patients O B_PERSON
with O O
dyskinesia O B_DISEASE
had O O
clinical O B_DISEASE
fluctuations O I_DISEASE
. O O

Patients O O
with O O
dyskinesia O O
had O O
lower O O
onset O O
age O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
longer O O
duration O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
longer O O
disease O O
duration O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
higher O O
total O O
daily O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
and O O
higher O O
total O O
UPDRS O O
scores O O
( O O
p O O
= O O
0 O O
. O O
005 O O
) O O
than O O
patients O O
without O O
dyskinesia O O
. O O

The O O
three O O
significant O O
predictors O O
of O O
dyskinesia O O
were O O
duration O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
, O O
onset O O
age O O
, O O
and O O
total O O
daily O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
. O O

CONCLUSIONS O O
: O O
The O O
prevalence O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
dyskinesia O O
in O O
our O O
patients O O
was O O
44 O O
% O O
. O O

The O O
most O O
significant O O
predictors O O
were O O
duration O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
total O O
daily O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
, O O
and O O
onset O O
age O O
. O O

Dose O O
- O O
dependent O O
neurotoxicity O O
of O O
high O O
- O O
dose O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
children O O
: O O
a O O
clinical O O
and O O
pharmacological O O
study O O
. O O

Busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
known O O
to O O
be O O
neurotoxic O O
in O O
animals O O
and O O
humans O O
, O O
but O O
its O O
acute O O
neurotoxicity O O
remains O O
poorly O O
characterized O O
in O O
children O O
. O O

We O O
report O O
here O O
a O O
retrospective O O
study O O
of O O
123 O O
children O O
( O O
median O O
age O O
, O O
6 O O
. O O
5 O O
years O O
) O O
receiving O O
high O O
- O O
dose O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
combined O O
chemotherapy O O
before O O
bone O O
marrow O O
transplantation O O
for O O
malignant O O
solid O O
tumors O O
, O O
brain O O
tumors O O
excluded O O
. O O

Busulfan B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
given O O
p O O
. O O
o O O
. O O
, O O
every O O
6 O O
hours O O
for O O
16 O O
doses O O
over O O
4 O O
days O O
. O O

Two O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total O I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
consecutively O O
used O O
: O O
16 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_MEASURE
, O O
then O O
600 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE
. O O

The O O
dose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O O
the O O
basis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
body O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
surface O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
area O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results O O
in O O
higher O B_MEASURE
doses O I_MEASURE
in O O
young O B_PERSON/B_ORGANIZATION
children O I_PERSON/I_ORGANIZATION
than O O
in O O
older O B_PERSON
patients O I_PERSON
( O O
16 O B_MEASURE
to O O
28 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
) O O
. O O

Ninety O O
- O O
six O O
patients O O
were O O
not O O
given O O
anticonvulsive O O
prophylaxis O O
; O O
7 O O
( O O
7 O O
. O O
5 O O
% O O
) O O
developed O O
seizures O O
during O O
the O O
4 O O
days O O
of O O
the O O
busulfan B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
course O O
or O O
within O O
24 O O
h O O
after O O
the O O
last O O
dosing O O
. O O

When O O
the O O
total O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
dose O O
was O O
taken O O
into O O
account O O
, O O
there O O
was O O
a O O
significant O O
difference O O
in O O
terms O O
of O O
neurotoxicity O O
incidence O O
among O O
patients O O
under O O
16 O O
mg O O
/ O O
kg O O
( O O
1 O O
of O O
57 O O
, O O
1 O O
. O O
7 O O
% O O
) O O
and O O
patients O O
under O O
600 O O
mg O O
/ O O
m2 O O
( O O
6 O O
of O O
39 O O
, O O
15 O O
. O O
4 O O
% O O
) O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

Twenty O O
- O O
seven O O
patients O O
were O O
given O O
a O O
600 O O
- O O
mg O O
/ O O
m2 O O
busulfan B B_TIME[MEASURE]/B_PERSON
total O O
dose O O
with O O
continuous O O
i O O
. O O
v O O
. O O
infusion O O
of O O
clonazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
none O O
had O O
any O O
neurological O O
symptoms O O
. O O

Busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
levels O O
were O O
measured O O
by O O
a O O
gas O O
chromatographic O O
- O O
mass O O
spectrometry O O
assay O O
in O O
the O O
plasma O O
and O O
cerebrospinal O O
fluid O O
of O O
9 O O
children O O
without O O
central O O
nervous O O
system O O
disease O O
under O O
600 O O
mg O O
/ O O
m2 O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O O
clonazepam B B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
busulfan B B_PERSON/B_MEASURE
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
was O O
1 O O
. O O
39 O O
. O O

This O O
was O O
significantly O O
different O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
from O O
the O O
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
previously O O
defined O O
in O O
children O O
receiving O O
a O O
16 O O
- O O
mg O O
/ O O
kg O O
total O O
dose O O
of O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

This O O
study O O
shows O O
that O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
neurotoxicity O O
is O O
dose O O
- O O
dependent O O
in O O
children O O
and O O
efficiently O O
prevented O O
by O O
clonazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
busulfan B B_MEASURE/B_BIO
dose O O
calculated O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
, O O
resulting O O
in O O
higher O O
doses O O
in O O
young O O
children O O
, O O
was O O
followed O O
by O O
increased O O
neurotoxicity O O
, O O
close O O
to O O
neurotoxicity O O
incidence O O
observed O O
in O O
adults O O
. O O

Since O O
plasma O O
pharmacokinetic O O
studies O O
showed O O
a O O
faster O O
busulfan B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
clearance O O
in O O
children O O
than O O
in O O
adults O O
, O O
this O O
new O O
dose O O
may O O
approximate O O
more O O
closely O O
the O O
adult O O
systemic O O
exposure O O
obtained O O
after O O
the O O
usual O O
16 O O
- O O
mg O O
/ O O
kg O O
total O O
dose O O
, O O
with O O
potential O O
inferences O O
in O O
terms O O
of O O
anticancer O O
or O O
myeloablative O O
effects O O
. O O

The O O
busulfan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
dose O O
in O O
children O O
and O O
infants O O
undergoing O O
bone O O
marrow O O
transplantation O O
should O O
be O O
reconsidered O O
on O O
the O O
basis O O
of O O
pharmacokinetic O O
studies O O
. O O

An O O
unexpected O O
diagnosis O O
in O O
a O O
renal O O
- O O
transplant O O
patient O O
with O O
proteinuria O O
treated O O
with O O
everolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
AL O O
amyloidosis O O
. O O

Proteinuria O O
is O O
an O O
expected O O
complication O O
in O O
transplant O O
patients O O
treated O O
with O O
mammalian O O
target O O
of O O
rapamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitors O O
( O O
mTOR O O
- O O
i O O
) O O
. O O

However O O
, O O
clinical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suspicion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O O
always O O
be O O
supported O O
by O O
histological O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
order O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
investigate O O
potential O B_DISEASE_ADJECTIVE[DISEASE]
alternate O I_DISEASE_ADJECTIVE[DISEASE]
diagnoses O I_DISEASE_ADJECTIVE[DISEASE]
such O I_DISEASE_ADJECTIVE[DISEASE]
as O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
or O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
rejection O I_DISEASE_ADJECTIVE[DISEASE]
, O O
interstitial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fibrosis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
tubular O B_DISEASE
atrophy O I_DISEASE
, O O
or O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
de O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
novo O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
glomerulopathy O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

In O O
this O O
case O O
we O O
report O O
the O O
unexpected O O
diagnosis O O
of O O
amyloidosis O O
in O O
a O O
renal O O
- O O
transplant O O
patient O O
with O O
pre O O
- O O
transplant O O
monoclonal O O
gammapathy O O
of O O
undetermined O O
significance O O
who O O
developed O O
proteinuria O O
after O O
conversion O O
from O O
tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
everolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Long O O
- O O
term O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
prevents O O
cognitive O O
deficits O O
in O O
male O O
Wistar O O
rats O O
treated O O
intracerebroventricularly O O
with O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Basic O O
and O O
clinical O O
research O O
has O O
demonstrated O O
that O O
dementia O O
of O O
sporadic O O
Alzheimer O O
' O O
s O O
disease O O
( O O
sAD O O
) O O
type O O
is O O
associated O O
with O O
dysfunction O O
of O O
the O O
insulin O O
- O O
receptor O O
( O O
IR O O
) O O
system O O
followed O O
by O O
decreased O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transport O O
via O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transporter O O
GLUT4 O O
and O O
decreased O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O O
in O O
brain O O
cells O O
. O O

An O O
alternative O O
source O O
of O O
energy O O
is O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
galactose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
the O O
C O O
- O O
4 O O
- O O
epimer O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
which O O
is O O
transported O O
into O O
the O O
brain O O
by O O
insulin O O
- O O
independent O O
GLUT3 O O
transporter O O
where O O
it O O
might O O
be O O
metabolized O O
to O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
via O O
the O O
Leloir O O
pathway O O
. O O

Exclusively O O
parenteral O O
daily O O
injections O O
of O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O O
memory O O
deterioration O O
in O O
rodents O O
and O O
are O O
used O O
to O O
generate O O
animal O O
aging O O
model O O
, O O
but O O
the O O
effects O O
of O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
on O O
cognitive O O
functions O O
have O O
never O O
been O O
tested O O
. O O

We O O
have O O
investigated O O
the O O
effects O O
of O O
continuous O O
daily O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
200 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
treatment O O
on O O
cognitive O O
deficits O O
in O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
( O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
icv O O
) O O
rat O O
model O O
of O O
sAD O O
, O O
tested O O
by O O
Morris O O
Water O O
Maze O O
and O O
Passive O O
Avoidance O O
test O O
, O O
respectively O O
. O O

One O O
month O O
of O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
initiated O O
immediately O O
after O O
the O O
STZ B B_LOCATION/B_DISEASE
- O O
icv O O
administration O O
, O O
successfully O O
prevented O O
development O O
of O O
the O O
STZ B B_LOCATION
- O O
icv O O
- O O
induced O O
cognitive O O
deficits O O
. O O

Beneficial O O
effect O O
of O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
independent O O
of O O
the O O
rat O O
age O O
and O O
of O O
the O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
ranging O O
from O O
100 O O
to O O
300 O O
mg O O
/ O O
kg O O
/ O O
day O O
. O O

Additionally O O
, O O
oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
led O O
to O O
the O O
appearance O O
of O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
blood O O
. O O

The O O
increase O O
of O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
in O O
the O O
cerebrospinal O O
fluid O O
was O O
several O O
times O O
lower O O
after O O
oral O O
than O O
after O O
parenteral O O
administration O O
of O O
the O O
same O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
. O O

Oral O O
galactose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O O
might O O
have O O
beneficial O O
effects O O
on O O
learning O O
and O O
memory O O
ability O O
and O O
could O O
be O O
worth O O
investigating O O
for O O
improvement O O
of O O
cognitive O O
deficits O O
associated O O
with O O
glucose O O
hypometabolism O O
in O O
AD O O
. O O

An O O
investigation O O
of O O
the O O
pattern O O
of O O
kidney O O
injury O O
in O O
HIV O O
- O O
positive O O
persons O O
exposed O O
to O O
tenofovir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disoproxil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
fumarate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
an O O
examination O O
of O O
a O O
large O O
population O O
database O O
( O O
MHRA O O
database O O
) O O
. O O

The O O
potential O O
for O O
tenofovir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
cause O O
a O O
range O O
of O O
kidney O O
syndromes O O
has O O
been O O
established O O
from O O
mechanistic O O
and O O
randomised O O
clinical O O
trials O O
. O O

However O O
, O O
the O O
exact O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
kidney O B_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
is O O
still O O
uncertain O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
undertook O O
a O O
descriptive O O
analysis O O
of O O
Yellow O O
Card O O
records O O
of O O
407 O O
HIV O O
- O O
positive O O
persons O O
taking O O
tenofovir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disoproxil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fumarate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TDF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
as O O
part O O
of O O
their O O
antiretroviral O O
therapy O O
regimen O O
and O O
submitted O O
to O O
the O O
Medicines O O
and O O
Healthcare O O
Products O O
Regulatory O O
Agency O O
( O O
MHRA O O
) O O
with O O
suspected O O
kidney O O
adverse O O
effects O O
. O O

Reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
satisfy O O
defined O O
criteria O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
classified O O
as O O
acute O B_DISEASE
kidney O I_DISEASE
injury O I_DISEASE
, O O
kidney O B_DISEASE
tubular O I_DISEASE
dysfunction O I_DISEASE
and O O
Fanconi O B_DISEASE/B_PERSON
syndrome O I_DISEASE/I_PERSON
. O O

Of O O
the O O
407 O O
Yellow O O
Card O O
records O O
analysed O O
, O O
106 O O
satisfied O O
criteria O O
for O O
TDF B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
kidney O O
disease O O
, O O
of O O
which O O
53 O O
( O O
50 O O
% O O
) O O
had O O
features O O
of O O
kidney O O
tubular O O
dysfunction O O
, O O
35 O O
( O O
33 O O
% O O
) O O
were O O
found O O
to O O
have O O
features O O
of O O
glomerular O O
dysfunction O O
and O O
18 O O
( O O
17 O O
% O O
) O O
had O O
Fanconi O O
syndrome O O
. O O

The O O
median O O
TDF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
exposure O O
was O O
316 O O
days O O
( O O
interquartile O O
range O O
120 O O
- O O
740 O O
) O O
. O O

The O O
incidence O O
of O O
hospitalisation O O
for O O
TDF B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kidney O O
adverse O O
effects O O
was O O
high O O
, O O
particularly O O
amongst O O
patients O O
with O O
features O O
of O O
Fanconi O O
syndrome O O
. O O

The O O
pattern O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
kidney O B_DISEASE_ADJECTIVE[DISEASE]
syndromes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mirrors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
reported O O
in O O
randomised O B_MEASURE/B_LOCATION
clinical O I_MEASURE/I_LOCATION
trials O I_MEASURE/I_LOCATION
. O O

Cessation O O
of O O
TDF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
associated O O
with O O
complete O O
restoration O O
of O O
kidney O O
function O O
in O O
up O O
half O O
of O O
the O O
patients O O
in O O
this O O
report O O
. O O

Incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
postoperative O B_DISEASE/B_LOCATION
delirium O I_DISEASE/I_LOCATION
is O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
even O O
in O O
a O O
population O B_PERSON/B_LOCATION
without O O
known O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Postoperative O B_DISEASE/B_GENE
delirium O I_DISEASE/I_GENE
is O O
a O O
recognized O O
complication O B_DISEASE
in O O
populations O B_LOCATION/B_PERSON
at O O
risk O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
assess O O
the O O
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
early O B_DISEASE
postoperative O I_DISEASE
delirium O I_DISEASE
in O O
a O O
population O B_PERSON/B_LOCATION
without O O
known O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admitted O O
to O O
the O O
ICU O B_LOCATION/B_ORGANIZATION
for O O
postoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O O
elective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
major O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
secondary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
investigated O O
is O O
to O O
identify O O
eventual O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
demographic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
anesthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
An O O
observational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
on O O
a O O
consecutive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
patients O B_PERSON
admitted O O
to O O
our O O
ICU O B_LOCATION/B_ORGANIZATION
within O O
and O O
for O O
at O O
least O O
24 O B_MEASURE
h O O
after O O
major O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
surgical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
procedures O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Exclusion O B_PERSON/B_LOCATION
criteria O I_PERSON/I_LOCATION
were O O
any O O
preexisting O O
predisposing O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
delirium O B_DISEASE
or O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
potentially O O
confounding O O
neurological O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunctions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O B_PERSON
were O O
assessed O O
daily O O
using O O
the O O
confusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assessment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
the O O
ICU O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
scale O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
surgical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
postoperative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
delirium O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
incidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
then O O
assessed O O
through O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
multiple O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
According O O
to O O
the O O
confusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
the O O
ICU O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
28 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
were O O
diagnosed O O
with O O
early O B_DISEASE/B_GENE
postoperative O I_DISEASE/I_GENE
delirium O I_DISEASE/I_GENE
. O O

The O O
use O O
of O O
thiopentone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
associated O O
with O O
an O O
eight O O
- O O
fold O O
- O O
higher O O
risk O O
for O O
delirium O O
compared O O
to O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
57 O O
. O O
1 O O
% O O
vs O O
. O O
7 O O
. O O
1 O O
% O O
, O O
RR O O
= O O
8 O O
. O O
0 O O
, O O
X2 O O
= O O
4 O O
. O O
256 O O
; O O
df O O
= O O
1 O O
; O O
0 O O
. O O
05 O O
< O O
p O O
< O O
0 O O
. O O
02 O O
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
early O O
postoperative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
to O O
be O O
a O O
very O O
common O B_DISEASE_ADJECTIVE[DISEASE]
complication O I_DISEASE_ADJECTIVE[DISEASE]
after O O
major O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
, O O
even O O
in O O
a O O
population O B_PERSON/B_LOCATION
without O O
known O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thiopentone B B_DISEASE/B_PERSON
was O O
independently O O
associated O O
with O O
an O O
increase O O
in O O
its O O
relative O O
risk O O
. O O

A O O
single O O
neurotoxic O O
dose O O
of O O
methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
a O O
long O O
- O O
lasting O O
depressive O O
- O O
like O O
behaviour O O
in O O
mice O O
. O O

Methamphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
triggers O O
a O O
disruption O O
of O O
the O O
monoaminergic O O
system O O
and O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O O
leads O O
to O O
negative O O
emotional O O
states O O
including O O
depressive O O
symptoms O O
during O O
drug O O
withdrawal O O
. O O

However O O
, O O
it O O
is O O
currently O O
unknown O O
if O O
the O O
acute O O
toxic O O
dosage O O
of O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
causes O O
a O O
long O O
- O O
lasting O O
depressive O O
phenotype O O
and O O
persistent O O
monoaminergic O O
deficits O O
. O O

Thus O O
, O O
we O O
now O O
assessed O O
the O O
depressive O O
- O O
like O O
behaviour O O
in O O
mice O O
at O O
early O O
and O O
long O O
- O O
term O O
periods O O
following O O
a O O
single O O
high O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
( O O
30 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
alter O O
the O O
motor O O
function O O
and O O
procedural O O
memory O O
of O O
mice O O
as O O
assessed O O
by O O
swimming O O
speed O O
and O O
escape O O
latency O O
to O O
find O O
the O O
platform O O
in O O
a O O
cued O O
version O O
of O O
the O O
water O O
maze O O
task O O
. O O

However O O
, O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O O
increased O O
the O O
immobility O O
time O O
in O O
the O O
tail O O
suspension O O
test O O
at O O
3 O O
and O O
49 O O
days O O
post O O
- O O
administration O O
. O O

This O O
depressive O O
- O O
like O O
profile O O
induced O O
by O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
accompanied O O
by O O
a O O
marked O O
depletion O O
of O O
frontostriatal O O
dopaminergic O O
and O O
serotonergic O O
neurotransmission O O
, O O
indicated O O
by O O
a O O
reduction O O
in O O
the O O
levels O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DOPAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
HVA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
tyrosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hydroxylase O O
and O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
observed O O
at O O
both O O
3 O O
and O O
49 O O
days O O
post O O
- O O
administration O O
. O O

In O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
another O O
neurochemical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
feature O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
depression O B_DISEASE
- O O
- O O
astroglial O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
was O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
cortex O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O O
the O O
striatal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
astrocytic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
glial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
were O O
only O O
transiently O O
increased O O
at O O
3 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
. O O

These O O
findings O O
demonstrate O O
for O O
the O O
first O O
time O O
that O O
a O O
single O O
high O O
dose O O
of O O
METH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
long O O
- O O
lasting O O
depressive O O
- O O
like O O
behaviour O O
in O O
mice O O
associated O O
with O O
a O O
persistent O O
disruption O O
of O O
frontostriatal O O
dopaminergic O O
and O O
serotonergic O O
homoeostasis O O
. O O

Linezolid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
optic O O
neuropathy O O
. O O

Many O B_PERSON
systemic O I_PERSON
antimicrobials O I_PERSON
have O O
been O O
implicated O O
to O O
cause O O
ocular O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
. O O

This O O
is O O
especially O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
multidrug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O O
more O B_MEASURE/B_PERSON
than O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
cause O O
a O O
similar O B_DISEASE
ocular O I_DISEASE
adverse O I_DISEASE
effect O I_DISEASE
. O O

We O O
describe O O
a O O
case O O
of O O
progressive O O
loss O O
of O O
vision O O
associated O O
with O O
linezolid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

A O O
45 O O
- O O
year O O
- O O
old O O
male O O
patient O O
who O O
was O O
on O O
treatment O O
with O O
multiple O O
second O O
- O O
line O O
anti O O
- O O
tuberculous O O
drugs O O
including O O
linezolid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
extensively O O
drug O O
- O O
resistant O O
tuberculosis O O
( O O
XDR O O
- O O
TB O O
) O O
presented O O
to O O
us O O
with O O
painless O O
progressive O O
loss O O
of O O
vision O O
in O O
both O O
eyes O O
. O O

Color O B_DISEASE/B_PERSON
vision O I_DISEASE/I_PERSON
was O O
defective O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
fundus O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
optic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disc O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
edema O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
both O O
eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
toxic O O
optic O O
neuropathy O O
was O O
suspected O O
and O O
tablet O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
withdrawn O O
. O O

Deterioration O O
of O O
vision O O
occurred O O
despite O O
withdrawal O O
of O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Discontinuation O O
of O O
linezolid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
marked O O
improvement O O
of O O
vision O O
. O O

Our O O
report O O
emphasizes O O
the O O
need O O
for O O
monitoring O O
of O O
visual O O
function O O
in O O
patients O O
on O O
long O O
- O O
term O O
linezolid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O O
. O O

Resuscitation O O
with O O
lipid O O
, O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
both O O
in O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
toxicity O O
in O O
newborn O O
piglets O O
. O O

BACKGROUND O O
: O O
The O O
optimal O O
dosing O O
regimens O O
of O O
lipid O O
emulsion O O
, O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
both O O
are O O
not O O
yet O O
determined O O
in O O
neonates O O
in O O
cases O O
of O O
local O O
anaesthetic O O
systemic O O
toxicity O O
( O O
LAST O O
) O O
. O O

METHODS O O
: O O
Newborn O O
piglets O O
received O O
levobupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O O
cardiovascular O O
collapse O O
occurred O O
. O O

Standard O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cardiopulmonary O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resuscitation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
started O O
and O O
electrocardiogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ECG O B_LOCATION/B_ORGANIZATION
) O O
was O O
monitored O O
for O O
ventricular O B_DISEASE
tachycardia O I_DISEASE
, O O
fibrillation O B_DISEASE
, O O
or O O
QRS O B_DISEASE
prolongation O I_DISEASE
. O O

Piglets O O
were O O
then O O
randomly O O
allocated O O
to O O
four O O
groups O O
: O O
control O O
( O O
saline O O
) O O
, O O
Intralipid O O
( O O
) O O
alone O O
, O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
or O O
a O O
combination O O
of O O
Intralipd O O
plus O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Resuscitation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
continued O O
for O O
30 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
or O O
until O O
there O O
was O O
a O O
return O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
spontaneous O B_DISEASE/B_MEASURE
circulation O I_DISEASE/I_MEASURE
( O O
ROSC O B_DISEASE/B_PROTEIN[GENE]
) O O
accompanied O O
by O O
a O O
mean O B_MEASURE/B_LOCATION
arterial O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
at O O
or O O
superior O B_PERSON/B_MEASURE
to O O
the O O
baseline O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
and O O
normal O B_DISEASE_ADJECTIVE[DISEASE]
sinus O I_DISEASE_ADJECTIVE[DISEASE]
rhythm O I_DISEASE_ADJECTIVE[DISEASE]
for O O
a O O
period O B_MEASURE/B_LOCATION
of O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
ROSC O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
achieved O O
in O O
only O O
one O B_NUMBER[MEASURE]
of O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
piglets O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O O
with O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
treated O O
piglets O B_BIO/B_PERSON
. O O

Mortality O B_DISEASE
was O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
but O O
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
number O O
of O O
ECG O O
abnormalities O O
was O O
zero O O
in O O
the O O
Intralipid O O
only O O
group O O
, O O
but O O
14 O O
and O O
17 O O
, O O
respectively O O
, O O
in O O
the O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
lipid O O
groups O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

CONCLUSIONS O O
: O O
Lipid O O
emulsion O O
with O O
or O O
without O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
were O O
equally O O
effective O O
in O O
achieving O O
a O O
return O O
to O O
spontaneous O O
circulation O O
in O O
this O O
model O O
of O O
LAST O O
. O O

Epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
in O O
combination O O
with O O
lipid O O
was O O
associated O O
with O O
an O O
increased O O
number O O
of O O
ECG O O
abnormalities O O
compared O O
with O O
lipid O O
emulsion O O
alone O O
. O O

Incidence O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
thrombocytopenia O O
type O O
II O O
and O O
postoperative O O
recovery O O
of O O
platelet O O
count O O
in O O
liver O O
graft O O
recipients O O
: O O
a O O
retrospective O O
cohort O O
analysis O O
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Thrombocytopenia O B_DISEASE
in O O
patients O B_PERSON/B_BIO
with O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE
liver O I_DISEASE
disease O I_DISEASE
is O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]
disorder O I_DISEASE_ADJECTIVE[DISEASE]
caused O O
mainly O O
by O O
portal O B_DISEASE
hypertension O I_DISEASE
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
thrombopoetin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
endotoxemia O B_DISEASE
. O O

The O O
impact O O
of O O
immune O O
- O O
mediated O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
type O O
II O O
( O O
HIT O O
type O O
II O O
) O O
as O O
a O O
cause O O
of O O
thrombocytopenia O O
after O O
liver O O
transplantation O O
is O O
not O O
yet O O
understood O O
, O O
with O O
few O O
literature O O
citations O O
reporting O O
contradictory O O
results O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
our O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
demonstrate O O
the O O
perioperative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
course O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
thrombocytopenia O B_DISEASE
after O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O O
determine O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
HIT O I_DISEASE_ADJECTIVE[DISEASE]
type O I_DISEASE_ADJECTIVE[DISEASE]
II O I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHOD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
retrospectively O O
evaluated O O
the O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
205 O B_PERSON
consecutive O I_PERSON
adult O I_PERSON
patients O I_PERSON
who O O
underwent O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
size O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O O
January O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
December O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
2010 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_ENT/B_MEASURE
or O O
malignant O B_DISEASE
liver O I_DISEASE
disease O I_DISEASE
. O O

Preoperative O B_TIME[MEASURE]/B_LOCATION
platelet O I_TIME[MEASURE]/I_LOCATION
count O I_TIME[MEASURE]/I_LOCATION
, O O
postoperative O B_MEASURE/B_LOCATION
course O I_MEASURE/I_LOCATION
of O O
platelets O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
signs O I_DISEASE_ADJECTIVE[DISEASE]
of O O
HIT O B_DISEASE
type O I_DISEASE
II O I_DISEASE
were O O
analyzed O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
total O B_MEASURE
of O O
155 O B_MEASURE
( O O
75 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
205 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
had O O
thrombocytopenia O B_DISEASE
before O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
significantly O O
influenced O O
by O O
Model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
End O B_NUMBER[MEASURE]/B_LOCATION
- O O
Stage O B_TIME[MEASURE]/B_LOCATION
Liver O I_TIME[MEASURE]/I_LOCATION
Disease O I_TIME[MEASURE]/I_LOCATION
score O I_TIME[MEASURE]/I_LOCATION
and O O
liver O B_DISEASE_ADJECTIVE[DISEASE]
cirrhosis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
platelet O B_MEASURE/B_DISEASE
count O I_MEASURE/I_DISEASE
exceeded O O
100 O B_MEASURE
, O O
000 O B_MEASURE
/ O O
uL O B_MEASURE
in O O
most O B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON/B_LOCATION
( O O
n O B_OTHER/B_MEASURE
= O O
193 O B_MEASURE
) O O
at O O
a O O
medium O B_MEASURE
of O O
7 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
d O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Regarding O O
HIT O B_DISEASE/B_PERSON
II O I_DISEASE/I_PERSON
, O O
there O O
were O O
four O B_NUMBER[MEASURE]
( O O
1 O B_MEASURE
. O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
patients O B_PERSON
with O O
a O O
background O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
HIT O B_DISEASE
type O I_DISEASE
II O I_DISEASE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
HIT O B_DISEASE/B_GENE
in O O
patients O B_PERSON/B_BIO
with O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE/B_LOCATION
hepatic O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
is O O
, O O
with O O
about O O
1 O B_MEASURE
. O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

For O O
further O O
reduction O O
of O O
HIT O O
type O O
II O O
, O O
the O O
use O O
of O O
intravenous O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
avoided O O
and O O
the O O
prophylactic O O
anticoagulation O O
should O O
be O O
performed O O
with O O
low O O
- O O
molecular O O
- O O
weight O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
normalization O O
of O O
platelet O O
count O O
. O O

Takotsubo O O
syndrome O O
( O O
or O O
apical O O
ballooning O O
syndrome O O
) O O
secondary O O
to O O
Zolmitriptan B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Takotsubo O B_DISEASE/B_GENE
syndrome O I_DISEASE/I_GENE
( O O
TS O B_LOCATION
) O O
, O O
also O O
known O O
as O O
broken O B_LOCATION
heart O I_LOCATION
syndrome O I_LOCATION
, O O
is O O
characterized O O
by O O
left O B_PERSON/B_DISEASE
ventricle O I_PERSON/I_DISEASE
apical O I_PERSON/I_DISEASE
ballooning O I_PERSON/I_DISEASE
with O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biomarkers O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
electrocardiographic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggestive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
acute O B_DISEASE/B_LOCATION
coronary O I_DISEASE/I_LOCATION
syndrome O I_DISEASE/I_LOCATION
( O O
ie O B_DISEASE/B_LOCATION
, O O
ST O B_NUMBER[MEASURE]/B_DISEASE
- O O
segment O B_DISEASE_ADJECTIVE[DISEASE]
elevation O I_DISEASE_ADJECTIVE[DISEASE]
, O O
T O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wave O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inversions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
pathologic O B_DISEASE
Q O I_DISEASE
waves O I_DISEASE
) O O
. O O

We O O
report O O
a O O
case O B_PERSON
of O O
54 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
woman O I_PERSON
with O O
medical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
mitral O B_DISEASE
valve O I_DISEASE
prolapse O I_DISEASE
and O O
migraines O B_DISEASE/B_LOCATION
, O O
who O O
was O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_PERSON
for O O
substernal O B_DISEASE
chest O I_DISEASE
pain O I_DISEASE
and O O
electrocardiogram O B_TIME[MEASURE]/B_LOCATION
demonstrated O O
1 O B_NUMBER[MEASURE]
/ O O
2 O B_NUMBER[MEASURE]
mm O I_NUMBER[MEASURE]
ST O I_NUMBER[MEASURE]
- O O
segment O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
elevation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
leads O O
II O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O O
III O B_PROTEIN[GENE]/B_LOCATION
, O O
aVF O B_MEASURE/B_PROTEIN[GENE]
, O O
V5 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
V6 O B_MEASURE/B_PROTEIN[GENE]
and O O
positive O B_MEASURE/B_LOCATION
troponin O I_MEASURE/I_LOCATION
I O O
. O O

Emergent O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
angiogram O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
revealed O O
normal O B_DISEASE/B_LOCATION
coronary O I_DISEASE/I_LOCATION
arteries O I_DISEASE/I_LOCATION
with O O
moderately O O
reduced O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
ejection O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
fraction O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
with O O
wall O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motion O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
TS O B_DISEASE
. O O

Detailed O O
history O O
obtained O O
retrospectively O O
revealed O O
that O O
the O O
patient O O
took O O
zolmitriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sparingly O O
only O O
when O O
she O O
had O O
migraines O O
. O O

But O O
before O O
this O O
event O O
, O O
she O O
was O O
taking O O
zolmitriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O O
- O O
3 O O
times O O
daily O O
for O O
several O O
days O O
because O O
of O O
a O O
persistent O O
migraine O O
headache O O
. O O

She O O
otherwise O O
reported O O
that O O
she O O
is O O
quite O O
active O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
rides O O
horses O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
does O O
show O O
jumping O O
without O O
any O O
limitations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
her O O
physical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
was O O
no O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
any O O
recent O B_DISEASE
stress O I_DISEASE
or O O
status O B_DISEASE
migrainosus O I_DISEASE
. O O

Extensive O O
literature O O
search O O
revealed O O
multiple O O
cases O O
of O O
coronary O O
artery O O
vasospasm O O
secondary O O
to O O
zolmitriptan B B_DISEASE/B_LOCATION
, O O
but O O
none O O
of O O
the O O
cases O O
were O O
associated O O
with O O
TS O O
. O O

Depression O O
, O O
impulsiveness O O
, O O
sleep O O
, O O
and O O
memory O O
in O O
past O O
and O O
present O O
polydrug O O
users O O
of O O
3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methylenedioxymethamphetamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MDMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
ecstasy B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

RATIONALE O O
: O O
Ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methylenedioxymethamphetamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
MDMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
a O O
worldwide O O
recreational O O
drug O O
of O O
abuse O O
. O O

Unfortunately O O
, O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigating O O
its O O
psychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
inconsistent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
aimed O O
to O O
be O O
the O O
largest O O
to O O
date O O
in O O
sample O O
size O O
and O O
5HT O O
- O O
related O O
behaviors O O
; O O
the O O
first O O
to O O
compare O O
present O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
with O O
past O O
users O O
after O O
an O O
abstinence O O
of O O
4 O O
or O O
more O O
years O O
, O O
and O O
the O O
first O O
to O O
include O O
robust O O
controls O O
for O O
other O O
recreational O O
substances O O
. O O

METHODS O O
: O O
A O O
sample O O
of O O
997 O O
participants O O
( O O
52 O O
% O O
male O O
) O O
was O O
recruited O O
to O O
four O O
control O O
groups O O
( O O
non O O
- O O
drug O O
( O O
ND O O
) O O
, O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AN B B_LOCATION
) O O
, O O
cannabis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
alcohol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAN B B_LOCATION/B_EDU[ORGANIZATION]
) O O
, O O
non O O
- O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polydrug O O
( O O
PD O O
) O O
) O O
, O O
and O O
two O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polydrug O O
groups O O
( O O
present O O
( O O
MDMA B B_LOCATION
) O O
and O O
past O O
users O O
( O O
EX O O
- O O
MDMA B B_LOCATION/B_PERSON
) O O
. O O

Participants O B_PERSON
completed O O
a O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
questionnaire O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
Beck O B_DISEASE
Depression O I_DISEASE
Inventory O I_DISEASE
, O O
Barratt O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Impulsiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Scale O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
Pittsburgh O B_TIME[MEASURE]/B_DISEASE
Sleep O I_TIME[MEASURE]/I_DISEASE
Quality O I_TIME[MEASURE]/I_DISEASE
Index O I_TIME[MEASURE]/I_DISEASE
, O O
and O O
Wechsler O B_DISEASE/B_MEASURE
Memory O I_DISEASE/I_MEASURE
Scale O I_DISEASE/I_MEASURE
- O O
Revised O O
which O O
, O O
in O O
total O B_MEASURE
, O O
provided O O
13 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
psychometric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O O
: O O
While O O
the O O
CAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
PD O O
groups O O
tended O O
to O O
record O O
greater O O
deficits O O
than O O
the O O
non O O
- O O
drug O O
controls O O
, O O
the O O
MDMA B B_LOCATION
and O O
EX O O
- O O
MDMA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O O
recorded O O
greater O O
deficits O O
than O O
all O O
the O O
control O O
groups O O
on O O
ten O O
of O O
the O O
13 O O
psychometric O O
measures O O
. O O

Strikingly O O
, O O
despite O O
prolonged O O
abstinence O O
( O O
mean O O
, O O
4 O O
. O O
98 O O
; O O
range O O
, O O
4 O O
- O O
9 O O
years O O
) O O
, O O
past O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
showed O O
few O O
signs O O
of O O
recovery O O
. O O

Compared O O
with O O
present O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
, O O
the O O
past O O
users O O
showed O O
no O O
change O O
for O O
ten O O
measures O O
, O O
increased O O
impairment O O
for O O
two O O
measures O O
, O O
and O O
improvement O O
on O O
just O O
one O O
measure O O
. O O

CONCLUSIONS O O
: O O
Given O O
this O O
record O O
of O O
impaired O O
memory O O
and O O
clinically O O
significant O O
levels O O
of O O
depression O O
, O O
impulsiveness O O
, O O
and O O
sleep O O
disturbance O O
, O O
the O O
prognosis O O
for O O
the O O
current O O
generation O O
of O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
is O O
a O O
major O O
cause O O
for O O
concern O O
. O O

Association O O
of O O
common O O
genetic O O
variants O O
of O O
HOMER1 O O
gene O O
with O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adverse O O
effects O O
in O O
Parkinson O O
' O O
s O O
disease O O
patients O O
. O O

Levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
the O O
most O O
effective O O
symptomatic O O
therapy O O
for O O
Parkinson O O
' O O
s O O
disease O O
, O O
but O O
its O O
chronic O O
use O O
could O O
lead O O
to O O
chronic O O
adverse O O
outcomes O O
, O O
such O O
as O O
motor O O
fluctuations O O
, O O
dyskinesia O O
and O O
visual O O
hallucinations O O
. O O

HOMER1 O O
is O O
a O O
protein O O
with O O
pivotal O O
function O O
in O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transmission O O
, O O
which O O
has O O
been O O
related O O
to O O
the O O
pathogenesis O O
of O O
these O O
complications O O
. O O

This O O
study O O
investigates O O
whether O O
polymorphisms O O
in O O
the O O
HOMER1 O O
gene O O
promoter O O
region O O
are O O
associated O O
with O O
the O O
occurrence O O
of O O
the O O
chronic O O
complications O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
. O O

A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
205 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
with O O
idiopathic O B_DISEASE/B_LOCATION
Parkinson O I_DISEASE/I_LOCATION
' O I_DISEASE/I_LOCATION
s O I_DISEASE/I_LOCATION
disease O I_DISEASE/I_LOCATION
were O O
investigated O O
. O O

Patients O B_PERSON
were O O
genotyped O O
for O O
rs4704559 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rs10942891 O B_MEASURE/B_GENE
and O O
rs4704560 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
allelic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discrimination O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
Taqman O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
rs4704559 O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
a O O
lower O B_MEASURE/B_LOCATION
prevalence O I_MEASURE/I_LOCATION
of O O
dyskinesia O B_DISEASE
( O O
prevalence O B_LOCATION
ratio O I_LOCATION
( O O
PR O B_LOCATION
) O O
= O O
0 O B_NUMBER[MEASURE]
. O O
615 O B_MEASURE
, O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
( O O
CI O B_LOCATION
) O O
0 O B_MEASURE
. O O
426 O B_MEASURE
- O O
0 O B_MEASURE
. O O
887 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
009 O B_MEASURE
) O O
and O O
visual O B_DISEASE
hallucinations O I_DISEASE
( O O
PR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
= O O
0 O B_MEASURE
. O O
515 O B_MEASURE
, O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
295 O B_MEASURE
- O O
0 O B_MEASURE
. O O
899 O B_MEASURE
, O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
020 O B_MEASURE
) O O
. O O

Our O O
data O O
suggest O O
that O O
HOMER1 O O
rs4704559 O O
G O O
allele O O
has O O
a O O
protective O O
role O O
for O O
the O O
development O O
of O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adverse O O
effects O O
. O O

Crocin B B_BIO/B_GENE
improves O O
lipid O O
dysregulation O O
in O O
subacute O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exposure O O
through O O
ERK1 O O
/ O O
2 O O
pathway O O
in O O
rat O O
liver O O
. O O

INTRODUCTION O O
: O O
Diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Yis O O
one O O
of O O
the O O
most O O
broadly O O
used O O
organophosphorus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
insecticides O O
in O O
agriculture O O
. O O

It O O
has O O
been O O
shown O O
that O O
exposure O O
to O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O O
interfere O O
with O O
lipid O O
metabolism O O
. O O

Moreover O O
, O O
the O O
hypolipidemic O O
effect O O
of O O
crocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
has O O
been O O
established O O
. O O

Earlier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O O
the O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
role O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O O
Extracellular O B_GENE
signal O I_GENE
- O O
regulated O O
kinase O B_ENZYME[GENE]
( O O
ERK O B_GENE/B_LOCATION
) O O
pathways O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
density O B_GENE/B_MEASURE
lipoprotein O I_GENE/I_MEASURE
receptor O I_GENE/I_MEASURE
( O O
LDLr O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
changes O O
in O O
the O O
regulation O O
of O O
lipid O O
metabolism O O
, O O
ERK O O
and O O
LDLr O O
expression O O
in O O
the O O
liver O O
of O O
rats O O
exposed O O
to O O
subacute O O
diazinon B B_DISEASE/B_BIO
. O O

Furthermore O O
ameliorating O O
effect O O
of O O
crocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
diazinon B B_DISEASE/B_BIO
induced O O
disturbed O O
cholesterol B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeostasis O O
was O O
studied O O
. O O

METHODS O O
: O O
24 O O
Rats O O
were O O
divided O O
into O O
4 O O
groups O O
and O O
received O O
following O O
treatments O O
for O O
4 O O
weeks O O
; O O
Corn O O
oil O O
( O O
control O O
) O O
, O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
15mg O O
/ O O
kg O O
per O O
day O O
, O O
orally O O
) O O
and O O
crocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
12 O O
. O O
5 O O
and O O
25mg O O
/ O O
kg O O
per O O
day O O
, O O
intraperitoneally O O
) O O
in O O
combination O O
with O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
15 O O
mg O O
/ O O
kg O O
) O O
. O O

The O O
levels O O
of O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
LDL O O
in O O
blood O O
of O O
rats O O
were O O
analyzed O O
. O O

Moreover O O
mRNA O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
LDLr O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ERK1 O B_GENE
/ O O
2 O B_NUMBER[MEASURE]
as O O
well O O
as O O
protein O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
of O O
total O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
activated O O
forms O B_DISEASE/B_GENE
of O O
ERK1 O B_GENE
/ O O
2 O B_NUMBER[MEASURE]
in O O
rat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
evaluated O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Our O O
data O O
showed O O
that O O
subacute O O
exposure O O
to O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
significantly O O
increased O O
concentrations O O
of O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
triglyceride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
LDL O O
. O O

Moreover O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
decreased O O
ERK1 O O
/ O O
2 O O
protein O O
phosphorylation O O
and O O
LDLr O O
transcript O O
. O O

Crocin B B_PERSON/B_LOCATION
reduced O O
inhibition O O
of O O
ERK O O
activation O O
and O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
hyperlipemia O O
and O O
increased O O
levels O O
of O O
LDLr O O
transcript O O
. O O

CONCLUSIONS O O
: O O
Crocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O O
be O O
considered O O
as O O
a O O
novel O O
protective O O
agent O O
in O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
hyperlipemia O O
through O O
modulating O O
of O O
ERK O O
pathway O O
and O O
increase O O
of O O
LDLr O O
expression O O
. O O

GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
P O O
chemotherapy O O
is O O
active O O
in O O
the O O
treatment O O
of O O
relapsed O O
Hodgkin O O
lymphoma O O
. O O

Hodgkin O B_DISEASE
lymphoma O I_DISEASE
( O O
HL O B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
a O O
relatively O O
chemosensitive O B_DISEASE_ADJECTIVE[DISEASE]
malignancy O I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
for O O
those O O
who O O
relapse O O
, O O
high O B_MEASURE
- O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
choice O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
which O O
relies O O
on O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
control O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
salvage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Regimens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
commonly O O
used O O
often O O
require O O
inpatient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
can O O
be O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
deliver O O
due O O
to O O
toxicity O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Gemcitabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
activity O O
in O O
HL O O
, O O
non O O
- O O
overlapping O O
toxicity O O
with O O
first O O
- O O
line O O
chemotherapeutics O O
, O O
and O O
may O O
be O O
delivered O O
in O O
an O O
outpatient O O
setting O O
. O O

In O O
this O O
retrospective O O
single O O
- O O
centre O O
analysis O O
, O O
patients O O
with O O
relapsed O O
or O O
refractory O O
HL O O
treated O O
with O O
gemcitabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
, O O
000 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
day O O
( O O
D O O
) O O
1 O O
, O O
D8 O O
and O O
D15 O O
; O O
methylprednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
, O O
000 O O
mg O O
D1 O O
- O O
5 O O
; O O
and O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
D15 O O
, O O
every O O
28 O O
days O O
( O O
GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
P O O
) O O
were O O
included O O
. O O

Demographic O B_LOCATION/B_TIME[MEASURE]
, O O
survival O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
toxicity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
recorded O O
. O O

Forty O B_NUMBER[MEASURE]
- O O
one O B_NUMBER[MEASURE]/B_PERSON
eligible O I_NUMBER[MEASURE]/I_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
were O O
identified O O
: O O
median O B_MEASURE/B_PERSON
age O I_MEASURE/I_PERSON
27 O I_MEASURE/I_PERSON
. O O

One O O
hundred O O
and O O
twenty O O
- O O
two O O
cycles O O
of O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
were O O
administered O O
in O O
total O O
( O O
median O O
3 O O
cycles O O
; O O
range O O
1 O O
- O O
6 O O
) O O
. O O

Twenty O O
of O O
41 O O
( O O
48 O O
% O O
) O O
patients O O
received O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
as O O
second O O
- O O
line O O
treatment O O
and O O
11 O O
/ O O
41 O O
( O O
27 O O
% O O
) O O
as O O
third O O
- O O
line O O
therapy O O
. O O

Overall O O
response O O
rate O O
( O O
ORR O O
) O O
to O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
in O O
the O O
entire O O
cohort O O
was O O
80 O O
% O O
( O O
complete O O
response O O
( O O
CR O O
) O O
37 O O
% O O
, O O
partial O O
response O O
44 O O
% O O
) O O
with O O
14 O O
/ O O
15 O O
CR O O
confirmed O O
as O O
a O O
metabolic O O
CR O O
on O O
PET O O
and O O
ORR O O
of O O
85 O O
% O O
in O O
the O O
20 O O
second O O
- O O
line O O
patients O O
. O O

The O O
most O O
common O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
grade O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
3 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
4 O B_SEQUENCE[MEASURE]/B_LOCATION
toxicities O I_SEQUENCE[MEASURE]/I_LOCATION
were O O
haematological O B_DISEASE_ADJECTIVE[DISEASE]
: O O
neutropenia O B_DISEASE/B_MEASURE
54 O I_DISEASE/I_MEASURE
% O I_DISEASE/I_MEASURE
and O O
thrombocytopenia O B_DISEASE
51 O I_DISEASE
% O I_DISEASE
. O O

Median O O
follow O O
- O O
up O O
from O O
the O O
start O O
of O O
GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
P O O
was O O
4 O O
. O O
5 O O
years O O
. O O

Following O O
GEM B B_LOCATION/B_ORGANIZATION
- O O
P O O
, O O
5 O O
- O O
year O O
progression O O
- O O
free O O
survival O O
was O O
46 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
, O O
30 O O
- O O
62 O O
% O O
) O O
and O O
5 O O
- O O
year O O
overall O O
survival O O
was O O
59 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
43 O O
- O O
74 O O
% O O
) O O
. O O

Fourteen O B_NUMBER[MEASURE]/B_PERSON
of O O
41 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
proceeded O O
directly O O
to O O
autologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

GEM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
P O O
is O O
a O O
salvage O O
chemotherapy O O
with O O
relatively O O
high O O
response O O
rates O O
, O O
leading O O
to O O
successful O O
transplantation O O
in O O
appropriate O O
patients O O
, O O
in O O
the O O
treatment O O
of O O
relapsed O O
or O O
refractory O O
HL O O
. O O

Basal O O
functioning O O
of O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
axis O O
and O O
psychological O O
distress O O
in O O
recreational O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
polydrug O O
users O O
. O O

RATIONALE O O
: O O
Ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
MDMA B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
psychostimulant O O
drug O O
which O O
is O O
increasingly O O
associated O O
with O O
psychobiological O O
dysfunction O O
. O O

While O O
some O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
neuroendocrine O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_MEASURE/B_LOCATION
changes O B_MEASURE/I_LOCATION
in O O
HPA O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functionality O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
recreational O B_PERSON/B_BIO
users O B_PERSON/I_BIO
. O O

OBJECTIVES O O
: O O
The O O
current O O
study O O
is O O
the O O
first O O
to O O
explore O O
the O O
effects O O
of O O
ecstasy B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
polydrug O O
use O O
on O O
psychological O O
distress O O
and O O
basal O O
functioning O O
of O O
the O O
HPA O O
axis O O
through O O
assessing O O
the O O
secretion O O
of O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
across O O
the O O
diurnal O O
period O O
. O O

METHOD O O
: O O
Seventy O O
- O O
six O O
participants O O
( O O
21 O O
nonusers O O
, O O
29 O O
light O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
polydrug O O
users O O
, O O
26 O O
heavy O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
polydrug O O
users O O
) O O
completed O O
a O O
substance O O
use O O
inventory O O
and O O
measures O O
of O O
psychological O O
distress O O
at O O
baseline O O
, O O
then O O
two O O
consecutive O O
days O O
of O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
sampling O O
( O O
on O O
awakening O O
, O O
30 O O
min O O
post O O
awakening O O
, O O
between O O
1400 O O
and O O
1600 O O
hours O O
and O O
pre O O
bedtime O O
) O O
. O O

On O O
day O B_TIME[MEASURE]/B_LOCATION
2 O I_TIME[MEASURE]/I_LOCATION
, O O
participants O B_PERSON
also O O
attended O O
the O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
complete O O
a O O
20 O B_MEASURE
- O O
min O B_PERSON/B_TIME[MEASURE]
multitasking O O
stressor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Both O O
user O B_PERSON/B_ORGANIZATION
groups O I_PERSON/I_ORGANIZATION
exhibited O O
significantly O O
greater O B_MEASURE
levels O I_MEASURE
of O O
anxiety O B_DISEASE
and O O
depression O B_DISEASE
than O O
nonusers O B_PERSON/B_MEASURE
. O O

On O O
day O O
1 O O
, O O
all O O
participants O O
exhibited O O
a O O
typical O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profile O O
, O O
though O O
light O O
users O O
had O O
significantly O O
elevated O O
levels O O
pre O O
- O O
bed O O
. O O

On O O
day O O
2 O O
, O O
heavy O O
users O O
demonstrated O O
elevated O O
levels O O
upon O O
awakening O O
and O O
all O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
polydrug O O
users O O
demonstrated O O
elevated O O
pre O O
- O O
bed O O
levels O O
compared O O
to O O
non O O
- O O
users O O
. O O

Significant O O
between O O
group O O
differences O O
were O O
also O O
observed O O
in O O
afternoon O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
and O O
in O O
overall O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
across O O
the O O
day O O
. O O

CONCLUSIONS O O
: O O
The O O
increases O O
in O O
anxiety O O
and O O
depression O O
are O O
in O O
line O O
with O O
previous O O
observations O O
in O O
recreational O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
polydrug O O
users O O
. O O

Dysregulated O O
diurnal O O
cortisol B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O O
be O O
indicative O O
of O O
inappropriate O O
anticipation O O
of O O
forthcoming O O
demands O O
and O O
hypersecretion O O
may O O
lead O O
to O O
the O O
increased O O
psychological O O
and O O
physical O O
morbidity O O
associated O O
with O O
heavy O O
recreational O O
use O O
of O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O O
encephalopathy O O
: O O
the O O
need O O
for O O
a O O
timely O O
EEG O O
evaluation O O
. O O

BACKGROUND O O
: O O
Ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
an O O
alkylating O O
agent O O
useful O O
in O O
the O O
treatment O O
of O O
a O O
wide O O
range O O
of O O
cancers O O
including O O
sarcomas O O
, O O
lymphoma O O
, O O
gynecologic O O
and O O
testicular O O
cancers O O
. O O

Encephalopathy O O
has O O
been O O
reported O O
in O O
10 O O
- O O
40 O O
% O O
of O O
patients O O
receiving O O
high O O
- O O
dose O O
IV O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
To O O
highlight O O
the O O
role O O
of O O
electroencephalogram O O
( O O
EEG O O
) O O
in O O
the O O
early O O
detection O O
and O O
management O O
of O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O O
encephalopathy O O
. O O

METHODS O O
: O O
Retrospective O O
chart O O
review O O
including O O
clinical O O
data O O
and O O
EEG O O
recordings O O
was O O
done O O
on O O
five O O
patients O O
, O O
admitted O O
to O O
MD O O
Anderson O O
Cancer O O
Center O O
between O O
years O O
2009 O O
and O O
2012 O O
, O O
who O O
developed O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O O
acute O O
encephalopathy O O
. O O

RESULTS O O
: O O
All O O
five O O
patients O O
experienced O O
symptoms O O
of O O
encephalopathy O O
soon O O
after O O
( O O
within O O
12 O O
h O O
- O O
2 O O
days O O
) O O
receiving O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
developed O O
generalized O B_DISEASE
convulsions O I_DISEASE
while O O
one O B_PERSON/B_NUMBER[MEASURE]
patient O B_PERSON/I_NUMBER[MEASURE]
developed O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]
non O I_DISEASE_ADJECTIVE[DISEASE]
- O O
convulsive O B_DISEASE
status O I_DISEASE
epilepticus O I_DISEASE
( O O
NCSE O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
required O O
ICU O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
intubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Initial O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EEG O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
epileptiform O B_DISEASE_ADJECTIVE[DISEASE]
discharges O I_DISEASE_ADJECTIVE[DISEASE]
in O O
three O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
; O O
run O O
of O O
triphasic O B_DISEASE/B_MEASURE
waves O I_DISEASE/I_MEASURE
in O O
one O B_PERSON/B_NUMBER[MEASURE]
patient O I_PERSON/I_NUMBER[MEASURE]
and O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
degree O I_DISEASE_ADJECTIVE[DISEASE]
diffuse O I_DISEASE_ADJECTIVE[DISEASE]
generalized O O
slowing O B_DISEASE
. O O

Mixed O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
sharps O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O O
triphasic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
waves O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O O
also O O
noted O O
. O O

Repeat O O
EEGs O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
24 O B_MEASURE
_ O I_MEASURE
h O O
of O O
symptom O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
onset O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
marked O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improvement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
was O O
correlated O O
with O O
clinical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
improvement O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

CONCLUSIONS O O
: O O
Severity O O
of O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O O
encephalopathy O O
correlates O O
with O O
EEG O O
changes O O
. O O

We O O
suggest O O
a O O
timely O O
EEG O O
evaluation O O
for O O
patients O O
receiving O O
ifosfamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O O
develop O O
features O O
of O O
encephalopathy O O
. O O

Incidence O O
of O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephropathy O O
in O O
hospitalised O O
patients O O
with O O
cancer O O
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
frequency O O
of O O
and O O
possible O O
factors O O
related O O
to O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
( O O
CIN O O
) O O
in O O
hospitalised O O
patients O O
with O O
cancer O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Ninety O B_MEASURE/B_PERSON
adult O B_MEASURE/I_PERSON
patients O B_MEASURE/I_PERSON
were O O
enrolled O O
. O O

Patients O B_PERSON/B_LOCATION
with O O
risk O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
factors O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
were O O
excluded O O
. O O

Blood O O
samples O O
were O O
examined O O
the O O
day O O
before O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
enhanced O O
computed O O
tomography O O
( O O
CT O O
) O O
and O O
serially O O
for O O
3 O O
days O O
thereafter O O
. O O

CIN O O
was O O
defined O O
as O O
an O O
increase O O
in O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Cr B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
of O O
0 O O
. O O
5 O O
mg O O
/ O O
dl O O
or O O
more O O
, O O
or O O
elevation O O
of O O
Cr B B_LOCATION/B_MEASURE
to O O
25 O O
% O O
over O O
baseline O O
. O O

Relationships O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
CIN O B_DISEASE
and O O
possible O B_DISEASE/B_ORGANIZATION
risk O I_DISEASE/I_ORGANIZATION
factors O I_DISEASE/I_ORGANIZATION
were O O
investigated O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
CIN O B_DISEASE/B_GENE
was O O
detected O O
in O O
18 O B_MEASURE
/ O O
90 O B_MEASURE
( O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
patients O B_PERSON
. O O

CIN O B_DISEASE
developed O O
in O O
25 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
patients O I_MEASURE/I_PERSON
who O O
underwent O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
in O O
11 O B_PERSON
% O I_PERSON
patients O I_PERSON
who O O
did O O
not O O
( O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
1 O B_MEASURE
) O O
. O O

CIN O B_DISEASE
more O O
frequently O O
developed O O
in O O
patients O B_PERSON
who O O
had O O
undergone O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O O
45 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
last O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
; O O
it O O
was O O
also O O
an O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
risk O I_DISEASE_ADJECTIVE[DISEASE]
factor O I_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
017 O B_MEASURE
) O O
. O O

CIN O O
was O O
significantly O O
more O O
after O O
treatment O O
with O O
bevacizumab B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
irinotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O O
= O O
0 O O
. O O
021 O O
) O O
and O O
in O O
patients O O
with O O
hypertension O O
( O O
P O O
= O O
0 O O
. O O
044 O O
) O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
incidence O B_MEASURE/B_DISEASE
of O O
CIN O B_DISEASE/B_LOCATION
after O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
hospitalised O B_PERSON/B_LOCATION
oncological O B_PERSON/I_LOCATION
patients O B_PERSON/I_LOCATION
was O O
20 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

CIN O B_DISEASE/B_GENE
developed O O
4 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
- O O
times O B_TIME[MEASURE]/B_LOCATION
more O O
frequently O O
in O O
patients O B_PERSON
with O O
cancer O B_DISEASE/B_LOCATION
who O O
had O O
undergone O O
recent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Hypertension O O
and O O
the O O
combination O O
of O O
bevacizumab B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
irinotecan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
additional O O
risk O O
factors O O
for O O
CIN O O
development O O
. O O

KEY O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
POINTS O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
. O O

Contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
( O O
CIN O O
) O O
is O O
a O O
concern O O
for O O
oncological O O
patients O O
undergoing O O
CT O O
. O O

. O O
CIN O B_DISEASE
occurs O O
more O O
often O O
when O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
performed O O
< O O
45 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

. O O
Hypertension O O
and O O
treatment O O
with O O
bevacizumab B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appear O O
to O O
be O O
additional O O
risk O O
factors O O
. O O

Syndrome O O
of O O
inappropriate O O
antidiuretic O O
hormone O O
secretion O O
associated O O
with O O
desvenlafaxine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
syndrome O O
of O O
inappropriate O O
anti O O
- O O
diuretic O O
hormone O O
( O O
SIADH O O
) O O
secretion O O
associated O O
with O O
desvenlafaxine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CASE O B_TIME[MEASURE]/B_PERSON
SUMMARY O I_TIME[MEASURE]/I_PERSON
: O O
A O O
57 O B_NUMBER[MEASURE]
- O O
year O B_PERSON/B_TIME[MEASURE]
old O B_PERSON/I_TIME[MEASURE]
female O B_PERSON/I_TIME[MEASURE]
with O O
hyponatraemia O B_DISEASE
. O O

Her O O
medications O O
included O O
desvenlafaxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
symptoms O O
included O O
nausea O O
, O O
anxiety O O
and O O
confusion O O
. O O

The O O
serum O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O O
this O O
time O O
was O O
120 O O
mmol O O
/ O O
L O O
, O O
serum O O
osmolality O O
was O O
263 O O
mosmol O O
/ O O
kg O O
, O O
urine O O
osmolality O O
410 O O
mosmol O O
/ O O
kg O O
and O O
urine O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
63 O O
mmol O O
/ O O
L O O
, O O
consistent O O
with O O
a O O
diagnosis O O
of O O
SIADH O O
. O O

Desvenlafaxine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
ceased O O
and O O
fluid O O
restriction O O
implemented O O
. O O

After O O
4 O O
days O O
the O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O O
to O O
128 O O
mmol O O
/ O O
L O O
and O O
fluid O O
restriction O O
was O O
relaxed O O
. O O

During O O
her O O
further O O
3 O O
weeks O O
inpatient O O
admission O O
the O O
serum O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ranged O O
from O O
134 O O
to O O
137 O O
mmol O O
/ O O
L O O
during O O
treatment O O
with O O
mirtazapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DISCUSSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
SIADH O B_DISEASE
has O O
been O O
widely O O
reported O O
with O O
a O O
range O B_MEASURE
of O O
antidepressants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
case O O
report O O
suggests O O
that O O
desvenlafaxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O O
cause O O
clinically O O
significant O O
hyponatremia O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Clinicians O B_PERSON
should O O
be O O
aware O B_PERSON
of O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
cause O O
hyponatremia O B_DISEASE
, O O
and O O
take O O
appropriate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corrective O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
action O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
where O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Oxidative O O
stress O O
on O O
cardiotoxicity O O
after O O
treatment O O
with O O
single O O
and O O
multiple O O
doses O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mechanism O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
- O O
induced O O
cardiotoxicity O O
remains O O
controversial O O
. O O

Wistar O O
rats O O
( O O
n O O
= O O
66 O O
) O O
received O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
injections O O
intraperitoneally O O
and O O
were O O
randomly O O
assigned O O
to O O
2 O O
experimental O O
protocols O O
: O O
( O O
1 O O
) O O
rats O O
were O O
killed O O
before O O
( O O
- O O
24 O O
h O O
, O O
n O O
= O O
8 O O
) O O
and O O
24 O O
h O O
after O O
( O O
+ O O
24 O O
h O O
, O O
n O O
= O O
8 O O
) O O
a O O
single O O
dose O O
of O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
4 O O
mg O O
/ O O
kg O O
body O O
weight O O
) O O
to O O
determine O O
the O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acute O O
effect O O
and O O
( O O
2 O O
) O O
rats O O
( O O
n O O
= O O
58 O O
) O O
received O O
4 O O
injections O O
of O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
/ O O
kg O O
body O O
weight O O
/ O O
week O O
) O O
and O O
were O O
killed O O
before O O
the O O
first O O
injection O O
( O O
M0 O O
) O O
and O O
1 O O
week O O
after O O
each O O
injection O O
( O O
M1 O O
, O O
M2 O O
, O O
M3 O O
, O O
and O O
M4 O O
) O O
to O O
determine O O
the O O
chronological O O
effects O O
. O O

Animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
at O O
M0 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_OTHER/B_MEASURE
= O O
8 O B_MEASURE
) O O
were O O
also O O
used O O
at O O
moment O B_MEASURE
- O O
24 O B_TIME[MEASURE]/B_LOCATION
h O I_TIME[MEASURE]/I_LOCATION
of O O
acute O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Cardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
total O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
performance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage O B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
morphology O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
carried O O
out O O
at O O
each O O
time O B_MEASURE/B_LOCATION
point O B_MEASURE/I_LOCATION
. O O

Single O O
dose O O
of O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
associated O O
with O O
increased O O
cardiac O O
disarrangement O O
, O O
necrosis O O
, O O
and O O
DNA O O
damage O O
( O O
strand O O
breaks O O
( O O
SBs O O
) O O
and O O
oxidized O O
pyrimidines O O
) O O
and O O
decreased O O
TAP O O
. O O

The O O
chronological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
cumulative O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
body O B_DISEASE/B_GENE
weight O I_DISEASE/I_GENE
( O O
R O B_MEASURE/B_PROTEIN[GENE]
= O B_MEASURE/I_PROTEIN[GENE]
- O O
0 O B_NUMBER[MEASURE]
. O O
99 O B_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
011 O B_MEASURE
) O O
, O O
necrosis O B_DISEASE/B_GENE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
1 O B_MEASURE
. O O
00 O B_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
004 O B_MEASURE
) O O
, O O
TAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
0 O B_NUMBER[MEASURE]
. O O
95 O B_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
049 O B_MEASURE
) O O
, O O
and O O
DNA O B_PROTEIN[GENE]/B_DISEASE
SBs O I_PROTEIN[GENE]/I_DISEASE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
- O O
0 O B_MEASURE
. O O
95 O B_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
049 O B_MEASURE
) O O
. O O

DNA O B_DISEASE/B_GENE
SBs O I_DISEASE/I_GENE
damage O I_DISEASE/I_GENE
was O O
negatively O O
associated O O
with O O
TAP O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
R O B_MEASURE/B_PROTEIN[GENE]
= O B_MEASURE/I_PROTEIN[GENE]
- O O
0 O B_MEASURE
. O O
98 O B_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
018 O B_MEASURE
) O O
, O O
and O O
necrosis O B_DISEASE/B_GENE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
- O O
0 O B_NUMBER[MEASURE]
. O O
97 O B_MEASURE
, O O
p O O
= O O
0 O B_MEASURE
. O O
027 O B_MEASURE
) O O
. O O

Our O O
results O O
suggest O O
that O O
oxidative O O
damage O O
is O O
associated O O
with O O
acute O O
cardiotoxicity O O
induced O O
by O O
a O O
single O O
dose O O
of O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
. O O

Increased O O
resistance O O
to O O
the O O
oxidative O O
stress O O
is O O
plausible O O
for O O
the O O
multiple O O
dose O O
of O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
involved O O
in O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
toxicity O I_DISEASE_ADJECTIVE[DISEASE]
versus O O
chronic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Tacrolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
seizure O O
after O O
pediatric O O
liver O O
transplantation O O
- O O
- O O
a O O
single O O
- O O
center O O
experience O O
. O O

To O O
identify O O
the O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
new O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O O
onset O B_DISEASE
seizures O I_DISEASE
after O O
pediatric O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
LT O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
assess O O
their O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
implications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
laboratory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
27 O B_PERSON
consecutive O I_PERSON
children O I_PERSON
who O O
underwent O O
LT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
January O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2007 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
our O O
center O B_LOCATION
were O O
analyzed O O
retrospectively O O
. O O

Patients O B_PERSON
were O O
divided O O
into O O
seizures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
a O O
non O B_DISEASE/B_MEASURE
- O O
seizures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_PERSON/B_ORGANIZATION
, O O
and O O
post O B_DISEASE
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
data O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
collected O O
. O O

Seizures O B_DISEASE
occurred O O
in O O
four O B_MEASURE/B_ENT
children O I_MEASURE/I_ENT
, O O
an O O
incidence O B_DISEASE/B_MEASURE
of O O
14 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

All O O
exhibited O O
generalized O O
tonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
clonic O B_DISEASE_ADJECTIVE[DISEASE]
seizures O I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
first O B_TIME[MEASURE]/B_ORGANIZATION
two O I_TIME[MEASURE]/I_ORGANIZATION
wk O I_TIME[MEASURE]/I_ORGANIZATION
after O O
LT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Univariate O O
analysis O O
showed O O
that O O
the O O
risk O O
factors O O
associated O O
with O O
seizures O O
after O O
pediatric O O
LT O O
included O O
gender O O
, O O
pediatric O O
end O O
- O O
stage O O
liver O O
disease O O
score O O
before O O
surgery O O
, O O
Child O O
- O O
Pugh O O
score O O
before O O
surgery O O
, O O
serum O O
total O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
surgery O O
, O O
and O O
trough O O
TAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
. O O

Multivariate O O
analysis O O
showed O O
that O O
trough O O
TAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
was O O
the O O
only O O
independent O O
risk O O
factor O O
associated O O
with O O
the O O
seizures O O
. O O

All O O
children O B_PERSON/B_BIO
who O O
experienced O O
seizures O B_DISEASE
survived O O
with O O
good O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
graft O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
function O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
remained O O
seizure O B_DISEASE
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
without O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
epileptic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O O
a O O
mean O B_MEASURE
follow O O
- O O
up O O
period O B_TIME[MEASURE]/B_LOCATION
of O O
33 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
14 O I_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

High O O
trough O O
TAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O O
was O O
the O O
predominant O O
factor O O
that O O
contributed O O
to O O
seizures O O
in O O
the O O
early O O
post O O
- O O
operative O O
period O O
after O O
pediatric O O
LT O O
. O O

High O O
PELD O O
and O O
Child O O
- O O
Pugh O O
scores O O
before O O
LT O O
and O O
high O O
post O O
- O O
operative O O
serum O O
Tbil O O
may O O
be O O
contributory O O
risk O O
factors O O
for O O
TAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
related O O
seizures O O
. O O

The O O
flavonoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delays O O
forgetting O O
of O O
passive O O
avoidance O O
conditioning O O
in O O
rats O O
. O O

The O O
present O O
experiments O O
were O O
performed O O
to O O
study O O
the O O
effect O O
of O O
the O O
flavonoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O O
mg O O
/ O O
kg O O
intraperitoneally O O
( O O
i O O
. O O
p O O
. O O
) O O
, O O
1 O O
h O O
before O O
acquisition O O
) O O
, O O
on O O
24 O O
h O O
retention O O
performance O O
and O O
forgetting O O
of O O
a O O
step O O
- O O
through O O
passive O O
avoidance O O
task O O
, O O
in O O
young O O
male O O
Wistar O O
rats O O
. O O

There O O
were O O
no O O
differences O O
between O O
saline O O
- O O
and O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
groups O O
in O O
the O O
24 O O
h O O
retention O O
trial O O
. O O

Furthermore O O
, O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
prevent O O
the O O
amnesia O O
induced O O
by O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
, O O
30 O O
min O O
before O O
the O O
acquisition O O
) O O
. O O

The O O
saline O O
- O O
and O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
that O O
did O O
not O O
step O O
through O O
into O O
the O O
dark O O
compartment O O
during O O
the O O
cut O O
- O O
off O O
time O O
( O O
540 O O
s O O
) O O
were O O
retested O O
weekly O O
for O O
up O O
to O O
eight O O
weeks O O
. O O

In O O
the O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
significant O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
passive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
observed O O
at O O
four O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
, O O
and O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
memory O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
five O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
the O O
acquisition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
the O O
passive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
avoidance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
task O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

At O O
the O O
end O O
of O O
the O O
experimental O O
period O O
, O O
60 O O
% O O
of O O
the O O
animals O O
treated O O
with O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O O
did O O
not O O
step O O
through O O
. O O

These O O
data O O
suggest O O
that O O
1 O O
) O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delays O O
the O O
long O O
- O O
term O O
forgetting O O
but O O
did O O
not O O
modulate O O
the O O
24 O O
h O O
retention O O
of O O
fear O O
memory O O
and O O
2 O O
) O O
the O O
obtained O O
beneficial O O
effect O O
of O O
apigenin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
passive O O
avoidance O O
conditioning O O
is O O
mediated O O
by O O
mechanisms O O
that O O
do O O
not O O
implicate O O
its O O
action O O
on O O
the O O
muscarinic O O
cholinergic O O
system O O
. O O

Histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O O
and O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypotension O O
in O O
cardiac O O
surgical O O
patients O O
. O O

Hemodynamic O O
effects O O
and O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
release O O
by O O
bolus O O
injection O O
of O O
0 O O
. O O
35 O O
mg O O
/ O O
kg O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
24 O O
patients O O
. O O

H1 O O
- O O
and O O
H2 O O
- O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O O
or O O
placebo O O
were O O
given O O
before O O
dosing O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
a O O
randomized O O
double O O
- O O
blind O O
fashion O O
to O O
four O O
groups O O
: O O
group O O
1 O O
- O O
- O O
placebo O O
; O O
group O O
2 O O
- O O
- O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
group O O
3 O O
- O O
- O O
chlorpheniramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O O
. O O
1 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
and O O
group O O
4 O O
- O O
- O O
cimetidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
chlorpheniramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release O O
occurred O O
in O O
most O O
patients O O
, O O
the O O
highest O O
level O O
2 O O
minutes O O
after O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosing O O
. O O

Group O O
1 O O
had O O
a O O
moderate O O
negative O O
correlation O O
between O O
plasma O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
change O O
and O O
systemic O O
vascular O O
resistance O O
( O O
r O O
= O O
0 O O
. O O
58 O O
; O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
not O O
present O O
in O O
group O O
4 O O
. O O

Prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O O
prevented O O
the O O
fall O B_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE/B_GENE
vascular O B_DISEASE/I_GENE
resistance O B_DISEASE/I_GENE
. O O

These O O
data O O
demonstrate O O
that O O
the O O
hemodynamic O O
changes O O
associated O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosing O O
are O O
only O O
partially O O
explained O O
by O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
release O O
. O O

Thus O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dosing O O
with O O
H1 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
H2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
only O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Cholecystokinin B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
octapeptide I I_PERSON/I_LOCATION
restored O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hippocampal O O
long O O
- O O
term O O
potentiation O O
impairment O O
in O O
rats O O
. O O

Cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
which O O
is O O
a O O
typical O O
brain O O
- O O
gut O O
peptide O O
, O O
exerts O O
a O O
wide O O
range O O
of O O
biological O O
activities O O
on O O
the O O
central O O
nervous O O
system O O
. O O

We O O
have O O
previously O O
reported O O
that O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
alleviated O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
amnesia O O
and O O
reversed O O
spine O O
density O O
decreases O O
in O O
the O O
CA1 O O
region O O
of O O
the O O
hippocampus O O
in O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
animals O O
. O O

Here O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
long O O
- O O
term O O
potentiation O O
( O O
LTP O O
) O O
in O O
the O O
lateral O O
perforant O O
path O O
( O O
LPP O O
) O O
- O O
granule O O
cell O O
synapse O O
of O O
rat O O
dentate O O
gyrus O O
( O O
DG O O
) O O
in O O
acute O O
saline O O
or O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
. O O

Population O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
PS O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
which O O
were O O
evoked O O
by O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
LPP O B_DISEASE/B_PROTEIN[GENE]
, O O
were O O
recorded O O
in O O
the O O
DG O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Acute O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
30mg O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
treatment O O
significantly O O
attenuated O O
hippocampal O O
LTP O O
and O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1ug O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
restored O O
the O O
amplitude O O
of O O
PS O O
that O O
was O O
attenuated O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

Furthermore O O
, O O
microinjection O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O O
. O O
1 O O
and O O
1ug O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
also O O
significantly O O
augmented O O
hippocampal O O
LTP O O
in O O
saline O O
- O O
treated O O
( O O
1ml O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
rats O O
. O O

Pre O O
- O O
treatment O O
of O O
the O O
CCK2 O O
receptor O O
antagonist O O
L O O
- O O
365 O O
, O O
260 O O
( O O
10ug O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
reversed O O
the O O
effects O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
the O O
CCK1 O O
receptor O O
antagonist O O
L O O
- O O
364 O O
, O O
718 O O
( O O
10ug O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
did O O
not O O
. O O

The O O
present O O
results O O
demonstrate O O
that O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
attenuates O O
the O O
effect O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
hippocampal O O
LTP O O
through O O
CCK2 O O
receptors O O
and O O
suggest O O
an O O
ameliorative O O
function O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
memory O O
impairment O O
. O O

Glial O O
activation O O
and O O
post O O
- O O
synaptic O O
neurotoxicity O O
: O O
the O O
key O O
events O O
in O O
Streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICV O O
) O O
induced O O
memory O O
impairment O O
in O O
rats O O
. O O

In O O
the O O
present O O
study O O
the O O
role O O
of O O
glial O O
activation O O
and O O
post O O
synaptic O O
toxicity O O
in O O
ICV O O
Streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_LOCATION
) O O
induced O O
memory O O
impaired O O
rats O O
was O O
explored O O
. O O

In O O
experiment O O
set O O
up O O
1 O O
: O O
Memory O O
deficit O O
was O O
found O O
in O O
Morris O O
water O O
maze O O
test O O
on O O
14 O O
- O O
16 O O
days O O
after O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ICV O O
; O O
3mg O O
/ O O
Kg O O
) O O
administration O O
. O O

STZ B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O O
increased O O
expression O O
of O O
GFAP O O
, O O
CD11b O O
and O O
TNF O O
- O O
a O O
indicating O O
glial O O
activation O O
and O O
neuroinflammation O O
. O O

STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
significantly O O
increased O O
the O O
level O O
of O O
ROS O O
, O O
nitrite B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
and O O
reduced O O
the O O
mitochondrial O O
activity O O
in O O
synaptosomal O O
preparation O O
illustrating O O
free O O
radical O O
generation O O
and O O
excitotoxicity O O
. O O

Increased O O
expression O O
and O O
activity O O
of O O
Caspase O O
- O O
3 O O
was O O
also O O
observed O O
in O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
treated O O
rat O O
which O O
specify O O
apoptotic O O
cell O O
death O O
in O O
hippocampus O O
and O O
cortex O O
. O O

STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
showed O O
decrease O O
expression O O
of O O
post O O
synaptic O O
markers O O
CaMKIIa O O
and O O
PSD O O
- O O
95 O O
, O O
while O O
, O O
expression O O
of O O
pre O O
synaptic O O
markers O O
( O O
synaptophysin O O
and O O
SNAP O O
- O O
25 O O
) O O
remains O O
unaltered O O
indicating O O
selective O O
post O O
synaptic O O
neurotoxicity O O
. O O

Oral O O
treatment O O
with O O
Memantine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
10mg O O
/ O O
kg O O
) O O
and O O
Ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
50 O O
mg O O
/ O O
kg O O
) O O
daily O O
for O O
13 O O
days O O
attenuated O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
glial O O
activation O O
, O O
apoptotic O O
cell O O
death O O
and O O
post O O
synaptic O O
neurotoxicity O O
in O O
rat O O
brain O O
. O O

Further O O
, O O
in O O
experiment O O
set O O
up O O
2 O O
: O O
where O O
memory O O
function O O
was O O
not O O
affected O O
i O O
. O O
e O O
. O O
7 O O
- O O
9 O O
days O O
after O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
. O O

The O O
level O O
of O O
GFAP O O
, O O
CD11b O O
, O O
TNF O O
- O O
a O O
, O O
ROS O O
and O O
nitrite B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
increased O O
. O O

On O O
the O O
other O O
hand O O
, O O
apoptotic O O
marker O O
, O O
synaptic O O
markers O O
, O O
mitochondrial O O
activity O O
and O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
levels O O
remained O O
unaffected O O
. O O

Collective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicates O O
that O O
neuroinflammatory O B_DISEASE_ADJECTIVE[DISEASE]
process O I_DISEASE_ADJECTIVE[DISEASE]
and O O
oxidative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O O
earlier O O
to O O
apoptosis O B_DISEASE/B_LOCATION
and O O
does O O
not O O
affect O O
memory O B_DISEASE_ADJECTIVE[DISEASE]
function O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Present O O
study O O
clearly O O
suggests O O
that O O
glial O O
activation O O
and O O
post O O
synaptic O O
neurotoxicity O O
are O O
the O O
key O O
factors O O
in O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
memory O O
impairment O O
and O O
neuronal O O
cell O O
death O O
. O O

Comparison O O
of O O
effects O O
of O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
prevention O O
of O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephropathy O O
. O O

INTRODUCTION O O
AND O O
OBJECTIVE O O
: O O
Contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
( O O
CIN O O
) O O
significantly O O
increases O O
the O O
morbidity O O
and O O
mortality O O
of O O
patients O O
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
investigate O O
and O O
compare O O
the O O
protective O O
effects O O
of O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
and O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O O
with O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blocker O O
, O O
in O O
preventing O O
CIN O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Our O O
study O O
included O O
patients O O
who O O
were O O
administered O O
30 O O
- O O
60 O O
mL O O
of O O
iodinated O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O O
for O O
percutaneous O O
coronary O O
angiography O O
( O O
PCAG O O
) O O
, O O
all O O
with O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O O
between O O
1 O O
. O O
1 O O
and O O
3 O O
. O O
1 O O
mg O O
/ O O
dL O O
. O O

Patients O B_PERSON
were O O
divided O O
into O O
three O B_ORGANIZATION/B_LOCATION
groups O B_ORGANIZATION/I_LOCATION
and O O
each O O
group O B_ORGANIZATION/B_LOCATION
had O O
20 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
. O O

The O O
first O O
group O O
of O O
patients O O
was O O
administered O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
the O O
second O O
group O O
was O O
administered O O
a O O
solution O O
that O O
of O O
5 O O
% O O
dextrose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
the O O
third O O
group O O
was O O
administered O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
before O O
and O O
after O O
the O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

The O O
third O O
group O O
received O O
an O O
additional O O
injection O O
of O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
day O O
before O O
and O O
first O O
2 O O
days O O
after O O
the O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
injection O O
. O O

All O O
of O O
the O O
patients O O
' O O
plasma O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BUN B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
measured O O
on O O
the O O
second O O
and O O
seventh O O
day O O
after O O
the O O
administration O O
of O O
intravenous O O
contrast B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
material O O
. O O

RESULTS O O
: O O
The O O
basal O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
similar O O
for O O
all O O
three O O
groups O O
( O O
p O O
> O O
0 O O
. O O
05 O O
) O O
. O O

Among O O
a O O
total O O
of O O
60 O O
patients O O
included O O
in O O
the O O
study O O
, O O
16 O O
patients O O
developed O O
acute O O
renal O O
failure O O
( O O
ARF O O
) O O
on O O
the O O
second O O
day O O
after O O
contrast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
material O O
was O O
injected O O
( O O
26 O O
. O O
6 O O
% O O
) O O
. O O

The O O
number O B_MEASURE/B_PERSON
of O O
patients O B_PERSON
who O O
developed O O
ARF O B_DISEASE
on O O
the O O
second O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
day O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
after O O
the O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
five O B_NUMBER[MEASURE]
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
, O O
in O O
the O O
second O B_SEQUENCE[MEASURE]/B_ORGANIZATION
group O I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O O
six O B_NUMBER[MEASURE]
( O O
30 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
and O O
the O O
third O B_SEQUENCE[MEASURE]/B_ORGANIZATION
group O I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O O
five O B_NUMBER[MEASURE]
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
( O O
p O B_MEASURE/B_LOCATION
> O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
) O O
. O O

CONCLUSION O O
: O O
There O O
was O O
no O O
significant O O
difference O O
between O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isotonic O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O O
in O O
prevention O O
of O O
CIN O O
. O O

Neurocognitive O O
and O O
neuroradiologic O O
central O O
nervous O O
system O O
late O O
effects O O
in O O
children O O
treated O O
on O O
Pediatric O O
Oncology O O
Group O O
( O O
POG O O
) O O
P9605 O O
( O O
standard O O
risk O O
) O O
and O O
P9201 O O
( O O
lesser O O
risk O O
) O O
acute O O
lymphoblastic O O
leukemia O O
protocols O O
( O O
ACCL0131 O O
) O O
: O O
a O O
methotrexate B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consequence O O
? O O

A O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O O
the O O
Children O B_ORGANIZATION/B_LOCATION
' O I_ORGANIZATION/I_LOCATION
s O I_ORGANIZATION/I_LOCATION
Oncology O I_ORGANIZATION/I_LOCATION
Group O I_ORGANIZATION/I_LOCATION
. O O

Concerns O O
about O O
long O O
- O O
term O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
neurotoxicity O O
in O O
the O O
1990s O O
led O O
to O O
modifications O O
in O O
intrathecal O O
( O O
IT O O
) O O
therapy O O
, O O
leucovorin O O
rescue O O
, O O
and O O
frequency O O
of O O
systemic O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
in O O
children O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
neurocognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
neuroradiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
leukoencephalopathy O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
compared O O
in O O
children O B_PERSON/B_BIO
treated O O
with O O
intense O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
nervous O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CNS O B_LOCATION/B_ORGANIZATION
) O O
- O O
directed O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
P9605 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
versus O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
those O O
receiving O O
fewer O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
CNS O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
directed O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
intensive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consolidation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P9201 O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

A O O
total O B_MEASURE
of O O
66 O B_MEASURE/B_PERSON
children O I_MEASURE/I_PERSON
from O O
16 O B_PERSON/B_ORGANIZATION
Pediatric O I_PERSON/I_ORGANIZATION
Oncology O I_PERSON/I_ORGANIZATION
Group O I_PERSON/I_ORGANIZATION
institutions O I_PERSON/I_ORGANIZATION
with O O
" O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
acute O B_DISEASE
lymphoblastic O I_DISEASE
leukemia O I_DISEASE
, O O
1 O B_MEASURE
. O O
00 O B_MEASURE
to O O
9 O B_MEASURE
. O O
99 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
at O O
diagnosis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
without O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CNS O B_DISEASE
leukemia O I_DISEASE
at O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
enrolled O O
on O O
ACCL0131 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
28 O B_MEASURE
from O O
P9201 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
38 O B_MEASURE
from O O
P9605 O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
scans O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
standard O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuropsychological O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
> O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
. O O
6 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
after O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Significantly O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
P9605 O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
patients O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
developed O O
leukoencephalopathy O B_DISEASE
compared O O
with O O
P9201 O B_PERSON
patients O I_PERSON
( O O
68 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
, O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
49 O I_MEASURE
% O I_MEASURE
- O O
83 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
. O O
22 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
5 O I_MEASURE
% O I_MEASURE
- O O
44 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
P O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
identified O O
as O O
late O O
as O O
7 O B_MEASURE
. O O
7 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
after O O
the O O
end O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Overall O O
, O O
40 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
scored O O
< O O
85 O B_MEASURE
on O O
either O O
Verbal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Performance O B_MEASURE/B_EDU[ORGANIZATION]
IQ O B_MEASURE/I_EDU[ORGANIZATION]
. O O

Children O B_PERSON
on O O
both O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
significant O B_DISEASE
attention O I_DISEASE
problems O I_DISEASE
, O O
but O O
P9605 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
children O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scored O O
below O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
on O O
more O O
neurocognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
those O O
treated O O
on O O
P9201 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
82 O B_MEASURE
% O I_MEASURE
, O O
14 O B_NUMBER[MEASURE]
/ O O
17 O B_MEASURE
measures O I_MEASURE
vs O I_MEASURE
. O O
24 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
4 O B_MEASURE
/ O O
17 O B_MEASURE
measures O I_MEASURE
) O O
. O O

This O O
supports O O
ongoing O O
concerns O O
about O O
intensive O O
MTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
as O O
a O O
major O O
contributor O O
to O O
CNS O O
late O O
effects O O
. O O

Tranexamic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdosage O O
- O O
induced O O
generalized O O
seizure O O
in O O
renal O O
failure O O
. O O

We O O
report O O
a O O
45 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
lady O I_PERSON
with O O
chronic O B_DISEASE/B_GENE
kidney O I_DISEASE/I_GENE
disease O I_DISEASE/I_GENE
stage O I_DISEASE/I_GENE
4 O I_DISEASE/I_GENE
due O O
to O O
chronic O B_DISEASE
tubulointerstial O I_DISEASE
disease O I_DISEASE
. O O

She O O
was O O
admitted O O
to O O
our O O
center O B_LOCATION
for O O
severe O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anemia O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
due O O
to O O
menorrhagia O B_DISEASE
and O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
of O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
was O O
infused O O
three O B_MEASURE/B_LOCATION
units O B_MEASURE/I_LOCATION
of O O
packed O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
during O O
a O O
session O B_TIME[MEASURE]
of O O
hemodialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TNA B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
1 O O
g O O
8 O O
- O O
hourly O O
was O O
administered O O
to O O
her O O
to O O
control O O
bleeding O O
per O O
vaginum O O
. O O

Two O O
hours O O
after O O
the O O
sixth O O
dose O O
of O O
TNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
she O O
had O O
an O O
episode O O
of O O
generalized O O
tonic O O
clonic O O
convulsions O O
. O O

TNA B B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
discontinued O O
. O O

Investigations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
no O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
central O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
could O O
have O O
provoked O O
the O O
convulsions O B_DISEASE
. O O

She O O
did O O
not O O
require O O
any O O
further O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialytic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
support O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

She O O
had O O
no O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
episodes O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O O
convulsion O B_DISEASE
till O O
dis O B_MEASURE
- O O
charge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O O
during O O
the O O
two O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
the O O
precipitating O O
cause O O
of O O
convulsions O O
was O O
believed O O
to O O
be O O
an O O
overdose O O
of O O
TNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Pre O O
- O O
treatment O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiovascular O O
depression O O
using O O
different O O
lipid O O
formulations O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Pre O O
- O O
treatment O O
with O O
lipid O O
emulsions O O
has O O
been O O
shown O O
to O O
increase O O
lethal O O
doses O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
lipid O O
content O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
alleviate O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
investigate O O
the O O
effects O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
intralipid O O
or O O
medialipid O O
emulsions O O
on O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

METHODS O O
: O O
Rats O O
were O O
anaesthetised O O
with O O
ketamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
given O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
/ O O
min O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
intralipid O O
( O O
Group O O
P O O
) O O
, O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
medialipid O O
( O O
Group O O
L O O
) O O
, O O
or O O
saline O O
( O O
Group O O
C O O
) O O
over O O
20 O O
min O O
. O O

Thereafter O O
, O O
2 O O
mg O O
/ O O
kg O O
/ O O
min O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
5 O O
% O O
was O O
infused O O
. O O

We O O
recorded O O
time O O
to O O
first O O
dysrhythmia O O
occurrence O O
, O O
respective O O
times O O
to O O
25 O O
% O O
and O O
50 O O
% O O
reduction O O
of O O
the O O
heart O O
rate O O
( O O
HR O O
) O O
and O O
mean O O
arterial O O
pressure O O
, O O
and O O
time O O
to O O
asystole O O
and O O
total O O
amount O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
. O O

Blood O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
tissue O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
collected O O
following O O
asystole O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
first O O
dysrhythmia O B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_DISEASE_ADJECTIVE[DISEASE]
, O O
time O B_MEASURE/B_LOCATION
to O O
25 O B_SEQUENCE[MEASURE]/B_LOCATION
% O I_SEQUENCE[MEASURE]/I_LOCATION
and O O
50 O B_MEASURE
% O I_MEASURE
reductions O I_MEASURE
in O O
HR O B_MEASURE/B_DISEASE
, O O
and O O
time O B_TIME[MEASURE]/B_DISEASE
to O O
asystole O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
longer O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
Group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
P O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
than O O
the O O
other O B_TIME[MEASURE]/B_PERSON
groups O I_TIME[MEASURE]/I_PERSON
. O O

The O O
cumulative O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
given O O
at O O
those O O
time O O
points O O
was O O
higher O O
in O O
Group O O
P O O
. O O
Plasma O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
were O O
significantly O O
lower O O
in O O
Group O O
P O O
than O O
in O O
Group O O
C O O
. O O
Bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
in O O
the O O
brain O O
and O O
heart O O
were O O
significantly O O
lower O O
in O O
Group O O
P O O
and O O
Group O O
L O O
than O O
in O O
Group O O
C O O
. O O

CONCLUSION O O
: O O
We O O
conclude O O
that O O
pre O O
- O O
treatment O O
with O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
intralipid O O
, O O
compared O O
with O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
medialipid O O
or O O
saline O O
, O O
delayed O O
the O O
onset O O
of O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxic O O
effects O O
as O O
well O O
as O O
reduced O O
plasma O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Further O O
studies O O
are O O
needed O O
to O O
explore O O
tissue O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
of O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
medialipid O O
and O O
adapt O O
these O O
results O O
to O O
clinical O O
practice O O
. O O

Drug O O
- O O
Induced O O
Acute O O
Liver O O
Injury O O
Within O O
12 O O
Hours O O
After O O
Fluvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Therapy O O
. O O

Although O O
statins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
generally O O
well O O
- O O
tolerated O O
drugs O O
, O O
recent O O
cases O O
of O O
drug O O
- O O
induced O O
liver O O
injury O O
associated O O
with O O
their O O
use O O
have O O
been O O
reported O O
. O O

A O O
52 O O
- O O
year O O
- O O
old O O
Chinese O O
man O O
reported O O
with O O
liver O O
damage O O
, O O
which O O
appeared O O
12 O O
hours O O
after O O
beginning O O
treatment O O
with O O
fluvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patient O B_PERSON
presented O O
with O O
complaints O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
increasing O O
nausea O B_DISEASE/B_MEASURE
, O O
anorexia O B_DISEASE
, O O
and O O
upper O B_DISEASE
abdominal O I_DISEASE
pain O I_DISEASE
. O O

His O O
laboratory O O
values O O
showed O O
elevated O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O O
and O O
transaminases O O
. O O

Testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
autoantibodies O B_DISEASE
was O O
also O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
liver O O
biochemistries O O
eventually O O
normalized O O
within O O
3 O O
weeks O O
of O O
stopping O O
the O O
fluvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Therefore O O
, O O
when O O
prescribing O O
statins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
possibility O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hepatic O B_DISEASE
damage O I_DISEASE
should O O
be O O
taken O O
into O O
account O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Fluconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O O
agranulocytosis O O
and O O
thrombocytopenia O O
. O O

CASE O O
: O O
We O O
describe O O
a O O
second O O
case O O
of O O
fluconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O O
agranulocytosis O O
with O O
thrombocytopenia O O
and O O
recovery O O
upon O O
discontinuation O O
of O O
therapy O O
. O O

The O O
patient O O
began O O
to O O
have O O
changes O O
in O O
white O O
blood O O
cells O O
and O O
platelets O O
within O O
48 O O
h O O
of O O
administration O O
of O O
fluconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
began O O
to O O
recover O O
with O O
48 O O
h O O
of O O
discontinuation O O
. O O

This O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlights O O
that O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
blood O B_DISEASE
dyscrasias O I_DISEASE
can O O
occur O O
unexpectedly O O
as O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
commonly O O
used O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thought O O
to O O
be O O
" O O
safe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
. O O

CONCLUSION O O
: O O
According O O
to O O
Naranjo O O
' O O
s O O
algorithm O O
the O O
likelihood O O
that O O
our O O
patient O O
' O O
s O O
agranulocytosis O O
and O O
thrombocytopenia O O
occurred O O
as O O
a O O
result O O
of O O
therapy O O
with O O
fluconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
probable O O
, O O
with O O
a O O
total O O
of O O
six O O
points O O
. O O

We O O
feel O O
that O O
the O O
weight O B_MEASURE
of O O
the O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

In O O
particular O O
the O O
temporal O O
relationship O O
of O O
bone O O
marrow O O
suppression O O
to O O
the O O
initiation O O
of O O
fluconazole B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
the O O
abatement O O
of O O
symptoms O O
that O O
rapidly O O
reversed O O
immediately O O
following O O
discontinuation O O
. O O

Two O O
- O O
dimensional O O
speckle O O
tracking O O
echocardiography O O
combined O O
with O O
high O O
- O O
sensitive O O
cardiac O O
troponin O O
T O O
in O O
early O O
detection O O
and O O
prediction O O
of O O
cardiotoxicity O O
during O O
epirubicine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
chemotherapy O O
. O O

AIMS O O
: O O
To O O
investigate O O
whether O O
alterations O O
of O O
myocardial O O
strain O O
and O O
high O O
- O O
sensitive O O
cardiac O O
troponin O O
T O O
( O O
cTnT O O
) O O
could O O
predict O O
future O O
cardiac O O
dysfunction O O
in O O
patients O O
after O O
epirubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
. O O

METHODS O O
: O O
Seventy O O
- O O
five O O
patients O O
with O O
non O O
- O O
Hodgkin O O
lymphoma O O
treated O O
with O O
epirubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
studied O O
. O O

Blood O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
collection O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
echocardiography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
1 O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
third O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
1 O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
after O O
completion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O B_PERSON
were O O
studied O O
using O O
echocardiography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Global O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
longitudinal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
GLS O B_LOCATION/B_ORGANIZATION
) O O
, O O
circumferential O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O O
GCS O B_LOCATION/B_ORGANIZATION
) O O
, O O
and O O
radial O B_MEASURE/B_LOCATION
strain O B_MEASURE/I_LOCATION
( O O
GRS O B_LOCATION
) O O
were O O
calculated O O
using O O
speckle O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tracking O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
echocardiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
analysed O O
by O O
real O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
time O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3D O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
echocardiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cardiotoxicity O B_DISEASE/B_LOCATION
was O O
defined O O
as O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
LVEF O B_MEASURE/B_DISEASE
of O O
> O B_MEASURE/B_LOCATION
5 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
to O O
< O O
55 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
with O O
symptoms O B_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE
failure O I_DISEASE
or O O
an O O
asymptomatic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
LVEF O B_MEASURE/B_LOCATION
of O O
> O O
10 O B_MEASURE
% O I_MEASURE
to O O
< O O
55 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Fourteen O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
( O O
18 O B_MEASURE
. O O
67 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
developed O O
cardiotoxicity O B_DISEASE/B_GENE
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

GLS O B_LOCATION/B_ORGANIZATION
( O O
- O O
18 O B_MEASURE
. O O
48 O B_MEASURE
+ O O
1 O B_MEASURE
. O O
72 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
. O O
- O O
15 O B_MEASURE
. O O
96 O B_MEASURE
+ O O
1 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
GCS O B_LOCATION
( O O
- O O
20 O B_MEASURE
. O O
93 O B_MEASURE
+ O I_MEASURE
2 O I_MEASURE
. O O
86 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
. O O
- O O
19 O B_MEASURE
. O O
20 O B_MEASURE
+ O O
3 O B_MEASURE
. O O
21 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
GRS O B_LOCATION/B_DISEASE
( O O
39 O B_MEASURE
. O O
23 O B_MEASURE
+ O I_MEASURE
6 O I_MEASURE
. O O
44 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
. O O
34 O B_MEASURE
. O O
98 O B_MEASURE
+ O O
6 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
were O O
markedly O O
reduced O O
and O O
cTnT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
elevated O O
from O O
0 O B_NUMBER[MEASURE]
. O O
0010 O B_MEASURE
+ O I_MEASURE
0 O I_MEASURE
. O O
0020 O B_MEASURE
to O O
0 O B_NUMBER[MEASURE]
. O O
0073 O B_MEASURE
+ O I_MEASURE
0 O I_MEASURE
. O O
0038 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
mL O B_MEASURE/B_LOCATION
( O O
P O B_OTHER/B_MEASURE
all O O
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
at O O
the O O
completion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
compared O O
with O O
baseline O B_TIME[MEASURE]/B_LOCATION
values O I_TIME[MEASURE]/I_LOCATION
. O O

A O O
> O B_MEASURE
15 O I_MEASURE
. O O
9 O B_MEASURE
% O I_MEASURE
decrease O I_MEASURE
in O O
GLS O B_MEASURE
[ O I_MEASURE
sensitivity O I_MEASURE
, O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
75 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
; O O
area O B_LOCATION/B_MEASURE
under O O
the O O
curve O B_MEASURE
( O O
AUC O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
= O O
0 O B_MEASURE
. O O
815 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
001 O B_MEASURE
] O I_MEASURE
and O O
a O O
> O O
0 O B_MEASURE
. O O
004 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
mL O B_MEASURE/B_LOCATION
elevation O I_MEASURE/I_LOCATION
in O O
cTnT O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
sensitivity O B_MEASURE
, O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
specificity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
64 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
; O O
AUC O B_LOCATION/B_MEASURE
= O O
0 O B_MEASURE
. O O
757 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
from O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O O
the O O
third O B_MEASURE/B_LOCATION
cycle O I_MEASURE/I_LOCATION
of O O
chemotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
predicted O O
later O B_DISEASE_ADJECTIVE[DISEASE]
cardiotoxicity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
GLS O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O O
the O O
only O B_MEASURE/B_LOCATION
independent O I_MEASURE/I_LOCATION
predictor O I_MEASURE/I_LOCATION
of O O
cardiotoxicity O B_DISEASE
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
000 O B_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
GLS O O
combined O O
with O O
cTnT O O
may O O
provide O O
a O O
reliable O O
and O O
non O O
- O O
invasive O O
method O O
to O O
predict O O
cardiac O O
dysfunction O O
in O O
patients O O
receiving O O
anthracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
based O O
chemotherapy O O
. O O

Prevention O O
of O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myoclonus O O
: O O
which O O
is O O
superior O O
: O O
Fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
a O O
combination O O
? O O

A O O
Retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
comparative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

BACKGROUND O O
: O O
In O O
this O O
retrospective O O
comparative O O
study O O
, O O
we O O
aimed O O
to O O
compare O O
the O O
effectiveness O O
of O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
combination O O
of O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prevent O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myoclonus O O
. O O

MATERIAL O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
based O O
on O O
anesthesia O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Depending O O
on O O
the O O
drugs O O
that O O
would O O
be O O
given O O
before O O
the O O
induction O O
of O O
anesthesia O O
with O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patients O O
were O O
separated O O
into O O
4 O O
groups O O
: O O
no O O
pretreatment O O
( O O
Group O O
NP O O
) O O
, O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
ug O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
F O O
) O O
, O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
03 O O
mg O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
M O O
) O O
, O O
and O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
015 O O
mg O O
. O O
kg O O
- O O
1 O O
+ O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
5 O O
ug O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
FM O O
) O O
. O O

Patients O O
who O O
received O O
the O O
same O O
anesthetic O O
procedure O O
were O O
selected O O
: O O
2 O O
minutes O O
after O O
intravenous O O
injections O O
of O O
the O O
pretreatment O O
drugs O O
, O O
anesthesia O O
is O O
induced O O
with O O
0 O O
. O O
3 O O
mg O O
. O O
kg O O
- O O
1 O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O O
intravenously O O
over O O
a O O
period O O
of O O
20 O O
- O O
30 O O
seconds O O
. O O

Myoclonic O O
movements O O
are O O
evaluated O O
, O O
which O O
were O O
observed O O
and O O
graded O O
according O O
to O O
clinical O O
severity O O
during O O
the O O
2 O O
minutes O O
after O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

The O O
severity O O
of O O
pain O O
due O O
to O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
, O O
mean O O
arterial O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
adverse O O
effects O O
were O O
also O O
evaluated O O
. O O

RESULTS O B_MEASURE
: O O
Study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
myoclonus O B_DISEASE_ADJECTIVE[DISEASE]
incidence O I_DISEASE_ADJECTIVE[DISEASE]
was O O
85 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
40 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
and O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
in O O
Group O B_LOCATION
NP O I_LOCATION
, O O
Group O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Group O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
FM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
respectively O O
, O O
and O O
were O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
Group O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
FM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

CONCLUSIONS O O
: O O
We O O
conclude O O
that O O
pretreatment O O
with O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
combination O O
of O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
midazolam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
effective O O
in O O
preventing O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myoclonus O O
. O O

Convulsant O O
effect O O
of O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
regional O O
brain O O
concentration O O
of O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
gamma B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
hexachlorocyclohexane I I_PROTEIN[GENE]/I_LOCATION
) O O
is O O
an O O
organochlorine O O
insecticide O O
with O O
known O O
neurotoxic O O
effects O O
. O O

Its O O
mechanism O O
of O O
action O O
is O O
not O O
well O O
understood O O
although O O
it O O
has O O
been O O
proposed O O
that O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acts O O
as O O
a O O
non O O
- O O
competitive O O
antagonist O O
at O O
the O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
- O O
A O O
receptor O O
. O O

We O O
studied O O
the O O
effect O O
of O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
150 O O
mg O O
/ O O
kg O O
) O O
on O O
the O O
GABAergic O O
and O O
dopaminergic O O
systems O O
by O O
measuring O O
the O O
concentration O O
of O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
its O O
metabolites O O
in O O
7 O O
brain O O
areas O O
at O O
the O O
onset O O
of O O
seizures O O
. O O

All O O
animals O O
suffered O O
tonic O O
convulsions O O
at O O
18 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
min O O
after O O
lindane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
. O O

The O O
concentration O O
of O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
only O O
slightly O O
but O O
significantly O O
decreased O O
in O O
the O O
colliculi O O
without O O
modifications O O
in O O
the O O
other O O
areas O O
. O O

The O O
concentration O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
increased O O
in O O
the O O
mesencephalon O O
and O O
that O O
of O O
its O O
metabolite O O
DOPAC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
increased O O
in O O
the O O
mesencephalon O O
and O O
the O O
striatum O O
. O O

Cholestatic O O
presentation O O
of O O
yellow O O
phosphorus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
poisoning O O
. O O

Yellow O O
phosphorus B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
component O O
of O O
certain O O
pesticide O O
pastes O O
and O O
fireworks O O
, O O
is O O
well O O
known O O
to O O
cause O O
hepatotoxicity O O
. O O

Poisoning O O
with O O
yellow O O
phosphorus B B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classically O O
manifests O O
with O O
acute O O
hepatitis O O
leading O O
to O O
acute O O
liver O O
failure O O
which O O
may O O
need O O
liver O O
transplantation O O
. O O

We O O
present O O
a O O
case O O
of O O
yellow O O
phosphorus B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O O
in O O
which O O
a O O
patient O O
presented O O
with O O
florid O O
clinical O O
features O O
of O O
cholestasis O O
highlighting O O
the O O
fact O O
that O O
cholestasis O O
can O O
rarely O O
be O O
a O O
presenting O O
feature O O
of O O
yellow O O
phosphorus B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hepatotoxicity O O
. O O

Vasovagal O O
syncope O O
and O O
severe O O
bradycardia O O
following O O
intranasal O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
pediatric O O
procedural O O
sedation O O
. O O

We O O
report O O
syncope O O
and O O
bradycardia O O
in O O
an O O
11 O O
- O O
year O O
- O O
old O O
girl O O
following O O
administration O O
of O O
intranasal O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
sedation O O
for O O
a O O
voiding O O
cystourethrogram O O
. O O

Following O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
completion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VCUG O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
a O O
60 O B_MEASURE
- O O
min O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
recovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
consciousness O B_DISEASE
and O O
vital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O O
to O O
presedation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Upon O O
leaving O O
the O O
sedation O B_LOCATION
area O I_LOCATION
, O O
the O O
patient O B_PERSON/B_LOCATION
collapsed O O
, O O
with O O
no O O
apparent O B_DISEASE
inciting O I_DISEASE
event O I_DISEASE
. O O

The O O
patient O B_PERSON
quickly O O
regained O O
consciousness O B_DISEASE/B_MEASURE
and O O
no O O
injury O B_DISEASE
occurred O O
. O O

The O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormality O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O O
was O O
persistent O B_DISEASE
bradycardia O I_DISEASE
, O O
and O O
she O O
was O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
for O O
telemetric O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
observation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
bradycardia O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasted O O
~ O O
2 O B_MEASURE
h O O
, O O
and O O
further O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workup O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
no O O
underlying O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormality O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Unanticipated O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
previously O O
unreported O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
witnessed O O
as O O
we O O
expand O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
certain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sedatives O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
alternative O B_NUMBER[MEASURE]/B_LOCATION
routes O B_NUMBER[MEASURE]/I_LOCATION
of O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Paradoxical O O
severe O O
agitation O O
induced O O
by O O
add O O
- O O
on O O
high O O
- O O
doses O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
schizo O O
- O O
affective O O
disorder O O
. O O

We O O
report O O
the O O
case O O
of O O
a O O
35 O O
- O O
year O O
- O O
old O O
patient O O
suffering O O
from O O
schizo O O
- O O
affective O O
disorder O O
since O O
the O O
age O O
of O O
19 O O
years O O
, O O
treated O O
by O O
a O O
combination O O
of O O
first O O
- O O
generation O O
antipsychotics O O
, O O
zuclopenthixol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
100 O O
mg O O
/ O O
day O O
) O O
and O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1200 O O
mg O O
/ O O
day O O
) O O
( O O
serum O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
= O O
0 O O
. O O
85 O O
mEq O O
/ O O
l O O
) O O
. O O

This O O
patient O B_PERSON
had O O
no O O
associated O B_DISEASE
personality O I_DISEASE
disorder O I_DISEASE
( O O
particularly O O
no O O
antisocial O B_DISEASE
disorder O I_DISEASE
) O O
and O O
no O O
substance O B_DISEASE
abuse O I_DISEASE
disorder O I_DISEASE
. O O

Within O O
the O O
48 O O
h O O
following O O
the O O
gradual O O
introduction O O
of O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
up O O
to O O
600 O O
mg O O
/ O O
day O O
) O O
, O O
the O O
patient O O
presented O O
severe O O
agitation O O
without O O
an O O
environmental O O
explanation O O
, O O
contrasting O O
with O O
the O O
absence O O
of O O
a O O
history O O
of O O
aggressiveness O O
or O O
personality O O
disorder O O
. O O

The O O
diagnoses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
manic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
akathisia O B_DISEASE
were O O
dismissed O O
. O O

The O O
withdrawal O O
and O O
the O O
gradual O O
reintroduction O O
of O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O O
weeks O O
later O O
, O O
which O O
led O O
to O O
another O O
severe O O
agitation O O
, O O
enabled O O
us O O
to O O
attribute O O
the O O
agitation O O
specifically O O
to O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Antioxidant O O
effects O O
of O O
bovine O O
lactoferrin O O
on O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
in O O
rat O O
. O O

Dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
( O O
Dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
) O O
induced O O
hypertension O O
is O O
associated O O
with O O
enhanced O O
oxidative O O
stress O O
. O O

Lactoferrin O O
( O O
LF O O
) O O
is O O
an O O
iron B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
binding O O
glycoprotein O O
with O O
antihypertensive O O
properties O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
chronic O O
administration O O
of O O
LF O O
on O O
oxidative O O
stress O O
and O O
hypertension O O
upon O O
Dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
. O O

Male O O
Wistar O O
rats O O
were O O
treated O O
by O O
Dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
30 O O
u O O
g O O
/ O O
kg O O
/ O O
day O O
subcutaneously O O
) O O
or O O
saline O O
for O O
14 O O
days O O
. O O

Oral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bovine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
LF O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
30 O B_MEASURE
, O O
100 O B_MEASURE
, O O
300 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
) O O
was O O
given O O
from O O
day O B_TIME[MEASURE]
8 O I_TIME[MEASURE]
to O O
14 O B_MEASURE
in O O
a O O
reversal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

In O O
a O O
prevention O O
study O O
, O O
rats O O
received O O
4 O O
days O O
of O O
LF O O
treatment O O
followed O O
by O O
Dex B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
continued O O
during O O
the O O
test O O
period O O
. O O

Systolic O B_MEASURE/B_DISEASE
blood O I_MEASURE/I_DISEASE
pressure O I_MEASURE/I_DISEASE
( O O
SBP O B_DISEASE/B_PROTEIN[GENE]
) O O
was O O
measured O O
using O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
cuff O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thymus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
used O O
as O O
a O O
marker O B_MEASURE/B_DISEASE
of O O
glucocorticoid O B_MEASURE/B_ORGANISM_FUNCTION
activity O B_MEASURE/I_ORGANISM_FUNCTION
. O O

Plasma O O
hydrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
H2O2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
concentration O O
and O O
ferric O O
reducing O O
antioxidant O O
power O O
( O O
FRAP O O
) O O
value O O
were O O
determined O O
. O O

Dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O O
increased O O
SBP O O
and O O
plasma O O
H2O2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
and O O
decreased O O
thymus O O
and O O
body O O
weights O O
. O O

LF O O
lowered O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
and O O
dose O O
dependently O O
prevented O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
Dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hypertension O O
. O O

LF O O
prevented O O
body O O
weight O O
loss O O
and O O
significantly O O
reduced O O
the O O
elevated O O
plasma O O
H2O2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
increased O O
FRAP O O
values O O
. O O

Chronic O O
administration O O
of O O
LF O O
strongly O O
reduced O O
the O O
blood O O
pressure O O
and O O
production O O
of O O
ROS O O
and O O
improved O O
antioxidant O O
capacity O O
in O O
Dex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
, O O
suggesting O O
the O O
role O O
of O O
inhibition O O
of O O
oxidative O O
stress O O
as O O
another O O
mechanism O O
of O O
antihypertensive O O
action O O
of O O
LF O O
. O O

The O O
association O O
between O O
tranexamic B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
convulsive O O
seizures O O
after O O
cardiac O O
surgery O O
: O O
a O O
multivariate O O
analysis O O
in O O
11 O O
529 O O
patients O O
. O O

Because O O
of O O
a O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
contemporary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
regarding O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
we O O
undertook O O
a O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prospectively O O
collected O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
11 O B_PERSON/B_LOCATION
529 O I_PERSON/I_LOCATION
patients O I_PERSON/I_LOCATION
in O O
whom O O
cardiopulmonary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bypass O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
used O O
from O O
January O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
December O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
convulsive O B_DISEASE
seizure O I_DISEASE
was O O
defined O O
as O O
a O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
episode O I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O O
disturbed O B_DISEASE
brain O I_DISEASE
function O I_DISEASE
characterised O O
by O O
abnormal O B_DISEASE
involuntary O I_DISEASE
motor O I_DISEASE
movements O I_DISEASE
. O O

Multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
performed O O
to O O
identify O O
independent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predictors O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
postoperative O B_DISEASE_ADJECTIVE[DISEASE]
seizures O I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
total O B_MEASURE
of O O
100 O B_MEASURE
( O O
0 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
patients O B_PERSON/B_LOCATION
developed O O
postoperative O B_DISEASE
convulsive O I_DISEASE
seizures O I_DISEASE
. O O

Generalised O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
focal O B_DISEASE/B_PERSON
seizures O I_DISEASE/I_PERSON
were O O
identified O O
in O O
68 O B_MEASURE
and O O
32 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
, O O
respectively O O
. O O

The O O
median O B_MEASURE
( O O
IQR O B_MEASURE/B_LOCATION
[ O O
range O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
) O O
time O B_MEASURE
after O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
when O O
the O O
seizure O B_DISEASE
occurred O O
was O O
7 O B_MEASURE
( O O
6 O B_MEASURE
- O O
12 O B_MEASURE
[ O I_MEASURE
1 O I_MEASURE
- O O
216 O B_MEASURE
] O I_MEASURE
) O O
h O B_TIME[MEASURE]/B_OTHER
and O O
8 O B_MEASURE
( O O
6 O B_MEASURE
- O O
11 O B_MEASURE
[ O I_MEASURE
4 O I_MEASURE
- O O
18 O B_MEASURE
] O I_MEASURE
) O O
h O B_TIME[MEASURE]/B_OTHER
, O O
respectively O O
. O O

Epileptiform O B_DISEASE_ADJECTIVE[DISEASE]
findings O I_DISEASE_ADJECTIVE[DISEASE]
on O O
electroencephalography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
seen O O
in O O
19 O B_TIME[MEASURE]/B_LOCATION
patients O B_TIME[MEASURE]/I_LOCATION
. O O

Independent O O
predictors O O
of O O
postoperative O O
seizures O O
included O O
age O O
, O O
female O O
sex O O
, O O
redo O O
cardiac O O
surgery O O
, O O
calcification O O
of O O
ascending O O
aorta O O
, O O
congestive O O
heart O O
failure O O
, O O
deep O O
hypothermic O O
circulatory O O
arrest O O
, O O
duration O O
of O O
aortic O O
cross O O
- O O
clamp O O
and O O
tranexamic B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
tested O O
in O O
a O O
multivariate O O
regression O O
analysis O O
, O O
tranexamic B B_DISEASE/B_BIO
acid I I_DISEASE/I_BIO
was O O
a O O
strong O O
independent O O
predictor O O
of O O
seizures O O
( O O
OR O O
14 O O
. O O
3 O O
, O O
95 O O
% O O
CI O O
5 O O
. O O
5 O O
- O O
36 O O
. O O
7 O O
; O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Patients O B_PERSON
with O O
convulsive O B_DISEASE
seizures O I_DISEASE
had O O
2 O B_MEASURE
. O O
5 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
higher O I_TIME[MEASURE]
in O O
- O O
hospital O B_MEASURE/B_LOCATION
mortality O I_MEASURE/I_LOCATION
rates O I_MEASURE/I_LOCATION
and O O
twice O O
the O O
length O B_MEASURE
of O O
hospital O B_LOCATION/B_PERSON
stay O O
compared O O
with O O
patients O B_PERSON
without O O
convulsive O B_DISEASE/B_PERSON
seizures O I_DISEASE/I_PERSON
. O O

Mean O O
( O O
IQR O B_MEASURE/B_LOCATION
[ O O
range O B_TIME[MEASURE]/B_LOCATION
] O I_TIME[MEASURE]/I_LOCATION
) O O
length O B_MEASURE/B_LOCATION
of O O
stay O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O O
the O O
intensive O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
care O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
unit O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
115 O B_MEASURE
( O O
49 O B_MEASURE
- O O
228 O B_MEASURE
[ O O
32 O B_MEASURE
- O O
481 O B_MEASURE
] O I_MEASURE
) O O
h O O
in O O
patients O B_PERSON
with O O
convulsive O B_DISEASE
seizures O I_DISEASE
compared O O
with O O
26 O B_MEASURE
( O O
22 O B_MEASURE
- O O
69 O B_TIME[MEASURE]
[ O I_TIME[MEASURE]
14 O I_TIME[MEASURE]
- O O
1080 O B_MEASURE
] O O
) O O
h O O
in O O
patients O B_PERSON/B_LOCATION
without O O
seizures O B_DISEASE/B_PERSON
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Convulsive O B_DISEASE_ADJECTIVE[DISEASE]
seizures O I_DISEASE_ADJECTIVE[DISEASE]
are O O
a O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
postoperative O I_DISEASE_ADJECTIVE[DISEASE]
complication O I_DISEASE_ADJECTIVE[DISEASE]
after O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

As O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
the O O
only O O
modifiable O O
factor O O
, O O
its O O
administration O O
, O O
particularly O O
in O O
doses O O
exceeding O O
80 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
, O O
should O O
be O O
weighed O O
against O O
the O O
risk O O
of O O
postoperative O O
seizures O O
. O O

Dysfunctional O O
overnight O O
memory O O
consolidation O O
in O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

Sleep O B_DISEASE
plays O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
consolidation O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
integration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
memory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
called O O
overnight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
consolidation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Previous O O
studies O O
indicate O O
that O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
have O O
marked O O
and O O
persistent O O
neurocognitive O O
and O O
sleep O O
- O O
related O O
impairments O O
. O O

We O O
extend O O
past O O
research O O
by O O
examining O O
overnight O O
memory O O
consolidation O O
among O O
regular O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
( O O
n O O
= O O
12 O O
) O O
and O O
drug O O
naive O O
healthy O O
controls O O
( O O
n O O
= O O
26 O O
) O O
. O O

Memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recall O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
word O B_PERSON/B_BIO
pairs O I_PERSON/I_BIO
was O O
evaluated O O
before O O
and O O
after O O
a O O
period O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sleep O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
with O O
and O O
without O O
interference O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
prior O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O O
testing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
assessed O O
neurocognitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performances O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
across O O
tasks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
learning O B_PERSON/B_DISEASE
, O O
memory O B_PERSON/B_DISEASE
and O O
executive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functioning O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
users O O
demonstrated O O
impaired O O
overnight O O
memory O O
consolidation O O
, O O
a O O
finding O O
that O O
was O O
more O O
pronounced O O
following O O
associative O O
interference O O
. O O

Additionally O O
, O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
demonstrated O O
impairments O O
on O O
tasks O O
recruiting O O
frontostriatal O O
and O O
hippocampal O O
neural O O
circuitry O O
, O O
in O O
the O O
domains O O
of O O
proactive O O
interference O O
memory O O
, O O
long O O
- O O
term O O
memory O O
, O O
encoding O O
, O O
working O O
memory O O
and O O
complex O O
planning O O
. O O

We O O
suggest O O
that O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
dysfunction O O
in O O
fronto O O
- O O
temporal O O
circuitry O O
may O O
underlie O O
overnight O O
consolidation O O
memory O O
impairments O O
in O O
regular O O
ecstasy B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O O
. O O

Normoammonemic O O
encephalopathy O O
: O O
solely O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
or O O
multiple O O
mechanisms O O
? O O

A O O
77 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
woman O I_PERSON
presented O O
with O O
subacute O B_DISEASE
onset O I_DISEASE
progressive O I_DISEASE
confusion O I_DISEASE
, O O
aggression O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
auditory O B_DISEASE
hallucinations O I_DISEASE
and O O
delusions O B_DISEASE
. O O

In O O
the O O
preceding O O
months O O
, O O
the O O
patient O O
had O O
a O O
number O O
of O O
admissions O O
with O O
transient O O
unilateral O O
hemiparesis O O
with O O
facial O O
droop O O
, O O
and O O
had O O
been O O
started O O
on O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
presumed O O
hemiplegic O O
migraine O O
. O O

Valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
withdrawn O O
soon O O
after O O
admission O O
and O O
her O O
cognitive O O
abilities O O
have O O
gradually O O
improved O O
over O O
3 O O
months O O
of O O
follow O O
- O O
up O O
. O O

Valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
taken O O
prior O O
to O O
withdrawal O O
were O O
subtherapeutic O O
and O O
the O O
patient O O
was O O
normoammonaemic O O
. O O

EEG O O
undertaken O O
during O O
inpatient O O
stay O O
showed O O
changes O O
consistent O O
with O O
encephalopathy O O
, O O
and O O
low O O
titre O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
receptor O O
antibodies O O
were O O
present O O
in O O
this O O
patient O O
. O O

The O O
possible O O
aetiologies O O
of O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
encephalopathy O O
and O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O O
- O O
associated O O
encephalitis O O
present O O
a O O
diagnostic O O
dilemma O O
. O O

We O O
present O O
a O O
putative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
combinatorial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hypothesis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
explain O O
this O O
patient O B_PERSON/B_BIO
' O O
s O B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cerebellar O O
and O O
oculomotor O O
dysfunction O O
induced O O
by O O
rapid O O
infusion O O
of O O
pethidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pethidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
opioid O O
that O O
gains O O
its O O
popularity O O
for O O
the O O
effective O O
pain O O
control O O
through O O
acting O O
on O O
the O O
opioid O O
- O O
receptors O O
. O O

However O O
, O O
rapid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relief O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sometimes O O
brings O O
about O O
unfavourable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
largely O O
limit O O
its O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
utility O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Common O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O O
nausea O B_DISEASE
, O O
vomiting O B_DISEASE
and O O
hypotension O B_DISEASE
. O O

In O O
patients O O
with O O
impaired O O
renal O O
and O O
liver O O
function O O
, O O
and O O
those O O
who O O
need O O
long O O
- O O
term O O
pain O O
control O O
, O O
pethidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
cause O O
excitatory O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
effects O O
through O O
its O O
neurotoxic O O
metabolite O O
, O O
norpethidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
resulting O O
in O O
irritability O O
and O O
seizure O O
attack O O
. O O

On O O
the O O
contrary O O
, O O
though O O
not O O
clinically O O
apparent O O
, O O
pethidine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentially O O
causes O O
inhibitory O O
impacts O O
on O O
the O O
CNS O O
and O O
impairs O O
normal O O
cerebellar O O
and O O
oculomotor O O
function O O
in O O
the O O
short O O
term O O
. O O

In O O
this O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O O
we O O
highlight O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
side O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
cerebellar O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
causes O O
dysmetria O B_DISEASE
, O O
dysarthria O B_DISEASE/B_LOCATION
, O O
reduced O O
smooth O B_DISEASE/B_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
and O O
decreased O O
saccadic O B_DISEASE
velocity O I_DISEASE
. O O

Baboon O O
syndrome O O
induced O O
by O O
ketoconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
27 O O
- O O
year O O
- O O
old O O
male O O
patient O O
presented O O
with O O
a O O
maculopapular O O
eruption O O
on O O
the O O
flexural O O
areas O O
and O O
buttocks O O
after O O
using O O
oral O O
ketoconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
patient O O
was O O
diagnosed O O
with O O
drug O O
- O O
induced O O
baboon O O
syndrome O O
based O O
on O O
his O O
history O O
, O O
which O O
included O O
prior O O
sensitivity O O
to O O
topical O O
ketoconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
physical O O
examination O O
, O O
and O O
histopathological O O
findings O O
. O O

Baboon O B_DISEASE/B_PROTEIN[GENE]
syndrome O B_DISEASE/I_PROTEIN[GENE]
is O O
a O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
or O O
contact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
allergen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
related O O
maculopapular O B_DISEASE
eruption O I_DISEASE
that O O
typically O O
involves O O
the O O
flexural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
gluteal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
ketoconazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
baboon O O
syndrome O O
in O O
the O O
English O O
literature O O
. O O

A O O
Case O O
of O O
Sudden O O
Cardiac O O
Death O O
due O O
to O O
Pilsicainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
Induced O O
Torsades O O
de O O
Pointes O O
. O O

An O O
84 O O
- O O
year O O
- O O
old O O
male O O
received O O
oral O O
pilsicainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
pure O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blocker O O
with O O
slow O O
recovery O O
kinetics O O
, O O
to O O
convert O O
his O O
paroxysmal O O
atrial O O
fibrillation O O
to O O
a O O
sinus O O
rhythm O O
; O O
the O O
patient O O
developed O O
sudden O O
cardiac O O
death O O
two O O
days O O
later O O
. O O

The O O
Holter O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrocardiogram O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
was O O
worn O O
by O O
chance O B_PERSON
, O O
revealed O O
torsade O B_DISEASE/B_LOCATION
de O I_DISEASE/I_LOCATION
pointes O I_DISEASE/I_LOCATION
with O O
gradually O O
prolonged O O
QT O B_TIME[MEASURE]/B_DISEASE
intervals O I_TIME[MEASURE]/I_DISEASE
. O O

This O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
rapidly O O
absorbed O O
from O O
the O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
most O B_DISEASE/B_MEASURE
of O O
it O O
is O O
excreted O O
from O O
the O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
the O O
patient O O
' O O
s O O
renal O O
function O O
was O O
not O O
highly O O
impaired O O
and O O
the O O
dose O O
of O O
pilsicainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
low O O
, O O
the O O
plasma O O
concentration O O
of O O
pilsicainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
have O O
been O O
high O O
, O O
which O O
can O O
produce O O
torsades O O
de O O
pointes O O
in O O
the O O
octogenarian O O
. O O

Although O O
the O O
oral O O
administration O O
of O O
class O O
IC O O
drugs O O
, O O
including O O
pilsicainide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
effective O O
to O O
terminate O O
atrial O O
fibrillation O O
, O O
careful O O
consideration O O
must O O
be O O
taken O O
before O O
giving O O
these O O
drugs O O
to O O
octogenarians O O
. O O

All B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
inflammatory O O
myositis O O
in O O
a O O
patient O O
with O O
acute O O
promyelocytic O O
leukemia O O
. O O

All B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ATRA B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
component O O
of O O
standard O O
therapy O O
for O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
, O O
is O O
associated O O
with O O
potentially O O
serious O O
but O O
treatable O O
adverse O O
effects O O
involving O O
numerous O O
organ O O
systems O O
, O O
including O O
rare O O
skeletal O O
muscle O O
involvement O O
. O O

Only O O
a O O
handful O O
of O O
cases O O
of O O
ATRA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myositis O O
in O O
children O O
have O O
been O O
reported O O
, O O
and O O
none O O
in O O
the O O
radiology O O
literature O O
. O O

We O O
present O O
such O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
15 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
boy O I_PERSON
with O O
APL O B_DISEASE/B_GENE
, O O
where O O
recognition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
imaging O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O O
a O O
crucial O B_PERSON/B_MEASURE
role O I_PERSON/I_MEASURE
in O O
making O O
the O O
diagnosis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
facilitated O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prompt O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
effective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Tolerability O O
of O O
lomustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
combination O O
with O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
dogs O O
with O O
lymphoma O O
. O O

This O O
retrospective O O
study O O
describes O O
toxicity O O
associated O O
with O O
a O O
protocol O O
of O O
lomustine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CCNU B B_LOCATION
) O O
and O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CTX B B_LOCATION/B_ORGANIZATION
) O O
in O O
dogs O O
with O O
lymphoma O O
. O O

CCNU B B_LOCATION
was O O
administered O O
per O O
os O O
( O O
PO O O
) O O
at O O
a O O
targeted O O
dosage O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
body O O
surface O O
area O O
on O O
day O O
0 O O
, O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
PO O O
at O O
a O O
targeted O O
dosage O O
of O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
divided O O
over O O
days O O
0 O O
through O O
4 O O
, O O
and O O
all O O
dogs O O
received O O
prophylactic O O
antibiotics O O
. O O

Ninety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
given O O
to O O
the O O
57 O B_PERSON/B_BIO
dogs O I_PERSON/I_BIO
included O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neutropenia O O
was O O
the O O
principal O O
toxic O O
effect O O
, O O
and O O
the O O
overall O O
frequency O O
of O O
grade O O
4 O O
neutropenia O O
after O O
the O O
first O O
treatment O O
of O O
CCNU B B_LOCATION
/ O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O O
30 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
19 O O
- O O
43 O O
% O O
) O O
. O O

The O O
mean O B_MEASURE/B_DISEASE
body O I_MEASURE/I_DISEASE
weight O I_MEASURE/I_DISEASE
of O O
dogs O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
grade O B_DISEASE
4 O I_DISEASE
neutropenia O I_DISEASE
( O O
19 O B_MEASURE
. O O
7 O B_MEASURE
kg O I_MEASURE
+ O O
13 O B_MEASURE
. O O
4 O B_MEASURE
kg O I_MEASURE
) O O
was O O
significantly O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
mean O B_MEASURE/B_PERSON
body O I_MEASURE/I_PERSON
weight O I_MEASURE/I_PERSON
of O O
dogs O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
did O O
not O O
develop O O
grade O B_DISEASE
4 O I_DISEASE
neutropenia O I_DISEASE
( O O
31 O B_MEASURE
. O O
7 O B_MEASURE
kg O I_MEASURE
+ O O
12 O B_MEASURE
. O O
4 O B_MEASURE
kg O I_MEASURE
; O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
. O O
005 O B_MEASURE
) O O
. O O

One O B_NUMBER[MEASURE]/B_PERSON
dog O I_NUMBER[MEASURE]/I_PERSON
( O O
3 O B_PERSON
% O I_PERSON
) O O
developed O O
hematologic O B_DISEASE
changes O I_DISEASE
suggestive O I_DISEASE
of O O
hepatotoxicity O B_DISEASE
. O O

No O O
dogs O B_BIO/B_PERSON
had O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
either O O
renal O B_DISEASE_ADJECTIVE[DISEASE]
toxicity O I_DISEASE_ADJECTIVE[DISEASE]
or O O
hemorrhagic O B_DISEASE
cystitis O I_DISEASE
. O O

Adverse O B_DISEASE_ADJECTIVE[DISEASE]
gastrointestinal O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
were O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
. O O

On O O
the O O
basis O O
of O O
the O O
findings O O
reported O O
herein O O
, O O
a O O
dose O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CCNU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combined O O
with O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
divided O O
over O O
5 O O
days O O
) O O
q O O
4 O O
wk O O
is O O
tolerable O O
in O O
tumor O O
- O O
bearing O O
dogs O O
. O O

Nelarabine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurotoxicity O O
with O O
concurrent O O
intrathecal O O
chemotherapy O O
: O O
Case O O
report O O
and O O
review O O
of O O
literature O O
. O O

Severe O O
nelarabine B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxicity O O
in O O
a O O
patient O O
who O O
received O O
concurrent O O
intrathecal O O
( O O
IT O O
) O O
chemotherapy O O
is O O
reported O O
. O O

A O O
37 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
Caucasian O I_PERSON
woman O I_PERSON
with O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
cell O B_DISEASE/B_GENE
lymphoblastic O I_DISEASE/I_GENE
lymphoma O I_DISEASE/I_GENE
was O O
admitted O O
for O O
relapsed O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
disease O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

She O O
was O O
originally O O
treated O O
with O O
induction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
an O O
autologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

She O O
developed O O
relapsed O B_DISEASE
disease O I_DISEASE
10 O I_DISEASE
months O I_DISEASE
later O O
with O O
leukemic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
was O O
re O O
- O O
induced O O
with O O
nelarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
on O O
days O O
1 O O
, O O
3 O O
, O O
and O O
5 O O
with O O
1 O O
dose O O
of O O
IT O O
cytarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
100 O O
mg O O
on O O
day O O
2 O O
as O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
prophylaxis O O
. O O

At O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
she O O
was O O
on O O
continuous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
sequelae O B_DISEASE_ADJECTIVE[DISEASE]
of O O
tumor O B_DISEASE
lysis O I_DISEASE
syndrome O I_DISEASE
( O O
TLS O B_DISEASE/B_GENE
) O O
. O O

She O O
tolerated O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
, O O
entered O O
a O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
recovered O O
her O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
received O O
a O O
second O O
cycle O O
of O O
nelarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
without O O
additional O O
IT O O
prophylaxis O O
one O O
month O O
later O O
. O O

A O O
week O B_TIME[MEASURE]
after O O
this O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
she O O
noted O O
numbness O B_DISEASE
in O O
her O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extremities O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Predominantly O O
sensory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
though O O
also O O
motor O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
autonomic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
neuropathy O I_DISEASE_ADJECTIVE[DISEASE]
started O O
in O O
her O O
feet O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ascended O O
proximally O O
to O O
the O O
mid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
thoracic O B_BODY_PART_OR_ORGAN_COMPONENT
region O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
eventually O O
included O O
her O O
distal O B_BODY_PART_OR_ORGAN_COMPONENT
upper O I_BODY_PART_OR_ORGAN_COMPONENT
extremities O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
of O O
her O O
spine O B_BODY_PART_OR_ORGAN_COMPONENT
demonstrated O O
changes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
C2 O B_PROTEIN[GENE]
to O O
C6 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
subacute O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
combined O O
degeneration O B_DISEASE
. O O

Nelarabine B B_DISEASE/B_PERSON
was O O
felt O O
to O O
be O O
the O O
cause O O
of O O
her O O
symptoms O O
. O O

Her O O
neuropathy O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stabilized O O
and O O
showed O O
slight O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
ultimately O O
received O O
an O O
unrelated O B_DISEASE_ADJECTIVE[DISEASE]
, O O
reduced O O
- O O
intensity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
allogeneic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transplant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
while O O
in O O
complete O B_DISEASE_ADJECTIVE[DISEASE]
remission O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
relapsed O O
disease O B_TIME[MEASURE]/B_ENT
10 O I_TIME[MEASURE]/I_ENT
weeks O I_TIME[MEASURE]/I_ENT
later O O
. O O

She O O
is O O
currently O O
being O O
treated O O
with O O
best O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
published O O
case O O
report O O
of O O
severe O O
neurotoxicity O O
caused O O
by O O
nelarabine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
patient O O
who O O
received O O
concurrent O O
IT O O
chemotherapy O O
. O O

Valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hyperammonemic O O
encephalopathy O O
in O O
a O O
renal O O
transplanted O O
patient O O
. O O

Neurological O B_DISEASE
complications O I_DISEASE
after O O
renal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
constitute O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
morbidity O B_DISEASE
and O O
mortality O B_DISEASE
. O O

Their O O
differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
difficult O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
essential O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
subsequent O B_PERSON/B_DISEASE
patient O I_PERSON/I_DISEASE
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
management O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hyperammonemic O O
encephalopathy O O
is O O
an O O
uncommon O O
but O O
serious O O
effect O O
of O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
. O O

Here O O
, O O
we O O
describe O O
the O O
case O O
of O O
a O O
15 O O
- O O
year O O
- O O
old O O
girl O O
who O O
was O O
on O O
a O O
long O O
- O O
term O O
therapy O O
with O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
epilepsy O O
and O O
revealed O O
impaired O O
consciousness O O
with O O
hyperammonemia O O
12 O O
days O O
after O O
renal O O
transplantation O O
. O O

After O O
withdraw O O
of O O
valproate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
patients O O
' O O
symptoms O O
resolved O O
within O O
24 O O
h O O
. O O

Clinicians O O
should O O
increase O O
their O O
awareness O O
for O O
potential O O
complication O O
of O O
valproate B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
especially O O
in O O
transplanted O O
patients O O
. O O

Necrotising O O
fasciitis O O
after O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
regimen O O
in O O
an O O
elderly O O
patient O O
of O O
Waldenstrom O O
macroglobulinaemia O O
. O O

Bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O O
high O O
- O O
dose O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
regimens O O
are O O
considered O O
to O O
be O O
generally O O
tolerable O O
with O O
few O O
severe O O
bacterial O O
infections O O
in O O
patients O O
with O O
B O O
- O O
cell O O
malignancies O O
. O O

However O O
, O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O O
limited O O
concerning O O
the O O
safety O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
regimen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elderly O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
report O O
a O O
case O O
of O O
a O O
76 O O
- O O
year O O
- O O
old O O
man O O
with O O
Waldenstrom O O
macroglobulinaemia O O
who O O
suffered O O
necrotising O O
fasciitis O O
without O O
neutropenia O O
after O O
the O O
combination O O
treatment O O
with O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
high O O
- O O
dose O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
rituximab O O
. O O

Despite O O
immediate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
antimicrobial O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
he O O
succumbed O O
23 O B_MEASURE/B_LOCATION
h O O
after O O
the O O
onset O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Physicians O O
should O O
recognise O O
the O O
possibility O O
of O O
fatal O O
bacterial O O
infections O O
related O O
to O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
high O O
- O O
dose O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elderly O O
patients O O
, O O
and O O
we O O
believe O O
this O O
case O O
warrants O O
further O O
investigation O O
. O O

An O O
integrated O O
characterization O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
in O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiotoxicity O O
. O O

Many O B_PERSON
efficacious O I_PERSON
cancer O I_PERSON
treatments O I_PERSON
cause O O
significant O B_DISEASE
cardiac O I_DISEASE
morbidity O I_DISEASE
, O O
yet O O
biomarkers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
early O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
damage O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
would O O
allow O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
lacking O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
utilized O O
a O O
rat O O
model O O
of O O
progressive O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
induced O O
cardiomyopathy O O
, O O
applying O O
multiple O O
approaches O O
, O O
including O O
cardiac O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
, O O
to O O
provide O O
the O O
most O O
comprehensive O O
characterization O O
to O O
date O O
of O O
the O O
timecourse O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
underlying O O
this O O
toxicity O O
. O O

Hannover O O
Wistar O O
rats O O
were O O
dosed O O
with O O
1 O O
. O O
25 O O
mg O O
/ O O
kg O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
weekly O O
for O O
8 O O
weeks O O
followed O O
by O O
a O O
4 O O
week O O
off O O
- O O
dosing O O
" O O
recovery O O
" O O
period O O
. O O

Electron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT
revealed O O
subcellular O B_DISEASE_ADJECTIVE[DISEASE]
degeneration O I_DISEASE_ADJECTIVE[DISEASE]
and O O
marked O O
mitochondrial O B_DISEASE/B_GENE
changes O I_DISEASE/I_GENE
after O O
a O O
single O B_MEASURE/B_DISEASE
dose O B_MEASURE/I_DISEASE
. O O

Histopathological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
progressive O B_DISEASE
cardiomyocyte O I_DISEASE
degeneration O I_DISEASE
, O O
hypertrophy O B_DISEASE
/ O O
cytomegaly O O
, O O
and O O
extensive O B_DISEASE/B_GENE
vacuolation O I_DISEASE/I_GENE
after O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Extensive O B_DISEASE
replacement O I_DISEASE
fibrosis O I_DISEASE
( O O
quantified O O
by O O
Sirius O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
red O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
developed O O
during O O
the O O
off O O
- O O
dosing O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
indices O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessed O O
by O O
cardiac O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
including O O
left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
LVEF O B_LOCATION/B_MEASURE
) O O
, O O
cardiac O B_MEASURE/B_LOCATION
output O B_MEASURE/I_LOCATION
, O O
and O O
E O B_OTHER/B_PROTEIN[GENE]
/ O O
A O B_LOCATION/B_MEASURE
ratio O I_LOCATION/I_MEASURE
) O O
declined O O
progressively O O
, O O
reaching O O
statistical O B_MEASURE/B_DISEASE
significance O I_MEASURE/I_DISEASE
after O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O O
culminating O O
in O O
" O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
LV O B_DISEASE_ADJECTIVE[DISEASE]
dysfunction O I_DISEASE_ADJECTIVE[DISEASE]
by O O
12 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peak O B_BODY_PART_OR_ORGAN_COMPONENT
myocardial O I_BODY_PART_OR_ORGAN_COMPONENT
contrast O I_BODY_PART_OR_ORGAN_COMPONENT
enhancement O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
serological O B_DISEASE
cardiac O I_DISEASE
troponin O I_DISEASE
I O I_DISEASE
( O O
cTnI O B_LOCATION/B_PROTEIN[GENE]
) O O
emerged O O
after O O
eight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
importantly O O
preceding O O
the O O
LVEF O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decline O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
< O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Troponin O O
I O O
levels O O
positively O O
correlated O O
with O O
delayed O O
and O O
peak O O
gadolinium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
contrast O O
enhancement O O
, O O
histopathological O O
grading O O
, O O
and O O
diastolic O O
dysfunction O O
. O O

In O O
summary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
subcellular O B_DISEASE/B_GENE
cardiomyocyte O I_DISEASE/I_GENE
degeneration O I_DISEASE/I_GENE
was O O
the O O
earliest O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
marker O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
followed O O
by O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functional O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decline O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
histopathological O B_DISEASE
manifestations O I_DISEASE
. O O

Myocardial O B_DISEASE
contrast O I_DISEASE
enhancement O I_DISEASE
and O O
elevations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cTnI O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
occurred O O
later O O
. O O

However O O
, O O
all O O
indices O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
predated O O
" O B_PERSON/B_BIO
clinical O I_PERSON/I_BIO
" O O
LV O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
thus O O
warrant O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biomarkers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Intradermal O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injections O O
: O O
intra O O
- O O
and O O
interindividual O O
variability O O
of O O
provoked O O
hyperalgesia O O
and O O
allodynia O O
. O O

Intradermal O O
injections O O
of O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
attractive O O
to O O
use O O
in O O
human O O
experimental O O
pain O O
models O O
because O O
hyperalgesia O O
and O O
allodynia O O
mimic O O
isolated O O
aspects O O
of O O
clinical O O
pain O O
disorders O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
to O O
investigate O O
the O O
reproducibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Twenty O O
healthy O O
male O O
volunteers O O
( O O
mean O O
age O O
24 O O
years O O
; O O
range O O
18 O O
- O O
38 O O
years O O
) O O
received O O
intradermal O O
injections O O
of O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
volar O O
forearm O O
. O O

Magnitudes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
secondary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pinprick O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hyperalgesia O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
brush O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
evoked O O
allodynia O B_DISEASE
were O O
investigated O O
using O O
von O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
Frey O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
filaments O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
gauges O B_MEASURE
10 O I_MEASURE
, O O
15 O B_MEASURE
, O O
60 O B_MEASURE
and O O
100 O B_MEASURE
g O I_MEASURE
) O O
and O O
brush O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strokes O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
secondary O B_DISEASE
hyperalgesia O I_DISEASE
and O O
allodynia O B_DISEASE
were O O
quantified O O
immediately O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
after O O
15 O B_MEASURE
, O O
30 O B_MEASURE
and O O
60 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

Two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
separated O O
by O O
at O O
least O O
7 O B_NUMBER[MEASURE]/B_ENT
days O I_NUMBER[MEASURE]/I_ENT
were O O
performed O O
. O O

Reproducibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
across O O
and O O
within O O
volunteers O B_PERSON/B_LOCATION
( O O
inter O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
intra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
respectively O O
) O O
was O O
assessed O O
using O O
intraclass O B_MEASURE/B_ORGANIZATION
correlation O I_MEASURE/I_ORGANIZATION
coefficient O I_MEASURE/I_ORGANIZATION
( O O
ICC O B_ORGANIZATION/B_DISEASE
) O O
and O O
coefficient O B_MEASURE
of O O
variation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
CV O B_LOCATION/B_ORGANIZATION
) O O
. O O

Secondary O O
pinprick O O
hyperalgesia O O
was O O
observed O O
as O O
a O O
marked O O
increase O O
in O O
the O O
visual O O
analogue O O
scale O O
( O O
VAS O O
) O O
response O O
to O O
von O O
Frey O O
gauges O O
60 O O
and O O
100 O O
g O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
after O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
. O O

For O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
secondary O O
pinprick O O
hyperalgesia O O
was O O
detected O O
with O O
all O O
von O O
Frey O O
gauges O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Glutamate B B_PERSON/B_LOCATION
evoked O O
reproducible O O
VAS O O
response O O
to O O
all O O
von O O
Frey O O
gauges O O
( O O
ICC O O
> O O
0 O O
. O O
60 O O
) O O
and O O
brush O O
strokes O O
( O O
ICC O O
> O O
0 O O
. O O
83 O O
) O O
. O O

Capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O O
was O O
reproducible O O
for O O
secondary O O
hyperalgesia O O
( O O
ICC O O
> O O
0 O O
. O O
70 O O
) O O
and O O
allodynia O O
( O O
ICC O O
> O O
0 O O
. O O
71 O O
) O O
. O O

Intra O B_DISEASE/B_MEASURE
- O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
generally O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
VAS O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
von O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Frey O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
brush O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compared O O
with O O
areas O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
secondary O B_DISEASE
hyperalgesia O I_DISEASE
and O O
allodynia O B_DISEASE
. O O

In O O
conclusion O O
, O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
capsaicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yield O O
reproducible O O
hyperalgesic O O
and O O
allodynic O O
responses O O
, O O
and O O
the O O
present O O
model O O
is O O
well O O
suited O O
for O O
basic O O
research O O
, O O
as O O
well O O
as O O
for O O
assessing O O
the O O
modulation O O
of O O
central O O
phenomena O O
. O O

Ocular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ER O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rescues O O
glaucoma O O
in O O
murine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
glaucoma O B_DISEASE
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
ocular O B_DISEASE
hypertension O I_DISEASE
in O O
some O O
patients O B_PERSON/B_BIO
. O O

If O O
untreated O B_DISEASE_ADJECTIVE[DISEASE]
, O O
these O O
patients O B_PERSON/B_BIO
can O O
develop O O
a O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]
glaucoma O I_DISEASE_ADJECTIVE[DISEASE]
that O O
resembles O O
primary O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
open O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
angle O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
POAG O B_LOCATION
) O O
. O O

The O O
underlying O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathology O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
glaucoma O B_DISEASE
is O O
not O O
fully O O
understood O O
, O O
due O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
appropriate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
, O O
we O O
developed O O
a O O
murine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
glaucoma O B_DISEASE
that O O
exhibits O O
glaucoma O B_DISEASE_ADJECTIVE[DISEASE]
features O I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
observed O O
in O O
patients O B_PERSON/B_BIO
. O O

Treatment O O
of O O
WT O O
mice O O
with O O
topical O O
ocular O O
0 O O
. O O
1 O O
% O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
led O O
to O O
elevation O O
of O O
intraocular O O
pressure O O
( O O
IOP O O
) O O
, O O
functional O O
and O O
structural O O
loss O O
of O O
retinal O O
ganglion O O
cells O O
, O O
and O O
axonal O O
degeneration O O
, O O
resembling O O
glucocorticoid O O
- O O
induced O O
glaucoma O O
in O O
human O O
patients O O
. O O

Furthermore O O
, O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O O
hypertension O O
was O O
associated O O
with O O
chronic O O
ER O O
stress O O
of O O
the O O
trabecular O O
meshwork O O
( O O
TM O O
) O O
. O O

Similar O O
to O O
patients O O
, O O
withdrawal O O
of O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
reduced O O
elevated O O
IOP O O
and O O
ER O O
stress O O
in O O
this O O
animal O O
model O O
. O O

Dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
the O O
transcriptional O O
factor O O
CHOP O O
, O O
a O O
marker O O
for O O
chronic O O
ER O O
stress O O
, O O
in O O
the O O
anterior O O
segment O O
tissues O O
, O O
and O O
Chop O O
deletion O O
reduced O O
ER O O
stress O O
in O O
these O O
tissues O O
and O O
prevented O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ocular O O
hypertension O O
. O O

Furthermore O O
, O O
reduction O O
of O O
ER O O
stress O O
in O O
the O O
TM O O
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phenylbutyrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
prevented O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O O
hypertension O O
in O O
WT O O
mice O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
ER O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contributes O O
to O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ocular O B_DISEASE/B_GENE
hypertension O I_DISEASE/I_GENE
and O O
suggest O O
that O O
reducing O O
ER O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O O
a O O
therapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
treating O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
glaucoma O B_DISEASE
. O O

Effects O O
of O O
ginsenosides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
opioid O O
- O O
induced O O
hyperalgesia O O
in O O
mice O O
. O O

Opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hyperalgesia O B_DISEASE
( O O
OIH O B_DISEASE/B_LOCATION
) O O
is O O
characterized O O
by O O
nociceptive O B_DISEASE
sensitization O I_DISEASE
caused O O
by O O
the O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
opioid O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OIH O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
can O O
limit O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analgesics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
complicate O O
withdrawal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
addiction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
Re B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rg1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rb1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ginsenosides I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
bioactive O O
components O O
of O O
ginseng O O
, O O
on O O
OIH O O
. O O

OIH O O
was O O
achieved O O
in O O
mice O O
after O O
subcutaneous O O
administration O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
7 O O
consecutive O O
days O O
three O O
times O O
per O O
day O O
. O O

During O O
withdrawal O O
( O O
days O O
8 O O
and O O
9 O O
) O O
, O O
these O O
mice O O
were O O
administered O O
Re B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
Rg1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
or O O
Rb1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragastrically O O
two O O
times O O
per O O
day O O
. O O

On O O
the O O
test O O
day O O
( O O
day O O
10 O O
) O O
, O O
mice O O
were O O
subjected O O
to O O
the O O
thermal O O
sensitivity O O
test O O
and O O
the O O
acetic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
writhing O O
test O O
. O O

Re B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
300 O O
mg O O
/ O O
kg O O
) O O
inhibited O O
OIH O O
in O O
both O O
the O O
thermal O O
sensitivity O O
test O O
and O O
the O O
acetic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
writhing O O
test O O
. O O

However O O
, O O
the O O
Rg1 B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
Rb1 I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ginsenosides I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
prevent O O
OIH O O
in O O
either O O
test O O
. O O

Furthermore O O
, O O
Rg1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O O
a O O
tendency O O
to O O
aggravate O O
OIH O O
in O O
the O O
acetic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
writhing O O
test O O
. O O

Our O O
data O O
suggested O O
that O O
the O O
ginsenoside B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Re I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
Rg1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Rb1 B B_PROTEIN[GENE]/B_LOCATION
, O O
may O O
contribute O O
toward O O
reversal O O
of O O
OIH O O
. O O

A O O
comparison O O
of O O
severe O O
hemodynamic O O
disturbances O O
between O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
sedation O O
in O O
neurocritical O O
care O O
patients O O
. O O

OBJECTIVE O O
: O O
Dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
commonly O O
used O O
sedatives O O
in O O
neurocritical O O
care O O
as O O
they O O
allow O O
for O O
frequent O O
neurologic O O
examinations O O
. O O

However O O
, O O
both O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
associated O O
with O O
significant O B_DISEASE
hemodynamic O I_DISEASE
side O I_DISEASE
effects O I_DISEASE
. O O

The O O
primary O O
objective O O
of O O
this O O
study O O
is O O
to O O
compare O O
the O O
prevalence O O
of O O
severe O O
hemodynamic O O
effects O O
in O O
neurocritical O O
care O O
patients O O
receiving O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DESIGN O B_PERSON/B_MEASURE
: O O
Multicenter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
propensity O B_MEASURE/B_PERSON
- O O
matched O O
cohort O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

SETTING O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Neurocritical O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
units O I_PERSON/I_ORGANIZATION
at O O
two O B_LOCATION/B_MEASURE
academic O I_LOCATION/I_MEASURE
medical O I_LOCATION/I_MEASURE
centers O I_LOCATION/I_MEASURE
with O O
dedicated O O
neurocritical O B_PERSON/B_ORGANIZATION
care O I_PERSON/I_ORGANIZATION
teams O I_PERSON/I_ORGANIZATION
and O O
board O B_ORGANIZATION/B_LOCATION
- O O
certified O O
neurointensivists O B_PERSON/B_ORGANIZATION
. O O

PATIENTS O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Neurocritical O B_PERSON/B_LOCATION
care O I_PERSON/I_LOCATION
patients O I_PERSON/I_LOCATION
admitted O O
between O O
July O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2009 O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
September O B_TIME[MEASURE]
2012 O I_TIME[MEASURE]
were O O
evaluated O O
and O O
then O O
matched O O
1 O B_MEASURE
: O O
1 O B_MEASURE
based O O
on O O
propensity O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
scoring O O
of O O
baseline O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

INTERVENTIONS O O
: O O
Continuous O O
sedation O O
with O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
A O O
total O O
of O O
342 O O
patients O O
( O O
105 O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
237 O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
were O O
included O O
in O O
the O O
analysis O O
, O O
with O O
190 O O
matched O O
( O O
95 O O
in O O
each O O
group O O
) O O
by O O
propensity O O
score O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
a O O
composite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
severe O B_DISEASE
hypotension O I_DISEASE
( O O
mean O B_DISEASE/B_GENE
arterial O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
< O O
60 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
) O O
and O O
bradycardia O B_DISEASE
( O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
< O O
50 O B_MEASURE
beats O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_PERSON
) O O
during O O
sedative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

No O O
difference O B_MEASURE
in O O
the O O
primary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composite O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
the O O
unmatched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
vs O I_MEASURE/I_LOCATION
30 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
, O O
p O O
= O O
0 O B_MEASURE
. O O
94 O B_MEASURE
) O O
or O O
matched O O
cohorts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
28 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
vs O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
34 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p O O
= O O
0 O B_MEASURE
. O O
35 O B_MEASURE
) O O
could O O
be O O
found O O
. O O

When O O
analyzed O O
separately O O
, O O
no O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
found O O
in O O
the O O
prevalence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
severe O B_DISEASE
hypotension O I_DISEASE
or O O
bradycardia O B_DISEASE
in O O
either O O
the O O
unmatched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
or O O
matched O O
cohorts O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Severe O O
hypotension O O
and O O
bradycardia O O
occur O O
at O O
similar O O
prevalence O O
in O O
neurocritical O O
care O O
patients O O
who O O
receive O O
dexmedetomidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Providers O B_PERSON
should O O
similarly O O
consider O O
the O O
likelihood O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hypotension O B_DISEASE
or O O
bradycardia O B_DISEASE
before O O
starting O O
either O O
sedative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ameliorates O O
oxidative O O
stress O O
and O O
mitochondrial O O
dysfunction O O
in O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
in O O
rats O O
with O O
breast O O
cancer O O
. O O

Oxidative O O
stress O O
is O O
involved O O
in O O
several O O
processes O O
including O O
cancer O O
, O O
aging O O
and O O
cardiovascular O O
disease O O
, O O
and O O
has O O
been O O
shown O O
to O O
potentiate O O
the O O
therapeutic O O
effect O O
of O O
drugs O O
such O O
as O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
causes O O
significant O O
cardiotoxicity O O
characterized O O
by O O
marked O O
increases O O
in O O
oxidative O O
stress O O
and O O
mitochondrial O O
dysfunction O O
. O O

Herein O O
, O O
we O O
investigate O O
whether O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
chronic O O
cardiac O O
toxicity O O
can O O
be O O
ameliorated O O
with O O
the O O
antioxidant O O
hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
rats O O
with O O
breast O O
cancer O O
. O O

Thirty O O
- O O
six O O
rats O O
bearing O O
breast O O
tumors O O
induced O O
chemically O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
control O O
, O O
hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
0 O O
. O O
5mg O O
/ O O
kg O O
, O O
5days O O
/ O O
week O O
) O O
, O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1mg O O
/ O O
kg O O
/ O O
week O O
) O O
, O O
and O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plus O O
hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

Cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
cellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
mitochondrial O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
level O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O O
mitochondrial O B_GENE/B_LOCATION
electron O I_GENE/I_LOCATION
transport O I_GENE/I_LOCATION
chain O I_GENE/I_LOCATION
complexes O I_GENE/I_LOCATION
I O I_GENE/I_LOCATION
- O O
IV O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
apoptosis O B_DISEASE/B_GENE
- O O
inducing O O
factor O B_MEASURE/B_BIO
, O O
and O O
oxidative O B_DISEASE/B_GENE
stress O I_DISEASE/I_GENE
markers O I_DISEASE/I_GENE
have O O
been O O
analyzed O O
. O O

Hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
improved O O
the O O
cardiac O O
disturbances O O
enhanced O O
by O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
significantly O O
reducing O O
the O O
percentage O O
of O O
altered O O
mitochondria O O
and O O
oxidative O O
damage O O
. O O

These O O
results O O
suggest O O
that O O
hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
improve O O
the O O
mitochondrial O O
electron O O
transport O O
chain O O
. O O

This O O
study O O
demonstrates O O
that O O
hydroxytyrosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
protect O O
rat O O
heart O O
damage O O
provoked O O
by O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
decreasing O O
oxidative O O
damage O O
and O O
mitochondrial O O
alterations O O
. O O

Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myxoedema O O
coma O O
. O O

A O O
62 O O
- O O
year O O
- O O
old O O
man O O
was O O
found O O
to O O
have O O
bradycardia O O
, O O
hypothermia O O
and O O
respiratory O O
failure O O
3 O O
weeks O O
after O O
initiation O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
atrial O O
fibrillation O O
. O O

Thyroid O O
- O O
stimulating O O
hormone O O
was O O
found O O
to O O
be O O
168 O O
uIU O O
/ O O
mL O O
( O O
nl O O
. O O
0 O O
. O O
3 O O
- O O
5 O O
uIU O O
/ O O
mL O O
) O O
and O O
free O O
thyroxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
FT4 O O
) O O
was O O
< O O
0 O O
. O O
2 O O
ng O O
/ O O
dL O O
( O O
nl O O
. O O
0 O O
. O O
8 O O
- O O
1 O O
. O O
8 O O
ng O O
/ O O
dL O O
) O O
. O O

He O O
received O O
intravenous O O
fluids O O
, O O
vasopressor O O
therapy O O
and O O
stress O O
dose O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
he O O
was O O
intubated O O
and O O
admitted O O
to O O
the O O
intensive O O
care O O
unit O O
. O O

He O O
received O O
500 O O
ug O O
of O O
intravenous O O
levothyroxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
first O O
18 O O
h O O
of O O
therapy O O
, O O
and O O
150 O O
ug O O
intravenous O O
daily O O
thereafter O O
. O O

Haemodynamic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
improvement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
along O O
with O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mental O B_DISEASE
status O I_DISEASE
, O O
occurred O O
after O O
48 O B_MEASURE
h O O
. O O

Twelve O B_TIME[MEASURE]/B_LOCATION
hours O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
FT4 O B_GENE
was O O
0 O B_MEASURE
. O O
96 O B_MEASURE/B_PERSON
ng O I_MEASURE/I_PERSON
/ O O
dL O B_PROTEIN[GENE]/B_MEASURE
. O O

The O O
patient O O
was O O
maintained O O
on O O
levothyroxine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 O O
( O O
g O O
POorally O O
daily O O
. O O

A O O
thyroid O B_SEQUENCE[MEASURE]/B_PERSON
ultrasound O I_SEQUENCE[MEASURE]/I_PERSON
showed O O
diffuse O B_DISEASE
heterogeneity O I_DISEASE
. O O

The O O
24 O O
hour O O
excretion O O
of O O
iodine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
3657 O O
( O O
mcg O O
( O O
25 O O
- O O
756 O O
( O O
mcg O O
) O O
. O O

The O O
only O O
two O O
cases O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myxoedema O O
coma O O
in O O
the O O
literature O O
report O O
patient O O
death O O
despite O O
supportive O O
therapy O O
and O O
thyroid O O
hormone O O
replacement O O
. O O

This O O
case O O
represents O O
the O O
most O O
thoroughly O O
investigated O O
case O O
of O O
amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
myxoedema O O
coma O O
with O O
a O O
history O O
significant O O
for O O
subclinical O O
thyroid O O
disease O O
. O O

Use O O
of O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
catheter O O
- O O
directed O O
thrombolysis O O
with O O
alteplase O O
in O O
an O O
oncology O O
patient O O
with O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
with O O
thrombosis O O
. O O

PURPOSE O O
: O O
The O O
case O O
of O O
an O O
oncology O O
patient O O
who O O
developed O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
with O O
thrombosis O O
( O O
HITT O O
) O O
and O O
was O O
treated O O
with O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
catheter O O
- O O
directed O O
thrombolysis O O
( O O
CDT O O
) O O
with O O
alteplase O O
is O O
presented O O
. O O

SUMMARY O O
: O O
A O O
63 O O
- O O
year O O
- O O
old O O
Caucasian O O
man O O
with O O
renal O O
amyloidosis O O
undergoing O O
peripheral O O
blood O O
stem O O
cell O O
collection O O
for O O
an O O
autologous O O
stem O O
cell O O
transplant O O
developed O O
extensive O O
bilateral O O
upper O O
- O O
extremity O O
deep O O
venous O O
thrombosis O O
( O O
DVT O O
) O O
and O O
pulmonary O O
embolism O O
secondary O O
to O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
thrombocytopenia O O
. O O

A O O
continuous O O
i O O
. O O
v O O
. O O
infusion O O
of O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
initiated O O
, O O
and O O
the O O
patient O O
was O O
managed O O
on O O
the O O
general O O
medical O O
floor O O
. O O

After O O
one O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
he O O
was O O
transferred O O
to O O
the O O
intensive O B_LOCATION/B_PERSON
care O I_LOCATION/I_PERSON
unit O I_LOCATION/I_PERSON
with O O
cardiopulmonary O B_DISEASE
compromise O I_DISEASE
related O O
to O O
superior O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vena O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cava O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SVC O B_DISEASE/B_PROTEIN[GENE]
) O O
syndrome O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
percutaneous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
thrombectomy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CDT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
alteplase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
attempted O O
, O O
but O O
the O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
aborted O O
due O O
to O O
epistaxis O O
. O O

The O O
epistaxis O O
resolved O O
the O O
next O O
day O O
, O O
and O O
the O O
patient O O
was O O
restarted O O
on O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
percutaneous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrombectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
six O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
and O O
resulted O O
in O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
revascularization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
SVC O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
central O B_DISEASE/B_LOCATION
veins O I_DISEASE/I_LOCATION
. O O

Postthrombectomy O O
continuous O O
CDT O O
with O O
alteplase O O
was O O
commenced O O
while O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
withheld O O
, O O
and O O
complete O O
patency O O
of O O
the O O
SVC O O
and O O
central O O
veins O O
was O O
achieved O O
after O O
three O O
days O O
of O O
therapy O O
. O O

Alteplase O O
was O O
discontinued O O
, O O
and O O
the O O
patient O O
was O O
reinitiated O O
on O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
ultimately O O
, O O
he O O
was O O
transitioned O O
to O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
long O O
- O O
term O O
anticoagulation O O
. O O

Although O O
the O O
patient O B_PERSON/B_BIO
recovered O O
, O O
he O O
experienced O O
permanent O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hearing O B_DISEASE
loss O I_DISEASE
, O O
as O O
well O O
as O O
end O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stage O B_DISEASE_ADJECTIVE[DISEASE]
renal O I_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O O
: O O
A O O
63 O O
- O O
year O O
- O O
old O O
man O O
with O O
renal O O
amyloidosis O O
and O O
SVC O O
syndrome O O
secondary O O
to O O
HITT O O
was O O
successfully O O
treated O O
with O O
argatroban B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
CDT O O
with O O
alteplase O O
. O O

Effects O O
of O O
dehydroepiandrosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
schizophrenia O O
models O O
in O O
mice O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
effects O O
of O O
dehydroepiandrosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
on O O
animal O O
models O O
of O O
schizophrenia O O
. O O

METHODS O O
: O O
Seventy O O
Swiss O O
albino O O
female O O
mice O O
( O O
25 O O
- O O
35 O O
g O O
) O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
free O O
( O O
control O O
) O O
, O O
amphetamine B B_MEASURE
, O O
50 O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
intraperitoneally O O
( O O
ip O O
) O O
for O O
5 O O
days O O
. O O

Amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
3 O O
mg O O
/ O O
kg O O
ip O O
) O O
induced O O
hyper O O
locomotion O O
, O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
subcutaneously O O
[ O O
sc O O
] O O
) O O
induced O O
climbing O O
, O O
and O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
sc O O
) O O
induced O O
catalepsy O O
tests O O
were O O
used O O
as O O
animal O O
models O O
of O O
schizophrenia O O
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
conducted O O
at O O
the O O
Animal O B_LOCATION/B_PERSON
Experiment O I_LOCATION/I_PERSON
Laboratories O I_LOCATION/I_PERSON
, O O
Department O B_ORGANIZATION/B_LOCATION
of O O
Pharmacology O B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Medical O B_LOCATION/B_EDU[ORGANIZATION]
School O B_LOCATION/I_EDU[ORGANIZATION]
, O O
Eskisehir O B_LOCATION
Osmangazi O I_LOCATION
University O I_LOCATION
, O O
Eskisehir O B_LOCATION/B_PERSON
, O O
Turkey O B_LOCATION
between O O
March O B_TIME[MEASURE]/B_LOCATION
and O O
May O B_TIME[MEASURE]
2012 O I_TIME[MEASURE]
. O O

Statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
using O O
Kruskal O B_PERSON/B_LOCATION
- O O
Wallis O B_PERSON
test O I_PERSON
for O O
hyper O B_SPORT[ENT]/B_LOCATION
locomotion O B_SPORT[ENT]/I_LOCATION
, O O
and O O
one O B_NUMBER[MEASURE]
- O O
way O B_SEQUENCE[MEASURE]/B_LOCATION
ANOVA O I_SEQUENCE[MEASURE]/I_LOCATION
for O O
climbing O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
catalepsy O B_SPORT[ENT]/B_LOCATION
tests O I_SPORT[ENT]/I_LOCATION
. O O

RESULTS O O
: O O
In O O
the O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
locomotion O O
test O O
, O O
there O O
were O O
significant O O
increases O O
in O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
free O O
group O O
. O O

Both O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
mg O O
/ O O
kg O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
significantly O O
decreased O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
locomotion O O
group O O
. O O

There O O
was O O
a O O
significant O O
difference O O
between O O
groups O O
in O O
the O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
catalepsy O O
test O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

There O O
was O O
no O O
significant O O
difference O O
between O O
groups O O
in O O
terms O O
of O O
total O O
climbing O O
time O O
in O O
the O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
climbing O O
test O O
( O O
p O O
> O O
0 O O
. O O
05 O O
) O O
. O O

CONCLUSION O O
: O O
We O O
observed O O
that O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
locomotor O O
activity O O
and O O
increased O O
catalepsy O O
at O O
both O O
doses O O
, O O
while O O
it O O
had O O
no O O
effect O O
on O O
climbing O O
behavior O O
. O O

We O O
suggest O O
that O O
DHEA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displays O O
typical O O
neuroleptic O O
- O O
like O O
effects O O
, O O
and O O
may O O
be O O
used O O
in O O
the O O
treatment O O
of O O
schizophrenia O O
. O O

Availability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_PERSON/B_SPECIES[BIO]
induced O O
pluripotent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
stem O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O O
derived O O
cardiomyocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
QT O B_DISEASE
prolongation O I_DISEASE
. O O

Field O O
potential O O
duration O O
( O O
FPD O O
) O O
in O O
human O O
- O O
induced O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
cardiomyocytes O O
( O O
hiPS O O
- O O
CMs O O
) O O
, O O
which O O
can O O
express O O
QT O O
interval O O
in O O
an O O
electrocardiogram O O
, O O
is O O
reported O O
to O O
be O O
a O O
useful O O
tool O O
to O O
predict O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O O
) O O
channel O O
and O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
channel O O
blocker O O
effects O O
on O O
QT O O
interval O O
. O O

However O O
, O O
there O O
is O O
no O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
showing O O
that O O
this O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O O
be O O
used O O
to O O
predict O O
multichannel O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
blocker O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
potential O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
QT O B_DISEASE
prolongation O I_DISEASE
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O O
to O O
show O O
that O O
FPD O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
MEA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
Multielectrode O B_MEASURE/B_LOCATION
array O B_MEASURE/I_LOCATION
) O O
of O O
hiPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
CMs O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
detect O O
QT O B_DISEASE
prolongation O I_DISEASE
induced O O
by O O
multichannel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

hiPS O B_LOCATION/B_DISEASE
- O O
CMs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O O
seeded O O
onto O O
MEA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
FPD O B_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
for O O
2min O B_MEASURE/B_LOCATION
every O O
10min O B_TIME[MEASURE]
for O O
30min O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concentration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

IKr O O
and O O
IKs O O
blockers O O
concentration O O
- O O
dependently O O
prolonged O O
corrected O O
FPD O O
( O O
FPDc O O
) O O
, O O
whereas O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
channel O O
blockers O O
concentration O O
- O O
dependently O O
shortened O O
FPDc O O
. O O

Also O O
, O O
the O O
multichannel O O
blockers O O
Amiodarone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Paroxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Terfenadine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Citalopram B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolonged O O
FPDc O O
in O O
a O O
concentration O O
dependent O O
manner O O
. O O

Finally O O
, O O
the O O
IKr O O
blockers O O
, O O
Terfenadine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Citalopram B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
are O O
reported O O
to O O
cause O O
Torsade O O
de O O
Pointes O O
( O O
TdP O O
) O O
in O O
clinical O O
practice O O
, O O
produced O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
. O O

hiPS O B_DISEASE/B_PROTEIN[GENE]
- O O
CMs O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
MEA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FPDc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
predict O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
candidates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
QT O B_DISEASE/B_GENE
interval O I_DISEASE/I_GENE
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
shows O O
that O O
this O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
help O O
detect O O
EAD O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
TdP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dermal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
developmental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
toxicity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
phenylimide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
herbicides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
53482 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
23121 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O O
N O O
- O O
phenylimide O O
herbicides O O
and O O
produced O O
embryolethality O O
, O O
teratogenicity O O
( O O
mainly O O
ventricular O O
septal O O
defects O O
and O O
wavy O O
ribs O O
) O O
, O O
and O O
growth O O
retardation O O
in O O
rats O O
in O O
conventional O O
oral O O
developmental O O
toxicity O O
studies O O
. O O

Our O O
objective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
investigate O O
whether O O
the O O
compounds O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O O
developmental O B_DISEASE/B_LOCATION
toxicity O I_DISEASE/I_LOCATION
via O O
the O O
dermal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
more O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
to O O
occupational O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
exposure O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
hence O O
better O O
addressing O O
human O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
risks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O O
: O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
53482 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
administered O O
dermally O O
to O O
rats O O
at O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
mg O O
/ O O
kg O O
during O O
organogenesis O O
, O O
and O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
at O O
200 O O
, O O
400 O O
, O O
and O O
800 O O
mg O O
/ O O
kg O O
( O O
the O O
maximum O O
applicable O O
dose O O
level O O
) O O
. O O

Fetuses O B_PERSON/B_LOCATION
were O O
obtained O O
by O O
a O O
Cesarean O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
section O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
and O O
examined O O
for O O
external O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O O
and O O
skeletal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
Dermal O O
exposure O O
of O O
rats O O
to O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
53482 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
300 O O
mg O O
/ O O
kg O O
produced O O
patterns O O
of O O
developmental O O
toxicity O O
similar O O
to O O
those O O
resulting O O
from O O
oral O O
exposure O O
. O O

Toxicity O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
embryolethality O B_DISEASE
, O O
teratogenicity O B_DISEASE
, O O
and O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
retardation O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Dermal O O
administration O O
of O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
800 O O
mg O O
/ O O
kg O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
embryonic O O
death O O
and O O
ventricular O O
septal O O
defect O O
, O O
but O O
retarded O O
fetal O O
growth O O
was O O
not O O
observed O O
as O O
it O O
was O O
following O O
oral O O
exposure O O
to O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Based O O
on O O
the O O
results O O
, O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
53482 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
teratogenic O O
when O O
administered O O
dermally O O
to O O
pregnant O O
rats O O
as O O
were O O
the O O
compounds O O
administered O O
orally O O
. O O

Thus O O
, O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
mechanism O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
its O O
human O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relevancy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
become O O
more O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Rates O O
of O O
Renal O O
Toxicity O O
in O O
Cancer O O
Patients O O
Receiving O O
Cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
With O O
and O O
Without O O
Mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

BACKGROUND O O
: O O
Cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
widely O O
used O O
antineoplastic O O
. O O

One O O
of O O
the O O
major O O
complications O O
of O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
is O O
dose O O
- O O
limiting O O
nephrotoxicity O O
. O O

There O O
are O O
many O O
strategies O O
to O O
prevent O O
this O O
toxicity O O
, O O
including O O
the O O
use O O
of O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
a O O
nephroprotectant O O
in O O
combination O O
with O O
hydration O O
. O O

OBJECTIVE O O
: O O
We O O
aimed O O
to O O
evaluate O O
the O O
rates O O
of O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephrotoxicity O O
in O O
cancer O O
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
and O O
without O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O O
: O O
This O O
single O O
- O O
center O O
retrospective O O
analysis O O
was O O
a O O
quasi O O
experiment O O
created O O
by O O
the O O
national O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shortage O O
. O O

Data O O
were O O
collected O O
on O O
adult O O
cancer O O
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
an O O
outpatient O O
from O O
January O O
2011 O O
to O O
September O O
2012 O O
. O O

The O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcome O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
acute O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AKI O B_DISEASE/B_GENE
) O O
. O O

RESULTS O O
: O O
We O O
evaluated O O
143 O O
patients O O
who O O
received O O
single O O
- O O
agent O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
97 O O
. O O
2 O O
% O O
of O O
patients O O
had O O
head O O
and O O
neck O O
cancer O O
as O O
their O O
primary O O
malignancy O O
. O O

Patients O O
who O O
did O O
not O O
receive O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
more O O
likely O O
to O O
develop O O
nephrotoxicity O O
: O O
odds O O
ratio O O
[ O O
OR O O
] O O
= O O
2 O O
. O O
646 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
008 O O
, O O
6 O O
. O O
944 O O
; O O
P O O
= O O
0 O O
. O O
048 O O
) O O
. O O

Patients O B_PERSON
who O O
received O O
the O O
100 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
m O B_OTHER/B_MEASURE
( O O
2 O B_TIME[MEASURE]/B_LOCATION
) O O
dosing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
patients O B_PERSON/B_LOCATION
who O O
had O O
a O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
hypertension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O O
had O O
a O O
higher O B_MEASURE
likelihood O I_MEASURE
of O O
developing O O
nephrotoxicity O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
OR O O
= O O
11 O B_MEASURE
. O O
494 O B_MEASURE
( O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
4 O B_MEASURE
. O O
149 O B_MEASURE
, O O
32 O B_MEASURE
. O O
258 O B_MEASURE
; O O
P O B_MEASURE
< O I_MEASURE
0 O I_MEASURE
. O O
0001 O B_MEASURE
) O O
and O O
OR O O
= O O
3 O B_MEASURE
. O O
219 O B_MEASURE
( O O
95 O B_LOCATION/B_MEASURE
% O I_LOCATION/I_MEASURE
CI O I_LOCATION/I_MEASURE
= O O
1 O B_MEASURE
. O O
228 O B_MEASURE
, O O
8 O B_MEASURE
. O O
439 O B_MEASURE
; O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
017 O B_MEASURE
) O O
, O O
respectively O O
. O O

CONCLUSIONS O O
: O O
When O O
limited O O
quantities O O
of O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
available O O
, O O
it O O
should O O
preferentially O O
be O O
given O O
to O O
patients O O
at O O
particularly O O
high O O
risk O O
of O O
nephrotoxicity O O
. O O

Our O O
analysis O O
suggests O O
that O O
those O O
patients O O
receiving O O
the O O
dosing O O
schedule O O
of O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
every O O
3 O O
weeks O O
and O O
those O O
with O O
hypertension O O
are O O
at O O
the O O
greatest O O
risk O O
of O O
nephrotoxicity O O
and O O
would O O
benefit O O
from O O
the O O
addition O O
of O O
mannitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protects O O
against O O
seizures O O
, O O
learning O O
and O O
memory O O
impairments O O
and O O
oxidative O O
damage O O
induced O O
by O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
kindling O O
in O O
mice O O
. O O

Cognitive O B_DISEASE
impairment O I_DISEASE
, O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
and O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
comorbidity O I_DISEASE_ADJECTIVE[DISEASE]
of O O
epilepsy O B_DISEASE/B_LOCATION
, O O
greatly O O
diminishes O O
the O O
quality O B_MEASURE
of O O
life O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
current O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapeutic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interventions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
epilepsy O B_DISEASE/B_LOCATION
can O O
also O O
cause O O
untoward O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cognitive O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
there O O
is O O
an O O
urgent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
need O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinds O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting O O
both O O
seizures O B_DISEASE
and O O
cognition O B_DISEASE
deficits O I_DISEASE
. O O

Oxidative O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considered O O
to O O
play O O
an O O
important O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
epileptogenesis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cognitive O B_DISEASE/B_ORGANISM_FUNCTION
deficits O I_DISEASE/I_ORGANISM_FUNCTION
, O O
and O O
antioxidants O B_LOCATION/B_PERSON
have O O
a O O
putative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiepileptic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
the O O
most O O
commonly O O
prescribed O O
antidiabetic O O
oral O O
drug O O
, O O
has O O
antioxidant O O
properties O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
ameliorative O O
effects O O
of O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
seizures O O
, O O
cognitive O O
impairment O O
and O O
brain O O
oxidative O O
stress O O
markers O O
observed O O
in O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
kindling O O
animals O O
. O O

Male O O
C57BL O O
/ O O
6 O O
mice O O
were O O
administered O O
with O O
subconvulsive O O
dose O O
of O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
37 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
every O O
other O O
day O O
for O O
14 O O
injections O O
. O O

Metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
injected O O
intraperitoneally O O
in O O
dose O O
of O O
200mg O O
/ O O
kg O O
along O O
with O O
alternate O O
- O O
day O O
PTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
found O O
that O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressed O O
the O O
progression O O
of O O
kindling O O
, O O
ameliorated O O
the O O
cognitive O O
impairment O O
and O O
decreased O O
brain O O
oxidative O O
stress O O
. O O

Thus O O
the O O
present O O
study O O
concluded O O
that O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
be O O
a O O
potential O O
agent O O
for O O
the O O
treatment O O
of O O
epilepsy O O
as O O
well O O
as O O
a O O
protective O O
medicine O O
against O O
cognitive O O
impairment O O
induced O O
by O O
seizures O O
. O O

P53 O O
inhibition O O
exacerbates O O
late O O
- O O
stage O O
anthracycline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity O O
. O O

AIMS O O
: O O
Doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
is O O
an O O
effective O O
anti O O
- O O
cancer O O
therapeutic O O
, O O
but O O
is O O
associated O O
with O O
both O O
acute O O
and O O
late O O
- O O
stage O O
cardiotoxicity O O
. O O

Children O O
are O O
particularly O O
sensitive O O
to O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
heart O O
failure O O
. O O

Here O O
, O O
the O O
impact O O
of O O
p53 O O
inhibition O O
on O O
acute O O
vs O O
. O O
late O O
- O O
stage O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity O O
was O O
examined O O
in O O
a O O
juvenile O O
model O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Two O O
- O O
week O O
- O O
old O O
MHC O O
- O O
CB7 O O
mice O O
( O O
which O O
express O O
dominant O O
- O O
interfering O O
p53 O O
in O O
cardiomyocytes O O
) O O
and O O
their O O
non O O
- O O
transgenic O O
( O O
NON O O
- O O
TXG O O
) O O
littermates O O
received O O
weekly O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections O O
for O O
5 O O
weeks O O
( O O
25 O O
mg O O
/ O O
kg O O
cumulative O O
dose O O
) O O
. O O

One O O
week O O
after O O
the O O
last O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
( O O
acute O O
stage O O
) O O
, O O
MHC O O
- O O
CB7 O O
mice O O
exhibited O O
improved O O
cardiac O O
function O O
and O O
lower O O
levels O O
of O O
cardiomyocyte O O
apoptosis O O
when O O
compared O O
with O O
the O O
NON O O
- O O
TXG O O
mice O O
. O O

Surprisingly O O
, O O
by O O
13 O O
weeks O O
following O O
the O O
last O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
( O O
late O O
stage O O
) O O
, O O
MHC O O
- O O
CB7 O O
exhibited O O
a O O
progressive O O
decrease O O
in O O
cardiac O O
function O O
and O O
higher O O
rates O O
of O O
cardiomyocyte O O
apoptosis O O
when O O
compared O O
with O O
NON O O
- O O
TXG O O
mice O O
. O O

p53 O O
inhibition O O
blocked O O
transient O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
STAT3 O O
activation O O
in O O
MHC O O
- O O
CB7 O O
mice O O
, O O
which O O
was O O
associated O O
with O O
enhanced O O
induction O O
of O O
the O O
DNA O O
repair O O
proteins O O
Ku70 O O
and O O
Ku80 O O
. O O

Mice O O
with O O
cardiomyocyte O O
- O O
restricted O O
deletion O O
of O O
STAT3 O O
exhibited O O
worse O O
cardiac O O
function O O
, O O
higher O O
levels O O
of O O
cardiomyocyte O O
apoptosis O O
, O O
and O O
a O O
greater O O
induction O O
of O O
Ku70 O O
and O O
Ku80 O O
in O O
response O O
to O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
during O O
the O O
acute O O
stage O O
when O O
compared O O
with O O
control O O
animals O O
. O O

CONCLUSION O O
: O O
These O O
data O O
support O O
a O O
model O O
wherein O O
a O O
p53 O O
- O O
dependent O O
cardioprotective O O
pathway O O
, O O
mediated O O
via O O
STAT3 O O
activation O O
, O O
mitigates O O
DOX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
stress O O
during O O
drug O O
delivery O O
. O O

Furthermore O O
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
to O O
how O O
p53 O B_DISEASE
inhibition O I_DISEASE
can O O
result O O
in O O
cardioprotection O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
, O O
paradoxically O O
, O O
enhanced O O
cardiotoxicity O B_DISEASE
long O O
after O O
the O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Metronidazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
encephalopathy O O
: O O
an O O
uncommon O O
scenario O O
. O O

Metronidazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
produce O O
neurological O O
complications O O
although O O
it O O
is O O
not O O
a O O
common O O
scenario O O
. O O

We O O
present O O
a O O
case O O
where O O
a O O
patient O O
developed O O
features O O
of O O
encephalopathy O O
following O O
prolonged O O
metronidazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O O
. O O

Magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
brain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
showed O O
abnormal O B_DISEASE
signal O I_DISEASE
intensity O I_DISEASE
involving O O
both O O
dentate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
splenium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
corpus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
callosum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
diagnosis O O
of O O
metronidazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O O
was O O
made O O
by O O
the O O
MRI O O
findings O O
and O O
supported O O
clinically O O
. O O

Aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
Ca2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
overload O O
causes O O
arrhythmia O O
and O O
triggers O O
apoptosis O O
through O O
p38 O O
MAPK O O
signaling O O
pathway O O
in O O
rats O O
. O O

Aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
major O O
bioactive O O
diterpenoid O O
alkaloid O O
with O O
high O O
content O O
derived O O
from O O
herbal O O
aconitum O O
plants O O
. O O

Emerging O O
evidence O O
indicates O O
that O O
voltage O O
- O O
dependent O O
Na B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
+ O O
) O O
channels O O
have O O
pivotal O O
roles O O
in O O
the O O
cardiotoxicity O O
of O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

However O O
, O O
no O O
reports O O
are O O
available O O
on O O
the O O
role O O
of O O
Ca B B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
+ O O
) O O
in O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O O
. O O

In O O
this O O
study O O
, O O
we O O
explored O O
the O O
importance O O
of O O
pathological O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
signaling O O
in O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
found O O
that O O
Ca B B_LOCATION/B_MEASURE
( O O
2 O O
+ O O
) O O
overload O O
lead O O
to O O
accelerated O O
beating O O
rhythm O O
in O O
adult O O
rat O O
ventricular O O
myocytes O O
and O O
caused O O
arrhythmia O O
in O O
conscious O O
freely O O
moving O O
rats O O
. O O

To O O
investigate O O
effects O O
of O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
myocardial O O
injury O O
, O O
we O O
performed O O
cytotoxicity O O
assay O O
in O O
neonatal O O
rat O O
ventricular O O
myocytes O O
( O O
NRVMs O O
) O O
, O O
as O O
well O O
as O O
measured O O
lactate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O O
level O O
in O O
the O O
culture O O
medium O O
of O O
NRVMs O O
and O O
activities O O
of O O
serum O O
cardiac O O
enzymes O O
in O O
rats O O
. O O

The O O
results O O
showed O O
that O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O O
in O O
myocardial O O
injury O O
and O O
reduced O O
NRVMs O O
viability O O
dose O O
- O O
dependently O O
. O O

To O O
confirm O O
the O O
pro O O
- O O
apoptotic O O
effects O O
, O O
we O O
performed O O
flow O O
cytometric O O
detection O O
, O O
cardiac O O
histology O O
, O O
transmission O O
electron O O
microscopy O O
and O O
terminal O O
deoxynucleotidyl O O
transferase O O
- O O
mediated O O
dUTP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
biotin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nick O O
end O O
labeling O O
assay O O
. O O

The O O
results O O
showed O O
that O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulated O O
apoptosis O O
time O O
- O O
dependently O O
. O O

The O O
expression O O
analysis O O
of O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
demonstrated O O
that O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoted O O
Ca B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O O
+ O O
) O O
overload O O
through O O
the O O
expression O O
regulation O O
of O O
Ca B B_LOCATION/B_PERSON
( O O
2 O O
+ O O
) O O
handling O O
proteins O O
. O O

The O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_DISEASE/B_GENE
- O O
related O O
proteins O B_GENE/B_DISEASE
revealed O O
that O O
pro O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
apoptotic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
upregulated O O
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
apoptotic O B_GENE/B_DISEASE
protein O I_GENE/I_DISEASE
BCL O I_GENE/I_DISEASE
- O O
2 O B_MEASURE/B_PROTEIN[GENE]
expression O I_MEASURE/I_PROTEIN[GENE]
was O O
downregulated O O
. O O

Furthermore O O
, O O
increased O O
phosphorylation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_MEASURE
of O O
MAPK O B_GENE
family O I_GENE
members O I_GENE
, O O
especially O O
the O O
P O B_GENE
- O O
P38 O B_GENE
/ O O
P38 O B_GENE
ratio O I_GENE
was O O
found O O
in O O
cardiac O B_DISEASE
tissues O I_DISEASE
. O O

Hence O O
, O O
our O O
results O O
suggest O O
that O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
aggravates O O
Ca B B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
+ O O
) O O
overload O O
and O O
causes O O
arrhythmia O O
and O O
finally O O
promotes O O
apoptotic O O
development O O
via O O
phosphorylation O O
of O O
P38 O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
. O O

Chronic O O
treatment O O
with O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O O
toll O O
- O O
like O O
receptor O O
4 O O
signaling O O
and O O
attenuates O O
left O O
ventricular O O
dysfunction O O
following O O
myocardial O O
infarction O O
. O O

Acute O O
treatment O O
with O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O O
a O O
protective O O
effect O O
in O O
myocardial O O
infarction O O
by O O
suppression O O
of O O
inflammatory O O
responses O O
due O O
to O O
activation O O
of O O
AMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
activated O O
protein O O
kinase O O
( O O
AMPK O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effect O O
of O O
chronic O O
pre O O
- O O
treatment O O
with O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
cardiac O O
dysfunction O O
and O O
toll O O
- O O
like O O
receptor O O
4 O O
( O O
TLR4 O O
) O O
activities O O
following O O
myocardial O O
infarction O O
and O O
their O O
relation O O
with O O
AMPK O O
were O O
assessed O O
. O O

Male O O
Wistar O O
rats O O
were O O
randomly O O
assigned O O
to O O
one O O
of O O
5 O O
groups O O
( O O
n O O
= O O
6 O O
) O O
: O O
normal O O
control O O
and O O
groups O O
were O O
injected O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O O
chronic O O
pre O O
- O O
treatment O O
with O O
0 O O
, O O
25 O O
, O O
50 O O
, O O
or O O
100mg O O
/ O O
kg O O
of O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O O
daily O O
for O O
14 O O
days O O
. O O

Isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
100mg O O
/ O O
kg O O
) O O
was O O
injected O O
subcutaneously O O
on O O
the O O
13th O O
and O O
14th O O
days O O
to O O
induce O O
acute O O
myocardial O O
infarction O O
. O O

Isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alone O O
decreased O O
left O O
ventricular O O
systolic O O
pressure O O
and O O
myocardial O O
contractility O O
indexed O O
as O O
LVdp O O
/ O O
dtmax O O
and O O
LVdp O O
/ O O
dtmin O O
. O O

The O O
left O O
ventricular O O
dysfunction O O
was O O
significantly O O
lower O O
in O O
the O O
groups O O
treated O O
with O O
25 O O
and O O
50mg O O
/ O O
kg O O
of O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Metfromin O O
markedly O O
lowered O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
elevation O O
in O O
the O O
levels O O
of O O
TLR4 O O
mRNA O O
, O O
myeloid O O
differentiation O O
protein O O
88 O O
( O O
MyD88 O O
) O O
, O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
a O O
) O O
, O O
and O O
interleukin O O
6 O O
( O O
IL O O
- O O
6 O O
) O O
in O O
the O O
heart O O
tissues O O
. O O

Similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
seen O O
in O O
the O O
serum O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
TNF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
a O B_PROTEIN[GENE]
and O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
6 O B_NUMBER[MEASURE]
. O O

However O O
, O O
the O O
lower O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
25 O B_MEASURE
and O O
50mg O B_MEASURE
/ O O
kg O B_MEASURE
were O O
more O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
100mg O B_MEASURE
/ O O
kg O B_MEASURE
. O O

Phosphorylated O O
AMPKa O O
( O O
p O O
- O O
AMPK O O
) O O
in O O
the O O
myocardium O O
was O O
significantly O O
elevated O O
by O O
25mg O O
/ O O
kg O O
of O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
slightly O O
by O O
50mg O O
/ O O
kg O O
, O O
but O O
not O O
by O O
100mg O O
/ O O
kg O O
. O O

Chronic O O
pre O O
- O O
treatment O O
with O O
metformin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
post O O
- O O
myocardial O O
infarction O O
cardiac O O
dysfunction O O
and O O
suppresses O O
inflammatory O O
responses O O
, O O
possibly O O
through O O
inhibition O O
of O O
TLR4 O O
activities O O
. O O

This O O
mechanism O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
considered O O
as O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
protect O O
infarcted O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Unusual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complications O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
antithyroid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O O
four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Two O O
cases O O
of O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
acute O O
hepatitis O O
, O O
one O O
case O O
of O O
fatal O O
methimazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
associated O O
hepatocellular O O
necrosis O O
and O O
one O O
case O O
of O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
lupus O O
- O O
like O O
syndrome O O
are O O
described O O
. O O

The O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
antithyroid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
their O O
occurrence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
reviewed O O
and O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
complications O B_DISEASE
of O O
thyroidectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
radioiodine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
to O O
those O O
of O O
antithyroid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

It O O
is O O
concluded O O
that O O
in O O
most O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
circumstances O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
131I O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
the O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
choice O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
for O O
hyperthyroidism O B_DISEASE/B_PERSON
. O O

Neuroleptic O O
malignant O O
syndrome O O
induced O O
by O O
combination O O
therapy O O
with O O
tetrabenazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
tiapride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
Japanese O O
patient O O
with O O
Huntington O O
' O O
s O O
disease O O
at O O
the O O
terminal O O
stage O O
of O O
recurrent O O
breast O O
cancer O O
. O O

We O O
herein O O
describe O O
the O O
case O O
of O O
an O O
81 O O
- O O
year O O
- O O
old O O
Japanese O O
woman O O
with O O
neuroleptic O O
malignant O O
syndrome O O
that O O
occurred O O
36 O O
days O O
after O O
the O O
initiation O O
of O O
combination O O
therapy O O
with O O
tiapride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
75 O O
mg O O
/ O O
day O O
) O O
and O O
tetrabenazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
12 O O
. O O
5 O O
mg O O
/ O O
day O O
) O O
for O O
Huntington O O
' O O
s O O
disease O O
. O O

The O O
patient O O
had O O
been O O
treated O O
with O O
tiapride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
tetrabenazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
without O O
any O O
adverse O O
effects O O
before O O
the O O
administration O O
of O O
the O O
combination O O
therapy O O
. O O

She O O
also O O
had O O
advanced O O
breast O B_DISEASE
cancer O I_DISEASE
when O O
the O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
initiated O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
the O O
occurrence O O
of O O
neuroleptic O O
malignant O O
syndrome O O
due O O
to O O
combination O O
therapy O O
with O O
tetrabenazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
tiapride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
previously O O
reported O O
. O O

Tetrabenazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
administered O O
very O O
carefully O O
in O O
combination O O
with O O
other O O
neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
particularly O O
in O O
patients O O
with O O
a O O
worsening O O
general O O
condition O O
. O O

A O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terbinafine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O O
induced O O
bradycardia O O
. O O

To O O
report O O
a O O
sinus O O
bradycardia O O
induced O O
by O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
terbinafine B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
drug O O
- O O
drug O O
interaction O O
and O O
its O O
management O O
. O O

A O O
63 O O
year O O
- O O
old O O
Caucasian O O
man O O
on O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O O
mg O O
/ O O
day O O
for O O
stable O O
coronary O O
artery O O
disease O O
was O O
prescribed O O
a O O
90 O O
- O O
day O O
course O O
of O O
oral O O
terbinafine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 O O
mg O O
/ O O
day O O
for O O
onychomycosis O O
. O O

On O O
the O O
49th O O
day O O
of O O
terbinafine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
he O O
was O O
brought O O
to O O
the O O
emergency O O
room O O
for O O
a O O
decrease O O
of O O
his O O
global O O
health O O
status O O
, O O
confusion O O
and O O
falls O O
. O O

The O O
electrocardiogram O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
a O O
37 O B_MEASURE
beats O I_MEASURE
/ O O
min O B_TIME[MEASURE]/B_LOCATION
sinus O I_TIME[MEASURE]/I_LOCATION
bradycardia O I_TIME[MEASURE]/I_LOCATION
. O O

A O O
score O O
of O O
7 O O
on O O
the O O
Naranjo O O
adverse O O
drug O O
reaction O O
probability O O
scale O O
indicates O O
a O O
probable O O
relationship O O
between O O
the O O
patient O O
' O O
s O O
sinus O O
bradycardia O O
and O O
the O O
drug O O
interaction O O
between O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
terbinafine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
heart O O
rate O O
ameliorated O O
first O O
with O O
a O O
decrease O O
in O O
the O O
dose O O
of O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
was O O
subsequently O O
changed O O
to O O
bisoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
heart O O
rate O O
remained O O
normal O O
. O O

By O O
inhibiting O O
the O O
cytochrome O O
P450 O O
2D6 O O
, O O
terbinafine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
had O O
decreased O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O O
s O O
clearance O O
, O O
leading O O
in O O
metoprolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
accumulation O O
which O O
has O O
resulted O O
in O O
clinically O O
significant O O
sinus O O
bradycardia O O
. O O

Optochiasmatic O O
and O O
peripheral O O
neuropathy O O
due O O
to O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overtreatment O O
. O O

Ethambutol B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
known O O
to O O
cause O O
optic O O
neuropathy O O
and O O
, O O
more O O
rarely O O
, O O
axonal O O
polyneuropathy O O
. O O

We O O
characterize O O
the O O
clinical O O
, O O
neurophysiological O O
, O O
and O O
neuroimaging O O
findings O O
in O O
a O O
72 O O
- O O
year O O
- O O
old O O
man O O
who O O
developed O O
visual O O
loss O O
and O O
paresthesias O O
after O O
11 O O
weeks O O
of O O
exposure O O
to O O
a O O
supratherapeutic O O
dose O O
of O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
case O O
demonstrates O O
the O O
selective O O
vulnerability O O
of O O
the O O
anterior O O
visual O O
pathways O O
and O O
peripheral O O
nerves O O
to O O
ethambutol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O O
. O O

Testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ameliorates O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
memory O O
impairment O O
in O O
male O O
rats O O
. O O

AIM O O
: O O
To O O
study O O
the O O
effects O O
of O O
testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
STZ B B_DISEASE/B_LOCATION
) O O
- O O
induced O O
memory O O
impairment O O
in O O
male O O
rats O O
. O O

METHODS O O
: O O
Adult O O
male O O
Wistar O O
rats O O
were O O
intracerebroventricularly O O
( O O
icv O O
) O O
infused O O
with O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
750 O O
ug O O
) O O
on O O
d O O
1 O O
and O O
d O O
3 O O
, O O
and O O
a O O
passive O O
avoidance O O
task O O
was O O
assessed O O
2 O O
weeks O O
after O O
the O O
first O O
injection O O
of O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Castration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
performed O O
in O O
another O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rats O B_BIO/B_PERSON
, O O
and O O
the O O
passive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
assessed O O
4 O B_TIME[MEASURE]
weeks O I_TIME[MEASURE]
after O O
the O O
operation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
1 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
sc O O
) O O
, O O
the O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O O
antagonist O O
flutamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
, O O
the O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O O
antagonist O O
tamoxifen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
or O O
the O O
aromatase O O
inhibitor O O
letrozole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
were O O
administered O O
for O O
6 O O
d O O
after O O
the O O
first O O
injection O O
of O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

RESULTS O O
: O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
and O O
castration O O
markedly O O
decreased O O
both O O
STL1 O O
( O O
the O O
short O O
memory O O
) O O
and O O
STL2 O O
( O O
the O O
long O O
memory O O
) O O
in O O
passive O O
avoidance O O
tests O O
. O O

Testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
replacement O O
almost O O
restored O O
the O O
STL1 O O
and O O
STL2 O O
in O O
castrated O O
rats O O
, O O
and O O
significantly O O
prolonged O O
the O O
STL1 O O
and O O
STL2 O O
in O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
rats O O
. O O

Administration O O
of O O
flutamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
letrozole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
tamoxifen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
impaired O O
the O O
memory O O
in O O
intact O O
rats O O
, O O
and O O
significantly O O
attenuated O O
the O O
testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
replacement O O
in O O
improving O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
castration O O
- O O
induced O O
memory O O
impairment O O
. O O

CONCLUSION O O
: O O
Testosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
ameliorates O O
STZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
castration O O
- O O
induced O O
memory O O
impairment O O
in O O
male O O
Wistar O O
rats O O
. O O

Behavioral O O
and O O
neurochemical O O
studies O O
in O O
mice O O
pretreated O O
with O O
garcinielliptone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
seizures O O
. O O

Garcinielliptone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
FC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O O
GFC B B_MEASURE
) O O
isolated O O
from O O
hexanic O O
fraction O O
seed O O
extract O O
of O O
species O O
Platonia O O
insignis O O
Mart O O
. O O

It O O
is O O
widely O O
used O O
in O O
folk O B_LOCATION/B_PERSON
medicine O I_LOCATION/I_PERSON
to O O
treat O O
skin O B_DISEASE
diseases O I_DISEASE
in O O
both O O
humans O B_PERSON/B_BIO
and O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
seed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
decoction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
has O O
been O O
used O O
to O O
treat O O
diarrheas O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
inflammatory O B_DISEASE
diseases O I_DISEASE
. O O

However O O
, O O
there O O
is O O
no O O
research O O
on O O
GFC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O O
in O O
the O O
central O O
nervous O O
system O O
of O O
rodents O O
. O O

The O O
present O O
study O O
aimed O O
to O O
evaluate O O
the O O
GFC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
at O O
doses O O
of O O
25 O O
, O O
50 O O
or O O
75 O O
mg O O
/ O O
kg O O
on O O
seizure O O
parameters O O
to O O
determine O O
their O O
anticonvulsant O O
activity O O
and O O
its O O
effects O O
on O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
r B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
, O O
glutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
aspartate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glutathione B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
levels O O
as O O
well O O
as O O
on O O
acetylcholinesterase O O
( O O
AChE O O
) O O
activity O O
in O O
mice O O
hippocampus O O
after O O
seizures O O
. O O

GFC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
an O O
increased O O
latency O O
to O O
first O O
seizure O O
, O O
at O O
doses O O
25mg O O
/ O O
kg O O
( O O
20 O O
. O O
12 O O
+ O O
2 O O
. O O
20 O O
min O O
) O O
, O O
50mg O O
/ O O
kg O O
( O O
20 O O
. O O
95 O O
+ O O
2 O O
. O O
21 O O
min O O
) O O
or O O
75 O O
mg O O
/ O O
kg O O
( O O
23 O O
. O O
43 O O
+ O O
1 O O
. O O
99 O O
min O O
) O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

In O O
addition O O
, O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O O
of O O
mice O O
hippocampus O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
showed O O
an O O
increase O O
of O O
46 O O
. O O
90 O O
% O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

In O O
aspartate B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
glutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
detected O O
a O O
decrease O O
of O O
5 O O
. O O
21 O O
% O O
, O O
13 O O
. O O
55 O O
% O O
and O O
21 O O
. O O
80 O O
% O O
, O O
respectively O O
in O O
mice O O
hippocampus O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

Hippocampus O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
treated O O
with O O
GFC75 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
P400 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AChE O B_DISEASE/B_MEASURE
activity O I_DISEASE/I_MEASURE
( O O
63 O B_MEASURE
. O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
when O O
compared O O
with O O
seized O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O O
indicate O O
that O O
GFC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O O
exert O O
anticonvulsant O O
activity O O
and O O
reduce O O
the O O
frequency O O
of O O
installation O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
status O O
epilepticus O O
, O O
as O O
demonstrated O O
by O O
increase O O
in O O
latency O O
to O O
first O O
seizure O O
and O O
decrease O O
in O O
mortality O O
rate O O
of O O
animals O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
GFC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
influence O O
in O O
epileptogenesis O O
and O O
promote O O
anticonvulsant O O
actions O O
in O O
pilocarpine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O O
by O O
modulating O O
the O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contents O O
and O O
of O O
AChE O O
activity O O
in O O
seized O O
mice O O
hippocampus O O
. O O

This O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
produce O O
neuronal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
can O O
be O O
considered O O
as O O
an O O
anticonvulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
operating O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
antibiotic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_DISEASE
kidney O I_DISEASE
injury O I_DISEASE
: O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
non O B_DISEASE
- O O
interventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
observational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

INTRODUCTION O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Acute O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AKI O B_DISEASE/B_LOCATION
) O O
occurs O O
in O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
hospitalized O O
and O O
66 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
Intensive O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Care O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
Unit O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
ICU O B_LOCATION/B_ORGANIZATION
) O O
patients O B_PERSON/B_LOCATION
. O O

It O O
increases O O
mortality O B_DISEASE
, O O
hospital O B_MEASURE/B_PERSON
length O I_MEASURE/I_PERSON
of O O
stay O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
and O O
costs O B_DISEASE
. O O

The O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O O
to O O
investigate O O
, O O
whether O O
there O O
is O O
an O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
adherence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
guidelines O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
( O O
standard O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
operating O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
procedures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
SOP O B_DISEASE/B_GENE
) O O
) O O
for O O
potentially O O
nephrotoxic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
AKI O B_DISEASE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
as O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
non O B_DISEASE
- O O
interventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
observational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Data O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
collection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O O
performed O O
over O O
a O O
total O B_MEASURE/B_LOCATION
of O O
170 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
in O O
three O B_MEASURE/B_LOCATION
ICUs O I_MEASURE/I_LOCATION
at O O
Charite O B_PERSON/B_LOCATION
- O O
Universitaetsmedizin O B_LOCATION/B_PERSON
Berlin O I_LOCATION/I_PERSON
. O O

A O O
total O O
of O O
675 O O
patients O O
were O O
included O O
; O O
163 O O
of O O
these O O
had O O
therapy O O
with O O
vancomycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
tobramycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
were O O
> O O
18 O O
years O O
; O O
and O O
treated O O
in O O
the O O
ICU O O
for O O
> O O
24 O O
hours O O
. O O

Patients O B_PERSON
with O O
an O O
adherence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
SOP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
were O O
classified O O
into O O
the O O
high O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adherence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
HAG O B_LOCATION/B_ORGANIZATION
) O O
and O O
patients O B_PERSON
with O O
an O O
adherence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
< O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
into O O
the O O
low O B_MEASURE/B_LOCATION
adherence O I_MEASURE/I_LOCATION
group O I_MEASURE/I_LOCATION
( O O
LAG O B_LOCATION/B_ORGANIZATION
) O O
. O O

AKI O B_DISEASE
was O O
defined O O
according O O
to O O
RIFLE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Adherence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
SOPs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
evaluated O O
by O O
retrospective O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expert O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audit O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Development O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
AKI O B_DISEASE
was O O
compared O O
between O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
exact O B_NUMBER[MEASURE]/B_PERSON
Chi2 O I_NUMBER[MEASURE]/I_PERSON
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
two O B_NUMBER[MEASURE]/B_LOCATION
- O O
sided O B_LOCATION/B_MEASURE
P O I_LOCATION/I_MEASURE
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
LAG O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O O
of O O
75 O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
( O O
46 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
versus O O
88 O B_MEASURE
HAG O I_MEASURE
patients O I_MEASURE
( O O
54 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

AKI O B_DISEASE/B_GENE
occurred O O
significantly O O
more O O
often O O
in O O
LAG O B_PERSON/B_DISEASE
with O O
36 O B_MEASURE/B_DISEASE
% O I_MEASURE/I_DISEASE
versus O I_MEASURE/I_DISEASE
21 O I_MEASURE/I_DISEASE
% O I_MEASURE/I_DISEASE
in O O
HAG O B_PERSON/B_LOCATION
( O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
035 O B_MEASURE
) O O
. O O

Basic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
comparable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
except O O
an O O
increased O O
rate O B_MEASURE
of O O
soft O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tissue O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
infections O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
LAG O B_PERSON/B_ORGANIZATION
. O O

Multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
revealed O O
an O O
odds O B_MEASURE
ratio O I_MEASURE
of O O
2 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_MEASURE
for O O
LAG O B_PROTEIN[GENE]/B_DISEASE
to O O
develop O O
AKI O B_DISEASE
compared O O
with O O
HAG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
1 O I_MEASURE
. O O
195 O B_MEASURE
to O O
5 O B_MEASURE
. O O
124 O B_MEASURE
, O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
039 O B_MEASURE
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adherence O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
SOPs O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
potentially O O
nephrotoxic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
antibiotics O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O O
associated O O
with O O
a O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
occurrence O I_DISEASE_ADJECTIVE[DISEASE]
of O O
AKI O B_DISEASE
. O O

TRIAL O B_LOCATION
REGISTRATION O I_LOCATION
: O O
Current O B_NUMBER[MEASURE]/B_LOCATION
Controlled O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ISRCTN54598675 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Registered O O
17 O B_PERSON
August O I_PERSON
2007 O I_PERSON
. O O

Rhabdomyolysis O O
in O O
a O O
hepatitis O O
C O O
virus O O
infected O O
patient O O
treated O O
with O O
telaprevir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
46 O O
- O O
year O O
old O O
man O O
with O O
a O O
chronic O O
hepatitis O O
C O O
virus O O
infection O O
received O O
triple O O
therapy O O
with O O
ribavirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
pegylated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
telaprevir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
patient O O
also O O
received O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
after O O
starting O O
the O O
antiviral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patient O B_PERSON
was O O
admitted O O
to O O
the O O
hospital O B_LOCATION/B_ORGANIZATION
because O O
he O O
developed O O
rhabdomyolysis O B_DISEASE
. O O

At O O
admission O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
and O O
all O O
antiviral O O
drugs O O
were O O
discontinued O O
because O O
toxicity O O
due O O
to O O
a O O
drug O O
- O O
drug O O
interaction O O
was O O
suspected O O
. O O

The O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O O
peaked O O
at O O
62 O O
, O O
246 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
treated O O
with O O
intravenous O O
normal O O
saline O O
. O O

The O O
patient O B_PERSON/B_BIO
' O O
s O O
renal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
remained O O
unaffected O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Fourteen O O
days O O
after O O
hospitalization O O
, O O
creatine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
kinase O O
level O O
had O O
returned O O
to O O
230 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
discharged O O
. O O

Telaprevir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
considered O O
the O O
probable O O
causative O O
agent O O
of O O
an O O
interaction O O
with O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
according O O
to O O
the O O
Drug O O
Interaction O O
Probability O O
Scale O O
. O O

The O O
interaction O O
is O O
due O O
to O O
inhibition O O
of O O
CYP3A4 O O
- O O
mediated O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearance O O
. O O

Simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O O
concentration O O
increased O O
30 O O
times O O
in O O
this O O
patient O O
and O O
statin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
induced O O
muscle O O
toxicity O O
is O O
related O O
to O O
the O O
concentration O O
of O O
the O O
statin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
blood O O
. O O

In O O
conclusion O O
, O O
with O O
this O O
case O O
we O O
illustrate O O
that O O
telaprevir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
statins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
susceptible O O
to O O
clinical O O
relevant O O
drug O O
- O O
drug O O
interactions O O
. O O

Combination O O
of O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VTD O O
) O O
as O O
a O O
consolidation O O
therapy O O
after O O
autologous O O
stem O O
cell O O
transplantation O O
for O O
symptomatic O O
multiple O O
myeloma O O
in O O
Japanese O O
patients O O
. O O

Consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
patients O B_PERSON/B_BIO
with O O
multiple O B_DISEASE
myeloma O I_DISEASE
( O O
MM O B_TIME[MEASURE]/B_LOCATION
) O O
has O O
been O O
widely O O
adopted O O
to O O
improve O O
treatment O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
following O O
autologous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stem O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
cell O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

In O O
this O O
study O O
, O O
we O O
retrospectively O O
analyzed O O
the O O
safety O O
and O O
efficacy O O
of O O
combination O O
regimen O O
of O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VTD O O
) O O
as O O
consolidation O O
therapy O O
in O O
24 O O
Japanese O O
patients O O
with O O
newly O O
diagnosed O O
MM O O
. O O

VTD O O
consisted O O
of O O
bortezomib B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
dose O O
of O O
1 O O
. O O
3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
and O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
day O O
on O O
days O O
1 O O
, O O
8 O O
, O O
15 O O
, O O
and O O
22 O O
of O O
a O O
35 O O
- O O
day O O
cycle O O
, O O
with O O
daily O O
oral O O
thalidomide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
dose O O
of O O
100 O O
mg O O
/ O O
day O O
. O O

Grade O B_DISEASE/B_TIME[MEASURE]
3 O B_DISEASE/I_TIME[MEASURE]
- O O
4 O B_DISEASE
neutropenia O I_DISEASE
and O O
thrombocytopenia O B_DISEASE
were O O
documented O O
in O O
four O B_NUMBER[MEASURE]
and O O
three O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
17 O B_MEASURE
and O O
13 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
respectively O O
, O O
but O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
cytopenia O B_DISEASE
was O O
not O O
required O O
in O O
any O O
case O B_PERSON
. O O

Peripheral O B_DISEASE
neuropathy O I_DISEASE
was O O
common O B_DISEASE_ADJECTIVE[DISEASE]
( O O
63 O B_MEASURE
% O I_MEASURE
) O O
, O O
but O O
severe O B_MEASURE/B_LOCATION
grade O I_MEASURE/I_LOCATION
3 O I_MEASURE/I_LOCATION
- O O
4 O B_DISEASE
peripheral O I_DISEASE
neuropathy O I_DISEASE
was O O
not O O
observed O O
. O O

Very O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
partial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O O
better O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
( O O
> O O
VGPR O B_MEASURE
) O O
rates O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
and O O
after O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
54 O B_MEASURE
and O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

Patients O B_PERSON
had O O
a O O
significant O B_MEASURE
probability O I_MEASURE
of O O
improving O O
from O O
< O B_PROTEIN[GENE]/B_DISEASE
VGPR O I_PROTEIN[GENE]/I_DISEASE
before O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O O
> O B_MEASURE
VGPR O I_MEASURE
after O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
p O B_PROTEIN[GENE]/B_MEASURE
= O O
0 O B_MEASURE
. O O
041 O B_MEASURE
) O O
. O O

The O O
VTD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MM O B_DISEASE/B_LOCATION
in O O
Japanese O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
. O O

Conversion O O
to O O
sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ameliorates O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
in O O
the O O
rat O O
: O O
focus O O
on O O
serum O O
, O O
urine O O
, O O
gene O O
, O O
and O O
protein O O
renal O O
expression O O
biomarkers O O
. O O

Protocols O O
of O O
conversion O O
from O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CsA B B_LOCATION/B_ORGANIZATION
) O O
to O O
sirolimus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRL B B_LOCATION/B_ORGANIZATION
) O O
have O O
been O O
widely O O
used O O
in O O
immunotherapy O O
after O O
transplantation O O
to O O
prevent O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
, O O
but O O
the O O
molecular O O
mechanisms O O
underlying O O
these O O
protocols O O
remain O O
nuclear O O
. O O

This O O
study O O
aimed O O
to O O
identify O O
the O O
molecular O O
pathways O O
and O O
putative O O
biomarkers O O
of O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
to O O
- O O
SRL B B_DISEASE
conversion O O
in O O
a O O
rat O O
model O O
. O O

Four O O
animal O O
groups O O
( O O
n O O
= O O
6 O O
) O O
were O O
tested O O
during O O
9 O O
weeks O O
: O O
control O O
, O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SRL B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
conversion O O
( O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O O
weeks O O
followed O O
by O O
SRL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
6 O O
weeks O O
) O O
. O O

Classical O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
emergent O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
gene O B_GENE
and O O
protein O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
markers O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
assessed O O
. O O

Renal O O
lesions O O
were O O
analyzed O O
in O O
hematoxylin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
eosin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
periodic O O
acid O O
- O O
Schiff O O
, O O
and O O
Masson O O
' O O
s O O
trichrome O O
stains O O
. O O

SRL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
rats O O
presented O O
proteinuria O O
and O O
NGAL O O
( O O
serum O O
and O O
urinary O O
) O O
as O O
the O O
best O O
markers O O
of O O
renal O O
impairment O O
. O O

Short O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
presented O O
slight O O
or O O
even O O
absent O O
kidney O O
lesions O O
and O O
TGF O O
- O O
b O O
, O O
NF O O
- O O
kb O O
, O O
mTOR O O
, O O
PCNA O O
, O O
TP53 O O
, O O
KIM O O
- O O
1 O O
, O O
and O O
CTGF O O
as O O
relevant O O
gene O O
and O O
protein O O
changes O O
. O O

Prolonged O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
aggravated O O
renal O O
damage O O
, O O
without O O
clear O O
changes O O
on O O
the O O
traditional O O
markers O O
, O O
but O O
with O O
changes O O
in O O
serums O O
TGF O O
- O O
b O O
and O O
IL O O
- O O
7 O O
, O O
TBARs O O
clearance O O
, O O
and O O
kidney O O
TGF O O
- O O
b O O
and O O
mTOR O O
. O O

Conversion O O
to O O
SRL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevented O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
renal O O
damage O O
evolution O O
( O O
absent O O
/ O O
mild O O
grade O O
lesions O O
) O O
, O O
while O O
NGAL O O
( O O
serum O O
versus O O
urine O O
) O O
seems O O
to O O
be O O
a O O
feasible O O
biomarker O O
of O O
CsA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
replacement O O
to O O
SRL B B_DISEASE
. O O

Kinin O O
B2 O O
receptor O O
deletion O O
and O O
blockage O O
ameliorates O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
renal O O
injury O O
. O O

Cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
has O O
been O O
adopted O O
in O O
some O O
chemotherapies O O
; O O
however O O
, O O
this O O
drug O O
can O O
induce O O
acute O O
kidney O O
injury O O
due O O
its O O
ability O O
to O O
negatively O O
affect O O
renal O O
function O O
, O O
augment O O
serum O O
levels O O
of O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
increase O O
the O O
acute O O
tubular O O
necrosis O O
score O O
and O O
up O O
- O O
regulate O O
cytokines O O
( O O
e O O
. O O
g O O
. O O
, O O
IL O O
- O O
1b O O
and O O
TNF O O
- O O
a O O
) O O
. O O

The O O
kinin O B_GENE/B_DISEASE
B2 O I_GENE/I_DISEASE
receptor O I_GENE/I_DISEASE
has O O
been O O
associated O O
with O O
the O O
inflammation O B_DISEASE
process O I_DISEASE
, O O
as O O
well O O
as O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cytokine O B_DISEASE
expression O I_DISEASE
, O O
and O O
its O O
deletion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
resulted O O
in O O
an O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
diabetic O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
examine O O
the O O
role O O
of O O
the O O
kinin O O
B2 O O
receptor O O
in O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
kidney O O
injury O O
, O O
kinin O O
B2 O O
receptor O O
knockout O O
mice O O
were O O
challenged O O
with O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Additionally O O
, O O
WT O O
mice O O
were O O
treated O O
with O O
a O O
B2 O O
receptor O O
antagonist O O
after O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O O
. O O

B2 O B_GENE
receptor O I_GENE
- O O
deficient O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
less O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
this O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O O
the O O
WT O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
, O O
as O O
shown O O
by O O
reduced O B_DISEASE
weight O I_DISEASE
loss O I_DISEASE
, O O
better O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
preservation O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
kidney O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
down O O
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
inflammatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
less O O
acute O B_DISEASE
tubular O I_DISEASE
necrosis O I_DISEASE
. O O

Moreover O O
, O O
treatment O O
with O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
effectively O O
reduced O O
the O O
levels O O
of O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
blood O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
after O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
the O O
kinin O O
B2 O O
receptor O O
is O O
involved O O
in O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
kidney O O
injury O O
by O O
mediating O O
the O O
necrotic O O
process O O
and O O
the O O
expression O O
of O O
inflammatory O O
cytokines O O
, O O
thus O O
resulting O O
in O O
declined O O
renal O O
function O O
. O O

These O O
results O O
highlight O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
treatment O O
in O O
amelioration O O
of O O
nephrotoxicity O O
induced O O
by O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

Safety O O
and O O
efficacy O O
of O O
fluocinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravitreal O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
in O O
birdshot O O
retinochoroidopathy O O
. O O

PURPOSE O O
: O O
To O O
report O O
the O O
treatment O O
outcomes O O
of O O
the O O
fluocinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravitreal O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
in O O
patients O O
with O O
birdshot O O
retinochoroidopathy O O
whose O O
disease O O
is O O
refractory O O
or O O
intolerant O O
to O O
conventional O O
immunomodulatory O O
therapy O O
. O O

METHODS O B_MEASURE
: O O
A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O O
11 O B_PERSON/B_BIO
birdshot O I_PERSON/I_BIO
retinochoroidopathy O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
( O O
11 O B_MEASURE/B_ENT
eyes O I_MEASURE/I_ENT
) O O
. O O

Eleven O O
patients O O
( O O
11 O O
eyes O O
) O O
underwent O O
surgery O O
for O O
fluocinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
. O O

Treatment O O
outcomes O O
of O O
interest O O
were O O
noted O O
at O O
baseline O O
, O O
before O O
fluocinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant O O
, O O
and O O
then O O
at O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
3 O O
years O O
, O O
and O O
beyond O O
3 O O
years O O
. O O

Disease O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
including O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ocular O B_DISEASE
inflammation O I_DISEASE
, O O
evidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
retinal O B_DISEASE
vasculitis O I_DISEASE
, O O
Swedish O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
interactive O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
threshold O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
algorithm O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
short O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
wavelength O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
automated O O
perimetry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Humphrey O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
visual O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
field O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
electroretinographic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
optical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coherence O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
recorded O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
cataract O B_DISEASE
and O O
raised O O
intraocular O B_DISEASE/B_MEASURE
pressure O I_DISEASE/I_MEASURE
were O O
collected O O
in O O
all O O
eyes O B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Intraocular O B_DISEASE
inflammation O I_DISEASE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
54 O B_MEASURE
. O O
5 O B_MEASURE
, O O
9 O B_MEASURE
. O O
9 O B_MEASURE
, O O
11 O B_MEASURE
. O O
1 O B_MEASURE
, O O
and O O
0 O B_MEASURE
% O I_MEASURE
of O O
patients O B_PERSON
at O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
6 O B_MEASURE/B_LOCATION
months O I_MEASURE/I_LOCATION
, O O
1 O B_TIME[MEASURE]
year O I_TIME[MEASURE]
, O O
2 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
, O O
3 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
, O O
and O O
beyond O O
3 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
after O O
receiving O O
the O O
implant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
respectively O O
. O O

Active O B_DISEASE_ADJECTIVE[DISEASE]
vasculitis O I_DISEASE_ADJECTIVE[DISEASE]
was O O
noted O O
in O O
36 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
patients O I_MEASURE
at O O
baseline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
0 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O O
3 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
up O B_MEASURE/B_LOCATION
. O O

More O B_MEASURE/B_LOCATION
than O O
20 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
47 O B_MEASURE
. O O
61 O B_MEASURE
- O O
67 O B_MEASURE
. O O
2 O B_MEASURE
% O I_MEASURE
) O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
central O B_DISEASE
retinal O I_DISEASE
thickness O I_DISEASE
was O O
noted O O
in O O
all O O
patients O B_PERSON/B_BIO
with O O
cystoid O B_DISEASE/B_LOCATION
macular O I_DISEASE/I_LOCATION
edema O I_DISEASE/I_LOCATION
at O O
6 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
1 O B_TIME[MEASURE]
year O I_TIME[MEASURE]
, O O
2 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
, O O
and O O
3 O B_TIME[MEASURE]/B_LOCATION
years O I_TIME[MEASURE]/I_LOCATION
postimplant O I_TIME[MEASURE]/I_LOCATION
. O O

At O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
54 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
patients O I_MEASURE
were O O
on O O
immunomodulatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
percentage O B_MEASURE/B_PERSON
decreased O O
to O O
45 O B_MEASURE
. O O
45 O B_MEASURE
, O O
44 O B_MEASURE
. O O
4 O B_MEASURE
, O O
and O O
14 O B_MEASURE
. O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
at O O
1 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
, O O
2 O B_SEQUENCE[MEASURE]/B_ENT
years O I_SEQUENCE[MEASURE]/I_ENT
, O O
and O O
3 O B_MEASURE/B_LOCATION
years O I_MEASURE/I_LOCATION
postimplant O I_MEASURE/I_LOCATION
, O O
respectively O O
. O O

Adverse O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
increased O O
intraocular O B_DISEASE
pressure O I_DISEASE
( O O
54 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
and O O
cataract O B_DISEASE
formation O I_DISEASE
( O O
100 O B_MEASURE
% O I_MEASURE
) O O
. O O

CONCLUSION O O
: O O
The O O
data O O
suggest O O
that O O
fluocinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
helps O O
to O O
control O O
inflammation O O
in O O
otherwise O O
treatment O O
- O O
refractory O O
cases O O
of O O
birdshot O O
retinochoroidopathy O O
. O O

It O O
is O O
associated O O
with O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
side O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
of O O
cataract O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ocular O B_DISEASE
hypertension O I_DISEASE
requiring O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Optimal O O
precurarizing O O
dose O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
decrease O O
fasciculation O O
and O O
myalgia O O
following O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
. O O

BACKGROUND O O
: O O
Succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
commonly O O
produces O O
frequent O O
adverse O O
effects O O
, O O
including O O
muscle O O
fasciculation O O
and O O
myalgia O O
. O O

The O O
current O O
study O O
identified O O
the O O
optimal O O
dose O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
prevent O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
fasciculation O O
and O O
myalgia O O
and O O
evaluated O O
the O O
influence O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
the O O
speed O O
of O O
onset O O
produced O O
by O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
double O B_MEASURE/B_PERSON
- O O
blinded O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
conducted O O
in O O
100 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
randomly O O
allocated O O
into O O
five O B_LOCATION/B_ORGANIZATION
groups O I_LOCATION/I_ORGANIZATION
of O O
20 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
each O O
. O O

Patients O O
were O O
randomized O O
to O O
receive O O
0 O O
. O O
02 O O
, O O
0 O O
. O O
03 O O
, O O
0 O O
. O O
04 O O
, O O
0 O O
. O O
05 O O
and O O
0 O O
. O O
06 O O
mg O O
/ O O
kg O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
precurarizing O O
dose O O
. O O

Neuromuscular O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monitoring O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
each O O
precurarizing O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
recorded O O
from O O
the O O
adductor O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pollicis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
using O O
acceleromyography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
train O B_LOCATION/B_NUMBER[MEASURE]
- O O
of O O
- O O
four O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
ulnar O B_BODY_PART_OR_ORGAN_COMPONENT
nerve O I_BODY_PART_OR_ORGAN_COMPONENT
. O O

All O O
patients O O
received O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
at O O
2 O O
minutes O O
after O O
the O O
precurarization O O
, O O
and O O
were O O
assessed O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculations O O
, O O
while O O
myalgia O O
was O O
assessed O O
at O O
24 O O
hours O O
after O O
surgery O O
. O O

RESULTS O O
: O O
The O O
incidence O O
and O O
severity O O
of O O
visible O O
muscle O O
fasciculation O O
was O O
significantly O O
less O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Those O O
of O O
myalgia O O
tend O O
to O O
decrease O O
according O O
to O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
there O O
was O O
no O O
significance O O
( O O
P O O
= O O
0 O O
. O O
072 O O
) O O
. O O

The O O
onset O O
time O O
of O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
longer O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Precurarization O O
with O O
0 O O
. O O
04 O O
mg O O
/ O O
kg O O
rocuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
the O O
optimal O O
dose O O
considering O O
the O O
reduction O O
in O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculation O O
and O O
myalgia O O
with O O
acceptable O O
onset O O
time O O
, O O
and O O
the O O
safe O O
and O O
effective O O
precurarization O O
. O O

Absence O O
of O O
PKC O O
- O O
alpha O O
attenuates O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
nephrogenic O O
diabetes O O
insipidus O O
. O O

Lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
an O O
effective O O
antipsychotic O O
, O O
induces O O
nephrogenic O O
diabetes O O
insipidus O O
( O O
NDI O O
) O O
in O O
40 O O
% O O
of O O
patients O O
. O O

The O O
decreased O O
capacity O O
to O O
concentrate O O
urine O O
is O O
likely O O
due O O
to O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acutely O O
disrupting O O
the O O
cAMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathway O O
and O O
chronically O O
reducing O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporter O O
( O O
UT O O
- O O
A1 O O
) O O
and O O
water O O
channel O O
( O O
AQP2 O O
) O O
expression O O
in O O
the O O
inner O O
medulla O O
. O O

Targeting O O
an O O
alternative O O
signaling O O
pathway O O
, O O
such O O
as O O
PKC O O
- O O
mediated O O
signaling O O
, O O
may O O
be O O
an O O
effective O O
method O O
of O O
treating O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
polyuria O O
. O O

PKC O O
- O O
alpha O O
null O O
mice O O
( O O
PKCa O O
KO O O
) O O
and O O
strain O O
- O O
matched O O
wild O O
type O O
( O O
WT O O
) O O
controls O O
were O O
treated O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
0 O O
, O O
3 O O
or O O
5 O O
days O O
. O O

WT O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
had O O
increased O O
urine O B_MEASURE/B_DISEASE
output O I_MEASURE/I_DISEASE
and O O
lowered O O
urine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O O
3 O B_NUMBER[MEASURE]
and O O
5 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
whereas O O
PKCa O B_BIO/B_GENE
KO O I_BIO/I_GENE
mice O I_BIO/I_GENE
had O O
no O O
change O B_MEASURE
in O O
urine O B_MEASURE
output O I_MEASURE
or O O
concentration O B_MEASURE
. O O

Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
that O O
AQP2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
medullary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
lowered O O
after O O
3 O B_NUMBER[MEASURE]
and O O
5 O B_SEQUENCE[MEASURE]/B_ENT
days O I_SEQUENCE[MEASURE]/I_ENT
in O O
WT O B_PROTEIN[GENE]/B_BIO
mice O I_PROTEIN[GENE]/I_BIO
; O O
however O O
, O O
AQP2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
PKCa O B_PERSON/B_GENE
KO O I_PERSON/I_GENE
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
observed O O
with O O
UT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
A1 O B_MEASURE
expression O I_MEASURE
. O O

Animals O O
were O O
also O O
treated O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
6 O O
weeks O O
. O O

Lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
WT O O
mice O O
had O O
19 O O
- O O
fold O O
increased O O
urine O O
output O O
whereas O O
treated O O
PKCa O O
KO O O
animals O O
had O O
a O O
4 O O
- O O
fold O O
increase O O
in O O
output O O
. O O

AQP2 O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
lowered O O
in O O
6 O O
week O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
WT O O
animals O O
whereas O O
in O O
treated O O
PKCa O O
KO O O
mice O O
, O O
AQP2 O O
was O O
only O O
reduced O O
by O O
2 O O
- O O
fold O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
unaffected O O
. O O

Urinary O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
elevated O O
in O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
fed O O
WT O O
but O O
not O O
in O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
fed O O
PKCa O O
KO O O
mice O O
. O O

Our O O
data O O
show O O
that O O
ablation O O
of O O
PKCa O O
preserves O O
AQP2 O O
and O O
UT O O
- O O
A1 O O
protein O O
expression O O
and O O
localization O O
in O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
NDI O O
, O O
and O O
prevents O O
the O O
development O O
of O O
the O O
severe O O
polyuria O O
associated O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Is O O
Dysguesia O O
Going O O
to O O
be O O
a O O
Rare O O
or O O
a O O
Common O O
Side O O
- O O
effect O O
of O O
Amlodipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

A O O
very O O
rare O O
side O O
- O O
effect O O
of O O
amlodipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dysguesia O O
. O O

A O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
only O O
one O B_NUMBER[MEASURE]
case O I_NUMBER[MEASURE]
. O O

We O O
report O O
a O O
case O O
about O O
a O O
female O O
with O O
essential O O
hypertension O O
on O O
drug O O
treatment O O
with O O
amlodipine B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
loss O O
of O O
taste O O
sensation O O
. O O

Condition O B_PERSON
moderately O O
improved O O
on O O
stoppage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
25 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
conclude O O
that O O
amlodipine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
cause O O
dysguesia O O
. O O

Here O O
, O O
we O O
describe O O
the O O
clinical O O
presentation O O
and O O
review O O
the O O
relevant O O
literature O O
on O O
amlodipine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dysguesia O O
. O O

Rhabdomyolysis O O
in O O
association O O
with O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dosage O O
increment O O
in O O
clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
the O O
most O O
documented O O
cytochrome O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
inhibitor O O
to O O
cause O O
an O O
adverse O O
interaction O O
with O O
simvastatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
particular O O
case O O
is O O
of O O
interest O O
as O O
rhabdomyolysis O O
only O O
occurred O O
after O O
an O O
increase O O
in O O
the O O
dose O O
of O O
clarithromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
patient O B_PERSON/B_ORGANIZATION
developed O O
raised O O
cardiac O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biomarkers O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
any O O
obvious O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
issues O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
a O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
has O O
been O O
linked O O
to O O
rhabdomyolysis O B_DISEASE
previously O O
. O O

To O O
date O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
there O O
has O O
been O O
no O O
reported O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
rhabdomyolysis O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
structure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cardiac O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Clinicians O B_PERSON
need O O
to O O
be O O
aware O B_PERSON
of O O
prescribing O O
concomitant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
increase O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
myopathy O B_DISEASE/B_GENE
or O O
inhibit O O
the O O
CYP3A4 O B_GENE/B_DISEASE
enzyme O B_GENE/I_DISEASE
. O O

Our O O
case O O
suggests O O
that O O
troponin O O
elevation O O
could O O
be O O
associated O O
with O O
statin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
rhabdomyolysis O O
, O O
which O O
may O O
warrant O O
further O O
studies O O
. O O

Characterization O O
of O O
a O O
novel O O
BCHE O O
" O O
silent O O
" O O
allele O O
: O O
point O O
mutation O O
( O O
p O O
. O O
Val204Asp O O
) O O
causes O O
loss O O
of O O
activity O O
and O O
prolonged O O
apnea O O
with O O
suxamethonium B B_DISEASE
. O O

Butyrylcholinesterase O O
deficiency O O
is O O
characterized O O
by O O
prolonged O O
apnea O O
after O O
the O O
use O O
of O O
muscle O O
relaxants O O
( O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
mivacurium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
patients O O
who O O
have O O
mutations O O
in O O
the O O
BCHE O O
gene O O
. O O

Here O O
, O O
we O O
report O O
a O O
case O O
of O O
prolonged O O
neuromuscular O O
block O O
after O O
administration O O
of O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leading O O
to O O
the O O
discovery O O
of O O
a O O
novel O O
BCHE O O
variant O O
( O O
c O O
. O O
695T O O
> O O
A O O
, O O
p O O
. O O
Val204Asp O O
) O O
. O O

Inhibition O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
kinetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
molecular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
undertaken O O
to O O
understand O O
how O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
disrupts O O
the O O
catalytic O B_LOCATION/B_ENZYME[GENE]
triad O B_LOCATION/I_ENZYME[GENE]
and O O
determines O O
a O O
" O O
silent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
" O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Low O O
activity O O
of O O
patient O O
plasma O O
butyrylcholinesterase O O
with O O
butyrylthiocholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
BTC B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
benzoylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
values O O
of O O
dibucaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
fluoride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O O
fit O O
with O O
heterozygous O O
atypical O O
silent O O
genotype O O
. O O

Electrophoretic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
BChE O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
proband O B_PERSON
and O O
his O O
mother O B_PERSON
showed O O
that O O
patient O B_PERSON/B_BIO
has O O
a O O
reduced O O
amount O B_MEASURE/B_LOCATION
of O O
tetrameric O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
that O O
minor O B_PERSON/B_NUMBER[MEASURE]
fast O O
- O O
moving O O
BChE O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
monomer O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dimer O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
monomer O B_GENE
- O O
albumin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
missing O O
. O O

Kinetic O O
analysis O O
showed O O
that O O
the O O
p O O
. O O
Val204Asp O O
/ O O
p O O
. O O
Asp70Gly O O
- O O
p O O
. O O
Ala539Thr O O
BChE O O
displays O O
a O O
pure O O
Michaelian O O
behavior O O
with O O
BTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O O
the O O
substrate O O
. O O

Both O O
catalytic O O
parameters O O
Km O O
= O O
265 O O
uM O O
for O O
BTC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
two O O
times O O
higher O O
than O O
that O O
of O O
the O O
atypical O O
enzyme O O
, O O
and O O
a O O
low O O
Vmax O O
are O O
consistent O O
with O O
the O O
absence O O
of O O
activity O O
against O O
suxamethonium B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Molecular O O
dynamic O O
( O O
MD O O
) O O
simulations O O
showed O O
that O O
the O O
overall O O
effect O O
of O O
the O O
mutation O O
p O O
. O O
Val204Asp O O
is O O
disruption O O
of O O
hydrogen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonding O O
between O O
Gln223 O O
and O O
Glu441 O O
, O O
leading O O
Ser198 O O
and O O
His438 O O
to O O
move O O
away O O
from O O
each O O
other O O
with O O
subsequent O O
disruption O O
of O O
the O O
catalytic O O
triad O O
functionality O O
regardless O O
of O O
the O O
type O O
of O O
substrate O O
. O O

MD O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
showed O O
that O O
the O O
enzyme O B_MEASURE
volume O I_MEASURE
is O O
increased O O
, O O
suggesting O O
a O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
denaturation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
state O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
fits O O
with O O
the O O
reduced O O
concentration O B_MEASURE
of O O
p O B_MEASURE/B_PROTEIN[GENE]
. O O
Ala204Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
p O B_PROTEIN[GENE]/B_LOCATION
. O O
Asp70Gly O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
p O B_PROTEIN[GENE]/B_LOCATION
. O O
Ala539Thr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tetrameric O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
plasma O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
non O O
- O O
detectable O B_DISEASE_ADJECTIVE[DISEASE]
fast O I_DISEASE_ADJECTIVE[DISEASE]
moving O I_DISEASE_ADJECTIVE[DISEASE]
- O O
bands O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
electrophoresis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Delayed O O
anemia O O
after O O
treatment O O
with O O
injectable O O
artesunate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
: O O
a O O
manageable O O
issue O O
. O O

Cases O O
of O O
delayed O O
hemolytic O O
anemia O O
have O O
been O O
described O O
after O O
treatment O O
with O O
injectable O O
artesunate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
current O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
- O O
recommended O O
first O O
- O O
line O O
drug O O
for O O
the O O
treatment O O
of O O
severe O O
malaria O O
. O O

A O O
total O O
of O O
350 O O
patients O O
( O O
215 O O
[ O O
61 O O
. O O
4 O O
% O O
] O O
< O O
5 O O
years O O
of O O
age O O
and O O
135 O O
[ O O
38 O O
. O O
6 O O
% O O
] O O
> O O
5 O O
years O O
of O O
age O O
) O O
were O O
followed O O
- O O
up O O
after O O
treatment O O
with O O
injectable O O
artesunate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
severe O O
malaria O O
in O O
hospitals O O
and O O
health O O
centers O O
of O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
. O O

Complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
hemoglobin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Hb O B_PROTEIN[GENE]
) O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
201 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

A O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
Hb O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O O
2 O B_NUMBER[MEASURE]
and O O
5 O B_MEASURE
g O I_MEASURE
/ O O
dL O B_TIME[MEASURE]/B_PROTEIN[GENE]
was O O
detected O O
in O O
23 O B_NUMBER[MEASURE]
( O O
11 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
patients O B_PERSON/B_BIO
during O O
the O O
follow O O
- O O
up O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
five O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
, O O
Hb O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
decreased O O
below O O
5 O B_MEASURE/B_PROTEIN[GENE]
g O I_MEASURE/I_PROTEIN[GENE]
/ O O
dL O B_TIME[MEASURE]/B_PROTEIN[GENE]
during O O
at O O
least O O
one O B_NUMBER[MEASURE]/B_PERSON
follow O O
- O O
up O O
visit O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
delayed O B_DISEASE
anemia O I_DISEASE
were O O
clinically O O
manageable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
resolved O O
within O O
one O B_TIME[MEASURE]
month O I_TIME[MEASURE]
. O O

Regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
and O O
apoptotic O O
pathways O O
by O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
myocardial O O
injury O O
in O O
rats O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
cardioprotective O O
effects O O
of O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
acute O O
myocardial O O
ischemia O O
induced O O
experimentally O O
in O O
rats O O
focusing O O
on O O
regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
( O O
STAT3 O O
) O O
and O O
apoptotic O O
pathways O O
as O O
the O O
potential O O
mechanism O O
underlying O O
the O O
drug O O
effect O O
. O O

Male O O
Sprague O O
Dawley O O
rats O O
were O O
treated O O
with O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
100 O O
, O O
200 O O
, O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
orally O O
for O O
40 O O
days O O
. O O

Acute O O
myocardial O O
ischemic O O
injury O O
was O O
induced O O
in O O
rats O O
by O O
subcutaneous O O
injection O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
85 O O
mg O O
/ O O
kg O O
) O O
, O O
for O O
two O O
consecutive O O
days O O
. O O

Serum O B_TIME[MEASURE]/B_LOCATION
cardiac O I_TIME[MEASURE]/I_LOCATION
marker O I_TIME[MEASURE]/I_LOCATION
enzyme O I_TIME[MEASURE]/I_LOCATION
, O O
histopathological O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
protein O B_GENE
levels O I_GENE
were O O
analyzed O O
. O O

Oral O O
administration O O
of O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
significantly O O
reduced O O
the O O
level O O
of O O
cardiac O O
marker O O
enzyme O O
in O O
the O O
serum O O
and O O
prevented O O
left O O
ventricular O O
remodeling O O
. O O

Western O O
blot O O
analysis O O
showed O O
that O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
phosphorylation O O
of O O
STAT3 O O
was O O
maintained O O
or O O
further O O
enhanced O O
by O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
in O O
myocardium O O
. O O

Furthermore O O
, O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
treatment O O
increased O O
the O O
ventricular O O
expression O O
of O O
Bcl O O
- O O
2 O O
and O O
reduced O O
the O O
level O O
of O O
Bax O O
, O O
therefore O O
causing O O
a O O
significant O O
increase O O
in O O
the O O
ratio O O
of O O
Bcl O O
- O O
2 O O
/ O O
Bax O O
. O O

The O O
protective O O
role O O
of O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
myocardial O O
damage O O
was O O
further O O
confirmed O O
by O O
histopathological O O
examination O O
. O O

In O O
summary O O
, O O
our O O
results O O
showed O O
that O O
betaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O O
attenuated O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
acute O O
myocardial O O
ischemia O O
via O O
the O O
regulation O O
of O O
STAT3 O O
and O O
apoptotic O O
pathways O O
. O O

Quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
neutropenia O O
in O O
a O O
bipolar O O
patient O O
with O O
hepatocellular O O
carcinoma O O
. O O

OBJECTIVE O O
: O O
Quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
dibenzothiazepine O O
derivative O O
, O O
similar O O
to O O
clozapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
has O O
the O O
highest O O
risk O O
of O O
causing O O
blood O O
dyscrasias O O
, O O
especially O O
neutropenia O O
. O O

There O O
are O O
some O O
case O O
reports O O
about O O
this O O
side O O
effect O O
of O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
possible O O
risk O O
factors O O
are O O
seldom O O
discussed O O
and O O
identified O O
. O O

A O O
case O O
of O O
a O O
patient O O
with O O
hepatocellular O O
carcinoma O O
that O O
developed O O
neutropenia O O
after O O
treatment O O
with O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
described O O
here O O
. O O

CASE O B_MEASURE
REPORT O I_MEASURE
: O O
A O O
62 O B_MEASURE
- O O
year O B_TIME[MEASURE]
- O O
old O B_PERSON
Taiwanese O I_PERSON
widow O I_PERSON
with O O
bipolar O B_DISEASE
disorder O I_DISEASE
was O O
diagnosed O O
with O O
hepatocellular O B_DISEASE
carcinoma O I_DISEASE
at O O
age O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
60 O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
developed O O
leucopenia O O
after O O
being O O
treated O O
with O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
, O O
her O O
white O O
blood O O
cell O O
count O O
returned O O
to O O
normal O O
. O O

CONCLUSIONS O O
: O O
Although O O
neutropenia O O
is O O
not O O
a O O
common O O
side O O
effect O O
of O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
physicians O O
should O O
be O O
cautious O O
about O O
its O O
presentation O O
and O O
associated O O
risk O O
factors O O
. O O

Hepatic O O
dysfunction O O
may O O
be O O
one O O
of O O
the O O
possible O O
risk O O
factors O O
, O O
and O O
concomitant O O
fever O O
may O O
be O O
a O O
diagnostic O O
marker O O
for O O
adverse O O
reaction O O
to O O
quetiapine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Lateral O O
antebrachial O O
cutaneous O O
neuropathy O O
after O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O O
at O O
lateral O O
epicondyle O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
This O O
report O O
aimed O O
to O O
present O O
a O O
case O O
of O O
lateral O O
antebrachial O O
cutaneous O O
neuropathy O O
( O O
LACNP O O
) O O
that O O
occurred O O
after O O
a O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O O
in O O
the O O
lateral O O
epicondyle O O
to O O
treat O O
lateral O O
epicondylitis O O
in O O
a O O
40 O O
- O O
year O O
- O O
old O O
woman O O
. O O

MATERIAL O O
AND O O
METHOD O O
: O O
A O O
40 O O
- O O
year O O
- O O
old O O
woman O O
presented O O
with O O
decreased O O
sensation O O
and O O
paresthesia O O
over O O
her O O
right O O
lateral O O
forearm O O
; O O
the O O
paresthesia O O
had O O
occurred O O
after O O
a O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
in O O
the O O
right O O
lateral O O
epicondyle O O
3 O O
months O O
before O O
. O O

Her O O
sensation O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
light O B_DISEASE/B_MEASURE
touch O I_DISEASE/I_MEASURE
and O O
pain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
diminished O O
over O O
the O O
lateral O B_MEASURE/B_LOCATION
side O I_MEASURE/I_LOCATION
of O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT
forearm O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
wrist O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
area O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
sensory O B_MEASURE
action O I_MEASURE
potential O I_MEASURE
amplitude O I_MEASURE
of O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
lateral O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
antebrachial O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cutaneous O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O O
LACN O B_DISEASE/B_PROTEIN[GENE]
) O O
( O O
6 O B_MEASURE
. O O
2 O B_MEASURE
uV O I_MEASURE
) O O
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
13 O B_MEASURE
. O O
1 O B_MEASURE/B_PERSON
uV O I_MEASURE/I_PERSON
) O O
. O O

The O O
difference O B_MEASURE
of O O
amplitude O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
both O O
sides O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
because O O
there O O
was O O
more O B_MEASURE
than O O
a O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
reduction O I_MEASURE/I_PERSON
. O O

She O O
was O O
diagnosed O O
with O O
right O B_DISEASE/B_LOCATION
LACNP O I_DISEASE/I_LOCATION
( O O
mainly O O
axonal O B_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
) O O
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
clinical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manifestation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
electrodiagnostic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Her O O
symptoms O B_DISEASE
improved O O
through O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O O
persisted O O
to O O
some O O
degree O B_TIME[MEASURE]/B_LOCATION
. O O

CONCLUSION O O
: O O
This O O
report O O
describes O O
the O O
case O O
of O O
a O O
woman O O
with O O
LACNP O O
that O O
developed O O
after O O
a O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O O
for O O
the O O
treatment O O
of O O
lateral O O
epicondylitis O O
. O O

An O O
electrodiagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
a O O
nerve O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
LACN O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
helpful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
diagnose O O
right O B_DISEASE
LACNP O I_DISEASE
and O O
to O O
find O O
the O O
passage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
the O O
LACN O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epicondyle O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Curcumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevents O O
maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephrotoxicity O O
: O O
relation O O
to O O
hemodynamic O O
alterations O O
, O O
oxidative O O
stress O O
, O O
mitochondrial O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
and O O
activity O O
of O O
respiratory O O
complex O O
I O O
. O O

The O O
potential O O
protective O O
effect O O
of O O
the O O
dietary O O
antioxidant O O
curcumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
120 O O
mg O O
/ O O
Kg O O
/ O O
day O O
for O O
6 O O
days O O
) O O
against O O
the O O
renal O O
injury O O
induced O O
by O O
maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
evaluated O O
. O O

Tubular O O
proteinuria O O
and O O
oxidative O O
stress O O
were O O
induced O O
by O O
a O O
single O O
injection O O
of O O
maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
400 O O
mg O O
/ O O
kg O O
) O O
in O O
rats O O
. O O

Maleate B B_DISEASE
- O O
induced O O
renal O O
injury O O
included O O
increase O O
in O O
renal O O
vascular O O
resistance O O
and O O
in O O
the O O
urinary O O
excretion O O
of O O
total O O
protein O O
, O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
neutrophil O O
gelatinase O O
- O O
associated O O
lipocalin O O
( O O
NGAL O O
) O O
and O O
N O O
- O O
acetyl O O
b O O
- O O
D O O
- O O
glucosaminidase O O
( O O
NAG O O
) O O
, O O
upregulation O O
of O O
kidney O O
injury O O
molecule O O
( O O
KIM O O
) O O
- O O
1 O O
, O O
decrease O O
in O O
renal O O
blood O O
flow O O
and O O
claudin O O
- O O
2 O O
expression O O
besides O O
of O O
necrosis O O
and O O
apoptosis O O
of O O
tubular O O
cells O O
on O O
24 O O
h O O
. O O

Oxidative O B_DISEASE
stress O I_DISEASE
was O O
determined O O
by O O
measuring O O
the O O
oxidation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lipids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
diminution O B_DISEASE_ADJECTIVE[DISEASE]
in O O
renal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Nrf2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
also O O
conducted O O
in O O
renal O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
epithelial O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
LLC O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O O
PK1 O B_NUMBER[MEASURE]/B_BIO
cells O I_NUMBER[MEASURE]/I_BIO
and O O
in O O
mitochondria O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O O
from O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
all O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
cell O O
damage O O
and O O
reactive O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
species O O
( O O
ROS O O
) O O
production O O
in O O
LLC O O
- O O
PK1 O O
cells O O
in O O
culture O O
. O O

In O O
addition O O
, O O
maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
reduced O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
in O O
ADP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
mitochondria O O
and O O
diminished O O
respiratory O O
control O O
index O O
when O O
using O O
malate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
glutamate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
substrate O O
. O O

The O O
activities O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
both O O
complex O B_LOCATION/B_PERSON
I O O
and O O
aconitase O B_PROTEIN[GENE]/B_TIME[MEASURE]
were O O
also O O
diminished O O
. O O

All O O
the O O
above O O
- O O
described O O
alterations O O
were O O
prevented O O
by O O
curcumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
concluded O O
that O O
curcumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
able O O
to O O
attenuate O O
in O O
vivo O O
maleate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephropathy O O
and O O
in O O
vitro O O
cell O O
damage O O
. O O

The O O
in O O
vivo O O
protection O O
was O O
associated O O
to O O
the O O
prevention O O
of O O
oxidative O O
stress O O
and O O
preservation O O
of O O
mitochondrial O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
and O O
activity O O
of O O
respiratory O O
complex O O
I O O
, O O
and O O
the O O
in O O
vitro O O
protection O O
was O O
associated O O
to O O
the O O
prevention O O
of O O
ROS O O
production O O
. O O

Anticonvulsant O O
actions O O
of O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O O
of O O
status O O
epilepticus O O
in O O
rats O O
. O O

MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
noncompetitive O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
receptor O O
antagonist O O
, O O
was O O
tested O O
for O O
anticonvulsant O O
effects O O
in O O
rats O O
using O O
two O O
seizure O O
models O O
, O O
coadministration O O
of O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
administration O O
of O O
a O O
high O O
dose O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
major O I_NUMBER[MEASURE]/I_PERSON
results O I_NUMBER[MEASURE]/I_PERSON
are O O
reported O O
. O O

First O O
, O O
pretreatment O O
with O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
an O O
effective O O
and O O
dose O O
- O O
dependent O O
anticonvulsant O O
action O O
with O O
the O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O O
but O O
not O O
with O O
rats O O
treated O O
with O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O O
, O O
suggesting O O
that O O
different O O
biochemical O O
mechanisms O O
control O O
seizures O O
in O O
these O O
two O O
models O O
. O O

Second O O
, O O
the O O
anticonvulsant O O
effect O O
of O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O O
only O O
occurred O O
after O O
initial O O
periods O O
of O O
seizure O O
activity O O
. O O

This O O
observation O O
is O O
suggested O O
to O O
be O O
an O O
in O O
vivo O O
demonstration O O
of O O
the O O
conclusion O O
derived O O
from O O
in O O
vitro O O
experiments O O
that O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
requires O O
agonist O O
- O O
induced O O
opening O O
of O O
the O O
channel O O
sites O O
of O O
the O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O O
. O O

Third O O
, O O
although O O
it O O
is O O
relatively O O
easy O O
to O O
block O O
seizures O O
induced O O
by O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pilocarpine B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
administration O O
of O O
anticonvulsants O O
prior O O
to O O
pilocarpine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
it O O
is O O
more O O
difficult O O
to O O
terminate O O
ongoing O O
status O O
epilepticus O O
and O O
block O O
the O O
lethality O O
of O O
the O O
seizures O O
. O O

Administration O O
of O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
30 O O
or O O
60 O O
min O O
after O O
pilocarpine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
i O O
. O O
e O O
. O O
, O O
during O O
status O O
epilepticus O O
, O O
gradually O O
reduced O O
electrical O O
and O O
behavioral O O
seizure O O
activity O O
and O O
greatly O O
enhanced O O
the O O
survival O O
rate O O
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
plays O O
an O O
important O O
role O O
in O O
status O O
epilepticus O O
and O O
brain O O
damage O O
in O O
the O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O O
. O O

This O O
was O O
further O O
supported O O
by O O
results O O
showing O O
that O O
nonconvulsive O O
doses O O
of O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
synergistic O O
, O O
resulting O O
in O O
status O O
epilepticus O O
and O O
subsequent O O
mortality O O
. O O

Continuous O O
infusion O O
tobramycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combined O O
with O O
carbenicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
infections O O
in O O
cancer O O
patients O O
. O O

The O O
cure O B_MEASURE
rate O I_MEASURE
of O O
infections O B_DISEASE
in O O
cancer O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
is O O
adversely O O
affected O O
by O O
neutropenia O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
1 O B_MEASURE
, O O
000 O B_MEASURE
/ O O
mm3 O B_MEASURE
) O O
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
patients O B_PERSON/B_BIO
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neutropenia O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_MEASURE
/ O O
mm3 O B_MEASURE
) O O
have O O
shown O O
a O O
poor O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
antibiotics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
overcome O O
the O O
adverse O O
effects O O
of O O
neutropenia O O
, O O
tobramycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
given O O
by O O
continuous O O
infusion O O
and O O
combined O O
with O O
intermittent O O
carbenicillin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Tobramycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
given O O
to O O
a O O
total O O
daily O O
dose O O
of O O
300 O O
mg O O
/ O O
m2 O O
and O O
carbenicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
given O O
at O O
a O O
dose O O
of O O
5 O O
gm O O
every O O
four O O
hours O O
. O O

There O O
were O O
125 O B_DISEASE
infectious O I_DISEASE
episodes O I_DISEASE
in O O
116 O B_PERSON/B_BIO
cancer O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
receiving O O
myelosuppressive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
overall O B_MEASURE/B_PERSON
cure O I_MEASURE/I_PERSON
rate O I_MEASURE/I_PERSON
was O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
. O O

Pneumonia O B_DISEASE
was O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
infection O I_DISEASE_ADJECTIVE[DISEASE]
and O O
61 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
59 O B_PERSON/B_TIME[MEASURE]
episodes O I_PERSON/I_TIME[MEASURE]
were O O
cured O O
. O O

Gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacilli O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
causative O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
organisms O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
and O O
69 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
these O O
infections O B_DISEASE/B_BIO
were O O
cured O O
. O O

The O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
pathogen O I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
was O O
Klebsiella O B_BACTERIUM[BIO]/B_DISEASE
pneumoniae O I_BACTERIUM[BIO]/I_DISEASE
and O O
this O O
, O O
together O O
with O O
Escherichia O B_BACTERIUM[BIO]
coli O I_BACTERIUM[BIO]
and O O
Pseudomonas O B_BACTERIUM[BIO]
aeruginosa O I_BACTERIUM[BIO]
, O O
accounted O O
for O O
74 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
all O O
gram O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacillary O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
infections O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
not O O
influenced O O
by O O
the O O
initial O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neutrophil O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
count O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
a O O
62 O B_MEASURE
% O I_MEASURE
cure O I_MEASURE
rate O I_MEASURE
for O O
39 O B_DISEASE/B_PERSON
episodes O I_DISEASE/I_PERSON
associated O O
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neutropenia O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
failure O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
neutrophil O B_MEASURE
count O I_MEASURE
to O O
increase O O
during O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adversely O O
affected O O
response O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Azotemia O B_DISEASE
was O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
side O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
recognized O O
, O O
and O O
it O O
occurred O O
in O O
11 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
episodes O B_ENT/B_PERSON
. O O

Major O O
azotemia O O
( O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
greater O O
than O O
2 O O
. O O
5 O O
mg O O
/ O O
dl O O
or O O
BUN O O
greater O O
than O O
50 O O
mg O O
/ O O
dl O O
) O O
occurred O O
in O O
only O O
2 O O
% O O
. O O

Azotemia O O
was O O
not O O
related O O
to O O
duration O O
of O O
therapy O O
or O O
serum O O
tobramycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O O
. O O

This O O
antibiotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regimen O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O O
both O O
therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
acceptable O B_DISEASE_ADJECTIVE[DISEASE]
renal O I_DISEASE_ADJECTIVE[DISEASE]
toxicity O I_DISEASE_ADJECTIVE[DISEASE]
for O O
these O O
patients O B_PERSON/B_BIO
. O O

Incidence O O
of O O
solid O O
tumours O O
among O O
pesticide O O
applicators O O
exposed O O
to O O
the O O
organophosphate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insecticide O O
diazinon B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
an O O
updated O O
analysis O O
. O O

OBJECTIVE O O
: O O
Diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
a O O
common O O
organophosphate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insecticide O O
with O O
genotoxic O O
properties O O
, O O
was O O
previously O O
associated O O
with O O
lung O O
cancer O O
in O O
the O O
Agricultural O O
Health O O
Study O O
( O O
AHS O O
) O O
cohort O O
, O O
but O O
few O O
other O O
epidemiological O O
studies O O
have O O
examined O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
associated O O
cancer O O
risk O O
. O O

We O O
used O O
updated O O
diazinon B B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exposure O O
and O O
cancer O O
incidence O O
information O O
to O O
evaluate O O
solid O O
tumour O O
risk O O
in O O
the O O
AHS O O
. O O

METHODS O O
: O O
Male O O
pesticide O O
applicators O O
in O O
Iowa O O
and O O
North O O
Carolina O O
reported O O
lifetime O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
use O O
at O O
enrolment O O
( O O
1993 O O
- O O
1997 O O
) O O
and O O
follow O O
- O O
up O O
( O O
1998 O O
- O O
2005 O O
) O O
; O O
cancer O O
incidence O O
was O O
assessed O O
through O O
2010 O O
( O O
North O O
Carolina O O
) O O
/ O O
2011 O O
( O O
Iowa O O
) O O
. O O

Among O O
applicators O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
usage O B_DISEASE
information O I_DISEASE
sufficient O I_DISEASE
to O O
evaluate O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
- O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
used O O
Poisson O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
estimate O O
adjusted O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
ratios O I_MEASURE/I_DISEASE
( O O
RRs O B_LOCATION/B_ORGANIZATION
) O O
and O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
for O O
cancer O B_LOCATION/B_ORGANIZATION
sites O I_LOCATION/I_ORGANIZATION
with O O
> O B_MEASURE
10 O I_MEASURE
exposed O O
cases O B_PERSON/B_LOCATION
for O O
both O O
lifetime O B_TIME[MEASURE]
( O O
LT O B_PERSON/B_LOCATION
) O O
exposure O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
and O O
intensity O B_MEASURE/B_DISEASE
- O O
weighted O O
( O O
IW O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
lifetime O B_TIME[MEASURE]/B_ENT
exposure O I_TIME[MEASURE]/I_ENT
days O I_TIME[MEASURE]/I_ENT
( O O
accounting O O
for O O
factors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
impacting O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O O
. O O

RESULTS O O
: O O
We O O
observed O O
elevated O O
lung O O
cancer O O
risks O O
( O O
N O O
= O O
283 O O
) O O
among O O
applicators O O
with O O
the O O
greatest O O
number O O
of O O
LT O O
( O O
RR O O
= O O
1 O O
. O O
60 O O
; O O
95 O O
% O O
CI O O
1 O O
. O O
11 O O
to O O
2 O O
. O O
31 O O
; O O
Ptrend O O
= O O
0 O O
. O O
02 O O
) O O
and O O
IW O O
days O O
of O O
diazinon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
use O O
( O O
RR O O
= O O
1 O O
. O O
41 O O
; O O
95 O O
% O O
CI O O
0 O O
. O O
98 O O
to O O
2 O O
. O O
04 O O
; O O
Ptrend O O
= O O
0 O O
. O O
08 O O
) O O
. O O

Kidney O B_DISEASE/B_MEASURE
cancer O I_DISEASE/I_MEASURE
( O O
N O B_OTHER/B_LOCATION
= O O
94 O B_MEASURE
) O O
risks O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
significantly O O
elevated O O
( O O
RRLT O B_LOCATION
days O I_LOCATION
= O O
1 O B_MEASURE
. O O
77 O B_MEASURE
; O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
90 O B_MEASURE
to O O
3 O B_MEASURE
. O O
51 O B_MEASURE
; O O
Ptrend O B_LOCATION/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
; O O
RRIW O B_TIME[MEASURE]
days O I_TIME[MEASURE]
1 O I_TIME[MEASURE]
. O O
37 O B_MEASURE
; O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
0 O I_MEASURE
. O O
64 O B_MEASURE
to O O
2 O B_MEASURE
. O O
92 O B_MEASURE
; O O
Ptrend O B_LOCATION
= O O
0 O B_MEASURE
. O O
50 O B_MEASURE
) O O
, O O
as O O
were O O
risks O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
aggressive O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
prostate O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
N O B_OTHER/B_LOCATION
= O O
656 O B_MEASURE
) O O
. O O

CONCLUSIONS O O
: O O
Our O O
updated O O
evaluation O O
of O O
diazinon B B_DISEASE/B_BIO
provides O O
additional O O
evidence O O
of O O
an O O
association O O
with O O
lung O O
cancer O O
risk O O
. O O

Newly O O
identified O O
links O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
kidney O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
and O O
associations O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
aggressive O B_DISEASE/B_ORGANISM_FUNCTION
prostate O I_DISEASE/I_ORGANISM_FUNCTION
cancer O I_DISEASE/I_ORGANISM_FUNCTION
require O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Associations O O
of O O
Ozone B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
PM2 O O
. O O
5 O O
Concentrations O O
With O O
Parkinson O O
' O O
s O O
Disease O O
Among O O
Participants O O
in O O
the O O
Agricultural O O
Health O O
Study O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
describes O O
associations O O
of O O
ozone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
fine O O
particulate B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
matter I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O O
Parkinson O O
' O O
s O O
disease O O
observed O O
among O O
farmers O O
in O O
North O O
Carolina O O
and O O
Iowa O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
used O O
logistic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regression O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
determine O O
the O O
associations O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
pollutants O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
self O B_PERSON/B_LOCATION
- O O
reported O O
, O O
doctor O B_PERSON/B_LOCATION
- O O
diagnosed O O
Parkinson O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
. O O

Daily O O
predicted O O
pollutant O B_MEASURE/B_LOCATION
concentrations O B_MEASURE/I_LOCATION
were O O
used O O
to O O
derive O O
surrogates O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_TIME[MEASURE]/B_LOCATION
exposure O I_TIME[MEASURE]/I_LOCATION
and O O
link O O
them O O
to O O
study O O
participants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
geocoded O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
addresses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

RESULTS O O
: O O
We O O
observed O O
positive O O
associations O O
of O O
Parkinson O O
' O O
s O O
disease O O
with O O
ozone B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
odds O O
ratio O O
= O O
1 O O
. O O
39 O O
; O O
95 O O
% O O
CI O O
: O O
0 O O
. O O
98 O O
to O O
1 O O
. O O
98 O O
) O O
and O O
fine O O
particulate B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
matter I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
odds O O
ratio O O
= O O
1 O O
. O O
34 O O
; O O
95 O O
% O O
CI O O
: O O
0 O O
. O O
93 O O
to O O
1 O O
. O O
93 O O
) O O
in O O
North O O
Carolina O O
but O O
not O O
in O O
Iowa O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
The O O
plausibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
an O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O O
ambient O B_NUMBER[MEASURE]/B_LOCATION
concentrations O I_NUMBER[MEASURE]/I_LOCATION
of O O
these O O
pollutants O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
Parkinson O B_DISEASE_ADJECTIVE[DISEASE]
' O I_DISEASE_ADJECTIVE[DISEASE]
s O I_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
risk O I_DISEASE_ADJECTIVE[DISEASE]
is O O
supported O O
by O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O O
damage O B_DISEASE
to O O
dopaminergic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
relevant O B_MEASURE/B_LOCATION
concentrations O I_MEASURE/I_LOCATION
. O O

Additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
needed O O
to O O
address O O
uncertainties O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
related O O
to O O
confounding O O
and O O
to O O
examine O O
temporal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
associations O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
observed O O
. O O

Low O O
functional O O
programming O O
of O O
renal O O
AT2R O O
mediates O O
the O O
developmental O O
origin O O
of O O
glomerulosclerosis O O
in O O
adult O O
offspring O O
induced O O
by O O
prenatal O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
. O O

UNASSIGNED O O
: O O
Our O O
previous O O
study O O
has O O
indicated O O
that O O
prenatal O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
( O O
PCE O O
) O O
could O O
induce O O
intrauterine O O
growth O O
retardation O O
( O O
IUGR O O
) O O
of O O
offspring O O
. O O

Recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggested O O
that O O
IUGR O B_DISEASE
is O O
a O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
glomerulosclerosis O B_DISEASE
. O O

However O O
, O O
whether O O
PCE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
could O O
induce O O
glomerulosclerosis O B_DISEASE/B_GENE
and O O
its O O
underlying O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O O
to O O
demonstrate O O
the O O
induction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
glomerulosclerosis O O
in O O
adult O B_PERSON
offspring O O
by O O
PCE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
intrauterine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
programming O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IUGR O B_DISEASE
was O O
established O O
by O O
PCE O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
male O B_PERSON/B_BIO
fetuses O I_PERSON/I_BIO
and O O
adult O B_PERSON/B_BIO
offspring O I_PERSON/I_BIO
at O O
the O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
postnatal O B_TIME[MEASURE]
week O I_TIME[MEASURE]
24 O I_TIME[MEASURE]
were O O
euthanized O O
. O O

The O O
results O O
revealed O O
that O O
the O O
adult O O
offspring O O
kidneys O O
in O O
the O O
PCE O O
group O O
exhibited O O
glomerulosclerosis O O
as O O
well O O
as O O
interstitial O O
fibrosis O O
, O O
accompanied O O
by O O
elevated O O
levels O O
of O O
serum O O
creatinine B B_MEASURE/B_GENE
and O O
urine O O
protein O O
. O O

Renal O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O O
type O O
2 O O
( O O
AT2R O O
) O O
gene O O
expression O O
in O O
adult O O
offspring O O
was O O
reduced O O
by O O
PCE O O
, O O
whereas O O
the O O
renal O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O O
type O O
1a O O
( O O
AT1aR O O
) O O
/ O O
AT2R O O
expression O O
ratio O O
was O O
increased O O
. O O

The O O
fetal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidneys O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
PCE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displayed O O
an O O
enlarged O O
Bowman O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
' O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
s O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
shrunken O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerular O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
accompanied O O
by O O
a O O
reduced O O
cortex O B_MEASURE/B_DISEASE
width O I_MEASURE/I_DISEASE
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
nephrogenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
zone O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
cortical O B_MEASURE/B_LOCATION
zone O B_MEASURE/I_LOCATION
ratio O B_MEASURE/I_LOCATION
. O O

Observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
electronic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
structural O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
podocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
; O O
the O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
podocyte O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
marker O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nephrin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
podocin O B_GENE/B_BACTERIUM[BIO]
, O O
was O O
also O O
detected O O
by O O
q O O
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Moreover O O
, O O
AT2R O O
gene O O
and O O
protein O O
expressions O O
in O O
fetal O O
kidneys O O
were O O
inhibited O O
by O O
PCE O O
, O O
associated O O
with O O
the O O
repression O O
of O O
the O O
gene O O
expression O O
of O O
glial O O
- O O
cell O O
- O O
line O O
- O O
derived O O
neurotrophic O O
factor O O
( O O
GDNF O O
) O O
/ O O
tyrosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O O
receptor O O
( O O
c O O
- O O
Ret O O
) O O
signaling O O
pathway O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
that O O
PCE O B_DISEASE
could O O
induce O O
dysplasia O B_DISEASE/B_ORGANISM_FUNCTION
of O O
fetal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kidneys O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
glomerulosclerosis O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
adult O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
offspring O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]
functional O I_DISEASE_ADJECTIVE[DISEASE]
programming O I_DISEASE_ADJECTIVE[DISEASE]
of O O
renal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
AT2R O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
might O O
mediate O O
the O O
developmental O B_DISEASE_ADJECTIVE[DISEASE]
origin O I_DISEASE_ADJECTIVE[DISEASE]
of O O
adult O B_DISEASE
glomerulosclerosis O I_DISEASE
. O O

1 B B_DISEASE
, I I_DISEASE
3 I I_DISEASE
- I I_DISEASE
Butadiene I I_DISEASE
, O O
CML O O
and O O
the O O
t O O
( O O
9 O O
: O O
22 O O
) O O
translocation O O
: O O
A O O
reality O O
check O O
. O O

UNASSIGNED O O
: O O
Epidemiological O O
studies O O
of O O
1 B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
butadiene I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
suggest O O
that O O
exposures O O
to O O
humans O O
are O O
associated O O
with O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
. O O

CML O B_DISEASE/B_LOCATION
has O O
a O O
well O O
- O O
documented O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
ionizing O O
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
but O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
associations O B_ORGANIZATION/B_DISEASE
with O O
chemical O B_DISEASE
exposures O I_DISEASE
have O O
been O O
questioned O O
. O O

Ionizing O O
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
capable O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
inducing O O
the O O
requisite O B_DISEASE
CML O I_DISEASE
- O O
associated O O
t O B_GENE/B_DISEASE
( O O
9 O B_MEASURE
: O O
22 O B_MEASURE
) O O
translocation O B_GENE/B_DISEASE
( O O
Philadelphia O B_LOCATION/B_ORGANIZATION
chromosome O I_LOCATION/I_ORGANIZATION
) O O
in O O
appropriate O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
, O O
thus O O
far O O
, O O
chemicals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O O
not O O
shown O O
this O O
capacity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
have O O
proposed O O
that O O
1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
3 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
butadiene I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
metabolites O O
be O O
so O O
tested O O
as O O
a O O
reality O O
check O O
on O O
the O O
epidemiological O O
reports O O
. O O

In O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
conduct O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
is O O
essential O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
a O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
induction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
be O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
used O O
ionizing O O
radiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
develop O O
such O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O O
here O O
demonstrate O O
that O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
in O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induce O O
pathogenic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
t O O
( O O
9 O B_MEASURE
: O O
22 O B_MEASURE
) O O
translocations O B_DISEASE/B_GENE
in O O
a O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myeloid O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
does O O
so O O
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequencies O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Conditions O O
that O O
will O O
be O O
required O O
for O O
studies O O
of O O
1 B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
3 I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
butadiene I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
discussed O O
. O O

Cancer O O
incidence O O
and O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O O
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
An O O
update O O
. O O

UNASSIGNED O O
: O O
Metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
a O O
widely O O
used O O
herbicide O O
, O O
is O O
classified O O
as O O
a O O
Group O O
C O O
carcinogen O O
by O O
the O O
U O O
. O O
S O O
. O O

Environmental O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Protection O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Agency O B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O O
on O O
increased O O
liver O B_DISEASE/B_ORGANISM_FUNCTION
neoplasms O I_DISEASE/I_ORGANISM_FUNCTION
in O O
female O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
. O O

Epidemiologic O O
studies O O
of O O
the O O
health O O
effects O O
of O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
have O O
been O O
limited O O
. O O

The O O
Agricultural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Health O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
AHS O B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
including O O
licensed O O
private O B_PERSON/B_LOCATION
and O O
commercial O B_ORGANIZATION/B_PERSON
pesticide O B_ORGANIZATION/I_PERSON
applicators O B_ORGANIZATION/I_PERSON
in O O
Iowa O B_LOCATION
and O O
North O B_LOCATION
Carolina O I_LOCATION
enrolled O O
1993 O B_MEASURE
- O O
1997 O B_MEASURE
. O O

We O O
evaluated O O
cancer O O
incidence O O
through O O
2010 O O
/ O O
2011 O O
( O O
NC O O
/ O O
IA O O
) O O
for O O
49 O O
, O O
616 O O
applicators O O
, O O
53 O O
% O O
of O O
whom O O
reported O O
ever O O
using O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

We O O
used O O
Poisson O O
regression O O
to O O
evaluate O O
relations O O
between O O
two O O
metrics O O
of O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O O
( O O
lifetime O O
days O O
, O O
intensity O O
- O O
weighted O O
lifetime O O
days O O
) O O
and O O
cancer O O
incidence O O
. O O

We O O
saw O O
no O O
association O O
between O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O O
and O O
incidence O O
of O O
all O O
cancers O O
combined O O
( O O
n O O
= O O
5 O O
, O O
701 O O
with O O
a O O
5 O O
- O O
year O O
lag O O
) O O
or O O
most O O
site O O
- O O
specific O O
cancers O O
. O O

For O O
liver O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
in O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restricted O O
to O O
exposed O B_PERSON/B_ORGANIZATION
workers O I_PERSON/I_ORGANIZATION
, O O
elevations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
at O O
higher O B_MEASURE/B_LOCATION
categories O B_MEASURE/I_LOCATION
of O O
use O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
not O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
trends O O
for O O
both O O
lifetime O O
and O O
intensity O O
- O O
weighted O O
lifetime O O
days O O
of O O
metolachor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
were O O
positive O O
and O O
statistically O O
significant O O
with O O
an O O
unexposed O O
reference O O
group O O
. O O

A O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
observed O O
for O O
follicular O B_DISEASE
cell O I_DISEASE
lymphoma O I_DISEASE
, O O
but O O
no O O
other O B_DISEASE/B_MEASURE
lymphoma O I_DISEASE/I_MEASURE
subtypes O I_DISEASE/I_MEASURE
. O O

An O O
earlier O O
suggestion O O
of O O
increased O O
lung O O
cancer O O
risk O O
at O O
high O O
levels O O
of O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O O
in O O
this O O
cohort O O
was O O
not O O
confirmed O O
in O O
this O O
update O O
. O O

This O O
suggestion O O
of O O
an O O
association O O
between O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
liver O O
cancer O O
among O O
pesticide O O
applicators O O
is O O
a O O
novel O O
finding O O
and O O
echoes O O
observation O O
of O O
increased O O
liver O O
neoplasms O O
in O O
some O O
animal O O
studies O O
. O O

However O O
, O O
our O O
findings O O
for O O
both O O
liver O O
cancer O O
and O O
follicular O O
cell O O
lymphoma O O
warrant O O
follow O O
- O O
up O O
to O O
better O O
differentiate O O
effects O O
of O O
metolachlor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O O
from O O
other O O
factors O O
. O O

Mechanisms O O
Underlying O O
Latent O O
Disease O O
Risk O O
Associated O O
with O O
Early O O
- O O
Life O O
Arsenic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Exposure O O
: O O
Current O O
Research O O
Trends O O
and O O
Scientific O O
Gaps O O
. O O

BACKGROUND O O
: O O
Millions O O
of O O
individuals O O
worldwide O O
, O O
particularly O O
those O O
living O O
in O O
rural O O
and O O
developing O O
areas O O
, O O
are O O
exposed O O
to O O
harmful O O
levels O O
of O O
inorganic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arsenic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
iAs B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
in O O
their O O
drinking O O
water O O
. O O

Inorganic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
As I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exposure O O
during O O
key O O
developmental O O
periods O O
is O O
associated O O
with O O
a O O
variety O O
of O O
adverse O O
health O O
effects O O
including O O
those O O
that O O
are O O
evident O O
in O O
adulthood O O
. O O

There O O
is O O
considerable O O
interest O O
in O O
identifying O O
the O O
molecular O O
mechanisms O O
that O O
relate O O
early O O
- O O
life O O
iAs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
to O O
the O O
development O O
of O O
these O O
latent O O
diseases O O
, O O
particularly O O
in O O
relationship O O
to O O
cancer O O
. O O

OBJECTIVES O O
: O O
This O O
work O O
summarizes O O
research O O
on O O
the O O
molecular O O
mechanisms O O
that O O
underlie O O
the O O
increased O O
risk O O
of O O
cancer O O
development O O
in O O
adulthood O O
that O O
is O O
associated O O
with O O
early O O
- O O
life O O
iAs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
. O O

DISCUSSION O O
: O O
Epigenetic O O
reprogramming O O
that O O
imparts O O
functional O O
changes O O
in O O
gene O O
expression O O
, O O
the O O
development O O
of O O
cancer O O
stem O O
cells O O
, O O
and O O
immunomodulation O O
are O O
plausible O O
underlying O O
mechanisms O O
by O O
which O O
early O O
- O O
life O O
iAs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
elicits O O
latent O O
carcinogenic O O
effects O O
. O O

CONCLUSIONS O O
: O O
Evidence O O
is O O
mounting O O
that O O
relates O O
early O O
- O O
life O O
iAs B B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exposure O O
and O O
cancer O O
development O O
later O O
in O O
life O O
. O O

Future O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O O
include O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
address O O
mechanistic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hypotheses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
populations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
integrate O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
- O O
life O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
latent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disease O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
outcomes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
bradycardia O O
in O O
a O O
patient O O
with O O
autonomic O O
neuropathy O O
. O O

An O O
80 O B_PERSON
year O I_PERSON
old O I_PERSON
diabetic O I_PERSON
male O I_PERSON
with O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
autonomic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
admitted O O
with O O
chest O B_DISEASE
pain O I_DISEASE
. O O

He O O
was O O
found O O
to O O
have O O
atrial O O
flutter O O
at O O
a O O
ventricular O O
rate O O
of O O
70 O O
/ O O
min O O
which O O
slowed O O
down O O
to O O
30 O O
- O O
40 O O
/ O O
min O O
when O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
60 O O
mg O O
) O O
in O O
3 O O
divided O O
doses O O
, O O
during O O
which O O
he O O
was O O
paced O O
at O O
a O O
rate O O
of O O
70 O O
/ O O
min O O
. O O

This O O
is O O
inconsistent O O
with O O
the O O
well O O
- O O
established O O
finding O O
that O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
tachycardia O O
in O O
normally O O
innervated O O
hearts O O
. O O

However O O
, O O
in O O
hearts O B_PERSON/B_BIO
deprived O O
of O O
compensatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drive O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
may O O
lead O O
to O O
bradycardia O B_DISEASE
. O O

The O O
effect O O
of O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O O
. O O

The O O
effectiveness O O
of O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O O
in O O
preventing O O
the O O
toxic O O
effects O O
of O O
high O O
doses O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
studied O O
in O O
rats O O
. O O

In O O
this O O
model O O
, O O
toxic O O
effects O O
were O O
induced O O
by O O
intraperitoneal O O
( O O
i O O
. O O
p O O
. O O
) O O
injection O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
75 O O
mg O O
/ O O
kg O O
( O O
100 O O
% O O
death O O
rate O O
) O O
or O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
70 O O
mg O O
/ O O
kg O O
( O O
82 O O
% O O
death O O
rate O O
) O O
. O O

Haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
prevent O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizures O O
, O O
but O O
did O O
lower O O
the O O
mortality O O
rate O O
at O O
most O O
doses O O
tested O O
. O O

Haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O O
the O O
incidence O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
seizures O O
at O O
the O O
two O O
highest O O
doses O O
, O O
but O O
the O O
lowering O O
of O O
the O O
mortality O O
rate O O
did O O
not O O
reach O O
statistical O O
significance O O
at O O
any O O
dose O O
. O O

These O O
data O O
suggest O O
a O O
protective O O
role O O
for O O
the O O
central O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blocker O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
death O O
from O O
high O O
- O O
dose O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
without O O
reducing O O
the O O
incidence O O
of O O
seizures O O
. O O

In O O
contrast O O
, O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
an O O
ability O O
to O O
reduce O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
seizures O O
without O O
significantly O O
reducing O O
mortality O O
. O O

Autoradiographic O O
evidence O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
sites O O
in O O
nuclei O O
of O O
diethylstilbesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
hamster O O
renal O O
carcinomas O O
. O O

Estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
sites O O
were O O
demonstrated O O
by O O
autoradiography O O
in O O
one O O
transplantable O O
and O O
five O O
primary O O
diethylstilbesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
renal O O
carcinomas O O
in O O
three O O
hamsters O O
. O O

Radiolabelling O O
, O O
following O O
the O O
in O O
vivo O O
injection O O
of O O
3H O O
- O O
17 O O
beta O O
estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
was O O
increased O O
only O O
over O O
the O O
nuclei O O
of O O
tumor O O
cells O O
; O O
stereologic O O
analysis O O
revealed O O
a O O
4 O O
. O O
5 O O
- O O
to O O
6 O O
. O O
7 O O
- O O
times O O
higher O O
concentration O O
of O O
reduced O O
silver B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grains O O
over O O
nuclei O O
than O O
cytoplasm O O
of O O
these O O
cells O O
. O O

Despite O O
rapid O O
tubular O O
excretion O O
of O O
estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
peaked O O
in O O
less O O
than O O
1 O O
h O O
, O O
the O O
normal O O
cells O O
did O O
not O O
appear O O
to O O
bind O O
the O O
ligand O O
. O O

This O O
is O O
the O O
first O O
published O O
report O O
documenting O O
the O O
preferential O O
in O O
vivo O O
binding O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
nuclei O O
of O O
cells O O
in O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
hamster O O
renal O O
carcinomas O O
. O O

Bradycardia O O
due O O
to O O
biperiden B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
a O O
38 O O
- O O
year O O
- O O
old O O
male O O
patient O O
suffering O O
from O O
a O O
severe O O
postzosteric O O
trigeminal O O
neuralgia O O
, O O
intravenous O O
application O O
of O O
10 O O
mg O O
biperiden B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
led O O
to O O
a O O
long O O
- O O
lasting O O
paradoxical O O
reaction O O
characterized O O
by O O
considerable O O
bradycardia O O
, O O
dysarthria O O
, O O
and O O
dysphagia O O
. O O

The O O
heart O O
rate O O
was O O
back O O
to O O
normal O O
within O O
12 O O
hours O O
upon O O
administration O O
of O O
orciprenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
cardiac O O
monitoring O O
in O O
an O O
intensive O O
care O O
unit O O
. O O

Bradycardia O O
induced O O
by O O
biperiden B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
attributed O O
to O O
the O O
speed O O
of O O
injection O O
and O O
to O O
a O O
dose O O
- O O
related O O
dual O O
effect O O
of O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O O
drugs O O
on O O
muscarine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O O
. O O

Deliberate O O
hypotension O O
induced O O
by O O
labetalol B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
enflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
isoflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
feasibility O O
of O O
using O O
labetalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
alpha O O
- O O
and O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
as O O
a O O
hypotensive O O
agent O O
in O O
combination O O
with O O
inhalation O O
anaesthetics O O
( O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
enflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
isoflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
studied O O
in O O
23 O O
adult O O
patients O O
undergoing O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
mean O O
arterial O O
pressure O O
was O O
decreased O O
from O O
86 O O
+ O O
/ O O
- O O
5 O O
( O O
s O O
. O O
e O O
. O O
mean O O
) O O
mmHg O O
to O O
52 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
11 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
to O O
6 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
98 O O
+ O O
/ O O
- O O
10 O O
min O O
in O O
the O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H B B_OTHER/B_PROTEIN[GENE]
) O O
group O O
, O O
from O O
79 O O
+ O O
/ O O
- O O
5 O O
to O O
53 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
10 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
to O O
7 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
129 O O
+ O O
/ O O
- O O
11 O O
min O O
in O O
the O O
enflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
E B B_OTHER/B_PROTEIN[GENE]
) O O
group O O
, O O
and O O
from O O
80 O O
+ O O
/ O O
- O O
4 O O
to O O
49 O O
+ O O
/ O O
- O O
1 O O
mmHg O O
( O O
10 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
to O O
6 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
kPa O O
) O O
for O O
135 O O
+ O O
/ O O
- O O
15 O O
min O O
in O O
the O O
isoflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
I B B_OTHER/B_MEASURE
) O O
group O O
. O O

The O O
mean O O
H B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentration O O
during O O
hypotension O O
in O O
the O O
inspiratory O O
gas O O
was O O
0 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
vol O O
% O O
, O O
the O O
mean O O
E B B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O O
1 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
vol O O
% O O
, O O
and O O
the O O
mean O O
I B B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O O
1 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
vol O O
% O O
. O O

In O O
addition O O
, O O
the O O
patients O O
received O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
initial O O
dose O O
of O O
labetalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
lowering O O
blood O O
pressure O O
was O O
similar O O
, O O
0 O O
. O O
52 O O
- O O
0 O O
. O O
59 O O
mg O O
/ O O
kg O O
, O O
in O O
all O O
the O O
groups O O
. O O

During O O
hypotension O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
heart O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
without O O
tachy O B_DISEASE
- O O
or O O
bradycardia O B_DISEASE
. O O

The O O
operating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
conditions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regarding O O
bleeding O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
estimated O O
in O O
a O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
and O O
did O O
not O O
differ O O
significantly O O
between O O
the O O
groups O B_ORGANIZATION/B_PERSON
. O O

During O O
hypotension O O
, O O
the O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
rose O O
significantly O O
in O O
all O O
groups O O
from O O
the O O
values O O
before O O
hypotension O O
and O O
returned O O
postoperatively O O
to O O
the O O
initial O O
level O O
in O O
the O O
other O O
groups O O
, O O
except O O
the O O
isoflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
. O O

After O O
hypotension O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O O
was O O
no O O
rebound O B_DISEASE_ADJECTIVE[DISEASE]
phenomenon O I_DISEASE_ADJECTIVE[DISEASE]
in O O
either O O
blood O B_DISEASE/B_PROTEIN[GENE]
pressure O B_DISEASE/I_PROTEIN[GENE]
or O O
heart O B_MEASURE/B_DISEASE
rate O B_MEASURE/I_DISEASE
. O O

These O O
results O O
indicate O O
that O O
labetalol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induces O O
easily O O
adjustable O O
hypotension O O
without O O
compensatory O O
tachycardia O O
and O O
rebound O O
hypertension O O
. O O

Convulsion O O
following O O
intravenous O O
fluorescein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
angiography O O
. O O

Tonic O O
- O O
clonic O O
seizures O O
followed O O
intravenous O O
fluorescein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O O
for O O
fundus O O
angiography O O
in O O
a O O
47 O O
- O O
year O O
- O O
old O O
male O O
. O O

Despite O O
precautions O O
this O O
adverse O O
reaction O O
recurred O O
on O O
re O O
- O O
exposure O O
to O O
intravenous O O
fluorescein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pharmacology O O
of O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodrug O O
) O O
. O O

ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
the O O
disodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ester I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxymethyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diphenylhydantoin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
a O O
prodrug O O
of O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
advantageous O O
physicochemical O O
properties O O
. O O

ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
rapidly O O
converted O O
enzymatically O O
to O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
equivalent O O
anticonvulsant O O
activity O O
against O O
seizures O O
induced O O
by O O
maximal O O
electroshock O O
( O O
MES O O
) O O
in O O
mice O O
following O O
i O O
. O O
p O O
. O O
, O O
oral O O
, O O
or O O
i O O
. O O
v O O
. O O
administration O O
. O O

The O O
ED50 O O
doses O O
were O O
16 O O
mg O O
/ O O
kg O O
for O O
i O O
. O O
v O O
. O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
8 O O
mg O O
/ O O
kg O O
for O O
i O O
. O O
v O O
. O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
similar O O
antiarrhythmic O O
activity O O
against O O
ouabain B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ventricular O O
tachycardia O O
in O O
anesthetized O O
dogs O O
. O O

The O O
total O O
doses O O
of O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necessary O O
to O O
convert O O
the O O
arrhythmia O O
to O O
a O O
normal O O
sinus O O
rhythm O O
were O O
24 O O
+ O O
/ O O
- O O
6 O O
and O O
14 O O
+ O O
/ O O
- O O
3 O O
mg O O
/ O O
kg O O
, O O
respectively O O
. O O

Only O O
phenytoin B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O O
in O O
vitro O O
antiarrhythmic O O
activity O O
against O O
strophanthidin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
arrhythmias O O
in O O
guinea O O
pig O O
right O O
atria O O
. O O

In O O
anesthetized O O
dogs O O
, O O
a O O
high O O
dose O O
of O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
31 O O
mg O O
/ O O
kg O O
) O O
was O O
infused O O
over O O
15 O O
, O O
20 O O
, O O
and O O
30 O O
min O O
and O O
the O O
responses O O
were O O
compared O O
to O O
an O O
equimolar O O
dose O O
of O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
21 O O
mg O O
/ O O
kg O O
) O O
. O O

The O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O O
produced O O
similar O O
marked O O
reductions O O
in O O
diastolic O O
blood O O
pressure O O
and O O
contractile O O
force O O
( O O
LVdP O O
/ O O
dt O O
) O O
. O O

The O O
maximum O O
effects O O
of O O
each O O
treatment O O
occurred O O
at O O
the O O
time O O
of O O
maximum O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
levels O O
. O O

Acute O O
toxicity O O
studies O O
of O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
in O O
mice O O
, O O
rats O O
, O O
rabbits O O
, O O
and O O
dogs O O
by O O
i O O
. O O
v O O
. O O
, O O
i O O
. O O
m O O
. O O
, O O
and O O
i O O
. O O
p O O
. O O
routes O O
of O O
administration O O
. O O

The O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
occurred O O
at O O
approximately O O
equivalent O B_MEASURE/B_LOCATION
doses O I_MEASURE/I_LOCATION
. O O

Importantly O O
, O O
the O O
local O O
irritation O O
of O O
ACC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
markedly O O
less O O
than O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sodium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O O
i O O
. O O
m O O
. O O
administration O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Tachyphylaxis O O
to O O
systemic O O
but O O
not O O
to O O
airway O O
responses O O
during O O
prolonged O O
therapy O O
with O O
high O O
dose O O
inhaled O O
salbutamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
asthmatics O O
. O O

High O O
doses O O
of O O
inhaled O O
salbutamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produce O O
substantial O O
improvements O O
in O O
airway O O
response O O
in O O
patients O O
with O O
asthma O O
, O O
and O O
are O O
associated O O
with O O
dose O O
- O O
dependent O O
systemic O O
beta O O
- O O
adrenoceptor O O
responses O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
whether O O
tachyphylaxis O O
occurs O O
during O O
prolonged O O
treatment O O
with O O
high O O
dose O O
inhaled O O
salbutamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Twelve O O
asthmatic O O
patients O O
( O O
FEV1 O O
, O O
81 O O
+ O O
/ O O
- O O
4 O O
% O O
predicted O O
) O O
, O O
requiring O O
only O O
occasional O O
inhaled O O
beta O O
- O O
agonists O O
as O O
their O O
sole O O
therapy O O
, O O
were O O
given O O
a O O
14 O O
- O O
day O O
treatment O O
with O O
high O O
dose O O
inhaled O O
salbutamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HDS O O
) O O
, O O
4 O O
, O O
000 O O
micrograms O O
daily O O
, O O
low O O
dose O O
inhaled O O
salbutamol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LDS O O
) O O
, O O
800 O O
micrograms O O
daily O O
, O O
or O O
placebo O O
( O O
PI O O
) O O
by O O
metered O O
- O O
dose O O
inhaler O O
in O O
a O O
double O O
- O O
blind O O
, O O
randomized O O
crossover O O
design O O
. O O

During O O
the O O
14 O O
- O O
day O O
run O O
- O O
in O O
and O O
during O O
washout O O
periods O O
, O O
inhaled O O
beta O O
- O O
agonists O O
were O O
withheld O O
and O O
ipratropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
substituted O O
for O O
rescue O O
purposes O O
. O O

At O O
the O O
end O O
of O O
each O O
14 O O
- O O
day O O
treatment O O
, O O
a O O
dose O O
- O O
response O O
curve O O
( O O
DRC O O
) O O
was O O
performed O O
, O O
and O O
airway O O
( O O
FEV1 O O
, O O
FEF25 O O
- O O
75 O O
) O O
chronotropic O O
( O O
HR O O
) O O
, O O
tremor O O
, O O
and O O
metabolic O O
( O O
K B B_OTHER/B_LOCATION
, O O
Glu B B_LOCATION/B_PERSON
) O O
responses O O
were O O
measured O O
at O O
each O O
step O O
( O O
from O O
100 O O
to O O
4 O O
, O O
000 O O
micrograms O O
) O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
had O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
baseline O B_DISEASE
values O I_DISEASE
. O O

There O O
were O O
dose O B_MEASURE
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
FEV1 O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FEF25 O B_LOCATION
- O O
75 O B_MEASURE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
, O O
and O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O O
HDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
displace O O
the O O
DRC O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

DRC O O
for O O
HR O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
K B B_OTHER/B_LOCATION
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
and O O
Glu B B_LOCATION/B_PERSON
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
were O O
attenuated O O
after O O
treatment O O
with O O
HDS O O
compared O O
with O O
PI O O
. O O

There O O
were O O
also O O
differences O O
between O O
HDS O O
and O O
LDS O O
for O O
HR O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
Glu B B_LOCATION/B_PROTEIN[GENE]
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
responses O O
. O O

Frequency O B_MEASURE
and O O
severity O B_MEASURE
of O O
subjective O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
were O O
also O O
reduced O O
after O O
HDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
tremor O B_DISEASE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
, O O
palpitations O B_DISEASE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O
( O O
ABSTRACT O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O O
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

Phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
induced O O
fatal O O
hepatic O O
injury O O
. O O

A O O
61 O O
year O O
old O O
female O O
developed O O
fatal O O
hepatic O O
failure O O
after O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

A O O
typical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
multisystem O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clinical O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
precedes O O
the O O
manifestations O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hepatic O B_DISEASE/B_LOCATION
injury O I_DISEASE/I_LOCATION
. O O

The O O
hematologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pathologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
a O O
mixed O B_DISEASE
hepatocellular O I_DISEASE
damage O I_DISEASE
due O O
to O O
drug O B_DISEASE
hypersensitivity O I_DISEASE
. O O

In O O
a O O
patient O O
receiving O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O O
presents O O
a O O
viral O O
- O O
like O O
illness O O
, O O
early O O
recognition O O
and O O
discontinuation O O
of O O
the O O
drug O O
are O O
mandatory O O
. O O

Treatment O O
of O O
lethal O O
pertussis B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
reaction O O
with O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
H1 O O
antagonists O O
. O O

We O O
studied O O
mortality O B_DISEASE
after O O
pertussis O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunization O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
mouse O B_BIO/B_LOCATION
. O O

Without O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
73 O B_MEASURE
of O O
92 O B_PERSON
animals O I_PERSON
( O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
died O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
bovine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
on O O
day O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
pertussis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immunization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

After O O
pretreatment O O
with O O
3 O O
mg O O
of O O
cyproheptadine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
2 O O
mg O O
mianserin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
2 O O
mg O O
chlorpheniramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
only O O
5 O O
of O O
105 O O
animals O O
( O O
5 O O
% O O
) O O
died O O
after O O
receiving O O
BSA O O
on O O
day O O
+ O O
7 O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

Blockade O O
of O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
H1 O O
receptors O O
may O O
reduce O O
mortality O O
in O O
pertussis O O
immunization O O
- O O
induced O O
encephalopathy O O
in O O
mice O O
. O O

Support O O
for O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
hypertension O O
hypothesis O O
: O O
18 O O
hour O O
pressor O O
effect O O
after O O
6 O O
hours O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

In O O
a O O
double O O
blind O O
, O O
crossover O O
study O O
6 O O
h O O
infusions O O
of O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
15 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5 O O
. O O
458 O O
pmol O O
) O O
, O O
noradrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5 O O
. O O
911 O O
pmol O O
) O O
, O O
and O O
a O O
5 O O
% O O
dextrose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O O
( O O
5 O O
. O O
4 O O
ml O O
/ O O
h O O
) O O
, O O
were O O
given O O
to O O
ten O O
healthy O O
volunteers O O
in O O
random O O
order O O
2 O O
weeks O O
apart O O
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
arterial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
ambulatory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
the O O
haemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
followed O O
for O O
18 O B_MEASURE
h O O
after O O
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
stopped O O
. O O

Adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
but O O
not O O
noradrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
caused O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

Over O O
the O O
total O O
postinfusion O O
period O O
systolic O O
and O O
diastolic O O
arterial O O
pressure O O
were O O
6 O O
( O O
SEM O O
2 O O
) O O
% O O
and O O
7 O O
( O O
2 O O
) O O
% O O
, O O
respectively O O
, O O
higher O O
than O O
after O O
dextrose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infusion O O
( O O
ANOVA O O
, O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

Thus O O
, O O
" O O
stress O O
" O O
levels O O
of O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
230 O O
pg O O
/ O O
ml O O
) O O
for O O
6 O O
h O O
cause O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

These O O
findings O O
are O O
strong O O
support O O
for O O
the O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
hypertension O O
hypothesis O O
in O O
man O O
. O O

Effect O O
of O O
alkylxanthines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
acute O O
renal O O
failure O O
in O O
the O O
rat O O
. O O

Adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O O
have O O
been O O
previously O O
shown O O
to O O
be O O
of O O
benefit O O
in O O
some O O
ischaemic O O
and O O
nephrotoxic O O
models O O
of O O
acute O O
renal O O
failure O O
( O O
ARF O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
three O O
alkylxanthines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O O
different O O
potencies O O
as O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O O
8 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
phenyltheophylline I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
enprofylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
examined O O
in O O
rats O O
developing O O
acute O O
renal O O
failure O O
after O O
4 O O
daily O O
injections O O
of O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
200 O O
mg O O
kg O O
- O O
1 O O
) O O
. O O

Renal O O
function O O
was O O
assessed O O
by O O
biochemical O O
( O O
plasma O O
urea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
functional O O
( O O
urine O O
analysis O O
and O O
[ O O
3H O O
] O O
inulin O O
and O O
[ O O
14C O O
] O O
p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminohippuric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
clearances O O
) O O
and O O
morphological O O
( O O
degree O O
of O O
necrosis O O
) O O
indices O O
. O O

The O O
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O O
improvements O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
some O O
, O O
but O O
not O O
all O O
, O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
any O O
improvement O O
produced O O
by O O
drug O O
treatment O O
was O O
largely O O
a O O
result O O
of O O
a O O
beneficial O O
effect O O
exerted O O
by O O
its O O
vehicle O O
( O O
polyethylene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glycol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
NaOH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
lack O O
of O O
any O O
consistent O O
protective O O
effect O O
noted O O
with O O
the O O
alkylxanthines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tested O O
in O O
the O O
present O O
study O O
indicates O O
that O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
little O O
, O O
if O O
any O O
, O O
pathophysiological O O
role O O
in O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
ARF O O
. O O

Adverse O O
ocular O O
reactions O O
possibly O O
associated O O
with O O
isotretinoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
total O O
of O O
261 O O
adverse O O
ocular O O
reactions O O
occurred O O
in O O
237 O O
patients O O
who O O
received O O
isotretinoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
commonly O O
used O O
drug O O
in O O
the O O
treatment O O
of O O
severe O O
cystic O O
acne O O
. O O

Blepharoconjunctivitis O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
subjective O B_DISEASE_ADJECTIVE[DISEASE]
complaints O I_DISEASE_ADJECTIVE[DISEASE]
of O O
dry O B_DISEASE
eyes O I_DISEASE
, O O
blurred O B_DISEASE
vision O I_DISEASE
, O O
contact O B_DISEASE
lens O I_DISEASE
intolerance O I_DISEASE
, O O
and O O
photodermatitis O B_DISEASE
are O O
reversible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

More O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
ocular O I_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
include O O
papilledema O B_DISEASE
, O O
pseudotumor O B_DISEASE
cerebri O I_DISEASE
, O O
and O O
white O B_COLOR
or O O
gray O B_DISEASE
subepithelial O I_DISEASE
corneal O I_DISEASE
opacities O I_DISEASE
; O O
all O O
of O O
these O O
are O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
if O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
discontinued O O
. O O

Reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
decreased O B_DISEASE
dark O I_DISEASE
adaptation O I_DISEASE
are O O
under O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Isotretinoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
contraindicated O O
in O O
pregnancy O O
because O O
of O O
the O O
many O O
reported O O
congenital O O
abnormalities O O
after O O
maternal O O
use O O
( O O
including O O
microphthalmos O O
, O O
orbital O O
hypertelorism O O
, O O
and O O
optic O O
nerve O O
hypoplasia O O
) O O
. O O

Procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
terbutaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
bronchial O O
asthma O O
. O O

A O O
double O B_MEASURE/B_PERSON
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
, O O
cross O O
- O O
over O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
a O O
new O O
beta O O
- O O
2 O O
adrenoceptor O O
stimulant O O
, O O
was O O
studied O O
in O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
cross O O
- O O
over O O
trial O O
in O O
patients O O
with O O
bronchial O O
asthma O O
. O O

Oral O O
procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
micrograms O O
b O O
. O O
d O O
. O O
, O O
procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
micrograms O O
b O O
. O O
d O O
. O O
, O O
and O O
terbutaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O O
mg O O
t O O
. O O
i O O
. O O
d O O
. O O
, O O
were O O
compared O O
when O O
given O O
randomly O O
in O O
1 O O
- O O
week O O
treatment O O
periods O O
. O O

The O O
best O O
clinical O O
effect O O
was O O
found O O
with O O
terbutaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Both O O
anti O O
- O O
asthmatic O O
and O O
tremorgenic O O
effects O O
of O O
procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
dose O O
- O O
related O O
. O O

Procaterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
effective O O
in O O
the O O
doses O O
tested O O
, O O
and O O
a O O
twice O O
daily O O
regimen O O
would O O
appear O O
to O O
be O O
suitable O O
with O O
this O O
drug O O
. O O

Subacute O O
effects O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
B O O
24 O O
/ O O
76 O O
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
rat O O
heart O O
hypertrophy O O
in O O
correlation O O
with O O
blood O O
pressure O O
. O O

We O O
compared O O
the O O
potential O O
beta O O
- O O
receptor O O
blocker O O
, O O
B O O
24 O O
/ O O
76 O O
i O O
. O O
e O O
. O O
1 O O
- O O
( O O
2 O O
, O O
4 O O
- O O
dichlorophenoxy O O
) O O
- O O
3 O O
[ O O
2 O O
- O O
3 O O
, O O
4 O O
- O O
dimethoxyphenyl O O
) O O
ethanolamino O O
] O O
- O O
prop O O
an O O
- O O
2 O O
- O O
ol O O
, O O
which O O
is O O
characterized O O
by O O
beta O O
1 O O
- O O
adrenoceptor O O
blocking O O
and O O
beta O O
2 O O
- O O
adrenoceptor O O
stimulating O O
properties O O
with O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
studies O O
were O O
performed O O
using O O
an O O
experimental O O
model O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
heart O O
hypertrophy O O
in O O
rats O O
. O O

A O O
correlation O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
neither O O
found O O
in O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
nor O O
in O O
the O O
attempt O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
suppress O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE/B_GENE
hypertrophy O I_DISEASE/I_GENE
with O O
the O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influenced O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
hypertrophy O B_DISEASE
to O O
a O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
reproducible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
was O O
possible O O
to O O
suppress O O
the O O
increased O O
ornithine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decarboxylase O O
activity O O
with O O
both O O
beta O O
- O O
blockers O O
in O O
hypertrophied O O
hearts O O
, O O
but O O
there O O
was O O
no O O
effect O O
on O O
the O O
heart O O
mass O O
. O O

Neither O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
B O O
24 O O
/ O O
76 O O
could O O
stop O O
the O O
changes O O
in O O
the O O
characteristic O O
myosin O O
isoenzyme O O
pattern O O
of O O
the O O
hypertrophied O O
rat O O
heart O O
. O O

Thus O O
, O O
the O O
investigations O O
did O O
not O O
provide O O
any O O
evidence O O
that O O
the O O
beta O O
- O O
receptor O O
blockers O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
B O O
24 O O
/ O O
76 O O
have O O
the O O
potency O O
to O O
prevent O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
producing O O
heart O O
hypertrophy O O
. O O

Increased O O
anxiogenic O O
effects O O
of O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
panic O O
disorders O O
. O O

The O O
effects O O
of O O
oral O O
administration O O
of O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mg O O
/ O O
kg O O
) O O
on O O
behavioral O O
ratings O O
, O O
somatic O O
symptoms O O
, O O
blood O O
pressure O O
and O O
plasma O O
levels O O
of O O
3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methoxy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxyphenethyleneglycol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MHPG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
determined O O
in O O
17 O O
healthy O O
subjects O O
and O O
21 O O
patients O O
meeting O O
DSM O O
- O O
III O O
criteria O O
for O O
agoraphobia O O
with O O
panic O O
attacks O O
or O O
panic O O
disorder O O
. O O

Caffeine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
produced O O
significantly O O
greater O O
increases O O
in O O
subject O O
- O O
rated O O
anxiety O O
, O O
nervousness O O
, O O
fear O O
, O O
nausea O O
, O O
palpitations O O
, O O
restlessness O O
, O O
and O O
tremors O O
in O O
the O O
patients O O
compared O O
with O O
healthy O O
subjects O O
. O O

In O O
the O O
patients O O
, O O
but O O
not O O
the O O
healthy O O
subjects O O
, O O
these O O
symptoms O O
were O O
significantly O O
correlated O O
with O O
plasma O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Seventy O O
- O O
one O O
percent O O
of O O
the O O
patients O O
reported O O
that O O
the O O
behavioral O O
effects O O
of O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
similar O O
to O O
those O O
experienced O O
during O O
panic O O
attacks O O
. O O

Caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O O
not O O
alter O O
plasma O O
MHPG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
either O O
the O O
healthy O O
subjects O O
or O O
patients O O
. O O

Caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O O
plasma O O
cortisol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
equally O O
in O O
the O O
patient O O
and O O
healthy O O
groups O O
. O O

Because O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
antagonist O O
, O O
these O O
results O O
suggest O O
that O O
some O O
panic O O
disorder O O
patients O O
may O O
have O O
abnormalities O O
in O O
neuronal O O
systems O O
involving O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Patients O O
with O O
anxiety O O
disorders O O
may O O
benefit O O
by O O
avoiding O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
containing O O
foods O O
and O O
beverages O O
. O O

Comparison O O
of O O
the O O
effect O O
of O O
oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
slow O O
- O O
release O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
nocturnal O O
asthma O O
. O O

The O O
effects O O
of O O
a O O
new O O
inhaled O O
antimuscarinic O O
drug O O
, O O
oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
of O O
a O O
slow O O
- O O
release O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O O
upon O O
nocturnal O O
asthma O O
were O O
compared O O
in O O
a O O
placebo O O
- O O
controlled O O
double O O
- O O
blind O O
study O O
. O O

Two O O
samples O O
were O O
studied O O
: O O
12 O O
patients O O
received O O
oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
600 O O
micrograms O O
( O O
6 O O
subjects O O
) O O
or O O
at O O
400 O O
micrograms O O
t O O
. O O
i O O
. O O
d O O
. O O

( O O
6 O O
subjects O O
) O O
whereas O O
11 O O
received O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
300 O O
mg O O
b O O
. O O
i O O
. O O
d O O
. O O

Morning O B_DISEASE
dipping O I_DISEASE
, O O
assessed O O
by O O
the O O
fall O B_DISEASE/B_MEASURE
in O O
peak O B_MEASURE/B_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
overnight O O
, O O
was O O
significantly O O
reduced O O
in O O
the O O
periods O B_TIME[MEASURE]/B_LOCATION
when O O
either O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
taken O O
, O O
whereas O O
no O O
difference O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
noticed O O
during O O
the O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

No O O
significant O O
difference O O
was O O
noticed O O
between O O
results O O
obtained O O
with O O
either O O
active O O
drug O O
, O O
as O O
well O O
as O O
with O O
either O O
dosage O O
of O O
oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

No O O
subject O O
reported O O
side O O
effects O O
of O O
oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
compared O O
to O O
three O O
subjects O O
reporting O O
nausea O O
, O O
vomiting O O
and O O
tremors O O
after O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Oxitropium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
proves O O
to O O
be O O
a O O
valuable O O
alternative O O
to O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
nocturnal O O
asthma O O
, O O
since O O
it O O
is O O
equally O O
potent O O
, O O
safer O O
and O O
does O O
not O O
require O O
the O O
titration O O
of O O
dosage O O
. O O

Penicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anaphylaxis O O
. O O

A O O
case O O
of O O
oral O O
penicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaphylaxis O O
is O O
described O O
, O O
and O O
the O O
terminology O O
, O O
occurrence O O
, O O
clinical O O
manifestations O O
, O O
pathogenesis O O
, O O
prevention O O
, O O
and O O
treatment O O
of O O
anaphylaxis O O
are O O
reviewed O O
. O O

Emergency O O
physicians O O
should O O
be O O
aware O O
of O O
oral O O
penicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaphylaxis O O
in O O
order O O
to O O
prevent O O
its O O
occurrence O O
by O O
prescribing O O
the O O
antibiotic O O
judiciously O O
and O O
knowledgeably O O
and O O
to O O
offer O O
optimal O O
medical O O
therapy O O
once O O
this O O
life O O
- O O
threatening O O
reaction O O
has O O
begun O O
. O O

Reversible O O
valproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
dementia O O
: O O
a O O
case O O
report O O
. O O

Reversible O O
valproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
dementia O O
was O O
documented O O
in O O
a O O
21 O O
- O O
year O O
- O O
old O O
man O O
with O O
epilepsy O O
who O O
had O O
a O O
3 O O
- O O
year O O
history O O
of O O
insidious O O
progressive O O
decline O O
in O O
global O O
cognitive O O
abilities O O
documented O O
by O O
serial O O
neuropsychological O O
studies O O
. O O

Repeat O O
neuropsychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
IQ O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
memory O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
naming O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
other O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
commensurate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
his O O
intellectual O B_MEASURE/B_PERSON
capacity O I_MEASURE/I_PERSON
. O O

Possible O O
pathophysiological O O
mechanisms O O
which O O
may O O
have O O
been O O
operative O O
in O O
this O O
case O O
include O O
: O O
a O O
direct O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
toxic O O
effect O O
of O O
valproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
a O O
paradoxical O O
epileptogenic O O
effect O O
secondary O O
to O O
the O O
drug O O
; O O
and O O
an O O
indirect O O
CNS O O
toxic O O
effect O O
mediated O O
through O O
valproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperammonemia O O
. O O

Reversal O O
of O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
amnesia O O
of O O
passive O O
avoidance O O
by O O
pre O O
- O O
and O O
post O O
- O O
training O O
naloxone B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
a O O
series O O
of O O
five O O
experiments O O
, O O
the O O
modulating O O
role O O
of O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
a O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
retention O O
deficit O O
in O O
a O O
passive O O
avoidance O O
paradigm O O
was O O
investigated O O
in O O
mice O O
. O O

Scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
but O O
not O O
methyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scopolamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
, O O
induced O O
an O O
amnesia O O
as O O
measured O O
by O O
latency O O
and O O
duration O O
parameters O O
. O O

Naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
0 O O
. O O
3 O O
, O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
injected O O
prior O O
to O O
training O O
attenuated O O
the O O
retention O O
deficit O O
with O O
a O O
peak O O
of O O
activity O O
at O O
3 O O
mg O O
/ O O
kg O O
. O O

The O O
effect O O
of O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O O
be O O
antagonized O O
with O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
, O O
demonstrating O O
the O O
opioid O O
specificity O O
of O O
the O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O O
. O O

Post O O
- O O
training O O
administration O O
of O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
mg O O
/ O O
kg O O
) O O
as O O
a O O
single O O
or O O
as O O
a O O
split O O
dose O O
also O O
attenuated O O
the O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
amnesia O O
. O O

Control O O
experiments O O
indicated O O
that O O
neither O O
an O O
increase O O
in O O
pain O O
sensitivity O O
( O O
pre O O
- O O
training O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nor O O
an O O
induced O O
aversive O O
state O O
( O O
post O O
- O O
training O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
appear O O
to O O
be O O
responsible O O
for O O
the O O
influence O O
of O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
retention O O
deficit O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extend O O
previous O B_LOCATION/B_MEASURE
findings O I_LOCATION/I_MEASURE
implicating O O
a O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
opioid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
memory O B_DISEASE
processes O I_DISEASE
. O O

A O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mechanism O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
this O O
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O O
the O O
septo O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
hippocampal O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cholinergic O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
is O O
discussed O O
. O O

Electron O O
microscopic O O
investigations O O
of O O
the O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
lesions O O
of O O
the O O
urinary O O
bladder O O
of O O
the O O
rat O O
and O O
their O O
prevention O O
by O O
mesna B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Fully O O
developed O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cystitis O O
is O O
characterized O O
by O O
nearly O O
complete O O
detachment O O
of O O
the O O
urothelium O O
, O O
severe O O
submucosal O O
edema O O
owing O O
to O O
damage O O
to O O
the O O
microvascular O O
bed O O
and O O
focal O O
muscle O O
necroses O O
. O O

The O O
initial O O
response O O
to O O
the O O
primary O O
attack O O
by O O
the O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O O
seems O O
to O O
be O O
fragmentation O O
of O O
the O O
luminal B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
membrane O O
. O O

This O O
damages O O
the O O
cellular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
barrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
against O O
the O O
hypertonic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Subsequent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
breaks O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
lateral O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
superficial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O O
in O O
all O O
the O O
plasma O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
intermediate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
intercellular O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
intracellular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
edema O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
disintegration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
desmosomes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
hemidesmosomes O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lead O O
to O O
progressive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degeneration O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
detachment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
exposure O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
splitting O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
basal O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
endothelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
become O O
more O O
pronounced O O
in O O
the O O
later O B_TIME[MEASURE]/B_LOCATION
stages O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
experiment O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
involvement O B_DISEASE/B_MEASURE
of O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vessels O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regardless O O
of O O
their O O
diameter O B_MEASURE/B_LOCATION
and O O
the O O
location O B_MEASURE
- O O
dependent O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
of O O
the O O
damage O B_DISEASE
indicate O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
damage O B_DISEASE
which O O
is O O
preceded O O
by O O
a O O
mediator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
permeability O B_DISEASE/B_MEASURE
, O O
the O O
morphological O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlate O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
which O O
is O O
the O O
formation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
gaps O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
interendothelial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
connections O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
venules O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
changes O O
can O O
be O O
effectively O O
prevented O O
by O O
mesna B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
possible O B_DISEASE
involvement O I_DISEASE
is O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
specific O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
granules O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
presumed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lysosomal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
superficial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Increase O O
in O O
intragastric O O
pressure O O
during O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
muscle O O
fasciculations O O
in O O
children O O
: O O
inhibition O O
by O O
alfentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Changes O O
in O O
intragastric O O
pressure O O
after O O
the O O
administration O O
of O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O O
. O O
5 O O
mg O O
kg O O
- O O
1 O O
i O O
. O O
v O O
. O O
were O O
studied O O
in O O
32 O O
children O O
( O O
mean O O
age O O
6 O O
. O O
9 O O
yr O O
) O O
pretreated O O
with O O
either O O
physiological O O
saline O O
or O O
alfentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
micrograms O O
kg O O
- O O
1 O O
. O O

Anaesthesia O O
was O O
induced O O
with O O
thiopentone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O O
mg O O
kg O O
- O O
1 O O
. O O

The O O
incidence O O
and O O
intensity O O
of O O
muscle O O
fasciculations O O
caused O O
by O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
significantly O O
greater O O
in O O
the O O
control O O
than O O
in O O
the O O
alfentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
. O O

The O O
intragastric O O
pressure O O
during O O
muscle O O
fasciculations O O
was O O
significantly O O
higher O O
in O O
the O O
control O O
group O O
( O O
16 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
( O O
SEM O O
) O O
cm O O
H2O B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
than O O
in O O
the O O
alfentanil B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
( O O
7 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
( O O
SEM O O
) O O
cm O O
H2O B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
intragastric O B_DISEASE/B_MEASURE
pressure O B_DISEASE/I_MEASURE
was O O
directly O O
related O O
to O O
the O O
intensity O B_MEASURE
of O O
muscle O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
regression O B_MEASURE
line O I_MEASURE
: O O
y O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
4 O I_MEASURE
. O O
78x O B_MEASURE
with O O
r O B_PROTEIN[GENE]/B_MEASURE
of O O
0 O B_MEASURE
. O O
78 O B_MEASURE
) O O
. O O

It O O
is O O
concluded O O
that O O
intragastric O O
pressure O O
increases O O
significantly O O
during O O
muscle O O
fasciculations O O
caused O O
by O O
suxamethonium B B_DISEASE
in O O
healthy O O
children O O
. O O

Alfentanil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
50 O O
micrograms O O
kg O O
- O O
1 O O
effectively O O
inhibits O O
the O O
incidence O O
and O O
intensity O O
of O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
muscle O O
fasciculations O O
; O O
moreover O O
, O O
intragastric O O
pressure O O
remains O O
at O O
its O O
control O O
value O O
. O O

Acute O O
insulin O O
treatment O O
normalizes O O
the O O
resistance O O
to O O
the O O
cardiotoxic O O
effect O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diabetic O O
rats O O
. O O

A O O
morphometric O O
study O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
myocardial O O
fibrosis O O
. O O

The O O
acute O O
effect O O
of O O
insulin O O
treatment O O
on O O
the O O
earlier O O
reported O O
protective O O
effect O O
of O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
diabetes O O
against O O
the O O
cardiotoxic O O
effect O O
of O O
high O O
doses O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
was O O
investigated O O
in O O
rats O O
. O O

Thirty O O
to O O
135 O O
min O O
after O O
the O O
injection O O
of O O
crystalline O O
insulin O O
, O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
given O O
subcutaneously O O
and O O
when O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O O
fibrosis O O
in O O
the O O
myocardium O O
was O O
morphometrically O O
analyzed O O
7 O O
days O O
later O O
, O O
a O O
highly O O
significant O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
83 O O
, O O
2 O O
p O O
= O O
0 O O
. O O
006 O O
) O O
to O O
the O O
slope O O
of O O
the O O
fall O O
in O O
blood O O
glucose B B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
after O O
insulin O O
treatment O O
appeared O O
. O O

The O O
myocardial O O
content O O
of O O
catecholamines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
estimated O O
in O O
these O O
8 O O
day O O
diabetic O O
rats O O
. O O

The O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O O
was O O
significantly O O
increased O O
while O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O O
unchanged O O
. O O

An O O
enhanced O O
sympathetic O O
nervous O O
system O O
activity O O
with O O
a O O
consequent O O
down O O
regulation O O
of O O
the O O
myocardial O O
beta O O
- O O
adrenergic O O
receptors O O
could O O
, O O
therefore O O
, O O
explain O O
this O O
catecholamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance O O
. O O

The O O
rapid O O
reversion O O
after O O
insulin O O
treatment O O
excludes O O
the O O
possibility O O
that O O
streptozotocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
itself O O
causes O O
the O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
resistance O O
and O O
points O O
towards O O
a O O
direct O O
insulin O O
effect O O
on O O
myocardial O O
catecholamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitivity O O
in O O
diabetic O O
rats O O
. O O

The O O
phenomenon O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
described O O
might O O
elucidate O O
pathogenetic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behind O O
toxic O B_DISEASE
myocardial O I_DISEASE
cell O I_DISEASE
degeneration O I_DISEASE
and O O
may O O
possibly O O
have O O
relevance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
acute O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiovascular O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complications O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
diabetic O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
. O O

Differential O O
effects O O
of O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
on O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
rats O O
. O O

The O O
muscarinic O O
cholinergic O O
agonist O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
in O O
rats O O
seizures O O
and O O
status O O
epilepticus O O
followed O O
by O O
widespread O O
damage O O
to O O
the O O
forebrain O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
effect O O
of O O
5 O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
, O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phenylbutazone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mefenamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Pretreatment O O
of O O
rats O O
with O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ED50 O O
103 O O
mg O O
/ O O
kg O O
( O O
60 O O
- O O
174 O O
) O O
, O O
and O O
phenylbutazone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
59 O O
mg O O
/ O O
kg O O
( O O
50 O O
- O O
70 O O
) O O
converted O O
the O O
non O O
- O O
convulsant O O
dose O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
200 O O
mg O O
/ O O
kg O O
, O O
to O O
a O O
convulsant O O
one O O
. O O

Indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
1 O O
- O O
10 O O
mg O O
/ O O
kg O O
, O O
and O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
10 O O
- O O
100 O O
mg O O
/ O O
kg O O
, O O
failed O O
to O O
modulate O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mefenamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
26 O O
( O O
22 O O
- O O
30 O O
) O O
mg O O
/ O O
kg O O
, O O
prevented O O
seizures O O
and O O
protected O O
rats O O
from O O
seizure O O
- O O
related O O
brain O O
damage O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
380 O O
mg O O
/ O O
kg O O
. O O

These O O
results O O
indicate O O
that O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
differentially O O
modulate O O
the O O
threshold O O
for O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
seizures O O
. O O

Acute O O
neurologic O O
dysfunction O O
after O O
high O O
- O O
dose O O
etoposide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
malignant O O
glioma O O
. O O

Etoposide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VP B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
16 I I_LOCATION/I_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
213 I I_LOCATION/I_PROTEIN[GENE]
) O O
has O O
been O O
used O O
in O O
the O O
treatment O O
of O O
many O O
solid O O
tumors O O
and O O
hematologic O O
malignancies O O
. O O

When O O
used O O
in O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplantation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
cancers O I_DISEASE_ADJECTIVE[DISEASE]
including O O
malignant O B_DISEASE
glioma O I_DISEASE
. O O

In O O
six O B_NUMBER[MEASURE]
of O O
eight O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
75 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
) O O
who O O
we O O
treated O O
for O O
recurrent O B_DISEASE_ADJECTIVE[DISEASE]
or O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]
glioma O I_DISEASE_ADJECTIVE[DISEASE]
, O O
sudden O B_DISEASE
severe O I_DISEASE
neurologic O I_DISEASE
deterioration O I_DISEASE
occurred O O
. O O

This O O
developed O O
a O O
median O O
of O O
9 O O
days O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
etoposide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

Significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
clinical O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
manifestations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
have O O
included O O
confusion O B_DISEASE
, O O
papilledema O B_DISEASE
, O O
somnolence O B_DISEASE
, O O
exacerbation O B_DISEASE
of O O
motor O B_DISEASE
deficits O I_DISEASE
, O O
and O O
sharp O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
seizure O B_DISEASE/B_MEASURE
activity O I_DISEASE/I_MEASURE
. O O

These O O
abnormalities O O
resolved O O
rapidly O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
intravenous O O
dexamethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

In O O
all O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
computerized O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tomographic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
CT O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
brain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scans O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O O
stability O B_DISEASE_ADJECTIVE[DISEASE]
in O O
tumor O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
size O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
peritumor O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
edema O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
when O O
compared O O
with O O
pretransplant O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scans O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
complication O O
appears O O
to O O
represent O O
a O O
significant O O
new O O
toxicity O O
of O O
high O O
- O O
dose O O
etoposide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
malignant O O
glioma O O
. O O

Progressive O O
bile O O
duct O O
injury O O
after O O
thiabendazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O O
. O O

A O O
27 O O
- O O
yr O O
- O O
old O O
man O O
developed O O
jaundice O O
2 O O
wk O O
after O O
exposure O O
to O O
thiabendazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Cholestasis O B_DISEASE/B_PERSON
persisted O O
for O O
3 O B_TIME[MEASURE]
yr O I_TIME[MEASURE]
, O O
at O O
which O O
time O B_TIME[MEASURE]/B_LOCATION
a O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
. O O

Two O B_PERSON
liver O I_PERSON
biopsy O I_PERSON
specimens O I_PERSON
and O O
the O O
hepatectomy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specimen O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
remarkable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
almost O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappearance O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
interlobular O B_DISEASE
bile O I_DISEASE
ducts O I_DISEASE
. O O

Prominent O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fibrosis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
hepatocellular O B_DISEASE
regeneration O I_DISEASE
were O O
also O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
the O O
lobular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
architecture O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
preserved O O
. O O

This O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O O
an O O
example O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
" O B_PERSON/B_LOCATION
idiosyncratic O I_PERSON/I_LOCATION
" O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
liver O B_DISEASE
damage O I_DISEASE
in O O
which O O
the O O
primary O B_LOCATION/B_PERSON
target O I_LOCATION/I_PERSON
of O O
injury O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
the O O
bile O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
duct O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
autoimmune O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
bile O B_DISEASE/B_BIO
duct O I_DISEASE/I_BIO
destruction O I_DISEASE/I_BIO
is O O
suggested O O
. O O

Differential O O
effects O O
of O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dihydropyridine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
calcium B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
therapeutic O O
implications O O
. O O

Increasing O O
recognition O O
of O O
the O O
importance O O
of O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
pathogenesis O O
of O O
cardiovascular O O
disease O O
has O O
stimulated O O
research O O
into O O
the O O
use O O
of O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocking I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
treatment O O
of O O
a O O
variety O O
of O O
cardiovascular O O
diseases O O
. O O

The O O
favorable O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
tolerability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
these O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
make O O
them O O
attractive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapeutic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
modalities O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Clinical O O
applications O O
of O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
parallel O O
their O O
tissue O O
selectivity O O
. O O

In O O
contrast O O
to O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
are O O
roughly O O
equipotent O O
in O O
their O O
actions O O
on O O
the O O
heart O O
and O O
vascular O O
smooth O O
muscle O O
, O O
the O O
dihydropyridine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
a O O
group O O
of O O
potent O O
peripheral O O
vasodilator O O
agents O O
that O O
exert O O
minimal O O
electrophysiologic O O
effects O O
on O O
cardiac O O
nodal O O
or O O
conduction O O
tissue O O
. O O

As O O
the O O
first O O
dihydropyridine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O O
for O O
use O O
in O O
the O O
United O O
States O O
, O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O O
angina O O
and O O
hypertension O O
with O O
minimal O O
depression O O
of O O
cardiac O O
function O O
. O O

Additional O O
members O O
of O O
this O O
group O O
of O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
studied O O
for O O
a O O
variety O O
of O O
indications O O
for O O
which O O
they O O
may O O
offer O O
advantages O O
over O O
current O O
therapy O O
. O O

Once O O
or O O
twice O O
daily O O
dosage O O
possible O O
with O O
nitrendipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nisoldipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
offers O O
a O O
convenient O O
administration O O
schedule O O
, O O
which O O
encourages O O
patient O O
compliance O O
in O O
long O O
- O O
term O O
therapy O O
of O O
hypertension O O
. O O

The O O
coronary O O
vasodilating O O
properties O O
of O O
nisoldipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
led O O
to O O
the O O
investigation O O
of O O
this O O
agent O O
for O O
use O O
in O O
angina O O
. O O

Selectivity O O
for O O
the O O
cerebrovascular O O
bed O O
makes O O
nimodipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potentially O O
useful O O
in O O
the O O
treatment O O
of O O
subarachnoid O O
hemorrhage O O
, O O
migraine O O
headache O O
, O O
dementia O O
, O O
and O O
stroke O O
. O O

In O O
general O O
, O O
the O O
dihydropyridine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
usually O O
well O O
tolerated O O
, O O
with O O
headache O O
, O O
facial O O
flushing O O
, O O
palpitations O O
, O O
edema O O
, O O
nausea O O
, O O
anorexia O O
, O O
and O O
dizziness O O
being O O
the O O
more O O
common O O
adverse O O
effects O O
. O O

The O O
enhancement O O
of O O
aminonucleoside B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrosis O O
by O O
the O O
co O O
- O O
administration O O
of O O
protamine O O
. O O

An O O
experimental O O
model O O
of O O
focal O O
segmental O O
glomerular O O
sclerosis O O
( O O
FSGS O O
) O O
was O O
developed O O
in O O
rats O O
by O O
the O O
combined O O
administration O O
of O O
puromycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminonucleoside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AMNS B B_LOCATION/B_ORGANIZATION
) O O
and O O
protamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PS B B_LOCATION/B_DISEASE
) O O
. O O

Male O O
Sprague O O
- O O
Dawley O O
rats O O
, O O
uninephrectomized O O
three O O
weeks O O
before O O
, O O
received O O
daily O O
injections O O
of O O
subcutaneous O O
AMNS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
1 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
and O O
intravenous O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O O
separated O O
doses O O
of O O
2 O O
. O O
5 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
for O O
four O O
days O O
. O O

The O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
injections O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
repeated O O
another O O
three O B_TIME[MEASURE]
times O I_TIME[MEASURE]
at O O
10 O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
intervals O I_TIME[MEASURE]/I_LOCATION
. O O

The O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
sacrificed O O
on O O
days O B_TIME[MEASURE]
24 O I_TIME[MEASURE]
, O O
52 O B_MEASURE
, O O
and O O
80 O B_MEASURE
. O O

They O O
developed O O
nephrotic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
finally O O
renal O B_DISEASE
failure O I_DISEASE
. O O

The O O
time O O
- O O
course O O
curve O O
of O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearance O O
dropped O O
and O O
showed O O
significant O O
difference O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
from O O
that O O
of O O
each O O
control O O
group O O
, O O
such O O
as O O
, O O
AMNS B B_LOCATION/B_ORGANIZATION
alone O O
, O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
or O O
saline O O
injected O O
. O O

Their O O
glomeruli O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
showed O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]
FSGS O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
ultrastructural O O
studies O O
in O O
the O O
initial O O
stage O O
revealed O O
significant O O
lack O O
of O O
particles O O
of O O
perfused O O
ruthenium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
red O O
on O O
the O O
lamina O O
rara O O
externa O O
and O O
marked O O
changes O O
in O O
epithelial O O
cell O O
cytoplasm O O
. O O

Therefore O O
, O O
it O O
is O O
suggested O O
that O O
the O O
administration O O
of O O
PS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enhances O O
the O O
toxicity O O
of O O
AMNS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
glomerulus O O
and O O
readily O O
produces O O
progressive O O
FSGS O O
in O O
rats O O
resulting O O
in O O
the O O
end O O
- O O
stage O O
renal O O
disease O O
. O O

Theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxicity O O
in O O
pregnant O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
investigation O O
was O O
to O O
determine O O
whether O O
the O O
neurotoxicity O O
of O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
altered O O
in O O
advanced O O
pregnancy O O
. O O

Sprague O O
- O O
Dawley O O
rats O O
that O O
were O O
20 O O
days O O
pregnant O O
and O O
nonpregnant O O
rats O O
of O O
the O O
same O O
age O O
and O O
strain O O
received O O
infusions O O
of O O
aminophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O O
onset O O
of O O
maximal O O
seizures O O
which O O
occurred O O
after O O
28 O O
and O O
30 O O
minutes O O
respectively O O
. O O

Theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
concentrations O O
at O O
this O O
endpoint O O
in O O
serum O O
( O O
total O O
) O O
and O O
CSF O O
were O O
similar O O
but O O
serum O O
( O O
free O O
) O O
and O O
brain O O
concentrations O O
were O O
slightly O O
different O O
in O O
pregnant O O
rats O O
. O O

Theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
serum O O
protein O O
binding O O
determined O O
by O O
equilibrium O O
dialysis O O
was O O
lower O O
in O O
pregnant O O
rats O O
. O O

Fetal O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
seizures O B_DISEASE/B_ORGANISM_FUNCTION
in O O
the O O
mother O B_PERSON
were O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
maternal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
CSF O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
concentrations O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O O
correlated O O
significantly O O
with O O
the O O
former O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

It O O
is O O
concluded O O
that O O
advanced O O
pregnancy O O
has O O
a O O
negligible O O
effect O O
on O O
the O O
neurotoxic O O
response O O
to O O
theophylline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O O
. O O

Hyperkalemia O O
induced O O
by O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
reversed O O
by O O
fludrocortisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
described O O
a O O
patient O O
with O O
severe O O
rheumatoid O O
arthritis O O
and O O
a O O
history O O
of O O
mefenamic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O O
in O O
whom O O
hyperkalemia O O
and O O
inappropriate O O
hypoaldosteronism O O
were O O
caused O O
by O O
both O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
naproxen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
without O O
major O O
decline O O
in O O
renal O O
function O O
. O O

It O O
is O O
likely O O
that O O
preexisting O O
renal O O
disease O O
predisposed O O
this O O
patient O O
to O O
type O O
IV O O
renal O O
tubular O O
acidosis O O
with O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthetase O O
inhibitors O O
. O O

Because O O
he O O
was O O
unable O O
to O O
discontinue O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
therapy O O
, O O
fludrocortisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
added O O
, O O
correcting O O
the O O
hyperkalemia O O
and O O
allowing O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
therapy O O
to O O
be O O
continued O O
safely O O
. O O

Hypotension O O
as O O
a O O
manifestation O O
of O O
cardiotoxicity O O
in O O
three O O
patients O O
receiving O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cardiac O O
symptoms O O
, O O
including O O
hypotension O O
, O O
developed O O
in O O
three O O
patients O O
with O O
advanced O O
colorectal O O
carcinoma O O
while O O
being O O
treated O O
with O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CDDP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
. O O

In O O
two O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
hypotension O B_DISEASE
was O O
associated O O
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
left O O
ventricular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysfunction O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

All O O
three O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
required O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
discontinuation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
enzymes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
remained O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
despite O O
transient O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrocardiographic O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EKG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
presentation O O
and O O
cardiac O O
evaluation O O
( O O
hemodynamic O O
, O O
echocardiographic O O
, O O
and O O
scintigraphic O O
) O O
of O O
these O O
patients O O
suggest O O
new O O
manifestations O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
that O O
may O O
be O O
influenced O O
by O O
CDDP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
possible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathophysiologic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

Fatal O O
aplastic O O
anemia O O
in O O
a O O
patient O O
treated O O
with O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
case O O
of O O
fatal O O
aplastic O O
anemia O O
due O O
to O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
an O O
epileptic O O
woman O O
is O O
reported O O
. O O

Despite O O
concerns O O
of O O
fatal O O
bone O O
marrow O O
toxicity O O
due O O
to O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
this O O
is O O
only O O
the O O
fourth O O
documented O O
and O O
published O O
report O O
. O O

Carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
safe O O
drug O O
, O O
but O O
physicians O O
and O O
patients O O
should O O
be O O
aware O O
of O O
the O O
exceedingly O O
rare O O
but O O
potentially O O
fatal O O
side O O
effects O O
, O O
better O O
prevented O O
by O O
clinical O O
than O O
by O O
laboratory O O
monitoring O O
. O O

Participation O O
of O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
in O O
the O O
rat O O
brain O O
in O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypotension O O
and O O
bradycardia O O
. O O

The O O
effects O O
of O O
microinjection O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O O
- O O
10 O O
micrograms O O
in O O
1 O O
microliter O O
) O O
into O O
a O O
region O O
adjacent O O
to O O
the O O
ventrolateral O O
surface O O
of O O
the O O
medulla O O
oblongata O O
on O O
cardiovascular O O
function O O
were O O
assessed O O
in O O
urethane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
anesthetized O O
rats O O
. O O

Intramedullary O O
administration O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
saline O O
vehicle O O
, O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
both O O
the O O
mean O O
arterial O O
pressure O O
and O O
the O O
heart O O
rate O O
. O O

The O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
hypotension O O
was O O
antagonized O O
by O O
prior O O
spinal O O
transection O O
, O O
but O O
not O O
bilateral O O
vagotomy O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
induced O O
bradycardia O O
was O O
antagonized O O
by O O
prior O O
bilateral O O
vagotomy O O
, O O
but O O
not O O
spinal O O
transection O O
. O O

Furthermore O O
, O O
selective O O
destruction O O
of O O
the O O
spinal O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
HT I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
nerves O O
, O O
produced O O
by O O
bilateral O O
spinal O O
injection O O
of O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydroxytryptamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
the O O
magnitude O O
of O O
the O O
vasodepressor O O
or O O
the O O
bradycardiac O O
responses O O
to O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microinjected O O
into O O
the O O
area O O
near O O
the O O
ventrolateral O O
surface O O
of O O
the O O
medulla O O
oblongata O O
in O O
rats O O
. O O

The O O
data O O
indicate O O
that O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
is O O
involved O O
in O O
development O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypotension O O
and O O
bradycardia O O
. O O

The O O
induced O B_DISEASE
hypotension O I_DISEASE
is O O
brought O O
about O O
by O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
sympathetic O B_DISEASE/B_GENE
efferent O I_DISEASE/I_GENE
activity O I_DISEASE/I_GENE
, O O
whereas O O
the O O
induced O O
bradycardia O B_DISEASE
was O O
due O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vagal O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efferent O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hypertension O O
in O O
neuroblastoma O O
induced O O
by O O
imipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Hypertension O B_DISEASE/B_GENE
is O O
a O O
well O O
- O O
known O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
some O O
patients O B_PERSON/B_BIO
with O O
neuroblastoma O B_DISEASE/B_LOCATION
. O O

However O O
, O O
it O O
has O O
not O O
previously O O
been O O
described O O
in O O
association O O
with O O
the O O
use O O
of O O
Imipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
report O O
the O O
occurrence O O
of O O
severe O O
hypertension O O
( O O
blood O O
pressure O O
190 O O
/ O O
160 O O
) O O
in O O
a O O
4 O O
- O O
year O O
- O O
old O O
girl O O
with O O
neuroblastoma O O
who O O
was O O
given O O
Imipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
control O O
a O O
behavior O O
disorder O O
. O O

It O O
was O O
determined O O
later O O
that O O
this O O
patient O B_PERSON
' O O
s O B_DISEASE
tumor O I_DISEASE
was O O
recurring O O
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
her O O
hypertensive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
episode O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Since O O
she O O
had O O
no O O
blood O O
pressure O O
elevation O O
at O O
initial O O
diagnosis O O
and O O
none O O
following O O
discontinuation O O
of O O
the O O
Imipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
when O O
she O O
was O O
in O O
florid O O
relapse O O
) O O
, O O
we O O
believe O O
that O O
this O O
drug O O
rather O O
than O O
her O O
underlying O O
disease O O
alone O O
caused O O
her O O
hypertension O O
. O O

The O O
mechanism O O
for O O
this O O
reaction O O
is O O
believed O O
to O O
be O O
increased O O
levels O O
of O O
vasoactive O O
catecholamines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
due O O
to O O
interference O O
of O O
their O O
physiologic O O
inactivation O O
by O O
Imipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

From O O
this O O
experience O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
urge O O
extreme O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caution O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
tricyclic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antidepressants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
children O B_PERSON/B_BIO
with O O
active O B_DISEASE
neuroblastoma O I_DISEASE
. O O

Rechallenge O O
of O O
patients O O
who O O
developed O O
oral O O
candidiasis O O
or O O
hoarseness O O
with O O
beclomethasone B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dipropionate I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Of O O
158 O O
asthmatic O O
patients O O
who O O
were O O
placed O O
on O O
inhaled O O
beclomethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
15 O O
( O O
9 O O
. O O
5 O O
% O O
) O O
developed O O
either O O
hoarseness O O
( O O
8 O O
) O O
, O O
oral O O
thrush O O
( O O
6 O O
) O O
, O O
or O O
both O O
( O O
1 O O
) O O
. O O

When O O
their O O
adverse O O
reactions O O
subsided O O
, O O
seven O O
of O O
these O O
15 O O
patients O O
were O O
rechallenged O O
with O O
inhaled O O
beclomethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
included O O
five O B_NUMBER[MEASURE]
cases O I_NUMBER[MEASURE]
who O O
developed O O
hoarseness O B_DISEASE
and O O
three O B_NUMBER[MEASURE]
who O O
developed O O
Candidiasis O B_DISEASE
. O O

One O B_PERSON
patient O I_PERSON
had O O
both O O
. O O

Oral O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrush O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
recur O B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
60 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
( O O
3 O B_MEASURE
/ O O
5 O B_SEQUENCE[MEASURE]
) O O
of O O
patients O B_PERSON/B_BIO
with O O
hoarseness O B_DISEASE
had O O
recurrence O B_DISEASE
. O O

We O O
conclude O O
that O O
patients O O
may O O
be O O
restarted O O
on O O
inhaled O O
beclomethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
clinically O O
indicated O O
; O O
however O O
, O O
because O O
of O O
the O O
high O O
recurrence O O
rate O O
, O O
patients O O
who O O
develop O O
hoarseness O O
should O O
not O O
be O O
re O O
- O O
challenged O O
. O O

Concomitant O O
use O O
of O O
oral O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
topical O O
beclomethasone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
increase O O
the O O
risk O O
of O O
developing O O
hoarseness O O
or O O
candidiasis O O
. O O

Cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cardiotoxicity O O
: O O
an O O
analysis O O
of O O
dosing O O
as O O
a O O
risk O O
factor O O
. O O

Patients O O
who O O
undergo O O
bone O O
marrow O O
transplantation O O
are O O
generally O O
immunosuppressed O O
with O O
a O O
dose O O
of O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CYA B B_LOCATION/B_ORGANIZATION
) O O
which O O
is O O
usually O O
calculated O O
based O O
on O O
the O O
patient O O
' O O
s O O
weight O O
. O O

At O O
these O O
high O O
doses O O
of O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
serious O O
cardiotoxicity O O
may O O
occur O O
, O O
but O O
definitive O O
risk O O
factors O O
for O O
the O O
development O O
of O O
such O O
cardiotoxicity O O
have O O
not O O
been O O
described O O
. O O

Since O O
chemotherapeutic O O
agent O O
toxicity O O
generally O O
correlates O O
with O O
dose O O
per O O
body O O
surface O O
area O O
, O O
we O O
retrospectively O O
calculated O O
the O O
dose O O
of O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
transplanted O O
at O O
our O O
institution O O
to O O
determine O O
whether O O
the O O
incidence O O
of O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
correlated O O
with O O
the O O
dose O O
per O O
body O O
surface O O
area O O
. O O

Eighty O O
patients O O
who O O
were O O
to O O
receive O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O O
mg O O
/ O O
kg O O
/ O O
d O O
for O O
four O O
days O O
as O O
preparation O O
for O O
marrow O O
grafting O O
underwent O O
a O O
total O O
of O O
84 O O
transplants O O
for O O
aplastic O O
anemia O O
, O O
Wiskott O O
- O O
Aldrich O O
syndrome O O
, O O
or O O
severe O O
combined O O
immunodeficiency O O
syndrome O O
. O O

Fourteen O O
of O O
84 O O
( O O
17 O O
% O O
) O O
patients O O
had O O
symptoms O O
and O O
signs O O
consistent O O
with O O
CYA B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
within O O
ten O O
days O O
of O O
receiving O O
1 O O
to O O
4 O O
doses O O
of O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Six O B_NUMBER[MEASURE]
of O O
the O O
14 O B_PERSON
patients O I_PERSON
died O O
with O O
congestive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
dose O O
of O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O O
body O O
surface O O
area O O
was O O
calculated O O
for O O
all O O
patients O O
and O O
the O O
patients O O
were O O
divided O O
into O O
two O O
groups O O
based O O
on O O
daily O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
: O O
Group O O
1 O O
, O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
less O O
than O O
or O O
equal O O
to O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
; O O
Group O O
2 O O
, O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
greater O O
than O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
. O O

Cardiotoxicity O O
that O O
was O O
thought O O
to O O
be O O
related O O
to O O
CYA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurred O O
in O O
1 O O
/ O O
32 O O
( O O
3 O O
% O O
) O O
of O O
patients O O
in O O
Group O O
1 O O
and O O
in O O
13 O O
/ O O
52 O O
( O O
25 O O
% O O
) O O
patients O O
in O O
Group O O
2 O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
. O O

Congestive O B_DISEASE/B_LOCATION
heart O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
caused O O
or O O
contributed O O
to O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
0 O B_MEASURE
/ O O
32 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
in O O
Group O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
v O O
6 O B_NUMBER[MEASURE]
/ O O
52 O B_MEASURE
( O O
12 O B_MEASURE
% O I_MEASURE
) O O
of O O
patients O B_PERSON
in O O
Group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
2 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
25 O B_MEASURE
) O O
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
the O O
rate O B_MEASURE
of O O
engraftment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
evaluable O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
patients O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
in O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
P O B_MEASURE/B_LOCATION
greater O I_MEASURE/I_LOCATION
than O O
0 O B_MEASURE
. O O
5 O B_MEASURE
) O O
. O O

We O O
conclude O O
that O O
the O O
CYA B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
correlates O O
with O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O O
as O O
calculated O O
by O O
body O O
surface O O
area O O
, O O
and O O
that O O
patients O O
with O O
aplastic O O
anemia O O
and O O
immunodeficiencies O O
can O O
be O O
effectively O O
prepared O O
for O O
bone O O
marrow O O
grafting O O
at O O
a O O
CYA B B_MEASURE
dose O O
of O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
for O O
four O O
days O O
with O O
a O O
lower O O
incidence O O
of O O
cardiotoxicity O O
than O O
patients O O
whose O O
CYA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O O
is O O
calculated O O
based O O
on O O
weight O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaffirms O O
the O O
principle O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
that O O
drug O B_DISEASE
toxicity O I_DISEASE
correlates O O
with O O
dose O B_MEASURE/B_DISEASE
per O O
body O B_TIME[MEASURE]/B_PERSON
surface O I_TIME[MEASURE]/I_PERSON
area O I_TIME[MEASURE]/I_PERSON
. O O

Studies O O
of O O
risk O O
factors O O
for O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity O O
. O O

The O O
epidemiology O O
of O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
nephrotoxicity O O
is O O
not O O
fully O O
understood O O
. O O

Experimental O O
studies O O
in O O
healthy O O
human O O
volunteers O O
indicate O O
aminoglycosides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cause O O
proximal O O
tubular O O
damage O O
in O O
most O O
patients O O
, O O
but O O
rarely O O
, O O
if O O
ever O O
, O O
cause O O
glomerular O O
or O O
tubular O O
dysfunction O O
. O O

Clinical O O
trials O O
of O O
aminoglycosides B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
seriously O O
ill O O
patients O O
indicate O O
that O O
the O O
relative O O
risk O O
for O O
developing O O
acute O O
renal O O
failure O O
during O O
therapy O O
ranges O O
from O O
8 O O
to O O
10 O O
and O O
that O O
the O O
attributable O O
risk O O
is O O
70 O O
% O O
to O O
80 O O
% O O
. O O

Further O O
analysis O O
of O O
these O O
data O O
suggests O O
that O O
the O O
duration O O
of O O
therapy O O
, O O
plasma O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
, O O
liver O O
disease O O
, O O
advanced O O
age O O
, O O
high O O
initial O O
estimated O O
creatinine B B_BODY_PART_OR_ORGAN_COMPONENT
clearance O O
and O O
, O O
possibly O O
, O O
female O O
gender O O
all O O
increase O O
the O O
risk O O
for O O
nephrotoxicity O O
. O O

Other O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
shock O B_DISEASE
, O O
appear O O
to O O
have O O
an O O
additive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Predictive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
been O O
developed O O
from O O
these O O
analyses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
should O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
identifying O O
patients O B_PERSON/B_LOCATION
at O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
models O O
may O O
also O O
be O O
useful O O
in O O
developing O O
insights O O
into O O
the O O
pathophysiology O O
of O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
nephrotoxicity O O
. O O

Central O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
narcotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesics O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
IV O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

Noradrenergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
analgesics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effect O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
naphazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
xylometazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
analgesia O O
induced O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
codeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pentazocine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
on O O
cataleptic O O
effect O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
codine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
studied O O
in O O
rats O O
. O O

The O O
biochemical O O
assays O O
on O O
the O O
influence O O
of O O
four O O
analgesics O O
on O O
the O O
brain O O
concentration O O
and O O
turnover O O
of O O
noradrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
were O O
also O O
performed O O
. O O

It O O
was O O
found O O
that O O
three O O
drugs O O
stimulating O O
central O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O O
failed O O
to O O
affect O O
the O O
analgesic O O
ED50 O O
of O O
all O O
antinociceptive O O
agents O O
and O O
they O O
enhanced O O
catalepsy O O
induced O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Codeine B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
catalepsy O O
was O O
increased O O
by O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
decreased O O
by O O
naphazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
xylometazoline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
brain O O
concentration O O
of O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
changed O O
by O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
one O O
of O O
the O O
doses O O
of O O
codeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
45 O O
mg O O
/ O O
kg O O
) O O
slightly O O
enhanced O O
it O O
. O O

Pentazocine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dose O O
- O O
dependently O O
decreased O O
the O O
brain O O
level O O
of O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
rate O O
of O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
turnover O O
was O O
not O O
altered O O
by O O
analgesics O O
except O O
for O O
the O O
higher O O
dose O O
of O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
2 O O
mg O O
/ O O
kg O O
) O O
following O O
which O O
the O O
disappearance O O
of O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O O
the O O
brain O O
was O O
diminished O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
discussed O O
in O O
the O O
light O B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
non O B_DISEASE/B_MEASURE
- O O
uniform O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
suggested O O
that O O
in O O
rats O O
the O O
brain O O
NA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O O
a O O
less O O
important O O
function O O
than O O
the O O
other O O
monoamines B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
behavioural O O
activity O O
of O O
potent O O
analgesics O O
. O O

Flurothyl B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
seizure O O
thresholds O O
in O O
mice O O
treated O O
neonatally O O
with O O
a O O
single O O
injection O O
of O O
monosodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
: O O
evaluation O O
of O O
experimental O O
parameters O O
in O O
flurothyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seizure O O
testing O O
. O O

Monosodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
administration O O
to O O
neonatal O O
rodents O O
produces O O
convulsions O O
and O O
results O O
in O O
numerous O O
biochemical O O
and O O
behavioral O O
deficits O O
. O O

These O O
studies O O
were O O
undertaken O O
to O O
determine O O
if O O
neonatal O O
administration O O
of O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
permanent O O
alterations O O
in O O
seizure O O
susceptibility O O
, O O
since O O
previous O O
investigations O O
were O O
inconclusive O O
. O O

A O O
flurothyl B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ether B I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seizure O O
screening O O
technique O O
was O O
used O O
to O O
evaluate O O
seizure O O
susceptibility O O
in O O
adult O O
mice O O
that O O
received O O
neonatal O O
injections O O
of O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O O
mg O O
/ O O
g O O
and O O
1 O O
mg O O
/ O O
g O O
) O O
. O O

MSG B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
resulted O O
in O O
significant O O
reductions O O
in O O
whole O O
brain O O
weight O O
but O O
did O O
not O O
alter O O
seizure O O
threshold O O
. O O

A O O
naloxone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
5 O O
mg O O
/ O O
kg O O
) O O
challenge O O
was O O
also O O
ineffective O O
in O O
altering O O
the O O
seizure O O
thresholds O O
of O O
either O O
control O O
of O O
MSG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
treated O O
mice O O
. O O

Flurothyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
ether B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
produced O O
hypothermia O O
which O O
was O O
correlated O O
with O O
the O O
duration O O
of O O
flurothyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
; O O
however O O
, O O
the O O
relationship O O
of O O
hypothermia O O
to O O
seizure O O
induction O O
was O O
unclear O O
. O O

Flurothyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seizure O O
testing O O
proved O O
to O O
be O O
a O O
rapid O O
and O O
reliable O O
technique O O
with O O
which O O
to O O
evaluate O O
seizure O O
susceptibility O O
. O O

Susceptibility O O
to O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
rats O O
after O O
microinjection O O
of O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vinyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GABA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
the O O
substantia O O
nigra O O
. O O

Pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
given O O
intraperitoneally O O
to O O
rats O O
, O O
reproduces O O
the O O
neuropathological O O
sequelae O O
of O O
temporal O O
lobe O O
epilepsy O O
and O O
provides O O
a O O
relevant O O
animal O O
model O O
for O O
studying O O
mechanisms O O
of O O
buildup O O
of O O
convulsive O O
activity O O
and O O
pathways O O
operative O O
in O O
the O O
generalization O O
and O O
propagation O O
of O O
seizures O O
within O O
the O O
forebrain O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
manipulating O O
the O O
activity O O
of O O
the O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
- O O
mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
on O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O O
, O O
were O O
investigated O O
. O O

In O O
animals O O
pretreated O O
with O O
microinjections O O
of O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
150 O O
micrograms O O
, O O
an O O
inhibitor O O
of O O
activity O O
of O O
the O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
synthesizing O O
enzyme O O
, O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decarboxylase O O
, O O
into O O
the O O
substantia O O
nigra O O
pars O O
reticulata O O
( O O
SNR O O
) O O
, O O
bilaterally O O
, O O
non O O
- O O
convulsant O O
doses O O
of O O
pilocarpine B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
100 O O
and O O
200 O O
mg O O
/ O O
kg O O
, O O
resulted O O
in O O
severe O O
motor O O
limbic O O
seizures O O
and O O
status O O
epilepticus O O
. O O

Electroencephalographic O O
and O O
behavioral O O
monitoring O O
revealed O O
a O O
profound O O
reduction O O
of O O
the O O
threshold O O
for O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
convulsions O O
. O O

Morphological O O
analysis O O
of O O
frontal O O
forebrain O O
sections O O
with O O
light O O
microscopy O O
revealed O O
seizure O O
- O O
related O O
damage O O
to O O
the O O
hippocampal O O
formation O O
, O O
thalamus O O
, O O
amygdala O O
, O O
olfactory O O
cortex O O
, O O
substantia O O
nigra O O
and O O
neocortex O O
, O O
which O O
is O O
typically O O
observed O O
with O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
doses O O
exceeding O O
350 O O
mg O O
/ O O
kg O O
. O O

Bilateral O O
intrastriatal O O
injections O O
of O O
isoniazid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
augment O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
200 O O
mg O O
/ O O
kg O O
. O O

Application O O
of O O
an O O
irreversible O O
inhibitor O O
of O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O O
, O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
vinyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GABA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
L I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
4 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
amino I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
hex I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
5 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
enoic I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
acid I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O O
, O O
5 O O
micrograms O O
, O O
into O O
the O O
SNR O O
, O O
bilaterally O O
, O O
suppressed O O
the O O
appearance O O
of O O
electrographic O O
and O O
behavioral O O
seizures O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
380 O O
mg O O
/ O O
kg O O
. O O

This O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
also O O
sufficient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
protect O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
occurrence O B_DISEASE
of O O
brain O B_DISEASE
damage O I_DISEASE
. O O

Microinjections O O
of O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
vinyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GABA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
5 O O
micrograms O O
, O O
into O O
the O O
dorsal O O
striatum O O
, O O
bilaterally O O
, O O
failed O O
to O O
prevent O O
the O O
development O O
of O O
convulsions O O
produced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
380 O O
mg O O
/ O O
kg O O
. O O

The O O
results O O
demonstrate O O
that O O
the O O
threshold O O
for O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizures O O
in O O
rats O O
is O O
subjected O O
to O O
the O O
regulation O O
of O O
the O O
GABA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
. O O

Human O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
canine O B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
ventricular O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
vasoactive O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
intestinal O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
polypeptide O I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
decrease O O
with O O
heart O B_DISEASE
failure O I_DISEASE
. O O

Vasoactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intestinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polypeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
VIP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasodilator O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
may O O
have O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inotropic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Myocardial O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VIP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
assayed O O
before O O
and O O
after O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE
failure O I_DISEASE
in O O
two O B_SPECIES[BIO]/B_PERSON
canine O I_SPECIES[BIO]/I_PERSON
models O I_SPECIES[BIO]/I_PERSON
. O O

In O O
the O O
first O O
, O O
cobalt B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy O O
was O O
induced O O
in O O
eight O O
dogs O O
; O O
VIP O O
( O O
by O O
radioimmunoassay O O
) O O
decreased O O
from O O
35 O O
+ O O
/ O O
- O O
11 O O
pg O O
/ O O
mg O O
protein O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
to O O
5 O O
+ O O
/ O O
- O O
4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
six O O
dogs O O
with O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
heart O O
failure O O
, O O
VIP O O
decreased O O
from O O
31 O O
+ O O
/ O O
- O O
7 O O
to O O
11 O O
+ O O
/ O O
- O O
4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
VIP O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
content O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
resected O O
failing O O
hearts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
10 O B_PERSON
patients O I_PERSON
receiving O O
a O O
heart O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
compared O O
with O O
the O O
papillary O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
muscles O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
14 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
five O B_NUMBER[MEASURE]
with O O
rheumatic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
nine O B_NUMBER[MEASURE]
with O O
myxomatous O B_DISEASE
degeneration O I_DISEASE
) O O
receiving O O
mitral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
prostheses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
lowest O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VIP O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
hearts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON
with O O
coronary O B_DISEASE
disease O I_DISEASE
( O O
one O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
receiving O O
a O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
three O B_NUMBER[MEASURE]/B_PERSON
receiving O O
mitral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
prostheses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
( O O
6 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
9 O B_MEASURE
pg O I_MEASURE
/ O O
mg O B_MEASURE
protein O I_MEASURE
) O O
. O O

The O O
other O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
patients O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
undergoing O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O O
an O O
average O B_MEASURE
ejection O I_MEASURE
fraction O I_MEASURE
of O O
17 O B_MEASURE
% O I_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
% O I_MEASURE
and O O
a O O
VIP O B_MEASURE
level O I_MEASURE
of O O
8 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
. O O
9 O B_MEASURE
pg O I_MEASURE
/ O O
mg O B_MEASURE
protein O I_MEASURE
. O O

The O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
without O O
coronary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
average O B_MEASURE/B_PERSON
ejection O B_MEASURE/I_PERSON
fraction O B_MEASURE/I_PERSON
of O O
this O O
group O B_MEASURE/B_ORGANIZATION
62 O I_MEASURE/I_ORGANIZATION
% O I_MEASURE/I_ORGANIZATION
+ O I_MEASURE/I_ORGANIZATION
/ O O
- O O
10 O B_MEASURE
% O I_MEASURE
) O O
had O O
a O O
VIP O B_MEASURE
concentration O I_MEASURE
of O O
14 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
7 O B_MEASURE
. O O
9 O B_MEASURE
pg O I_MEASURE
/ O O
mg O B_MEASURE
protein O I_MEASURE
, O O
and O O
this O O
was O O
greater O B_MEASURE
than O O
in O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
with O O
coronary O B_DISEASE
disease O I_DISEASE
and O O
the O O
hearts O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
patients O B_PERSON
receiving O O
a O O
transplant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Myocardial O O
catecholamines B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
also O O
determined O O
in O O
14 O O
subjects O O
; O O
a O O
weak O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
57 O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
between O O
the O O
tissue O O
concentrations O O
of O O
VIP O O
and O O
norepinephrine B B_LOCATION/B_ORGANIZATION
was O O
noted O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Non O O
- O O
invasive O O
detection O O
of O O
coronary O O
artery O O
disease O O
by O O
body O O
surface O O
electrocardiographic O O
mapping O O
after O O
dipyridamole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

Electrocardiographic O O
changes O O
after O O
dipyridamole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
( O O
0 O O
. O O
568 O O
mg O O
/ O O
kg O O
/ O O
4 O O
min O O
) O O
were O O
studied O O
in O O
41 O O
patients O O
with O O
coronary O O
artery O O
disease O O
and O O
compared O O
with O O
those O O
after O O
submaximal O O
treadmill O O
exercise O O
by O O
use O O
of O O
the O O
body O O
surface O O
mapping O O
technique O O
. O O

Patients O B_PERSON
were O O
divided O O
into O O
three O B_MEASURE/B_ORGANIZATION
groups O B_MEASURE/I_ORGANIZATION
; O O
19 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
without O O
myocardial O B_DISEASE/B_LOCATION
infarction O I_DISEASE/I_LOCATION
( O O
non O B_LOCATION
- O O
MI O B_LOCATION/B_ORGANIZATION
group O I_LOCATION/I_ORGANIZATION
) O O
, O O
14 O B_NUMBER[MEASURE]
with O O
anterior O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarction O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ANT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
MI O B_LOCATION/B_DISEASE
) O O
and O O
eight O B_NUMBER[MEASURE]
with O O
inferior O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
INF O B_DISEASE/B_PROTEIN[GENE]
- O O
MI O B_LOCATION/B_DISEASE
) O O
. O O

Eighty O B_NUMBER[MEASURE]
- O O
seven O B_NUMBER[MEASURE]
unipolar O I_NUMBER[MEASURE]
electrocardiograms O I_NUMBER[MEASURE]
( O O
ECGs O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
distributed O O
over O O
the O O
entire O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
thoracic O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
surface O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
simultaneously O O
recorded O O
. O O

After O O
dipyridamole B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
ischemic O O
ST O O
- O O
segment O O
depression O O
( O O
0 O O
. O O
05 O O
mV O O
or O O
more O O
) O O
was O O
observed O O
in O O
84 O O
% O O
of O O
the O O
non O O
- O O
MI O O
group O O
, O O
29 O O
% O O
of O O
the O O
ANT O O
- O O
MI O O
group O O
, O O
63 O O
% O O
of O O
the O O
INF O O
- O O
MI O O
group O O
and O O
61 O O
% O O
of O O
the O O
total O O
population O O
. O O

Exercise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
ST O B_DISEASE
depression O I_DISEASE
was O O
observed O O
in O O
84 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
of O O
the O O
non O B_LOCATION
- O O
MI O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
, O O
43 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
ANT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
MI O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
38 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
INF O B_DISEASE/B_LOCATION
- O O
MI O B_ORGANIZATION/B_LOCATION
group O B_ORGANIZATION/I_LOCATION
and O O
61 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
total O B_MEASURE/B_PERSON
. O O

For O O
individual O B_PERSON
patients O I_PERSON
, O O
there O O
were O O
no O O
obvious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
the O O
body O B_MEASURE
surface O I_MEASURE
distribution O I_MEASURE
of O O
ST O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depression O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
increase O O
in O O
pressure O O
rate O O
product O O
after O O
dipyridamole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
significantly O O
less O O
than O O
that O O
during O O
the O O
treadmill O O
exercise O O
. O O

The O O
data O O
suggest O O
that O O
the O O
dipyridamole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
ischemia O O
is O O
caused O O
by O O
the O O
inhomogenous O O
distribution O O
of O O
myocardial O O
blood O O
flow O O
. O O

We O O
conclude O O
that O O
the O O
dipyridamole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ECG O O
test O O
is O O
as O O
useful O O
as O O
the O O
exercise O O
ECG O O
test O O
for O O
the O O
assessment O O
of O O
coronary O O
artery O O
disease O O
. O O

Bradycardia O O
after O O
high O O
- O O
dose O O
intravenous O O
methylprednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

In O O
5 O O
consecutive O O
patients O O
with O O
rheumatoid O O
arthritis O O
who O O
received O O
intravenous O O
high O O
- O O
dose O O
methylprednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
therapy O O
( O O
1 O O
g O O
daily O O
for O O
2 O O
or O O
3 O O
consecutive O O
days O O
) O O
, O O
a O O
decline O O
in O O
pulse O O
rate O O
was O O
observed O O
, O O
most O O
pronounced O O
on O O
day O O
4 O O
. O O

In O O
one O B_NUMBER[MEASURE]
of O O
the O O
5 O B_PERSON
patients O I_PERSON
the O O
bradycardia O B_DISEASE
was O O
associated O O
with O O
complaints O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
substernal O B_DISEASE
pressure O I_DISEASE
. O O

Reversal O B_MEASURE/B_PERSON
to O O
normal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
heart O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
rate O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
found O O
on O O
day O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Electrocardiographic O B_PERSON/B_ORGANIZATION
registrations O I_PERSON/I_ORGANIZATION
showed O O
sinus O B_DISEASE_ADJECTIVE[DISEASE]
bradycardia O I_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
cases O B_PERSON/B_BIO
. O O

No O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electrolytes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
found O O
. O O

Careful O O
observation O O
of O O
patients O O
receiving O O
high O O
- O O
dose O O
MP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
recommended O O
. O O

High O O
- O O
dose O O
MP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
contraindicated O O
in O O
patients O O
with O O
known O O
heart O O
disease O O
. O O

Two O O
cases O O
of O O
downbeat O O
nystagmus O O
and O O
oscillopsia O O
associated O O
with O O
carbamazepine B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Downbeat O B_DISEASE/B_LOCATION
nystagmus O I_DISEASE/I_LOCATION
is O O
often O O
associated O O
with O O
structural O B_DISEASE
lesions O I_DISEASE
at O O
the O O
craniocervical O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junction O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
has O O
occasionally O O
been O O
reported O O
as O O
a O O
manifestation O B_DISEASE
of O O
metabolic O B_DISEASE_ADJECTIVE[DISEASE]
imbalance O I_DISEASE_ADJECTIVE[DISEASE]
or O O
drug O B_DISEASE
intoxication O I_DISEASE
. O O

We O O
recorded O O
the O O
eye O O
movements O O
of O O
two O O
patients O O
with O O
reversible O O
downbeat O O
nystagmus O O
related O O
to O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

The O O
nystagmus O O
of O O
both O O
patients O O
resolved O O
after O O
reduction O O
of O O
the O O
serum O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
. O O

Neuroradiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scans O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
showed O O
no O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intracranial O B_DISEASE
abnormality O I_DISEASE
. O O

In O O
patients O B_PERSON/B_LOCATION
with O O
downbeat O B_DISEASE/B_LOCATION
nystagmus O I_DISEASE/I_LOCATION
who O O
are O O
taking O O
anticonvulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
consideration O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O O
be O O
given O O
to O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
dose O B_MEASURE/B_DISEASE
before O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
undertaken O O
. O O

Improvement O O
by O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TA B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
064 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
failure O O
in O O
the O O
dog O O
heart O O
- O O
lung O O
preparation O O
. O O

The O O
efficacy O O
of O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
orally O O
active O O
beta O O
1 O O
- O O
adrenoceptor O O
agonist O O
, O O
in O O
improving O O
cardiac O O
failure O O
was O O
assessed O O
in O O
dog O O
heart O O
- O O
lung O O
preparations O O
. O O

Cardiac O O
functions O O
depressed O O
by O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
118 O O
+ O O
/ O O
- O O
28 O O
mg O O
; O O
mean O O
value O O
+ O O
/ O O
- O O
SD O O
) O O
such O O
that O O
cardiac O O
output O O
and O O
maximum O O
rate O O
of O O
rise O O
of O O
left O O
ventricular O O
pressure O O
( O O
LV O O
dP O O
/ O O
dt O O
max O O
) O O
had O O
been O O
reduced O O
by O O
about O O
35 O O
% O O
and O O
26 O O
% O O
of O O
the O O
respective O O
controls O O
were O O
improved O O
by O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
- O O
300 O O
micrograms O O
) O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

With O O
100 O O
micrograms O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
almost O O
complete O O
restoration O O
of O O
cardiac O O
performance O O
was O O
attained O O
, O O
associated O O
with O O
a O O
slight O O
increase O O
in O O
heart O O
rate O O
. O O

No O O
arrhythmias O O
were O O
induced O O
by O O
these O O
doses O O
of O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O O
warrant O O
clinical O O
trials O O
of O O
denopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
cardiac O O
failure O O
. O O

Clonazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monotherapy O O
for O O
epilepsy O O
in O O
childhood O O
. O O

Sixty O O
patients O O
( O O
age O O
- O O
range O O
one O O
month O O
to O O
14 O O
years O O
) O O
with O O
other O O
types O O
of O O
epilepsy O O
than O O
infantile O O
spasms O O
were O O
treated O O
with O O
clonazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Disappearance O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
seizures O B_DISEASE
and O O
normalization O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
abnormal O B_DISEASE
EEG O I_DISEASE
with O O
disappearance O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
seizures O B_DISEASE
were O O
recognized O O
in O O
77 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
and O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

Seizures O B_DISEASE/B_PERSON
disappeared O O
in O O
71 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
patients O B_PERSON/B_LOCATION
with O O
generalized O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
seizures O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
89 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
of O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
seizures O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Improvement O B_DISEASE_ADJECTIVE[DISEASE]
of O O
abnormal O B_DISEASE
EEG O I_DISEASE
was O O
noticed O O
in O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
diffuse O B_DISEASE_ADJECTIVE[DISEASE]
paroxysms O I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
67 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
focal O B_DISEASE_ADJECTIVE[DISEASE]
paroxysms O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
excellent O B_MEASURE/B_PERSON
cases O I_MEASURE/I_PERSON
, O O
mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effective O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosages O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
0 O B_MEASURE
. O O
086 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
021 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
day O B_TIME[MEASURE]/B_PERSON
in O O
infants O B_PERSON
and O O
0 O B_MEASURE
. O O
057 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
022 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
day O B_TIME[MEASURE]/B_PERSON
in O O
schoolchildren O B_PERSON/B_BIO
, O O
this O O
difference O B_MEASURE
was O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE/B_LOCATION
. O O
005 O B_MEASURE
) O O
. O O

The O O
incidence O B_MEASURE
of O O
side O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
drowsiness O B_DISEASE
and O O
ataxia O B_DISEASE
was O O
only O O
5 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Postmarketing O O
study O O
of O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
hydrochlorothiazide B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antihypertensive O O
therapy O O
. O O

A O O
postmarketing O O
surveillance O O
study O O
was O O
conducted O O
to O O
determine O O
the O O
safety O O
and O O
efficacy O O
of O O
a O O
fixed O O
- O O
ratio O O
combination O O
containing O O
10 O O
mg O O
of O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maleate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
25 O O
mg O O
of O O
hydrochlorothiazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
administered O O
twice O O
daily O O
for O O
one O O
month O O
to O O
hypertensive O O
patients O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
9 O B_MEASURE
, O O
037 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
were O O
collected O O
by O O
1 O B_MEASURE
, O O
455 O B_MEASURE
participating O O
physicians O B_PERSON/B_LOCATION
. O O

Mean O O
systolic O O
blood O O
pressure O O
decreased O O
25 O O
mmHg O O
and O O
mean O O
diastolic O O
blood O O
pressure O O
declined O O
15 O O
mmHg O O
after O O
one O O
month O O
of O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
hydrochlorothiazide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
, O O
both O O
comparisons O O
) O O
. O O

Age O B_TIME[MEASURE]/B_PERSON
, O O
race O B_SPORT[ENT]/B_PERSON
, O O
and O O
sex O B_PERSON/B_MEASURE
appeared O O
to O O
have O O
no O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
blood O B_DISEASE/B_MEASURE
pressure O I_DISEASE/I_MEASURE
. O O

The O O
antihypertensive O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
patients O B_PERSON/B_BIO
with O O
more O O
severe O B_DISEASE
hypertension O I_DISEASE
. O O

Overall O O
, O O
1 O B_MEASURE
, O O
453 O B_MEASURE
patients O I_MEASURE
experienced O O
a O O
total O B_MEASURE/B_ENT
of O O
2 O B_MEASURE
, O O
658 O B_TIME[MEASURE]
adverse O I_TIME[MEASURE]
events O I_TIME[MEASURE]
, O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
being O I_DISEASE_ADJECTIVE[DISEASE]
fatigue O I_DISEASE_ADJECTIVE[DISEASE]
, O O
dizziness O B_DISEASE
, O O
and O O
weakness O B_DISEASE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
590 O B_MEASURE
patients O I_MEASURE
was O O
discontinued O O
because O O
of O O
adverse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Salicylate B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O O
in O O
the O O
Gunn O O
rat O O
: O O
potential O O
role O O
of O O
prostaglandins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

We O O
examined O O
the O O
potential O O
role O O
of O O
prostaglandins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
development O O
of O O
analgesic O O
nephropathy O O
in O O
the O O
Gunn O O
strain O O
of O O
rat O O
. O O

The O O
homozygous O O
Gunn O O
rats O O
have O O
unconjugated O O
hyperbilirubinemia O O
due O O
to O O
the O O
absence O O
of O O
glucuronyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transferase O O
, O O
leading O O
to O O
marked O O
bilirubin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deposition O O
in O O
renal O O
medulla O O
and O O
papilla O O
. O O

These O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
also O O
highly O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
develop O O
papillary O B_DISEASE
necrosis O I_DISEASE
with O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
used O O
homozygous O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
jj O B_LOCATION/B_PERSON
) O O
and O O
phenotypically O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
heterozygous O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
jJ O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O O
groups O O
of O O
rats O O
( O O
n O O
= O O
7 O O
) O O
were O O
studied O O
: O O
jj O O
and O O
jJ O O
rats O O
treated O O
either O O
with O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O O
mg O O
/ O O
kg O O
every O O
other O O
day O O
or O O
sham O O
- O O
treated O O
. O O

After O O
one O O
week O O
, O O
slices O O
of O O
cortex O O
, O O
outer O O
and O O
inner O O
medulla O O
from O O
one O O
kidney O O
were O O
incubated O O
in O O
buffer O O
and O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
was O O
determined O O
by O O
radioimmunoassay O O
. O O

The O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
kidney O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O O
examined O O
histologically O O
. O O

A O O
marked O O
corticomedullary O O
gradient O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
was O O
observed O O
in O O
all O O
groups O O
. O O

PGE2 B B_GENE
synthesis O O
was O O
significantly O O
higher O O
in O O
outer O O
medulla O O
, O O
but O O
not O O
cortex O O
or O O
inner O O
medulla O O
, O O
of O O
jj O O
( O O
38 O O
+ O O
/ O O
- O O
6 O O
ng O O
/ O O
mg O O
prot O O
) O O
than O O
jJ O O
rats O O
( O O
15 O O
+ O O
/ O O
- O O
3 O O
) O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

Aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O O
reduced O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
in O O
all O O
regions O O
, O O
but O O
outer O O
medullary O O
PGE2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O O
higher O O
in O O
jj O O
( O O
18 O O
+ O O
/ O O
- O O
3 O O
) O O
than O O
jJ O O
rats O O
( O O
9 O O
+ O O
/ O O
- O O
2 O O
) O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

PGF2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
also O O
significantly O O
higher O O
in O O
the O O
outer O O
medulla O O
of O O
jj O O
rats O O
with O O
and O O
without O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

The O O
changes O O
in O O
renal O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
were O O
accompanied O O
by O O
evidence O O
of O O
renal O O
damage O O
in O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
jj O O
but O O
not O O
jJ O O
rats O O
as O O
evidenced O O
by O O
: O O
increased O O
incidence O O
and O O
severity O O
of O O
hematuria O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
; O O
increased O O
serum O O
creatinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
; O O
and O O
increase O O
in O O
outer O O
medullary O O
histopathologic O O
lesions O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
compared O O
to O O
either O O
sham O O
- O O
treated O O
jj O O
or O O
aspirin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
jJ O O
) O O
. O O

These O O
results O O
suggest O O
that O O
enhanced O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
contributes O O
to O O
maintenance O O
of O O
renal O O
function O O
and O O
morphological O O
integrity O O
, O O
and O O
that O O
inhibition O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
may O O
lead O O
to O O
pathological O O
renal O O
medullary O O
lesions O O
and O O
deterioration O O
of O O
renal O O
function O O
. O O

Prophylactic O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
early O O
phase O O
of O O
suspected O O
myocardial O O
infarction O O
. O O

Four O O
hundred O O
two O O
patients O O
with O O
suspected O O
myocardial O O
infarction O O
seen O O
within O O
6 O O
hours O O
of O O
the O O
onset O O
of O O
symptoms O O
entered O O
a O O
double O O
- O O
blind O O
randomized O O
trial O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O O
placebo O O
. O O

During O O
the O O
1 O B_TIME[MEASURE]/B_ENT
hour O I_TIME[MEASURE]/I_ENT
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
ventricular O B_DISEASE_ADJECTIVE[DISEASE]
fibrillation O I_DISEASE_ADJECTIVE[DISEASE]
or O O
sustained O O
ventricular O B_DISEASE
tachycardia O I_DISEASE
among O O
the O O
204 O B_PERSON
patients O I_PERSON
with O O
acute O B_DISEASE
myocardial O I_DISEASE
infarction O I_DISEASE
was O O
low O B_MEASURE/B_COLOR
, O O
1 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
. O O

Lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
given O O
in O O
a O O
300 O O
mg O O
dose O O
intramuscularly O O
followed O O
by O O
100 O O
mg O O
intravenously O O
, O O
did O O
not O O
prevent O O
sustained O O
ventricular O O
tachycardia O O
, O O
although O O
there O O
was O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
patients O O
with O O
warning O O
arrhythmias O O
between O O
15 O O
and O O
45 O O
minutes O O
after O O
the O O
administration O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

The O O
average O O
plasma O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
10 O O
minutes O O
after O O
administration O O
for O O
patients O O
without O O
a O O
myocardial O O
infarction O O
was O O
significantly O O
higher O O
than O O
that O O
for O O
patients O O
with O O
an O O
acute O O
infarction O O
. O O

The O O
mean O O
plasma O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O O
of O O
patients O O
on O O
beta O O
- O O
blocking O O
agents O O
was O O
no O O
different O O
from O O
that O O
in O O
patients O O
not O O
on O O
beta O O
blocking O O
agents O O
. O O

During O O
the O O
1 O O
- O O
hour O O
study O O
period O O
, O O
the O O
incidence O O
of O O
central O O
nervous O O
system O O
side O O
effects O O
was O O
significantly O O
greater O O
in O O
the O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
, O O
hypotension O O
occurred O O
in O O
11 O O
patients O O
, O O
nine O O
of O O
whom O O
had O O
received O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
four O O
patients O O
died O O
from O O
asystole O O
, O O
three O O
of O O
whom O O
had O O
had O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
cannot O O
advocate O O
the O O
administration O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prophylactically O O
in O O
the O O
early O O
hours O O
of O O
suspected O O
myocardial O O
infarction O O
. O O

Evidence O O
for O O
a O O
cholinergic O O
role O O
in O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
catalepsy O O
. O O

Experiments O O
in O O
mice O O
tested O O
previous O O
evidence O O
that O O
activation O O
of O O
cholinergic O O
systems O O
promotes O O
catalepsy O O
and O O
that O O
cholinergic O O
mechanisms O O
need O O
to O O
be O O
intact O O
for O O
full O O
expression O O
of O O
neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
catalepsy O O
. O O

Large O O
doses O O
of O O
the O O
cholinomimetic O O
, O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
could O O
induce O O
catalepsy O O
when O O
peripheral O O
cholinergic O O
receptors O O
were O O
blocked O O
. O O

Low O O
doses O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
a O O
pronounced O O
enhancement O O
of O O
the O O
catalepsy O O
that O O
was O O
induced O O
by O O
the O O
dopaminergic O O
blocker O O
, O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
muscarinic O O
receptor O O
blocker O O
, O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
disrupted O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
catalepsy O O
. O O

Intracranial O O
injection O O
of O O
an O O
acetylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
synthesis O O
inhibitor O O
, O O
hemicholinium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prevented O O
the O O
catalepsy O O
that O O
is O O
usually O O
induced O O
by O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
findings O O
suggest O O
the O O
hypothesis O O
that O O
the O O
catalepsy O O
that O O
is O O
produced O O
by O O
neuroleptics B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
actually O O
mediated O O
by O O
intrinsic O O
central O O
cholinergic O O
systems O O
. O O

Alternatively O O
, O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O O
central O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cholinergic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
systems O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O O
promote O O
catalepsy O B_DISEASE/B_ORGANISM_FUNCTION
by O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
dopaminergic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Cardiovascular O O
dysfunction O O
and O O
hypersensitivity O O
to O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
chronic O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
chloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ingestion O O
. O O

Barium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
supplemented O O
Long O O
- O O
Evans O O
hooded O O
rats O O
were O O
characterized O O
by O O
a O O
persistent O O
hypertension O O
that O O
was O O
evident O O
after O O
1 O O
month O O
of O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
100 O O
micrograms O O
/ O O
ml O O
mineral O O
fortified O O
water O O
) O O
treatment O O
. O O

Analysis O O
of O O
in O O
vivo O O
myocardial O O
excitability O O
, O O
contractility O O
, O O
and O O
metabolic O O
characteristics O O
at O O
16 O O
months O O
revealed O O
other O O
significant O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
disturbances O O
within O O
the O O
cardiovascular O O
system O O
. O O

The O O
most O O
distinctive O O
aspect O O
of O O
the O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effect O O
was O O
a O O
demonstrated O O
hypersensitivity O O
of O O
the O O
cardiovascular O O
system O O
to O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Under O O
barbiturate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O O
, O O
virtually O O
all O O
of O O
the O O
myocardial O O
contractile O O
indices O O
were O O
depressed O O
significantly O O
in O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
rats O O
relative O O
to O O
the O O
corresponding O O
control O O
- O O
fed O O
rats O O
. O O

The O O
lack O O
of O O
a O O
similar O O
response O O
to O O
ketamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
xylazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O O
revealed O O
that O O
the O O
cardiovascular O O
actions O O
of O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
were O O
linked O O
specifically O O
to O O
this O O
anesthetic O O
, O O
and O O
were O O
not O O
representative O O
of O O
a O O
generalized O O
anesthetic O O
response O O
. O O

Other O O
myocardial O O
pathophysiologic O O
and O O
metabolic O O
changes O O
induced O O
by O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
manifest O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
employed O O
. O O

The O O
contractile O O
element O O
shortening O O
velocity O O
of O O
the O O
cardiac O O
muscle O O
fibers O O
was O O
significantly O O
slower O O
in O O
both O O
groups O O
of O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
relative O O
to O O
the O O
control O O
groups O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
regimen O O
. O O

Similarly O O
, O O
significant O O
disturbances O O
in O O
myocardial O O
energy O O
metabolism O O
were O O
detected O O
in O O
the O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
exposed O O
rats O O
which O O
were O O
consistent O O
with O O
the O O
reduced O O
contractile O O
element O O
shortening O O
velocity O O
. O O

In O O
addition O O
, O O
the O O
excitability O O
of O O
the O O
cardiac O O
conduction O O
system O O
was O O
depressed O O
preferentially O O
in O O
the O O
atrioventricular O O
nodal O O
region O O
of O O
hearts O O
from O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
exposed O O
rats O O
. O O

Overall O O
, O O
the O O
altered O O
cardiac O O
contractility O O
and O O
excitability O O
characteristics O O
, O O
the O O
myocardial O O
metabolic O O
disturbances O O
, O O
and O O
the O O
hypersensitivity O O
of O O
the O O
cardiovascular O O
system O O
to O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O O
the O O
existence O O
of O O
a O O
heretofore O O
undescribed O O
cardiomyopathic O O
disorder O O
induced O O
by O O
chronic O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O O
. O O

These O O
experimental O O
findings O O
represent O O
the O O
first O O
indication O O
that O O
life O O
- O O
long O O
barium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ingestion O O
may O O
have O O
significant O O
adverse O O
effects O O
on O O
the O O
mammalian O O
cardiovascular O O
system O O
. O O

Propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonism O O
of O O
phenylpropanolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypertension O O
. O O

Phenylpropanolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
PPA B B_DISEASE
) O O
overdose O O
can O O
cause O O
severe O O
hypertension O O
, O O
intracerebral O O
hemorrhage O O
, O O
and O O
death O O
. O O

We O O
studied O O
the O O
efficacy O O
and O O
safety O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
PPA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hypertension O O
. O O

Subjects O O
received O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
by O O
mouth O O
for O O
48 O O
hours O O
before O O
PPA B B_DISEASE
or O O
as O O
a O O
rapid O O
intravenous O O
infusion O O
after O O
PPA B B_DISEASE
. O O

PPA B B_MEASURE/B_DISEASE
, O O
75 O O
mg O O
alone O O
, O O
increased O O
blood O O
pressure O O
( O O
31 O O
+ O O
/ O O
- O O
14 O O
mm O O
Hg O O
systolic O O
, O O
20 O O
+ O O
/ O O
- O O
5 O O
mm O O
Hg O O
diastolic O O
) O O
, O O
and O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pretreatment O O
antagonized O O
this O O
increase O O
( O O
12 O O
+ O O
/ O O
- O O
10 O O
mm O O
Hg O O
systolic O O
, O O
10 O O
+ O O
/ O O
- O O
7 O O
mm O O
Hg O O
diastolic O O
) O O
. O O

Intravenous O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
PPA B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O O
decreased O O
blood O O
pressure O O
. O O

Left O O
ventricular O O
function O O
( O O
assessed O O
by O O
echocardiography O O
) O O
showed O O
that O O
PPA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
the O O
stroke O O
volume O O
30 O O
% O O
( O O
from O O
62 O O
. O O
5 O O
+ O O
/ O O
- O O
20 O O
. O O
9 O O
to O O
80 O O
. O O
8 O O
+ O O
/ O O
- O O
22 O O
. O O
4 O O
ml O O
) O O
, O O
the O O
ejection O O
fraction O O
9 O O
% O O
( O O
from O O
64 O O
% O O
+ O O
/ O O
- O O
10 O O
% O O
to O O
70 O O
% O O
+ O O
/ O O
- O O
7 O O
% O O
) O O
, O O
and O O
cardiac O O
output O O
14 O O
% O O
( O O
from O O
3 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
to O O
4 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
L O O
/ O O
min O O
) O O
. O O

Intravenous O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversed O O
these O O
effects O O
. O O

Systemic O O
vascular O O
resistance O O
was O O
increased O O
by O O
PPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
28 O O
% O O
( O O
from O O
1710 O O
+ O O
/ O O
- O O
200 O O
to O O
2190 O O
+ O O
/ O O
- O O
700 O O
dyne O O
X O O
sec O O
/ O O
cm5 O O
) O O
and O O
was O O
further O O
increased O O
by O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
22 O O
% O O
( O O
to O O
2660 O O
+ O O
/ O O
- O O
1200 O O
dyne O O
X O O
sec O O
/ O O
cm5 O O
) O O
. O O

We O O
conclude O O
that O O
PPA B B_DISEASE/B_GENE
increases O O
blood O O
pressure O O
by O O
increasing O O
systemic O O
vascular O O
resistance O O
and O O
cardiac O O
output O O
, O O
and O O
that O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O O
this O O
increase O O
by O O
reversing O O
the O O
effect O O
of O O
PPA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cardiac O O
output O O
. O O

That O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonizes O O
the O O
pressor O O
effect O O
of O O
PPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
in O O
contrast O O
to O O
the O O
interaction O O
in O O
which O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
enhances O O
the O O
pressor O O
effect O O
of O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

This O O
is O O
probably O O
because O O
PPA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
less O O
beta O O
2 O O
activity O O
than O O
does O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

Mesangial O O
function O O
and O O
glomerular O O
sclerosis O O
in O O
rats O O
with O O
aminonucleoside B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrosis O O
. O O

The O O
possible O O
relationship O O
between O O
mesangial O O
dysfunction O O
and O O
development O O
of O O
glomerular O O
sclerosis O O
was O O
studied O O
in O O
the O O
puromycin B B_DISEASE
aminonucleoside I I_DISEASE
( O O
PAN B B_DISEASE
) O O
model O O
. O O

Five O O
male O O
Wistar O O
rats O O
received O O
repeated O O
subcutaneous O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injections O O
; O O
five O O
controls O O
received O O
saline O O
only O O
. O O

After O O
4 O O
weeks O O
the O O
PAN B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O O
were O O
severely O O
proteinuric O O
( O O
190 O O
+ O O
/ O O
- O O
80 O O
mg O O
/ O O
24 O O
hr O O
) O O
, O O
and O O
all O O
rats O O
were O O
given O O
colloidal O O
carbon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CC O O
) O O
intravenously O O
. O O

At O O
5 O O
months O O
glomerular O O
sclerosis O O
was O O
found O O
in O O
7 O O
. O O
6 O O
+ O O
/ O O
- O O
3 O O
. O O
4 O O
% O O
of O O
the O O
glomeruli O O
of O O
PAN B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O O
; O O
glomeruli O O
of O O
the O O
controls O O
were O O
normal O O
. O O

Glomeruli O O
of O O
PAN B B_DISEASE
rats O O
contained O O
significantly O O
more O O
CC O O
than O O
glomeruli O O
of O O
controls O O
. O O

Glomeruli O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
sclerosis O B_DISEASE
contained O O
significantly O O
more O O
CC O B_DISEASE/B_GENE
than O O
non O B_DISEASE
- O O
sclerotic O B_DISEASE/B_LOCATION
glomeruli O I_DISEASE/I_LOCATION
in O O
the O O
same O B_BODY_PART_OR_ORGAN_COMPONENT/B_ENT
kidneys O I_BODY_PART_OR_ORGAN_COMPONENT/I_ENT
. O O

CC O B_GENE/B_DISEASE
was O O
preferentially O O
localized O O
within O O
the O O
sclerotic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
affected O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
glomeruli O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Since O O
mesangial O O
CC O O
clearance O O
from O O
the O O
mesangium O O
did O O
not O O
change O O
during O O
chronic O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
, O O
we O O
conclude O O
that O O
this O O
preferential O O
CC O O
localization O O
within O O
the O O
lesions O O
is O O
caused O O
by O O
an O O
increased O O
CC O O
uptake O O
shortly O O
after O O
injection O O
in O O
apparent O O
vulnerable O O
areas O O
where O O
sclerosis O O
will O O
develop O O
subsequently O O
. O O

Cluster O O
analysis O O
showed O O
a O O
random O O
distribution O O
of O O
lesions O O
in O O
the O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
glomeruli O O
in O O
concordance O O
with O O
the O O
random O O
localization O O
of O O
mesangial O O
areas O O
with O O
dysfunction O O
in O O
this O O
model O O
. O O

Similar O O
to O O
the O O
remnant O O
kidney O O
model O O
in O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]
nephrosis O O
the O O
development O O
of O O
glomerular O O
sclerosis O O
may O O
be O O
related O O
to O O
" O O
mesangial O O
overloading O O
. O O
" O O

Relationship O O
between O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizures O O
and O O
hippocampal O O
nicotinic O O
receptors O O
. O O

A O O
controversy O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
existed O O
for O O
several O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
years O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
concerning O O
the O O
physiological O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
nicotinic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measured O O
by O O
alpha O B_PROTEIN[GENE]/B_MEASURE
- O O
bungarotoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
mice O O
derived O O
from O O
a O O
classical O O
F2 O O
and O O
backcross O O
genetic O O
design O O
, O O
a O O
relationship O O
between O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizures O O
and O O
alpha O O
- O O
bungarotoxin O O
nicotinic O O
receptor O O
concentration O O
was O O
found O O
. O O

Mice O O
sensitive O O
to O O
the O O
convulsant O O
effects O O
of O O
nicotine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O O
greater O O
alpha O O
- O O
bungarotoxin O O
binding O O
in O O
the O O
hippocampus O O
than O O
seizure O O
insensitive O O
mice O O
. O O

The O O
binding O O
sites O O
from O O
seizure O O
sensitive O O
and O O
resistant O O
mice O O
were O O
equally O O
affected O O
by O O
treatment O O
with O O
dithiothreitol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
, O O
trypsin O O
or O O
heat O O
. O O

Thus O O
it O O
appears O O
that O O
the O O
difference O B_MEASURE
between O O
seizure O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sensitive O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
insensitive O B_DISEASE_ADJECTIVE[DISEASE]
animals O I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
a O O
difference O B_MEASURE
in O O
hippocampal O B_MEASURE/B_DISEASE
nicotinic O I_MEASURE/I_DISEASE
receptor O I_MEASURE/I_DISEASE
concentration O I_MEASURE/I_DISEASE
as O O
measured O O
with O O
alpha O B_PROTEIN[GENE]
- O O
bungarotoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
role O O
of O O
p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aminophenol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nephrotoxicity O O
: O O
effect O O
of O O
bis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrophenyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminophenol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrotoxicity O O
and O O
metabolism O O
in O O
Fischer O O
344 O O
rats O O
. O O

Acetaminophen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
produces O O
proximal O O
tubular O O
necrosis O O
in O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rats O O
. O O

Recently O O
, O O
p B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
aminophenol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PAP B B_GENE/B_DISEASE
) O O
, O O
a O O
known O O
potent O O
nephrotoxicant O O
, O O
was O O
identified O O
as O O
a O O
metabolite O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
F344 O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formation O O
is O O
a O O
requisite O O
step O O
in O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephrotoxicity O O
. O O

Therefore O O
, O O
the O O
effect O O
of O O
bis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
p I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrophenyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BNPP B B_DISEASE/B_GENE
) O O
, O O
an O O
acylamidase O O
inhibitor O O
, O O
on O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nephrotoxicity O O
and O O
metabolism O O
was O O
determined O O
. O O

BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O O
to O O
8 O O
mM O O
) O O
reduced O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deacetylation O O
and O O
covalent O O
binding O O
in O O
F344 O O
renal O O
cortical O O
homogenates O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Pretreatment O O
of O O
animals O O
with O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prior O O
to O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PAP B B_PROTEIN[GENE]/B_DISEASE
administration O O
resulted O O
in O O
marked O O
reduction O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
900 O O
mg O O
/ O O
kg O O
) O O
nephrotoxicity O O
but O O
not O O
PAP B B_PROTEIN[GENE]
nephrotoxicity O O
. O O

This O O
result O O
was O O
not O O
due O O
to O O
altered O O
disposition O O
of O O
either O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
acetylated O O
metabolites O O
in O O
plasma O O
or O O
renal O O
cortical O O
and O O
hepatic O O
tissue O O
. O O

Rather O O
, O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pretreatment O O
reduced O O
the O O
fraction O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excreted O O
as O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O O
64 O O
and O O
75 O O
% O O
after O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O O
of O O
750 O O
and O O
900 O O
mg O O
/ O O
kg O O
. O O

BNPP B B_DISEASE/B_GENE
did O O
not O O
alter O O
the O O
excretion O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
any O O
of O O
its O O
non O O
- O O
deacetylated O O
metabolites O O
nor O O
did O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alter O O
excretion O O
of O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
its O O
metabolites O O
after O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
doses O O
of O O
150 O O
and O O
300 O O
mg O O
/ O O
kg O O
. O O

Therefore O O
, O O
the O O
BNPP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
reduction O O
in O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
nephrotoxicity O O
appears O O
to O O
be O O
due O O
to O O
inhibition O O
of O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deacetylation O O
. O O

It O O
is O O
concluded O O
that O O
PAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formation O O
, O O
in O O
vivo O O
, O O
accounts O O
, O O
at O O
least O O
in O O
part O O
, O O
for O O
APAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
renal O O
tubular O O
necrosis O O
. O O

Morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
seizures O O
in O O
newborn O O
infants O O
. O O

Two O O
neonates O O
suffered O O
from O O
generalized O O
seizures O O
during O O
the O O
course O O
of O O
intravenous O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
post O O
- O O
operative O O
analgesia O O
. O O

They O O
received O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
doses O O
of O O
32 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
40 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
larger O O
than O O
a O O
group O O
of O O
10 O O
neonates O O
who O O
received O O
6 O O
- O O
24 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
had O O
no O O
seizures O O
. O O

Plasma O O
concentrations O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
neonates O O
was O O
excessive O O
( O O
60 O O
and O O
90 O O
mg O O
/ O O
ml O O
) O O
. O O

Other O O
known O O
reasons O O
for O O
seizures O O
were O O
ruled O O
out O O
and O O
the O O
convulsions O O
stopped O O
a O O
few O O
hours O O
after O O
cessation O O
of O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
did O O
not O O
reoccur O O
in O O
the O O
subsequent O O
8 O O
months O O
. O O

It O O
is O O
suggested O O
that O O
post O O
- O O
operative O O
intravenous O O
morphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
not O O
exceed O O
20 O O
micrograms O O
/ O O
kg O O
/ O O
ml O O
in O O
neonates O O
. O O

Indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
induced O O
hypotension O O
in O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
volume O O
depleted O O
rats O O
. O O

After O O
a O O
single O O
oral O O
dose O O
of O O
4 O O
mg O O
/ O O
kg O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IDM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
to O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
volume O O
depleted O O
rats O O
plasma O O
renin O O
activity O O
( O O
PRA O O
) O O
and O O
systolic O O
blood O O
pressure O O
fell O O
significantly O O
within O O
four O O
hours O O
. O O

In O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repleted O O
animals O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
change O O
systolic O O
blood O O
pressure O O
( O O
BP O O
) O O
although O O
plasma O O
renin O O
activity O O
was O O
decreased O O
. O O

Thus O O
, O O
indomethacin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O O
inhibition O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
may O O
diminish O O
the O O
blood O O
pressure O O
maintaining O O
effect O O
of O O
the O O
stimulated O O
renin O O
- O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O O
in O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
volume O O
depletion O O
. O O

On O O
the O O
antiarrhythmic O O
activity O O
of O O
one O O
N O O
- O O
substituted O O
piperazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative O O
of O O
trans B B_LOCATION
- I I_LOCATION
2 I I_LOCATION
- I I_LOCATION
amino I I_LOCATION
- I I_LOCATION
3 I I_LOCATION
- I I_LOCATION
hydroxy I I_LOCATION
- I I_LOCATION
1 I I_LOCATION
, I I_LOCATION
2 I I_LOCATION
, I I_LOCATION
3 I I_LOCATION
, I I_LOCATION
4 I I_LOCATION
- I I_LOCATION
tetrahydroanaphthalene I I_LOCATION
. O O

The O O
antiarrhythmic O O
activity O O
of O O
the O O
compound O O
N B B_TIME[MEASURE]/B_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
( I B_TIME[MEASURE]/I_PROTEIN[GENE]
trans I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
hydroxy I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
1 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
, I B_TIME[MEASURE]/I_PROTEIN[GENE]
4 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
tetrahydro I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
naphthyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
) I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
N I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
( I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
oxo I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
3 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
phenyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
2 I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
methylpropyl I B_TIME[MEASURE]/I_PROTEIN[GENE]
) I B_TIME[MEASURE]/I_PROTEIN[GENE]
- I B_TIME[MEASURE]/I_PROTEIN[GENE]
piperazine I B_TIME[MEASURE]/I_PROTEIN[GENE]
hydrochloride I B_TIME[MEASURE]/I_PROTEIN[GENE]
, O O
referred O O
to O O
as O O
P11 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
is O O
studied O O
on O O
anaesthesized O O
cats O O
and O O
Wistar O O
albino O O
rats O O
, O O
as O O
well O O
as O O
on O O
non O O
- O O
anaesthesized O O
rabbits O O
. O O

Four O O
types O O
of O O
experimental O O
arrhythmia O O
are O O
used O O
- O O
- O O
with O O
BaCl2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
chloroform B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
strophantine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
with O O
aconitine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
compound O O
P11 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
introduced O O
in O O
doses O O
of O O
0 O O
. O O
25 O O
and O O
0 O O
. O O
50 O O
mg O O
/ O O
kg O O
intravenously O O
and O O
10 O O
mg O O
/ O O
kg O O
orally O O
. O O

The O O
compound O O
manifests O O
antiarrhythmic O O
activity O O
in O O
all O O
models O O
of O O
experimental O O
arrhythmia O O
used O O
, O O
causing O O
greatest O O
inhibition O O
on O O
the O O
arrhythmia O O
induced O O
by O O
chloroform B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
in O O
90 O O
per O O
cent O O
) O O
and O O
with O O
BaCl2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
in O O
84 O O
per O O
cent O O
) O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
are O O
associated O O
with O O
the O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoblocking O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
with O O
the O O
membrane O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stabilizing O O
action O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Recurrent O O
subarachnoid O O
hemorrhage O O
associated O O
with O O
aminocaproic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
and O O
acute O O
renal O O
artery O O
thrombosis O O
. O O

Case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Epsilon B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
aminocaproic I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
acid I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
EACA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
has O O
been O O
used O O
to O O
prevent O O
rebleeding O O
in O O
patients O O
with O O
subarachnoid O O
hemorrhage O O
( O O
SAH O O
) O O
. O O

Although O O
this O O
agent O O
does O O
decrease O O
the O O
frequency O O
of O O
rebleeding O O
, O O
several O O
reports O O
have O O
described O O
thrombotic O O
complications O O
of O O
EACA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

These O O
complications O O
have O O
included O O
clinical O O
deterioration O O
and O O
intracranial O O
vascular O O
thrombosis O O
in O O
patients O O
with O O
SAH O O
, O O
arteriolar O O
and O O
capillary O O
fibrin O O
thrombi O O
in O O
patients O O
with O O
fibrinolytic O O
syndromes O O
treated O O
with O O
EACA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
other O O
thromboembolic O O
phenomena O O
. O O

Since O O
intravascular O O
fibrin O O
thrombi O O
are O O
often O O
observed O O
in O O
patients O O
with O O
fibrinolytic O O
disorders O O
, O O
EACA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O O
not O O
be O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
fibrin O O
thrombi O O
in O O
patients O O
with O O
disseminated O O
intravascular O O
coagulation O O
or O O
other O O
" O O
consumption O O
coagulopathies O O
. O O
" O O
This O O
report O O
describes O O
subtotal O O
infarction O O
of O O
the O O
kidney O O
due O O
to O O
thrombosis O O
of O O
a O O
normal O O
renal O O
artery O O
. O O

This O O
occlusion O O
occurred O O
after O O
EACA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
a O O
patient O O
with O O
SAH O O
and O O
histopathological O O
documentation O O
of O O
recurrent O O
SAH O O
. O O

The O O
corresponding O B_DISEASE
clinical O I_DISEASE
event O I_DISEASE
was O O
characterized O O
by O O
marked O B_DISEASE
hypertension O I_DISEASE
and O O
abrupt O B_DISEASE
neurological O I_DISEASE
deterioration O I_DISEASE
. O O

Effect O O
of O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
Pseudomonas O O
infections O O
in O O
monkeys O O
. O O

In O O
rhesus O B_SPECIES[BIO]
monkeys O I_SPECIES[BIO]
, O O
intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
0 O B_MEASURE/B_LOCATION
. O O
6 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
10 O B_MEASURE
) O O
to O O
2 O B_MEASURE
. O O
2 O B_MEASURE
x O O
10 O B_MEASURE
( O O
10 O B_MEASURE
) O O
Pseudomonas O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
aeruginosa O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
organisms O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
caused O O
acute O B_DISEASE
illness O I_DISEASE
of O O
4 O B_NUMBER[MEASURE]/B_LOCATION
to O O
5 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
' O I_TIME[MEASURE]
duration O I_TIME[MEASURE]
with O O
spontaneous O B_DISEASE
recovery O I_DISEASE
in O O
13 O B_NUMBER[MEASURE]/B_PERSON
of O O
15 O B_MEASURE/B_PERSON
monkeys O B_MEASURE/I_PERSON
; O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
became O O
negative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
17 O B_SEQUENCE[MEASURE]/B_ENT
days O I_SEQUENCE[MEASURE]/I_ENT
after O O
challenge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Leukocytosis O B_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
all O O
monkeys O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Intravenous O O
or O O
intratracheal O O
inoculation O O
of O O
2 O O
. O O
0 O O
to O O
2 O O
. O O
5 O O
mg O O
of O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
followed O O
by O O
leukopenia O O
in O O
4 O O
to O O
5 O O
days O O
. O O

Intravenous O O
inoculation O O
of O O
4 O O
. O O
2 O O
x O O
10 O O
( O O
10 O O
) O O
to O O
7 O O
. O O
8 O O
x O O
10 O O
( O O
10 O O
) O O
pyocin O O
type O O
6 O O
Pseudomonas O O
organisms O O
in O O
monkeys O O
given O O
vincristine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O O
days O O
previously O O
resulted O O
in O O
fatal O O
infection O O
in O O
11 O O
of O O
14 O O
monkeys O O
, O O
whereas O O
none O O
of O O
four O O
receiving O O
Pseudomonas O O
alone O O
died O O
. O O

These O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
an O O
antimetabolite O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
leukopenia O B_DISEASE
predisposes O O
to O O
severe O B_DISEASE
Pseudomonas O I_DISEASE
sepsis O I_DISEASE
and O O
that O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
monkeys O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
may O O
serve O O
as O O
a O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
comparative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
antimicrobial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Modification O O
by O O
propranolol B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cardiovascular O O
effects O O
of O O
induced O O
hypoglycaemia O O
. O O

The O O
cardiovascular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hypoglycaemia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
with O O
and O O
without O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockade O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
were O O
compared O O
in O O
fourteen O B_TIME[MEASURE]/B_PERSON
healthy O I_TIME[MEASURE]/I_PERSON
men O I_TIME[MEASURE]/I_PERSON
. O O

Eight O O
received O O
insulin O O
alone O O
, O O
and O O
eight O O
, O O
including O O
two O O
of O O
the O O
original O O
insulin O O
- O O
only O O
group O O
, O O
were O O
given O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
insulin O O
. O O

In O O
the O O
insulin O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
period O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
hypoglycaemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
rate O B_MEASURE/B_ENT
and O O
a O O
fall O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
diastolic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O O
pressure O B_MEASURE
. O O

In O O
the O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
insulin O O
group O O
there O O
was O O
a O O
significant O O
fall O O
in O O
heart O O
- O O
rate O O
in O O
most O O
subjects O O
and O O
an O O
increase O O
in O O
diastolic O O
pressure O O
. O O

Typical O O
S O O
- O O
T O O
/ O O
T O O
changes O O
occurred O O
in O O
the O O
insulin O O
- O O
group O O
but O O
in O O
none O O
of O O
the O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
insulin O O
group O O
. O O

Hypertension O B_DISEASE/B_PERSON
in O O
diabetics O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prone O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
hypoglycaemia O B_DISEASE/B_GENE
attacks O I_DISEASE/I_GENE
should O O
not O O
be O O
treated O O
with O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O O
these O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
cause O O
a O O
sharp O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rise O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
pressure O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
such O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Long O O
- O O
term O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
pregnancy O O
: O O
maternal O O
and O O
fetal O O
outcome O O
. O O

Propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
has O O
found O O
an O O
important O O
position O O
in O O
the O O
practice O O
of O O
medicine O O
. O O

Its O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pregnancy O B_PERSON
, O O
however O O
, O O
is O O
an O O
open O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
question O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
number O B_MEASURE/B_PERSON
of O O
detrimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
side O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O O
been O O
reported O O
in O O
the O O
fetus O B_PERSON/B_BIO
and O O
neonate O B_PERSON/B_BIO
. O O

Ten O O
patients O O
and O O
12 O O
pregnancies O O
are O O
reported O O
where O O
chronic O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
administered O O
. O O

Five O O
patients O O
with O O
serial O O
pregnancies O O
with O O
and O O
without O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
are O O
also O O
examined O O
. O O

Maternal O B_PERSON
, O O
fetal O B_PERSON
, O O
and O O
neonatal O B_PERSON
complications O I_PERSON
are O O
examined O O
. O O

An O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
made O O
to O O
differentiate O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
- O O
related O O
complications O B_DISEASE
from O O
maternal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
related O O
complications O B_DISEASE
. O O

We O O
conclude O O
that O O
previously O O
reported O O
hypoglycemia O O
, O O
hyperbilirubinemia O O
, O O
polycythemia O O
, O O
neonatal O O
apnea O O
, O O
and O O
bradycardia O O
are O O
not O O
invariable O O
and O O
cannot O O
be O O
statistically O O
correlated O O
with O O
chronic O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
. O O

Growth O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retardation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
however O O
, O O
appears O O
to O O
be O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
of O O
our O O
series O B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Central O O
excitatory O O
actions O O
of O O
flurazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Toxic O O
actions O O
of O O
flurazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FZP B B_PROTEIN[GENE]/B_DISEASE
) O O
were O O
studied O O
in O O
cats O O
, O O
mice O O
and O O
rats O O
. O O

High O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
caused O O
an O O
apparent O B_DISEASE
central O I_DISEASE
excitation O I_DISEASE
, O O
most O O
clearly O O
seen O O
as O O
clonic O B_DISEASE_ADJECTIVE[DISEASE]
convulsions O I_DISEASE_ADJECTIVE[DISEASE]
, O O
superimposed O O
on O O
general O B_DISEASE
depression O I_DISEASE
. O O

Following O O
a O O
lethal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
always O O
associated O O
with O O
convulsions O B_DISEASE
. O O

Comparing O O
the O O
relative O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depression O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
excitation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
that O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
least O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
to O O
have O O
convulsions O B_DISEASE
at O O
doses O B_TIME[MEASURE]/B_LOCATION
that O O
did O O
not O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
consciousness O B_DISEASE
, O O
while O O
cats O B_SPECIES[BIO]
most O O
clearly O O
showed O O
marked O O
central O B_DISEASE
excitatory O I_DISEASE
actions O I_DISEASE
. O O

Signs O O
of O O
FZP B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxocity O O
in O O
cats O O
included O O
excessive O O
salivation O O
, O O
extreme O O
apprehensive O O
behavior O O
, O O
retching O O
, O O
muscle O O
tremors O O
and O O
convulsions O O
. O O

An O O
interaction O O
between O O
FZP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
pentylenetetrazol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
was O O
shown O O
by O O
pretreating O O
mice O O
with O O
FZP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
before O O
PTZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
challenge O O
. O O

As O O
a O O
function O O
of O O
dose O O
, O O
FZP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
first O O
protected O O
against O O
convulsions O O
and O O
death O O
. O O

At O O
higher O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
however O O
, O O
convulsions O B_DISEASE
again O O
emerged O O
. O O

These O O
doses O O
of O O
FZP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
lower O O
than O O
those O O
that O O
would O O
alone O O
cause O O
convulsions O O
. O O

These O O
results O O
may O O
be O O
relevant O O
to O O
the O O
use O O
of O O
FZP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
clinical O O
situations O O
in O O
which O O
there O O
is O O
increased O O
neural O O
excitability O O
, O O
such O O
as O O
epilepsy O O
or O O
sedative O O
- O O
hypnotic O O
drug O O
withdrawal O O
. O O

Use O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
treatment O O
of O O
idiopathic O O
orthostatic O O
hypotension O O
. O O

Five O B_PERSON
patients O I_PERSON
with O O
idiopathic O B_DISEASE/B_GENE
orthostatic O I_DISEASE/I_GENE
hypotension O I_DISEASE/I_GENE
who O O
had O O
physiologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
severe O B_DISEASE
autonomic O I_DISEASE
dysfunction O I_DISEASE
were O O
included O O
in O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

They O O
all O O
exhibited O O
markedly O O
reduced O O
plasma O O
catecholamines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
plasma O O
renin O O
activity O O
in O O
both O O
recumbent O O
and O O
upright O O
positions O O
and O O
had O O
marked O O
hypersensitivity O O
to O O
the O O
pressor O O
effects O O
of O O
infused O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Treatment O O
with O O
propanolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O O
intravenously O O
( O O
1 O O
- O O
5 O O
mg O O
) O O
produced O O
increases O O
in O O
supine O O
and O O
upright O O
blood O O
pressure O O
in O O
4 O O
of O O
the O O
5 O O
individuals O O
with O O
rises O O
ranging O O
from O O
11 O O
/ O O
6 O O
to O O
22 O O
/ O O
11 O O
mmHg O O
. O O

Chronic O O
oral O O
administration O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
40 O O
- O O
160 O O
mg O O
/ O O
day O O
) O O
also O O
elevated O O
the O O
blood O O
pressures O O
of O O
these O O
individuals O O
with O O
increases O O
in O O
the O O
order O O
of O O
20 O O
- O O
35 O O
/ O O
15 O O
- O O
25 O O
mmg O O
being O O
observed O O
. O O

In O O
1 O O
patient O O
, O O
marked O O
hypertension O O
was O O
induced O O
by O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
drug O O
had O O
to O O
be O O
withdrawn O O
. O O

It O O
otherwise O O
was O O
well O O
tolerated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
no O O
important O B_DISEASE_ADJECTIVE[DISEASE]
side O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
continued O O
in O O
3 O B_PERSON/B_BIO
individuals O I_PERSON/I_BIO
for O O
6 O B_NUMBER[MEASURE]
- O O
13 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
with O O
persistence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
pressor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
although O O
there O O
appears O O
to O O
have O O
been O O
some O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
degree O B_MEASURE
of O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
time O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hemodynamic O O
measurements O O
in O O
1 O O
of O O
the O O
patients O O
demonstrated O O
an O O
increase O O
in O O
total O O
peripheral O O
resistance O O
and O O
essentially O O
no O O
change O O
in O O
cardiac O O
output O O
following O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

The O O
studies O O
suggest O O
that O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
useful O O
drug O O
in O O
selected O O
patients O O
with O O
severe O O
idiopathic O O
orthostatic O O
hypotension O O
. O O

Total O O
intravenous O O
anesthesia O O
with O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

III O B_NUMBER[MEASURE]
. O O

Some O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
adults O B_PERSON/B_LOCATION
. O O

An O O
investigation O O
was O O
undertaken O O
to O O
determine O O
the O O
dosage O O
of O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
to O O
maintain O O
sleep O O
in O O
adults O O
undergoing O O
surgery O O
under O O
regional O O
local O O
anesthesia O O
. O O

Premedication O O
of O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O O
mg O O
and O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
5 O O
mg O O
was O O
given O O
, O O
and O O
sleep O O
was O O
induced O O
and O O
maintained O O
by O O
intermittent O O
intravenous O O
injections O O
of O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
1 O O
/ O O
mg O O
/ O O
kg O O
, O O
given O O
whenever O O
the O O
patient O O
would O O
open O O
his O O
eyes O O
on O O
request O O
. O O

A O O
mean O O
overall O O
dose O O
of O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
17 O O
. O O
4 O O
microgram O O
/ O O
kg O O
/ O O
min O O
. O O
was O O
required O O
to O O
maintain O O
sleep O O
, O O
but O O
great O O
individual O O
variation O O
occurred O O
, O O
with O O
older O O
patients O O
requiring O O
less O O
drug O O
. O O

The O O
investigation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
discontinued O O
after O O
18 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
the O O
frequency O B_MEASURE/B_LOCATION
and O O
intensity O B_MEASURE
of O O
side O B_DISEASE_ADJECTIVE[DISEASE]
- O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
particularly O O
pain O B_DISEASE
and O O
myoclonia O B_DISEASE
, O O
which O O
caused O O
the O O
technique O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
abandoned O O
in O O
two O B_MEASURE/B_LOCATION
cases O I_MEASURE/I_LOCATION
. O O

It O O
is O O
considered O O
unlikely O O
that O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
prove O O
to O O
be O O
the O O
hypnotic O O
of O O
choice O O
for O O
a O O
totally O O
intravenous O O
anesthetic O O
technique O O
in O O
adults O O
because O O
of O O
the O O
high O O
incidence O O
of O O
myoclonia O O
after O O
prolonged O O
administration O O
. O O

In O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uncontrollable O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
movements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O O
for O O
many O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
consciousness O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cardiac O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_PERSON/B_BIO
. O O

We O O
compared O O
the O O
effects O O
of O O
single O O
doses O O
of O O
50 O O
mg O O
atenolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
cardioselective O O
) O O
, O O
40 O O
mg O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
nonselective O O
) O O
, O O
and O O
placebo O O
on O O
both O O
exercise O O
- O O
and O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
tachycardia O O
in O O
two O O
experiments O O
involving O O
nine O O
normal O O
subjects O O
. O O

Maximal O O
exercise O O
heart O O
rate O O
was O O
reduced O O
from O O
187 O O
+ O O
/ O O
- O O
4 O O
( O O
SEM O O
) O O
after O O
placebo O O
to O O
146 O O
+ O O
/ O O
- O O
7 O O
bpm O O
after O O
atenolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
138 O O
+ O O
/ O O
- O O
6 O O
bpm O O
after O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
there O O
were O O
no O O
differences O O
between O O
the O O
drugs O O
. O O

The O O
effects O O
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tachycardia O O
were O O
determined O O
before O O
and O O
after O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
04 O O
mg O O
/ O O
kg O O
IV O O
) O O
. O O

Isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sensitivity O O
was O O
determined O O
as O O
the O O
intravenous O O
dose O O
that O O
increased O O
heart O O
rate O O
by O O
25 O O
bpm O O
( O O
CD25 O O
) O O
and O O
this O O
was O O
increased O O
from O O
1 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
micrograms O O
after O O
placebo O O
to O O
38 O O
. O O
9 O O
+ O O
/ O O
- O O
8 O O
. O O
3 O O
micrograms O O
after O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
8 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
micrograms O O
after O O
atenolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

The O O
difference O B_MEASURE
in O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
two O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
CD25 O O
was O O
unchanged O O
after O O
placebo O O
( O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
micrograms O O
) O O
and O O
atenolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
7 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
micrograms O O
) O O
; O O
it O O
was O O
reduced O O
after O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
24 O O
. O O
8 O O
+ O O
/ O O
- O O
5 O O
. O O
0 O O
micrograms O O
) O O
, O O
but O O
remained O O
different O O
from O O
atenolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

This O O
change O O
with O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O O
was O O
calculated O O
as O O
the O O
apparent O O
Ka O O
, O O
this O O
was O O
unchanged O O
by O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
11 O O
. O O
7 O O
+ O O
/ O O
- O O
2 O O
. O O
1 O O
and O O
10 O O
. O O
1 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
ml O O
/ O O
ng O O
) O O
. O O

These O O
data O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
exercise O O
- O O
induced O O
tachycardia O O
results O O
largely O O
from O O
beta O O
1 O O
- O O
receptor O O
activation O O
that O O
is O O
blocked O O
by O O
both O O
cardioselective O O
and O O
nonselective O O
drugs O O
, O O
whereas O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
both O O
beta O O
1 O O
- O O
and O O
beta O O
2 O O
- O O
receptors O O
so O O
that O O
after O O
cardioselective O O
blockade O O
there O O
remains O O
a O O
beta O O
2 O O
- O O
component O O
that O O
can O O
be O O
blocked O O
with O O
a O O
nonselective O O
drug O O
. O O

While O O
there O O
appear O O
to O O
be O O
beta O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
human O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
their O O
physiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
pathologic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O O
to O O
be O O
defined O O
. O O

Hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
breast O B_DISEASE
cancer O I_DISEASE
. O O

This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
50 O B_PERSON
menopausal O I_PERSON
women O I_PERSON
receiving O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
majority O B_PERSON
( O O
29 O O
) O O
had O O
surgical O B_PERSON/B_LOCATION
menopause O I_PERSON/I_LOCATION
; O O
their O O
mean O B_TIME[MEASURE]
age O I_TIME[MEASURE]
was O O
45 O B_MEASURE
. O O
7 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
. O O

It O O
was O O
hypothesized O O
that O O
progestins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O O
equilibrate O O
the O O
effects O O
of O O
the O O
estrogenic O O
stimulation O O
on O O
the O O
mammary O O
and O O
endometrial O O
target O O
tissues O O
of O O
women O O
on O O
hormonal O O
replacement O O
therapy O O
. O O

The O O
treatment O O
schedule O O
consisted O O
of O O
conjugated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
estrogens I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Premarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
1 O O
. O O
25 O O
mg O O
/ O O
day O O
for O O
21 O O
days O O
and O O
Medroxyprogesterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
10 O O
mg O O
/ O O
day O O
for O O
10 O O
days O O
in O O
each O O
month O O
. O O

The O O
mean O B_TIME[MEASURE]/B_PERSON
treatment O I_TIME[MEASURE]/I_PERSON
period O I_TIME[MEASURE]/I_PERSON
was O O
18 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

During O O
the O O
follow O O
- O O
up O O
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
attention O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
paid O O
to O O
breast O B_DISEASE_ADJECTIVE[DISEASE]
modifications O I_DISEASE_ADJECTIVE[DISEASE]
as O O
evidenced O O
by O O
symptomatology O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
physical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
plate O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mastodynia O B_DISEASE_ADJECTIVE[DISEASE]
was O O
reported O O
by O O
21 O B_PERSON
patients O I_PERSON
, O O
and O O
physical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
a O O
light O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
breast O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
firmness O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
12 O B_NUMBER[MEASURE]/B_PERSON
women O I_NUMBER[MEASURE]/I_PERSON
and O O
a O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
breast O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nodularity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
2 O B_PERSON/B_NUMBER[MEASURE]
women O I_PERSON/I_NUMBER[MEASURE]
. O O

Themography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirmed O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
excessive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breast O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
1 O B_PERSON/B_NUMBER[MEASURE]
women O B_PERSON/I_NUMBER[MEASURE]
who O O
complained O O
of O O
moderate O B_DISEASE
mastodynia O I_DISEASE
and O O
in O O
5 O B_NUMBER[MEASURE]
of O O
the O O
7 O B_PERSON/B_SPORT[ENT]
women O I_PERSON/I_SPORT[ENT]
who O O
complained O O
of O O
severe O B_DISEASE
mastodynia O I_DISEASE
. O O

Normalization O O
was O O
obtained O O
by O O
halving O O
the O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
safely O O
prescribed O O
if O O
the O O
following O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
satisfied O O
: O O
1 O B_SEQUENCE[MEASURE]
) O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
metabolic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
cytologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
mammographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
; O O
2 O B_NUMBER[MEASURE]
) O O
cyclic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
schedule O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
a O O
progestative O B_MEASURE/B_LOCATION
phase O I_MEASURE/I_LOCATION
of O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
and O O
3 O B_NUMBER[MEASURE]
) O O
periodic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complete O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
follow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
with O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
breast O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissues O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Early O O
infections O O
in O O
kidney O O
, O O
heart O O
, O O
and O O
liver O O
transplant O O
recipients O O
on O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Eighty O B_NUMBER[MEASURE]
- O O
one O B_NUMBER[MEASURE]/B_PERSON
renal O I_NUMBER[MEASURE]/I_PERSON
, O O
seventeen O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
twenty O B_NUMBER[MEASURE]
- O O
four O B_NUMBER[MEASURE]
liver O I_NUMBER[MEASURE]
transplant O I_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
were O O
followed O O
for O O
infection O B_DISEASE
. O O

Seventeen O O
renal O O
patients O O
received O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Aza B B_SPECIES[BIO]/B_LOCATION
) O O
and O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
part O O
of O O
a O O
randomized O O
trial O O
of O O
immunosuppression O O
with O O
21 O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
- O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
renal O O
transplant O O
patients O O
. O O

All O O
others O O
received O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prednisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
randomized O O
Aza B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
patients O O
had O O
more O O
overall O O
infections O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
and O O
more O O
nonviral O O
infections O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
than O O
the O O
randomized O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
. O O

Heart O O
and O O
liver O O
patients O O
had O O
more O O
infections O O
than O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
renal O O
patients O O
but O O
fewer O O
infections O O
than O O
the O O
Aza B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
renal O O
patients O O
. O O

There O O
were O O
no O O
infectious O O
deaths O O
in O O
renal O O
transplant O O
patients O O
on O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O O
Aza B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
but O O
infection O O
played O O
a O O
major O O
role O O
in O O
3 O O
out O O
of O O
6 O O
cardiac O O
transplant O O
deaths O O
and O O
in O O
8 O O
out O O
of O O
9 O O
liver O O
transplant O O
deaths O O
. O O

Renal O O
patients O O
on O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
the O O
fewest O O
bacteremias O O
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
site O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
infection O B_DISEASE
showed O O
a O O
preponderance O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
abdominal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infections O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
liver O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
intrathoracic O B_DISEASE
infections O I_DISEASE
in O O
heart O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
, O O
and O O
urinary O B_DISEASE/B_PERSON
tract O I_DISEASE/I_PERSON
infections O I_DISEASE/I_PERSON
in O O
renal O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Pulmonary O O
infections O O
were O O
less O O
common O O
in O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
renal O O
patients O O
than O O
in O O
Aza B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- O O
treated O O
patients O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Aza B B_PERSON/B_BIO
patients O O
had O O
significantly O O
more O O
staphylococcal O O
infections O O
than O O
all O O
other O O
transplant O O
groups O O
( O O
P O O
less O O
than O O
0 O O
. O O
005 O O
) O O
, O O
and O O
systemic O O
fungal O O
infections O O
occurred O O
only O O
in O O
the O O
liver O O
transplant O O
group O O
. O O

Cytomegalovirus O O
( O O
CMV O O
) O O
shedding O O
or O O
serological O O
rises O O
in O O
antibody O O
titer O O
, O O
or O O
both O O
occurred O O
in O O
78 O O
% O O
of O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patients O O
and O O
76 O O
% O O
of O O
Aza B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
patients O O
. O O

Of O O
the O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
, O O
15 O O
% O O
had O O
symptoms O O
related O O
to O O
CMV O O
infection O O
. O O

Serological O O
evidence O O
for O O
Epstein O O
Barr O O
Virus O O
infection O O
was O O
found O O
in O O
20 O O
% O O
of O O
65 O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
patients O O
studied O O
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
had O O
associated O O
symptoms O B_DISEASE
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
developed O O
a O O
lymphoma O B_DISEASE
. O O

Structure O O
- O O
activity O O
and O O
dose O O
- O O
effect O O
relationships O O
of O O
the O O
antagonism O O
of O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
seizures O O
by O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
fragments O O
and O O
analogues O O
of O O
cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
mice O O
. O O

Intraperitoneal O O
administration O O
of O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulphate O O
ester O O
( O O
CCK B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
8 I I_LOCATION/I_GENE
- O O
SE O O
) O O
and O O
nonsulphated O O
cholecystokinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
NS O O
) O O
enhanced O O
the O O
latency O O
of O O
seizures O O
induced O O
by O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O O
mice O O
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
terminal O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
that O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_PROTEIN[GENE]/B_LOCATION
tetrapeptide O B_PROTEIN[GENE]/I_LOCATION
( O O
CCK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5 O B_MEASURE/B_LOCATION
- O O
8 O B_NUMBER[MEASURE]
) O O
was O O
the O O
active O B_LOCATION/B_PERSON
centre O I_LOCATION/I_PERSON
of O O
the O O
CCK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octapeptide O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
analogues O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
SE O O
and O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
NS O O
( O O
dose O O
range O O
0 O O
. O O
2 O O
- O O
6 O O
. O O
4 O O
mumol O O
/ O O
kg O O
) O O
and O O
caerulein B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
range O O
0 O O
. O O
1 O O
- O O
0 O O
. O O
8 O O
mumol O O
/ O O
kg O O
) O O
showed O O
bell O O
- O O
shaped O O
dose O O
- O O
effect O O
curves O O
, O O
with O O
the O O
greatest O O
maximum O O
inhibition O O
for O O
CCK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
NS O O
. O O

The O O
peptide O O
CCK O O
- O O
5 O O
- O O
8 O O
had O O
weak O O
anticonvulsant O O
activity O O
in O O
comparison O O
to O O
the O O
octapeptides O O
, O O
3 O O
. O O
2 O O
mumol O O
/ O O
kg O O
and O O
larger O O
doses O O
of O O
the O O
reference O O
drug O O
, O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
totally O O
prevented O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O O
induced O O
seizures O O
and O O
mortality O O
. O O

The O O
maximum O O
effect O O
of O O
the O O
peptides O O
tested O O
was O O
less O O
than O O
that O O
of O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Experiments O O
with O O
analogues O O
and O O
derivatives O O
of O O
CCK O O
- O O
5 O O
- O O
8 O O
demonstrated O O
that O O
the O O
effectiveness O O
of O O
the O O
beta O O
- O O
alanyl O O
derivatives O O
of O O
CCK O O
- O O
5 O O
- O O
8 O O
were O O
enhanced O O
and O O
that O O
they O O
were O O
equipotent O O
with O O
CCK B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
8 I I_LOCATION/I_ORGANIZATION
- O O
SE O O
. O O

Of O O
the O O
CCK O O
- O O
2 O O
- O O
8 O O
analogues O O
, O O
Ser O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Thr O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Hyp O O
( O O
SO3H O O
) O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
were O O
slightly O O
more O O
active O O
than O O
CCK B B_LOCATION
- I I_LOCATION
8 I I_LOCATION
- O O
SE O O
. O O

Vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O O
a O O
possible O O
contributor O O
to O O
hypertension O O
. O O

The O O
role O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
pressor O O
agent O O
to O O
the O O
hypertensive O O
process O O
was O O
examined O O
. O O

Vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plays O O
a O O
major O O
role O O
in O O
the O O
pathogenesis O O
of O O
DOCA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
salt O O
hypertension O O
, O O
since O O
the O O
elevation O O
of O O
blood O O
pressure O O
was O O
not O O
substantial O O
in O O
the O O
rats O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
diabetes O O
insipidus O O
after O O
DOCA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
salt O O
treatment O O
. O O

Administration O O
of O O
DDAVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
has O O
antidiuretic O O
action O O
but O O
minimal O O
vasopressor O O
effect O O
failed O O
to O O
increase O O
blood O O
pressure O O
to O O
the O O
levels O O
observed O O
after O O
administration O O
of O O
AVP O O
. O O

Furthermore O O
, O O
the O O
pressor O O
action O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
appears O O
to O O
be O O
important O O
in O O
the O O
development O O
of O O
this O O
model O O
of O O
hypertension O O
, O O
since O O
the O O
enhanced O O
pressor O O
responsiveness O O
to O O
the O O
hormone O O
was O O
observed O O
in O O
the O O
initial O O
stage O O
of O O
hypertension O O
. O O

Increased O O
secretion O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O O
neurohypophysis O O
also O O
promotes O O
the O O
function O O
of O O
the O O
hormone O O
as O O
a O O
pathogenetic O O
factor O O
in O O
hypertension O O
. O O

An O O
unproportional O O
release O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
to O O
plasma O O
osmolality O O
may O O
be O O
induced O O
by O O
the O O
absence O O
of O O
an O O
adjusting O O
control O O
of O O
angiotensin B B_GENE/B_MEASURE
II O O
forming O O
and O O
receptor O O
binding O O
capacity O O
for O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
balance O O
in O O
the O O
brain O O
. O O

However O O
, O O
the O O
role O O
of O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remains O O
to O O
be O O
determined O O
in O O
human O O
essential O O
hypertension O O
. O O

Toxic O O
hepatitis O O
induced O O
by O O
disulfiram B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O O
a O O
non O O
- O O
alcoholic O O
. O O

A O O
reversible O O
toxic O O
liver O O
damage O O
was O O
observed O O
in O O
a O O
non O O
- O O
alcoholic O O
woman O O
treated O O
with O O
disulfiram B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

The O O
causative O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
proven O O
by O O
challenge O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Atrial O O
thrombosis O O
involving O O
the O O
heart O O
of O O
F O O
- O O
344 O O
rats O O
ingesting O O
quinacrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Quinacrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
toxic O O
for O O
the O O
heart O O
of O O
F O O
- O O
344 O O
rats O O
. O O

Rats O O
treated O O
with O O
500 O O
ppm O O
quinacrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
diet O O
all O O
developed O O
a O O
high O O
incidence O O
of O O
left O O
atrial O O
thrombosis O O
. O O

The O O
lesion O B_DISEASE
was O O
associated O O
with O O
cardiac O B_DISEASE
hypertrophy O I_DISEASE
and O O
dilatation O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
focal O B_DISEASE
myocardial O I_DISEASE
degeneration O I_DISEASE
. O O

Rats O B_BIO/B_PERSON
died O O
from O O
cardiac O B_DISEASE
hypertrophy O I_DISEASE
with O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
acute O I_DISEASE_ADJECTIVE[DISEASE]
and O O
chronic O B_DISEASE
congestion O I_DISEASE
of O O
the O O
lungs O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
organs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Seventy O O
percent O O
of O O
rats O O
given O O
250 O O
ppm O O
quinacrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O O
, O O
000 O O
ppm O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
simultaneously O O
in O O
the O O
diet O O
had O O
thrombosis O O
of O O
the O O
atria O O
of O O
the O O
heart O O
, O O
while O O
untreated O O
control O O
rats O O
in O O
this O O
laboratory O O
did O O
not O O
have O O
atrial O O
thrombosis O O
. O O

Sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
combination O O
with O O
quinacrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
have O O
no O O
additional O O
effect O O
. O O

Alternating O O
sinus O O
rhythm O O
and O O
intermittent O O
sinoatrial O O
block O O
induced O O
by O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Alternating O O
sinus O O
rhythm O O
and O O
intermittent O O
sinoatrial O O
( O O
S O O
- O O
A O O
) O O
block O O
was O O
observed O O
in O O
a O O
57 O O
- O O
year O O
- O O
old O O
woman O O
, O O
under O O
treatment O O
for O O
angina O O
with O O
80 O O
mg O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
. O O

The O O
electrocardiogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
showed O O
alternation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
short O B_DISEASE_ADJECTIVE[DISEASE]
P O I_DISEASE_ADJECTIVE[DISEASE]
- O O
P O B_MEASURE
intervals O I_MEASURE
and O O
occasional O B_DISEASE/B_MEASURE
pauses O I_DISEASE/I_MEASURE
. O O

These O O
pauses O B_DISEASE/B_TIME[MEASURE]
were O O
always O O
preceded O O
by O O
the O O
short O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
P O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
P O B_MEASURE
intervals O I_MEASURE
and O O
were O O
usually O O
followed O O
by O O
one O B_NUMBER[MEASURE]/B_PERSON
or O O
two O B_NUMBER[MEASURE]
P O I_NUMBER[MEASURE]
- O O
P O B_TIME[MEASURE]/B_LOCATION
intervals O I_TIME[MEASURE]/I_LOCATION
of O O
0 O B_MEASURE
. O O
92 O B_MEASURE
- O O
0 O B_NUMBER[MEASURE]
. O O
95 O B_MEASURE
s O I_MEASURE
representing O O
the O O
basic O B_TIME[MEASURE]/B_PERSON
sinus O I_TIME[MEASURE]/I_PERSON
cycle O I_TIME[MEASURE]/I_PERSON
. O O

Following O O
these O O
basic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycles O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
alternating O O
rhythm O B_ENT/B_DISEASE
started O O
with O O
the O O
longer O B_LOCATION/B_PROTEIN[GENE]
P O I_LOCATION/I_PROTEIN[GENE]
- O O
P O B_MEASURE
interval O I_MEASURE
. O O

The O O
long O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
P O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O O
P O B_LOCATION/B_MEASURE
intervals O I_LOCATION/I_MEASURE
ranged O O
between O O
1 O B_MEASURE/B_LOCATION
. O O
04 O B_MEASURE
- O O
1 O B_MEASURE
. O O
12 O B_TIME[MEASURE]
s O I_TIME[MEASURE]
and O O
the O O
short O B_MEASURE/B_LOCATION
P O I_MEASURE/I_LOCATION
- O O
P O B_MEASURE/B_LOCATION
intervals O I_MEASURE/I_LOCATION
between O O
0 O B_MEASURE/B_LOCATION
. O O
80 O B_MEASURE
- O O
0 O B_MEASURE
. O O
84 O B_MEASURE
s O I_MEASURE
, O O
respectively O O
. O O

The O O
duration O B_MEASURE/B_LOCATION
of O O
the O O
pauses O B_DISEASE/B_TIME[MEASURE]
were O O
equal O B_MEASURE
or O O
almost O O
equal O B_MEASURE
to O O
one O B_NUMBER[MEASURE]
short O I_NUMBER[MEASURE]
plus O O
one O B_NUMBER[MEASURE]/B_LOCATION
long O I_NUMBER[MEASURE]/I_LOCATION
P O I_NUMBER[MEASURE]/I_LOCATION
- O O
P O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
or O O
to O O
twice O O
the O O
basic O B_MEASURE
sinus O I_MEASURE
cycle O I_MEASURE
. O O

In O O
one O B_MEASURE/B_ENT
recording O I_MEASURE/I_ENT
a O O
short O B_TIME[MEASURE]
period O I_TIME[MEASURE]
of O O
regular O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
intermittent O B_MEASURE
2 O I_MEASURE
/ O O
1 O B_SEQUENCE[MEASURE]/B_LOCATION
S O I_SEQUENCE[MEASURE]/I_LOCATION
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
. O O

This O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sinus O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
interrupted O O
by O O
sudden O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
P O B_OTHER/B_LOCATION
- O O
P O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
starting O O
the O O
alternative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
rhythm O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
were O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
the O O
shape O B_MEASURE/B_LOCATION
of O O
the O O
P O B_LOCATION
waves O I_LOCATION
and O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
R O B_MEASURE/B_LOCATION
intervals O I_MEASURE/I_LOCATION
. O O

S O B_DISEASE/B_PROTEIN[GENE]
- O O
A O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conduction O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
two O B_LOCATION
pathways O I_LOCATION
, O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
with O O
2 O B_NUMBER[MEASURE]
/ O O
1 O B_MEASURE
block O O
the O O
second O B_SEQUENCE[MEASURE]/B_PERSON
having O O
0 O B_MEASURE/B_LOCATION
. O O
12 O B_MEASURE
- O O
0 O B_MEASURE
. O O
14 O B_MEASURE
s O I_MEASURE
longer O I_MEASURE
conduction O I_MEASURE
time O I_MEASURE
and O O
with O O
occasional O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
/ O O
1 O B_MEASURE/B_LOCATION
block O I_MEASURE/I_LOCATION
was O O
proposed O O
for O O
the O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
alternating O O
P O B_OTHER/B_LOCATION
- O O
P O B_MEASURE
interval O I_MEASURE
and O O
other O B_DISEASE/B_PROTEIN[GENE]
electrocardiographic O B_DISEASE/I_PROTEIN[GENE]
features O B_DISEASE/I_PROTEIN[GENE]
seen O O
. O O

Atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O O
mg O O
given O O
intravenously O O
resulted O O
in O O
shortening O O
of O O
all O O
P O O
- O O
P O O
intervals O O
without O O
changing O O
the O O
rhythm O O
. O O

The O O
abnormal O O
rhythm O O
disappeared O O
with O O
the O O
withdrawal O O
of O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
when O O
the O O
drug O O
was O O
restarted O O
a O O
2 O O
/ O O
1 O O
S O O
- O O
A O O
block O O
was O O
seen O O
. O O

This O O
was O O
accepted O O
as O O
evidence O O
for O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
being O O
the O O
cause O O
of O O
this O O
conduction O O
disorder O O
. O O

Antitumor O O
effect O O
, O O
cardiotoxicity O O
, O O
and O O
nephrotoxicity O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
IgM O O
solid O O
immunocytoma O O
- O O
bearing O O
LOU O O
/ O O
M O O
/ O O
WSL O O
rat O O
. O O

Antitumor O O
activity O O
, O O
cardiotoxicity O O
, O O
and O O
nephrotoxicity O O
induced O O
by O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
LOU O O
/ O O
M O O
/ O O
WSL O O
inbred O O
rats O O
each O O
bearing O O
a O O
transplantable O O
solid O O
IgM O O
immunocytoma O O
. O O

Animals O O
with O O
a O O
tumor O O
( O O
diameter O O
, O O
15 O O
. O O
8 O O
+ O O
/ O O
- O O
3 O O
. O O
3 O O
mm O O
) O O
were O O
treated O O
with O O
iv O O
injections O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
5 O O
consecutive O O
days O O
, O O
followed O O
by O O
1 O O
weekly O O
injection O O
for O O
7 O O
weeks O O
( O O
dose O O
range O O
, O O
0 O O
. O O
015 O O
- O O
4 O O
. O O
0 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
. O O

Tumor O O
regression O O
was O O
observed O O
with O O
0 O O
. O O
5 O O
mg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O O
. O O

Complete O O
disappearance O O
of O O
the O O
tumor O O
was O O
induced O O
with O O
1 O O
. O O
0 O O
mg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O O
. O O

Histologic O O
evidence O O
of O O
cardiotoxicity O O
scored O O
as O O
grade O O
III O O
was O O
only O O
observed O O
at O O
a O O
dose O O
of O O
1 O O
. O O
0 O O
mg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
kg O O
. O O

Light O O
microscopic O O
evidence O O
of O O
renal O O
damage O O
was O O
seen O O
above O O
a O O
dose O O
of O O
0 O O
. O O
5 O O
mg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
kg O O
, O O
which O O
resulted O O
in O O
albuminuria O O
and O O
very O O
low O O
serum O O
albumin O O
levels O O
. O O

In O O
the O O
group O O
that O O
received O O
1 O O
. O O
0 O O
mg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O O
kg O O
, O O
the O O
serum O O
albumin O O
level O O
decreased O O
from O O
33 O O
. O O
6 O O
+ O O
/ O O
- O O
4 O O
. O O
1 O O
to O O
1 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
g O O
/ O O
liter O O
. O O

Ascites O B_DISEASE
and O O
hydrothorax O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
were O O
observed O O
simultaneously O O
. O O

The O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
with O O
non O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
tumor O B_DISEASE
- O O
bearing O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rats O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
in O O
which O O
no O O
major O B_DISEASE
differences O I_DISEASE
were O O
observed O O
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
antitumor O B_DISEASE
activity O I_DISEASE
, O O
cardiotoxicity O B_DISEASE
, O O
and O O
nephrotoxicity O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
simultaneously O O
in O O
the O O
same O B_PERSON/B_LOCATION
LOU O B_PERSON/I_LOCATION
/ O O
M O B_OTHER/B_PERSON
/ O O
WSL O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Albuminuria O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
renal O B_DISEASE
damage O I_DISEASE
led O O
to O O
extremely O O
low O B_DISEASE
serum O I_DISEASE
albumin O I_DISEASE
levels O I_DISEASE
, O O
so O O
ascites O B_DISEASE
and O O
hydrothorax O B_DISEASE
were O O
not O O
necessarily O O
a O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
observed O B_DISEASE
cardiomyopathy O I_DISEASE
. O O

Intraoperative O O
bradycardia O O
and O O
hypotension O O
associated O O
with O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye O O
drops O O
. O O

A O O
69 O O
- O O
yr O O
- O O
old O O
man O O
, O O
who O O
was O O
concurrently O O
being O O
treated O O
with O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maleate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye O O
drops O O
, O O
developed O O
a O O
bradycardia O O
and O O
became O O
hypotensive O O
during O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O O
. O O

Both O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
subsequently O O
identified O O
in O O
a O O
24 O O
- O O
h O O
collection O O
of O O
urine O O
. O O

Timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
but O O
not O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
was O O
detected O O
in O O
a O O
sample O O
of O O
plasma O O
removed O O
during O O
surgery O O
; O O
the O O
plasma O O
concentration O O
of O O
timolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
2 O O
. O O
6 O O
ng O O
ml O O
- O O
1 O O
) O O
was O O
consistent O O
with O O
partial O O
beta O O
- O O
adrenoceptor O O
blockade O O
. O O

It O O
is O O
postulated O O
that O O
this O O
action O O
may O O
have O O
been O O
enhanced O O
during O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O O
with O O
resultant O O
bradycardia O O
and O O
hypotension O O
. O O

Pilocarpine B B_PERSON/B_LOCATION
may O O
have O O
had O O
a O O
contributory O O
effect O O
. O O

Succinylcholine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O O
: O O
attempted O O
reversal O O
with O O
anticholinesterases O O
. O O

Anticholinesterases O O
were O O
administered O O
in O O
an O O
attempt O O
to O O
antagonize O O
prolonged O O
neuromuscular O O
blockade O O
following O O
the O O
administration O O
of O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
patient O O
later O O
found O O
to O O
be O O
homozygous O O
for O O
atypical O O
plasma O O
cholinesterase O O
. O O

Edrophonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
10 O O
mg O O
, O O
given O O
74 O O
min O O
after O O
succinylcholine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
when O O
train O O
- O O
of O O
- O O
four O O
stimulation O O
was O O
characteristic O O
of O O
phase O O
II O O
block O O
, O O
produced O O
partial O O
antagonism O O
which O O
was O O
not O O
sustained O O
. O O

Repeated O O
doses O O
of O O
edrophonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
70 O O
mg O O
and O O
neostigmine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
2 O O
. O O
5 O O
mg O O
did O O
not O O
antagonize O O
or O O
augment O O
the O O
block O O
. O O

Spontaneous O O
respiration O O
recommenced O O
200 O O
min O O
after O O
succinylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O O
. O O

It O O
is O O
concluded O O
that O O
anticholinesterases O O
are O O
only O O
partially O O
effective O O
in O O
restoring O O
neuromuscular O O
function O O
in O O
succinylcholine B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O O
despite O O
muscle O O
twitch O O
activity O O
typical O O
of O O
phase O O
II O O
block O O
. O O

Effect O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
omega I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
131 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
heptadecanoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
myocardial O O
scintigraphy O O
and O O
echocardiography O O
in O O
dogs O O
. O O

The O O
effects O O
of O O
serial O O
treatment O O
with O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dynamic O O
myocardial O O
scintigraphy O O
with O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
omega I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heptadecanoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
I B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
131 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
HA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
, O O
and O O
on O O
global O O
left O O
- O O
ventricular O O
function O O
determined O O
echocardiographically O O
, O O
were O O
studied O O
in O O
a O O
group O O
of O O
nine O O
mongrel O O
dogs O O
. O O

Total O O
extractable O O
myocardial O O
lipid O O
was O O
compared O O
postmortem O O
between O O
a O O
group O O
of O O
control O O
dogs O O
and O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
dogs O O
. O O

A O O
significant O O
and O O
then O O
progressive O O
fall O O
in O O
global O O
LV O O
function O O
was O O
observed O O
at O O
a O O
cumulative O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O O
of O O
4 O O
mg O O
/ O O
kg O O
. O O

A O O
significant O O
increase O O
in O O
the O O
myocardial O O
t1 O O
/ O O
2 O O
of O O
the O O
I B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
only O O
at O O
a O O
higher O O
cumulative O O
dose O O
, O O
10 O O
mg O O
/ O O
kg O O
. O O

No O O
significant O O
alteration O O
in O O
total O O
extractable O O
myocardial O O
lipids O O
was O O
observed O O
between O O
control O O
dogs O O
and O O
those O O
treated O O
with O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
findings O O
suggest O O
that O O
the O O
changes O O
leading O O
to O O
an O O
alteration O O
of O O
myocardial O O
dynamic O O
imaging O O
with O O
I B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
not O O
the O O
initiating O O
factor O O
in O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O O
. O O

Hemodynamics O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
myocardial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
deliberate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hypotension O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

An O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
dogs O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Coronary O O
blood O O
flow O O
, O O
cardiac O O
work O O
and O O
metabolism O O
were O O
studied O O
in O O
dogs O O
under O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP B B_LOCATION/B_ORGANIZATION
) O O
and O O
trimetaphan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TMP B B_LOCATION/B_ORGANIZATION
) O O
deliberate O O
hypotension O O
( O O
20 O O
% O O
and O O
40 O O
% O O
mean O O
pressure O O
decrease O O
from O O
baseline O O
) O O
. O O

Regarding O O
the O O
effects O O
of O O
drug O O
- O O
induced O O
hypotension O O
on O O
coronary O O
blood O O
flow O O
, O O
aortic O O
and O O
coronary O O
sinus O O
metabolic O O
data O O
( O O
pH O O
, O O
pO2 O O
, O O
pCO2 O O
) O O
we O O
could O O
confirm O O
that O O
nitroprusside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypotension O O
could O O
be O O
safely O O
used O O
to O O
30 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
from O O
control O O
, O O
trimetaphan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypotension O O
to O O
20 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
. O O

Cardiac O O
work O O
was O O
significantly O O
reduced O O
during O O
SNP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypotension O O
. O O

Myocardial O O
O2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
and O O
O2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
availability O O
were O O
directly O O
dependent O O
on O O
the O O
coronary O O
perfusion O O
. O O

Careful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gases O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
of O O
the O O
ECG O B_DISEASE/B_PROTEIN[GENE]
ST O B_DISEASE/I_PROTEIN[GENE]
- O O
T O B_NUMBER[MEASURE]/B_LOCATION
segment O I_NUMBER[MEASURE]/I_LOCATION
is O O
mandatory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Evidence O O
for O O
a O O
selective O O
brain O O
noradrenergic O O
involvement O O
in O O
the O O
locomotor O O
stimulant O O
effects O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rat O O
. O O

Male O O
rats O O
received O O
the O O
noradrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurotoxin O O
DSP4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
50 O O
mg O O
/ O O
kg O O
) O O
7 O O
days O O
prior O O
to O O
injection O O
of O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amphetamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
or O O
40 O O
mumol O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
. O O

The O O
hyperactivity O O
induced O O
by O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amphetamine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
mumol O O
/ O O
kg O O
) O O
was O O
significantly O O
reduced O O
by O O
DSP4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment O O
. O O

However O O
, O O
the O O
increased O O
rearings O O
and O O
the O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
stereotypies O O
were O O
not O O
blocked O O
by O O
pretreatment O O
with O O
DSP4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
reduction O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hyperactivity O O
induced O O
by O O
DSP4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
blocked O O
by O O
pretreatment O O
with O O
the O O
noradrenaline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
uptake O O
blocking O O
agent O O
, O O
desipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
prevents O O
the O O
neurotoxic O O
action O O
of O O
DSP4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
present O O
results O O
suggest O O
a O O
selective O O
involvement O O
of O O
central O O
noradrenergic O O
neurones O O
in O O
the O O
locomotor O O
stimulant O O
effect O O
of O O
amphetamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
rat O O
. O O

Accelerated O O
junctional O O
rhythms O O
during O O
oral O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

This O O
study O O
examined O O
the O O
frequency O O
of O O
atrioventricular O O
( O O
AV O O
) O O
dissociation O O
and O O
accelerated O O
junctional O O
rhythms O O
in O O
59 O O
patients O O
receiving O O
oral O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Accelerated O O
junctional O B_DISEASE
rhythms O I_DISEASE
and O O
AV O B_DISEASE
dissociation O I_DISEASE
were O O
frequent O B_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON/B_BIO
with O O
supraventricular O B_DISEASE/B_PROTEIN[GENE]
tachyarrhythmias O B_DISEASE/I_PROTEIN[GENE]
, O O
particularly O O
AV O B_DISEASE/B_PERSON
nodal O I_DISEASE/I_PERSON
reentry O I_DISEASE/I_PERSON
. O O

Verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
to O O
these O O
patients O O
led O O
to O O
an O O
asymptomatic O O
increase O O
in O O
activity O O
of O O
these O O
junctional O O
pacemakers O O
. O O

In O O
patients O O
with O O
various O O
chest O O
pain O O
syndromes O O
, O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neither O O
increased O O
the O O
frequency O O
of O O
junctional O O
rhythms O O
nor O O
suppressed O O
their O O
role O O
as O O
escape O O
rhythms O O
under O O
physiologically O O
appropriate O O
circumstances O O
. O O

Interstrain O O
variation O O
in O O
acute O O
toxic O O
response O O
to O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O O
inbred O O
mice O O
. O O

Acute O O
toxic O O
dosage O O
- O O
dependent O O
behavioral O O
effects O O
of O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
in O O
adult O O
males O O
from O O
seven O O
inbred O O
mouse O O
strains O O
( O O
A O O
/ O O
J O O
, O O
BALB O O
/ O O
cJ O O
, O O
CBA O O
/ O O
J O O
, O O
C3H O O
/ O O
HeJ O O
, O O
C57BL O O
/ O O
6J O O
, O O
DBA O O
/ O O
2J O O
, O O
SWR O O
/ O O
J O O
) O O
. O O

C57BL O O
/ O O
6J O O
, O O
chosen O O
as O O
a O O
" O O
prototypic O O
" O O
mouse O O
strain O O
, O O
was O O
used O O
to O O
determine O O
behavioral O O
responses O O
to O O
a O O
broad O O
range O O
( O O
5 O O
- O O
500 O O
mg O O
/ O O
kg O O
) O O
of O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O O
. O O

Five O O
phenotypic O O
characteristics O O
- O O
- O O
locomotor O O
activity O O
, O O
righting O O
ability O O
, O O
clonic O O
seizure O O
induction O O
, O O
stress O O
- O O
induced O O
lethality O O
, O O
death O O
without O O
external O O
stress O O
- O O
- O O
were O O
scored O O
at O O
various O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O O
in O O
drug O O
- O O
naive O O
animals O O
under O O
empirically O O
optimized O O
, O O
rigidly O O
constant O O
experimental O O
conditions O O
. O O

Mice O O
( O O
n O O
= O O
12 O O
for O O
each O O
point O O
) O O
received O O
single O O
IP O O
injections O O
of O O
a O O
fixed O O
volume O O
/ O O
g O O
body O O
weight O O
of O O
physiological O O
saline O O
carrier O O
with O O
or O O
without O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
doses O O
ranging O O
from O O
125 O O
- O O
500 O O
mg O O
/ O O
kg O O
. O O

Loss O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
righting O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
scored O O
at O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_MEASURE
, O O
5 O B_SEQUENCE[MEASURE]
min O I_SEQUENCE[MEASURE]
post O I_SEQUENCE[MEASURE]
dosing O I_SEQUENCE[MEASURE]
and O O
at O O
5 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
intervals O I_TIME[MEASURE]/I_LOCATION
thereafter O O
for O O
20 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
min O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
the O O
same O B_PERSON/B_ENT
animals O I_PERSON/I_ENT
the O O
occurrence O B_DISEASE/B_MEASURE
of O O
clonic O B_DISEASE
seizures O I_DISEASE
was O O
scored O O
as O O
to O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
onset O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O O
20 O B_TIME[MEASURE]/B_DISEASE
min O B_TIME[MEASURE]/I_DISEASE
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

When O O
these O O
proceeded O O
to O O
tonic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
death O B_PERSON/B_DISEASE
occurred O O
in O O
less O B_MEASURE
than O O
20 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

Animals O B_BIO/B_PERSON
surviving O O
for O O
20 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
immediately O O
stressed O O
by O O
a O O
swim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
25 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
death O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
producing O O
tonic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
seizures O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
scored O O
for O O
2 O B_DISEASE
min O I_DISEASE
. O O

In O O
other O O
animals O O
locomotor O O
activity O O
was O O
measured O O
15 O O
or O O
60 O O
min O O
after O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
. O O

By O O
any O O
single O O
behavioral O O
criterion O O
or O O
a O O
combination O O
of O O
these O O
criteria O O
, O O
marked O O
differences O O
in O O
response O O
to O O
toxic O O
caffeine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O O
were O O
observed O O
between O O
strains O O
. O O

These O O
results O O
indicate O O
that O O
behavioral O O
toxicity O O
testing O O
of O O
alkylxanthines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
single O O
mouse O O
strain O O
may O O
be O O
misleading O O
and O O
suggest O O
that O O
toxic O O
responses O O
of O O
the O O
central O O
nervous O O
system O O
to O O
this O O
class O O
of O O
compounds O O
are O O
genetically O O
influenced O O
in O O
mammals O O
. O O

Treatment O O
of O O
ovarian O O
cancer O O
with O O
a O O
combination O O
of O O
cis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
platinum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hexamethylmelamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

During O O
the O O
last O O
2 O O
1 O O
/ O O
2 O O
years O O
, O O
38 O O
patients O O
with O O
ovarian O O
cancer O O
were O O
treated O O
with O O
a O O
combination O O
of O O
cisplatinum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
CPDD B B_LOCATION/B_ORGANIZATION
) O O
, O O
50 O O
mg O O
/ O O
m2 O O
, O O
adriamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
30 O O
mg O O
/ O O
m2 O O
, O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
300 O O
mg O O
/ O O
m2 O O
, O O
on O O
day O O
1 O O
; O O
and O O
hexamethylmelamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HMM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
6 O O
mg O O
/ O O
kg O O
daily O O
, O O
for O O
14 O O
days O O
. O O

Each O O
course O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
repeated O O
monthly O O
. O O

2 O B_PERSON
patients O I_PERSON
had O O
stage O B_DISEASE_ADJECTIVE[DISEASE]
II O I_DISEASE_ADJECTIVE[DISEASE]
, O O
14 O B_TIME[MEASURE]/B_DISEASE
stage O I_TIME[MEASURE]/I_DISEASE
III O I_TIME[MEASURE]/I_DISEASE
and O O
22 O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
stage O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

14 O O
of O O
the O O
38 O O
patients O O
were O O
previously O O
treated O O
with O O
chemotherapy O O
, O O
1 O O
with O O
radiation O O
, O O
6 O O
with O O
both O O
chemotherapy O O
and O O
radiation O O
, O O
and O O
17 O O
did O O
not O O
have O O
any O O
treatment O O
before O O
CPDD B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
combination O O
. O O

31 O B_MEASURE
of O O
the O O
38 O B_MEASURE/B_PERSON
cases O I_MEASURE/I_PERSON
( O O
81 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
demonstrated O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lasting O O
for O O
2 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
or O O
more O B_TIME[MEASURE]/B_LOCATION
. O O

These O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
partial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
19 O B_NUMBER[MEASURE]
and O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
12 O B_MEASURE
cases O I_MEASURE
. O O

Hematologic O B_DISEASE
toxicity O I_DISEASE
was O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
with O O
reversible O B_DISEASE
anemia O I_DISEASE
developing O O
in O O
71 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
patients O B_PERSON/B_DISEASE
. O O

Gastrointestinal O O
side O O
effects O O
from O O
CPDD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
universal O O
. O O

HMM B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gastrointestinal O O
toxicity O O
necessitated O O
discontinuation O O
of O O
the O O
drug O O
in O O
5 O O
patients O O
. O O

Severe O B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity O I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
2 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
but O O
was O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
. O O

There O O
were O O
no O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
deaths O B_DISEASE
. O O

Nontraumatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dissecting O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
basilar O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

A O O
case O O
of O O
nontraumatic O O
dissecting O O
aneurysm O O
of O O
the O O
basilar O O
artery O O
in O O
association O O
with O O
hypertension O O
, O O
smoke O O
, O O
and O O
oral B B_DISEASE
contraceptives I I_DISEASE
is O O
reported O O
in O O
a O O
young O O
female O O
patient O O
with O O
a O O
locked O O
- O O
in O O
syndrome O O
. O O

A O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tremor O B_DISEASE/B_GENE
, O O
and O O
a O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
tocolytic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
beta O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
mimetics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permitting O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
finger O B_DISEASE/B_MEASURE
tremor O B_DISEASE/I_MEASURE
as O O
a O O
displacement O B_TIME[MEASURE]/B_LOCATION
- O O
time O B_MEASURE
curve O I_MEASURE
is O O
described O O
, O O
using O O
a O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
with O O
simple O B_DISEASE_ADJECTIVE[DISEASE]/B_PRODUCT[OBJECT]
amplitude O B_DISEASE_ADJECTIVE[DISEASE]/I_PRODUCT[OBJECT]
calibration O B_DISEASE_ADJECTIVE[DISEASE]/I_PRODUCT[OBJECT]
. O O

The O O
coordinates O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
inversion O B_LOCATION/B_MEASURE
points O I_LOCATION/I_MEASURE
of O O
the O O
displacement O B_TIME[MEASURE]/B_LOCATION
- O O
time O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
transferred O O
through O O
graphical O B_PRODUCT[OBJECT]/B_LOCATION
input O I_PRODUCT[OBJECT]/I_LOCATION
equipment O I_PRODUCT[OBJECT]/I_LOCATION
to O O
punched O B_PERSON/B_PRODUCT[OBJECT]
tape O I_PERSON/I_PRODUCT[OBJECT]
. O O

By O O
means O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
computer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
periods O B_MEASURE/B_LOCATION
and O O
amplitudes O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
tremor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oscillations O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
calculated O O
and O O
classified O O
. O O

The O O
event O B_MEASURE
frequency O I_MEASURE
for O O
each O O
class O B_PERSON/B_MEASURE
of O O
periods O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
amplitudes O B_TIME[MEASURE]/B_ENT
was O O
determined O O
. O O

The O O
actions O O
of O O
fenoterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrobromide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ritodrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
placebo O O
given O O
to O O
10 O O
healthy O O
subjects O O
by O O
intravenous O O
infusion O O
in O O
a O O
double O O
- O O
blind O O
crossover O O
study O O
were O O
tested O O
by O O
this O O
method O O
. O O

At O O
therapeutic O B_TIME[MEASURE]/B_LOCATION
doses O I_TIME[MEASURE]/I_LOCATION
both O O
substances O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raised O O
the O O
mean O B_MEASURE/B_DISEASE
tremor O I_MEASURE/I_DISEASE
amplitude O I_MEASURE/I_DISEASE
to O O
about O O
three O B_MEASURE/B_LOCATION
times O I_MEASURE/I_LOCATION
the O O
control O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
. O O

At O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
mean O B_TIME[MEASURE]
period O I_TIME[MEASURE]
within O O
each O O
class O B_PERSON/B_LOCATION
of O O
amplitudes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shortened O O
by O O
10 O B_MEASURE/B_LOCATION
- O O
- O O
20 O B_TIME[MEASURE]
ms O I_TIME[MEASURE]
, O O
whereas O O
the O O
mean O B_MEASURE
periods O I_MEASURE
calculated O O
from O O
all O O
oscillations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
together O O
did O O
not O O
change O O
significantly O O
. O O

After O O
the O O
end O O
of O O
fenoterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrobromide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
, O O
tremor O O
amplitudes O O
decreased O O
significantly O O
faster O O
than O O
those O O
following O O
ritodrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

Propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hepatic O O
damage O O
. O O

Two O O
cases O O
of O O
propylthiouracil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
liver O O
damage O O
have O O
been O O
observed O O
. O O

The O O
first O B_SEQUENCE[MEASURE]
case O I_SEQUENCE[MEASURE]
is O O
of O O
an O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
type O I_DISEASE_ADJECTIVE[DISEASE]
of O O
damage O B_DISEASE
, O O
proven O O
by O O
rechallenge O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
the O O
second O B_SEQUENCE[MEASURE]/B_PERSON
presents O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
histologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
picture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resembling O O
chronic O B_DISEASE/B_GENE
active O I_DISEASE/I_GENE
hepatitis O I_DISEASE/I_GENE
, O O
with O O
spontaneous O B_DISEASE
remission O I_DISEASE
. O O

Studies O O
on O O
the O O
bradycardia O O
induced O O
by O O
bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
novel O O
active O O
compound O O
for O O
prophylactic O O
treatment O O
of O O
anginal O O
attacks O O
, O O
induced O O
persistent O O
bradycardia O O
and O O
a O O
non O O
- O O
specific O O
anti O O
- O O
tachycardial O O
effect O O
, O O
the O O
mechanisms O O
of O O
which O O
were O O
investigated O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

In O O
vitro O O
perfusion O O
of O O
bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
life O O
- O O
support O O
medium O O
for O O
isolated O O
sino O O
- O O
atrial O O
tissue O O
from O O
rabbit O O
heart O O
, O O
caused O O
a O O
reduction O O
in O O
action O O
potential O O
( O O
AP O O
) O O
spike O O
frequency O O
( O O
recorded O O
by O O
KCl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
microelectrodes O O
) O O
starting O O
at O O
doses O O
of O O
5 O O
X O O
10 O O
( O O
- O O
6 O O
) O O
M O O
. O O

This O O
effect O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
dose O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
up O O
to O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
5 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
- O O
5 O B_MEASURE
) O O
M O B_OTHER/B_MEASURE
, O O
whereupon O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blockade O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
sinus O B_DISEASE/B_GENE
activity O B_DISEASE/I_GENE
set O O
in O O
. O O

Bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
a O O
dose O O
of O O
5 O O
X O O
10 O O
( O O
- O O
6 O O
) O O
M O O
, O O
induced O O
a O O
concomitant O O
reduction O O
in O O
AP O O
amplitude O O
( O O
falling O O
from O O
71 O O
+ O O
/ O O
- O O
8 O O
mV O O
to O O
47 O O
+ O O
/ O O
- O O
6 O O
mV O O
) O O
, O O
maximum O O
systolic O O
depolarization O O
velocity O O
( O O
phase O O
0 O O
) O O
which O O
fell O O
from O O
1 O O
. O O
85 O O
+ O O
/ O O
- O O
0 O O
. O O
35 O O
V O O
/ O O
s O O
to O O
0 O O
. O O
84 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
V O O
/ O O
s O O
, O O
together O O
with O O
maximum O O
diastolic O O
depolarization O O
velocity O O
( O O
phase O O
4 O O
) O O
which O O
fell O O
from O O
38 O O
+ O O
/ O O
- O O
3 O O
mV O O
/ O O
s O O
to O O
24 O O
+ O O
/ O O
- O O
5 O O
mV O O
/ O O
s O O
. O O

In O O
vivo O O
injection O O
of O O
bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
a O O
dose O O
of O O
5 O O
mg O O
/ O O
kg O O
( O O
i O O
. O O
v O O
. O O
) O O
into O O
6 O O
anaesthetized O O
dogs O O
which O O
had O O
undergone O O
ablation O O
of O O
all O O
the O O
extrinsic O O
cardiac O O
afferent O O
nerve O O
supply O O
, O O
together O O
with O O
a O O
bilateral O O
medullo O O
- O O
adrenalectomy O O
, O O
caused O O
a O O
marked O O
reduction O O
in O O
heart O O
rate O O
which O O
fell O O
from O O
98 O O
. O O
7 O O
+ O O
/ O O
- O O
4 O O
. O O
2 O O
beats O O
/ O O
min O O
to O O
76 O O
+ O O
/ O O
- O O
5 O O
. O O
3 O O
beats O O
/ O O
min O O
sustained O O
for O O
more O O
than O O
45 O O
min O O
. O O

It O O
is O O
concluded O O
that O O
bepridil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
heart O O
rate O O
by O O
acting O O
directly O O
on O O
the O O
sinus O O
node O O
. O O

This O O
effect O O
, O O
which O O
results O O
in O O
a O O
flattening O O
of O O
the O O
phase O O
0 O O
and O O
phase O O
4 O O
slope O O
, O O
together O O
with O O
a O O
longer O O
AP O O
duration O O
, O O
may O O
be O O
due O O
to O O
an O O
increase O O
in O O
the O O
time O O
constants O O
of O O
slow O O
inward O O
ionic O O
currents O O
( O O
already O O
demonstrated O O
elsewhere O O
) O O
, O O
but O O
also O O
to O O
an O O
increased O O
time O O
constant O O
for O O
deactivation O O
of O O
the O O
outward O O
potassium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
current O O
( O O
Ip O O
) O O
. O O

Hepatitis O O
and O O
renal O O
tubular O O
acidosis O O
after O O
anesthesia O O
with O O
methoxyflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
69 O O
- O O
year O O
- O O
old O O
man O O
operated O O
for O O
acute O O
cholecystitis O O
under O O
methoxyflurane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O O
developed O O
postoperatively O O
a O O
hepatic O O
insufficiency O O
syndrome O O
and O O
renal O O
tubular O O
acidosis O O
. O O

Massive O B_PERSON
bleeding O I_PERSON
appeared O O
during O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
lasted O O
for O O
six O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
. O O

Postoperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evolution O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
under O O
supportive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
favourable O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
repeated O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O O
over O O
a O O
period O B_MEASURE/B_LOCATION
of O O
one O B_TIME[MEASURE]
year O I_TIME[MEASURE]
after O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Pituitary O O
response O O
to O O
luteinizing O O
hormone O O
- O O
releasing O O
hormone O O
during O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperprolactinemia O O
. O O

The O O
effects O O
of O O
a O O
6 O O
- O O
hour O O
infusion O O
with O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
serum O O
prolactin O O
and O O
luteinizing O O
hormone O O
( O O
LH O O
) O O
levels O O
was O O
studied O O
in O O
a O O
group O O
of O O
male O O
subjects O O
. O O

Five O B_TIME[MEASURE]/B_ENT
hours O I_TIME[MEASURE]/I_ENT
after O O
starting O O
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
pituitary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
LH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
releasing O O
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LH O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RH O B_PROTEIN[GENE]/B_DISEASE
) O O
was O O
carried O O
out O O
. O O

Control O O
patients O O
received O O
infusions O O
of O O
0 O O
. O O
9 O O
% O O
NaCl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O O
. O O

During O O
the O O
course O O
of O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusions O O
, O O
significant O O
hyperprolactinemia O O
was O O
found O O
, O O
together O O
with O O
an O O
abolished O O
pituitary O O
response O O
to O O
LH O O
- O O
RH O O
, O O
as O O
compared O O
with O O
responses O O
of O O
control O O
subjects O O
. O O

Antirifampicin O O
antibodies O O
in O O
acute O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
renal O O
failure O O
. O O

5 O O
patients O O
with O O
acute O O
renal O O
failure O O
( O O
3 O O
with O O
thrombopenia O O
and O O
hemolysis O O
) O O
induced O O
by O O
the O O
reintroduction O O
of O O
rifampicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
described O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
the O O
severity O B_MEASURE
of O O
clinical O B_DISEASE
manifestations O I_DISEASE
and O O
the O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
taken O O
by O O
the O O
patients O B_PERSON
. O O

In O O
all O O
but O O
1 O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
, O O
antirifampicin O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibodies O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
detected O O
. O O

Antibodies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suggested O O
to O O
be O O
of O O
the O O
IgM O B_GENE/B_DISEASE
class O B_GENE/I_DISEASE
were O O
detected O O
in O O
all O O
3 O B_PERSON
patients O I_PERSON
with O O
hematological O B_DISEASE/B_GENE
disorders O I_DISEASE/I_GENE
. O O

The O O
pattern O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
non O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubular O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
necrosis O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
found O O
in O O
the O O
2 O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
biopsied O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
patients O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
indistinguishable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O O
that O O
of O O
ischemic O B_DISEASE/B_PERSON
origin O I_DISEASE/I_PERSON
, O O
raised O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
vascular O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
mediated O O
damage O B_DISEASE
. O O

In O O
3 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
, O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
triggering O O
immunoallergic O B_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]
is O O
discussed O O
. O O

Cardiovascular O O
effects O O
of O O
hypotension O O
induced O O
by O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triphosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dogs O O
with O O
denervated O O
hearts O O
. O O

Adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
triphosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ATP B B_ORGANIZATION/B_GENE
) O O
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNP B B_PROTEIN[GENE]/B_LOCATION
) O O
are O O
administered O O
to O O
patients O O
to O O
induce O O
and O O
control O O
hypotension O O
during O O
anesthesia O O
. O O

SNP B B_LOCATION/B_ORGANIZATION
is O O
authorized O O
for O O
clinical O O
use O O
in O O
USA O O
and O O
UK O O
, O O
and O O
ATP B B_GENE/B_DISEASE
is O O
clinically O O
used O O
in O O
other O O
countries O O
such O O
as O O
Japan O O
. O O

We O O
investigated O O
how O O
these O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
act O O
on O O
the O O
cardiovascular O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems O I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
20 O B_PERSON/B_ENT
dogs O I_PERSON/I_ENT
whose O O
hearts O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
been O O
denervated O O
by O O
a O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
we O O
had O O
devised O O
. O O

ATP B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
dogs O O
) O O
or O O
SNP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
10 O O
dogs O O
) O O
was O O
administered O O
to O O
reduce O O
mean O O
arterial O O
pressure O O
by O O
30 O O
% O O
to O O
70 O O
% O O
of O O
control O O
. O O

Before O O
, O O
during O O
and O O
after O O
induced O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hypotension O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
we O O
measured O O
major O B_DISEASE/B_GENE
cardiovascular O B_DISEASE/I_GENE
parameters O B_DISEASE/I_GENE
. O O

Hypotension O O
induced O O
by O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
accompanied O O
by O O
significant O O
decreases O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
total O O
body O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
and O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
; O O
all O O
these O O
variables O O
returned O O
normal O O
within O O
30 O O
min O O
after O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
stopped O O
. O O

Cardiac O B_PERSON/B_MEASURE
output O I_PERSON/I_MEASURE
did O O
not O O
change O B_MEASURE
. O O

During O O
hypotension O O
produced O O
by O O
SNP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
similar O O
decreases O O
were O O
observed O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
and O O
oxygen B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
content O O
difference O O
between O O
arterial O O
and O O
mixed O O
venous O O
blood O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
while O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
cardiac O O
output O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
were O O
increased O O
. O O

Recoveries O O
of O O
heart O O
rate O O
and O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
were O O
not O O
shown O O
within O O
60 O O
min O O
after O O
SNP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O O
been O O
stopped O O
. O O

Both O O
ATP B B_ORGANIZATION/B_LOCATION
and O O
SNP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
should O O
act O O
on O O
the O O
pacemaker O O
tissue O O
of O O
the O O
heart O O
. O O

Comparative O O
study O O
: O O
Endografine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
diatrizoate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Vasurix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
polyvidone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
acetrizoate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
Dimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
iocarmate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
Hexabrix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
ioxaglate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
hysterosalpingography O O
. O O

Side O O
effects O O
of O O
hysterosalpingography O O
with O O
Dimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Hexabrix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Vasurix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polyvidone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
Endografine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
142 O O
consecutive O O
patients O O
, O O
receiving O O
one O O
of O O
the O O
four O O
tested O O
media O O
were O O
evaluated O O
from O O
replies O O
to O O
postal O O
questionnaires O O
. O O

The O O
Dimer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
had O O
a O O
higher O O
incidence O O
of O O
nausea O O
and O O
dizziness O O
. O O

The O O
Endografine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
had O O
a O O
higher O O
incidence O O
of O O
abdominal O O
pain O O
. O O

These O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occur O O
especially O O
in O O
the O O
age O B_PERSON
groups O I_PERSON
under O O
30 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
. O O

Hexabrix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
Vasurix B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyvidone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
considered O O
the O O
best O O
contrast B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
media I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
hysterosalpingography O O
and O O
perhaps O O
because O O
of O O
its O O
low O O
toxicity O O
Hexabrix B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
should O O
be O O
preferred O O
. O O

Post O O
- O O
suxamethonium B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pains O O
in O O
Nigerian O O
surgical O O
patients O O
. O O

Contrary O O
to O O
an O O
earlier O O
report O O
by O O
Coxon O O
, O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
occurs O O
in O O
African O O
negroes O O
. O O

Its O O
incidence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
determined O O
in O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O O
a O O
total O B_MEASURE/B_LOCATION
of O O
100 O B_MEASURE
Nigerian O I_MEASURE
patients O I_MEASURE
( O O
50 O B_LOCATION/B_ENT
out O I_LOCATION/I_ENT
- O O
patients O B_PERSON/B_DISEASE
and O O
50 O B_MEASURE
in O O
- O O
patients O B_PERSON/B_ORGANIZATION
) O O
. O O

About O O
62 O O
% O O
of O O
the O O
out O O
- O O
patients O O
developed O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
as O O
compared O O
with O O
about O O
26 O O
% O O
among O O
the O O
in O O
- O O
patients O O
. O O

The O O
abolition O O
of O O
muscle O O
fasciculations O O
( O O
by O O
0 O O
. O O
075mg O O
/ O O
kg O O
dose O O
of O O
Fazadinium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
did O O
not O O
influence O O
the O O
occurrence O O
of O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O O
. O O

Neither O O
the O O
type O O
of O O
induction O O
agent O O
( O O
Althesin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
Thiopentone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nor O O
the O O
salt O O
preparation O O
of O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
used O O
( O O
chloride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
bromide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
affected O O
the O O
incidence O O
of O O
scoline B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain O O
. O O

Invasive O O
carcinoma O O
of O O
the O O
renal O O
pelvis O O
following O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
for O O
nonmalignant O O
disease O O
. O O

A O O
47 O O
- O O
year O O
- O O
old O O
woman O O
with O O
right O O
hydroureteronephrosis O O
due O O
to O O
ureterovesical O O
junction O O
obstruction O O
had O O
gross O O
hematuria O O
after O O
being O O
treated O O
for O O
five O O
years O O
wtih O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
cerebral O O
vasculitis O O
. O O

A O O
right O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephroureterectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
required O O
for O O
control O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
bleeding O B_DISEASE
. O O

The O O
pathology O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimen O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O O
clinically O O
occult O B_DISEASE
invasive O I_DISEASE
carcinoma O I_DISEASE
of O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pelvis O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
the O O
ability O O
of O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
cause O O
hemorrhagic O O
cystitis O O
and O O
urine O O
cytologic O O
abnormalities O O
indistinguishable O O
from O O
high O O
grade O O
carcinoma O O
is O O
well O O
known O O
, O O
it O O
is O O
less O O
widely O O
appreciated O O
that O O
it O O
is O O
also O O
associated O O
with O O
carcinoma O O
of O O
the O O
urinary O O
tract O O
. O O

Twenty O B_DISEASE
carcinomas O I_DISEASE
of O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
one O B_NUMBER[MEASURE]/B_LOCATION
carcinoma O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
prostate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
have O O
been O O
reported O O
in O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
its O O
use O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
present O O
case O O
is O O
the O O
first O O
carcinoma O O
of O O
the O O
renal O O
pelvis O O
reported O O
in O O
association O O
with O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
. O O

It O O
is O O
the O O
third O O
urinary O O
tract O O
cancer O O
reported O O
in O O
association O O
with O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
for O O
nonmalignant O O
disease O O
. O O

The O O
association O O
of O O
the O O
tumor O O
with O O
preexisting O O
hydroureteronephrosis O O
suggests O O
that O O
stasis O O
prolonged O O
and O O
intensified O O
exposure O O
of O O
upper O O
urinary O O
tract O O
epithelium O O
to O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Patients O O
who O O
are O O
candidates O O
for O O
long O O
- O O
term O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
should O O
be O O
routinely O O
evaluated O O
for O O
obstructive O O
uropathy O O
. O O

Medial O O
changes O O
in O O
arterial O O
spasm O O
induced O O
by O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
norepinephrine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
the O O
media O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
small O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O B_MEASURE/B_LOCATION
. O O
4 O B_MEASURE
- O O
- O O
0 O B_MEASURE
. O O
2 O B_MEASURE
mm O I_MEASURE
in O O
diameter O B_MEASURE
) O O
previously O O
was O O
shown O O
to O O
contain O O
intracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vacuoles O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
identified O O
ultrastructurally O O
as O O
herniations O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
one O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
smooth O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
into O O
another O O
. O O

The O O
hypothesis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
intense O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoconstriction O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
increase O O
the O O
number O B_MEASURE
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
vacuoles O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
has O O
been O O
tested O O
. O O

In O O
the O O
media O O
of O O
the O O
saphenous O O
artery O O
and O O
its O O
distal O O
branch O O
, O O
vasoconstriction O O
induced O O
by O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
norepinephrine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
many O O
cell O O
- O O
to O O
- O O
cell O O
hernias O O
within O O
15 O O
minutes O O
. O O

At O O
1 O B_TIME[MEASURE]/B_LOCATION
day O I_TIME[MEASURE]/I_LOCATION
their O O
number O B_MEASURE/B_PERSON
was O O
reduced O O
to O O
about O O
1 O B_MEASURE
/ O O
10 O B_SEQUENCE[MEASURE]
of O O
the O O
original O B_MEASURE/B_ORGANIZATION
number O B_MEASURE/I_ORGANIZATION
. O O

By O O
7 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
vessel O B_DISEASE/B_MEASURE
was O O
almost O O
restored O O
to O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Triple O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
over O O
1 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
more O B_DISEASE
severe O I_DISEASE
changes O I_DISEASE
in O O
the O O
media O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
smooth O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
damage O B_DISEASE
in O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
specific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
discussed O O
in O O
relation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
medial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
instances O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
arterial O B_DISEASE
spasm O I_DISEASE
. O O

Endothelial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
developed O O
in O O
the O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experimental O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
described O O
in O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
paper O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Bilateral O O
retinal O O
artery O O
and O O
choriocapillaris O O
occlusion O O
following O O
the O O
injection O O
of O O
long O O
- O O
acting O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspensions O O
in O O
combination O O
with O O
other O O
drugs O O
: O O
I O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Two O O
well O O
- O O
documented O O
cases O O
of O O
bilateral O O
retinal O O
artery O O
and O O
choriocapillaris O O
occlusions O O
with O O
blindness O O
following O O
head O O
and O O
neck O O
soft O O
- O O
tissue O O
injection O O
with O O
methylprednisolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
combination O O
with O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
penicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
reported O O
. O O

One O B_PERSON
case O I_PERSON
had O O
only O O
a O O
unilateral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
observations O I_DISEASE_ADJECTIVE[DISEASE]
included O O
hazy O B_DISEASE
sensorium O I_DISEASE
, O O
superior O B_DISEASE
gaze O I_DISEASE
palsy O I_DISEASE
, O O
pupillary O B_DISEASE
abnormalities O I_DISEASE
, O O
and O O
conjunctival O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhages O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
edema O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Follow O O
- O O
up O O
changes O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
marked O B_DISEASE
visual O I_DISEASE
loss O I_DISEASE
, O O
constricted O B_DISEASE
visual O I_DISEASE
fields O I_DISEASE
, O O
optic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pallor O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
vascular O B_DISEASE
attenuation O I_DISEASE
, O O
and O O
chorioretinal O B_DISEASE
atrophy O I_DISEASE
. O O

The O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
reviewed O O
, O O
and O O
possible O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

Abnormalities O O
of O O
the O O
pupil O O
and O O
visual O O
- O O
evoked O O
potential O O
in O O
quinine B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
amblyopia O O
. O O

Total O O
blindness O O
with O O
a O O
transient O O
tonic O O
pupillary O O
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
developed O O
in O O
a O O
54 O O
- O O
year O O
- O O
old O O
man O O
after O O
the O O
use O O
of O O
quinine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
sulfate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
for O O
leg O O
cramps O O
. O O

He O O
later O O
recovered O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
visual O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
acuity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

A O O
transient O O
tonic O O
pupillary O O
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
in O O
quinine B B_DISEASE/B_PROTEIN[GENE]
toxicity O O
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O
. O O

Suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
jaw O O
stiffness O O
and O O
myalgia O O
associated O O
with O O
atypical O O
cholinesterase O O
: O O
case O O
report O O
. O O

An O O
11 O O
- O O
year O O
- O O
old O O
boy O O
was O O
given O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nitrous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oxygen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pancuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
0 O O
. O O
4 O O
mg O O
and O O
suxamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
100 O O
mg O O
for O O
induction O O
of O O
anaesthesia O O
. O O

In O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
this O O
a O O
marked O O
jaw O B_DISEASE
stiffness O I_DISEASE
occurred O O
which O O
lasted O O
for O O
two O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
and O O
the O O
anaesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O O
terminated O O
. O O

Four O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hours O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
apnoea O B_DISEASE
ensued O O
and O O
he O O
suffered O O
generalized O B_DISEASE
severe O I_DISEASE
myalgia O I_DISEASE
lasting O O
for O O
one O B_TIME[MEASURE]
week O I_TIME[MEASURE]
. O O

He O O
was O O
found O O
to O O
have O O
atypical O O
plasma O O
cholinesterase O O
with O O
a O O
dibucaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
number O O
of O O
12 O O
, O O
indicating O O
homozygocity O O
. O O

This O O
was O O
verified O O
by O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
family O B_PERSON/B_LOCATION
. O O

The O O
case O O
shows O O
that O O
prolonged O O
jaw O O
rigidity O O
and O O
myalgia O O
may O O
occur O O
after O O
suxamethonium B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O O
with O O
atypical O O
cholinesterase O O
despite O O
pretreatment O O
with O O
pancuronium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
hyperkalemia O O
in O O
three O O
patients O O
with O O
gouty O O
arthritis O O
. O O

We O O
describe O O
three O O
patients O O
in O O
whom O O
severe O O
, O O
life O O
- O O
threatening O O
hyperkalemia O O
and O O
renal O O
insufficiency O O
developed O O
after O O
treatment O O
of O O
acute O O
gouty O O
arthritis O O
with O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
complication O O
may O O
result O O
from O O
an O O
inhibition O O
of O O
prostaglandin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O O
and O O
consequent O O
hyporeninemic O O
hypoaidosteronism O O
. O O

Careful O O
attention O O
to O O
renal O O
function O O
and O O
potassium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance O O
in O O
patients O O
receiving O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
other O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
agents O O
, O O
particularly O O
in O O
those O O
patients O O
with O O
diabetes O O
mellitus O O
or O O
preexisting O O
renal O O
disease O O
, O O
will O O
help O O
prevent O O
this O O
potentially O O
serious O O
complication O O
. O O

Etomidate B B_MEASURE
: O O
a O O
foreshortened O O
clinical O O
trial O O
. O O

A O O
clinical O O
evaluation O O
of O O
etomidate B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
outpatient O O
cystoscopy O O
was O O
embarked O O
upon O O
. O O

Unpremedicated O O
patients O O
were O O
given O O
fentanyl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
microgram O O
/ O O
kg O O
followed O O
by O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
3 O O
mg O O
/ O O
kg O O
. O O

Anaesthesia O O
was O O
maintained O O
with O O
intermittent O O
etomidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
2 O O
- O O
4 O O
mg O O
doses O O
. O O

Patients O B_PERSON
were O O
interviewed O O
personally O O
later O O
the O O
same O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
by O O
questionnaire O B_NUMBER[MEASURE]/B_LOCATION
three O I_NUMBER[MEASURE]/I_LOCATION
to O O
four O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
later O O
. O O

The O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
after O O
20 O B_TIME[MEASURE]
cases O I_TIME[MEASURE]
because O O
of O O
an O O
unacceptable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
side O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Venous O B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
in O O
68 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
and O O
50 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
had O O
redness O B_DISEASE
, O O
pain O B_DISEASE
or O O
swelling O O
related O O
to O O
the O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
site O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
in O O
some O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasting O O
up O O
to O O
three O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
anaesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Skeletal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movements O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
in O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
; O O
30 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
experienced O O
respiratory O B_DISEASE
upset O I_DISEASE
, O O
one O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sufficiently O O
severe O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
necessitate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abandoning O O
the O O
technique O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Nausea O B_DISEASE
and O O
vomiting O B_DISEASE
occurred O O
in O O
40 O B_PERSON/B_LOCATION
% O I_PERSON/I_LOCATION
and O O
25 O B_PERSON/B_LOCATION
% O I_PERSON/I_LOCATION
had O O
disturbing O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
emergence O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
psychoses O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesias O O
are O O
improved O O
by O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
evaluated O O
the O O
severity O O
of O O
motor O O
disability O O
and O O
dyskinesias O O
in O O
seven O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
responsive O O
patients O O
with O O
Parkinson O O
' O O
s O O
disease O O
after O O
an O O
acute O O
challenge O O
with O O
the O O
mixed O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
, O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
before O O
and O O
after O O
the O O
administration O O
of O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O O
mg O O
twice O O
per O O
day O O
) O O
for O O
11 O O
+ O O
/ O O
- O O
1 O O
days O O
. O O

After O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
there O O
was O O
a O O
significant O O
47 O O
% O O
improvement O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
of O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
dyskinesias O O
without O O
modification O O
of O O
parkinsonian O O
motor O O
disability O O
. O O

The O O
dyskinesias O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
reduced O O
predominantly O O
in O O
the O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
disappearance O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
dystonic O B_DISEASE
dyskinesias O I_DISEASE
( O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
and O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
of O O
- O O
dose O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dyskinesias O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
) O O
and O O
in O O
the O O
upper O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O O
choreic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mid O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
dose O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dyskinesias O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O

The O O
results O O
suggest O O
that O O
increased O O
brain O O
serotoninergic O O
transmission O O
with O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
reduce O O
levodopa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
or O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
- O O
induced O O
dyskinesias O O
without O O
aggravating O O
parkinsonian O O
motor O O
disability O O
. O O

A O O
large O O
population O O
- O O
based O O
follow O O
- O O
up O O
study O O
of O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
cephalexin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
uncommon O O
serious O O
drug O O
toxicity O O
. O O

We O O
conducted O O
a O O
population O O
- O O
based O O
45 O O
- O O
day O O
follow O O
- O O
up O O
study O O
of O O
232 O O
, O O
390 O O
people O O
who O O
were O O
prescribed O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
SMZ I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
, O O
266 O O
, O O
951 O O
prescribed O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
and O O
196 O O
, O O
397 O O
prescribed O O
cephalexin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
to O O
estimate O O
the O O
risk O O
of O O
serious O O
liver O O
, O O
blood O O
, O O
skin O O
, O O
and O O
renal O O
disorders O O
resulting O O
in O O
referral O O
or O O
hospitalization O O
associated O O
with O O
these O O
drugs O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
based O O
on O O
information O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recorded O O
on O O
office O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computers O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
selected O B_PERSON/B_ORGANIZATION
general O I_PERSON/I_ORGANIZATION
practitioners O I_PERSON/I_ORGANIZATION
in O O
the O O
United O B_LOCATION/B_ORGANIZATION
Kingdom O I_LOCATION/I_ORGANIZATION
, O O
together O O
with O O
a O O
review O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
risk O O
of O O
clinically O O
important O O
idiopathic O O
liver O O
disease O O
was O O
similar O O
for O O
persons O O
prescribed O O
TMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
. O O
2 O O
/ O O
100 O O
, O O
000 O O
) O O
and O O
those O O
prescribed O O
trimethoprim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
( O O
3 O O
. O O
8 O O
/ O O
100 O O
, O O
000 O O
) O O
. O O

The O O
risk O O
for O O
those O O
prescribed O O
cephalexin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
somewhat O O
lower O O
( O O
2 O O
. O O
0 O O
/ O O
100 O O
, O O
000 O O
) O O
. O O

Only O O
five O O
patients O O
experienced O O
blood O O
disorders O O
, O O
one O O
of O O
whom O O
was O O
exposed O O
to O O
TMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
of O O
seven O O
with O O
erythema O O
multiforme O O
and O O
Stevens O O
- O O
Johnson O O
syndrome O O
, O O
four O O
were O O
exposed O O
to O O
TMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
one O O
case O O
of O O
toxic O O
epidermal O O
necrolysis O O
occurred O O
in O O
a O O
patient O O
who O O
took O O
cephalexin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Finally O O
, O O
only O O
five O B_TIME[MEASURE]/B_PERSON
cases O B_TIME[MEASURE]/I_PERSON
of O O
acute O B_DISEASE
parenchymal O I_DISEASE
renal O I_DISEASE
disease O I_DISEASE
occurred O O
, O O
none O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
likely O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
be O O
caused O O
by O O
a O O
study O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

We O O
conclude O O
that O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
studied O O
is O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
the O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
compares O O
reasonably O O
with O O
the O O
risk O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
many O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
other O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Clinical O O
safety O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
myocardial O O
infarction O O
. O O

STUDY O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
safety O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
setting O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
infarction O O
( O O
MI O O
) O O
. O O

DESIGN O B_PERSON/B_MEASURE
: O O
A O O
retrospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
multicenter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

SETTING O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Twenty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]/B_LOCATION
university O I_NUMBER[MEASURE]/I_LOCATION
, O O
university O B_LOCATION/B_PERSON
- O O
affiliated O O
, O O
or O O
community O B_PERSON/B_LOCATION
hospitals O I_PERSON/I_LOCATION
during O O
a O O
6 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
period O I_TIME[MEASURE]
( O O
total O B_MEASURE/B_LOCATION
of O O
117 O B_NUMBER[MEASURE]/B_LOCATION
cumulative O I_NUMBER[MEASURE]/I_LOCATION
hospital O I_NUMBER[MEASURE]/I_LOCATION
- O O
years O B_TIME[MEASURE]/B_LOCATION
) O O
. O O

PARTICIPANTS O O
: O O
Patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
MI O O
who O O
received O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
emergency O O
department O O
. O O

RESULTS O O
: O O
Of O O
29 O O
patients O O
who O O
received O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
setting O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
MI O O
, O O
no O O
patient O O
died O O
; O O
exhibited O O
bradydysrhythmias O O
, O O
ventricular O O
tachycardia O O
, O O
or O O
ventricular O O
fibrillation O O
; O O
or O O
experienced O O
seizures O O
after O O
administration O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
95 O O
% O O
confidence O O
interval O O
, O O
0 O O
% O O
to O O
11 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
Despite O O
theoretical O O
concerns O O
that O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
enhance O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O O
, O O
the O O
use O O
of O O
lidocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
MI O O
was O O
not O O
associated O O
with O O
significant O O
cardiovascular O O
or O O
central O O
nervous O O
system O O
toxicity O O
. O O

Experimental O B_DISEASE
progressive O I_DISEASE
muscular O I_DISEASE
dystrophy O I_DISEASE
and O O
its O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anabolizing O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
are O O
still O O
a O O
long O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
way O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
from O O
discovering O O
an O O
unequivocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
progressive O B_DISEASE
muscular O I_DISEASE
dystrophy O I_DISEASE
in O O
man O B_PERSON/B_BIO
. O O

Noteworthy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
have O O
been O O
made O O
in O O
the O O
experimental O B_LOCATION/B_ORGANIZATION
field O I_LOCATION/I_ORGANIZATION
; O O
a O O
recessive O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
autosomic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O O
in O O
the O O
mouse O B_SPECIES[BIO]/B_DISEASE
seems O O
to O O
bear O O
the O O
closest O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
resemblance O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
human O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
genetic O B_LOCATION/B_MEASURE
point O I_LOCATION/I_MEASURE
of O O
view O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Myopathy O O
due O O
to O O
lack O O
of O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
myopathy O O
induced O O
by O O
certain O O
viruses O O
have O O
much O O
in O O
common O O
anatomically O O
and O O
pathologically O O
with O O
the O O
human O O
form O O
. O O

The O O
authors O O
induced O O
myodystrophy O O
in O O
the O O
rat O O
by O O
giving O O
it O O
a O O
diet O O
lacking O O
in O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pharmacological O O
characteristics O O
of O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
degenerative O O
changes O O
brought O O
about O O
by O O
its O O
deficiency O O
, O O
especially O O
in O O
the O O
muscles O O
, O O
are O O
illustrated O O
. O O

It O O
is O O
thus O O
confirmed O O
that O O
the O O
histological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
myopathic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
rat O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
induced O O
experimentally O O
are O O
extraordinarily O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
of O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myopathy O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O O
confirmed O O
during O O
biopsies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O O
at O O
the O O
Orthopaedic O B_LOCATION/B_ORGANIZATION
Traumatological O I_LOCATION/I_ORGANIZATION
Centre O I_LOCATION/I_ORGANIZATION
, O O
Florence O B_LOCATION
. O O

The O O
encouraging O O
results O O
obtained O O
in O O
various O O
authoratative O O
departments O O
in O O
myopathic O O
patients O O
by O O
using O O
anabolizing O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
encouraged O O
the O O
authors O O
to O O
investigate O O
the O O
beneficial O O
effects O O
of O O
one O O
anabolizing O O
agent O O
( O O
Dianabol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CIBA B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
at O O
high O O
doses O O
in O O
rats O O
rendered O O
myopathic O O
by O O
a O O
diet O O
deficient O O
in O O
vitamin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

In O O
this O O
way O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
they O O
obtained O O
appreciable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
body O B_MEASURE
weight O I_MEASURE
( O O
increased O O
from O O
50 O B_MEASURE
to O O
70 O B_MEASURE
g O I_MEASURE
after O O
forty O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O O
a O O
dose O B_MEASURE/B_DISEASE
of O O
5 O B_MEASURE
mg O I_MEASURE
per O O
day O B_TIME[MEASURE]
of O O
anabolizing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
but O O
most O B_SEQUENCE[MEASURE]
of O O
all O O
they O O
found O O
histological O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
" O O
regenerative O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
" O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
muscle O B_BODY_PART_OR_ORGAN_COMPONENT
tissue O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
which O O
however O O
maintained O O
its O O
myopathic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
were O O
not O O
treated O O
with O O
the O O
anabolizing O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
authors O O
conclude O O
by O O
affirming O O
the O O
undoubted O O
efficacy O O
of O O
the O O
anabolizing O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
experimental O O
myopathic O O
disease O O
, O O
but O O
they O O
have O O
reservations O O
as O O
to O O
the O O
transfer O O
of O O
the O O
results O O
into O O
the O O
human O O
field O O
, O O
where O O
high O O
dosage O O
cannot O O
be O O
carried O O
out O O
continuously O O
because O O
of O O
the O O
effects O O
of O O
the O O
drug O O
on O O
virility O O
; O O
because O O
the O O
tissue O O
injury O O
too O O
often O O
occurs O O
at O O
an O O
irreversible O O
stage O O
vis O O
- O O
a O O
- O O
vis O O
the O O
" O O
regeneration O O
" O O
of O O
the O O
muscle O O
tissue O O
; O O
and O O
finally O O
because O O
the O O
dystrophic O O
injurious O O
agent O O
is O O
certainly O O
not O O
the O O
lack O O
of O O
vitamin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
E I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
but O O
something O O
as O O
yet O O
unknown O O
. O O

Paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O O
- O O
hour O O
infusion O O
given O O
alone O O
and O O
combined O O
with O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
preliminary O O
results O O
of O O
dose O O
- O O
escalation O O
trials O O
. O O

Paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Taxol B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
by O O
3 O O
- O O
hour O O
infusion O O
was O O
combined O O
with O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
phase O O
I O O
/ O O
II O O
study O O
directed O O
to O O
patients O O
with O O
non O O
- O O
small O O
cell O O
lung O O
cancer O O
. O O

Carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
given O O
at O O
a O O
fixed O O
target O O
area O O
under O O
the O O
concentration O O
- O O
time O O
curve O O
of O O
6 O O
. O O
0 O O
by O O
the O O
Calvert O O
formula O O
, O O
whereas O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
escalated O O
in O O
patient O O
cohorts O O
from O O
150 O O
mg O O
/ O O
m2 O O
( O O
dose O O
level O O
I O O
) O O
to O O
175 O O
, O O
200 O O
, O O
225 O O
, O O
and O O
250 O O
mg O O
/ O O
m2 O O
. O O

The O O
225 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O O
m2 O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
was O O
expanded O O
for O O
the O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
II O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
since O O
the O O
highest O B_MEASURE/B_LOCATION
level O I_MEASURE/I_LOCATION
achieved O O
( O O
250 O B_MEASURE
mg O I_MEASURE
/ O O
m2 O B_MEASURE/B_LOCATION
) O O
required O O
modification O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
nonhematologic O B_DISEASE
toxicities O I_DISEASE
( O O
arthralgia O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
sensory O B_DISEASE
neuropathy O I_DISEASE
) O O
. O O

Therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
noted O O
at O O
all O O
dose O B_MEASURE/B_LOCATION
levels O B_MEASURE/I_LOCATION
, O O
with O O
objective O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
17 O B_NUMBER[MEASURE]
( O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
15 O B_DISEASE_ADJECTIVE[DISEASE]
partial O I_DISEASE_ADJECTIVE[DISEASE]
regressions O I_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
41 O B_NUMBER[MEASURE]
previously O O
untreated O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Toxicities O O
were O O
compared O O
with O O
a O O
cohort O O
of O O
patients O O
in O O
a O O
phase O O
I O O
trial O O
of O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
at O O
identical O O
dose O O
levels O O
. O O

Carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O O
not O O
appear O O
to O O
add O O
to O O
the O O
hematologic O O
toxicities O O
observed O O
, O O
and O O
the O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
carboplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O O
could O O
be O O
dosed O O
every O O
3 O O
weeks O O
. O O

The O O
dose O O
- O O
dependent O O
effect O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
renal O O
dysfunction O O
in O O
well O O
compensated O O
cirrhosis O O
. O O

Misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
200 O O
micrograms O O
) O O
has O O
been O O
shown O O
to O O
acutely O O
counteract O O
the O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
renal O O
dysfunction O O
in O O
well O O
compensated O O
cirrhotic O O
patients O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
the O O
prophylactic O O
value O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
dose O O
- O O
dependent O O
. O O

Parameters O O
of O O
renal O O
hemodynamics O O
and O O
tubular O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
water O O
handling O O
were O O
assessed O O
by O O
clearance O O
techniques O O
in O O
26 O O
well O O
compensated O O
cirrhotic O O
patients O O
before O O
and O O
after O O
an O O
oral O O
combination O O
of O O
50 O O
mg O O
of O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
various O O
doses O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
200 O O
- O O
micrograms O O
dose O O
was O O
able O O
to O O
totally O O
abolish O O
the O O
deleterious O O
renal O O
effects O O
of O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
whereas O O
the O O
800 O O
- O O
micrograms O O
dose O O
resulted O O
in O O
significant O O
worsening O O
of O O
renal O O
hemodynamics O O
and O O
sodium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retention O O
. O O

These O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
maximal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
hour O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
after O O
medications O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
slowly O O
returned O O
toward O O
base O B_LOCATION/B_COLOR
- O O
line O B_MEASURE/B_ORGANIZATION
levels O I_MEASURE/I_ORGANIZATION
thereafter O O
. O O

These O O
results O O
suggest O O
that O O
the O O
renal O O
protective O O
effects O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dose O O
- O O
dependent O O
. O O

However O O
, O O
until O O
this O O
apparent O O
ability O O
of O O
200 O O
micrograms O O
of O O
misoprostol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prevent O O
the O O
adverse O O
effects O O
of O O
indomethacin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
renal O O
function O O
is O O
confirmed O O
with O O
chronic O O
frequent O O
dosing O O
, O O
it O O
would O O
be O O
prudent O O
to O O
avoid O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
therapy O O
in O O
patients O O
with O O
cirrhosis O O
. O O

Increased O O
frequency O O
and O O
severity O O
of O O
angio O O
- O O
oedema O O
related O O
to O O
long O O
- O O
term O O
therapy O O
with O O
angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
two O O
patients O O
. O O

Adverse O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
well O O
recognized O O
as O O
a O O
cause O B_DISEASE
of O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]
urticaria O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
angio O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
oedema O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Angiotensin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
converting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
ACE I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
used O O
to O O
treat O O
hypertension O O
and O O
congestive O O
heart O O
failure O O
, O O
were O O
introduced O O
in O O
Europe O O
in O O
the O O
middle O O
of O O
the O O
eighties O O
, O O
and O O
the O O
use O O
of O O
these O O
drugs O O
has O O
increased O O
progressively O O
. O O

Soon O O
after O O
the O O
introduction O O
of O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
acute O O
bouts O O
of O O
angio O O
- O O
oedema O O
were O O
reported O O
in O O
association O O
with O O
the O O
use O O
of O O
these O O
drugs O O
. O O

We O O
wish O O
to O O
draw O O
attention O O
to O O
the O O
possibility O O
of O O
adverse O O
reactions O O
to O O
ACE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O O
long O O
- O O
term O O
use O O
and O O
in O O
patients O O
with O O
pre O O
- O O
existing O O
angio O O
- O O
oedema O O
. O O

Myoclonus O O
associated O O
with O O
lorazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
very O O
- O O
low O O
- O O
birth O O
- O O
weight O O
infants O O
. O O

Lorazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
being O O
used O O
with O O
increasing O O
frequency O O
as O O
a O O
sedative O O
in O O
the O O
newborn O O
and O O
the O O
young O O
infant O O
. O O

Concern O O
has O O
been O O
raised O O
with O O
regard O O
to O O
the O O
safety O O
of O O
lorazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
this O O
age O O
group O O
, O O
especially O O
in O O
very O O
- O O
low O O
- O O
birth O O
- O O
weight O O
( O O
VLBW O O
; O O
< O O
1 O O
, O O
500 O O
g O O
) O O
infants O O
. O O

Three O O
young O O
infants O O
, O O
all O O
of O O
birth O O
weight O O
< O O
1 O O
, O O
500 O O
g O O
, O O
experienced O O
myoclonus O O
following O O
the O O
intravenous O O
administration O O
of O O
lorazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
and O O
its O O
vehicle O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O O
in O O
this O O
population O B_PERSON/B_LOCATION
are O O
discussed O O
. O O

Injectable O O
lorazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
used O O
with O O
caution O O
in O O
VLBW O O
infants O O
. O O

Transvenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
right O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pacing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
cardiopulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resuscitation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
pediatric O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
acute O B_DISEASE
cardiomyopathy O I_DISEASE
. O O

We O O
describe O O
the O O
cardiopulmonary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
resuscitation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
efforts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
five O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
who O O
presented O O
in O O
acute O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
circulatory O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
myocardial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Three O O
patients O O
had O O
acute O O
viral O O
myocarditis O O
, O O
one O O
had O O
a O O
carbamazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
acute O O
eosinophilic O O
myocarditis O O
, O O
and O O
one O O
had O O
cardiac O O
hemosiderosis O O
resulting O O
in O O
acute O O
cardiogenic O O
shock O O
. O O

All O O
patients O B_PERSON/B_LOCATION
were O O
continuously O O
monitored O O
with O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
venous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
arterial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
catheters O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
routine O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
noninvasive O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
introducer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sheath O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
pacemaker O B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
sterile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wires O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
made O O
readily O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
patients O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
should O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
arise O O
to O O
terminate O O
resistant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysrhythmias O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

All O O
patients O B_PERSON
developed O O
cardiocirculatory O B_DISEASE
arrest O I_DISEASE
associated O O
with O O
extreme O B_DISEASE
hypotension O I_DISEASE
and O O
dysrhythmias O B_DISEASE
within O O
the O O
first O B_TIME[MEASURE]/B_SPORT[ENT]
48 O I_TIME[MEASURE]/I_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
of O O
their O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
the O O
pediatric O B_LOCATION/B_ORGANIZATION
intensive O I_LOCATION/I_ORGANIZATION
care O I_LOCATION/I_ORGANIZATION
unit O I_LOCATION/I_ORGANIZATION
( O O
PICU O B_LOCATION/B_ORGANIZATION
) O O
. O O

Right O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ventricular O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pacemaker O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
wires O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
inserted O O
in O O
all O O
of O O
them O O
during O O
cardiopulmonary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
resuscitation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CPR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

In O O
four O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
, O O
cardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
, O O
resulting O O
in O O
a O O
temporary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
captured O O
rhythm O B_DISEASE/B_MEASURE
and O O
restoration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
cardiac O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
patients O B_PERSON
had O O
a O O
second O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
arrest O I_DISEASE
, O O
resulting O O
in O O
death O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
within O O
10 O B_NUMBER[MEASURE]/B_LOCATION
to O O
60 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
. O O

In O O
one O B_PERSON/B_MEASURE
patient O B_PERSON/I_MEASURE
, O O
cardiac O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
used O O
, O O
because O O
he O O
converted O O
to O O
normal O B_DISEASE
sinus O I_DISEASE
rhythm O I_DISEASE
by O O
electrical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
defibrillation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
three O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
of O O
initiating O O
CPR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

We O O
conclude O O
that O O
cardiac O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
resuscitative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
efforts O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
pediatric O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
suffering O O
from O O
acute O B_DISEASE
myocardial O I_DISEASE
dysfunction O I_DISEASE
may O O
not O O
have O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_TIME[MEASURE]/B_LOCATION
value O I_TIME[MEASURE]/I_LOCATION
in O O
and O O
of O O
itself O O
; O O
however O O
, O O
if O O
temporary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hemodynamic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stability O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
achieved O O
by O O
this O O
procedure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
it O O
may O O
provide O O
additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
needed O O
to O O
institute O O
other O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapeutic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
modalities O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Efficacy O O
and O O
safety O O
of O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
selective O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxytryptamine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
3 O O
receptor O O
antagonist O O
, O O
in O O
the O O
prevention O O
of O O
nausea O O
and O O
vomiting O O
induced O O
by O O
high O O
- O O
dose O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

PURPOSE O O
: O O
To O O
assess O O
the O O
antiemetic O O
effects O O
and O O
safety O O
profile O O
of O O
four O O
different O O
doses O O
of O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Kytril B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
SmithKline O O
Beecham O O
Pharmaceuticals O O
, O O
Philadelphia O O
, O O
PA O O
) O O
when O O
administered O O
as O O
a O O
single O O
intravenous O O
( O O
IV O O
) O O
dose O O
for O O
prophylaxis O O
of O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
nausea O O
and O O
vomiting O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
One O O
hundred O O
eighty O O
- O O
four O O
chemotherapy O O
- O O
naive O O
patients O O
receiving O O
high O O
- O O
dose O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
81 O O
to O O
120 O O
mg O O
/ O O
m2 O O
) O O
were O O
randomized O O
to O O
receive O O
one O O
of O O
four O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O O
( O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
or O O
40 O O
micrograms O O
/ O O
kg O O
) O O
administered O O
before O O
chemotherapy O O
. O O

Patients O B_PERSON/B_DISEASE
were O O
observed O O
on O O
an O O
inpatient O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
basis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
18 O B_NUMBER[MEASURE]
to O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
, O O
and O O
vital O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nausea O B_DISEASE
, O O
vomiting O B_DISEASE
, O O
retching O B_DISEASE
, O O
and O O
appetite O B_DISEASE
were O O
assessed O O
. O O

Safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
incidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
adverse O B_DISEASE
experiences O I_DISEASE
and O O
laboratory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O O
: O O
After O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O O
of O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
and O O
40 O O
micrograms O O
/ O O
kg O O
, O O
a O O
major O O
response O O
( O O
< O O
or O O
= O O
two O O
vomiting O O
or O O
retching O O
episodes O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
was O O
recorded O O
in O O
23 O O
% O O
, O O
57 O O
% O O
, O O
58 O O
% O O
, O O
and O O
60 O O
% O O
of O O
patients O O
, O O
respectively O O
, O O
and O O
a O O
complete O O
response O O
( O O
no O O
vomiting O O
or O O
retching O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
in O O
18 O O
% O O
, O O
41 O O
% O O
, O O
40 O O
% O O
, O O
and O O
47 O O
% O O
of O O
patients O O
, O O
respectively O O
. O O

There O O
was O O
a O O
statistically O O
longer O B_TIME[MEASURE]
time O I_TIME[MEASURE]
to O O
first O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episode O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nausea O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P O B_MEASURE
= O I_MEASURE
. O O
0015 O B_MEASURE
) O O
and O O
vomiting O B_DISEASE
( O O
P O B_OTHER/B_LOCATION
= O O
. O O
0001 O B_MEASURE
) O O
, O O
and O O
fewer O B_PERSON
patients O I_PERSON
were O O
administered O O
additional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
10 O B_MEASURE
- O O
micrograms O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE
dosing O I_MEASURE
groups O I_MEASURE
than O O
in O O
the O O
5 O B_MEASURE
- O O
micrograms O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE/B_ORGANIZATION
dosing O I_MEASURE/I_ORGANIZATION
group O I_MEASURE/I_ORGANIZATION
. O O

As O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
increased O O
, O O
appetite O O
return O O
increased O O
( O O
P O O
= O O
. O O
040 O O
) O O
. O O

Headache O B_DISEASE
was O O
the O O
most O O
frequently O O
reported O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O B_MEASURE/B_DISEASE
% O I_MEASURE/I_DISEASE
) O O
. O O

CONCLUSION O O
: O O
A O O
single O O
10 O O
- O O
, O O
20 O O
- O O
, O O
or O O
40 O O
- O O
micrograms O O
/ O O
kg O O
dose O O
of O O
granisetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
effective O O
in O O
controlling O O
vomiting O O
in O O
57 O O
% O O
to O O
60 O O
% O O
of O O
patients O O
who O O
received O O
cisplatin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
doses O O
greater O O
than O O
81 O O
mg O O
/ O O
m2 O O
and O O
totally O O
prevented O O
vomiting O O
in O O
40 O O
% O O
to O O
47 O O
% O O
of O O
patients O O
. O O

There O O
were O O
no O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
efficacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O O
the O O
10 O B_MEASURE
- O O
micrograms O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE/B_PERSON
dose O I_MEASURE/I_PERSON
and O O
the O O
20 O B_MEASURE
- O O
and O O
40 O B_MEASURE
- O O
micrograms O B_MEASURE/B_BIO
/ O O
kg O B_MEASURE/B_PERSON
doses O I_MEASURE/I_PERSON
. O O

Granisetron B B_PERSON
was O O
well O O
tolerated O O
at O O
all O O
doses O O
. O O

Adverse O O
interaction O O
between O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVE O O
: O O
To O O
report O O
two O O
cases O O
of O O
a O O
possible O O
adverse O O
interaction O O
between O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulting O O
in O O
atrioventricular O O
( O O
AV O O
) O O
block O O
in O O
both O O
patients O O
and O O
severe O O
hypotension O O
in O O
one O O
patient O O
. O O

CASE O O
SUMMARIES O O
: O O
A O O
54 O O
- O O
year O O
- O O
old O O
woman O O
with O O
hyperaldosteronism O O
was O O
treated O O
with O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
480 O O
mg O O
/ O O
d O O
and O O
spironolactone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
a O O
minimal O O
dose O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
15 O O
mg O O
bid O O
) O O
, O O
she O O
developed O O
complete O O
AV O O
block O O
and O O
severe O O
hypotension O O
, O O
which O O
resolved O O
upon O O
cessation O O
of O O
all O O
medications O O
. O O

A O O
65 O O
- O O
year O O
- O O
old O O
woman O O
was O O
treated O O
with O O
extended O O
- O O
release O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
240 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O O
. O O
15 O O
mg O O
bid O O
she O O
developed O O
complete O O
AV O O
block O O
, O O
which O O
resolved O O
after O O
all O O
therapy O O
was O O
stopped O O
. O O

DISCUSSION O O
: O O
An O O
adverse O O
interaction O O
between O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
reported O O
previously O O
. O O

We O O
describe O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
discuss O O
the O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
might O O
cause O O
such O O
an O O
interaction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Clinicians O B_PERSON
should O O
be O O
acquainted O O
with O O
this O O
possibly O O
fatal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O O
two O B_NUMBER[MEASURE]/B_PERSON
commonly O O
used O O
antihypertensive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O O
: O O
Caution O O
is O O
recommended O O
in O O
combining O O
clonidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
, O O
even O O
in O O
patients O O
who O O
do O O
not O O
have O O
sinus O O
or O O
AV O O
node O O
dysfunction O O
. O O

The O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
act O O
synergistically O O
on O O
both O O
the O O
AV O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
node O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
peripheral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
circulation O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Pharmacological O O
studies O O
on O O
a O O
new O O
dihydrothienopyridine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O O
, O O
S B B_LOCATION
- I I_LOCATION
312 I I_LOCATION
- I I_LOCATION
d I I_LOCATION
. O O

5th O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
communication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
anticonvulsant O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

S B B_MEASURE/B_LOCATION
- I I_MEASURE/I_LOCATION
312 I I_MEASURE/I_LOCATION
, O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
312 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
d I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
but O O
not O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
312 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
L O O
- O O
type O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
channel O O
antagonists O O
, O O
showed O O
anticonvulsant O O
effects O O
on O O
the O O
audiogenic O O
tonic O O
convulsions O O
in O O
DBA O O
/ O O
2 O O
mice O O
; O O
and O O
their O O
ED50 O O
values O O
were O O
18 O O
. O O
4 O O
( O O
12 O O
. O O
8 O O
- O O
27 O O
. O O
1 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
and O O
15 O O
. O O
0 O O
( O O
10 O O
. O O
2 O O
- O O
23 O O
. O O
7 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
, O O
respectively O O
, O O
while O O
that O O
of O O
flunarizine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
34 O O
. O O
0 O O
( O O
26 O O
. O O
0 O O
- O O
44 O O
. O O
8 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O

Although O O
moderate O O
anticonvulsant O O
effects O O
of O O
S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
312 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
d I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
higher O O
doses O O
were O O
observed O O
against O O
the O O
clonic O O
convulsions O O
induced O O
by O O
pentylenetetrazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
85 O O
mg O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
or O O
bemegride B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
40 O O
mg O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
, O O
no O O
effects O O
were O O
observed O O
in O O
convulsions O O
induced O O
by O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
picrotoxin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
or O O
electroshock O O
in O O
Slc O O
: O O
ddY O O
mice O O
. O O

S B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
312 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
d I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O O
be O O
useful O O
in O O
the O O
therapy O O
of O O
certain O O
types O O
of O O
human O O
epilepsy O O
. O O

Transmural O O
myocardial O O
infarction O O
with O O
sumatriptan B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

For O O
sumatriptan B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
tightness O O
in O O
the O O
chest O O
caused O O
by O O
an O O
unknown O O
mechanism O O
has O O
been O O
reported O O
in O O
3 O O
- O O
5 O O
% O O
of O O
users O O
. O O

We O O
describe O O
a O O
47 O O
- O O
year O O
- O O
old O O
woman O O
with O O
an O O
acute O O
myocardial O O
infarction O O
after O O
administration O O
of O O
sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O O
mg O O
subcutaneously O O
for O O
cluster O O
headache O O
. O O

The O O
patient O B_PERSON/B_BIO
had O O
no O O
history O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
underlying O O
ischaemic O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
Prinzmetal O B_PERSON
' O O
s O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
angina O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

She O O
recovered O O
without O O
complications O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O O
seizures O O
and O O
death O O
in O O
mixed O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxications O O
. O O

STUDY O O
HYPOTHESIS O O
: O O
Administration O O
of O O
the O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
unmask O O
seizures O O
in O O
mixed O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O O
. O O

DESIGN O O
: O O
Male O O
Sprague O O
- O O
Dawley O O
rats O O
received O O
100 O O
mg O O
/ O O
kg O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IP O O
alone O O
, O O
5 O O
mg O O
/ O O
kg O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
or O O
a O O
combination O O
of O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Three O O
minutes O O
later O O
, O O
groups O O
were O O
challenged O O
with O O
vehicle O O
or O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O O
or O O
10 O O
mg O O
/ O O
kg O O
IP O O
. O O

Animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
behavior O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
seizures O B_DISEASE/B_ORGANISM_FUNCTION
( O O
time O B_TIME[MEASURE]
to O O
and O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O O
, O O
death O B_DISEASE
( O O
time O B_TIME[MEASURE]/B_LOCATION
to O O
and O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
cortical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
EEG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tracings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
recorded O O
. O O

INTERVENTIONS O O
: O O
Administration O O
of O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
animals O O
after O O
they O O
had O O
received O O
a O O
combination O O
dose O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O O
: O O
In O O
group O O
1 O O
, O O
animals O O
received O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
vehicle O O
. O O

This O O
resulted O O
in O O
100 O B_PERSON
% O I_PERSON
developing O O
seizures O B_DISEASE
and O O
death O B_DISEASE
. O O

Group O O
2 O O
received O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
followed O O
by O O
vehicle O O
. O O

Animals O B_BIO/B_NUMBER[MEASURE]
became O O
somnolent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
none O B_PERSON/B_NUMBER[MEASURE]
died O O
. O O

Group O O
3 O O
received O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Animals O O
became O O
somnolent O O
after O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
then O O
active O O
after O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
. O O

In O O
group O O
4 O O
, O O
a O O
combination O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
administered O O
simultaneously O O
. O O

This O O
resulted O O
in O O
no O O
overt O B_DISEASE
or O O
EEG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
detectable O B_DISEASE
seizures O I_DISEASE
and O O
a O O
50 O B_MEASURE
% O I_MEASURE
incidence O I_MEASURE
of O O
death O B_DISEASE
. O O

Group O O
5 O O
received O O
a O O
similar O O
combination O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
followed O O
later O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
resulted O O
in O O
an O O
increased O O
incidence O B_MEASURE
of O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O B_DISEASE
% O I_DISEASE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
01 O B_MEASURE
) O O
, O O
and O O
death O B_DISEASE
, O O
100 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
01 O B_MEASURE
) O O
, O O
compared O O
with O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Group O O
6 O O
received O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O O
by O O
10 O O
mg O O
/ O O
kg O O
flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
also O O
resulted O O
in O O
an O O
increased O O
incidence O B_MEASURE
of O O
seizures O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O B_DISEASE
% O I_DISEASE
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
01 O B_MEASURE
) O O
, O O
and O O
death O B_DISEASE
, O O
90 O B_MEASURE
% O I_MEASURE
( O O
P O B_MEASURE
< O I_MEASURE
or O O
= O O
. O O
05 O B_MEASURE
) O O
, O O
compared O O
with O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
4 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

CONCLUSION O O
: O O
Flumazenil B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
unmask O O
seizures O O
and O O
increase O O
the O O
incidence O O
of O O
death O O
in O O
a O O
model O O
of O O
combined O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxications O O
. O O

Mechanisms O O
for O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mediated O O
nephropathy O O
in O O
rats O O
. O O

Studies O O
were O O
performed O O
to O O
examine O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
GM B B_ORGANIZATION/B_PROTEIN[GENE]
) O O
- O O
mediated O O
nephropathy O O
. O O

Administration O O
of O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O O
40 O O
mg O O
/ O O
kg O O
sc O O
for O O
13 O O
days O O
to O O
rats O O
induced O O
a O O
significant O O
reduction O O
in O O
renal O O
blood O O
flow O O
( O O
RBF O O
) O O
and O O
inulin O O
clearance O O
( O O
CIn O O
) O O
as O O
well O O
as O O
marked O O
tubular O O
damage O O
. O O

A O O
significant O O
reduction O O
in O O
urinary O O
guanosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monophosphate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cGMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
excretion O O
and O O
a O O
significant O O
increase O O
in O O
renal O O
cortical O O
renin O O
and O O
endothelin O O
- O O
1 O O
contents O O
were O O
also O O
observed O O
in O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
nephropathy O O
. O O

Superoxide B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dismutase O O
( O O
SOD O O
) O O
or O O
dimethylthiourea B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DMTU B B_LOCATION/B_ORGANIZATION
) O O
significantly O O
lessened O O
the O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
decrement O O
in O O
CIn O O
. O O

The O O
SOD O O
- O O
induced O O
increase O O
in O O
glomerular O O
filtration O O
rate O O
was O O
associated O O
with O O
a O O
marked O O
improvement O O
in O O
RBF O O
, O O
an O O
increase O O
in O O
urinary O O
cGMP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excretion O O
, O O
and O O
a O O
decrease O O
in O O
renal O O
renin O O
and O O
endothelin O O
- O O
1 O O
content O O
. O O

SOD O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
attenuate O O
the O O
tubular O B_DISEASE_ADJECTIVE[DISEASE]
damage O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
DMTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O O
reduced O O
the O O
tubular O O
damage O O
and O O
lipid O O
peroxidation O O
, O O
but O O
it O O
did O O
not O O
affect O O
renal O O
hemodynamics O O
and O O
vasoactive O O
substances O O
. O O

Neither O O
SOD O O
nor O O
DMTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affected O O
the O O
renal O O
cortical O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O O
in O O
GM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O O
. O O

These O O
results O O
suggest O O
that O O
1 O O
) O O
both O O
SOD O O
and O O
DMTU B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O O
protective O O
effects O O
on O O
GM B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
nephropathy O O
, O O
2 O O
) O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
differ O O
for O O
SOD O O
and O O
DMTU B B_LOCATION/B_ORGANIZATION
, O O
and O O
3 O O
) O O
superoxide B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anions O O
play O O
a O O
critical O O
role O O
in O O
GM B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
renal O O
vasoconstriction O O
. O O

Cephalothin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
induced O O
immune O O
hemolytic O O
anemia O O
. O O

A O O
patient O O
with O O
renal O O
disease O O
developed O O
Coombs O O
- O O
positive O O
hemolytic O O
anemia O O
while O O
receiving O O
cephalothin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
therapy O O
. O O

An O O
anti O O
- O O
cephalothin B B_VIRUS[BIO]/B_DISEASE
IgG O O
antibody O O
was O O
detected O O
in O O
the O O
patient O O
' O O
s O O
serum O O
and O O
in O O
the O O
eluates O O
from O O
her O O
erythrocytes O O
. O O

In O O
addition O O
, O O
nonimmunologic O O
binding O O
of O O
normal O O
and O O
patient O O
' O O
s O O
serum O O
proteins O O
to O O
her O O
own O O
and O O
cephalothin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
coated O O
normal O O
red O O
cells O O
was O O
demonstrated O O
. O O

Skin O O
tests O O
and O O
in O O
vitro O O
lymphocyte O O
stimulation O O
revealed O O
that O O
the O O
patient O O
was O O
sensitized O O
to O O
cephalothin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
also O O
to O O
ampicillin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Careful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hemolytic O B_DISEASE_ADJECTIVE[DISEASE]
anemias O I_DISEASE_ADJECTIVE[DISEASE]
reveals O O
the O O
complexity O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
immune O B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]
involved O O
. O O

Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiomyocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
during O O
hypertrophy O B_DISEASE/B_ORGANISM_FUNCTION
in O O
adult O B_SPECIES[BIO]/B_DISEASE
mice O I_SPECIES[BIO]/I_DISEASE
. O O

The O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiomyocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
synthesize O O
DNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
experimentally O O
induced O O
cardiac O B_DISEASE
hypertrophy O I_DISEASE
was O O
assessed O O
in O O
adult O B_SPECIES[BIO]
mice O I_SPECIES[BIO]
. O O

Isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
delivered O O
by O O
osmotic O O
minipump O O
implantation O O
in O O
adult O O
C3Heb O O
/ O O
FeJ O O
mice O O
resulted O O
in O O
a O O
46 O O
% O O
increase O O
in O O
heart O O
weight O O
and O O
a O O
19 O O
. O O
3 O O
% O O
increase O O
in O O
cardiomyocyte O O
area O O
. O O

No O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
assessed O O
by O O
autoradiographic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
isolated O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiomyocytes O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
observed O O
in O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
hypertrophic O B_DISEASE/B_ENT
hearts O I_DISEASE/I_ENT
. O O

A O O
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
15 O B_MEASURE/B_BIO
independent O I_MEASURE/I_BIO
inbred O I_MEASURE/I_BIO
strains O I_MEASURE/I_BIO
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
that O O
ventricular O B_MEASURE/B_PERSON
cardiomyocyte O B_MEASURE/I_PERSON
nuclear O B_MEASURE/I_PERSON
number O B_MEASURE/I_PERSON
ranged O O
from O O
3 O B_NUMBER[MEASURE]
to O O
13 O B_MEASURE
% O I_MEASURE
mononucleate O I_MEASURE
, O O
suggesting O O
that O O
cardiomyocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
terminal O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
influenced O O
directly O O
or O O
indirectly O O
by O O
genetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
background O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

To O O
determine O O
whether O O
the O O
capacity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O O
reactive O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
synthesis O I_DISEASE/I_GENE
was O O
also O O
subject O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
genetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
cardiac O B_DISEASE
hypertrophy O I_DISEASE
was O O
induced O O
in O O
the O O
strains O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comprising O O
the O O
extremes O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
nuclear O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
number O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
survey O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

These O O
data O O
indicate O O
that O O
adult O O
mouse O O
atrial O O
and O O
ventricular O O
cardiomyocytes O O
do O O
not O O
synthesize O O
DNA O O
in O O
response O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
hypertrophy O O
. O O

Central O O
cardiovascular O O
effects O O
of O O
AVP B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ANP O O
in O O
normotensive O O
and O O
spontaneously O O
hypertensive O O
rats O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
compare O O
influence O O
of O O
central O O
arginine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
vasopressin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
AVP B B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
of O O
atrial O O
natriuretic O O
peptide O O
( O O
ANP O O
) O O
on O O
control O O
of O O
arterial O O
blood O O
pressure O O
( O O
MAP O O
) O O
and O O
heart O O
rate O O
( O O
HR O O
) O O
in O O
normotensive O O
( O O
WKY O O
) O O
and O O
spontaneously O O
hypertensive O O
( O O
SHR O O
) O O
rats O O
. O O

Three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
on O O
30 O B_MEASURE/B_LOCATION
WKY O I_MEASURE/I_LOCATION
and O O
30 O B_TIME[MEASURE]/B_LOCATION
SHR O I_TIME[MEASURE]/I_LOCATION
, O O
chronically O O
instrumented O O
with O O
guide O B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubes O I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LV O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
arterial O B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
venous O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
catheters O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MAP O O
and O O
HR O O
were O O
monitored O O
before O O
and O O
after O O
i O O
. O O
v O O
. O O
injections O O
of O O
either O O
vehicle O O
or O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
25 O O
, O O
125 O O
and O O
500 O O
ng O O
of O O
ANP O O
. O O

Sensitivity O O
of O O
cardiac O O
component O O
of O O
baroreflex O O
( O O
CCB O O
) O O
, O O
expressed O O
as O O
a O O
slope O O
of O O
the O O
regression O O
line O O
was O O
determined O O
from O O
relationships O O
between O O
systolic O O
arterial O O
pressure O O
( O O
SAP O O
) O O
and O O
HR O O
period O O
( O O
HRp O O
) O O
during O O
phenylephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Phe B B_LOCATION/B_PERSON
) O O
- O O
induced O O
hypertension O O
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SN B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
hypotension O O
. O O

CCB O O
was O O
measured O O
before O O
and O O
after O O
administration O O
of O O
either O O
vehicle O O
, O O
AVP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ANP O O
, O O
or O O
both O O
peptides O O
together O O
. O O

Increases O O
of O O
MAP O O
occurred O O
after O O
LV O O
administration O O
of O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
WKY O O
and O O
of O O
10 O O
and O O
50 O O
ng O O
in O O
SHR O O
. O O

ANP O O
did O O
not O O
cause O O
significant O O
changes O O
in O O
MAP O O
in O O
both O O
strains O O
as O O
compared O O
to O O
vehicle O O
, O O
but O O
it O O
abolished O O
AVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
MAP O O
increase O O
in O O
WKY O O
and O O
SHR O O
. O O

CCB O O
was O O
reduced O O
in O O
WKY O O
and O O
SHR O O
after O O
LV O O
administration O O
of O O
AVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
SN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
hypotension O O
. O O

In O O
SHR O O
but O O
not O O
in O O
WKY O O
administration O O
of O O
ANP O O
, O O
AVP B B_LOCATION/B_GENE
and O O
ANP O O
+ O O
AVP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O O
CCB O O
during O O
Phe B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
induced O O
MAP O O
elevation O O
. O O

The O O
results O O
indicate O O
that O O
centrally O O
applied O O
AVP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ANP O O
exert O O
differential O O
effects O O
on O O
blood O O
pressure O O
and O O
baroreflex O O
control O O
of O O
heart O O
rate O O
in O O
WKY O O
and O O
SHR O O
and O O
suggest O O
interaction O O
of O O
these O O
two O O
peptides O O
in O O
blood O O
pressure O O
regulation O O
at O O
the O O
level O O
of O O
central O O
nervous O O
system O O
. O O

Cutaneous O O
exposure O O
to O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
like O O
anticoagulant O O
causing O O
an O O
intracerebral O O
hemorrhage O O
: O O
a O O
case O O
report O O
. O O

A O O
case O O
of O O
intercerebral O O
hematoma O O
due O O
to O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
coagulopathy O O
is O O
presented O O
. O O

The O O
39 O O
- O O
year O O
- O O
old O O
woman O O
had O O
spread O O
a O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- O O
type O O
rat O O
poison O O
around O O
her O O
house O O
weekly O O
using O O
her O O
bare O O
hands O O
, O O
with O O
no O O
washing O O
post O O
application O O
. O O

Percutaneous O O
absorption O O
of O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causing O O
coagulopathy O O
, O O
reported O O
three O O
times O O
in O O
the O O
past O O
, O O
is O O
a O O
significant O O
risk O O
if O O
protective O O
measures O O
, O O
such O O
as O O
gloves O O
, O O
are O O
not O O
used O O
. O O

An O O
adverse O O
drug O O
interaction O O
with O O
piroxicam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
she O O
took O O
occasionally O O
, O O
may O O
have O O
exacerbated O O
the O O
coagulopathy O O
. O O

Pediatric O O
heart O O
transplantation O O
without O O
chronic O O
maintenance O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
1986 O B_TIME[MEASURE]
to O O
February O B_TIME[MEASURE]
1993 O I_TIME[MEASURE]
, O O
40 O B_PERSON/B_ENT
children O I_PERSON/I_ENT
aged O O
2 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
to O O
18 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
( O O
average O B_MEASURE
age O I_MEASURE
10 O I_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
underwent O O
heart O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Indications O O
for O O
transplantation O O
were O O
idiopathic O O
cardiomyopathy O O
( O O
52 O O
% O O
) O O
, O O
congenital O O
heart O O
disease O O
( O O
35 O O
% O O
) O O
with O O
and O O
without O O
prior O O
repair O O
( O O
71 O O
% O O
and O O
29 O O
% O O
, O O
respectively O O
) O O
, O O
hypertrophic O O
cardiomyopathy O O
( O O
5 O O
% O O
) O O
, O O
valvular O O
heart O O
disease O O
( O O
3 O O
% O O
) O O
, O O
and O O
doxorubicin B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiomyopathy O O
( O O
5 O O
% O O
) O O
. O O

Patients O O
were O O
managed O O
with O O
cyclosporine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
azathioprine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

No O O
prophylaxis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
antilymphocyte O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
used O O
. O O

Steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O O
given O O
to O O
39 O O
% O O
of O O
patients O O
for O O
refractory O O
rejection O O
, O O
but O O
weaning O O
was O O
always O O
attempted O O
and O O
generally O O
successful O O
( O O
64 O O
% O O
) O O
. O O

Five O O
patients O O
( O O
14 O O
% O O
) O O
received O O
maintenance O O
steroids B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
died O O
in O O
the O O
perioperative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
one O B_NUMBER[MEASURE]/B_PERSON
died O O
4 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
later O O
. O O

There O O
have O O
been O O
no O O
deaths O B_DISEASE
related O O
to O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Average O B_TIME[MEASURE]/B_PERSON
follow O I_TIME[MEASURE]/I_PERSON
- O O
up O B_LOCATION/B_MEASURE
was O O
36 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
19 O B_TIME[MEASURE]/B_PERSON
months O I_TIME[MEASURE]/I_PERSON
( O O
range O B_MEASURE
1 O I_MEASURE
to O O
65 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
) O O
. O O

Cumulative O B_PERSON/B_LOCATION
survival O I_PERSON/I_LOCATION
is O O
88 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
5 O B_TIME[MEASURE]/B_LOCATION
years O I_TIME[MEASURE]/I_LOCATION
. O O

In O O
patients O B_PERSON
less O I_PERSON
than O O
7 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
age O B_TIME[MEASURE]/B_PERSON
, O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
monitored O O
noninvasively O O
. O O

In O O
the O O
first O B_TIME[MEASURE]/B_LOCATION
postoperative O B_TIME[MEASURE]/I_LOCATION
month O B_TIME[MEASURE]/I_LOCATION
, O O
89 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
were O O
treated O O
for O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Freedom O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
serious O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
83 O B_MEASURE
% O I_MEASURE
at O O
1 O B_TIME[MEASURE]
month O I_TIME[MEASURE]
and O O
65 O B_MEASURE
% O I_MEASURE
at O O
1 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
. O O

Cytomegalovirus O O
infections O O
were O O
treated O O
successfully O O
with O O
ganciclovir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
11 O O
patients O O
. O O

No O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]
of O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
children O B_PERSON/B_BIO
who O O
underwent O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
with O O
a O O
control O B_PERSON/B_BIO
population O I_PERSON/I_BIO
. O O

Twenty O B_NUMBER[MEASURE]
- O O
one O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
have O O
undergone O O
annual O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
catheterizations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O O
no O O
sign O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
graft O B_DISEASE
atherosclerosis O I_DISEASE
has O O
been O O
observed O O
. O O

Seizures O B_DISEASE
occurred O O
in O O
five O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
( O O
14 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
and O O
hypertension O B_DISEASE
was O O
treated O O
in O O
10 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

No O O
patient O B_PERSON/B_DISEASE
was O O
disabled O O
and O O
no O O
lymphoproliferative O B_DISEASE_ADJECTIVE[DISEASE]
disorder O I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
. O O
( O O
ABSTRACT O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O I_MEASURE
AT O O
250 O B_PERSON/B_LOCATION
WORDS O B_PERSON/I_LOCATION
) O O

Delirium O O
during O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
. O O

A O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

The O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
high O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
serum O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tricyclic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
antidepressant O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concentrations O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
central O B_DISEASE
nervous O I_DISEASE
system O I_DISEASE
side O I_DISEASE
effects O I_DISEASE
has O O
been O O
well O O
established O O
. O O

Only O O
a O O
few O O
reports O O
exist O O
, O O
however O O
, O O
on O O
the O O
relationship O O
between O O
the O O
serum O O
concentrations O O
of O O
selective O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O O
inhibitors O O
( O O
SSRIs O O
) O O
and O O
their O O
toxic O O
effects O O
. O O

In O O
some O O
cases O O
, O O
a O O
high O O
serum O O
concentration O O
of O O
citalopram B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
> O O
600 O O
nmol O O
/ O O
L O O
) O O
in O O
elderly O O
patients O O
has O O
been O O
associated O O
with O O
increased O O
somnolence O O
and O O
movement O O
difficulties O O
. O O

Widespread O B_DISEASE_ADJECTIVE[DISEASE]
cognitive O I_DISEASE_ADJECTIVE[DISEASE]
disorders O I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
delirium O B_DISEASE/B_LOCATION
, O O
have O O
not O O
been O O
previously O O
linked O O
with O O
high O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
SSRIs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
acute O O
hyperkinetic O O
delirium O O
connected O O
with O O
a O O
high O O
serum O O
total O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
fluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
desmethylfluoxetine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
concentration O O
. O O

Pulmonary O O
edema O O
and O O
shock O O
after O O
high O O
- O O
dose O O
aracytine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
lymphoma O O
; O O
possible O O
role O O
of O O
TNF O O
- O O
alpha O O
and O O
PAF O O
. O O

Four O O
out O O
of O O
23 O O
consecutive O O
patients O O
treated O O
with O O
high O O
- O O
dose O O
Ara B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
lymphomas O O
in O O
our O O
institution O O
developed O O
a O O
strikingly O O
similar O O
syndrome O O
during O O
the O O
perfusion O O
. O O

It O O
was O O
characterized O O
by O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]
of O O
fever O B_DISEASE
, O O
diarrhea O B_DISEASE
, O O
shock O B_DISEASE
, O O
pulmonary O B_DISEASE
edema O I_DISEASE
, O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
, O O
metabolic O B_DISEASE
acidosis O I_DISEASE
, O O
weight O B_DISEASE
gain O I_DISEASE
and O O
leukocytosis O B_DISEASE
. O O

Thorough O B_PERSON
bacteriological O I_PERSON
screening O I_PERSON
failed O O
to O O
provide O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sequential O O
biological O O
assays O O
of O O
IL O O
- O O
1 O O
, O O
IL O O
- O O
2 O O
, O O
TNF O O
and O O
PAF O O
were O O
performed O O
during O O
Ara B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infusion O O
to O O
ten O O
patients O O
, O O
including O O
the O O
four O O
who O O
developed O O
the O O
syndrome O O
. O O

TNF O B_LOCATION/B_ORGANIZATION
and O O
PAF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
the O O
serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
respectively O O
two O B_NUMBER[MEASURE]
and O O
four O B_NUMBER[MEASURE]
of O O
the O O
cases O B_PERSON/B_BIO
, O O
but O O
not O O
in O O
the O O
six O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
controls O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O O

As O O
TNF O O
and O O
PAF O O
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
development O O
of O O
septic O O
shock O O
and O O
adult O O
respiratory O O
distress O O
syndrome O O
, O O
we O O
hypothesize O O
that O O
high O O
- O O
dose O O
Ara B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
associated O O
with O O
cytokine O O
release O O
. O O

Protective O O
effect O O
of O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
injury O O
in O O
rats O O
. O O

We O O
investigated O O
the O O
effects O O
of O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
benzothiazepine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O O
, O O
on O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiomyopathy O O
in O O
rats O O
. O O

With O O
2 O O
- O O
week O O
chronic O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O O
, O O
16 O O
of O O
30 O O
rats O O
died O O
within O O
4 O O
days O O
, O O
and O O
severe O O
ischemic O O
lesions O O
and O O
fibrosis O O
of O O
the O O
left O O
ventricles O O
were O O
observed O O
. O O

In O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
, O O
left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
reduced O O
, O O
but O O
responses O O
to O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
normal O O
or O O
enhanced O O
compared O O
to O O
controls O O
. O O

Left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT
alpha O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
beta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
densities O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
reduced O O
compared O O
to O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Treatment O O
with O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevented O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
death O O
( O O
P O O
< O O
. O O
05 O O
) O O
, O O
and O O
attenuated O O
the O O
ventricular O O
ischemic O O
lesions O O
and O O
fibrosis O O
, O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

Left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
reduced O O
compared O O
to O O
controls O O
in O O
groups O O
treated O O
with O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
but O O
combined O O
with O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
clentiazem B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
restored O O
left O O
atrial O O
responses O O
and O O
enhanced O O
left O O
ventricular O O
papillary O O
responses O O
to O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
other O O
hand O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
prevent O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
down O O
- O O
regulation O O
of O O
alpha O O
and O O
beta O O
adrenoceptors O O
. O O

Interestingly O O
, O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
infused O O
alone O O
, O O
resulted O O
in O O
decreased O O
adrenergic O O
receptor O O
densities O O
in O O
the O O
left O O
ventricle O O
. O O

Clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O O
did O O
not O O
prevent O O
the O O
enhanced O O
responses O O
to O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O O
in O O
the O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
animals O O
, O O
although O O
the O O
high O O
dose O O
of O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O O
attenuated O O
the O O
maximal O O
response O O
to O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
to O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
clentiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuated O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiac O O
injury O O
, O O
possibly O O
through O O
its O O
effect O O
on O O
the O O
adrenergic O O
pathway O O
. O O

Kaliuretic O O
effect O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
in O O
parkinsonian O O
patients O O
. O O

Hypokalemia O O
, O O
sometimes O O
severe O O
, O O
was O O
observed O O
in O O
some O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
parkinsonian O O
patients O O
. O O

The O O
influence O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O O
the O O
renal O O
excretion O O
of O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
studied O O
in O O
3 O O
patients O O
with O O
hypokalemia O O
and O O
in O O
5 O O
normokalemic O O
patients O O
by O O
determination O O
of O O
renal O O
plasma O O
flow O O
, O O
glomerular O O
filtration O O
rate O O
, O O
plasma O O
concentration O O
of O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
urinary O O
excretion O O
of O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
aldosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dopa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O O
was O O
found O O
to O O
cause O O
an O O
increased O O
excretion O O
of O O
potassium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
sometimes O O
also O O
of O O
sodium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
hypokalemic O O
but O O
not O O
in O O
the O O
normokalemic O O
patients O O
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
prohibited O O
by O O
the O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
peripheral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopa O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decarbodylase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
not O O
known O O
why O O
this O O
effect O O
occurred O O
in O O
some O O
individuals O O
but O O
not O O
in O O
others O O
, O O
but O O
our O O
results O O
indicate O O
a O O
correlation O O
between O O
aldosterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O O
and O O
this O O
renal O O
effect O O
of O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dopa I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cocaine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
induced O O
myocardial O O
ischemia O O
. O O

We O O
report O O
a O O
case O O
of O O
myocardial O O
ischemia O O
induced O O
by O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
ischemia O O
probably O O
induced O O
by O O
coronary O O
artery O O
spasm O O
was O O
reversed O O
by O O
nitroglycerin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
blocking O O
agents O O
. O O

Doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
cardiotoxicity O O
monitored O O
by O O
ECG O O
in O O
freely O O
moving O O
mice O O
. O O

A O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
potential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protectors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
laboratory O O
animals O O
, O O
histology O O
is O O
most O O
commonly O O
used O O
to O O
study O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
. O O

However O O
, O O
for O O
monitoring O O
during O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
numbers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
animals O B_BIO/B_PERSON
are O O
needed O O
. O O

Recently O O
we O O
developed O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
measure O O
ECG O B_DISEASE
values O I_DISEASE
in O O
freely O O
moving O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
telemetry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

With O O
this O O
model O O
we O O
investigated O O
the O O
effect O O
of O O
chronic O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
on O O
the O O
ECG O O
of O O
freely O O
moving O O
BALB O O
/ O O
c O O
mice O O
and O O
the O O
efficacy O O
of O O
ICRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
187 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
protective O O
agent O O
. O O

The O O
ST O O
interval O O
significantly O O
widened O O
from O O
15 O O
. O O
0 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
to O O
56 O O
. O O
8 O O
+ O O
/ O O
- O O
11 O O
. O O
8 O O
ms O O
in O O
week O O
10 O O
( O O
7 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
i O O
. O O
v O O
. O O
plus O O
3 O O
weeks O O
of O O
observation O O
) O O
. O O

The O O
ECG O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
control O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
change O O
during O O
the O O
entire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
sacrifice O O
the O O
hearts O O
of O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
animals O O
were O O
enlarged O O
and O O
the O O
atria O O
were O O
hypertrophic O O
. O O

As O O
this O O
schedule O O
exerted O O
more O O
toxicity O O
than O O
needed O O
to O O
investigate O O
protective O O
agents O O
, O O
the O O
protection O O
of O O
ICRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
187 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
determined O O
using O O
a O O
dose O O
schedule O O
with O O
lower O O
general O O
toxicity O O
( O O
6 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
given O O
i O O
. O O
v O O
. O O
plus O O
2 O O
weeks O O
of O O
observation O O
) O O
. O O

On O O
this O O
schedule O O
, O O
the O O
animals O O
' O O
hearts O O
appeared O O
normal O O
after O O
sacrifice O O
and O O
ICRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
187 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O O
mg O O
/ O O
kg O O
given O O
i O O
. O O
p O O
. O O
1 O O
h O O
before O O
doxorubicin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O O
provided O O
almost O O
full O O
protection O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
confirmed O O
by O O
histology O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
this O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
very O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
and O O
enables O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
cardiotoxicity O B_DISEASE
with O O
time O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

These O O
findings O O
result O O
in O O
a O O
model O O
that O O
allows O O
the O O
testing O O
of O O
protectors O O
against O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
cardiotoxicity O O
as O O
demonstrated O O
by O O
the O O
protection O O
provided O O
by O O
ICRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
187 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dysrhythmogenicity O O
is O O
not O O
enhanced O O
by O O
subtoxic O O
bupivacaine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
dogs O O
. O O

Since O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
both O O
precipitate O O
dysrhythmias O O
, O O
circulating O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
regional O O
anesthesia O O
could O O
potentiate O O
dysrhythmogenic O O
effects O O
of O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
therefore O O
examined O O
whether O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alters O O
the O O
dysrhythmogenicity O O
of O O
subsequent O O
administration O O
of O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
conscious O O
, O O
healthy O O
dogs O O
and O O
in O O
anesthetized O O
dogs O O
with O O
myocardial O O
infarction O O
. O O

Forty O O
- O O
one O O
conscious O O
dogs O O
received O O
10 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Seventeen O B_PERSON
animals O I_PERSON
responded O O
with O O
ventricular O B_DISEASE
tachycardia O I_DISEASE
( O O
VT O B_PROTEIN[GENE]/B_DISEASE
) O O
within O O
3 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

After O O
3 O O
h O O
, O O
these O O
responders O O
randomly O O
received O O
1 O O
or O O
2 O O
mg O O
/ O O
kg O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
saline O O
over O O
5 O O
min O O
, O O
followed O O
by O O
10 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O O
, O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
fewer O O
prodysrhythmic O O
effects O O
than O O
without O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

VT O B_DISEASE/B_PERSON
appeared O O
in O O
fewer O B_TIME[MEASURE]
dogs O I_TIME[MEASURE]
and O O
at O O
a O O
later O B_MEASURE/B_LOCATION
time O I_MEASURE/I_LOCATION
, O O
and O O
there O O
were O O
more O O
sinoatrial O B_DISEASE
beats O I_DISEASE
and O O
less O B_DISEASE
ectopies O I_DISEASE
. O O

Epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shortened O O
QT O O
less O O
after O O
bupivacaine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O O
in O O
control O O
animals O O
. O O

One O O
day O O
after O O
experimental O O
myocardial O O
infarction O O
, O O
six O O
additional O O
halothane B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
anesthetized O O
dogs O O
received O O
4 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O O
VT O O
appeared O O
. O O

After O O
45 O O
min O O
, O O
1 O O
mg O O
/ O O
kg O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
injected O O
over O O
5 O O
min O O
, O O
again O O
followed O O
by O O
4 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
these O O
dogs O O
, O O
the O O
prodysrhythmic O O
response O O
to O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
mitigated O O
by O O
preceding O O
bupivacaine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonizes O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dysrhythmogenicity O O
in O O
conscious O O
dogs O O
susceptible O O
to O O
VT O O
and O O
in O O
anesthetized O O
dogs O O
with O O
spontaneous O O
postinfarct O O
dysrhythmias O O
. O O

There O O
is O O
no O O
evidence O O
that O O
systemic O O
subtoxic O O
bupivacaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
enhances O O
the O O
dysrhythmogenicity O O
of O O
subsequent O O
epinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Milk O O
- O O
alkali O O
syndrome O O
induced O O
by O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
25 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OH I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
a O O
patient O O
with O O
hypoparathyroidism O O
. O O

Milk O O
- O O
alkali O O
syndrome O O
was O O
first O O
described O O
70 O O
years O O
ago O O
in O O
the O O
context O O
of O O
the O O
treatment O O
of O O
peptic O O
ulcer O O
disease O O
with O O
large O O
amounts O O
of O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
alkali B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
with O O
current O O
ulcer O O
therapy O O
( O O
H O O
- O O
2 O O
blockers O O
, O O
omeprazole B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
sucralfate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
the O O
frequency O O
of O O
milk O O
- O O
alkali O O
syndrome O O
has O O
decreased O O
significantly O O
, O O
the O O
classic O O
triad O O
of O O
hypercalcemia O O
, O O
alkalosis O O
, O O
and O O
renal O O
impairment O O
remains O O
the O O
hallmark O O
of O O
the O O
syndrome O O
. O O

Milk O B_DISEASE
- O O
alkali O B_DISEASE
syndrome O I_DISEASE
can O O
present O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
and O O
occasionally O O
life O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
threatening O O
illness O B_DISEASE
unless O O
diagnosed O O
and O O
treated O O
appropriately O O
. O O

This O O
article O O
presents O O
a O O
patient O O
with O O
hypoparathyroidism O O
who O O
was O O
treated O O
with O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carbonate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
calcitriol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulting O O
in O O
two O O
admissions O O
to O O
the O O
hospital O O
for O O
milk O O
- O O
alkali O O
syndrome O O
. O O

The O O
patient O O
was O O
successfully O O
treated O O
with O O
intravenous O O
pamidronate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
his O O
first O O
admission O O
and O O
with O O
hydrocortisone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
second O O
. O O

This O O
illustrates O O
intravenous O O
pamidronate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
valuable O O
therapeutic O O
tool O O
when O O
milk O O
- O O
alkali O O
syndrome O O
presents O O
as O O
hypercalcemic O O
emergency O O
. O O

Famotidine B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
associated O O
delirium O O
. O O

A O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
six O B_ENT/B_PERSON
cases O I_ENT/I_PERSON
. O O

Famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
histamine O O
H2 O O
- O O
receptor O O
antagonist O O
used O O
in O O
inpatient O O
settings O O
for O O
prevention O O
of O O
stress O O
ulcers O O
and O O
is O O
showing O O
increasing O O
popularity O O
because O O
of O O
its O O
low O O
cost O O
. O O

Although O O
all O O
of O O
the O O
currently O O
available O O
H2 O O
- O O
receptor O O
antagonists O O
have O O
shown O O
the O O
propensity O O
to O O
cause O O
delirium O O
, O O
only O O
two O O
previously O O
reported O O
cases O O
have O O
been O O
associated O O
with O O
famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
authors O O
report O O
on O O
six O O
cases O O
of O O
famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
associated O O
delirium O O
in O O
hospitalized O O
patients O O
who O O
cleared O O
completely O O
upon O O
removal O O
of O O
famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
pharmacokinetics O O
of O O
famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
reviewed O O
, O O
with O O
no O O
change O O
in O O
its O O
metabolism O O
in O O
the O O
elderly O O
population O O
seen O O
. O O

The O O
implications O O
of O O
using O O
famotidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
elderly O O
persons O O
are O O
discussed O O
. O O

Encephalopathy O O
during O O
amitriptyline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
: O O
are O O
neuroleptic O O
malignant O O
syndrome O O
and O O
serotonin O O
syndrome O O
spectrum O O
disorders O O
? O O

This O O
report O O
describes O O
a O O
case O O
of O O
encephalopathy O O
developed O O
in O O
the O O
course O O
of O O
amitriptyline B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
during O O
a O O
remission O O
of O O
unipolar O O
depression O O
. O O

This O O
patient O B_PERSON/B_BIO
could O O
have O O
been O O
diagnosed O O
as O O
having O O
either O O
neuroleptic O B_DISEASE
malignant O I_DISEASE
syndrome O I_DISEASE
( O O
NMS O B_LOCATION
) O O
or O O
serotonin O B_DISEASE
syndrome O I_DISEASE
( O O
SS O B_LOCATION
) O O
. O O

The O O
major O O
determinant O O
of O O
the O O
symptoms O O
may O O
have O O
been O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imbalance O O
in O O
the O O
central O O
nervous O O
system O O
. O O

The O O
NMS O B_DISEASE/B_GENE
- O O
like O B_DISEASE
encephalopathy O I_DISEASE
that O O
develops O O
in O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O O
antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O O
that O O
NMS O B_LOCATION
and O O
SS O B_DISEASE
are O O
spectrum O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disorders O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
induced O O
by O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
both O O
antidopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Genetic O O
separation O O
of O O
tumor O O
growth O O
and O O
hemorrhagic O O
phenotypes O O
in O O
an O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
tumor O O
. O O

Chronic O O
administration O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rat O O
induces O O
growth O O
of O O
large O O
, O O
hemorrhagic O O
pituitary O O
tumors O O
. O O

Ten O O
weeks O O
of O O
diethylstilbestrol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DES B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
treatment O O
caused O O
female O O
F344 O O
rat O O
pituitaries O O
to O O
grow O O
to O O
an O O
average O O
of O O
109 O O
. O O
2 O O
+ O O
/ O O
- O O
6 O O
. O O
3 O O
mg O O
( O O
mean O O
+ O O
/ O O
- O O
SE O O
) O O
versus O O
11 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
mg O O
for O O
untreated O O
rats O O
, O O
and O O
to O O
become O O
highly O O
hemorrhagic O O
. O O

The O O
same O O
DES B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
produced O O
no O O
significant O O
growth O O
( O O
8 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
mg O O
for O O
treated O O
females O O
versus O O
8 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
1 O O
for O O
untreated O O
females O O
) O O
or O O
morphological O O
changes O O
in O O
Brown O O
Norway O O
( O O
BN O O
) O O
rat O O
pituitaries O O
. O O

An O O
F1 O O
hybrid O O
of O O
F344 O O
and O O
BN O O
exhibited O O
significant O O
pituitary O O
growth O O
after O O
10 O O
weeks O O
of O O
DES B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O O
with O O
an O O
average O O
mass O O
of O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mg O O
compared O O
with O O
8 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
mg O O
for O O
untreated O O
rats O O
. O O

Surprisingly O O
, O O
the O O
F1 O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybrid O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
hemorrhagic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
had O O
hemoglobin O B_MEASURE/B_LOCATION
content O B_MEASURE/I_LOCATION
and O O
outward O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
appearance O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
identical O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
that O O
of O O
BN O B_PERSON/B_DISEASE
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
both O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
due O O
to O O
multiple O B_DISEASE/B_GENE
genes O I_DISEASE/I_GENE
. O O

However O O
, O O
while O O
DES B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
pituitary O O
growth O O
exhibited O O
quantitative O O
, O O
additive O O
inheritance O O
, O O
the O O
hemorrhagic O O
phenotype O O
exhibited O O
recessive O O
, O O
epistatic O O
inheritance O O
. O O

Only O O
5 O B_MEASURE
of O O
the O O
160 O B_MEASURE/B_PERSON
F2 O I_MEASURE/I_PERSON
pituitaries O I_MEASURE/I_PERSON
exhibited O O
the O O
hemorrhagic O B_DISEASE/B_MEASURE
phenotype O I_DISEASE/I_MEASURE
; O O
36 O B_MEASURE
of O O
the O O
160 O B_MEASURE/B_PERSON
F2 O I_MEASURE/I_PERSON
pituitaries O I_MEASURE/I_PERSON
were O O
in O O
the O O
F344 O B_MEASURE/B_LOCATION
range O B_MEASURE/I_LOCATION
of O O
mass O B_MEASURE/B_ORGANISM_FUNCTION
, O O
but O O
31 O B_NUMBER[MEASURE]
of O O
these O O
were O O
not O O
hemorrhagic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
indicating O O
that O O
the O O
hemorrhagic O B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
merely O O
a O O
consequence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
extensive O B_DISEASE/B_ORGANISM_FUNCTION
growth O I_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
hemorrhagic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pituitaries O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
all O O
among O O
the O O
most O O
massive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
indicating O O
that O O
some O O
of O O
the O O
genes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulate O O
both O O
phenotypes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Increased O O
expression O O
of O O
neuronal O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O O
in O O
bladder O O
afferent O O
pathways O O
following O O
chronic O O
bladder O O
irritation O O
. O O

Immunocytochemical O O
techniques O O
were O O
used O O
to O O
examine O O
alterations O O
in O O
the O O
expression O O
of O O
neuronal O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O O
( O O
NOS O O
) O O
in O O
bladder O O
pathways O O
following O O
acute O O
and O O
chronic O O
irritation O O
of O O
the O O
urinary O O
tract O O
of O O
the O O
rat O O
. O O

Chemical O O
cystitis O O
was O O
induced O O
by O O
cyclophosphamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
CYP B B_PROTEIN[GENE]/B_LOCATION
) O O
which O O
is O O
metabolized O O
to O O
acrolein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
irritant O O
eliminated O O
in O O
the O O
urine O O
. O O

Injection O O
of O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
n O O
= O O
10 O O
, O O
75 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
2 O O
hours O O
prior O O
to O O
perfusion O O
( O O
acute O O
treatment O O
) O O
of O O
the O O
animals O O
increased O O
Fos O O
- O O
immunoreactivity O O
( O O
IR O O
) O O
in O O
neurons O O
in O O
the O O
dorsal O O
commissure O O
, O O
dorsal O O
horn O O
, O O
and O O
autonomic O O
regions O O
of O O
spinal O O
segments O O
( O O
L1 O O
- O O
L2 O O
and O O
L6 O O
- O O
S1 O O
) O O
which O O
receive O O
afferent O O
inputs O O
from O O
the O O
bladder O O
, O O
urethra O O
, O O
and O O
ureter O O
. O O

Fos O O
- O O
IR O O
in O O
the O O
spinal O O
cord O O
was O O
not O O
changed O O
in O O
rats O O
receiving O O
chronic O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
treatment O O
( O O
n O O
= O O
15 O O
, O O
75 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
, O O
every O O
3rd O O
day O O
for O O
2 O O
weeks O O
) O O
. O O

In O O
control O O
animals O O
and O O
in O O
animals O O
treated O O
acutely O O
with O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
only O O
small O O
numbers O O
of O O
NOS O O
- O O
IR O O
cells O O
( O O
0 O O
. O O
5 O O
- O O
0 O O
. O O
7 O O
cell O O
profiles O O
/ O O
sections O O
) O O
were O O
detected O O
in O O
the O O
L6 O O
- O O
S1 O O
dorsal O O
root O O
ganglia O O
( O O
DRG O O
) O O
. O O

Chronic O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O O
significantly O O
( O O
P O O
< O O
or O O
= O O
. O O
002 O O
) O O
increased O O
bladder O O
weight O O
by O O
60 O O
% O O
and O O
increased O O
( O O
7 O O
- O O
to O O
11 O O
- O O
fold O O
) O O
the O O
numbers O O
of O O
NOS O O
- O O
immunoreactive O O
( O O
IR O O
) O O
afferent O O
neurons O O
in O O
the O O
L6 O O
- O O
S1 O O
DRG O O
. O O

A O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
1 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_MEASURE
) O O
also O O
occurred O O
in O O
the O O
L1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DRG O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
no O O
change O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
detected O O
in O O
the O O
L2 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
L5 O B_PROTEIN[GENE]/B_DISEASE
DRG O I_PROTEIN[GENE]/I_DISEASE
. O O

Bladder O O
afferent O O
cells O O
in O O
the O O
L6 O O
- O O
S1 O O
DRG O O
labeled O O
by O O
Fluorogold O O
( O O
40 O O
microliters O O
) O O
injected O O
into O O
the O O
bladder O O
wall O O
did O O
not O O
exhibit O O
NOS O O
- O O
IR O O
in O O
control O O
animals O O
; O O
however O O
, O O
following O O
chronic O O
CYP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O O
, O O
a O O
significant O O
percentage O O
of O O
bladder O O
afferent O O
neurons O O
were O O
NOS O O
- O O
IR O O
: O O
L6 O O
( O O
19 O O
. O O
8 O O
+ O O
/ O O
- O O
4 O O
. O O
6 O O
% O O
) O O
and O O
S1 O O
( O O
25 O O
. O O
3 O O
+ O O
/ O O
- O O
2 O O
. O O
9 O O
% O O
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
neuronal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
visceral O B_DISEASE/B_SPECIES[BIO]
sensory O B_DISEASE/I_SPECIES[BIO]
pathways O B_DISEASE/I_SPECIES[BIO]
can O O
be O O
upregulated O O
by O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
afferent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
that O O
pathological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O O
initiate O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
alter O O
the O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
afferent O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Effects O O
of O O
a O O
new O O
calcium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O O
, O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
ischemia O O
in O O
dogs O O
with O O
partial O O
coronary O O
stenosis O O
. O O

Effects O O
of O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
- O O
induced O O
myocardial O O
ischemia O O
were O O
studied O O
in O O
dogs O O
with O O
partial O O
coronary O O
stenosis O O
of O O
the O O
left O O
circumflex O O
coronary O O
artery O O
and O O
findings O O
were O O
compared O O
with O O
those O O
for O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
presence O O
of O O
coronary O O
artery O O
stenosis O O
, O O
3 O O
- O O
min O O
periods O O
of O O
intracoronary O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O O
( O O
10 O O
ng O O
/ O O
kg O O
/ O O
min O O
) O O
increased O O
heart O O
rate O O
and O O
maximal O O
rate O O
of O O
left O O
ventricular O O
pressure O O
rise O O
, O O
which O O
resulted O O
in O O
a O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
and O O
ST O O
- O O
segment O O
elevation O O
of O O
the O O
epicardial O O
electrocardiogram O O
. O O

After O O
the O O
control O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
with O O
stenosis O O
was O O
performed O O
, O O
equihypotensive O O
doses O O
of O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
3 O O
and O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
, O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
and O O
3 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
9 O O
) O O
or O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O O
and O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
were O O
infused O O
5 O O
min O O
before O O
and O O
during O O
the O O
second O O
and O O
third O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
infusion O O
. O O

Both O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
significantly O O
reduced O O
the O O
increase O O
in O O
heart O O
rate O O
induced O O
by O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
. O O

In O O
contrast O O
to O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
32 O O
+ O O
/ O O
- O O
12 O O
% O O
to O O
115 O O
+ O O
/ O O
- O O
26 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
. O O
01 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
5 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
mV O O
to O O
1 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
mV O O
( O O
P O O
< O O
. O O
01 O O
) O O
at O O
3 O O
min O O
after O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
with O O
stenosis O O
. O O

Diltiazem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
also O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
34 O O
+ O O
/ O O
- O O
14 O O
% O O
to O O
63 O O
+ O O
/ O O
- O O
18 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
. O O
05 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mV O O
to O O
2 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mV O O
( O O
P O O
< O O
. O O
01 O O
) O O
at O O
3 O O
min O O
after O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
with O O
stenosis O O
. O O

These O O
data O O
show O O
that O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
improves O O
myocardial O O
ischemia O O
during O O
ISO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion O O
with O O
stenosis O O
and O O
suggest O O
that O O
the O O
negative O O
chronotropic O O
property O O
of O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plays O O
a O O
major O O
role O O
in O O
the O O
beneficial O O
effects O O
of O O
CD B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
effect O O
of O O
recombinant O O
human O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
I O O
on O O
chronic O O
puromycin B B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I I_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
in O O
rats O O
. O O

We O O
recently O O
demonstrated O O
that O O
recombinant O O
hGH O O
exacerbates O O
renal O O
functional O O
and O O
structural O O
injury O O
in O O
chronic O O
puromycin B B_DISEASE
aminonucleoside I I_DISEASE
( O O
PAN B B_DISEASE/B_LOCATION
) O O
nephropathy O O
, O O
an O O
experimental O O
model O O
of O O
glomerular O O
disease O O
. O O

Therefore O O
, O O
we O O
examined O O
whether O O
recombinant O O
human O O
( O O
rh O O
) O O
IGF O O
- O O
I O O
is O O
a O O
safer O O
alternative O O
for O O
the O O
treatment O O
of O O
growth O O
failure O O
in O O
rats O O
with O O
chronic O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O O
. O O

The O O
glomerulopathy O O
was O O
induced O O
by O O
seven O O
serial O O
injections O O
of O O
PAN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O O
12 O O
wk O O
. O O

Experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
n O B_MEASURE/B_LOCATION
= O O
6 O B_MEASURE
) O O
received O O
rhIGF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
400 O B_MEASURE/B_LOCATION
micrograms O I_MEASURE/I_LOCATION
/ O O
d O B_OTHER/B_TIME[MEASURE]
, O O
whereas O O
control O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
( O O
n O B_LOCATION
= O O
6 O B_MEASURE
) O O
received O O
the O O
vehicle O B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

rhIGF O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
I O O
improved O O
weight O B_DISEASE/B_GENE
gain O I_DISEASE/I_GENE
by O O
14 O B_DISEASE/B_MEASURE
% O B_DISEASE/I_MEASURE
( O O
p O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
05 O B_MEASURE
) O O
, O O
without O O
altering O O
hematocrit O B_DISEASE
or O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pressure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
rats O B_BIO/B_PERSON
with O O
renal O B_DISEASE/B_GENE
disease O I_DISEASE/I_GENE
. O O

Urinary O O
protein O O
excretion O O
was O O
unaltered O O
by O O
rhIGF O O
- O O
I O O
treatment O O
in O O
rats O O
with O O
chronic O O
PAN B B_DISEASE
nephropathy O O
. O O

After O O
12 O O
wk O O
, O O
the O O
inulin O O
clearance O O
was O O
higher O O
in O O
rhIGF O O
- O O
I O O
- O O
treated O O
rats O O
, O O
0 O O
. O O
48 O O
+ O O
/ O O
- O O
0 O O
. O O
08 O O
versus O O
0 O O
. O O
24 O O
+ O O
/ O O
- O O
0 O O
. O O
06 O O
mL O O
/ O O
min O O
/ O O
100 O O
g O O
of O O
body O O
weight O O
in O O
untreated O O
PAN B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nephropathy O O
animals O O
, O O
p O O
< O O
0 O O
. O O
05 O O
. O O

The O O
improvement O O
in O O
GFR O O
was O O
not O O
associated O O
with O O
enhanced O O
glomerular O O
hypertrophy O O
or O O
increased O O
segmental O O
glomerulosclerosis O O
, O O
tubulointerstitial O O
injury O O
, O O
or O O
renal O O
cortical O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O O
. O O

In O O
rats O O
with O O
PAN B B_DISEASE
nephropathy O O
, O O
administration O O
of O O
rhIGF O O
- O O
I O O
increased O O
IGF O O
- O O
I O O
and O O
GH O O
receptor O O
gene O O
expression O O
, O O
without O O
altering O O
the O O
steady O O
state O O
level O O
of O O
IGF O O
- O O
I O O
receptor O O
mRNA O O
. O O

In O O
normal O O
rats O O
with O O
intact O O
kidneys O O
, O O
rhIGF O O
- O O
I O O
administration O O
( O O
n O O
= O O
4 O O
) O O
did O O
not O O
alter O O
weight O O
gain O O
, O O
blood O O
pressure O O
, O O
proteinuria O O
, O O
GFR O O
, O O
glomerular O O
planar O O
area O O
, O O
renal O O
cortical O O
malondialdehyde B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O O
, O O
or O O
glomerular O O
or O O
tubulointerstitial O O
damage O O
, O O
compared O O
with O O
untreated O O
animals O O
( O O
n O O
= O O
4 O O
) O O
. O O

rhIGF O B_GENE/B_MEASURE
- O O
I O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduced O O
the O O
steady O B_GENE/B_LOCATION
state O I_GENE/I_LOCATION
renal O I_GENE/I_LOCATION
IGF O I_GENE/I_LOCATION
- O O
I O O
mRNA O B_MEASURE/B_LOCATION
level O B_MEASURE/I_LOCATION
but O O
did O O
not O O
modify O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
IGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
I O O
or O O
GH O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
: O O
1 O O
) O O
administration O O
of O O
rhIGF O O
- O O
I O O
improves O O
growth O O
and O O
GFR O O
in O O
rats O O
with O O
chronic O O
PAN B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O O
and O O
2 O O
) O O
unlike O O
rhGH O O
, O O
long O O
- O O
term O O
use O O
of O O
rhIGF O O
- O O
I O O
does O O
not O O
worsen O O
renal O O
functional O O
and O O
structural O O
injury O O
in O O
this O O
disease O O
model O O
. O O

Nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
DM B B_MEASURE/B_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
9384 I I_MEASURE/I_PROTEIN[GENE]
) O O
reverses O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
amnesia O O
of O O
a O O
passive O O
avoidance O O
response O O
: O O
delayed O O
emergence O O
of O O
the O O
memory O O
retention O O
effects O O
. O O

Nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
novel O O
pyrrolidone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derivative O O
which O O
attenuates O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
learning O O
and O O
post O O
- O O
training O O
consolidation O O
deficits O O
. O O

Given O O
that O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibits O O
passive O O
avoidance O O
retention O O
when O O
given O O
during O O
training O O
or O O
in O O
a O O
defined O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
, O O
we O O
evaluated O O
the O O
ability O O
of O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
attenuate O O
amnesia O O
induced O O
by O O
dopaminergic O O
agonism O O
. O O

A O O
step O O
- O O
down O O
passive O O
avoidance O O
paradigm O O
was O O
employed O O
and O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
mg O O
/ O O
kg O O
) O O
and O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
given O O
alone O O
or O O
in O O
combination O O
during O O
training O O
and O O
at O O
the O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
of O O
consolidation O O
. O O

Co O O
- O O
administration O O
of O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
training O O
or O O
10h O O
thereafter O O
produced O O
no O O
significant O O
anti O O
- O O
amnesic O O
effect O O
. O O

However O O
, O O
administration O O
of O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
during O O
training O O
completely O O
reversed O O
the O O
amnesia O O
induced O O
by O O
apomorphine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
the O O
10h O O
post O O
- O O
training O O
time O O
and O O
the O O
converse O O
was O O
also O O
true O O
. O O

These O O
effects O O
were O O
not O O
mediated O O
by O O
a O O
dopaminergic O O
mechanism O O
as O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
at O O
millimolar O O
concentrations O O
, O O
failed O O
to O O
displace O O
either O O
[ O O
3H O O
] O O
SCH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
23390 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
[ O O
3H O O
] O O
spiperone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
from O O
D1 O O
or O O
D2 O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
subtypes O O
, O O
respectively O O
. O O

It O O
is O O
suggested O O
that O O
nefiracetam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
augments O O
molecular O O
processes O O
in O O
the O O
early O O
stages O O
of O O
events O O
which O O
ultimately O O
lead O O
to O O
consolidation O O
of O O
memory O O
. O O

Phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
encephalopathy O O
as O O
probable O O
idiosyncratic O O
reaction O O
: O O
case O O
report O O
. O O

A O O
case O O
of O O
phenytoin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DPH B B_DISEASE/B_PROTEIN[GENE]
) O O
encephalopathy O O
with O O
increasing O O
seizures O O
and O O
EEG O O
and O O
mental O O
changes O O
is O O
described O O
. O O

Despite O O
adequate O O
oral O O
dosage O O
of O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
5 O O
mg O O
/ O O
kg O O
/ O O
daily O O
) O O
the O O
plasma O O
level O O
was O O
very O O
low O O
( O O
2 O O
. O O
8 O O
microgramg O O
/ O O
ml O O
) O O
. O O

The O O
encephalopathy O B_DISEASE
was O O
probably O O
an O O
idiosyncratic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
not O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
or O O
allergic O B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
fact O O
the O O
concentration O O
of O O
free O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
normal O O
, O O
the O O
patient O O
presented O O
a O O
retarded O O
morbilliform O O
rash O O
during O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O O
, O O
the O O
protidogram O O
was O O
normal O O
, O O
and O O
an O O
intradermic O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injection O O
had O O
no O O
local O O
effect O O
. O O

The O O
authors O O
conclude O O
that O O
in O O
a O O
patient O O
starting O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O O
an O O
unexpected O O
increase O O
in O O
seizures O O
, O O
with O O
EEG O O
and O O
mental O O
changes O O
occurring O O
simultaneously O O
, O O
should O O
alert O O
the O O
physician O O
to O O
the O O
possible O O
need O O
for O O
eliminating O O
DPH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
therapeutic O O
regimen O O
, O O
even O O
if O O
plasma O O
concentrations O O
are O O
low O O
. O O

Prevention O O
and O O
treatment O O
of O O
endometrial O O
disease O O
in O O
climacteric O O
women O O
receiving O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

The O O
treatment O O
regimens O O
are O O
described O O
in O O
74 O O
patients O O
with O O
endometrial O O
disease O O
among O O
850 O O
climacteric O O
women O O
receiving O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

Cystic O O
hyperplasia O O
was O O
associated O O
with O O
unopposed O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O O
without O O
progestagen B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Two O O
courses O O
of O O
21 O O
days O O
of O O
5 O O
mg O O
norethisterone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
caused O O
reversion O O
to O O
normal O O
in O O
all O O
57 O O
cases O O
of O O
cystic O O
hyperplasia O O
and O O
6 O O
of O O
the O O
8 O O
cases O O
of O O
atypical O O
hyperplasia O O
. O O

4 O O
cases O O
of O O
endometrial O O
carcinoma O O
referred O O
from O O
elsewhere O O
demonstrated O O
the O O
problems O O
of O O
inappropriate O O
and O O
unsupervised O O
unopposed O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
and O O
the O O
difficulty O O
in O O
distinguishing O O
severe O O
hyperplasia O O
from O O
malignancy O O
. O O

Cyclical O O
low O O
- O O
dose O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
with O O
7 O O
- O O
- O O
13 O O
days O O
of O O
progestagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
does O O
not O O
seem O O
to O O
increase O O
the O O
risk O O
of O O
endometrial O O
hyperplasia O O
or O O
carcinoma O O
. O O

Effects O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
infarction O O
. O O

The O O
effect O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O O
infarction O O
was O O
studied O O
in O O
male O O
rats O O
. O O

Ninety O B_NUMBER[MEASURE]
- O O
three O B_NUMBER[MEASURE]
rats O I_NUMBER[MEASURE]
were O O
randomly O O
divided O O
into O O
three O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
. O O

The O O
exercise O O
- O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
E O O
- O O
1 O O
) O O
and O O
exercise O O
control O O
( O O
EC O O
) O O
groups O O
exercised O O
daily O O
for O O
thirty O O
days O O
on O O
a O O
treadmill O O
at O O
1 O O
mph O O
, O O
2 O O
% O O
grade O O
while O O
animals O O
of O O
the O O
sedentary O O
- O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
S O O
- O O
I O O
) O O
group O O
remained O O
sedentary O O
. O O

Eight O B_PERSON/B_ENT
animals O I_PERSON/I_ENT
were O O
assigned O O
to O O
the O O
sedentary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
SC O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
group O B_ORGANIZATION/B_LOCATION
which O O
remained O O
sedentary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O O
the O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Forty O O
- O O
eight O O
hours O O
after O O
the O O
final O O
exercise O O
period O O
, O O
S O O
- O O
I O O
and O O
E O O
- O O
I O O
animals O O
received O O
a O O
single O O
subcutaneous O O
injection O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
250 O O
mg O O
/ O O
kg O O
body O O
weight O O
) O O
. O O

Animals O O
of O O
the O O
S O O
- O O
I O O
group O O
exhibited O O
significantly O O
( O O
Pp O O
less O O
than O O
0 O O
. O O
05 O O
) O O
greater O O
mortality O O
from O O
the O O
effects O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
animals O O
of O O
the O O
E O O
- O O
I O O
group O O
. O O

Serum O O
CPK O O
activity O O
for O O
E O O
- O O
I O O
animals O O
was O O
significantly O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
greater O O
than O O
for O O
animals O O
in O O
the O O
S O O
- O O
I O O
and O O
EC O O
groups O O
twenty O O
hours O O
following O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O O
. O O

No O O
statistically O O
significant O O
differences O O
were O O
observed O O
between O O
the O O
two O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
groups O O
for O O
severity O O
of O O
the O O
induced O O
lesions O O
, O O
changes O O
in O O
heart O O
weight O O
, O O
or O O
heart O O
weight O O
to O O
body O O
weight O O
ratios O O
. O O

The O O
results O O
indicated O O
that O O
exercise O O
reduced O O
the O O
mortality O O
associated O O
with O O
the O O
effects O O
of O O
large O O
dosages O O
of O O
isoproterenol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
had O O
little O O
on O O
the O O
severity O O
of O O
the O O
infarction O O
. O O

Human O O
corticotropin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
and O O
thyrotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
modulate O O
the O O
hypercapnic O O
ventilatory O O
response O O
in O O
humans O O
. O O

Human O O
corticotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
( O O
hCRH O O
) O O
and O O
thyrotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
releasing O O
hormone O O
( O O
TRH O O
) O O
are O O
known O O
to O O
stimulate O O
ventilation O O
after O O
i O O
. O O
v O O
. O O
administration O O
in O O
humans O O
. O O

In O O
a O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
, O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
aimed O O
to O O
clarify O O
if O O
both O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O O
by O O
altering O O
central O B_DISEASE
chemosensitivity O I_DISEASE
. O O

Two O O
subsequent O O
CO2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
rebreathing O O
tests O O
were O O
performed O O
in O O
healthy O O
young O O
volunteers O O
. O O

During O O
the O O
first O O
test O O
0 O O
. O O
9 O O
% O O
NaCl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
given O O
i O O
. O O
v O O
. O O
; O O
during O O
the O O
second O O
test O O
200 O O
micrograms O O
of O O
hCRH O O
( O O
n O O
= O O
12 O O
) O O
or O O
400 O O
micrograms O O
of O O
TRH O O
( O O
n O O
= O O
6 O O
) O O
was O O
administered O O
i O O
. O O
v O O
. O O
Nine O O
subjects O O
received O O
0 O O
. O O
9 O O
% O O
NaCl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i O O
. O O
v O O
. O O
during O O
both O O
rebreathing O O
manoeuvres O O
. O O

The O O
CO2 B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
response O O
curves O O
for O O
the O O
two O O
tests O O
were O O
compared O O
within O O
the O O
same O O
subject O O
. O O

In O O
the O O
hCRH O O
group O O
a O O
marked O O
parallel O O
shift O O
of O O
the O O
CO2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
response O O
curve O O
to O O
the O O
left O O
was O O
observed O O
after O O
hCRH O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

The O O
same O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
following O O
TRH O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O O
was O O
less O O
striking O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

hCRH O O
and O O
TRH O O
caused O O
a O O
reduction O O
in O O
the O O
CO2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
threshold O O
. O O

The O O
CO2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
response O O
curves O O
in O O
the O O
control O O
group O O
were O O
nearly O O
identical O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
an O O
additive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
both O O
releasing O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
hypercapnic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
response O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
humans O B_SPECIES[BIO]/B_DISEASE
, O O
presumably O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemosensitivity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
effective O O
in O O
suppressing O O
hepatitis O O
B O O
virus O O
DNA O O
in O O
Chinese O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antigen I I_DISEASE
carriers O O
: O O
a O O
placebo O O
- O O
controlled O O
trial O O
. O O

Lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
novel O O
2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dideoxy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analogue O O
that O O
has O O
potent O O
inhibitory O O
effects O O
on O O
hepatitis O O
B O O
virus O O
replication O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
performed O O
a O O
single O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
to O O
assess O O
its O O
effectiveness O O
and O O
safety O O
in O O
Chinese O O
hepatitis B B_DISEASE
B I I_DISEASE
surface I I_DISEASE
antigen I I_DISEASE
( O O
HBsAg B B_DISEASE/B_GENE
) O O
carriers O O
. O O

Forty O O
- O O
two O O
Chinese O O
HBsAg B B_DISEASE
carriers O O
were O O
randomized O O
to O O
receive O O
placebo O O
( O O
6 O O
patients O O
) O O
or O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orally O O
in O O
dosages O O
of O O
25 O O
mg O O
, O O
100 O O
mg O O
, O O
or O O
300 O O
mg O O
daily O O
( O O
12 O O
patients O O
for O O
each O O
dosage O O
) O O
. O O

The O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
given O O
for O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
patients O B_PERSON/B_BIO
were O O
closely O O
monitored O O
clinically O O
, O O
biochemically O O
, O O
and O O
serologically O O
up O O
to O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

All O O
36 O O
patients O O
receiving O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
decrease O O
in O O
hepatitis O O
B O O
virus O O
( O O
HBV O O
) O O
DNA O O
values O O
of O O
> O O
90 O O
% O O
( O O
P O O
< O O
. O O
001 O O
compared O O
with O O
placebo O O
) O O
. O O

Although O O
25 O O
mg O O
of O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
slightly O O
less O O
effective O O
than O O
100 O O
mg O O
( O O
P O O
= O O
. O O
011 O O
) O O
and O O
300 O O
mg O O
( O O
P O O
= O O
. O O
005 O O
) O O
, O O
it O O
still O O
induced O O
94 O O
% O O
suppression O O
of O O
HBV O O
DNA O O
after O O
the O O
fourth O O
week O O
of O O
therapy O O
. O O

HBV O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O O
to O O
pretreatment O B_MEASURE/B_PERSON
levels O I_MEASURE/I_PERSON
within O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
of O O
cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

There O O
was O O
no O O
change O B_MEASURE
in O O
the O O
hepatitis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
e O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
status O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
in O O
aminotransferase O B_DISEASE
levels O I_DISEASE
. O O

No O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
. O O

In O O
conclusion O O
, O O
a O O
4 O O
- O O
week O O
course O O
of O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
safe O O
and O O
effective O O
in O O
suppression O O
of O O
HBV O O
DNA O O
in O O
Chinese O O
HBsAg B B_DISEASE/B_PERSON
carriers O O
. O O

The O O
suppression O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
> O B_DISEASE_ADJECTIVE[DISEASE]
90 O I_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Studies O O
with O O
long O O
- O O
term O O
lamivudine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
should O O
be O O
performed O O
to O O
determine O O
if O O
prolonged O O
suppression O O
of O O
HBV O O
DNA O O
can O O
be O O
achieved O O
. O O

Population O O
- O O
based O O
study O O
of O O
risk O O
of O O
venous O O
thromboembolism O O
associated O O
with O O
various O O
oral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contraceptives I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O O
: O O
Four O O
studies O O
published O O
since O O
December O O
, O O
1995 O O
, O O
reported O O
that O O
the O O
incidence O O
of O O
venous O O
thromboembolism O O
( O O
VTE O O
) O O
was O O
higher O O
in O O
women O O
who O O
used O O
oral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contraceptives I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
OCs B B_LOCATION/B_ORGANIZATION
) O O
containing O O
the O O
third O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gestodene B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O O
in O O
users O O
of O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
containing O O
second O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
confounding O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
bias O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
design O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
have O O
affected O O
the O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
re O O
- O O
examine O O
the O O
association O O
between O O
risk O O
of O O
VTE O O
and O O
OC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
with O O
a O O
different O O
study O O
design O O
and O O
analysis O O
to O O
avoid O O
some O O
of O O
the O O
bias O O
and O O
confounding O O
of O O
the O O
earlier O O
studies O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
used O O
computer O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
143 O B_LOCATION/B_PERSON
general O I_LOCATION/I_PERSON
practices O I_LOCATION/I_PERSON
in O O
the O O
UK O B_LOCATION
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
based O O
on O O
the O O
medical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
about O O
540 O B_MEASURE
, O O
000 O B_TIME[MEASURE]
women O I_TIME[MEASURE]
born O O
between O O
1941 O B_MEASURE
and O O
1981 O B_MEASURE
. O O

All O O
women O B_PERSON
who O O
had O O
a O O
recorded O O
diagnosis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
deep O B_LOCATION/B_DISEASE
- O O
vein O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thrombosis O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
venous O B_DISEASE
thrombosis O I_DISEASE
not O O
otherwise O O
specified O O
, O O
or O O
pulmonary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
embolus O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
and O O
who O O
had O O
been O O
treated O O
with O O
an O O
anticoagulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
identified O O
as O O
potential O B_PERSON/B_DISEASE
cases O I_PERSON/I_DISEASE
of O O
VTE O B_DISEASE
. O O

We O O
did O O
a O O
cohort O O
analysis O O
to O O
estimate O O
and O O
compare O O
incidence O O
of O O
VTE O O
in O O
users O O
of O O
the O O
main O O
OC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O O
, O O
and O O
a O O
nested O O
case O O
- O O
control O O
study O O
to O O
calculate O O
the O O
odds O O
ratios O O
of O O
VTE O O
associated O O
with O O
use O O
of O O
different O O
types O O
of O O
OC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
after O O
adjustment O O
for O O
potential O O
confounding O O
factors O O
. O O

In O O
the O O
case O O
- O O
control O O
study O O
, O O
we O O
matched O O
cases O O
to O O
controls O O
by O O
exact O O
year O O
of O O
birth O O
, O O
practice O O
, O O
and O O
current O O
use O O
of O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
used O O
a O O
multiple O O
logistic O O
regression O O
model O O
that O O
included O O
body O O
- O O
mass O O
index O O
, O O
number O O
of O O
cycles O O
, O O
change O O
in O O
type O O
of O O
OC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prescribed O O
within O O
3 O O
months O O
of O O
the O O
event O O
, O O
previous O O
pregnancy O O
, O O
and O O
concurrent O O
disease O O
. O O

FINDINGS O O
: O O
85 O O
women O O
met O O
the O O
inclusion O O
criteria O O
for O O
VTE O O
, O O
two O O
of O O
whom O O
were O O
users O O
of O O
progestagen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
only O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Of O O
the O O
83 O O
cases O O
of O O
VTE O O
associated O O
with O O
use O O
of O O
combined O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
43 O O
were O O
recorded O O
as O O
deep O O
- O O
vein O O
thrombosis O O
, O O
35 O O
as O O
pulmonary O O
thrombosis O O
, O O
and O O
five O O
as O O
venous O O
thrombosis O O
not O O
otherwise O O
specified O O
. O O

The O O
crude O O
rate O O
of O O
VTE O O
per O O
10 O O
, O O
000 O O
woman O O
- O O
years O O
was O O
4 O O
. O O
10 O O
in O O
current O O
users O O
of O O
any O O
OC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
3 O O
. O O
10 O O
in O O
users O O
of O O
second O O
- O O
generation O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
4 O O
. O O
96 O O
in O O
users O O
of O O
third O O
- O O
generation O O
preparations O O
. O O

After O O
adjustment O O
for O O
age O O
, O O
the O O
rate O O
ratio O O
of O O
VTE O O
in O O
users O O
of O O
third O O
- O O
generation O O
relative O O
to O O
second O O
- O O
generation O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
1 O O
. O O
68 O O
( O O
95 O O
% O O
CI O O
1 O O
. O O
04 O O
- O O
2 O O
. O O
75 O O
) O O
. O O

Logistic O O
regression O O
showed O O
no O O
significant O O
difference O O
in O O
the O O
risk O O
of O O
VTE O O
between O O
users O O
of O O
third O O
- O O
generation O O
and O O
second O O
- O O
generation O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Among O O
users O O
of O O
third O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
risk O O
of O O
VTE O O
was O O
higher O O
in O O
users O O
of O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
20 O O
g O O
ethinyloestradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O O
in O O
users O O
of O O
gestodene B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
30 O O
g O O
ethinyloestradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

With O O
all O O
second O O
- O O
generation O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
reference O O
, O O
the O O
odds O O
ratios O O
for O O
VTE O O
were O O
3 O O
. O O
49 O O
( O O
1 O O
. O O
21 O O
- O O
10 O O
. O O
12 O O
) O O
for O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
20 O O
g O O
ethinyloestradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
1 O O
. O O
18 O O
( O O
0 O O
. O O
66 O O
- O O
2 O O
. O O
17 O O
) O O
for O O
the O O
other O O
third O O
- O O
generation O O
progestagens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

INTERPRETATION O O
: O O
The O O
previously O O
reported O O
increase O O
in O O
odds O O
ratio O O
associated O O
with O O
third O O
- O O
generation O O
OCs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
compared O O
with O O
second O O
- O O
generation O O
products O O
is O O
likely O O
to O O
have O O
been O O
the O O
result O O
of O O
residual O O
confounding O O
by O O
age O O
. O O

The O O
increased O O
odds O O
ratio O O
associated O O
with O O
products O O
containing O O
20 O O
micrograms O O
ethinyloestradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
desogestrel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
with O O
the O O
30 O O
micrograms O O
product O O
is O O
biologically O O
implausible O O
, O O
and O O
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
preferential O O
prescribing O O
and O O
, O O
thus O O
, O O
confounding O O
. O O

MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
augments O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
electrographic O O
seizure O O
but O O
protects O O
against O O
brain O O
damage O O
in O O
rats O O
. O O

1 O B_NUMBER[MEASURE]
. O O

The O O
authors O O
examined O O
the O O
anticonvulsant O O
effects O O
of O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
seizure O O
model O O
. O O

Intraperitoneal O O
injection O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
400 O O
mg O O
/ O O
kg O O
) O O
induced O O
tonic O O
and O O
clonic O O
seizure O O
. O O

Scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
10 O O
mg O O
/ O O
kg O O
) O O
and O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
/ O O
kg O O
) O O
prevented O O
development O O
of O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
behavioral O O
seizure O O
but O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
) O O
did O O
not O O
. O O

2 O B_NUMBER[MEASURE]
. O O

An O O
electrical O O
seizure O O
measured O O
with O O
hippocampal O O
EEG O O
appeared O O
in O O
the O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
group O O
. O O

Scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
the O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
electrographic O O
seizure O O
, O O
MK B B_LOCATION
- I I_LOCATION
801 I I_LOCATION
treatment O O
augmented O O
the O O
electrographic O O
seizure O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

3 O B_NUMBER[MEASURE]
. O O

Brain O B_DISEASE_ADJECTIVE[DISEASE]
damage O I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
by O O
examining O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
microscopically O O
. O O

Pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O O
neuronal O O
death O O
in O O
the O O
hippocampus O O
, O O
which O O
showed O O
pyknotic O O
changes O O
. O O

Pentobarbital B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
scopolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protected O O
the O O
brain O O
damage O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
though O O
in O O
the O O
MK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
group O O
, O O
the O O
pyramidal O O
cells O O
of O O
hippocampus O O
appeared O O
darker O O
than O O
normal O O
. O O

In O O
all O O
treatments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
granule O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
dentate O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
gyrus O I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
were O O
not O O
affected O O
. O O

4 O B_NUMBER[MEASURE]
. O O

These O O
results O O
indicate O O
that O O
status O O
epilepticus O O
induced O O
by O O
pilocarpine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
initiated O O
by O O
cholinergic O O
overstimulation O O
and O O
propagated O O
by O O
glutamatergic O O
transmission O O
, O O
the O O
elevation O O
of O O
which O O
may O O
cause O O
brain O O
damage O O
through O O
an O O
excitatory O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
- O O
mediated O O
mechanism O O
. O O

Paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
metastatic O O
breast O O
cancer O O
: O O
BRE O O
- O O
26 O O
, O O
a O O
phase O O
II O O
trial O O
. O O

5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Taxol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
are O O
effective O O
salvage O O
therapies O O
for O O
metastatic O O
breast O O
cancer O O
patients O O
. O O

Paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
additive O O
cytotoxicity O O
in O O
MCF O O
- O O
7 O O
cell O O
lines O O
. O O

We O O
performed O O
a O O
phase O O
II O O
trial O O
of O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 O O
mg O O
/ O O
m2 O O
over O O
3 O O
hours O O
on O O
day O O
I O O
followed O O
by O O
folinic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O O
mg O O
over O O
1 O O
hour O O
before O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
350 O O
mg O O
/ O O
m2 O O
on O O
days O O
1 O O
to O O
3 O O
every O O
28 O O
days O O
( O O
TFL O O
) O O
in O O
women O O
with O O
metastatic O O
breast O O
cancer O O
. O O

Analysis O O
is O O
reported O O
on O O
37 O O
patients O O
with O O
a O O
minimum O O
of O O
6 O O
months O O
follow O O
- O O
up O O
who O O
received O O
a O O
total O O
of O O
192 O O
cycles O O
of O O
TFL O O
: O O
nine O O
cycles O O
( O O
5 O O
% O O
) O O
were O O
associated O O
with O O
grade O O
3 O O
/ O O
4 O O
neutropenia O O
requiring O O
hospitalization O O
; O O
seven O O
( O O
4 O O
% O O
) O O
cycles O O
in O O
two O O
patients O O
required O O
granulocyte B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
colony I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulating I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
neutropenia O O
; O O
no O O
patient O O
required O O
platelet O O
transfusions O O
. O O

Grade O B_MEASURE/B_PROTEIN[GENE]
3 O I_MEASURE/I_PROTEIN[GENE]
/ O O
4 O B_MEASURE
nonhematologic O I_MEASURE
toxicities O I_MEASURE
were O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Among O O
the O O
34 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
evaluable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
there O O
were O O
three O B_MEASURE
complete O I_MEASURE
responses O I_MEASURE
( O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
18 O B_NUMBER[MEASURE]
partial O I_NUMBER[MEASURE]
responses O I_NUMBER[MEASURE]
( O O
53 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
for O O
an O O
overall O B_MEASURE
response O I_MEASURE
rate O I_MEASURE
of O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Of O O
the O O
19 O O
evaluable O O
patients O O
with O O
prior O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O O
, O O
11 O O
( O O
58 O O
% O O
) O O
responded O O
compared O O
with O O
nine O O
of O O
15 O O
( O O
60 O O
% O O
) O O
without O O
prior O O
doxorubicin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Plasma O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O O
were O O
measured O O
at O O
the O O
completion O O
of O O
paclitaxel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion O O
and O O
at O O
24 O O
hours O O
in O O
19 O O
patients O O
. O O

TFL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
active O B_DISEASE_ADJECTIVE[DISEASE]
, O O
well O O
- O O
tolerated O O
regimen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
metastatic O B_DISEASE/B_BIO
breast O I_DISEASE/I_BIO
cancer O I_DISEASE/I_BIO
. O O

Efficacy O O
and O O
proarrhythmia O O
with O O
the O O
use O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
sustained O O
ventricular O O
tachyarrhythmias O O
. O O

This O O
study O O
prospectively O O
evaluated O O
the O O
clinical O O
efficacy O O
, O O
the O O
incidence O O
of O O
torsades O O
de O O
pointes O O
, O O
and O O
the O O
presumable O O
risk O O
factors O O
for O O
torsades O O
de O O
pointes O O
in O O
patients O O
treated O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
sustained O O
ventricular O O
tachyarrhythmias O O
. O O

Eighty O O
- O O
one O O
consecutive O O
patients O O
( O O
54 O O
with O O
coronary O O
artery O O
disease O O
, O O
and O O
20 O O
with O O
dilated O O
cardiomyopathy O O
) O O
with O O
inducible O O
sustained O O
ventricular O O
tachycardia O O
or O O
ventricular O O
fibrillation O O
received O O
oral O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
prevent O O
induction O O
of O O
the O O
ventricular O O
tachyarrhythmia O O
. O O

During O O
oral O O
loading O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
continuous O O
electrocardiographic O O
( O O
ECG O O
) O O
monitoring O O
was O O
performed O O
. O O

Those O O
patients O O
in O O
whom O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevented O O
induction O O
of O O
ventricular O O
tachycardia O O
or O O
ventricular O O
fibrillation O O
were O O
discharged O O
with O O
the O O
drug O O
and O O
followed O O
up O O
on O O
an O O
outpatient O O
basis O O
for O O
21 O O
+ O O
/ O O
- O O
18 O O
months O O
. O O

Induction O O
of O O
the O O
ventricular O O
tachyarrhythmia O O
was O O
prevented O O
by O O
oral O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
35 O O
( O O
43 O O
% O O
) O O
patients O O
; O O
the O O
ventricular O O
tachyarrhythmia O O
remained O O
inducible O O
in O O
40 O O
( O O
49 O O
% O O
) O O
patients O O
; O O
and O O
two O O
( O O
2 O O
. O O
5 O O
% O O
) O O
patients O O
did O O
not O O
tolerate O O
even O O
40 O O
mg O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O O
daily O O
. O O

Four O O
( O O
5 O O
% O O
) O O
patients O O
had O O
from O O
torsades O O
de O O
pointes O O
during O O
the O O
initial O O
oral O O
treatment O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neither O O
ECG O B_DISEASE/B_MEASURE
[ O I_DISEASE/I_MEASURE
sinus O I_DISEASE/I_MEASURE
- O O
cycle O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
( O O
SCL O B_LOCATION/B_DISEASE
) O O
, O O
QT O B_MEASURE/B_PROTEIN[GENE]
or O O
QTc O B_LOCATION/B_ORGANIZATION
interval O I_LOCATION/I_ORGANIZATION
, O O
or O O
U O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wave O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nor O O
clinical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
identified O O
patients O B_PERSON/B_LOCATION
at O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
torsades O B_DISEASE
de O I_DISEASE
pointes O I_DISEASE
. O O

However O O
, O O
the O O
oral O O
dose O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
lower O O
in O O
patients O O
with O O
torsades O O
de O O
pointes O O
( O O
200 O O
+ O O
/ O O
- O O
46 O O
vs O O
. O O
328 O O
+ O O
/ O O
- O O
53 O O
mg O O
/ O O
day O O
; O O
p O O
= O O
0 O O
. O O
0017 O O
) O O
. O O

Risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
torsades O B_DISEASE
de O I_DISEASE
pointes O I_DISEASE
were O O
the O O
appearance O B_PERSON/B_DISEASE
of O O
an O O
U O B_DISEASE
wave O I_DISEASE
( O O
p O O
= O O
0 O B_MEASURE
. O O
049 O B_MEASURE
) O O
, O O
female O B_DISEASE
gender O I_DISEASE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
015 O B_MEASURE
) O O
, O O
and O O
significant O B_MEASURE/B_DISEASE
dose O I_MEASURE/I_DISEASE
- O O
corrected O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
SCL O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
QT O B_LOCATION/B_PROTEIN[GENE]
interval O I_LOCATION/I_PROTEIN[GENE]
, O O
and O O
QTc O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

During O O
follow O O
- O O
up O O
, O O
seven O B_NUMBER[MEASURE]
( O O
20 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
) O O
patients O B_PERSON
had O O
a O O
nonfatal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recurrence O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
two O B_NUMBER[MEASURE]
( O O
6 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
patients O B_PERSON
died O O
suddenly O O
. O O

One O O
female O O
patient O O
with O O
stable O O
cardiac O O
disease O O
had O O
recurrent O O
torsades O O
de O O
pointes O O
after O O
2 O O
years O O
of O O
successful O O
treatment O O
with O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Torsades O O
de O O
pointes O O
occurred O O
early O O
during O O
treatment O O
even O O
with O O
low O O
doses O O
of O O
oral O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pronounced O O
changes O O
in O O
the O O
surface O O
ECG O O
( O O
cycle O O
length O O
, O O
QT O O
, O O
and O O
QTc O O
) O O
in O O
relation O O
to O O
the O O
dose O O
of O O
oral O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
identify O O
a O O
subgroup O O
of O O
patients O O
with O O
an O O
increased O O
risk O O
for O O
torsades O O
de O O
pointes O O
. O O

Other O O
ECG O O
parameters O O
before O O
the O O
application O O
of O O
d B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
l I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sotalol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O O
not O O
identify O O
patients O O
at O O
increased O O
risk O O
for O O
torsades O O
de O O
pointes O O
. O O

Recurrence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
ventricular O B_DISEASE
tachyarrhythmias O I_DISEASE
are O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
despite O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suppression O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
arrhythmia O B_DISEASE
during O O
programmed O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Therefore O O
programmed O O
electrical O O
stimulation O O
in O O
the O O
case O O
of O O
d B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O O
to O O
be O O
of O O
limited O O
prognostic O O
value O O
. O O

Chronic O O
hyperprolactinemia O O
and O O
changes O O
in O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurons O O
. O O

The O O
tuberoinfundibular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIDA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
known O O
to O O
inhibit O O
prolactin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
PRL O B_PROTEIN[GENE]/B_LOCATION
) O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
young O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
this O O
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
responds O O
to O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
elevations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PRL O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
increasing O O
its O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

However O O
, O O
this O O
responsiveness O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
lost O O
in O O
aging O O
rats O B_BIO/B_PERSON
with O O
chronically O O
high O B_DISEASE
serum O I_DISEASE
PRL O I_DISEASE
levels O I_DISEASE
. O O

The O O
purpose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
induce O O
hyperprolactinemia O B_DISEASE
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
extended O B_TIME[MEASURE]/B_LOCATION
periods O I_TIME[MEASURE]/I_LOCATION
of O O
time O B_TIME[MEASURE]
and O O
examine O O
its O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
dopaminergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Hyperprolactinemia O O
was O O
induced O O
by O O
treatment O O
with O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O O
antagonist O O
, O O
and O O
Palkovits O O
' O O
microdissection O O
technique O O
in O O
combination O O
with O O
high O O
- O O
performance O O
liquid O O
chromatography O O
was O O
used O O
to O O
measure O O
neurotransmitter O O
concentrations O O
in O O
several O O
areas O O
of O O
the O O
brain O O
. O O

After O O
6 O O
months O O
of O O
hyperprolactinemia O O
, O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DA B B_LOCATION
) O O
concentrations O O
in O O
the O O
median O O
eminence O O
( O O
ME O O
) O O
increased O O
by O O
84 O O
% O O
over O O
the O O
control O O
group O O
. O O

Nine O O
months O O
of O O
hyperprolactinemia O O
produced O O
a O O
50 O O
% O O
increase O O
in O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O O
in O O
the O O
ME O O
over O O
the O O
control O O
group O O
. O O

However O O
, O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
response O O
was O O
lost O O
if O O
a O O
9 O O
- O O
month O O
long O O
haloperidol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hyperprolactinemia O O
was O O
followed O O
by O O
a O O
1 O O
1 O O
/ O O
2 O O
month O O
- O O
long O O
extremely O O
high O O
increase O O
in O O
serum O O
PRL O O
levels O O
produced O O
by O O
implantation O O
of O O
MMQ O O
cells O O
under O O
the O O
kidney O O
capsule O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
levels O O
of O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
norepinephrine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
NE B B_LOCATION/B_ORGANIZATION
) O O
, O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 B B_LOCATION
- I I_LOCATION
HT I I_LOCATION
) O O
, O O
or O O
their O O
metabolites O O
in O O
the O O
arcuate O O
nucleus O O
( O O
AN O O
) O O
, O O
medial O O
preoptic O O
area O O
( O O
MPA O O
) O O
, O O
caudate O O
putamen O O
( O O
CP O O
) O O
, O O
substantia O O
nigra O O
( O O
SN O O
) O O
, O O
and O O
zona O O
incerta O O
( O O
ZI O O
) O O
, O O
except O O
for O O
a O O
decrease O O
in O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxyindoleacetic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
5 B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
HIAA I I_LOCATION/I_ORGANIZATION
) O O
in O O
the O O
AN O O
after O O
6 O O
- O O
months O O
of O O
hyperprolactinemia O O
and O O
an O O
increase O O
in O O
DA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations O O
in O O
the O O
AN O O
after O O
9 O O
- O O
months O O
of O O
hyperprolactinemia O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O O
that O O
hyperprolactinemia O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
affects O O
TIDA O B_DISEASE/B_GENE
neurons O B_DISEASE/I_GENE
and O O
these O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vary O O
, O O
depending O O
on O O
the O O
duration O B_MEASURE/B_LOCATION
and O O
intensity O B_MEASURE/B_LOCATION
of O O
hyperprolactinemia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
age O O
- O O
related O O
decrease O O
in O O
hypothalamic O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O O
may O O
be O O
associated O O
with O O
increases O O
in O O
PRL O O
secretion O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
disseminated O O
necrotizing O B_DISEASE
leukoencephalopathy O I_DISEASE
with O O
characteristic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contrast O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enhancement O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
white O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
report O O
describes O O
unique O O
contrast O O
enhancement O O
of O O
the O O
white O O
matter O O
on O O
T1 O O
- O O
weighted O O
magnetic O O
resonance O O
images O O
of O O
two O O
patients O O
with O O
disseminated O O
necrotizing O O
leukoencephalopathy O O
, O O
which O O
developed O O
from O O
acute O O
lymphoblastic O O
leukemia O O
treated O O
with O O
high O O
- O O
dose O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
both O O
patients O B_PERSON/B_LOCATION
, O O
the O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]
was O O
more O O
pronounced O O
near O O
the O O
base O B_LOCATION/B_MEASURE
of O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
than O O
at O O
the O O
vertex O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Necropsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
first O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
loss O B_DISEASE_ADJECTIVE[DISEASE]
of O O
myelination O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
necrosis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
white O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Possible O B_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]
causing O O
such O O
a O O
leukoencephalopathy O B_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

Thrombotic O O
complications O O
in O O
acute O O
promyelocytic O O
leukemia O O
during O O
all B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
. O O

A O O
case O O
of O O
acute O O
renal O O
failure O O
, O O
due O O
to O O
occlusion O O
of O O
renal O O
vessels O O
in O O
a O O
patient O O
with O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
treated O O
with O O
all B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATRA B B_ORGANIZATION/B_LOCATION
) O O
and O O
tranexamic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
described O O
recently O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
renal O O
failure O O
in O O
an O O
APL O O
patient O O
treated O O
with O O
ATRA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
. O O

This O O
case O O
further O O
supports O O
the O O
concern O O
about O O
thromboembolic O O
complications O O
associated O O
with O O
ATRA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
in O O
APL O O
patients O O
. O O

The O O
patients O O
, O O
a O O
43 O O
- O O
year O O
- O O
old O O
man O O
, O O
presented O O
all O O
the O O
signs O O
and O O
symptoms O O
of O O
APL O O
and O O
was O O
included O O
in O O
a O O
treatment O O
protocol O O
with O O
ATRA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
10 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
he O O
developed O O
acute O B_DISEASE
renal O I_DISEASE
failure O I_DISEASE
that O O
was O O
completely O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]
after O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
APL O B_DISEASE
was O O
achieved O O
and O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discontinued O O
. O O

We O O
conclude O O
that O O
ATRA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
valid O O
therapeutic O O
choice O O
for O O
patients O O
with O O
APL O O
, O O
although O O
the O O
procoagulant O O
tendency O O
is O O
not O O
completely O O
corrected O O
. O O

Thrombotic O O
events O O
, O O
however O O
, O O
could O O
be O O
avoided O O
by O O
using O O
low O O
- O O
dose O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pupillary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
stimulant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
mania O B_DISEASE/B_LOCATION
: O O
a O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

A O O
30 O O
- O O
year O O
- O O
old O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
man O O
who O O
was O O
a O O
subject O O
in O O
a O O
study O O
evaluating O O
the O O
anticraving O O
efficacy O O
of O O
the O O
stimulant O O
medication O O
diethylpropion B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DEP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
became O O
manic O O
during O O
his O O
second O O
week O O
on O O
the O O
study O O
drug O O
. O O

Pupillometric O O
changes O O
while O O
on O O
DEP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
changes O O
in O O
the O O
total O O
power O O
of O O
pupillary O O
oscillation O O
, O O
were O O
dramatically O O
different O O
than O O
those O O
observed O O
in O O
the O O
eight O O
other O O
study O O
subjects O O
who O O
did O O
not O O
become O O
manic O O
. O O

The O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
total O B_MEASURE/B_LOCATION
power O I_MEASURE/I_LOCATION
of O O
pupillary O B_DISEASE/B_PROTEIN[GENE]
oscillation O B_DISEASE/I_PROTEIN[GENE]
occurred O O
a O O
few O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
before O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
became O O
fully O O
manic O B_DISEASE/B_PERSON
. O O

Such O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
medication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
associated O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
total O B_MEASURE
power O I_MEASURE
of O O
pupillary O B_DISEASE/B_PROTEIN[GENE]
oscillation O B_DISEASE/I_PROTEIN[GENE]
might O O
be O O
of O O
utility O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
identifying O O
persons O B_PERSON/B_LOCATION
at O O
risk O B_DISEASE_ADJECTIVE[DISEASE]
for O O
manic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
medical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
psychomotor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
sympathomimetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Fetal O O
risks O O
due O O
to O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
during O O
pregnancy O O
. O O

Two O O
mothers O O
with O O
heart O O
valve O O
prosthesis O O
were O O
treated O O
with O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
pregnancy O O
. O O

In O O
the O O
first O O
case O O
a O O
caesarean O O
section O O
was O O
done O O
one O O
week O O
after O O
replacement O O
of O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
baby O B_PERSON
died O O
of O O
cerebral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
pulmonary O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
second O B_PERSON/B_LOCATION
mother O I_PERSON/I_LOCATION
had O O
a O O
male O B_PERSON
infant O I_PERSON
by O O
caesarean O B_TIME[MEASURE]/B_PERSON
section O B_TIME[MEASURE]/I_PERSON
. O O

The O O
baby O O
showed O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
embryopathy O O
with O O
nasal O O
hypoplasia O O
and O O
stippled O O
epiphyses O O
( O O
chondrodysplasia O O
punctata O O
) O O
. O O

Nasal O O
hypoplasia O O
with O O
or O O
without O O
stippled O O
epiphyses O O
has O O
now O O
been O O
reported O O
in O O
11 O O
infants O O
born O O
to O O
mothers O O
treated O O
with O O
warfarin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
first O O
trimester O O
, O O
and O O
a O O
causal O O
association O O
is O O
probable O O
. O O

In O O
view O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
risks O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
both O O
mother O B_PERSON/B_BIO
and O O
fetus O B_PERSON
in O O
women O B_PERSON
with O O
prosthetic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valves O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
it O O
is O O
recommended O O
that O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abortion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
be O O
advised O O
as O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
separating O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
peripheral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
man O B_PERSON/B_BIO
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
wanted O O
to O O
test O O
whether O O
assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
both O O
a O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
related O O
signal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
chemo O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
somatosensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O O
potential O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
CSSEP O B_LOCATION/B_DISEASE
) O O
and O O
a O O
concomitantly O O
recorded O O
peripheral O B_DISEASE/B_MEASURE
signal O I_DISEASE/I_MEASURE
( O O
negative O B_LOCATION
mucosal O I_LOCATION
potential O I_LOCATION
, O O
NMP O B_LOCATION/B_DISEASE
) O O
allows O O
for O O
separation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
peripheral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

For O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
experimental O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
created O O
in O O
which O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O O
previously O O
been O O
observed O O
to O O
produce O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
phasic O B_DISEASE_ADJECTIVE[DISEASE]
and O O
tonic O B_DISEASE/B_ORGANISM_FUNCTION
pain O I_DISEASE/I_ORGANISM_FUNCTION
by O O
either O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

METHODS O O
: O O
According O O
to O O
a O O
double O O
- O O
blind O O
, O O
randomised O O
, O O
controlled O O
, O O
threefold O O
cross O O
- O O
over O O
design O O
, O O
18 O O
healthy O O
subjects O O
( O O
11 O O
males O O
, O O
7 O O
females O O
; O O
mean O O
age O O
26 O O
years O O
) O O
received O O
either O O
placebo O O
, O O
400 O O
mg O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
800 O O
mg O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Phasic O O
pain O O
was O O
applied O O
by O O
means O O
of O O
short O O
pulses O O
of O O
CO2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
nasal O O
mucosa O O
( O O
stimulus O O
duration O O
500 O O
ms O O
, O O
interval O O
approximately O O
60 O O
s O O
) O O
, O O
and O O
tonic O O
pain O O
was O O
induced O O
in O O
the O O
nasal O O
cavity O O
by O O
means O O
of O O
dry O O
air O O
of O O
controlled O O
temperature O O
, O O
humidity O O
and O O
flow O O
rate O O
( O O
22 O O
degrees O O
C O O
, O O
0 O O
% O O
relative O O
humidity O O
, O O
145 O O
ml O O
. O O
s O O
- O O
1 O O
) O O
. O O

Both O O
CSSEPs O O
as O O
central O O
and O O
NMPs O O
as O O
peripheral O O
correlates O O
of O O
pain O O
were O O
obtained O O
in O O
response O O
to O O
the O O
CO2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimuli O O
. O O

Additionally O O
, O O
the O O
subjects O B_PERSON/B_ORGANIZATION
rated O O
the O O
intensity O B_MEASURE
of O O
both O O
phasic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
tonic O B_DISEASE
pain O I_DISEASE
by O O
means O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
visual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogue O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scales O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

RESULTS O O
: O O
As O O
described O O
earlier O O
, O O
administration O O
of O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
followed O O
by O O
a O O
decrease O O
in O O
tonic O O
pain O O
but O O
- O O
relative O O
to O O
placebo O O
- O O
an O O
increase O O
in O O
correlates O O
of O O
phasic O O
pain O O
, O O
indicating O O
a O O
specific O O
effect O O
of O O
ibuprofen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
interaction O O
between O O
the O O
pain O O
stimuli O O
under O O
these O O
special O O
experimental O O
conditions O O
. O O

Based O O
on O O
the O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behaviour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
CSSEP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NMP O B_DISEASE
, O O
it O O
was O O
concluded O O
that O O
the O O
pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underlying O O
this O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
localised O O
in O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
simultaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recording O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interrelated O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
electrophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
correlates O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
nociception O B_DISEASE
, O O
it O O
was O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
peripheral O B_LOCATION
effects O I_LOCATION
of O O
an O O
NSAID O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantage O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
pain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O O
the O O
possibility O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
obtaining O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
pain O I_DISEASE_ADJECTIVE[DISEASE]
- O O
related O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
directly O O
using O O
a O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
invasive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
humans O B_PERSON/B_SPECIES[BIO]
. O O

Effect O O
of O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glucarates I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
basic O O
antibiotic O O
- O O
induced O O
renal O O
damage O O
in O O
rats O O
. O O

Dehydrated O O
rats O O
regularly O O
develop O O
acute O O
renal O O
failure O O
following O O
single O O
injection O O
of O O
aminoglycoside B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O O
combined O O
with O O
dextran O O
or O O
of O O
antibiotics O O
only O O
. O O

Oral O O
administration O O
of O O
2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
5 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
di I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
O I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acetyl I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
D I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
glucaro I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dilactone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protected O O
rats O O
against O O
renal O O
failure O O
induced O O
by O O
kanamycin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
dextran O O
. O O

The O O
protective O O
effect O O
was O O
prevalent O O
among O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
glucarates I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
and O O
also O O
to O O
other O O
saccharic B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
acid I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O O
hexauronic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
hexaaldonic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acids I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
although O O
to O O
a O O
lesser O O
degree O O
, O O
but O O
not O O
to O O
a O O
hexaaldose O O
, O O
sugar B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohols I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
substances O O
inthe O O
TCA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle O O
and O O
other O O
acidic O O
compounds O O
. O O

D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Glucarates I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
effective O O
against O O
renal O O
damage O O
induced O O
by O O
peptide O O
antibiotics O O
as O O
well O O
as O O
various O O
aminoglycoside B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibitocis O O
. O O

Dose O O
- O O
responses O O
were O O
observed O O
in O O
the O O
protective O O
effect O O
of O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glucarates I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

With O O
a O O
D B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glucarate I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
a O O
fixed O O
size O O
of O O
dose O O
, O O
approximately O O
the O O
same O O
degree O O
of O O
protection O O
was O O
obtained O O
against O O
renal O O
damages O O
induced O O
by O O
different O O
basic O O
antibiotics O O
despite O O
large O O
disparities O O
in O O
administration O O
doses O O
of O O
different O O
antibiotics O O
. O O

D B B_PERSON
- I I_PERSON
Glucarates I I_PERSON
had O O
the O O
ability O O
to O O
prevent O O
renal O O
damage O O
but O O
not O O
to O O
cure O O
it O O
. O O

Rats O O
excreted O O
acidic O O
urine O O
when O O
they O O
were O O
spared O O
from O O
renal O O
lesions O O
by O O
monosaccharides B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
. O O

The O O
reduction O O
effect O O
of O O
D B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucarates I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
nephrotoxicity O O
of O O
basic O O
antibiotics O O
was O O
discussed O O
. O O

Acute O O
severe O O
depression O O
following O O
peri O O
- O O
operative O O
ondansetron B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

A O O
41 O O
- O O
year O O
- O O
old O O
woman O O
with O O
a O O
strong O O
history O O
of O O
postoperative O O
nausea O O
and O O
vomiting O O
presented O O
for O O
abdominal O O
hysterectomy O O
3 O O
months O O
after O O
a O O
previous O O
anaesthetic O O
where O O
ondansetron B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prophylaxis O O
had O O
been O O
used O O
. O O

She O O
had O O
developed O O
a O O
severe O O
acute O O
major O O
depression O O
disorder O O
almost O O
immediately O O
thereafter O O
, O O
possibly O O
related O O
to O O
the O O
use O O
of O O
a O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O O
. O O

Nine O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
before O O
she O O
had O O
experienced O O
a O O
self O B_PERSON/B_LOCATION
- O O
limited O O
puerperal O B_DISEASE
depressive O I_DISEASE
episode O I_DISEASE
. O O

Anaesthesia O O
with O O
a O O
propofol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O O
and O O
avoidance O O
of O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O O
provided O O
a O O
nausea O O
- O O
free O O
postoperative O O
course O O
without O O
exacerbation O O
of O O
the O O
depression O O
disorder O O
. O O

Hypertensive O O
response O O
during O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O O
echocardiography O O
. O O

Among O O
3 O O
, O O
129 O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O O
echocardiographic O O
studies O O
, O O
a O O
hypertensive O O
response O O
, O O
defined O O
as O O
systolic O O
blood O O
pressure O O
( O O
BP O O
) O O
> O O
or O O
= O O
220 O O
mm O O
Hg O O
and O O
/ O O
or O O
diastolic O O
BP O O
> O O
or O O
= O O
110 O O
mm O O
Hg O O
, O O
occurred O O
in O O
30 O O
patients O O
( O O
1 O O
% O O
) O O
. O O

Patients O O
with O O
this O O
response O O
more O O
often O O
had O O
a O O
history O O
of O O
hypertension O O
and O O
had O O
higher O O
resting O O
systolic O O
and O O
diastolic O O
BP O O
before O O
dobutamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O O
. O O

Continuously O O
nebulized O O
albuterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
severe O O
exacerbations O O
of O O
asthma O O
in O O
adults O O
: O O
a O O
case O O
- O O
controlled O O
study O O
. O O

A O O
retrospective O O
, O O
case O O
- O O
controlled O O
analysis O O
comparing O O
patients O O
admitted O O
to O O
a O O
medical O O
intensive O O
care O O
unit O O
with O O
severe O O
exacerbations O O
of O O
asthma O O
who O O
received O O
continuously O O
nebulized O O
albuterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CNA O O
) O O
versus O O
intermittent O O
albuterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
INA O O
) O O
treatments O O
is O O
reported O O
. O O

Forty O B_NUMBER[MEASURE]/B_LOCATION
matched O O
pairs O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
asthma O B_DISEASE/B_LOCATION
are O O
compared O O
. O O

CNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
administered O O
for O O
a O O
mean O B_MEASURE/B_LOCATION
of O O
11 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_TIME[MEASURE]
hr O I_TIME[MEASURE]
. O O

The O O
incidence O B_MEASURE
of O O
cardiac O B_DISEASE
dysrhythmias O I_DISEASE
was O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Symptomatic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypokalemia O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
occur O O
. O O

CNA O B_PERSON
patients O I_PERSON
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
heart O I_DISEASE_ADJECTIVE[DISEASE]
rates O I_DISEASE_ADJECTIVE[DISEASE]
during O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
which O O
may O O
reflect O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
illness O B_DISEASE
. O O

The O O
incidence O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intubation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
CNA O B_LOCATION/B_ORGANIZATION
and O O
INA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
demonstrated O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
safety O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
morbidity O B_DISEASE
, O O
and O O
mortality O B_DISEASE
. O O

Paraplegia O O
following O O
intrathecal O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
report O O
of O O
a O O
case O O
and O O
review O O
of O O
the O O
literature O O
. O O

A O O
patient O O
who O O
developed O O
paraplegia O O
following O O
the O O
intrathecal O O
instillation O O
of O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
discribed O O
. O O

The O O
ten O B_NUMBER[MEASURE]
previously O O
reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
unusual O B_DISEASE
complication O I_DISEASE
are O O
reviewed O O
. O O

The O O
following O O
factors O O
appear O O
to O O
predispose O O
to O O
the O O
development O O
of O O
this O O
complication O O
: O O
abnormal O O
cerebrospinal O O
dynamics O O
related O O
to O O
the O O
presence O O
of O O
central O O
nervous O O
system O O
leukemia O O
, O O
and O O
epidural O O
cerebrospinal O O
leakage O O
; O O
elevated O O
cerebrospinal O O
fluid O O
methothexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
concentration O O
related O O
to O O
abnormal O O
cerebrospinal O O
fluid O O
dynamics O O
and O O
to O O
inappropriately O O
high O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O O
based O O
on O O
body O O
surface O O
area O O
calculations O O
in O O
older O O
children O O
and O O
adults O O
; O O
the O O
presence O O
of O O
neurotoxic O O
preservatives O O
in O O
commercially O O
available O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O O
and O O
diluents O O
; O O
and O O
the O O
use O O
of O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diluents O O
of O O
unphysiologic O O
pH O O
, O O
ionic O O
content O O
and O O
osmolarity O O
. O O

The O O
role O O
of O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
contaminants O O
, O O
local O O
folate O O
deficiency O O
, O O
and O O
cranial O O
irradiation O O
in O O
the O O
pathogenesis O O
of O O
intrathecal O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O O
is O O
unclear O O
. O O

The O O
incidence O O
of O O
neurotoxicity O O
may O O
be O O
reduced O O
by O O
employing O O
lower O O
doses O O
of O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
presence O O
of O O
central O O
nervous O O
system O O
leukemia O O
, O O
in O O
older O O
children O O
and O O
adults O O
, O O
and O O
in O O
the O O
presence O O
of O O
epidural O O
leakage O O
. O O

Only O O
preservative O O
- O O
free O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Elliott O O
' O O
s O O
B O O
Solution O O
at O O
a O O
concentration O O
of O O
not O O
more O O
than O O
1 O O
mg O O
/ O O
ml O O
should O O
be O O
used O O
for O O
intrathecal O O
administration O O
. O O

Periodic O O
monitoring O O
of O O
cerebruspinal O O
fluid O O
methotrexate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
may O O
be O O
predictive O O
of O O
the O O
development O O
of O O
serious O O
neurotoxicity O O
. O O

Hyperosmolar O O
nonketotic O O
coma O O
precipitated O O
by O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
- O O
induced O O
nephrogenic O O
diabetes O O
insipidus O O
. O O

A O O
45 O O
- O O
year O O
- O O
old O O
man O O
, O O
with O O
a O O
10 O O
- O O
year O O
history O O
of O O
manic O O
depression O O
treated O O
with O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
admitted O O
with O O
hyperosmolar O O
, O O
nonketotic O O
coma O O
. O O

He O O
gave O O
a O O
five O O
- O O
year O O
history O O
of O O
polyuria O O
and O O
polydipsia O O
, O O
during O O
which O O
time O O
urinalysis O O
had O O
been O O
negative O O
for O O
glucose B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

After O O
recovery O O
from O O
hyperglycaemia O O
, O O
he O O
remained O O
polyuric O O
despite O O
normal O O
blood O O
glucose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
concentrations O O
; O O
water O O
deprivation O O
testing O O
indicated O O
nephrogenic O O
diabetes O O
insipidus O O
, O O
likely O O
to O O
be O O
lithium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
. O O

We O O
hypothesize O O
that O O
when O O
this O O
man O B_PERSON/B_BIO
developed O O
type O B_DISEASE
2 O I_DISEASE
diabetes O I_DISEASE
, O O
chronic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
polyuria O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
nephrogenic O B_DISEASE
diabetes O I_DISEASE
insipidus O I_DISEASE
was O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
precipitate O O
hyperosmolar O B_DISEASE
dehydration O I_DISEASE
. O O

Effects O O
of O O
the O O
intracoronary O O
infusion O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
left O O
ventricular O O
systolic O O
and O O
diastolic O O
function O O
in O O
humans O O
. O O

BACKGROUND O O
: O O
In O O
dogs O O
, O O
a O O
large O O
amount O O
of O O
intravenous O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O O
a O O
profound O O
deterioration O O
of O O
left O O
ventricular O O
( O O
LV O O
) O O
systolic O O
function O O
and O O
an O O
increase O O
in O O
LV O O
end O O
- O O
diastolic O O
pressure O O
. O O

This O O
study O O
was O O
done O O
to O O
assess O O
the O O
influence O O
of O O
a O O
high O O
intracoronary O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O O
on O O
LV O O
systolic O O
and O O
diastolic O O
function O O
in O O
humans O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
In O O
20 O O
patients O O
( O O
14 O O
men O O
and O O
6 O O
women O O
aged O O
39 O O
to O O
72 O O
years O O
) O O
referred O O
for O O
cardiac O O
catheterization O O
for O O
the O O
evaluation O O
of O O
chest O O
pain O O
, O O
we O O
measured O O
heart O O
rate O O
, O O
systemic O O
arterial O O
pressure O O
, O O
LV O O
pressure O O
and O O
its O O
first O O
derivative O O
( O O
dP O O
/ O O
dt O O
) O O
, O O
and O O
LV O O
volumes O O
and O O
ejection O O
fraction O O
before O O
and O O
during O O
the O O
final O O
2 O O
to O O
3 O O
minutes O O
of O O
a O O
15 O O
- O O
minute O O
intracoronary O O
infusion O O
of O O
saline O O
( O O
n O O
= O O
10 O O
, O O
control O O
subjects O O
) O O
or O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O O
mg O O
/ O O
min O O
( O O
n O O
= O O
10 O O
) O O
. O O

No O O
variable O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O O
with O O
saline O B_LOCATION/B_MEASURE
. O O

With O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
drug O O
concentration O O
in O O
blood O O
obtained O O
from O O
the O O
coronary O O
sinus O O
was O O
3 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
mg O O
/ O O
L O O
, O O
similar O O
in O O
magnitude O O
to O O
the O O
blood O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O O
reported O O
in O O
abusers O O
dying O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O O
. O O

Cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
no O O
significant O O
change O O
in O O
heart O O
rate O O
, O O
LV O O
dP O O
/ O O
dt O O
( O O
positive O O
or O O
negative O O
) O O
, O O
or O O
LV O O
end O O
- O O
diastolic O O
volume O O
, O O
but O O
it O O
caused O O
an O O
increase O O
in O O
systolic O O
and O O
mean O O
arterial O O
pressures O O
, O O
LV O O
end O O
- O O
diastolic O O
pressure O O
, O O
and O O
LV O O
end O O
- O O
systolic O O
volume O O
, O O
as O O
well O O
as O O
a O O
decrease O O
in O O
LV O O
ejection O O
fraction O O
. O O

CONCLUSIONS O O
: O O
In O O
humans O O
, O O
the O O
intracoronary O O
infusion O O
of O O
cocaine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sufficient O O
in O O
amount O O
to O O
achieve O O
a O O
high O O
drug O O
concentration O O
in O O
coronary O O
sinus O O
blood O O
causes O O
a O O
deterioration O O
of O O
LV O O
systolic O O
and O O
diastolic O O
performance O O
. O O

Ascending O O
dose O O
tolerance O O
study O O
of O O
intramuscular O O
carbetocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
administered O O
after O O
normal O O
vaginal O O
birth O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
maximum O O
tolerated O O
dose O O
( O O
MTD O O
) O O
of O O
carbetocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
a O O
long O O
- O O
acting O O
synthetic O O
analogue O O
of O O
oxytocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
when O O
administered O O
immediately O O
after O O
vaginal O O
delivery O O
at O O
term O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Carbetocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O O
given O O
as O O
an O O
intramuscular O O
injection O O
immediately O O
after O O
the O O
birth O O
of O O
the O O
infant O O
in O O
45 O O
healthy O O
women O O
with O O
normal O O
singleton O O
pregnancies O O
who O O
delivered O O
vaginally O O
at O O
term O O
. O O

Dosage O O
groups O O
of O O
15 O O
, O O
30 O O
, O O
50 O O
, O O
75 O O
, O O
100 O O
, O O
125 O O
, O O
150 O O
, O O
175 O O
or O O
200 O O
microg O O
carbetocin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
were O O
assigned O O
to O O
blocks O O
of O O
three O O
women O O
according O O
to O O
the O O
continual O O
reassessment O O
method O O
( O O
CRM O O
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
All O O
dosage O B_PERSON/B_ORGANIZATION
groups O I_PERSON/I_ORGANIZATION
consisted O O
of O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
women O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O O
except O O
those O O
with O O
100 O B_MEASURE
microg O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
6 O B_MEASURE
) O O
and O O
200 O B_MEASURE
microg O I_MEASURE
( O O
n O B_OTHER/B_MEASURE
= O O
18 O B_MEASURE
) O O
. O O

Recorded O O
were O O
dose O B_MEASURE/B_DISEASE
- O O
limiting O O
adverse O B_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
: O O
hyper O B_DISEASE/B_GENE
- O O
or O O
hypotension O B_DISEASE
( O O
three O B_NUMBER[MEASURE]
) O O
, O O
severe O B_DISEASE
abdominal O I_DISEASE
pain O I_DISEASE
( O O
0 O B_NUMBER[MEASURE]
) O O
, O O
vomiting O B_DISEASE
( O O
0 O B_NUMBER[MEASURE]
) O O
and O O
retained O B_DISEASE
placenta O I_DISEASE
( O O
four O B_NUMBER[MEASURE]
) O O
. O O

Serious O B_DISEASE/B_PERSON
adverse O I_DISEASE/I_PERSON
events O I_DISEASE/I_PERSON
occurred O O
in O O
seven O B_NUMBER[MEASURE]/B_ENT
women O I_NUMBER[MEASURE]/I_ENT
: O O
six O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
with O O
blood O B_MEASURE
loss O I_MEASURE
> O I_MEASURE
or O O
= O O
1000 O B_MEASURE
ml O I_MEASURE
, O O
four O B_NUMBER[MEASURE]
cases O I_NUMBER[MEASURE]
of O O
manual O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
placenta O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
five O B_NUMBER[MEASURE]
cases O I_NUMBER[MEASURE]
of O O
additional O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxytocics O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
five O B_TIME[MEASURE]/B_DISEASE
cases O B_TIME[MEASURE]/I_DISEASE
of O O
blood O B_DISEASE/B_ORGANISM_FUNCTION
transfusion O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Maximum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
loss O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
greatest O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O O
the O O
upper O B_MEASURE
and O O
lower O B_MEASURE/B_LOCATION
dose O B_MEASURE/I_LOCATION
levels O B_MEASURE/I_LOCATION
, O O
and O O
lowest O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
70 O B_MEASURE
- O O
125 O B_TIME[MEASURE]/B_LOCATION
microg O I_TIME[MEASURE]/I_LOCATION
dose O I_TIME[MEASURE]/I_LOCATION
range O I_TIME[MEASURE]/I_LOCATION
. O O

Four O B_NUMBER[MEASURE]
out O O
of O O
six O B_NUMBER[MEASURE]
cases O I_NUMBER[MEASURE]
with O O
blood O B_MEASURE/B_LOCATION
loss O I_MEASURE/I_LOCATION
> O I_MEASURE/I_LOCATION
or O O
= O O
1000 O B_MEASURE
ml O I_MEASURE
occurred O O
in O O
the O O
200 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microg O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
majority O B_MEASURE
of O O
additional O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxytocics O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O B_MEASURE
/ O O
5 O B_MEASURE
) O O
and O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3 O B_MEASURE
/ O O
5 O B_MEASURE
) O O
occurred O O
in O O
the O O
dose O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
200 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

All O O
retained O O
placentae O B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
in O O
the O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
200 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
microg O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSION O O
: O O
The O O
MTD O O
was O O
calculated O O
to O O
be O O
at O O
200 O O
microg O O
carbetocin B B_LOCATION
. O O

Heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
, O O
paradoxical O O
thromboembolism O O
, O O
and O O
other O O
side O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O O
the O O
drug O O
of O O
choice O O
for O O
most O O
anticoagulation O O
needs O O
. O O

The O O
clinical O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Important O O
untoward O O
effects O O
of O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
including O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
thrombocytopenia O O
, O O
heparin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
associated O O
osteoporosis O O
, O O
eosinophilia O O
, O O
skin O O
reactions O O
, O O
allergic O O
reactions O O
other O O
than O O
thrombocytopenia O O
and O O
alopecia O O
will O O
be O O
discussed O O
in O O
this O O
article O O
. O O

Nonopaque O O
crystal O O
deposition O O
causing O O
ureteric O O
obstruction O O
in O O
patients O O
with O O
HIV O O
undergoing O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

OBJECTIVE O O
: O O
We O O
describe O O
the O O
unique O O
CT O O
features O O
of O O
ureteric O O
calculi O O
in O O
six O O
HIV O O
- O O
infected O O
patients O O
receiving O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
most O O
commonly O O
used O O
HIV O O
protease O O
inhibitor O O
, O O
which O O
is O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
urolithiasis O O
. O O

CONCLUSION O O
: O O
Ureteric O O
obstruction O O
caused O O
by O O
precipitated O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
crystals O O
may O O
be O O
difficult O O
to O O
diagnose O O
with O O
unenhanced O O
CT O O
. O O

The O O
calculi O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
are O O
not O O
opaque O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signs O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
obstruction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
be O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
minimal O B_DISEASE_ADJECTIVE[DISEASE]
and O O
should O O
be O O
sought O O
carefully O O
. O O

Images O O
may O O
need O O
to O O
be O O
obtained O O
using O O
i O O
. O O
v O O
. O O
contrast O O
material O O
to O O
enable O O
diagnosis O O
of O O
ureteric O O
stones O O
or O O
obstruction O O
in O O
patients O O
with O O
HIV O O
infection O O
who O O
receive O O
indinavir B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O O
. O O

Ischemic O O
colitis O O
and O O
sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

Sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
succinate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
serotonin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O O
( O O
5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hydroxytryptamine I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O O
) O O
receptor O O
agonist O O
, O O
is O O
an O O
antimigraine O O
drug O O
that O O
is O O
reported O O
to O O
act O O
by O O
selectively O O
constricting O O
intracranial O O
arteries O O
. O O

Recently O O
, O O
vasopressor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
are O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O O
the O O
cranial O B_DISEASE/B_MEASURE
circulation O I_DISEASE/I_MEASURE
have O O
been O O
demonstrated O O
to O O
occur O O
in O O
the O O
systemic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
coronary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circulations O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cases O O
have O O
been O O
published O O
of O O
coronary O O
vasospasm O O
, O O
myocardial O O
ischemia O O
, O O
and O O
myocardial O O
infarction O O
occurring O O
after O O
sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O O
. O O

We O O
report O O
on O O
the O O
development O O
of O O
8 O O
serious O O
cases O O
of O O
ischemic O O
colitis O O
in O O
patients O O
with O O
migraine O O
treated O O
with O O
sumatriptan B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Pallidotomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O O
the O O
gamma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
: O O
a O O
positive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
experience O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

51 O O
patients O O
with O O
medically O O
refractory O O
Parkinson O O
' O O
s O O
disease O O
underwent O O
stereotactic O O
posteromedial O O
pallidotomy O O
between O O
August O O
1993 O O
and O O
February O O
1997 O O
for O O
treatment O O
of O O
bradykinesia O O
, O O
rigidity O O
, O O
and O O
L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
DOPA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
dyskinesias O O
. O O

In O O
29 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
, O O
the O O
pallidotomies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O O
performed O O
with O O
the O O
Leksell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Gamma O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
in O O
22 O B_MEASURE
they O O
were O O
performed O O
with O O
the O O
standard O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
radiofrequency O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
RF O B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O O
well O O
as O O
blinded O O
ratings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Unified O B_DISEASE
Parkinson O I_DISEASE
' O I_DISEASE
s O I_DISEASE
Disease O I_DISEASE
Rating O I_DISEASE
Scale O I_DISEASE
( O O
UPDRS O B_DISEASE
) O O
scores O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
carried O O
out O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
and O O
postoperatively O O
. O O

Mean O B_MEASURE/B_PERSON
follow O O
- O O
up O O
time O B_TIME[MEASURE]
is O O
20 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
range O B_MEASURE/B_LOCATION
6 O I_MEASURE/I_LOCATION
- O O
48 O B_MEASURE
) O O
and O O
all O O
except O O
4 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
have O O
been O O
followed O O
more O B_TIME[MEASURE]
than O O
one O B_TIME[MEASURE]/B_LOCATION
year O I_TIME[MEASURE]/I_LOCATION
. O O

85 O B_NUMBER[MEASURE]/B_PERSON
percent O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
with O O
dyskinesias O B_DISEASE
were O O
relieved O O
of O O
symptoms O B_DISEASE
, O O
regardless O O
of O O
whether O O
the O O
pallidotomies O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O O
performed O O
with O O
the O O
Gamma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
radiofrequency O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
methods O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O O

About O O
2 O B_NUMBER[MEASURE]
/ O O
3 O B_SEQUENCE[MEASURE]
of O O
the O O
patients O B_PERSON
in O O
both O O
Gamma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
radiofrequency O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
groups O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
showed O O
improvements O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
bradykinesia O B_DISEASE/B_MEASURE
and O O
rigidity O B_DISEASE
, O O
although O O
when O O
considered O O
as O O
a O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neither O O
the O O
Gamma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
Knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
nor O O
the O O
radiofrequency O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
group O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
showed O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
improvements O I_DISEASE_ADJECTIVE[DISEASE]
in O O
UPDRS O B_MEASURE/B_DISEASE
scores O I_MEASURE/I_DISEASE
. O O

One O B_PERSON
patient O I_PERSON
in O O
the O O
Gamma O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Knife O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
group O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
3 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
developed O O
a O O
homonymous O B_DISEASE
hemianopsia O I_DISEASE
9 O I_DISEASE
months O I_DISEASE
following O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
5 O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
( O O
27 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
in O O
the O O
radiofrequency O B_ORGANIZATION/B_MEASURE
group O B_ORGANIZATION/I_MEASURE
became O O
transiently O O
confused O O
postoperatively O O
. O O

No O O
other O B_DISEASE
complications O I_DISEASE
were O O
seen O O
. O O

Gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Knife O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pallidotomy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
as O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
radiofrequency O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pallidotomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
controlling O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
of O O
the O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Parkinson O B_DISEASE
' O I_DISEASE
s O I_DISEASE
disease O I_DISEASE
. O O

It O O
may O O
be O O
the O O
only O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
practical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
technique O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
available O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
certain O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O O
those O O
who O O
take O O
anticoagulants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
have O O
bleeding O O
diatheses O B_DISEASE_ADJECTIVE[DISEASE]
or O O
serious O B_DISEASE
systemic O I_DISEASE
medical O I_DISEASE
illnesses O I_DISEASE
. O O

It O O
is O O
a O O
viable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
option O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
other O B_PERSON
patients O I_PERSON
as O O
well O O
. O O

Centrally O O
mediated O O
cardiovascular O O
effects O O
of O O
intracisternal O O
application O O
of O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
anesthetized O O
rats O O
. O O

The O O
pressor O O
response O O
to O O
the O O
intracisternal O O
( O O
i O O
. O O
c O O
. O O
) O O
injection O O
of O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mug O O
) O O
in O O
anesthetized O O
rats O O
was O O
analyzed O O
. O O

This O O
response O O
was O O
significantly O O
reduced O O
by O O
the O O
intravenous O O
( O O
i O O
. O O
v O O
. O O
) O O
injection O O
of O O
guanethidine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
) O O
, O O
hexamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
10 O O
mg O O
) O O
or O O
phentolamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O O
mg O O
) O O
, O O
and O O
conversely O O
, O O
potentiated O O
by O O
i O O
. O O
v O O
. O O
desmethylimipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
3 O O
mg O O
) O O
, O O
while O O
propranolol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O O
. O O
5 O O
mg O O
) O O
i O O
. O O
v O O
. O O
selectively O O
inhibited O O
the O O
enlargement O O
of O O
pulse O O
pressure O O
and O O
the O O
tachycardia O O
following O O
i O O
. O O
c O O
. O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mug O O
) O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
pressor O O
response O O
to O O
i O O
. O O
c O O
. O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mug O O
) O O
was O O
almost O O
completely O O
blocked O O
by O O
i O O
. O O
c O O
. O O
atropine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O O
mug O O
) O O
or O O
hexamethonium B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
500 O O
mug O O
) O O
, O O
and O O
significantly O O
reduced O O
by O O
i O O
. O O
c O O
. O O
chlorpromazine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O O
mug O O
) O O
but O O
significantly O O
potentiated O O
by O O
i O O
. O O
c O O
. O O
desmethylimipramine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O O
mug O O
) O O
. O O

The O O
pressor O O
response O O
to O O
i O O
. O O
c O O
. O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O O
mug O O
) O O
remained O O
unchanged O O
after O O
sectioning O O
of O O
the O O
bilateral O O
cervical O O
vagal O O
nerves O O
but O O
disappeared O O
after O O
sectioning O O
of O O
the O O
spinal O O
cord O O
( O O
C7 O O
- O O
C8 O O
) O O
. O O

From O O
the O O
above O O
result O O
it O O
is O O
suggested O O
that O O
the O O
pressor O O
response O O
to O O
i O O
. O O
c O O
. O O
carbachol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ortral O O
and O O
peripheral O O
adrenergic O O
mechanisms O O
, O O
and O O
that O O
the O O
sympathetic O O
trunk O O
is O O
the O O
main O O
pathway O O
. O O

Neuroleptic O O
malignant O O
syndrome O O
and O O
methylphenidate B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
1 O O
- O O
year O O
- O O
old O O
female O O
presented O O
with O O
neuroleptic O O
malignant O O
syndrome O O
probably O O
caused O O
by O O
methylphenidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

She O O
had O O
defects O B_DISEASE
in O O
the O O
supratentorial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
including O O
the O O
basal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
striatum O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
multicystic O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
encephalomalacia O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
due O O
to O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
perinatal O I_DISEASE_ADJECTIVE[DISEASE]
hypoxic O I_DISEASE_ADJECTIVE[DISEASE]
- O O
ischemic O B_DISEASE
encephalopathy O I_DISEASE
, O O
which O O
was O O
considered O O
to O O
be O O
a O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predisposing O O
factor O B_DISEASE
causing O O
neuroleptic O B_DISEASE
malignant O I_DISEASE
syndrome O I_DISEASE
. O O

A O O
dopaminergic O B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]
generally O O
is O O
accepted O O
as O O
the O O
pathogenesis O B_DISEASE
of O O
this O O
syndrome O B_DISEASE
. O O

However O O
, O O
methylphenidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
via O O
the O O
inhibition O O
of O O
uptake O O
of O O
dopamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
therefore O O
dopaminergic O O
systems O O
in O O
the O O
brainstem O O
( O O
mainly O O
the O O
midbrain O O
) O O
and O O
the O O
spinal O O
cord O O
were O O
unlikely O O
to O O
participate O O
in O O
the O O
onset O O
of O O
this O O
syndrome O O
. O O

A O O
relative O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ergic O O
deficiency O O
might O O
occur O O
because O O
diazepam B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
mimetic O O
agent O O
, O O
was O O
strikingly O O
effective O O
. O O

This O O
is O O
the O O
first O O
reported O O
patient O O
with O O
neuroleptic O O
malignant O O
syndrome O O
probably O O
caused O O
by O O
methylphenidate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Differential O O
effects O O
of O O
17alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
the O O
neutral O O
and O O
acidic O O
pathways O O
of O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
salt I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O O
in O O
the O O
rat O O
. O O

Effects O O
of O O
17alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
EE B B_LOCATION/B_ORGANIZATION
) O O
on O O
the O O
neutral O O
and O O
acidic O O
biosynthetic O O
pathways O O
of O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
salt I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
BS B B_LOCATION
) O O
synthesis O O
were O O
evaluated O O
in O O
rats O O
with O O
an O O
intact O O
enterohepatic O O
circulation O O
and O O
in O O
rats O O
with O O
long O O
- O O
term O O
bile O O
diversion O O
to O O
induce O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis O O
. O O

For O O
this O O
purpose O O
, O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
salt I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
pool O O
composition O O
, O O
synthesis O O
of O O
individual O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
, O O
hepatic O O
activities O O
, O O
and O O
expression O O
levels O O
of O O
cholesterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7alpha O O
- O O
hydroxylase O O
( O O
CYP7A O O
) O O
, O O
and O O
sterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
27 O O
- O O
hydroxylase O O
( O O
CYP27 O O
) O O
, O O
as O O
well O O
as O O
of O O
other O O
enzymes O O
involved O O
in O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
, O O
were O O
analyzed O O
in O O
rats O O
treated O O
with O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
5 O O
mg O O
/ O O
kg O O
, O O
3 O O
days O O
) O O
or O O
its O O
vehicle O O
. O O

BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
pool O O
size O O
was O O
decreased O O
by O O
27 O O
% O O
but O O
total O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O O
was O O
not O O
affected O O
by O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
intact O O
rats O O
. O O

Synthesis O O
of O O
cholate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
by O O
68 O O
% O O
in O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
rats O O
, O O
while O O
that O O
of O O
chenodeoxycholate B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
increased O O
by O O
60 O O
% O O
. O O

The O O
recently O O
identified O O
Delta22 O O
- O O
isomer O O
of O O
beta O O
- O O
muricholate O O
contributed O O
for O O
5 O O
. O O
4 O O
% O O
and O O
18 O O
. O O
3 O O
% O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
to O O
the O O
pool O O
in O O
control O O
and O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O O
, O O
respectively O O
, O O
but O O
could O O
not O O
be O O
detected O O
in O O
bile O O
after O O
exhaustion O O
of O O
the O O
pool O O
. O O

A O O
clear O O
reduction O O
of O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O O
was O O
found O O
in O O
bile O O
- O O
diverted O O
rats O O
treated O O
with O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
yet O O
biliary O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composition O O
was O O
only O O
minimally O O
affected O O
. O O

Activity O O
of O O
CYP7A O O
was O O
decreased O O
by O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
both O O
intact O O
and O O
bile O O
- O O
diverted O O
rats O O
, O O
whereas O O
the O O
activity O O
of O O
the O O
CYP27 O O
was O O
not O O
affected O O
. O O

Hepatic O O
mRNA O O
levels O O
of O O
CYP7A O O
were O O
significantly O O
reduced O O
by O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
bile O O
- O O
diverted O O
rats O O
only O O
; O O
CYP27 O O
mRNA O O
levels O O
were O O
not O O
affected O O
by O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

In O O
addition O O
, O O
mRNA O O
levels O O
of O O
sterol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
12alpha O O
- O O
hydroxylase O O
and O O
lithocholate O O
6beta O O
- O O
hydroxylase O O
were O O
increased O O
by O O
bile O O
diversion O O
and O O
suppressed O O
by O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

This O O
study O O
shows O O
that O O
17alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
EE B B_LOCATION/B_ORGANIZATION
) O O
- O O
induced O O
intrahepatic O O
cholestasis O O
in O O
rats O O
is O O
associated O O
with O O
selective O O
inhibition O O
of O O
the O O
neutral O O
pathway O O
of O O
bile B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BS B B_LOCATION/B_ORGANIZATION
) O O
synthesis O O
. O O

Simultaneous O O
impairment O O
of O O
other O O
enzymes O O
in O O
the O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biosynthetic O O
pathways O O
may O O
contribute O O
to O O
overall O O
effects O O
of O O
EE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
BS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O O
. O O

Glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
sensitive O O
hypotension O O
produced O O
by O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assessed O O
in O O
the O O
rat O O
. O O

The O O
effects O O
of O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
basic O O
35 O O
- O O
amino B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
peptide O O
isolated O O
from O O
the O O
venom O O
of O O
a O O
lizard O O
salivary O O
gland O O
, O O
on O O
arterial O O
blood O O
pressure O O
and O O
heart O O
rate O O
were O O
examined O O
in O O
the O O
rat O O
, O O
focusing O O
on O O
the O O
possibility O O
that O O
activation O O
of O O
ATP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
( O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATP B B_PROTEIN[GENE]/B_LOCATION
) O O
) O O
channels O O
is O O
involved O O
in O O
the O O
responses O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
also O O
compared O O
with O O
those O O
of O O
vasoactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intestinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
polypeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
VIP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Helodermin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
hypotension O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
with O O
approximately O O
similar O O
potency O O
and O O
duration O O
to O O
VIP O O
. O O

Hypotension O O
induced O O
by O O
both O O
peptides O O
was O O
significantly O O
attenuated O O
by O O
glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
abolished O O
a O O
levcromakalim B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
produced O O
decrease O O
in O O
arterial O O
blood O O
pressure O O
. O O

Oxyhemoglobin O O
did O O
not O O
affect O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
hypotension O O
, O O
whereas O O
it O O
shortened O O
the O O
duration O O
of O O
acetylcholine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
ACh B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
- O O
produced O O
hypotension O O
. O O

These O O
findings O O
suggest O O
that O O
helodermin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
produced O O
hypotension O O
is O O
partly O O
attributable O O
to O O
the O O
activation O O
of O O
glibenclamide B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
sensitive O O
K B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
channels O O
( O O
K B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATP B B_PROTEIN[GENE]/B_LOCATION
) O O
channels O O
) O O
, O O
which O O
presumably O O
exist O O
on O O
arterial O O
smooth O O
muscle O O
cells O O
. O O

EDRF O O
( O O
endothelium O O
- O O
derived O O
relaxing O O
factor O O
) O O
/ O O
nitric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
seem O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
peptide O O
- O O
produced O O
hypotension O O
. O O

Long O O
- O O
term O O
efficacy O O
and O O
adverse O O
event O O
of O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sustained O O
- O O
release O O
tablets O O
for O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
induced O O
hypertension O O
in O O
patients O O
with O O
psoriasis O O
. O O

Thirteen O O
psoriatic O O
patients O O
with O O
hypertension O O
during O O
the O O
course O O
of O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
were O O
treated O O
for O O
25 O O
months O O
with O O
a O O
calcium B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O O
blocker O O
, O O
sustained O O
- O O
release O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
study O O
the O O
clinical O O
antihypertensive O O
effects O O
and O O
adverse O O
events O O
during O O
treatment O O
with O O
both O O
drugs O O
. O O

Seven O O
of O O
the O O
13 O O
patients O O
had O O
exhibited O O
a O O
subclinical O O
hypertensive O O
state O O
before O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy O O
. O O

Both O O
systolic O O
and O O
diastolic O O
blood O O
pressures O O
of O O
these O O
13 O O
patients O O
were O O
decreased O O
significantly O O
after O O
4 O O
weeks O O
of O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
, O O
and O O
blood O O
pressure O O
was O O
maintained O O
within O O
the O O
normal O O
range O O
thereafter O O
for O O
25 O O
months O O
. O O

The O O
adverse O O
events O O
during O O
combined O O
therapy O O
with O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
an O O
increase O O
in O O
blood B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O O
in O O
9 O O
of O O
the O O
13 O O
patients O O
and O O
development O O
of O O
gingival O O
hyperplasia O O
in O O
2 O O
of O O
the O O
13 O O
patients O O
. O O

Our O O
findings O O
indicate O O
that O O
sustained O O
- O O
release O O
nifedipine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
useful O O
for O O
hypertensive O O
psoriatic O O
patients O O
under O O
long O O
- O O
term O O
treatment O O
with O O
cyclosporin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
that O O
these O O
patients O O
should O O
be O O
monitored O O
for O O
gingival O O
hyperplasia O O
. O O

